data_2k0l_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2k0l _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.816 0.341 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.425 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.8 t-105 -146.62 129.9 16.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.423 ' CE1' ' HA3' ' A' ' 59' ' ' GLY . 6.1 p90 -136.92 139.65 41.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.795 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.08 149.49 52.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.197 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.75 -164.44 22.37 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.471 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.16 138.59 6.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.583 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 pttp -120.18 150.92 39.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.985 0.421 . . . . 0.0 111.033 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.0 tp -129.27 139.66 51.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.595 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.531 -179.945 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.304 -0.318 . . . . 0.0 112.304 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -99.95 144.52 28.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.768 0.318 . . . . 0.0 110.996 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -147.75 122.97 1.63 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.88 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.87 125.71 39.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.635 0.255 . . . . 0.0 110.459 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.423 ' HB2' ' NH2' ' A' ' 160' ' ' ARG . 2.8 m-85 -115.24 145.93 41.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.045 0.45 . . . . 0.0 111.583 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -144.92 124.84 2.23 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.786 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.423 ' HA3' ' CE1' ' A' ' 20' ' ' TYR . . . -123.13 146.98 16.64 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.035 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.425 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 53.4 p90 -153.53 126.04 8.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.851 0.358 . . . . 0.0 110.771 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.811 0.338 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -127.24 155.09 19.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.435 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 2.4 m-85 -82.79 141.56 32.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.617 0.246 . . . . 0.0 110.564 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -125.67 118.67 26.13 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.88 0.371 . . . . 0.0 111.133 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 10.3 mtt -108.19 124.72 50.7 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.5 179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 163.05 12.47 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.541 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.404 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 57.4 m-85 -137.54 114.91 11.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.684 0.278 . . . . 0.0 110.76 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.43 114.96 22.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.059 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 17.0 t90 . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.097 179.868 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.741 0.305 . . . . 0.0 110.715 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -85.59 135.3 13.29 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.639 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -123.81 122.03 63.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -108.88 142.25 39.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.189 0.519 . . . . 0.0 111.878 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -128.6 114.5 16.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.617 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -153.69 165.2 36.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.066 0.46 . . . . 0.0 111.739 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.02 129.73 51.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.307 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.53 132.2 55.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.051 0.453 . . . . 0.0 111.517 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.8 pp -132.76 127.8 35.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.279 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.24 -171.66 23.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.971 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.414 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.09 147.06 5.64 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.897 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.414 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 90.6 Cg_endo . . . . . 0 C--N 1.345 0.387 0 C-N-CA 122.745 2.297 . . . . 0.0 112.617 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.46 0.055 0 CA-C-O 120.617 0.246 . . . . 0.0 110.367 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -141.41 152.84 44.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.041 0.448 . . . . 0.0 111.763 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.434 ' CG2' ' CG1' ' A' ' 149' ' ' VAL . 1.1 pt -116.93 146.24 21.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.318 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -153.59 156.34 37.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.111 0.481 . . . . 0.0 111.693 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 68.2 p -136.37 135.72 39.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.246 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.35 128.33 55.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.998 0.427 . . . . 0.0 111.518 -179.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.6 tt -126.78 124.45 39.73 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.445 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 178.71 -133.56 2.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.462 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -153.24 168.68 32.02 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.404 -0.903 . . . . 0.0 112.939 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -119.17 141.99 48.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.785 0.326 . . . . 0.0 110.731 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -135.03 112.01 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.73 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 40.7 p-90 . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 120.914 0.388 . . . . 0.0 111.115 -179.737 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.674 0.274 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.1 134.76 7.04 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.349 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.41 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 96.4 Cg_endo -79.99 142.32 15.48 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.633 2.222 . . . . 0.0 112.12 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.9 m -156.84 158.48 3.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.968 0.413 . . . . 0.0 111.46 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -149.04 124.04 10.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.582 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -119.7 168.86 10.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.933 0.396 . . . . 0.0 111.23 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.57 138.77 6.58 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.382 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -160.77 -159.7 10.14 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.756 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.434 ' CG1' ' CG2' ' A' ' 110' ' ' ILE . 5.7 m -130.66 166.91 27.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.702 0.287 . . . . 0.0 110.933 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -136.03 148.09 48.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.873 0.368 . . . . 0.0 111.178 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 10.1 m0 -131.29 128.68 40.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.791 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.53 122.53 40.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.303 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 45.5 t . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 179.789 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.816 0.341 . . . . 0.0 111.221 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.82 167.72 10.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.189 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 22.3 p -125.52 144.41 50.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.354 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.423 ' NH2' ' HB2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 153.45 50.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.127 0.489 . . . . 0.0 111.87 -179.504 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.5 tt -126.55 124.38 39.86 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.913 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 184' ' ' LEU . 2.8 mt-10 -106.83 145.15 32.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.162 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.405 ' CE1' HD22 ' A' ' 184' ' ' LEU . 0.7 OUTLIER -131.16 166.02 22.04 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.625 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.067 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . 0.41 ' HA ' ' O ' ' A' ' 162' ' ' GLU . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.648 0.261 . . . . 0.0 110.817 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 12.7 p -171.07 166.73 7.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.97 0.414 . . . . 0.0 111.547 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.64 140.15 49.72 Favored 'General case' 0 N--CA 1.462 0.134 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.275 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -154.06 171.21 32.69 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 119.945 -1.122 . . . . 0.0 113.48 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.48 139.85 50.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.683 -0.259 . . . . 0.0 110.359 179.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 83.6 p -134.95 175.08 9.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.041 0.448 . . . . 0.0 111.497 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -145.38 149.81 35.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.696 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.942 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 t . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.886 0.374 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -121.29 132.32 54.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -129.76 135.97 49.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.974 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.45 141.63 29.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.232 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.23 -172.14 41.49 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.586 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.08 148.24 19.71 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.98 152.52 51.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.937 0.398 . . . . 0.0 111.278 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -130.35 148.75 52.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.443 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.226 0 C-N-CA 120.542 -0.837 . . . . 0.0 112.772 -179.883 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.458 -0.257 . . . . 0.0 112.458 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -116.52 161.08 19.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.762 0.315 . . . . 0.0 110.938 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -163.81 146.64 11.77 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.681 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -96.25 160.99 14.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.73 0.3 . . . . 0.0 110.898 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.411 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 19.6 p90 -151.6 139.52 19.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.988 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -136.33 125.05 3.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.349 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -98.13 129.98 10.08 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.581 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -129.14 110.24 11.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.82 0.343 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.805 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.652 0.263 . . . . 0.0 111.095 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 165.22 22.11 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 -81.83 132.49 35.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.775 0.322 . . . . 0.0 110.624 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -112.08 115.92 29.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.172 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -105.53 115.48 30.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.17 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.8 157.25 15.17 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.803 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -128.95 129.56 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.738 0.304 . . . . 0.0 110.718 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.401 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.9 OUTLIER -96.34 121.01 37.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.754 -179.979 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.233 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.785 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 17.8 tt0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.816 0.341 . . . . 0.0 110.567 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.401 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -84.3 141.27 19.73 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.718 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.89 121.03 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.746 0.308 . . . . 0.0 110.31 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -108.91 136.09 49.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.055 0.455 . . . . 0.0 111.817 -179.233 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.6 tt -122.18 106.57 11.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.58 179.296 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 7.5 p -145.45 168.77 19.75 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.044 0.449 . . . . 0.0 111.644 -178.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.68 121.97 45.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.009 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.34 132.42 56.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.146 0.498 . . . . 0.0 111.885 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.4 pp -126.96 127.39 44.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.814 179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -120.2 -177.49 16.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.323 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.416 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 24.3 t80 -166.11 123.12 1.02 Allowed Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.455 0.169 . . . . 0.0 110.738 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.416 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 83.7 Cg_endo . . . . . 0 C--N 1.347 0.464 0 C-N-CA 122.457 2.105 . . . . 0.0 112.671 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.773 0.321 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.04 163.27 23.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.066 0.46 . . . . 0.0 111.451 -179.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.408 ' HA ' ' HA ' ' A' ' 149' ' ' VAL . 1.6 pt -114.79 158.93 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.343 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -156.09 138.74 15.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.028 0.442 . . . . 0.0 111.604 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.8 t -132.99 126.94 33.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.243 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -118.47 130.46 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.954 0.407 . . . . 0.0 111.43 -179.416 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -131.52 122.84 26.82 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.438 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -176.37 -140.18 3.44 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.591 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.417 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -138.6 163.31 25.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.832 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.1 ptt? -122.26 135.65 54.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.764 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.17 119.81 49.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 19.4 t90 . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.021 -179.94 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.1 p . . . . . 0 C--O 1.231 0.132 0 CA-C-O 120.733 0.301 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t -157.1 143.18 12.94 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.291 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.417 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 98.9 Cg_endo -79.55 147.45 19.9 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.658 2.239 . . . . 0.0 112.113 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.7 m -156.98 161.83 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.951 0.405 . . . . 0.0 111.528 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.8 p90 -149.01 119.44 7.37 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.572 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -109.79 129.07 55.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.935 0.398 . . . . 0.0 111.321 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.4 124.98 4.05 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.224 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.412 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -158.56 -152.16 6.33 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.309 -0.948 . . . . 0.0 113.04 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.408 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 6.1 m -135.48 167.31 25.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 111.317 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -136.8 137.4 39.75 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -119.93 127.25 52.49 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.731 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -88.43 124.34 33.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.479 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 53.1 t . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.824 179.658 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 6.5 mt . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -131.69 158.82 40.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.314 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.0 141.63 33.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.201 179.558 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -124.29 122.95 39.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.11 0.481 . . . . 0.0 111.881 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.402 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 1.4 tt -117.41 116.69 27.67 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.536 178.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.48 145.02 36.92 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -178.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.412 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.4 p90 -133.99 165.77 24.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.557 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.877 -179.989 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 7.2 mp . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.65 0.262 . . . . 0.0 110.776 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 67.2 m -152.44 150.89 30.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.949 0.404 . . . . 0.0 111.298 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -116.31 145.18 43.38 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.454 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -160.64 173.66 37.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.921 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 2.1 m -127.49 138.16 55.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.759 0.314 . . . . 0.0 110.652 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 189' ' ' SER . . . . . 0.411 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 60.7 p -139.86 170.59 15.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.258 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 1.9 p90 -147.95 160.02 43.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.929 179.969 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.796 0.331 . . . . 0.0 110.933 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.413 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.2 OUTLIER -141.83 154.58 45.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.885 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.424 ' CE1' ' HB3' ' A' ' 191' ' ' ARG . 1.2 m-85 -145.71 135.92 23.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.801 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.34 140.0 27.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.222 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.7 -171.55 41.27 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.424 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.04 150.46 22.69 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.368 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.32 154.57 48.4 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.898 0.38 . . . . 0.0 111.114 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 49.4 tp -128.17 139.6 52.39 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.528 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.385 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.545 -179.929 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.389 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -101.19 139.88 36.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.02 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -145.57 126.85 2.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.424 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.89 141.82 28.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.747 0.308 . . . . 0.0 110.97 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -123.8 126.16 45.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.957 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -154.65 124.99 1.62 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -157.98 -168.31 20.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.413 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 8.8 p90 -154.97 161.08 41.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.782 0.325 . . . . 0.0 110.807 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.993 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.754 0.311 . . . . 0.0 110.798 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 153.49 19.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.525 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.07 128.37 42.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.66 0.266 . . . . 0.0 110.439 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -122.2 130.16 52.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.984 0.421 . . . . 0.0 111.417 -179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 19.1 mtt -118.97 127.17 53.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.328 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.73 158.2 14.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.495 -0.859 . . . . 0.0 112.699 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -129.18 114.94 16.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.781 0.324 . . . . 0.0 110.78 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -83.41 115.55 22.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.889 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.7 t90 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.931 179.917 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.769 0.319 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -99.68 142.64 16.07 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.122 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.76 122.1 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -108.8 140.32 42.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.065 0.459 . . . . 0.0 111.678 -179.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.4 tt -128.43 116.21 19.39 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.751 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -153.97 164.38 38.52 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.035 0.445 . . . . 0.0 111.84 -178.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.25 124.98 46.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.285 179.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -102.76 132.53 48.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.029 0.442 . . . . 0.0 111.71 -179.255 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -134.95 124.16 24.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.347 179.296 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -156.3 -175.84 27.73 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.821 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -166.02 159.97 12.85 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.656 0.265 . . . . 0.0 110.993 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo . . . . . 0 C--N 1.345 0.352 0 C-N-CA 122.631 2.22 . . . . 0.0 112.132 179.832 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.073 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -136.76 160.01 40.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 111.812 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -115.09 147.27 18.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.219 179.436 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -149.06 145.13 27.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.114 0.483 . . . . 0.0 111.51 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -137.81 129.82 28.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.179 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -111.93 133.11 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.081 0.467 . . . . 0.0 111.522 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.424 ' HB2' ' CD2' ' A' ' 145' ' ' PHE . 7.8 tt -124.34 122.86 38.87 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.296 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 179.91 -134.07 2.16 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.815 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.452 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -151.43 169.1 30.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.933 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -122.68 138.82 54.49 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 111.24 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.1 125.89 60.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.503 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 1.1 p-90 . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 111.244 -179.787 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.9 p . . . . . 0 C--O 1.233 0.187 0 CA-C-O 120.645 0.26 . . . . 0.0 111.132 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -157.07 142.67 12.64 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.496 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.452 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 4.7 Cg_exo -73.93 153.4 47.47 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.834 2.356 . . . . 0.0 111.768 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.8 m -156.33 161.19 2.0 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 121.084 0.469 . . . . 0.0 111.717 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.424 ' CD2' ' HB2' ' A' ' 114' ' ' LEU . 10.5 t80 -142.94 118.96 10.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.237 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.49 136.38 52.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.014 0.435 . . . . 0.0 111.397 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -133.73 125.74 4.05 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.004 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -157.96 -164.99 14.67 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.354 -0.927 . . . . 0.0 112.873 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 6.8 m -131.75 162.68 39.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.806 0.336 . . . . 0.0 111.046 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.51 140.11 51.36 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.188 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 18.8 m95 -123.22 120.02 31.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.808 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.51 126.71 35.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.391 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.009 179.801 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 17.7 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.771 0.32 . . . . 0.0 111.035 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -116.47 168.83 9.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.008 0.432 . . . . 0.0 111.362 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 5.8 t -126.77 144.41 50.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.198 179.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 150.19 47.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.232 0.539 . . . . 0.0 112.016 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.413 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.9 OUTLIER -115.56 122.35 45.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.482 178.943 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -111.94 145.09 40.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.05 0.452 . . . . 0.0 111.7 -178.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.413 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 17.5 m-85 -128.71 147.05 50.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.657 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.978 -179.938 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.785 0.326 . . . . 0.0 110.784 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 9.5 t -138.51 147.88 43.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.389 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.8 131.97 54.01 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.407 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.85 168.63 28.71 Favored Glycine 0 N--CA 1.453 -0.213 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.236 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.1 m -127.99 143.51 40.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.671 0.272 . . . . 0.0 110.472 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.42 172.98 11.96 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 121.006 0.431 . . . . 0.0 111.468 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.7 p90 -138.05 160.03 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . 0.424 ' HB3' ' CE1' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.4 m . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.749 0.309 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 3.9 m-90 -135.64 148.4 48.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.106 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.427 ' CZ ' ' HA3' ' A' ' 59' ' ' GLY . 6.6 p90 -159.95 149.0 17.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.69 153.75 46.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.171 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.87 -171.18 38.07 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.463 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -143.7 147.64 19.06 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.39 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 3.1 pptp? -134.59 146.94 50.09 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.911 0.386 . . . . 0.0 111.043 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.9 tt -121.5 146.29 47.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.653 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.486 -179.882 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.436 -0.266 . . . . 0.0 112.436 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.428 ' HB2' ' CZ3' ' A' ' 74' ' ' TRP . . . -125.07 148.48 48.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.662 0.268 . . . . 0.0 110.837 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.44 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.04 147.85 18.48 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.322 -0.942 . . . . 0.0 112.937 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.83 128.76 53.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.635 0.255 . . . . 0.0 110.643 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -120.3 143.96 48.07 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 0.0 111.397 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -128.15 124.89 4.92 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.045 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.427 ' HA3' ' CZ ' ' A' ' 20' ' ' TYR . . . -100.3 139.72 14.56 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.987 -179.492 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -135.39 114.11 11.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.702 0.287 . . . . 0.0 110.593 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.256 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.9 pp . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 120.862 0.363 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -107.14 177.02 21.46 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.548 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -90.55 142.77 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.833 0.349 . . . . 0.0 110.654 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -122.49 111.96 17.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.151 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.9 mtt -100.39 114.82 28.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.888 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 152.16 17.28 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.392 -0.909 . . . . 0.0 113.261 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.44 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 38.6 m-85 -130.3 114.96 16.28 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.5 122.94 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.763 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . 0.436 ' CD1' ' HA2' ' A' ' 55' ' ' GLY . 17.9 p-90 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.646 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.186 0 CA-C-O 120.726 0.298 . . . . 0.0 110.679 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.48 124.5 8.1 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.783 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.09 117.8 56.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.08 139.76 46.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.124 0.488 . . . . 0.0 111.831 -178.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.3 tt -129.98 110.97 12.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.556 179.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.407 ' CB ' ' HA3' ' A' ' 115' ' ' GLY . 2.5 p -150.02 178.12 9.24 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.083 0.468 . . . . 0.0 111.812 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.2 44.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.033 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 8.8 tttt -126.57 132.01 51.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.096 0.475 . . . . 0.0 111.841 -179.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.6 pp -134.55 123.96 24.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.981 179.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.427 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -126.24 -175.04 14.02 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.437 -0.887 . . . . 0.0 113.302 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.415 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 0.8 OUTLIER -166.15 122.96 1.0 Allowed Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 115.674 -0.263 . . . . 0.0 110.576 -179.881 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.415 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 58.3 Cg_endo . . . . . 0 C--N 1.347 0.462 0 C-N-CA 122.485 2.123 . . . . 0.0 112.672 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.675 0.274 . . . . 0.0 110.443 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -145.07 159.28 43.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.009 0.433 . . . . 0.0 111.522 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 149' ' ' VAL . 1.3 pt -114.63 148.58 17.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.351 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.427 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 5.7 m-85 -138.13 144.46 40.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.049 0.452 . . . . 0.0 111.736 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -128.91 127.1 41.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.356 179.416 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.25 130.07 56.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.338 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.425 ' HB2' ' CE2' ' A' ' 145' ' ' PHE . 7.2 tt -137.4 122.95 19.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.636 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.407 ' HA3' ' CB ' ' A' ' 97' ' ' THR . . . 179.51 -143.05 5.5 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.431 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -146.23 163.86 28.37 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.929 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.57 144.37 49.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.807 0.337 . . . . 0.0 110.94 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.2 t -129.44 135.73 60.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 6.2 m95 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.795 179.994 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.4 p . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.66 0.267 . . . . 0.0 110.948 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -157.14 152.91 22.63 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.803 0.335 . . . . 0.0 111.577 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.431 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 71.6 Cg_endo -77.04 162.1 32.17 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.769 2.313 . . . . 0.0 112.094 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.6 m -155.96 159.05 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.003 0.43 . . . . 0.0 111.503 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.425 ' CE2' ' HB2' ' A' ' 114' ' ' LEU . 10.5 t80 -147.24 118.89 7.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.486 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -115.78 122.54 45.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.25 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.405 ' O ' ' CD1' ' A' ' 163' ' ' TYR . . . -126.32 132.21 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.218 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.414 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -166.52 -153.76 7.98 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.817 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.448 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 6.0 m -134.7 170.53 19.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.63 0.253 . . . . 0.0 111.016 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -138.3 144.6 40.52 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.904 0.383 . . . . 0.0 111.317 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -127.24 133.51 50.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.566 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.71 137.2 36.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 179.706 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 32.0 mt . . . . . 0 C--O 1.232 0.165 0 CA-C-O 120.943 0.402 . . . . 0.0 111.651 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -140.03 155.53 47.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.089 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.8 m -101.02 149.97 23.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.481 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.06 134.2 36.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.068 0.461 . . . . 0.0 111.8 -179.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.4 tt -117.56 119.57 35.43 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.792 179.038 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -112.42 143.89 42.79 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.989 0.423 . . . . 0.0 111.703 -179.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.414 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 6.4 p90 -134.21 162.83 31.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.516 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.938 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.7 mp . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.642 0.258 . . . . 0.0 110.703 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.8 m -141.51 151.55 43.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.926 0.394 . . . . 0.0 111.345 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -114.81 132.06 56.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.342 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -149.25 167.5 29.58 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.326 -0.94 . . . . 0.0 113.002 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.2 m -127.57 139.81 50.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.65 0.262 . . . . 0.0 110.706 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 80.6 p -140.11 173.98 10.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.999 0.428 . . . . 0.0 111.241 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -148.0 151.28 35.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.724 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.93 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.677 0.275 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 64.4 p-90 -150.33 148.74 29.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.974 0.416 . . . . 0.0 111.165 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 9.5 p90 -130.91 143.35 50.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.652 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.62 149.64 52.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.234 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.456 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.62 -159.98 19.1 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.779 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -132.19 142.36 13.8 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.349 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.4 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -127.67 140.34 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.97 0.414 . . . . 0.0 111.127 -179.86 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 19.2 tp -128.08 141.01 51.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.461 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.364 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.624 -179.857 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -134.94 136.03 41.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.799 0.333 . . . . 0.0 110.878 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.403 ' CA ' ' O ' ' A' ' 72' ' ' TYR . . . -156.07 166.56 33.09 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.693 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.97 155.01 16.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 110.706 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.455 ' CZ ' ' NH2' ' A' ' 113' ' ' ARG . 47.0 m-85 -143.69 132.49 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.934 0.397 . . . . 0.0 111.124 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -130.83 124.8 4.31 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.377 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -100.5 130.65 10.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.494 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -122.09 120.69 35.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.825 0.345 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.98 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.943 0.401 . . . . 0.0 111.317 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -134.98 166.04 24.47 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.323 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -86.18 132.95 33.9 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.783 0.325 . . . . 0.0 111.069 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.407 ' HB2' ' HG2' ' A' ' 99' ' ' LYS . 25.9 tt0 -109.98 112.09 23.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.171 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.0 mmt -108.28 111.98 24.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.945 179.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -118.37 163.74 12.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.35 -0.929 . . . . 0.0 113.104 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.403 ' O ' ' CA ' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -128.61 114.81 17.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.673 0.273 . . . . 0.0 110.471 179.701 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.69 129.63 34.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.416 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.633 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.631 0.253 . . . . 0.0 110.617 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -94.68 131.64 10.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.87 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.52 121.8 66.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.28 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 17.7 mt-30 -108.79 134.6 51.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.037 0.446 . . . . 0.0 111.712 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.3 tt -128.86 112.48 14.17 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.868 179.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -151.1 162.47 40.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.077 0.465 . . . . 0.0 111.658 -178.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.9 122.37 43.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.041 179.102 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.407 ' HG2' ' HB2' ' A' ' 69' ' ' GLU . 0.0 OUTLIER -112.58 132.13 55.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.145 0.498 . . . . 0.0 112.071 -179.039 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.9 pp -122.49 128.39 50.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.807 178.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.426 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -119.96 -179.91 16.5 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.133 -179.201 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -166.08 125.84 1.2 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.763 -0.219 . . . . 0.0 110.664 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo . . . . . 0 C--N 1.346 0.405 0 C-N-CA 122.553 2.169 . . . . 0.0 112.489 -179.785 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.415 HD23 ' CH2' ' A' ' 151' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.09 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -138.53 162.99 33.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.106 0.479 . . . . 0.0 111.722 -179.241 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.417 ' HA ' ' HA ' ' A' ' 149' ' ' VAL . 1.4 pt -114.81 157.06 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.28 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.426 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 96.3 m-85 -153.47 144.82 23.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.081 0.467 . . . . 0.0 111.73 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 38.8 p -142.48 126.96 17.8 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.167 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.455 ' NH2' ' CZ ' ' A' ' 57' ' ' PHE . 1.4 ppt_? -118.27 134.7 54.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.009 0.433 . . . . 0.0 111.78 -179.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.8 tt -133.63 122.9 24.13 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.078 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -177.65 -132.95 1.76 Allowed Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.602 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.437 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.43 165.55 31.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.302 -0.951 . . . . 0.0 113.082 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.7 ptt? -120.44 140.99 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.922 0.392 . . . . 0.0 110.744 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.8 t -134.32 124.5 45.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.926 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 54.2 p-90 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.925 179.926 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.4 p . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.752 0.311 . . . . 0.0 111.029 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 36.2 t -157.22 140.65 11.23 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.293 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.437 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.4 Cg_endo -80.65 148.15 17.83 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.73 2.286 . . . . 0.0 112.259 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 33.9 m -156.27 159.07 2.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.989 0.423 . . . . 0.0 111.492 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -149.1 123.54 9.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.499 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.36 145.32 40.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.838 0.352 . . . . 0.0 111.425 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.64 133.66 6.22 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.265 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.415 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -169.76 -149.99 6.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.556 -0.831 . . . . 0.0 113.023 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.417 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 13.8 m -135.23 168.78 22.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.813 0.34 . . . . 0.0 111.396 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -131.6 136.61 47.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.881 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . 0.415 ' CH2' HD23 ' A' ' 108' ' ' LEU . 4.6 t-105 -125.14 131.59 53.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.033 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -91.53 137.2 32.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.074 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 62.2 t . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.899 0.38 . . . . 0.0 110.86 179.942 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.351 . . . . 0.0 110.988 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.47 160.18 38.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.187 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.1 m -100.96 153.34 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.45 124.99 29.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.294 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.1 tt -123.95 116.51 23.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.112 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . 0.415 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 42.1 mt-10 -136.32 145.17 45.16 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.143 0.497 . . . . 0.0 111.45 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -123.48 166.01 16.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.625 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 8.5 mm-40 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 179.963 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 5.9 mp . . . . . 0 CA--C 1.526 0.057 0 CA-C-O 120.79 0.329 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -128.6 141.6 51.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.854 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.98 146.37 50.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.814 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . 0.4 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -163.42 -176.77 35.73 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.584 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.46 142.66 42.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.729 0.3 . . . . 0.0 110.825 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 189' ' ' SER . . . . . 0.456 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 29.6 t -135.96 161.03 36.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.152 0.501 . . . . 0.0 111.857 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . 0.403 ' CE1' ' O ' ' A' ' 191' ' ' ARG . 7.0 t80 -125.01 135.16 52.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.363 179.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . 0.403 ' O ' ' CE1' ' A' ' 190' ' ' TYR . 8.4 ptt180 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.113 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 t . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.741 0.305 . . . . 0.0 110.812 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.418 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 17.6 t90 -142.74 129.92 20.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.0 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.42 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 10.5 m-85 -119.69 135.91 54.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.833 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.57 139.98 35.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.073 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -171.1 -159.2 16.59 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -148.1 147.48 18.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.61 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.401 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 3.0 mttp -123.63 161.14 25.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.988 0.423 . . . . 0.0 111.031 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 2.5 tt -141.35 143.24 33.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.695 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.55 -179.998 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.612 -0.195 . . . . 0.0 112.612 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -129.24 153.68 47.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.721 0.296 . . . . 0.0 110.876 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.04 172.18 35.14 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.769 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -114.12 131.27 56.47 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.744 0.307 . . . . 0.0 110.887 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -118.72 128.22 54.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.073 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.97 126.39 3.23 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.39 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -127.5 136.14 9.12 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.608 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.45 ' CZ ' ' CB ' ' A' ' 68' ' ' PHE . 42.1 p90 -134.25 130.62 37.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.993 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.766 0.317 . . . . 0.0 110.941 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 167.69 21.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.45 ' CB ' ' CZ ' ' A' ' 60' ' ' TYR . 0.3 OUTLIER -85.56 131.86 34.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 110.749 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -113.09 119.86 39.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.089 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.17 123.48 47.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.555 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 148.43 17.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.571 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -130.04 115.05 16.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.802 0.334 . . . . 0.0 110.614 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.38 120.84 33.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.993 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.224 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.697 0.284 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -99.31 130.53 10.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.105 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.51 121.67 65.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 179.269 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -108.89 142.83 38.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.145 0.498 . . . . 0.0 111.8 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -132.3 110.62 10.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.738 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.401 HG21 ' HA3' ' A' ' 115' ' ' GLY . 2.8 p -150.85 167.39 27.64 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 120.932 0.396 . . . . 0.0 111.677 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -102.45 120.89 41.29 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.132 179.131 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -106.03 132.34 52.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.042 0.449 . . . . 0.0 111.909 -179.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.8 pp -135.87 128.35 30.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.281 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -150.25 -173.3 20.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.919 -179.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 30.4 p90 -166.17 143.12 4.31 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.585 0.231 . . . . 0.0 111.012 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.419 ' HA ' ' CB ' ' A' ' 109' ' ' ASP . 98.5 Cg_endo . . . . . 0 C--N 1.345 0.371 0 C-N-CA 122.778 2.319 . . . . 0.0 112.941 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.681 0.277 . . . . 0.0 110.302 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.419 ' CB ' ' HA ' ' A' ' 103' ' ' PRO . 4.6 p-10 -144.76 158.4 43.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.966 0.413 . . . . 0.0 111.678 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.405 ' CG2' HG13 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 147.93 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.467 179.472 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.431 ' CZ ' ' HD3' ' A' ' 160' ' ' ARG . 17.7 p90 -142.33 143.32 32.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.11 0.481 . . . . 0.0 111.599 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 46.7 p -138.56 126.96 23.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.132 179.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.421 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 0.0 OUTLIER -121.2 138.48 54.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.982 0.42 . . . . 0.0 111.608 -179.241 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.44 ' HB2' ' CD2' ' A' ' 145' ' ' PHE . 7.8 tt -129.53 122.91 30.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.349 179.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' A' ' 97' ' ' THR . . . -177.44 -141.76 4.22 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.723 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.458 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.19 169.13 25.89 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.434 -0.889 . . . . 0.0 112.843 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 14.7 tmm? -125.92 141.71 51.85 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 120.888 0.375 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -127.03 130.53 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.764 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 4.2 p-90 . . . . . 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 111.035 -179.85 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.637 0.256 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 p -157.11 131.85 5.28 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.368 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.458 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.5 Cg_exo -73.66 150.34 44.99 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.65 2.234 . . . . 0.0 111.791 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.1 m -156.28 163.53 1.41 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.26 0 CA-C-O 121.116 0.484 . . . . 0.0 111.84 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.44 ' CD2' ' HB2' ' A' ' 114' ' ' LEU . 10.9 t80 -137.07 118.76 15.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.245 179.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -103.63 126.72 50.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.929 0.395 . . . . 0.0 111.327 -179.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.57 124.88 3.61 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.176 179.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.75 -160.57 11.03 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.693 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.405 HG13 ' CG2' ' A' ' 110' ' ' ILE . 6.0 m -134.75 163.39 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.659 0.266 . . . . 0.0 110.915 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -127.71 142.54 51.3 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 120.918 0.39 . . . . 0.0 111.099 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -126.57 119.16 26.42 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.66 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.59 137.23 32.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.388 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.511 179.631 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 21.5 mt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.887 0.375 . . . . 0.0 111.686 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -135.63 155.93 49.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.994 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 1.7 t -117.63 140.56 49.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.094 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.431 ' HD3' ' CZ ' ' A' ' 111' ' ' TYR . 0.0 OUTLIER -134.59 151.58 51.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.328 0.585 . . . . 0.0 112.123 -179.33 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -113.12 124.8 53.43 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.725 179.093 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -106.89 145.13 32.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.985 0.421 . . . . 0.0 111.622 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.45 ' CE2' ' CD2' ' A' ' 184' ' ' LEU . 0.8 OUTLIER -131.12 126.48 35.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.383 179.673 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.17 -179.787 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . 0.45 ' CD2' ' CE2' ' A' ' 163' ' ' TYR . 2.5 mp . . . . . 0 N--CA 1.457 -0.089 0 CA-C-O 120.732 0.301 . . . . 0.0 110.771 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.3 p -136.76 155.78 49.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.068 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -119.33 133.06 55.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.461 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . 0.401 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -145.67 162.37 28.26 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.207 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.73 133.94 67.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.773 0.32 . . . . 0.0 110.402 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -136.14 175.09 9.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.943 0.401 . . . . 0.0 111.378 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -139.84 155.8 47.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.636 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . 0.42 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.933 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.72 0.295 . . . . 0.0 110.833 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 13.3 p-90 -143.79 148.17 35.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.955 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.8 m-85 -119.97 140.0 51.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.709 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.35 139.98 47.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.384 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.15 -158.47 19.82 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.499 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -155.86 150.45 21.81 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.533 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.401 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 9.1 ptmm? -131.71 154.04 49.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.914 0.388 . . . . 0.0 111.07 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -128.29 148.89 50.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.675 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.564 -179.932 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.38 144.4 34.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.55 130.85 3.36 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.747 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.91 145.67 24.75 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.689 0.28 . . . . 0.0 110.773 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -135.62 133.35 38.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.023 0.44 . . . . 0.0 111.425 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.82 125.04 1.89 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.849 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -134.39 164.36 24.58 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.934 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -143.91 134.04 24.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.897 0.38 . . . . 0.0 110.657 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.965 0.412 . . . . 0.0 111.325 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.75 177.1 18.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.294 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -98.04 142.37 29.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.653 0.263 . . . . 0.0 110.703 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -132.96 121.29 22.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.917 0.389 . . . . 0.0 111.07 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.16 129.32 53.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.421 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.01 156.91 15.35 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.636 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.41 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 40.0 m-85 -130.48 115.04 16.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.774 0.321 . . . . 0.0 110.463 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.83 120.48 30.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.186 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 . . . . . 0 C--N 1.331 -0.236 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.889 179.825 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.807 0.336 . . . . 0.0 110.645 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.36 128.47 8.5 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.666 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.66 117.96 51.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.641 0.258 . . . . 0.0 110.324 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -110.55 142.53 42.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.116 0.484 . . . . 0.0 111.72 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.5 tt -129.06 110.23 11.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.483 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.1 p -148.2 174.66 11.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.235 0.541 . . . . 0.0 111.769 -178.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -111.55 135.24 52.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.304 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.66 132.13 55.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.918 0.389 . . . . 0.0 111.448 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -132.18 131.69 42.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.587 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.38 -174.3 34.85 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.569 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.438 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -165.36 150.8 8.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.73 0.3 . . . . 0.0 110.925 -179.882 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.438 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 37.6 Cg_exo . . . . . 0 C--N 1.348 0.507 0 C-N-CA 122.709 2.272 . . . . 0.0 112.108 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.052 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.411 ' HB3' ' HA ' ' A' ' 103' ' ' PRO . 3.0 p30 -131.64 160.26 35.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.032 0.444 . . . . 0.0 112.016 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.429 ' CG2' HG11 ' A' ' 149' ' ' VAL . 1.4 pp -116.07 141.25 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.133 179.332 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -156.69 160.28 39.18 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.103 0.478 . . . . 0.0 111.925 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 9.3 t -138.4 151.07 47.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.02 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 3.7 ppt_? -120.5 127.99 52.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.514 -179.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.6 tt -125.75 122.67 36.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.127 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -179.59 -141.52 4.59 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.512 -0.851 . . . . 0.0 112.669 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.402 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.11 168.65 25.64 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.796 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 8.3 ptp -126.56 142.48 51.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.879 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -124.45 144.05 35.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.807 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.7 t90 . . . . . 0 C--N 1.329 -0.307 0 CA-C-O 120.808 0.337 . . . . 0.0 110.974 -179.882 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 N--CA 1.457 -0.094 0 CA-C-O 120.667 0.27 . . . . 0.0 110.964 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.0 p -157.05 148.65 17.12 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.335 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.402 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 72.4 Cg_endo -76.55 158.47 36.08 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.665 2.243 . . . . 0.0 112.084 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.0 m -155.92 154.41 6.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.031 0.443 . . . . 0.0 111.52 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 59.4 t80 -149.15 118.66 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.416 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -129.37 147.48 51.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.94 0.4 . . . . 0.0 111.345 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.22 145.37 17.19 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.078 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.424 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -164.77 -171.03 30.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.799 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.429 HG11 ' CG2' ' A' ' 110' ' ' ILE . 3.4 m -129.56 148.95 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.746 0.308 . . . . 0.0 111.107 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -110.83 127.15 55.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 5.3 t90 -128.61 120.29 26.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.757 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.57 132.92 34.46 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.354 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.1 t . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.756 179.746 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.425 HD11 HG22 ' A' ' 157' ' ' ILE . 18.6 mt . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.766 0.317 . . . . 0.0 111.209 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -112.68 168.56 9.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.254 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.3 m -135.92 146.63 47.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.348 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 147.69 46.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.201 0.524 . . . . 0.0 111.902 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.2 tt -119.68 124.1 45.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.776 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -114.42 144.48 43.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.084 0.469 . . . . 0.0 111.592 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.424 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 18.7 p90 -134.14 155.17 50.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.494 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.972 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.6 mp . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.712 0.291 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 47.4 m -151.86 155.74 38.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.901 0.382 . . . . 0.0 111.264 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -118.26 135.77 54.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.366 179.589 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . 0.401 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -147.92 167.24 28.84 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 119.967 -1.111 . . . . 0.0 113.139 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.3 m -123.74 145.07 31.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 67.4 p -152.29 174.98 13.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.055 0.455 . . . . 0.0 111.593 -179.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -145.16 152.37 39.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.541 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . 0.4 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.878 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.8 m . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.871 0.367 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.424 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 27.0 m-90 -131.78 131.93 43.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.986 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -128.26 135.96 50.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.722 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.14 141.25 34.17 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.49 -166.6 33.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.546 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -156.01 150.07 21.28 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.414 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -126.85 160.05 32.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.902 0.382 . . . . 0.0 111.157 -179.904 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.66 140.88 46.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.609 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.499 -179.888 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.645 -0.182 . . . . 0.0 112.645 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.11 144.54 33.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.34 117.78 1.2 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.619 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.73 136.1 35.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.75 0.31 . . . . 0.0 110.667 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 22.4 m-85 -125.93 132.8 52.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.974 0.416 . . . . 0.0 111.186 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.57 125.04 1.78 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.201 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.401 ' HA3' ' HA ' ' A' ' 69' ' ' GLU . . . -155.87 -173.42 24.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.858 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 60' ' ' TYR . 1.9 p90 -147.96 158.31 43.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.756 0.312 . . . . 0.0 110.8 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 32.8 mt-30 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.994 -179.787 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.6 pp . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.823 0.345 . . . . 0.0 110.7 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -137.97 175.66 21.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.615 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -115.36 138.16 51.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.823 0.344 . . . . 0.0 110.648 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.401 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . 1.2 pt-20 -140.13 143.14 36.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.002 0.43 . . . . 0.0 111.198 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -110.68 142.25 42.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.531 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 158.24 14.6 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.617 -0.802 . . . . 0.0 112.441 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -130.83 114.79 15.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.678 0.275 . . . . 0.0 110.77 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.407 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.4 t0 -90.35 119.36 30.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.914 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 2.2 t90 . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.955 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.782 0.325 . . . . 0.0 110.458 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.407 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -88.74 133.65 11.94 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.991 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.83 117.74 45.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -108.98 149.03 29.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.236 0.541 . . . . 0.0 111.875 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.6 tt -135.11 113.78 11.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.629 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 t -154.11 166.33 33.41 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.099 0.476 . . . . 0.0 111.638 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.34 134.57 50.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.481 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.59 130.18 54.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.315 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -135.25 124.27 24.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.537 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -166.89 -169.77 30.91 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.693 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -165.1 157.62 13.67 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.727 0.299 . . . . 0.0 111.112 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 109' ' ' ASP . 90.5 Cg_endo . . . . . 0 C--N 1.346 0.413 0 C-N-CA 122.787 2.325 . . . . 0.0 112.634 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.045 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 7.5 t0 -125.39 147.68 49.08 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.382 0.611 . . . . 0.0 112.385 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -129.33 123.54 58.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.763 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -143.04 168.84 18.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.027 0.441 . . . . 0.0 111.559 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 31.0 p -141.15 140.26 34.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.548 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.7 ptt-85 -111.64 127.93 55.9 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.205 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.5 tt -124.83 125.02 43.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.623 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 176.94 -132.74 2.1 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.422 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.03 169.18 32.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.982 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.0 tmm? -125.94 144.47 50.67 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 120.682 0.277 . . . . 0.0 110.639 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.63 129.65 64.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . 0.404 ' CZ2' ' HB3' ' A' ' 73' ' ' ASP . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.2 p . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.791 0.329 . . . . 0.0 111.036 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 38.1 m -157.24 148.18 16.47 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.387 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.422 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.5 Cg_endo -78.0 147.96 24.4 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.766 2.311 . . . . 0.0 112.049 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.11 158.38 3.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.988 0.423 . . . . 0.0 111.52 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -145.88 119.93 9.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.418 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -120.97 163.95 17.47 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.904 0.383 . . . . 0.0 111.396 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -140.7 148.42 20.06 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.246 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.37 -171.99 31.3 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.705 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.8 m -131.98 167.05 27.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.669 0.271 . . . . 0.0 111.08 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -134.64 151.49 51.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.946 0.403 . . . . 0.0 111.291 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -133.06 117.61 17.77 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.582 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -81.68 122.46 27.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.422 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 56.4 t . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.957 179.706 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.4 mt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.925 0.393 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -113.25 167.91 10.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.288 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.4 t -123.27 143.3 50.15 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.261 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.09 147.19 45.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.13 0.49 . . . . 0.0 111.783 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -113.95 126.11 54.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.806 179.043 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.7 138.51 45.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.385 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -134.19 156.18 48.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.664 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.929 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 4.2 mp . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.67 0.272 . . . . 0.0 110.629 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.22 155.46 37.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.01 0.433 . . . . 0.0 111.285 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -115.24 131.87 56.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.169 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . 0.414 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -146.15 168.06 27.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.367 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -127.59 141.01 47.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -144.57 174.98 10.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.043 0.449 . . . . 0.0 111.522 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -146.15 155.67 42.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.712 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 1.6 ptp180 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.977 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.763 0.316 . . . . 0.0 110.92 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -118.29 130.74 56.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.857 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -126.06 135.88 52.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.799 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.23 153.85 44.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.17 -165.28 37.91 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.42 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -160.54 151.51 22.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.532 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.402 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -133.05 157.91 44.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 0.0 111.034 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -127.46 146.19 50.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.7 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.546 -179.929 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.14 52.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.69 0.281 . . . . 0.0 110.948 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.5 135.46 7.44 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.737 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -103.75 135.64 44.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.781 0.324 . . . . 0.0 110.882 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -119.41 133.69 55.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.206 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -157.27 125.55 1.59 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.389 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -146.18 -178.65 21.78 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.69 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 14.3 p90 -153.35 160.81 42.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.843 0.354 . . . . 0.0 110.927 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.798 179.859 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.821 0.343 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.23 169.8 21.05 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.439 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.6 m-85 -98.75 138.74 35.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.63 0.253 . . . . 0.0 110.817 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -125.95 129.55 49.49 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.952 0.406 . . . . 0.0 110.965 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.11 129.31 55.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.424 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.27 17.43 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.362 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -125.61 114.85 19.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.748 0.309 . . . . 0.0 110.676 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.449 ' HB2' ' HA3' ' A' ' 93' ' ' GLY . 0.3 OUTLIER -87.15 118.28 26.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.758 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.968 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.695 0.283 . . . . 0.0 110.374 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.449 ' HA3' ' HB2' ' A' ' 73' ' ' ASP . . . -83.92 133.73 12.12 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.017 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.85 117.98 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.8 0.333 . . . . 0.0 110.208 179.355 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 -108.98 138.11 45.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.109 0.481 . . . . 0.0 111.728 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.7 tt -127.6 107.24 9.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.696 179.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 27.0 p -144.68 162.05 37.65 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 121.158 0.504 . . . . 0.0 111.796 -178.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -92.92 126.5 38.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.006 178.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -104.87 130.98 52.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.029 0.442 . . . . 0.0 111.845 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.8 pp -136.29 123.78 22.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.21 177.46 34.06 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.507 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.415 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.19 153.95 9.4 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.733 0.302 . . . . 0.0 111.344 -179.925 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.415 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 38.1 Cg_exo . . . . . 0 C--N 1.347 0.483 0 C-N-CA 122.76 2.306 . . . . 0.0 112.05 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.524 -0.048 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -135.03 160.09 39.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.722 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.408 ' CG2' HG13 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.93 144.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.209 179.359 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -142.26 141.82 32.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.008 0.432 . . . . 0.0 111.527 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 9.6 t -137.15 126.91 25.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.199 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.4 ' NH2' ' N ' ' A' ' 148' ' ' GLY . 0.0 OUTLIER -114.41 131.6 56.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.913 0.387 . . . . 0.0 111.511 -179.358 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.0 tt -128.06 122.93 33.35 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.451 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -175.82 -135.45 2.12 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.622 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.441 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.12 161.7 26.4 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.899 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.47 138.63 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.716 0.293 . . . . 0.0 110.705 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -129.57 134.68 63.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . 0.427 ' CZ2' ' HB2' ' A' ' 73' ' ' ASP . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.8 p . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.621 0.248 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -157.1 144.72 13.92 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.337 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.441 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 90.9 Cg_endo -80.73 139.99 12.76 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.752 2.302 . . . . 0.0 112.115 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 30.3 m -157.04 162.84 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 121.002 0.43 . . . . 0.0 111.504 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.9 p90 -142.35 121.12 12.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.45 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -105.74 141.16 37.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.976 0.417 . . . . 0.0 111.402 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.59 135.03 7.88 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.994 179.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.424 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -159.68 -171.99 26.26 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.895 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.408 HG13 ' CG2' ' A' ' 110' ' ' ILE . 4.4 m -131.12 150.98 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.663 0.268 . . . . 0.0 111.138 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -122.32 133.99 54.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.169 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 9.4 m95 -121.76 122.17 38.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.649 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.412 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -78.77 137.01 37.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.406 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 72.8 t . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.682 179.758 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 5.2 mt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.809 0.338 . . . . 0.0 111.226 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.412 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -132.5 161.85 32.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.375 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 9.7 t -117.72 143.98 45.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.965 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -137.0 150.87 48.39 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.204 0.526 . . . . 0.0 112.158 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.7 tt -114.39 123.87 50.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.585 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -107.83 139.54 42.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.986 0.422 . . . . 0.0 111.557 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.424 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 36.3 p90 -134.14 160.15 38.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.723 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.058 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 6.3 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.693 0.283 . . . . 0.0 110.65 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 11.0 p -142.53 158.91 43.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.73 134.64 54.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . 0.402 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -149.29 172.62 29.31 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.004 -1.093 . . . . 0.0 113.404 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.65 141.37 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.677 0.275 . . . . 0.0 110.388 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 32.8 p -139.55 171.48 14.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.42 . . . . 0.0 111.268 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -148.03 157.51 43.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.776 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.95 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.7 p . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.818 0.342 . . . . 0.0 110.885 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -121.94 145.39 48.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.401 ' CE2' ' HG3' ' A' ' 191' ' ' ARG . 89.6 m-85 -142.16 135.98 29.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.401 ' HB2' ' CE1' ' A' ' 190' ' ' TYR . . . -144.41 140.02 28.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.08 -161.11 26.09 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.384 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.85 147.27 17.1 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.56 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.72 153.81 35.07 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.923 0.392 . . . . 0.0 110.906 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 55.7 tp -136.7 138.61 41.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.649 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.604 -179.827 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.33 -0.308 . . . . 0.0 112.33 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -117.78 142.86 46.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.806 0.336 . . . . 0.0 111.137 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -143.17 134.73 6.07 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.67 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.9 140.28 30.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.304 . . . . 0.0 110.837 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -126.45 134.31 51.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.935 0.398 . . . . 0.0 111.126 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -161.62 126.42 1.58 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.254 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -158.55 -166.2 17.24 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.653 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -151.21 146.56 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.879 0.371 . . . . 0.0 110.989 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.756 179.877 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.785 0.326 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 158.38 23.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.483 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -105.28 129.03 53.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.632 0.253 . . . . 0.0 110.62 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -122.54 128.46 50.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.86 0.362 . . . . 0.0 111.149 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.3 ttt -108.96 127.0 53.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.538 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 163.92 12.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.742 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.403 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 95.5 m-85 -138.18 114.85 10.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.24 120.27 25.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.023 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.224 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.832 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.698 0.285 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -115.1 141.01 16.76 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.203 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.11 128.11 67.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.175 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 145.29 35.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.135 0.493 . . . . 0.0 111.855 -178.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -140.08 116.14 10.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.742 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -153.01 165.43 35.6 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.211 0.529 . . . . 0.0 111.809 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -99.19 133.42 43.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.358 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 9.5 pttt -112.79 132.33 55.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.515 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -136.08 122.33 20.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.534 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.31 -176.73 37.14 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.663 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.409 ' HB2' ' HD2' ' A' ' 103' ' ' PRO . 30.3 p90 -166.18 157.61 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 120.657 0.265 . . . . 0.0 111.009 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.409 ' HD2' ' HB2' ' A' ' 102' ' ' TYR . 19.9 Cg_endo . . . . . 0 C--N 1.346 0.427 0 C-N-CA 122.599 2.2 . . . . 0.0 111.813 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.077 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -127.43 155.91 42.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.983 0.42 . . . . 0.0 111.925 -178.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.425 ' CG2' HG12 ' A' ' 149' ' ' VAL . 1.5 pp -125.18 136.35 61.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.369 179.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 37.8 p90 -150.14 159.35 44.49 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.106 0.479 . . . . 0.0 111.494 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 36.8 p -130.86 149.22 52.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.479 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.1 ppt_? -123.75 127.85 48.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.87 0.367 . . . . 0.0 111.394 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -127.89 122.74 33.29 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.205 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -179.47 -133.18 1.91 Allowed Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.735 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.402 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.1 169.12 33.64 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.809 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -126.02 143.7 51.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.823 0.344 . . . . 0.0 110.906 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.3 t -124.89 125.23 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.839 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 19.7 m0 . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.904 -179.806 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.749 0.309 . . . . 0.0 111.286 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 54.4 p -157.02 130.6 4.69 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.402 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.9 Cg_endo -78.23 146.94 22.84 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.548 2.165 . . . . 0.0 112.152 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.6 m -156.09 151.11 9.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.872 0.368 . . . . 0.0 111.442 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.2 p90 -149.08 124.27 10.15 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.501 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -134.91 167.04 21.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.979 0.418 . . . . 0.0 111.447 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -133.76 146.14 18.12 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.007 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -155.39 -179.83 30.82 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.901 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.425 HG12 ' CG2' ' A' ' 110' ' ' ILE . 11.4 m -128.42 153.31 37.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.828 0.347 . . . . 0.0 110.994 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -122.12 139.74 53.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.203 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -128.48 118.48 23.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.804 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.411 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -82.24 137.01 34.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.23 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 84.6 t . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 179.839 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.3 mt . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.801 0.334 . . . . 0.0 111.274 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.411 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.04 155.67 46.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.383 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 6.4 t -102.5 145.73 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.299 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.24 139.09 40.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.068 0.461 . . . . 0.0 111.823 -179.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -115.74 130.48 56.87 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.754 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.25 142.58 39.91 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.047 0.451 . . . . 0.0 111.626 -179.256 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.451 ' CE2' ' CD2' ' A' ' 184' ' ' LEU . 0.1 OUTLIER -134.14 130.68 37.68 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.372 179.582 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 5.6 mp0 . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.12 -179.771 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . 0.451 ' CD2' ' CE2' ' A' ' 163' ' ' TYR . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.779 0.323 . . . . 0.0 110.696 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.9 m -125.43 151.01 46.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.104 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.47 128.44 52.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.414 179.712 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -145.7 167.24 27.67 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.997 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.7 m -129.56 137.34 57.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.659 0.266 . . . . 0.0 110.588 179.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.7 p -139.88 175.06 9.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.953 0.406 . . . . 0.0 111.318 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . 0.401 ' CE1' ' HB2' ' A' ' 21' ' ' ALA . 3.8 p90 -141.66 159.92 41.23 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.812 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . 0.401 ' HG3' ' CE2' ' A' ' 20' ' ' TYR . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.851 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.6 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.886 0.374 . . . . 0.0 110.775 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 70.2 p-90 -149.6 132.3 15.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.987 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.5 m-85 -114.38 141.15 48.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.55 141.64 28.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.884 0.373 . . . . 0.0 111.278 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.442 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.21 -166.55 30.21 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.879 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -134.3 141.76 13.12 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.466 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.494 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 6.3 ptpt -128.84 149.72 50.63 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.078 0.466 . . . . 0.0 111.412 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 47.4 tp -126.46 150.11 48.89 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.511 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.342 -179.972 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.22 0 N-CA-C 112.413 -0.275 . . . . 0.0 112.413 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -118.05 170.02 9.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.688 0.28 . . . . 0.0 110.932 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.58 157.34 27.67 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.783 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -108.97 140.58 42.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 110.876 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.401 ' CD1' ' OE2' ' A' ' 69' ' ' GLU . 3.0 m-85 -126.48 128.76 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.031 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.65 124.99 2.2 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.254 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.13 172.26 23.0 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.763 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -140.11 160.49 39.83 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.827 0.346 . . . . 0.0 110.786 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 . . . . . 0 C--N 1.331 -0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.908 -179.982 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.664 0.268 . . . . 0.0 110.831 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -121.23 161.56 15.25 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.584 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -114.08 134.7 54.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.779 0.323 . . . . 0.0 110.696 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.401 ' OE2' ' CD1' ' A' ' 57' ' ' PHE . 2.0 tt0 -129.95 129.93 44.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.918 0.389 . . . . 0.0 111.085 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 ttm -108.01 135.43 49.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.422 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 158.52 14.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.512 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 19.9 m-85 -138.0 115.02 10.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.646 0.26 . . . . 0.0 110.657 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.412 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.2 t0 -87.97 121.09 29.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.88 0.372 . . . . 0.0 110.924 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 21.3 t-105 . . . . . 0 C--N 1.332 -0.193 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.977 -179.958 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.617 0.246 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.412 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -85.26 135.76 13.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.926 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.42 120.33 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 179.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -108.95 148.51 30.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.154 0.502 . . . . 0.0 111.744 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 tt -138.13 114.04 9.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.703 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 8.6 p -149.72 164.45 35.22 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 121.054 0.455 . . . . 0.0 111.764 -178.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -97.52 132.28 43.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.314 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.86 132.23 53.66 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.036 0.446 . . . . 0.0 111.643 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.4 pp -135.93 124.07 23.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.431 179.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.96 -169.86 30.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.711 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.437 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 2.9 t80 -160.62 145.17 10.59 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.69 0.281 . . . . 0.0 111.12 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.437 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 95.3 Cg_endo . . . . . 0 C--N 1.347 0.472 0 C-N-CA 122.884 2.389 . . . . 0.0 112.479 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.41 HD22 ' CE2' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.087 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 . . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.415 ' CB ' ' HA ' ' A' ' 103' ' ' PRO . 11.4 p-10 -131.38 155.11 47.83 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.031 0.443 . . . . 0.0 111.893 -179.19 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.418 ' CG2' ' CG1' ' A' ' 149' ' ' VAL . 1.0 OUTLIER -119.91 146.82 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.271 179.351 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.42 ' CE2' ' HB2' ' A' ' 150' ' ' GLU . 4.4 p90 -162.44 164.01 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.103 0.478 . . . . 0.0 111.763 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 17.4 m -140.54 139.77 35.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.497 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.405 ' NH1' ' HB3' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -114.96 127.99 56.01 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.152 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -127.79 122.91 33.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.44 179.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -178.89 -134.54 2.15 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.536 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -149.42 163.06 29.19 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.751 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.9 ppp? -117.64 145.03 44.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 110.917 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.7 t -127.05 141.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.861 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.5 t90 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.003 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.714 0.293 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.02 117.33 2.84 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.347 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.42 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 6.3 Cg_exo -73.65 137.62 25.3 Favored 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 122.605 2.203 . . . . 0.0 111.85 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 26.4 m -156.96 164.03 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.862 0.363 . . . . 0.0 111.386 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -148.59 122.37 9.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.796 179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.52 142.85 45.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.173 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.34 142.12 13.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.299 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.412 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -170.55 -157.69 13.12 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.107 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.418 ' CG1' ' CG2' ' A' ' 110' ' ' ILE . 4.9 m -129.83 163.25 35.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 111.127 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.42 ' HB2' ' CE2' ' A' ' 111' ' ' TYR . 0.7 OUTLIER -133.19 129.38 37.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . 0.41 ' CE2' HD22 ' A' ' 108' ' ' LEU . 1.4 t-105 -118.43 132.55 56.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.792 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.427 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -99.36 134.43 42.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 0.0 111.528 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.413 ' O ' ' CG1' ' A' ' 153' ' ' VAL . 47.8 t . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.751 179.754 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.816 0.341 . . . . 0.0 111.073 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.427 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -115.88 154.26 30.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.342 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.99 151.53 22.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.247 179.499 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 2.1 ptm180 -136.93 132.76 34.89 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.9 0.381 . . . . 0.0 111.897 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.419 HD23 ' CE1' ' A' ' 163' ' ' TYR . 1.1 tt -123.61 120.79 33.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.734 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . 0.412 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 0.7 OUTLIER -116.34 145.12 43.44 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.606 -179.043 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.457 ' N ' ' CD1' ' A' ' 163' ' ' TYR . 2.1 m-85 -126.76 165.81 18.58 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.551 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.938 -179.998 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 6.7 mp . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.826 0.346 . . . . 0.0 110.779 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.2 m -132.59 145.8 51.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.91 137.84 49.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.568 179.705 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -158.8 -176.65 31.09 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.449 -0.881 . . . . 0.0 113.042 -179.569 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -126.16 141.86 44.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.637 0.256 . . . . 0.0 110.52 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 189' ' ' SER . . . . . 0.442 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 1.4 t -137.93 159.72 41.24 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.112 0.482 . . . . 0.0 111.576 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -117.81 146.42 43.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.41 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.235 0 CA-C-O 120.813 0.34 . . . . 0.0 110.822 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -121.19 146.97 46.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.415 ' CD1' ' HB2' ' A' ' 189' ' ' SER . 0.1 OUTLIER -142.35 135.81 29.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.724 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 145.22 31.03 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.336 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.72 -168.9 38.65 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.566 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -137.0 147.04 19.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.546 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.423 ' HE3' ' CE2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -121.2 153.14 37.98 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 -179.924 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.1 tt -133.43 139.34 46.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.723 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.383 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.577 -179.989 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.628 -0.189 . . . . 0.0 112.628 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -127.97 159.63 34.38 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.812 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.417 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -158.44 155.66 26.68 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.802 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -113.59 126.69 55.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.797 0.332 . . . . 0.0 110.856 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.423 ' CE2' ' HE3' ' A' ' 24' ' ' LYS . 38.9 p90 -115.59 133.46 56.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.111 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.1 125.15 1.78 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.132 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -150.41 -176.98 23.93 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.747 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -155.06 154.48 32.52 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.896 0.379 . . . . 0.0 111.006 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.567 179.867 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.976 0.417 . . . . 0.0 111.159 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.49 176.76 18.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.398 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.405 ' CE2' ' HG ' ' A' ' 96' ' ' LEU . 1.2 t80 -103.85 138.24 40.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.634 0.254 . . . . 0.0 110.724 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -134.51 125.9 28.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.852 0.358 . . . . 0.0 111.116 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.1 mtt -107.27 133.38 51.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.434 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.87 159.4 13.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.615 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.417 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -131.53 114.88 15.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.679 0.276 . . . . 0.0 110.613 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -86.18 120.51 27.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.998 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 42.8 t90 . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.917 -179.974 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.675 0.274 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -98.21 130.22 10.16 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.968 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.77 118.96 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 15.8 mt-30 -108.86 144.4 36.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.241 0.543 . . . . 0.0 111.937 -178.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.405 ' HG ' ' CE2' ' A' ' 68' ' ' PHE . 1.3 tt -133.45 112.19 11.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.266 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.422 ' CB ' ' HA3' ' A' ' 115' ' ' GLY . 6.0 p -147.03 178.05 8.67 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.219 0.533 . . . . 0.0 111.984 -178.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -117.27 135.81 53.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.039 179.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -110.65 131.98 54.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.021 0.439 . . . . 0.0 111.379 -179.387 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -135.45 125.71 26.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.259 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.429 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -168.14 -169.82 32.09 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.944 -179.538 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.425 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 24.5 p90 -156.51 152.43 22.85 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.819 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.421 ' HA ' ' CB ' ' A' ' 109' ' ' ASP . 83.8 Cg_endo . . . . . 0 N--CA 1.463 -0.321 0 C-N-CA 122.721 2.281 . . . . 0.0 112.803 -179.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.227 -0.106 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.421 ' CB ' ' HA ' ' A' ' 103' ' ' PRO . 9.5 m-20 -129.27 145.59 51.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.987 0.422 . . . . 0.0 111.809 -179.234 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.425 HD13 ' CZ ' ' A' ' 102' ' ' TYR . 1.3 pt -114.9 142.17 28.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.657 179.314 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.429 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 33.4 m-85 -149.12 158.33 44.1 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.058 0.456 . . . . 0.0 111.695 -179.35 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.6 m -130.89 141.92 50.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.457 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 36.8 ttp180 -120.83 127.94 52.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.278 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -136.34 122.92 20.92 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.929 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.422 ' HA3' ' CB ' ' A' ' 97' ' ' THR . . . -177.12 -140.71 3.73 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.583 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.7 167.74 25.48 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.868 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 9.0 ttp -130.2 141.1 50.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 0.0 110.735 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.4 t -125.69 115.63 43.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.826 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.888 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.1 p . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.705 0.288 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -157.16 148.49 16.84 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.831 0.348 . . . . 0.0 111.464 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.443 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -79.81 145.66 18.11 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.752 2.302 . . . . 0.0 112.222 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.7 m -156.71 157.1 4.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.927 0.394 . . . . 0.0 111.404 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -149.13 127.19 11.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.476 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -124.01 143.85 50.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.245 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -130.02 146.95 17.85 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.09 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -167.72 -164.39 23.31 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.936 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.413 ' CG1' ' CG2' ' A' ' 110' ' ' ILE . 6.7 m -128.65 166.89 25.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.685 0.279 . . . . 0.0 111.134 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -135.4 149.1 49.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.92 0.391 . . . . 0.0 111.196 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 5.2 m0 -131.39 123.07 27.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.735 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.86 130.2 34.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.225 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 51.1 t . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.052 179.942 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.42 HG12 ' CD2' ' A' ' 190' ' ' TYR . 22.8 mt . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.697 0.284 . . . . 0.0 110.754 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -132.99 160.86 35.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.984 0.421 . . . . 0.0 111.59 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 24.5 m -119.35 145.45 46.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.973 179.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.403 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 147.42 46.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.179 0.514 . . . . 0.0 111.976 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.425 HD23 ' CZ ' ' A' ' 163' ' ' TYR . 1.3 tt -113.92 123.57 50.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.533 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -107.5 143.88 35.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.044 0.45 . . . . 0.0 111.616 -179.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.433 ' CD1' HD23 ' A' ' 184' ' ' LEU . 45.4 m-85 -130.94 163.53 27.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.504 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.993 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . 0.433 HD23 ' CD1' ' A' ' 163' ' ' TYR . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.658 0.266 . . . . 0.0 110.605 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -135.71 152.37 51.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.973 0.416 . . . . 0.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.13 128.72 54.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.3 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -143.2 167.31 26.48 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.16 -1.019 . . . . 0.0 113.082 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -128.42 139.49 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.687 0.28 . . . . 0.0 110.374 179.445 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 189' ' ' SER . . . . . 0.415 ' HB2' ' CD1' ' A' ' 20' ' ' TYR . 0.3 OUTLIER -136.27 168.7 18.93 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 111.723 -179.125 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . 0.452 ' N ' ' CD1' ' A' ' 190' ' ' TYR . 2.7 m-85 -131.71 157.99 42.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.366 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 38.0 mtm180 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.943 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.815 0.341 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 25.9 m-90 -117.28 132.45 56.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.055 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.417 ' CZ ' ' HG3' ' A' ' 191' ' ' ARG . 5.1 m-85 -120.41 135.87 54.91 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.522 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.22 140.26 43.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.488 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 179.14 -163.78 31.57 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.414 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -162.73 161.33 33.67 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.552 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.433 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 0.1 OUTLIER -135.32 160.9 36.97 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.005 0.431 . . . . 0.0 111.044 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.9 tt -130.85 149.17 52.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.735 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.463 179.98 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -132.37 132.64 43.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.752 0.311 . . . . 0.0 110.914 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.37 158.08 26.79 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.753 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -126.85 134.72 50.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.51 0.195 . . . . 0.0 110.793 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.433 ' CE2' ' HG2' ' A' ' 24' ' ' LYS . 6.3 p90 -142.37 165.39 27.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.176 0.512 . . . . 0.0 111.738 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -140.13 141.87 11.96 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.79 179.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -114.59 143.26 17.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.896 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.425 ' CZ ' ' HB3' ' A' ' 68' ' ' PHE . 1.8 p90 -144.62 121.3 11.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.898 0.38 . . . . 0.0 110.631 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.976 -179.775 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.861 0.362 . . . . 0.0 110.99 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 172.16 20.33 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.425 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . 0.9 OUTLIER -96.87 141.46 30.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.684 0.278 . . . . 0.0 110.611 179.902 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.77 120.24 28.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.976 0.417 . . . . 0.0 111.281 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.3 mtt -106.17 139.03 41.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.859 179.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . 0.427 ' CA ' ' HB3' ' A' ' 57' ' ' PHE . . . -133.0 166.63 23.61 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.643 -179.278 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -136.92 115.43 11.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.363 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -81.52 129.73 34.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.18 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 46.0 m95 . . . . . 0 C--N 1.33 -0.264 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.737 179.87 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.713 0.292 . . . . 0.0 110.519 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -105.53 140.56 15.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.429 -0.891 . . . . 0.0 112.913 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.81 122.62 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.201 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -108.53 143.85 36.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.115 0.483 . . . . 0.0 111.9 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -137.48 113.88 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.849 179.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.2 t -155.1 166.82 32.37 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 111.784 -179.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.1 139.45 39.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.32 179.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.9 ttpp -118.92 132.25 56.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.897 0.379 . . . . 0.0 111.598 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.8 pp -134.03 126.58 30.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.737 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 102' ' ' TYR . . . -167.99 -177.81 39.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.514 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.407 ' CG ' ' O ' ' A' ' 101' ' ' GLY . 6.5 m-85 -166.1 158.89 12.51 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.777 0.322 . . . . 0.0 110.987 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo . . . . . 0 C--N 1.346 0.442 0 C-N-CA 122.741 2.294 . . . . 0.0 111.944 179.806 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.459 0.019 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -135.15 156.19 49.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.071 0.462 . . . . 0.0 111.996 -179.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.406 ' CG2' HG11 ' A' ' 149' ' ' VAL . 1.6 pp -121.34 138.86 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.394 179.309 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 48.1 p90 -151.28 163.51 38.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.071 0.463 . . . . 0.0 111.557 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 18.5 p -137.63 145.69 43.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.53 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -119.76 127.78 53.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.883 0.373 . . . . 0.0 111.315 -179.756 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -126.98 123.64 37.59 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.328 179.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 178.39 -132.49 1.94 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.42 -179.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.89 168.61 33.95 Favored Glycine 0 C--N 1.331 0.3 0 C-N-CA 120.285 -0.96 . . . . 0.0 112.9 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.95 140.98 52.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.711 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.5 t -133.91 118.16 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.657 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 64.5 p-90 . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 120.833 0.349 . . . . 0.0 111.049 -179.792 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.8 p . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.744 0.307 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.21 141.29 11.67 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.397 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.418 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 92.2 Cg_endo -78.69 149.95 23.96 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.603 2.202 . . . . 0.0 112.02 179.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.8 m -156.3 157.93 3.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.04 0.448 . . . . 0.0 111.702 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -149.08 118.9 7.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.303 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -127.76 159.21 35.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.986 0.422 . . . . 0.0 111.537 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -130.95 151.82 19.75 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.036 179.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -162.73 -177.71 35.96 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.346 -0.931 . . . . 0.0 112.979 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.406 HG11 ' CG2' ' A' ' 110' ' ' ILE . 4.2 m -127.82 154.27 38.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 0.0 111.005 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -124.75 140.46 52.91 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.938 0.399 . . . . 0.0 111.116 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 1.9 t90 -131.63 127.77 37.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.779 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.62 137.2 34.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.329 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 76.0 t . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.664 179.819 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 33.4 mt . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.927 0.394 . . . . 0.0 111.288 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -136.35 164.35 28.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.233 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -118.53 144.8 45.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.151 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.415 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 0.0 OUTLIER -137.16 152.07 49.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.276 0.56 . . . . 0.0 112.051 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -117.97 125.36 50.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.551 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -117.72 137.54 52.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.049 0.452 . . . . 0.0 111.595 -179.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -134.19 152.29 51.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.489 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 4.3 mp . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.777 0.323 . . . . 0.0 110.681 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 72.0 m -148.71 153.25 37.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.975 0.416 . . . . 0.0 111.226 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.73 136.07 53.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.23 179.706 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.92 170.33 28.59 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.056 -1.069 . . . . 0.0 113.196 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.6 m -132.09 148.09 32.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.602 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 189' ' ' SER . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 160' ' ' ARG . 89.4 p -151.79 175.06 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.054 0.455 . . . . 0.0 111.466 -179.701 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -145.92 156.54 43.59 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.621 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . 0.417 ' HG3' ' CZ ' ' A' ' 20' ' ' TYR . 8.4 ttm180 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.92 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 39.9 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.717 0.294 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.418 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.2 t-105 -135.66 135.07 39.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.415 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 7.9 m-85 -121.98 145.05 48.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.77 141.6 28.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.256 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.55 -166.67 34.06 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.552 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.38 146.71 18.42 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.544 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -127.93 149.32 50.37 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 120.858 0.361 . . . . 0.0 111.082 -179.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 2.0 tt -132.55 145.55 51.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.668 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.593 179.954 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.396 -0.282 . . . . 0.0 112.396 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -136.57 173.13 12.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.915 0.388 . . . . 0.0 111.052 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.87 156.6 26.06 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.626 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.95 160.17 14.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.822 0.344 . . . . 0.0 111.011 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -147.77 126.39 12.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.984 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.43 137.05 5.69 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.299 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.414 ' HA3' ' HB3' ' A' ' 69' ' ' GLU . . . -171.39 -165.84 29.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.649 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.418 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 6.0 p90 -143.57 161.01 39.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.994 0.426 . . . . 0.0 111.039 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.59 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.793 0.33 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -128.87 156.41 21.12 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.32 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -128.99 128.43 43.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.621 0.248 . . . . 0.0 110.769 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.414 ' HB3' ' HA3' ' A' ' 59' ' ' GLY . 1.4 pm0 -147.44 153.46 39.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.149 0.499 . . . . 0.0 111.505 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 4.0 ptt? -118.15 138.21 52.45 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.186 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.86 175.63 18.73 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.689 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -134.71 114.94 13.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.661 0.267 . . . . 0.0 110.621 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -78.27 121.64 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.084 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 6.1 m95 . . . . . 0 C--N 1.331 -0.216 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.878 179.886 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.699 0.285 . . . . 0.0 110.631 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.85 141.54 15.32 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.898 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -112.05 126.0 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.249 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -108.86 146.84 33.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.224 0.535 . . . . 0.0 112.03 -178.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.0 tt -139.13 116.1 10.92 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.347 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.412 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 0.9 OUTLIER -154.32 170.03 22.28 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.191 0.519 . . . . 0.0 112.054 -178.694 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -108.95 149.64 28.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.134 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.82 132.23 53.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.966 0.412 . . . . 0.0 111.704 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 4.0 pp -133.34 125.11 28.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.18 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -163.06 -169.82 27.04 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.872 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.423 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -157.35 145.3 14.07 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.674 0.273 . . . . 0.0 110.923 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.435 ' HA ' ' CB ' ' A' ' 109' ' ' ASP . 84.7 Cg_endo . . . . . 0 C--N 1.347 0.485 0 C-N-CA 122.764 2.309 . . . . 0.0 112.643 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.46 0.064 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.435 ' CB ' ' HA ' ' A' ' 103' ' ' PRO . 5.8 p-10 -134.35 152.48 51.83 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.12 0.486 . . . . 0.0 112.09 -178.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.42 ' CG2' ' CG1' ' A' ' 149' ' ' VAL . 1.3 pt -114.82 147.63 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 179.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -157.77 166.19 33.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.1 0.476 . . . . 0.0 111.823 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 27.4 m -142.28 132.29 24.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.513 179.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 52.6 mtt180 -109.92 128.91 55.66 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.188 -179.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -132.98 125.52 29.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.715 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.412 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . -179.98 -135.51 2.49 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.477 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.432 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -152.19 169.04 31.45 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.48 -0.867 . . . . 0.0 112.792 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.5 ptp -128.13 140.91 51.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.849 0.357 . . . . 0.0 110.995 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -130.63 111.88 21.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.715 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.5 p-90 . . . . . 0 C--N 1.329 -0.308 0 CA-C-O 120.927 0.394 . . . . 0.0 111.055 -179.831 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.9 p . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.732 0.301 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.17 147.4 15.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.247 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.432 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.3 Cg_endo -78.1 151.89 27.38 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.749 2.3 . . . . 0.0 112.209 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.8 m -156.38 157.29 3.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.379 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -149.13 123.78 9.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.628 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -118.34 124.83 48.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -125.59 137.33 10.22 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.306 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -170.87 -150.76 7.17 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.435 -0.888 . . . . 0.0 113.076 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.42 ' CG1' ' CG2' ' A' ' 110' ' ' ILE . 9.0 m -131.3 168.21 24.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.822 0.344 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -134.79 136.74 42.8 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -119.56 128.72 54.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.81 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.73 131.7 40.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.916 0.388 . . . . 0.0 111.456 -179.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 59.5 t . . . . . 0 C--N 1.331 -0.21 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.747 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.2 mt . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.784 0.326 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -136.87 162.8 32.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.439 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 1.7 m -109.73 150.6 28.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.202 179.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.07 136.58 38.49 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.077 0.465 . . . . 0.0 111.864 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.422 HD22 ' CE1' ' A' ' 163' ' ' TYR . 1.4 tt -119.17 120.76 38.04 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.505 178.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -117.39 145.13 44.29 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.115 0.483 . . . . 0.0 111.819 -178.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.422 ' CE1' HD22 ' A' ' 161' ' ' LEU . 0.0 OUTLIER -134.05 166.09 23.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.202 179.428 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.937 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 2.0 mp . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.756 0.312 . . . . 0.0 110.615 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -156.13 149.23 24.33 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 111.401 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.96 136.0 53.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.439 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -151.85 169.78 31.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.405 -0.903 . . . . 0.0 112.911 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.2 140.05 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.688 0.28 . . . . 0.0 110.714 179.663 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 90.3 p -144.77 175.0 10.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.93 0.395 . . . . 0.0 111.343 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -142.57 159.61 41.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.736 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . 0.415 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.75 0.31 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.431 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.0 OUTLIER -151.09 130.02 12.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.859 -179.924 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.5 m-85 -131.22 135.79 47.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.751 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.43 140.43 21.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.864 0.364 . . . . 0.0 111.341 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.86 173.74 43.42 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.696 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -125.5 141.25 12.84 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.297 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.479 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.4 OUTLIER -130.66 149.08 52.48 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.093 0.473 . . . . 0.0 111.434 -179.787 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 31.9 tp -127.53 153.83 45.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.492 -179.947 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.393 -0.283 . . . . 0.0 112.393 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -119.97 149.1 42.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 111.177 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -153.69 152.11 23.76 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.398 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.84 148.04 28.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.776 0.322 . . . . 0.0 111.049 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.43 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 35.9 p90 -135.38 118.17 16.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -143.2 129.02 3.58 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.069 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -137.09 169.12 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.963 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.431 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 29.8 p90 -134.34 134.59 41.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.35 . . . . 0.0 110.846 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 . . . . . 0 C--N 1.327 -0.378 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.808 179.99 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.934 0.397 . . . . 0.0 111.355 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 174.5 20.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.369 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -83.61 144.52 29.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.655 0.264 . . . . 0.0 110.703 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -128.05 125.23 38.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.884 0.373 . . . . 0.0 111.137 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.8 tpp -106.45 127.51 53.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.569 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.92 148.28 17.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.672 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -127.23 120.03 27.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.696 0.284 . . . . 0.0 110.648 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -97.62 122.71 41.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.899 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.876 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.865 0.364 . . . . 0.0 110.747 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.62 139.29 14.32 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.911 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.65 122.77 61.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.712 0.291 . . . . 0.0 110.292 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.02 136.97 47.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.111 0.481 . . . . 0.0 111.721 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.9 tt -121.08 104.73 10.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.624 -0.717 . . . . 0.0 109.291 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.6 p -145.93 171.37 14.94 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.251 0.548 . . . . 0.0 112.078 -178.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -106.09 131.07 53.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.373 -0.83 . . . . 0.0 109.864 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 19.6 ttpt -116.55 132.12 56.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.148 0.499 . . . . 0.0 111.682 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -127.65 131.33 49.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.626 -0.716 . . . . 0.0 109.587 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.426 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -132.28 175.43 19.86 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 -179.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -166.1 134.4 2.36 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.698 -0.251 . . . . 0.0 110.701 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 C--N 1.347 0.471 0 C-N-CA 122.588 2.192 . . . . 0.0 112.39 179.998 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.523 -0.061 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -139.75 161.84 36.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.131 0.491 . . . . 0.0 111.811 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.6 tt -114.51 144.93 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.037 179.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.426 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 60.7 m-85 -141.68 138.21 32.3 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.362 . . . . 0.0 111.445 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.87 128.18 30.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.715 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 18.6 mtm105 -118.38 127.91 54.13 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.264 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -134.38 122.78 23.06 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.491 179.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -178.93 -137.86 3.02 Favored Glycine 0 C--N 1.332 0.332 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.456 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.468 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -139.14 160.72 25.9 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.923 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 8.4 ptp -120.7 137.28 54.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.759 0.314 . . . . 0.0 110.775 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -131.62 113.2 22.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.842 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.7 p-90 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.917 -179.91 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.7 p . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.702 0.287 . . . . 0.0 110.969 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -157.12 149.22 17.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.777 0.322 . . . . 0.0 111.557 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.468 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 87.5 Cg_endo -80.59 140.9 13.54 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.923 2.416 . . . . 0.0 112.126 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 31.2 m -156.91 160.56 2.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.004 0.431 . . . . 0.0 111.583 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -149.06 130.28 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.377 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -116.51 155.37 28.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.895 0.378 . . . . 0.0 111.502 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.34 136.49 7.93 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.22 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -162.85 -165.24 19.59 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.854 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -133.72 170.72 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.554 0.216 . . . . 0.0 110.95 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -146.72 149.7 33.93 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.941 0.401 . . . . 0.0 111.266 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 24.8 p90 -137.04 132.18 33.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.631 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.04 135.52 34.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.52 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.0 t . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.823 179.662 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.42 HG12 ' CE2' ' A' ' 190' ' ' TYR . 45.1 mt . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.781 0.324 . . . . 0.0 110.941 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -126.76 167.62 15.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.357 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.73 144.71 40.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.172 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.61 132.47 44.07 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.124 0.488 . . . . 0.0 111.89 -179.307 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -115.55 117.08 29.35 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.498 178.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.8 mm-40 -107.04 145.03 32.85 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.127 0.489 . . . . 0.0 111.634 -178.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.425 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 48.9 t80 -133.95 158.28 43.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.455 179.656 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.008 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . 0.425 ' HG ' ' CD1' ' A' ' 163' ' ' TYR . 2.5 mp . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.774 0.321 . . . . 0.0 110.687 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 28.9 t -128.53 145.38 51.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.115 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.42 136.59 46.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.584 179.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . 0.479 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -154.63 -176.86 27.38 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.942 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -126.64 135.9 62.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.647 0.261 . . . . 0.0 110.442 179.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 189' ' ' SER . . . . . 0.43 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 43.3 p -130.84 165.37 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.208 0.528 . . . . 0.0 111.721 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . 0.447 ' N ' ' CD1' ' A' ' 190' ' ' TYR . 2.2 m-85 -124.96 143.19 51.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.471 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 8.6 mtp180 . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.905 -179.813 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.457 -0.087 0 CA-C-O 120.782 0.325 . . . . 0.0 110.735 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 10.3 t90 -111.09 132.91 53.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.088 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.427 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 2.7 t80 -122.57 135.79 54.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.383 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.59 146.93 25.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.953 0.406 . . . . 0.0 111.5 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.01 -172.84 45.44 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.482 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.65 148.57 20.24 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.489 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.27 151.0 47.21 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.072 0.463 . . . . 0.0 111.354 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 18.7 tp -122.12 145.53 48.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.29 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.794 -179.854 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.417 -0.273 . . . . 0.0 112.417 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -114.93 142.18 46.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.718 0.294 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.5 143.83 11.13 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.293 -0.956 . . . . 0.0 112.895 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -98.07 164.46 12.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.648 0.261 . . . . 0.0 110.668 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.439 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 52.2 p90 -152.38 141.03 20.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.062 0.458 . . . . 0.0 111.409 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -133.55 124.92 3.81 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.044 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -97.39 145.73 17.96 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.893 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -131.93 112.26 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.698 0.285 . . . . 0.0 110.574 179.783 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 5.1 mm100 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.101 -179.806 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.924 0.393 . . . . 0.0 111.256 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.67 159.19 26.82 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.313 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -82.9 127.57 33.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 110.566 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -114.64 127.08 55.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.966 0.412 . . . . 0.0 111.317 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.2 mtm -104.21 128.44 51.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.962 179.364 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.93 157.7 14.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.951 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -132.68 120.19 21.38 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.731 0.301 . . . . 0.0 110.508 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.418 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.8 OUTLIER -94.54 127.14 40.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.688 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t90 . . . . . 0 C--O 1.233 0.225 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.944 179.909 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.685 0.279 . . . . 0.0 110.547 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.418 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -81.66 128.08 8.27 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.795 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.2 m -133.21 117.77 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.716 0.293 . . . . 0.0 110.257 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -123.92 149.74 45.53 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.107 0.48 . . . . 0.0 111.791 -179.269 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.63 120.1 30.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.517 179.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.408 ' CB ' ' HA3' ' A' ' 115' ' ' GLY . 4.3 p -148.28 171.81 15.38 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-O 121.088 0.471 . . . . 0.0 111.789 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.37 123.04 47.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.987 178.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.5 tttt -114.74 132.33 56.48 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.107 0.479 . . . . 0.0 111.7 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.6 pp -126.83 125.69 42.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.341 179.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.418 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -145.45 160.08 28.02 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.419 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.483 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.2 OUTLIER -166.27 148.49 6.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.676 0.274 . . . . 0.0 111.483 -179.758 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.483 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 73.3 Cg_endo . . . . . 0 C--N 1.348 0.505 0 C-N-CA 122.807 2.338 . . . . 0.0 112.332 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.083 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 0.6 OUTLIER -124.39 155.14 39.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.258 0.552 . . . . 0.0 112.045 -178.999 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.415 ' CG2' HG11 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 151.76 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.937 178.984 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.418 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 20.1 m-85 -146.86 146.1 30.08 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.948 0.404 . . . . 0.0 111.706 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.3 m -142.54 129.87 21.1 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.325 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.24 130.22 52.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 121.02 0.438 . . . . 0.0 111.752 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.1 tt -133.59 122.94 24.25 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.252 179.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.408 ' HA3' ' CB ' ' A' ' 97' ' ' THR . . . -175.87 -140.8 3.57 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.576 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.53 161.52 27.37 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.888 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -119.53 146.55 45.37 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.847 0.356 . . . . 0.0 110.753 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -129.82 144.08 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.985 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.913 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.6 p . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.752 0.31 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.428 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 1.5 t -157.08 130.19 4.48 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.228 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 142' ' ' SER . 5.7 Cg_exo -73.8 147.31 39.37 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.639 2.226 . . . . 0.0 112.009 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.2 m -156.49 153.79 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.918 0.389 . . . . 0.0 111.46 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -149.1 124.05 10.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.658 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -117.75 145.81 44.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 0.0 111.339 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.49 132.72 5.91 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.226 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -163.32 -154.49 7.72 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.962 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.415 HG11 ' CG2' ' A' ' 110' ' ' ILE . 12.9 m -137.3 170.88 17.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.631 0.253 . . . . 0.0 110.949 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -147.25 150.75 35.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.953 0.406 . . . . 0.0 111.267 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . 0.423 ' CE2' ' HB ' ' A' ' 159' ' ' THR . 37.1 p90 -126.74 138.61 53.41 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.811 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.404 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -91.65 137.24 32.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.411 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 52.3 t . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.48 179.62 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 27.2 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.982 0.42 . . . . 0.0 111.554 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . 0.404 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.11 161.15 38.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.057 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' THR . . . . . 0.423 ' HB ' ' CE2' ' A' ' 151' ' ' TRP . 9.7 m -106.26 150.78 25.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.227 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? -137.09 142.23 42.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.172 0.511 . . . . 0.0 111.834 -179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.4 tt -123.65 117.89 26.02 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.601 178.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -107.82 141.11 39.89 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.979 0.419 . . . . 0.0 111.635 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.429 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 27.2 p90 -134.33 166.08 23.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.653 179.615 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.33 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.005 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.9 mp . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.792 0.33 . . . . 0.0 110.908 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 51.0 m -140.98 150.09 42.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.132 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.65 138.04 54.5 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.521 179.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -157.06 176.31 34.33 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.955 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -125.9 137.78 56.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.737 0.304 . . . . 0.0 110.496 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 189' ' ' SER . . . . . 0.439 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 3.6 p -138.59 171.57 14.17 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.377 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -148.0 156.62 42.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.642 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . 0.427 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.038 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.862 0.363 . . . . 0.0 110.843 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.417 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 2.7 m-90 -132.3 129.97 40.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.037 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.421 ' CZ ' ' HB3' ' A' ' 191' ' ' ARG . 0.2 OUTLIER -121.67 135.85 54.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.683 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.05 139.82 23.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.396 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.9 -158.56 20.49 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.417 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.79 149.65 21.52 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.534 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -130.61 154.91 47.37 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.055 0.455 . . . . 0.0 111.135 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.4 tt -127.04 141.7 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.641 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.592 -179.93 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.534 -0.226 . . . . 0.0 112.534 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -131.26 138.7 49.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.689 0.28 . . . . 0.0 110.863 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.62 156.32 26.8 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.336 -0.935 . . . . 0.0 112.921 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.45 133.84 49.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.717 0.294 . . . . 0.0 110.844 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -119.75 127.17 52.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.967 0.413 . . . . 0.0 111.075 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.56 124.85 2.18 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.139 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -128.5 173.38 19.17 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.798 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.417 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 21.7 p90 -154.02 131.75 11.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 110.781 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.883 -179.894 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.233 0.219 0 CA-C-O 120.764 0.316 . . . . 0.0 111.191 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.03 175.17 19.61 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.44 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -95.7 134.71 38.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.417 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 0.0 OUTLIER -114.67 128.41 56.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -114.15 119.76 38.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.33 179.437 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 154.59 16.48 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.481 -0.866 . . . . 0.0 112.783 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 -130.09 114.83 16.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.579 0.228 . . . . 0.0 110.659 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.32 125.77 35.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.115 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 10.8 m95 . . . . . 0 C--N 1.331 -0.219 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.844 179.876 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 12.1 pm0 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.761 0.315 . . . . 0.0 110.734 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -82.26 130.94 10.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.586 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.47 119.74 55.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.786 0.327 . . . . 0.0 110.446 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 139.87 43.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.534 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.7 tt -130.25 110.88 11.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.972 179.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.49 168.94 22.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.993 0.425 . . . . 0.0 111.565 -179.147 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.401 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -104.1 125.91 50.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.197 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.424 ' HD2' ' CD1' ' A' ' 111' ' ' TYR . 0.6 OUTLIER -104.25 132.21 50.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.997 0.427 . . . . 0.0 111.752 -179.165 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.8 pp -134.82 115.74 14.01 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.388 179.114 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.05 41.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.672 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -166.28 167.05 8.83 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.713 0.292 . . . . 0.0 111.116 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo . . . . . 0 C--N 1.347 0.476 0 C-N-CA 122.488 2.125 . . . . 0.0 111.941 179.635 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.44 ' CD2' ' CE2' ' A' ' 151' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.074 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.408 ' HB2' ' CG ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -125.41 152.95 44.16 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.225 0.536 . . . . 0.0 112.009 -178.903 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.93 130.88 73.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.044 179.291 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.424 ' CD1' ' HD2' ' A' ' 99' ' ' LYS . 53.1 p90 -144.06 153.62 42.38 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.915 0.388 . . . . 0.0 111.526 -179.446 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 2.1 t -136.94 133.11 35.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.69 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 5.8 ptp180 -111.42 128.36 55.96 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.145 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -124.64 123.61 40.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.619 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 178.82 -132.46 1.9 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.547 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.463 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -148.24 169.08 28.94 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.821 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.07 139.86 51.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.795 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -126.17 132.9 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.809 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 85.3 t90 . . . . . 0 C--N 1.33 -0.252 0 CA-C-O 120.864 0.364 . . . . 0.0 110.95 -179.822 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.2 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.697 0.284 . . . . 0.0 111.054 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.27 150.12 18.33 Favored Pre-proline 0 C--N 1.331 -0.217 0 CA-C-O 120.922 0.392 . . . . 0.0 111.421 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.463 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -78.77 141.14 16.91 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.758 2.306 . . . . 0.0 112.133 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.5 m -156.86 160.66 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.855 0.36 . . . . 0.0 111.418 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.6 p90 -141.6 122.47 14.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.472 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -111.8 138.2 48.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.962 0.41 . . . . 0.0 111.473 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -127.66 138.22 10.32 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.818 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -163.71 -165.71 21.34 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.078 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 17.2 m -135.47 167.05 26.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.659 0.266 . . . . 0.0 111.149 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.408 ' CG ' ' HB2' ' A' ' 109' ' ' ASP . 13.4 pt-20 -136.34 141.09 43.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.999 0.428 . . . . 0.0 111.172 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . 0.44 ' CE2' ' CD2' ' A' ' 108' ' ' LEU . 0.0 OUTLIER -122.31 123.07 40.57 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.628 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.16 131.86 35.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.013 179.948 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 28.3 mt . . . . . 0 C--O 1.232 0.178 0 CA-C-O 120.809 0.337 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.25 163.77 14.8 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.385 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.9 t -110.8 143.24 41.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.098 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 146.64 45.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.28 0.562 . . . . 0.0 111.855 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -116.63 124.8 50.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.698 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -116.51 141.01 48.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.029 0.442 . . . . 0.0 111.524 -179.181 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 14.2 p90 -134.22 157.61 45.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.468 179.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 -179.93 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 5.9 mp . . . . . 0 C--O 1.233 0.194 0 CA-C-O 120.719 0.295 . . . . 0.0 110.741 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.99 155.58 41.69 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.996 0.427 . . . . 0.0 111.221 -179.768 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.53 139.08 50.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.355 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -153.53 171.1 32.35 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.281 -0.961 . . . . 0.0 113.166 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.5 137.23 57.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.694 0.283 . . . . 0.0 110.489 179.584 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 77.9 p -140.77 174.95 10.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.992 0.425 . . . . 0.0 111.294 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -137.41 157.1 47.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.585 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . 0.421 ' HB3' ' CZ ' ' A' ' 20' ' ' TYR . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.916 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 68.9 p . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.82 0.343 . . . . 0.0 110.81 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.9 m95 -139.88 138.54 35.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.979 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.7 m-85 -131.8 135.88 47.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.685 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.71 146.03 30.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.322 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.36 -177.62 48.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.9 150.29 21.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.441 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.448 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -135.57 153.68 51.61 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 111.21 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.9 tp -124.03 147.93 47.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.541 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.481 179.992 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.88 133.42 51.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.767 0.317 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.407 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -139.73 137.95 8.85 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.881 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -99.5 144.76 28.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.803 0.335 . . . . 0.0 110.563 179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.425 ' CE2' ' HD3' ' A' ' 24' ' ' LYS . 51.3 m-85 -136.16 133.52 37.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.035 0.445 . . . . 0.0 111.345 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.73 126.52 2.22 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.963 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -125.58 169.45 17.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.839 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.408 ' CE2' ' HB3' ' A' ' 68' ' ' PHE . 42.6 p90 -147.12 135.53 21.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.846 -179.935 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.906 0.384 . . . . 0.0 111.148 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.43 159.53 22.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.472 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.408 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . 0.8 OUTLIER -82.09 144.86 30.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.554 0.216 . . . . 0.0 110.706 179.928 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.93 127.29 33.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.422 . . . . 0.0 111.074 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.0 ptp -109.26 133.21 53.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.86 17.34 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.766 -179.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.407 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 14.6 m-85 -129.93 118.13 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.615 0.245 . . . . 0.0 110.55 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.0 122.0 37.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.133 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.083 179.885 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.758 0.313 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.78 135.37 12.11 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.937 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.32 117.98 46.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.798 0.333 . . . . 0.0 110.123 179.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . 0.401 ' CG ' ' CB ' ' A' ' 117' ' ' MET . 8.2 mt-30 -108.86 145.39 35.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.192 0.52 . . . . 0.0 111.925 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.3 tt -130.02 110.32 11.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.256 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.8 p -150.22 170.04 19.9 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.233 0.54 . . . . 0.0 111.984 -178.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.51 45.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.014 178.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -118.85 131.95 56.1 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.062 0.458 . . . . 0.0 111.581 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -131.85 121.67 24.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.96 179.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.423 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -115.95 -177.02 18.34 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.088 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -166.07 122.58 0.99 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 115.803 -0.198 . . . . 0.0 110.71 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo . . . . . 0 C--N 1.349 0.567 0 C-N-CA 122.435 2.09 . . . . 0.0 112.391 -179.925 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.435 HD23 ' CD1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 N--CA 1.461 0.087 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -143.07 159.64 41.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.101 0.477 . . . . 0.0 111.628 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.414 ' HA ' ' HA ' ' A' ' 149' ' ' VAL . 1.3 pt -114.64 154.81 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.316 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.423 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 91.5 m-85 -143.04 138.57 30.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.664 -179.508 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 31.6 m -125.2 127.63 47.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.313 179.393 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -116.54 127.88 54.92 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.38 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -137.96 122.58 18.59 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.511 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 179.26 -137.7 3.24 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.524 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.428 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.93 162.34 27.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.945 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.401 ' CB ' ' CG ' ' A' ' 95' ' ' GLN . 2.2 ptt? -119.63 142.31 48.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.801 0.334 . . . . 0.0 110.771 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -133.88 123.81 45.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.688 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 61.8 p-90 . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.003 -179.945 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.9 p . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.705 0.288 . . . . 0.0 111.012 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -157.01 137.38 8.99 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.329 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.428 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 89.4 Cg_endo -81.09 143.47 14.26 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 122.682 2.254 . . . . 0.0 112.084 179.75 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 29.2 m -157.08 163.53 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 111.516 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -149.04 126.36 11.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.574 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -111.91 152.48 27.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.906 0.384 . . . . 0.0 111.267 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.0 131.45 4.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.239 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.426 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -161.03 -160.05 10.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.824 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 5.5 m -134.41 167.72 25.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.628 0.252 . . . . 0.0 110.951 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -134.8 137.05 43.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.007 0.432 . . . . 0.0 111.189 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . 0.435 ' CD1' HD23 ' A' ' 108' ' ' LEU . 1.4 t90 -114.91 123.32 48.85 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.574 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.81 130.74 36.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.523 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.852 179.647 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.1 mt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.703 0.287 . . . . 0.0 111.008 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.32 168.55 18.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.952 0.406 . . . . 0.0 111.242 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 29.1 p -113.43 153.18 29.04 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.135 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 14.8 ptp180 -137.19 141.66 42.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 111.892 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -121.54 118.16 28.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.656 178.853 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -108.34 143.66 36.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.97 0.414 . . . . 0.0 111.768 -178.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.426 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.2 p90 -134.25 162.88 30.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.509 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.782 -179.935 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.5 mp . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.839 0.352 . . . . 0.0 110.973 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 30.2 t -118.52 147.42 43.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.768 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -126.52 139.36 53.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.709 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . 0.448 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -156.67 -177.03 29.43 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.414 -0.898 . . . . 0.0 113.063 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.3 m -130.82 142.84 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.675 0.274 . . . . 0.0 110.598 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 89.0 p -143.24 170.83 15.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.998 0.427 . . . . 0.0 111.449 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 44.3 p90 -138.66 154.88 48.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.58 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 t . . . . . 0 N--CA 1.458 -0.059 0 CA-C-O 120.868 0.366 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -151.1 129.87 12.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.009 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.408 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 28.5 m-85 -127.24 135.92 51.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.718 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.15 146.29 30.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.359 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.45 168.73 38.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.566 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.75 143.7 14.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.446 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . 0.449 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 2.8 pttp -131.97 146.52 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.095 0.474 . . . . 0.0 111.286 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 23.1 tp -121.14 152.03 39.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.514 -179.934 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.258 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -110.87 151.01 28.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.817 0.341 . . . . 0.0 111.078 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -143.36 122.92 1.97 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.82 135.93 35.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.682 0.277 . . . . 0.0 110.895 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.422 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 24.9 p90 -124.99 127.46 47.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.212 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.8 124.97 1.76 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.011 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -148.22 -172.59 18.32 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.759 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -150.63 156.03 40.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.871 0.367 . . . . 0.0 110.853 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.83 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.88 0.371 . . . . 0.0 111.434 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.91 177.0 19.43 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.249 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -99.74 134.59 42.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.619 0.247 . . . . 0.0 110.841 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.8 tp10 -124.03 131.51 53.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.989 0.424 . . . . 0.0 111.076 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 6.9 tpt -111.44 130.28 55.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.544 179.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.84 153.32 17.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.558 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 34.2 m-85 -134.19 114.95 13.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.829 0.347 . . . . 0.0 110.746 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.6 122.22 33.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.017 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.88 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 . . . . . 0 C--O 1.23 0.039 0 CA-C-O 120.678 0.275 . . . . 0.0 110.607 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.23 128.42 9.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.074 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.43 117.85 48.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -112.16 145.62 39.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.182 0.515 . . . . 0.0 112.016 -178.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -134.93 112.81 10.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.249 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.7 p -150.81 172.99 14.74 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.228 0.537 . . . . 0.0 112.027 -178.448 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.12 131.41 48.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.83 178.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.424 ' HD2' ' CD1' ' A' ' 111' ' ' TYR . 3.4 ttpt -118.79 132.11 56.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.101 0.477 . . . . 0.0 111.738 -179.035 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -134.95 133.64 39.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.916 179.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.429 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -147.62 -179.41 23.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.182 -1.009 . . . . 0.0 113.102 -179.437 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -166.3 128.84 1.44 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.734 -0.233 . . . . 0.0 110.654 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo . . . . . 0 C--N 1.348 0.523 0 C-N-CA 122.391 2.061 . . . . 0.0 112.116 -179.97 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.051 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.403 ' OD1' ' CE2' ' A' ' 111' ' ' TYR . 8.8 t70 -144.46 155.7 43.85 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.065 0.46 . . . . 0.0 111.751 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.0 tt -114.51 132.36 63.87 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.022 179.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.429 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 25.5 m-85 -133.14 147.64 52.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.975 0.417 . . . . 0.0 111.734 -179.307 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.49 129.55 23.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.446 179.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -121.33 129.13 52.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.424 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.4 tt -134.85 122.7 22.4 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.488 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -176.94 -136.98 2.54 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.467 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.12 161.62 27.58 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.801 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.11 142.96 48.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.777 0.322 . . . . 0.0 110.706 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.5 t -130.36 138.42 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.89 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 70.5 p-90 . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.963 -179.99 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.764 0.316 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.2 p -156.41 129.61 4.45 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.301 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.418 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 84.5 Cg_endo -77.92 142.57 19.95 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.595 2.197 . . . . 0.0 112.11 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.8 m -157.07 162.4 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.015 0.436 . . . . 0.0 111.455 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.01 124.04 11.39 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.484 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.03 137.12 52.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.862 0.363 . . . . 0.0 111.458 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.04 134.26 7.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.07 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -159.39 -157.31 8.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.919 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -135.18 167.78 24.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.805 0.336 . . . . 0.0 111.207 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -131.42 140.24 49.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.969 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -124.38 125.77 44.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.771 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -88.1 137.11 32.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.423 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 99.2 t . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.95 179.848 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 157' ' ' ILE . 18.0 mt . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.757 0.313 . . . . 0.0 110.954 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -117.76 162.45 18.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.213 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 61.1 p -100.99 150.83 22.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.145 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 4.6 ttt85 -137.14 133.12 34.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.062 0.458 . . . . 0.0 111.951 -179.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.11 119.23 33.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.448 178.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -110.04 145.22 37.42 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.189 0.519 . . . . 0.0 111.907 -178.569 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.43 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 8.4 t80 -131.79 147.87 52.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.232 179.474 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.388 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . 0.43 ' HG ' ' CD1' ' A' ' 163' ' ' TYR . 2.4 mp . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.801 0.334 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 88.1 p -121.13 146.5 46.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.084 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -125.48 141.04 52.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.647 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -161.7 -176.96 34.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.952 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -128.74 140.54 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.621 0.248 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 189' ' ' SER . . . . . 0.422 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 97.1 p -139.51 175.0 9.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.055 0.455 . . . . 0.0 111.464 -179.497 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 14.8 p90 -146.85 151.43 37.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.653 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . 0.408 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 25.0 ptt-85 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.927 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.2 t . . . . . 0 C--O 1.233 0.198 0 CA-C-O 120.814 0.34 . . . . 0.0 110.771 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -150.66 130.03 12.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.988 -179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -138.91 136.32 35.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.778 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 143.18 38.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.354 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.12 -157.9 10.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.541 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.22 145.87 15.32 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.597 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.91 156.08 32.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.939 0.4 . . . . 0.0 111.107 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -135.66 138.76 43.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.611 179.709 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.357 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.542 -179.891 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.374 -0.29 . . . . 0.0 112.374 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -132.76 156.72 46.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.843 0.354 . . . . 0.0 111.157 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.58 154.64 25.71 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.451 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.43 124.7 39.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.74 0.305 . . . . 0.0 110.946 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -111.69 119.06 37.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.039 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.75 124.94 2.84 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.058 179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.17 165.59 25.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.771 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.424 ' CZ ' ' HB2' ' A' ' 68' ' ' PHE . 4.9 p90 -154.26 134.78 13.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.994 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.1 mt-30 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.714 179.981 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.851 0.358 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -123.71 169.83 15.92 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.394 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . 0.424 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 50.9 m-85 -83.98 134.49 34.64 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.682 0.277 . . . . 0.0 110.853 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.66 112.08 19.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.741 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.4 mtp -104.43 118.1 35.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.552 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.0 152.32 17.28 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -130.7 115.02 16.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.846 0.355 . . . . 0.0 110.576 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -81.66 123.13 28.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.023 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.861 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.8 0.333 . . . . 0.0 110.722 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -95.92 134.01 11.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.753 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.68 117.86 54.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.755 0.312 . . . . 0.0 110.447 179.536 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -109.01 137.89 46.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.074 0.464 . . . . 0.0 111.744 -179.1 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.617 179.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 p -149.36 166.28 29.51 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.072 0.463 . . . . 0.0 111.796 -178.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.65 127.7 52.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.1 179.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.84 132.14 56.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.031 0.443 . . . . 0.0 111.749 -179.145 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 4.0 pp -130.09 130.14 44.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.316 179.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -154.03 -173.52 23.17 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.442 -0.885 . . . . 0.0 113.032 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -166.15 148.95 6.4 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 120.596 0.236 . . . . 0.0 110.885 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.414 ' HA ' ' CB ' ' A' ' 109' ' ' ASP . 89.1 Cg_endo . . . . . 0 C--N 1.345 0.383 0 C-N-CA 122.73 2.287 . . . . 0.0 112.7 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.639 0.257 . . . . 0.0 110.561 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.414 ' CB ' ' HA ' ' A' ' 103' ' ' PRO . 2.7 p30 -144.91 157.89 43.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.887 0.375 . . . . 0.0 111.603 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.408 ' CG2' ' CG1' ' A' ' 149' ' ' VAL . 1.1 pt -120.81 144.5 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.471 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 4.7 p90 -148.05 149.07 31.42 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 121.225 0.536 . . . . 0.0 111.83 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 21.4 p -130.64 133.2 45.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.988 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.402 ' NE ' ' CB ' ' A' ' 146' ' ' ALA . 0.2 OUTLIER -115.46 130.73 56.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.063 0.459 . . . . 0.0 111.707 -179.261 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.44 ' HB2' ' CD2' ' A' ' 145' ' ' PHE . 7.9 tt -126.26 122.63 36.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.153 179.267 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -178.29 -142.09 4.56 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.294 -0.955 . . . . 0.0 112.869 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.446 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.73 169.08 25.35 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.771 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.4 tmm? -127.57 137.84 52.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.849 0.357 . . . . 0.0 110.948 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -127.29 127.7 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.674 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 2.9 p-90 . . . . . 0 C--N 1.328 -0.354 0 CA-C-O 120.798 0.333 . . . . 0.0 110.987 -179.912 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.696 0.284 . . . . 0.0 110.994 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.463 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -157.18 141.38 11.75 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.436 -179.978 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 142' ' ' SER . 5.8 Cg_exo -73.91 153.41 47.54 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.869 2.379 . . . . 0.0 111.858 179.719 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.0 m -156.74 162.92 1.48 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.181 0 CA-C-O 121.221 0.534 . . . . 0.0 111.764 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' PHE . . . . . 0.44 ' CD2' ' HB2' ' A' ' 114' ' ' LEU . 10.2 t80 -143.05 118.84 10.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.256 179.619 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.402 ' CB ' ' NE ' ' A' ' 113' ' ' ARG . . . -117.15 140.96 48.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.991 0.424 . . . . 0.0 111.16 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.07 134.89 7.16 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.152 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.03 -167.5 21.58 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.81 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.417 HG21 ' CZ2' ' A' ' 151' ' ' TRP . 4.1 m -127.18 160.02 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.869 0.366 . . . . 0.0 111.042 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.433 ' HG2' ' HB3' ' A' ' 160' ' ' ARG . 1.4 tm-20 -120.85 136.39 54.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' TRP . . . . . 0.417 ' CZ2' HG21 ' A' ' 149' ' ' VAL . 37.5 m95 -120.78 120.27 35.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.469 179.525 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.43 119.0 32.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.571 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 40.5 t . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.807 179.569 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 3.5 mp . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.829 0.347 . . . . 0.0 111.144 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.77 161.82 17.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.946 0.403 . . . . 0.0 111.35 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -131.39 144.02 50.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.173 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.433 ' HB3' ' HG2' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -137.1 155.12 50.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.243 0.544 . . . . 0.0 112.009 -179.288 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.408 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.4 OUTLIER -120.41 121.45 38.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.635 179.006 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -107.41 145.05 33.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.116 0.484 . . . . 0.0 111.787 -178.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' TYR . . . . . 0.408 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 5.7 m-85 -129.86 151.36 50.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.491 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.029 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 184' ' ' LEU . . . . . 0.403 ' CD1' ' N ' ' A' ' 184' ' ' LEU . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.782 0.325 . . . . 0.0 110.717 . . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.9 m -131.87 151.52 51.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.93 0.395 . . . . 0.0 111.282 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -120.22 134.46 55.25 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.347 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -146.41 165.36 28.29 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.231 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.22 139.83 50.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.376 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.56 168.58 19.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.103 0.478 . . . . 0.0 111.694 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -123.47 146.61 47.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.466 179.624 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.958 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.326 0 CA-C-O 120.878 0.371 . . . . 0.0 111.044 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.99 91.29 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 22.8 mt -134.79 138.85 48.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.131 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.1 tpt -64.58 131.1 46.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.982 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.84 66.42 1.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.847 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -113.47 -73.45 0.66 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.04 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.1 pt -147.05 30.64 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.094 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -120.49 72.59 0.96 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.832 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 10.2 m -83.85 130.7 35.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.111 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -110.74 -31.28 7.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.908 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -71.41 -50.7 29.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.908 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -147.5 139.37 24.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.174 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.76 168.15 7.64 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.035 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.38 61.04 3.39 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.529 2.152 . . . . 0.0 112.437 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 3.8 mptt -153.16 128.19 9.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.85 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -89.3 41.08 1.02 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.289 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -108.11 80.84 1.41 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.863 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m -108.03 161.84 14.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.906 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.425 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.8 t-105 -146.62 129.9 16.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.423 ' CE1' ' HA3' ' A' ' 59' ' ' GLY . 6.1 p90 -136.92 139.65 41.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.795 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.08 149.49 52.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.197 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.75 -164.44 22.37 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.471 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.16 138.59 6.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.583 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 pttp -120.18 150.92 39.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.985 0.421 . . . . 0.0 111.033 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.0 tp -129.27 139.66 51.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.595 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.81 -139.38 3.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.531 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 11.0 m0 -112.42 133.87 54.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.779 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 m -97.77 -48.68 5.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.942 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -130.48 158.14 40.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.02 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 18.6 t80 -176.7 146.24 0.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.864 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.1 t60 -102.77 126.48 49.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -137.31 -47.56 0.58 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -99.0 156.02 17.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.934 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.74 154.94 30.18 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.465 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -144.71 -178.63 6.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.817 0.341 . . . . 0.0 110.937 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -139.79 153.23 47.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.17 40.13 2.53 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.51 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -109.22 140.15 43.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.885 0.374 . . . . 0.0 110.847 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -61.84 -41.46 99.63 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.483 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -79.99 105.89 11.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.84 0.353 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -101.72 -65.48 0.98 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.886 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -109.11 96.87 6.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.96 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 18.2 p-10 -69.13 -37.06 78.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.843 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -131.97 144.42 50.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.799 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -130.45 65.39 0.59 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.52 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.51 -173.39 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.517 2.145 . . . . 0.0 112.248 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.44 25.65 5.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.064 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -142.3 112.01 6.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.899 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -98.78 58.57 1.19 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.854 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -75.67 88.91 2.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.95 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 -125.73 95.22 4.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.834 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -132.23 124.89 29.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.059 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.98 132.09 10.47 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.304 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -99.95 144.52 28.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.768 0.318 . . . . 0.0 110.996 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -147.75 122.97 1.63 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.88 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.87 125.71 39.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.635 0.255 . . . . 0.0 110.459 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.423 ' HB2' ' NH2' ' A' ' 160' ' ' ARG . 2.8 m-85 -115.24 145.93 41.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.045 0.45 . . . . 0.0 111.583 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -144.92 124.84 2.23 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.786 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.423 ' HA3' ' CE1' ' A' ' 20' ' ' TYR . . . -123.13 146.98 16.64 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.035 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.425 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 53.4 p90 -153.53 126.04 8.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.851 0.358 . . . . 0.0 110.771 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -96.16 137.18 35.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 43.1 t -111.56 -30.27 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.092 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -137.35 153.62 74.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.799 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.26 63.61 1.08 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.596 2.198 . . . . 0.0 112.296 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -154.36 -45.61 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.971 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -168.79 163.71 11.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.913 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -127.24 155.09 19.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.435 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 2.4 m-85 -82.79 141.56 32.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.617 0.246 . . . . 0.0 110.564 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -125.67 118.67 26.13 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.88 0.371 . . . . 0.0 111.133 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 10.3 mtt -108.19 124.72 50.7 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.5 179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 163.05 12.47 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.541 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.404 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 57.4 m-85 -137.54 114.91 11.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.684 0.278 . . . . 0.0 110.76 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.43 114.96 22.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.059 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 17.0 t90 -139.16 148.83 43.72 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.097 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.4 tp 61.86 157.86 0.05 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.897 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 160.52 -28.21 0.32 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.518 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 11.7 ttt180 -112.16 149.63 31.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.762 0.315 . . . . 0.0 110.946 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -107.2 104.85 14.58 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.838 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -171.64 98.46 0.18 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.146 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -153.08 75.89 1.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.889 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.1 tttm -163.59 100.46 0.91 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.876 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -167.11 160.08 33.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.498 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 50.6 m -69.07 -48.15 63.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.329 . . . . 0.0 110.924 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.5 m -140.98 128.82 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.107 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -116.58 -177.7 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -117.83 146.55 43.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.898 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -145.46 39.21 1.18 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.551 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -64.07 -61.04 2.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.81 0.338 . . . . 0.0 111.055 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -112.63 142.48 45.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.905 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 4.4 mtmp? -107.58 138.37 43.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.79 145.57 30.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.97 131.91 7.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.715 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -85.59 135.3 13.29 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.639 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -123.81 122.03 63.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -108.88 142.25 39.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.189 0.519 . . . . 0.0 111.878 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -128.6 114.5 16.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.617 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -153.69 165.2 36.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.066 0.46 . . . . 0.0 111.739 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.02 129.73 51.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.307 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.53 132.2 55.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.051 0.453 . . . . 0.0 111.517 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.8 pp -132.76 127.8 35.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.279 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.24 -171.66 23.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.971 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.414 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.09 147.06 5.64 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.897 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.414 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 90.6 Cg_endo -81.03 171.7 13.81 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.745 2.297 . . . . 0.0 112.617 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 18.4 mm -106.1 -30.88 2.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.727 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 4.5 m -154.9 -62.35 0.12 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.71 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 177.89 45.64 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.586 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 21.9 p-10 179.07 -30.11 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.49 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -112.67 122.33 47.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.617 0.246 . . . . 0.0 110.367 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -141.41 152.84 44.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.041 0.448 . . . . 0.0 111.763 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.434 ' CG2' ' CG1' ' A' ' 149' ' ' VAL . 1.1 pt -116.93 146.24 21.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.318 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -153.59 156.34 37.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.111 0.481 . . . . 0.0 111.693 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 68.2 p -136.37 135.72 39.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.246 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.35 128.33 55.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.998 0.427 . . . . 0.0 111.518 -179.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.6 tt -126.78 124.45 39.73 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.445 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 178.71 -133.56 2.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.462 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -153.24 168.68 32.02 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.404 -0.903 . . . . 0.0 112.939 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -119.17 141.99 48.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.785 0.326 . . . . 0.0 110.731 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -135.03 112.01 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.73 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.419 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 40.7 p-90 -129.14 161.04 30.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.914 0.388 . . . . 0.0 111.115 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 11.6 ptm180 -112.08 155.55 23.67 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.874 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -89.93 157.53 17.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.129 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.86 127.45 32.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.92 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 13.3 t -61.24 164.26 5.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.898 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -72.13 135.89 46.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.913 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.64 -144.78 4.02 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.426 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 24.6 m-20 -87.38 66.6 9.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.927 0.394 . . . . 0.0 110.889 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -105.01 162.34 13.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.813 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -135.22 109.39 8.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.088 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -139.78 156.14 46.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.5 p -138.1 30.67 2.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.901 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 179.96 -71.46 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.451 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 12.3 p -101.0 120.44 50.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.829 0.347 . . . . 0.0 111.018 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.4 p -170.66 164.12 8.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 23.8 mtt180 -111.61 104.57 12.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.877 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 23.9 m -110.83 31.81 5.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -127.68 161.53 28.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 6.2 p80 -122.6 72.81 1.09 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.899 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -112.47 166.64 11.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.861 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 26.5 p -105.15 119.92 40.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.419 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -79.14 127.51 8.04 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.4 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.9 p -146.02 130.18 11.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.674 0.274 . . . . 0.0 111.136 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.1 134.76 7.04 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.349 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.41 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 96.4 Cg_endo -79.99 142.32 15.48 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.633 2.222 . . . . 0.0 112.12 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.9 m -156.84 158.48 3.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.968 0.413 . . . . 0.0 111.46 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.423 ' CZ ' ' HB2' ' A' ' 181' ' ' ASN . 5.0 p90 -149.04 124.04 10.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.582 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -119.7 168.86 10.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.933 0.396 . . . . 0.0 111.23 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.57 138.77 6.58 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.382 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -160.77 -159.7 10.14 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.756 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.434 ' CG1' ' CG2' ' A' ' 110' ' ' ILE . 5.7 m -130.66 166.91 27.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.702 0.287 . . . . 0.0 110.933 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -136.03 148.09 48.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.873 0.368 . . . . 0.0 111.178 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 10.1 m0 -131.29 128.68 40.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.791 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.53 122.53 40.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.303 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 45.5 t -110.32 -64.82 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 1.4 m -81.75 171.2 14.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 4.2 mtt-85 -67.14 -26.69 66.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.119 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -143.83 31.45 1.29 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.155 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 15.9 mt -151.1 100.85 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.221 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.82 167.72 10.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.189 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 22.3 p -125.52 144.41 50.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.354 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.423 ' NH2' ' HB2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 153.45 50.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.127 0.489 . . . . 0.0 111.87 -179.504 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.5 tt -126.55 124.38 39.86 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.913 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 184' ' ' LEU . 2.8 mt-10 -106.83 145.15 32.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.162 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.405 ' CE1' HD22 ' A' ' 184' ' ' LEU . 0.7 OUTLIER -131.16 166.02 22.04 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.625 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.28 -34.35 28.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.067 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -108.97 156.97 19.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.98 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 23.1 t -117.57 145.06 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.004 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -59.98 -40.75 90.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.956 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -114.75 -179.86 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.905 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 8.4 tt -139.39 119.63 14.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.108 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -77.43 -100.75 0.18 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.494 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -128.15 134.22 49.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.794 0.331 . . . . 0.0 110.86 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -163.76 131.65 3.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.086 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -104.75 -31.49 4.49 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.509 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.0 t -151.35 148.54 28.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.802 0.334 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 31.4 m -132.92 119.96 39.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -121.19 90.39 0.46 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.448 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 2.3 p -137.87 104.45 5.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.849 0.357 . . . . 0.0 110.935 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . 0.407 ' N ' ' HD2' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -73.32 -61.02 1.55 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.198 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 178' ' ' ARG . 36.5 Cg_endo -66.34 -52.22 0.88 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.42 2.08 . . . . 0.0 112.47 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -173.56 170.31 4.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.984 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . 0.423 ' HB2' ' CZ ' ' A' ' 145' ' ' PHE . 9.7 p30 -96.72 -44.62 7.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.953 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -138.49 -170.68 11.92 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.564 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.98 132.36 25.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.763 0.316 . . . . 0.0 110.852 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . 0.41 ' HA ' ' O ' ' A' ' 162' ' ' GLU . 1.0 OUTLIER -89.55 136.55 32.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.817 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 12.7 p -171.07 166.73 7.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.97 0.414 . . . . 0.0 111.547 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.64 140.15 49.72 Favored 'General case' 0 N--CA 1.462 0.134 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.275 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -154.06 171.21 32.69 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 119.945 -1.122 . . . . 0.0 113.48 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.48 139.85 50.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.683 -0.259 . . . . 0.0 110.359 179.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 83.6 p -134.95 175.08 9.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.041 0.448 . . . . 0.0 111.497 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -145.38 149.81 35.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.696 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -78.94 156.98 28.29 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.942 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -78.49 90.36 4.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.913 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -118.68 134.59 10.96 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.474 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.77 111.32 3.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.891 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -82.21 156.43 24.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.9 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.77 161.43 25.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.84 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -148.93 131.09 15.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.029 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -144.03 128.26 9.22 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.059 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.75 93.78 0.04 OUTLIER 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.432 2.088 . . . . 0.0 112.276 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 21.2 t -141.98 95.09 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 14.6 m -79.43 69.89 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.044 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . 0.4 ' CB ' ' CD ' ' A' ' 203' ' ' PRO . . . -75.75 -61.03 0.96 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.212 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . 0.4 ' CD ' ' CB ' ' A' ' 202' ' ' ALA . 63.5 Cg_endo -73.58 -44.45 0.51 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.577 2.185 . . . . 0.0 112.514 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -70.98 112.05 12.0 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.159 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -77.03 111.79 3.3 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.469 2.113 . . . . 0.0 112.424 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . 0.415 ' CB ' ' HD3' ' A' ' 207' ' ' PRO . . . -93.18 -55.05 0.24 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.289 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . 0.415 ' HD3' ' CB ' ' A' ' 206' ' ' ALA . 53.8 Cg_exo -52.45 98.99 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.5 2.133 . . . . 0.0 112.39 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . 0.419 ' CB ' ' CD ' ' A' ' 209' ' ' PRO . . . -83.68 -62.88 0.26 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.262 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . 0.419 ' CD ' ' CB ' ' A' ' 208' ' ' ALA . 64.0 Cg_endo -74.37 -45.96 0.31 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 122.399 2.066 . . . . 0.0 112.444 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.895 -179.979 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.856 0.36 . . . . 0.0 110.998 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 6.8 ptp180 -132.57 84.61 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.94 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.3 pt -121.63 153.7 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.126 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.4 ttp -138.93 101.34 4.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.963 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.13 139.3 50.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.9 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -98.35 33.69 2.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.024 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.7 tt -71.91 111.73 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.073 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -159.14 81.76 0.77 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.846 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.4 t -115.98 -59.02 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.065 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -92.86 165.85 12.7 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.843 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 27.8 m120 -89.02 53.33 2.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -94.5 114.62 26.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.095 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.7 147.4 78.27 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.97 -40.62 2.48 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.596 2.198 . . . . 0.0 112.367 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.8 ttmt -131.85 111.15 11.35 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.95 167.41 9.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.02 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -108.07 -71.48 0.76 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.937 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 t -156.7 154.28 29.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.826 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -121.29 132.32 54.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -129.76 135.97 49.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.974 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.45 141.63 29.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.232 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.23 -172.14 41.49 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.586 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.08 148.24 19.71 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.98 152.52 51.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.937 0.398 . . . . 0.0 111.278 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -130.35 148.75 52.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.443 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -164.23 -165.35 21.32 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.542 -0.837 . . . . 0.0 112.772 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -143.12 160.36 40.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.925 0.393 . . . . 0.0 111.142 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.66 145.87 46.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.919 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -146.85 117.03 7.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.9 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -119.09 170.47 9.04 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.914 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 8.3 t60 -143.5 124.02 14.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.953 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -134.58 153.24 52.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.949 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 2.7 t -109.71 -29.28 8.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.971 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 102.98 141.03 11.21 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.483 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -116.69 -67.78 0.97 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.893 0.378 . . . . 0.0 110.836 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -129.61 -51.81 1.16 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.883 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.88 119.32 6.37 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.467 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -74.74 -36.88 62.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.339 . . . . 0.0 110.808 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -136.29 -169.63 11.79 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -108.79 170.12 8.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.862 0.363 . . . . 0.0 110.839 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -61.97 -50.38 72.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -92.34 143.54 26.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -60.26 98.09 0.06 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.904 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -129.34 106.12 8.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.915 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.61 138.26 5.86 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.469 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -74.64 -173.93 1.69 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.622 2.215 . . . . 0.0 112.299 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.0 p -144.84 -73.12 0.25 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.2 mmt85 -148.21 29.88 0.87 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.91 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -119.68 162.83 18.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.005 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -98.62 176.77 5.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 1.3 tp-100 -106.31 84.23 2.0 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.839 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.75 144.77 50.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.825 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -154.43 159.2 28.74 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.458 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -116.52 161.08 19.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.762 0.315 . . . . 0.0 110.938 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -163.81 146.64 11.77 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.681 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -96.25 160.99 14.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.73 0.3 . . . . 0.0 110.898 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.411 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 19.6 p90 -151.6 139.52 19.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.988 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -136.33 125.05 3.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.349 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -98.13 129.98 10.08 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.581 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -129.14 110.24 11.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.82 0.343 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -89.5 137.02 32.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.805 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 22.6 t -133.6 -49.41 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.966 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -107.05 143.71 27.65 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.591 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.02 73.08 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.329 2.019 . . . . 0.0 112.236 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -177.05 -38.69 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.206 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -168.35 164.05 12.89 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.095 -179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 165.22 22.11 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 -81.83 132.49 35.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.775 0.322 . . . . 0.0 110.624 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -112.08 115.92 29.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.172 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -105.53 115.48 30.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.17 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.8 157.25 15.17 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.803 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -128.95 129.56 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.738 0.304 . . . . 0.0 110.718 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.401 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.9 OUTLIER -96.34 121.01 37.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.754 -179.979 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -136.8 118.64 15.16 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.785 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.23 81.09 1.86 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.877 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 155.33 173.38 23.98 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.469 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.61 -173.01 2.4 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.801 0.334 . . . . 0.0 111.002 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.7 mmm -99.12 31.36 3.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.825 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -107.44 56.75 0.63 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.134 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -112.51 -34.8 5.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.986 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 17.8 mttt -59.37 150.27 26.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.861 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -92.83 -149.02 24.24 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -154.85 -46.8 0.09 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 110.912 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.9 p -135.09 42.82 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -86.08 -176.9 6.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -113.21 -61.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.867 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -69.47 -158.79 1.93 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.484 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -116.0 130.82 56.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.931 0.396 . . . . 0.0 111.075 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . 0.41 ' CE2' ' HA ' ' A' ' 123' ' ' SER . 0.7 OUTLIER -116.96 109.4 16.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 -179.982 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.85 135.87 19.96 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -148.75 133.48 17.88 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 17.8 tt0 -175.12 138.98 0.46 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.567 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.401 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -84.3 141.27 19.73 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.718 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.89 121.03 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.746 0.308 . . . . 0.0 110.31 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -108.91 136.09 49.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.055 0.455 . . . . 0.0 111.817 -179.233 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.6 tt -122.18 106.57 11.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.58 179.296 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 7.5 p -145.45 168.77 19.75 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.044 0.449 . . . . 0.0 111.644 -178.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.68 121.97 45.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.009 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.34 132.42 56.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.146 0.498 . . . . 0.0 111.885 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.4 pp -126.96 127.39 44.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.814 179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -120.2 -177.49 16.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.323 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.416 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 24.3 t80 -166.11 123.12 1.02 Allowed Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.455 0.169 . . . . 0.0 110.738 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.416 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 83.7 Cg_endo -78.02 160.64 30.15 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.457 2.105 . . . . 0.0 112.671 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 17.9 mm -116.28 -37.51 2.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -161.62 39.2 0.13 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.065 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 57.56 47.86 15.33 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.935 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -177.56 -38.19 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.64 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -117.53 105.29 11.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.164 179.688 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.04 163.27 23.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.066 0.46 . . . . 0.0 111.451 -179.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.408 ' HA ' ' HA ' ' A' ' 149' ' ' VAL . 1.6 pt -114.79 158.93 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.343 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -156.09 138.74 15.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.028 0.442 . . . . 0.0 111.604 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.8 t -132.99 126.94 33.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.243 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -118.47 130.46 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.954 0.407 . . . . 0.0 111.43 -179.416 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -131.52 122.84 26.82 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.438 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -176.37 -140.18 3.44 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.591 -179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.417 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -138.6 163.31 25.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.832 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.1 ptt? -122.26 135.65 54.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.764 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.17 119.81 49.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 19.4 t90 -114.52 143.75 44.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.021 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 14.2 mtp180 -140.18 119.95 13.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.954 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.39 155.21 50.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.087 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -159.24 131.69 6.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.847 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' SER . . . . . 0.41 ' HA ' ' CE2' ' A' ' 89' ' ' PHE . 32.0 t -130.59 96.28 4.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 6.4 mtmt -125.89 88.14 2.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.746 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -84.9 79.11 1.94 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.575 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -112.73 144.58 42.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.892 0.377 . . . . 0.0 110.892 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -82.89 -35.25 26.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.886 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -116.2 -176.04 2.87 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.08 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 39.1 t -106.91 44.21 1.08 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.939 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.8 t -70.6 161.17 31.19 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.914 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -105.36 157.15 16.47 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.588 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.0 m -144.55 163.78 13.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.735 0.302 . . . . 0.0 111.16 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 65.2 m -79.12 -34.01 43.78 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.818 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 12.3 ttt85 -104.02 144.45 31.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -124.35 154.59 40.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.985 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.91 84.85 2.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.79 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 11.5 t-160 -141.64 121.28 13.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.91 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -131.85 148.35 52.54 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 5.1 t -133.4 115.84 15.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -90.4 132.25 11.17 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.486 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.1 p -146.05 126.13 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.733 0.301 . . . . 0.0 111.152 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t -157.1 143.18 12.94 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.291 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.417 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 98.9 Cg_endo -79.55 147.45 19.9 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.658 2.239 . . . . 0.0 112.113 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.7 m -156.98 161.83 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.951 0.405 . . . . 0.0 111.528 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.8 p90 -149.01 119.44 7.37 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.572 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -109.79 129.07 55.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.935 0.398 . . . . 0.0 111.321 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.4 124.98 4.05 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.224 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.412 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -158.56 -152.16 6.33 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.309 -0.948 . . . . 0.0 113.04 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.408 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 6.1 m -135.48 167.31 25.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 111.317 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -136.8 137.4 39.75 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -119.93 127.25 52.49 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.731 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -88.43 124.34 33.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.479 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.401 ' O ' ' CG2' ' A' ' 154' ' ' THR . 53.1 t -116.07 60.06 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.824 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' THR . . . . . 0.401 ' CG2' ' O ' ' A' ' 153' ' ' VAL . 14.6 t 45.85 -168.56 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.366 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 9.5 tpp180 57.6 21.87 7.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.266 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 56.29 24.3 8.09 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.204 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 6.5 mt -129.3 137.48 56.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -131.69 158.82 40.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.314 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.0 141.63 33.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.201 179.558 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -124.29 122.95 39.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.11 0.481 . . . . 0.0 111.881 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.402 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 1.4 tt -117.41 116.69 27.67 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.536 178.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.48 145.02 36.92 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -178.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.412 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.4 p90 -133.99 165.77 24.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.557 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -178.12 108.16 0.05 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.877 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 24.1 t90 -162.88 118.92 1.83 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 10.7 p -124.23 120.28 58.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.079 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -113.88 -37.71 4.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -70.15 67.34 0.3 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.856 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 2.7 pp -153.25 30.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -96.56 59.74 1.28 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.43 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -97.35 126.72 42.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.778 0.323 . . . . 0.0 110.927 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -131.47 125.87 33.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.11 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -137.01 -63.97 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.564 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 25.6 p -113.51 -42.47 3.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.822 0.344 . . . . 0.0 110.892 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 15.8 m -130.27 166.17 28.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.008 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -111.76 164.18 12.14 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.491 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.4 m -136.79 158.37 44.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.839 0.352 . . . . 0.0 111.024 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -98.49 103.61 19.45 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.81 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.0 137.48 37.77 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.396 2.064 . . . . 0.0 112.314 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -119.73 111.56 18.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.819 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 11.7 p-10 -96.29 150.33 20.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -110.94 -149.35 11.71 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.51 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -155.37 167.03 31.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.837 0.351 . . . . 0.0 110.956 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 7.2 mp -94.8 153.98 17.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.776 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 67.2 m -152.44 150.89 30.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.949 0.404 . . . . 0.0 111.298 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -116.31 145.18 43.38 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.454 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -160.64 173.66 37.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.921 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 2.1 m -127.49 138.16 55.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.759 0.314 . . . . 0.0 110.652 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 189' ' ' SER . . . . . 0.411 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 60.7 p -139.86 170.59 15.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.258 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 1.9 p90 -147.95 160.02 43.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 -95.15 150.15 20.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.929 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -67.63 109.19 3.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.81 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -140.97 -171.03 12.36 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.529 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 -126.33 82.03 2.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.847 0.356 . . . . 0.0 110.903 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -93.6 171.36 8.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.001 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -127.6 164.53 21.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.95 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -132.33 33.5 3.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.167 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -151.83 73.97 7.87 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -78.35 55.86 5.58 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.656 2.237 . . . . 0.0 112.436 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 10.8 p -118.44 -29.15 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.356 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 24.9 t -117.61 148.5 20.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.212 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -114.01 112.42 47.34 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.982 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.16 110.83 2.08 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.47 2.113 . . . . 0.0 112.2 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -112.52 91.5 17.11 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.188 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_exo -51.01 119.61 5.57 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.534 2.156 . . . . 0.0 112.426 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -77.39 -53.23 1.64 Allowed Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.12 112.17 0.86 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.484 2.123 . . . . 0.0 112.381 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -69.99 -61.05 3.13 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.08 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -72.66 144.54 39.86 Favored 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.534 2.156 . . . . 0.0 112.303 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.985 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.303 0 CA-C-O 120.888 0.375 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 10.9 mtp180 -151.57 -47.15 0.11 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.866 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.2 mt -84.97 136.23 23.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.959 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -138.11 40.03 2.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.979 0.419 . . . . 0.0 110.763 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.8 mttt -140.25 115.65 9.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.846 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.91 96.55 1.7 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.066 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.92 157.64 3.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.079 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -158.84 116.31 2.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -131.42 -66.76 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.145 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -148.89 72.78 1.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.929 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 26.6 m-20 -76.97 -59.73 2.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.021 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -123.99 31.46 5.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.095 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -108.75 116.68 55.57 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.034 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.72 -44.69 1.96 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.372 2.048 . . . . 0.0 112.325 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.3 mttm -150.84 119.27 6.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.943 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.94 83.87 0.67 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.799 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -87.84 137.49 32.29 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.939 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -154.66 177.01 11.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.933 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.413 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.2 OUTLIER -141.83 154.58 45.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.885 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.424 ' CE1' ' HB3' ' A' ' 191' ' ' ARG . 1.2 m-85 -145.71 135.92 23.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.801 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.34 140.0 27.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.222 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.7 -171.55 41.27 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.424 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.04 150.46 22.69 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.368 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.32 154.57 48.4 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.898 0.38 . . . . 0.0 111.114 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 49.4 tp -128.17 139.6 52.39 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.528 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -146.41 171.31 27.29 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.545 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 1.5 m-90 -78.97 144.51 34.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.765 0.317 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.65 -69.47 0.75 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.829 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 50.4 mt-30 -146.82 155.18 42.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.898 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -117.96 122.17 42.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -70.18 105.75 3.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.926 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 32.0 p-10 -116.29 -38.44 3.57 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.907 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 61.1 m -59.4 -57.93 10.84 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.01 -154.52 26.64 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.393 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -141.62 -69.35 0.37 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.818 0.342 . . . . 0.0 110.858 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 8.2 p90 -156.81 175.23 14.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.931 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -158.43 93.81 0.13 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.534 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 23.1 m-20 -77.21 -52.02 9.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 111.015 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -157.72 -65.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.511 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 76.9 t80 -85.65 139.87 31.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.778 0.323 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -151.32 172.34 16.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.868 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -116.63 81.07 1.57 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.936 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -75.23 -57.32 3.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.887 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -144.94 39.75 1.23 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.913 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -92.03 -91.54 1.43 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.56 -61.74 0.45 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.588 2.192 . . . . 0.0 112.367 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.8 p -138.99 156.53 47.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 4.2 ptp180 -119.25 -40.41 2.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.95 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 21.8 p30 -59.27 162.14 4.87 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.852 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -114.74 -172.11 2.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -55.79 158.0 3.92 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.921 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.5 pp -139.01 164.82 28.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.042 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -131.47 134.47 7.7 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.488 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -101.19 139.88 36.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.02 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -145.57 126.85 2.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.424 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.89 141.82 28.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.747 0.308 . . . . 0.0 110.97 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -123.8 126.16 45.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.957 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -154.65 124.99 1.62 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -157.98 -168.31 20.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.413 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 8.8 p90 -154.97 161.08 41.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.782 0.325 . . . . 0.0 110.807 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -109.58 135.22 50.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.9 t -141.46 29.22 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.036 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -162.32 163.53 18.36 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.78 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.37 -40.8 69.99 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.611 2.207 . . . . 0.0 112.328 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 24.7 p90 -148.63 37.59 0.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.899 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -139.39 115.7 10.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.798 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 153.49 19.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.525 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.07 128.37 42.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.66 0.266 . . . . 0.0 110.439 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -122.2 130.16 52.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.984 0.421 . . . . 0.0 111.417 -179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 19.1 mtt -118.97 127.17 53.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.328 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.73 158.2 14.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.495 -0.859 . . . . 0.0 112.699 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -129.18 114.94 16.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.781 0.324 . . . . 0.0 110.78 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -83.41 115.55 22.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.889 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.7 t90 -139.08 133.85 32.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.931 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.85 69.38 1.12 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.882 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 177.41 -144.97 6.94 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.41 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.0 ttt180 -165.9 156.61 13.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.773 0.32 . . . . 0.0 110.875 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 6.7 ttt -63.39 96.85 0.12 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.897 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -154.45 -174.49 4.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.007 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -58.78 178.79 0.1 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.93 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.7 mttp -60.79 125.5 23.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.881 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -87.46 -94.26 0.94 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.498 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 19.1 m -74.89 177.16 6.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.787 0.327 . . . . 0.0 110.905 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 17.1 m -123.99 120.94 60.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.205 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -166.27 163.01 17.7 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -134.83 138.79 44.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 129.27 -93.66 0.34 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.488 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -66.55 -30.74 71.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.819 0.342 . . . . 0.0 111.099 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 12.0 t80 60.93 95.01 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.893 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.35 -177.61 0.1 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.888 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.04 160.92 38.64 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.074 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -158.45 125.06 4.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.668 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -99.68 142.64 16.07 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.122 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.76 122.1 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -108.8 140.32 42.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.065 0.459 . . . . 0.0 111.678 -179.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.4 tt -128.43 116.21 19.39 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.751 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -153.97 164.38 38.52 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.035 0.445 . . . . 0.0 111.84 -178.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.25 124.98 46.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.285 179.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -102.76 132.53 48.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.029 0.442 . . . . 0.0 111.71 -179.255 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -134.95 124.16 24.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.347 179.296 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -156.3 -175.84 27.73 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.821 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -166.02 159.97 12.85 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.656 0.265 . . . . 0.0 110.993 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -73.97 169.79 21.59 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.631 2.22 . . . . 0.0 112.132 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -122.26 -39.85 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.495 -0.321 . . . . 0.0 111.367 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 71.8 p -136.78 -59.17 0.72 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.021 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -166.81 -42.95 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.166 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -125.35 28.15 6.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.272 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -143.37 119.09 10.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.081 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -136.76 160.01 40.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 111.812 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -115.09 147.27 18.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.219 179.436 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -149.06 145.13 27.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.114 0.483 . . . . 0.0 111.51 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -137.81 129.82 28.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.179 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -111.93 133.11 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.081 0.467 . . . . 0.0 111.522 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.424 ' HB2' ' CD2' ' A' ' 145' ' ' PHE . 7.8 tt -124.34 122.86 38.87 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.296 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 179.91 -134.07 2.16 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.815 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.452 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -151.43 169.1 30.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.933 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -122.68 138.82 54.49 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 111.24 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.1 125.89 60.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.503 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 1.1 p-90 -150.95 179.88 7.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 111.244 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.0 mtm180 -97.93 161.2 13.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.899 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.69 134.2 40.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.992 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -144.8 162.03 37.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.902 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 19.7 p -163.79 -44.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 21.9 mtpt -102.51 112.63 25.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.907 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -177.59 107.66 0.24 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.505 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -142.8 -50.64 0.36 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.817 0.342 . . . . 0.0 110.946 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -112.96 118.01 33.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -96.63 152.76 18.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.044 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -137.79 165.39 26.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 7.1 p -91.15 98.84 11.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.841 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -105.63 140.2 15.01 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.541 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 21.5 t -66.81 -44.78 88.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.842 0.353 . . . . 0.0 111.123 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.3 m -75.81 166.56 23.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.955 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -128.07 100.56 5.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.935 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 25.5 p -82.34 153.12 25.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.883 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 17.0 mm-40 -80.0 170.84 15.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.914 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.0 p-80 -114.38 163.0 15.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.954 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -76.21 141.28 41.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.89 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 78.3 p -135.07 147.69 49.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.968 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -116.42 135.56 12.16 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.329 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.9 p -146.07 127.67 7.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.645 0.26 . . . . 0.0 111.132 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -157.07 142.67 12.64 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.496 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.452 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 4.7 Cg_exo -73.93 153.4 47.47 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.834 2.356 . . . . 0.0 111.768 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.8 m -156.33 161.19 2.0 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 121.084 0.469 . . . . 0.0 111.717 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.424 ' CD2' ' HB2' ' A' ' 114' ' ' LEU . 10.5 t80 -142.94 118.96 10.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.237 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.49 136.38 52.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.014 0.435 . . . . 0.0 111.397 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -133.73 125.74 4.05 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.004 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -157.96 -164.99 14.67 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.354 -0.927 . . . . 0.0 112.873 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 6.8 m -131.75 162.68 39.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.806 0.336 . . . . 0.0 111.046 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.51 140.11 51.36 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.188 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 18.8 m95 -123.22 120.02 31.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.808 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.51 126.71 35.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.391 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 48.4 t -116.14 -68.6 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.009 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.88 -173.69 2.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.903 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 5.0 mtt-85 -75.05 -31.81 61.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.957 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -146.26 36.06 1.0 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.114 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 17.7 mt -149.52 100.95 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.035 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -116.47 168.83 9.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.008 0.432 . . . . 0.0 111.362 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 5.8 t -126.77 144.41 50.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.198 179.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 150.19 47.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.232 0.539 . . . . 0.0 112.016 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.413 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.9 OUTLIER -115.56 122.35 45.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.482 178.943 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -111.94 145.09 40.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.05 0.452 . . . . 0.0 111.7 -178.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.413 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 17.5 m-85 -128.71 147.05 50.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.657 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -58.87 -53.65 55.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.978 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 3.9 m95 -143.63 134.06 24.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.788 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 23.1 m -85.67 -32.9 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.177 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -85.37 168.38 14.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.835 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -128.88 -52.01 1.23 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.83 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 7.6 pt -69.58 157.53 6.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.105 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -162.92 -87.81 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.546 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -138.05 144.5 41.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.787 0.327 . . . . 0.0 110.899 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -115.75 108.19 16.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.137 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -99.93 -28.52 7.31 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.445 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 68.7 p -125.43 -47.73 1.72 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.724 0.297 . . . . 0.0 110.866 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 11.3 p -156.51 158.5 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.119 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.59 55.34 4.69 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.413 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.5 m -138.75 59.67 1.62 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.971 0.415 . . . . 0.0 110.861 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 16.1 mtm-85 -79.59 155.24 76.19 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.941 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.05 134.95 50.97 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.512 2.141 . . . . 0.0 112.304 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -100.14 146.79 26.41 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.974 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 60.65 160.68 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.872 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -131.49 -85.22 0.31 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.586 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 4.4 tpp -147.88 149.18 31.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.829 0.347 . . . . 0.0 110.863 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -130.49 136.12 48.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.784 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 9.5 t -138.51 147.88 43.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.389 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.8 131.97 54.01 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.407 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.85 168.63 28.71 Favored Glycine 0 N--CA 1.453 -0.213 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.236 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.1 m -127.99 143.51 40.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.671 0.272 . . . . 0.0 110.472 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.42 172.98 11.96 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 121.006 0.431 . . . . 0.0 111.468 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.7 p90 -138.05 160.03 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.424 ' HB3' ' CE1' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -113.26 141.88 46.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -91.41 106.65 18.65 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.819 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -122.73 152.89 16.89 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.515 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -90.81 140.42 29.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.773 0.32 . . . . 0.0 110.991 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -124.24 -71.51 0.71 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.928 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.36 91.08 3.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.93 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -81.97 98.81 8.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.051 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . 0.43 ' CB ' ' CD ' ' A' ' 199' ' ' PRO . . . -173.11 -63.05 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.171 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . 0.43 ' CD ' ' CB ' ' A' ' 198' ' ' ALA . 57.3 Cg_endo -70.74 72.03 1.96 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.464 2.109 . . . . 0.0 112.298 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 10.9 p -138.91 -45.67 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.085 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 20.8 m -127.67 141.15 47.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.103 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -119.48 135.74 24.23 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.071 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -77.52 105.98 2.13 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.584 2.189 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . 0.413 ' CB ' ' CD ' ' A' ' 205' ' ' PRO . . . -81.62 -61.93 0.36 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.105 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . 0.413 ' CD ' ' CB ' ' A' ' 204' ' ' ALA . 86.5 Cg_endo -77.98 58.27 6.46 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.589 2.193 . . . . 0.0 112.397 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -138.29 172.95 5.85 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_exo -51.95 -45.55 37.99 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.56 2.174 . . . . 0.0 112.293 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -131.61 140.31 37.94 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.107 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -75.0 -44.07 0.36 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.536 2.157 . . . . 0.0 112.363 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.916 -179.975 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.887 0.375 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.79 178.21 4.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.77 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.6 pt -73.1 81.77 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.102 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 13.8 mtt -127.96 54.56 1.7 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.928 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.09 173.94 11.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.931 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -58.9 179.4 0.09 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.146 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 mp -67.43 -50.28 63.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.092 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -117.03 139.47 50.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.931 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.6 t -106.29 72.23 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.2 pp -161.13 29.21 0.14 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.927 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -89.09 -61.29 1.74 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -167.91 -169.68 1.2 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.088 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -120.99 77.83 31.62 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.074 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -54.99 -36.32 92.18 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.618 2.212 . . . . 0.0 112.204 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.44 112.55 24.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.011 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -88.98 150.75 22.67 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.862 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -89.56 116.06 27.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.933 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.4 m -151.08 132.79 14.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.914 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 3.9 m-90 -135.64 148.4 48.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.106 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.427 ' CZ ' ' HA3' ' A' ' 59' ' ' GLY . 6.6 p90 -159.95 149.0 17.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.69 153.75 46.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.171 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.87 -171.18 38.07 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.463 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -143.7 147.64 19.06 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.39 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 3.1 pptp? -134.59 146.94 50.09 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.911 0.386 . . . . 0.0 111.043 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.9 tt -121.5 146.29 47.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.653 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -155.73 175.57 33.52 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.486 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 11.9 m-90 -108.55 159.93 16.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.791 0.329 . . . . 0.0 111.0 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 84.9 p -137.79 58.39 1.69 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.927 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -169.29 -169.75 0.99 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -95.98 148.06 23.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.948 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.2 t60 -147.66 -64.66 0.26 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 68.5 m-20 -146.35 31.9 0.99 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.94 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.5 154.8 19.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.863 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.37 -110.86 3.96 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.566 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 38.0 m-85 -122.46 -178.11 3.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.836 0.35 . . . . 0.0 110.922 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 13.4 m-85 -71.56 168.15 18.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.829 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -158.13 124.49 1.4 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.418 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -114.45 101.78 9.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.928 0.394 . . . . 0.0 110.866 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -160.91 -150.99 6.06 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.509 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -92.8 170.2 9.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.786 0.326 . . . . 0.0 110.886 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -113.16 -170.25 1.64 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -90.99 125.48 35.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.834 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 11.5 m-20 -131.6 -48.18 0.97 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -120.25 85.41 2.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.851 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -157.78 90.13 0.11 Allowed Glycine 0 CA--C 1.518 0.247 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.447 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -70.09 -28.18 23.99 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.49 2.126 . . . . 0.0 112.295 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 9.8 t -71.47 -31.32 67.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.901 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -59.56 107.41 0.58 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -127.35 134.62 49.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.846 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -75.72 151.6 37.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 21.7 mt-30 -109.12 87.98 2.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.813 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.21 139.41 42.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.922 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -139.3 143.09 13.52 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.436 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.428 ' HB2' ' CZ3' ' A' ' 74' ' ' TRP . . . -125.07 148.48 48.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.662 0.268 . . . . 0.0 110.837 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.44 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.04 147.85 18.48 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.322 -0.942 . . . . 0.0 112.937 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.83 128.76 53.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.635 0.255 . . . . 0.0 110.643 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -120.3 143.96 48.07 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 0.0 111.397 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -128.15 124.89 4.92 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.045 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.427 ' HA3' ' CZ ' ' A' ' 20' ' ' TYR . . . -100.3 139.72 14.56 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.987 -179.492 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -135.39 114.11 11.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.702 0.287 . . . . 0.0 110.593 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.79 126.76 33.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.256 -179.627 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 19.0 t -153.82 -44.22 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.105 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -80.55 173.64 7.4 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.895 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -65.95 98.69 0.37 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.868 2.379 . . . . 0.0 113.029 -179.255 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.408 ' OH ' ' CE2' ' A' ' 102' ' ' TYR . 0.2 OUTLIER 57.24 44.88 21.33 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.496 179.201 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.9 pp -176.65 115.72 0.11 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.871 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -107.14 177.02 21.46 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.548 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -90.55 142.77 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.833 0.349 . . . . 0.0 110.654 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -122.49 111.96 17.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.151 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.9 mtt -100.39 114.82 28.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.888 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 152.16 17.28 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.392 -0.909 . . . . 0.0 113.261 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.44 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 38.6 m-85 -130.3 114.96 16.28 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.5 122.94 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.763 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . 0.436 ' CD1' ' HA2' ' A' ' 55' ' ' GLY . 17.9 p-90 -139.2 148.09 42.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.646 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.09 176.25 5.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.041 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.24 178.94 39.92 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.523 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 10.3 ttt180 -98.15 30.05 3.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.818 0.342 . . . . 0.0 110.857 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 5.8 mtt -160.38 -172.63 3.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.778 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -167.54 -57.57 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.14 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -157.07 35.95 0.29 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 3.7 mtpm? -98.53 31.06 2.98 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.825 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.22 135.09 12.13 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.42 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 5.3 p -99.67 -39.09 8.44 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.77 0.319 . . . . 0.0 110.874 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -87.98 -31.8 5.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.074 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -135.43 148.8 49.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -84.3 -59.03 2.51 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.88 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.75 119.64 1.21 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.567 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.75 -30.61 14.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.338 . . . . 0.0 111.122 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 64.27 -78.93 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.97 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 3.0 mtmt -158.57 -54.67 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.904 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -176.37 -178.0 0.91 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.082 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -121.33 135.72 55.06 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.679 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.48 124.5 8.1 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.783 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.09 117.8 56.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.08 139.76 46.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.124 0.488 . . . . 0.0 111.831 -178.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.3 tt -129.98 110.97 12.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.556 179.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.407 ' CB ' ' HA3' ' A' ' 115' ' ' GLY . 2.5 p -150.02 178.12 9.24 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.083 0.468 . . . . 0.0 111.812 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.2 44.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.033 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 8.8 tttt -126.57 132.01 51.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.096 0.475 . . . . 0.0 111.841 -179.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.6 pp -134.55 123.96 24.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.981 179.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.427 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -126.24 -175.04 14.02 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.437 -0.887 . . . . 0.0 113.302 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.415 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 0.8 OUTLIER -166.15 122.96 1.0 Allowed Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 115.674 -0.263 . . . . 0.0 110.576 -179.881 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.415 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 58.3 Cg_endo -71.6 167.24 27.0 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.485 2.123 . . . . 0.0 112.672 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 20.4 mm -109.68 -63.96 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.714 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.99 -50.21 2.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.664 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.1 t0 179.05 -36.21 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.165 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -113.66 16.47 18.62 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -141.86 125.84 17.23 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.675 0.274 . . . . 0.0 110.443 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -145.07 159.28 43.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.009 0.433 . . . . 0.0 111.522 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 149' ' ' VAL . 1.3 pt -114.63 148.58 17.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.351 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.427 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 5.7 m-85 -138.13 144.46 40.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.049 0.452 . . . . 0.0 111.736 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -128.91 127.1 41.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.356 179.416 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.25 130.07 56.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.338 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.425 ' HB2' ' CE2' ' A' ' 145' ' ' PHE . 7.2 tt -137.4 122.95 19.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.636 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.407 ' HA3' ' CB ' ' A' ' 97' ' ' THR . . . 179.51 -143.05 5.5 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.431 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -146.23 163.86 28.37 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.929 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.57 144.37 49.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.807 0.337 . . . . 0.0 110.94 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.2 t -129.44 135.73 60.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 6.2 m95 -123.41 141.08 52.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.795 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 2.0 ptt180 -150.61 126.83 10.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.0 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -88.34 139.61 30.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.065 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 -156.68 156.89 34.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.936 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 30.9 t -126.24 112.12 15.37 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.952 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -143.82 90.95 2.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.789 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -108.84 168.27 13.39 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.479 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -88.05 -37.29 16.41 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.771 0.319 . . . . 0.0 110.885 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -110.26 31.71 5.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.972 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -135.62 171.99 13.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.048 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.2 m -86.28 141.78 29.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.925 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.7 m -84.92 107.79 17.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -69.96 135.3 26.13 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.517 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 8.9 m -120.35 -42.02 2.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.874 0.368 . . . . 0.0 111.125 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 22.5 t -76.45 107.21 8.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.853 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 15.4 mtt180 -68.44 104.97 2.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.929 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 93.4 p -106.12 -50.99 3.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.921 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -131.8 79.68 1.88 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.005 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -140.68 124.75 17.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -125.99 137.35 53.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.835 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 60.0 p -108.79 165.89 11.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.943 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -145.31 140.05 8.78 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.518 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.4 p -146.02 123.94 4.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 120.66 0.267 . . . . 0.0 110.948 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -157.14 152.91 22.63 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.803 0.335 . . . . 0.0 111.577 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.431 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 71.6 Cg_endo -77.04 162.1 32.17 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.769 2.313 . . . . 0.0 112.094 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.6 m -155.96 159.05 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.003 0.43 . . . . 0.0 111.503 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.425 ' CE2' ' HB2' ' A' ' 114' ' ' LEU . 10.5 t80 -147.24 118.89 7.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.486 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -115.78 122.54 45.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.25 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.405 ' O ' ' CD1' ' A' ' 163' ' ' TYR . . . -126.32 132.21 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.218 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.414 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -166.52 -153.76 7.98 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.817 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.448 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 6.0 m -134.7 170.53 19.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.63 0.253 . . . . 0.0 111.016 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -138.3 144.6 40.52 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.904 0.383 . . . . 0.0 111.317 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -127.24 133.51 50.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.566 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.71 137.2 36.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.64 -63.68 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 33.6 p -90.55 -169.47 2.4 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.295 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 4.5 mtp180 -96.38 38.89 1.17 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.919 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -179.58 -28.33 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.941 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 32.0 mt -111.7 133.13 58.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-O 120.943 0.402 . . . . 0.0 111.651 -179.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -140.03 155.53 47.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.089 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.8 m -101.02 149.97 23.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.481 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.06 134.2 36.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.068 0.461 . . . . 0.0 111.8 -179.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.4 tt -117.56 119.57 35.43 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.792 179.038 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -112.42 143.89 42.79 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.989 0.423 . . . . 0.0 111.703 -179.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.414 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 6.4 p90 -134.21 162.83 31.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.516 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -82.52 155.04 24.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.938 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 13.8 t-105 -140.82 -62.33 0.48 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.984 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 11.3 p -65.53 130.03 30.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.086 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 65.8 m-80 -127.88 120.66 28.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.951 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 30.3 m120 -111.27 83.27 1.74 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.877 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 4.4 tp -112.15 138.74 39.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.052 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -141.37 -51.61 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.472 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -99.29 159.98 14.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.775 0.321 . . . . 0.0 110.863 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -92.41 166.39 12.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.001 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -133.13 131.31 6.06 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.417 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.7 m -89.55 -62.06 1.56 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.798 0.332 . . . . 0.0 110.761 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 24.5 t -113.12 -40.81 3.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.033 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.31 158.63 31.56 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.464 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 30.8 p -143.6 99.51 3.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.871 0.367 . . . . 0.0 110.999 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . 0.404 ' CB ' ' CD ' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -72.98 -60.41 1.85 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.857 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . 0.404 ' CD ' ' CB ' ' A' ' 178' ' ' ARG . 63.2 Cg_endo -73.7 135.83 22.35 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.614 2.21 . . . . 0.0 112.301 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.7 101.55 12.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.833 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -66.09 130.06 41.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.896 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 64.12 137.2 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.393 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 1.6 ttp -162.06 109.17 1.35 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.758 0.313 . . . . 0.0 111.213 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.7 mp -125.11 141.45 52.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.703 179.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.8 m -141.51 151.55 43.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.926 0.394 . . . . 0.0 111.345 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -114.81 132.06 56.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.342 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -149.25 167.5 29.58 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.326 -0.94 . . . . 0.0 113.002 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.2 m -127.57 139.81 50.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.65 0.262 . . . . 0.0 110.706 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 80.6 p -140.11 173.98 10.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.999 0.428 . . . . 0.0 111.241 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -148.0 151.28 35.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.724 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 -86.32 153.51 21.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -83.03 119.2 24.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.819 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -108.78 156.57 15.61 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.398 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -77.5 -32.03 53.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.792 0.329 . . . . 0.0 110.871 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -94.57 123.99 38.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.904 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.19 144.94 28.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.945 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -109.24 118.07 35.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.016 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -72.1 154.43 92.33 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.128 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.23 164.23 1.32 Allowed 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.572 2.181 . . . . 0.0 112.271 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.92 103.99 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.142 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 21.3 t -102.05 84.83 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.042 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -124.07 117.76 26.95 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.061 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -73.52 -39.07 2.14 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.415 2.076 . . . . 0.0 112.48 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -89.09 159.45 45.18 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.253 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -53.98 134.83 61.43 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.664 2.243 . . . . 0.0 112.371 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . 0.422 ' CB ' ' CD ' ' A' ' 207' ' ' PRO . . . -88.37 -63.5 0.21 Allowed Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.446 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . 0.422 ' CD ' ' CB ' ' A' ' 206' ' ' ALA . 73.1 Cg_endo -76.12 161.94 34.86 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.44 2.093 . . . . 0.0 112.539 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -133.91 170.94 10.0 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.081 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -52.75 -31.23 50.08 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.475 2.117 . . . . 0.0 112.396 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.329 -0.844 . . . . 0.0 110.91 -179.964 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 120.773 0.32 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 39.6 mmt180 -136.94 -57.32 0.72 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 1.4 pt -75.03 113.52 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.095 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.5 tpt -102.49 39.73 1.47 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.873 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.3 tptm -150.0 36.86 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.838 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -95.18 -2.24 50.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.702 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 22.1 mt -98.09 30.63 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.844 0.354 . . . . 0.0 111.138 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -142.89 22.09 1.94 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.094 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 3.7 m -120.12 -32.75 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.348 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.6 mp -133.47 87.51 2.39 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.843 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 35.1 m120 -75.65 118.2 18.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.978 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -81.8 -76.36 0.26 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.131 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -117.87 92.96 43.07 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.134 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -54.98 152.22 30.48 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.542 2.161 . . . . 0.0 112.255 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -107.21 -44.39 4.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 55.5 m-20 -77.96 101.57 6.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.916 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -87.1 -43.77 12.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.858 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.55 131.8 13.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.683 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 64.4 p-90 -150.33 148.74 29.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.974 0.416 . . . . 0.0 111.165 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 9.5 p90 -130.91 143.35 50.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.652 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.62 149.64 52.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.234 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.456 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.62 -159.98 19.1 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.779 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -132.19 142.36 13.8 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.349 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.4 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -127.67 140.34 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.97 0.414 . . . . 0.0 111.127 -179.86 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 19.2 tp -128.08 141.01 51.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.461 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.11 -173.4 39.47 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.624 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 11.0 m0 -100.5 148.16 25.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.875 0.369 . . . . 0.0 110.858 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 32.2 p -117.69 175.37 5.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -151.64 90.69 1.58 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.873 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.451 ' CE2' ' CE ' ' A' ' 117' ' ' MET . 3.8 m-85 -133.82 106.03 7.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.909 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -107.73 121.52 44.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.849 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -136.31 31.71 2.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.2 p -101.27 -31.26 11.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.53 -116.08 5.42 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.483 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -151.67 128.83 11.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.866 0.365 . . . . 0.0 110.836 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -89.11 140.5 29.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.85 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.43 161.38 33.92 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.523 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -62.75 138.85 58.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.86 0.362 . . . . 0.0 110.892 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -110.25 179.86 20.52 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.476 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -74.39 -67.73 0.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -158.31 83.51 0.84 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -118.15 174.01 6.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 12.4 m-80 -129.3 163.24 26.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.932 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -122.08 165.99 15.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -81.95 -150.19 8.02 Favored Glycine 0 CA--C 1.519 0.285 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.493 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.11 171.43 0.18 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.564 2.176 . . . . 0.0 112.331 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.9 p -90.82 -55.12 3.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.938 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -87.33 146.08 26.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.931 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 -121.36 142.1 50.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.916 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -74.72 64.34 1.23 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.756 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -89.98 82.31 6.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.959 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.9 pp -127.72 144.35 51.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.84 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -123.81 135.85 9.99 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.473 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -134.94 136.03 41.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.799 0.333 . . . . 0.0 110.878 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.403 ' CA ' ' O ' ' A' ' 72' ' ' TYR . . . -156.07 166.56 33.09 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.693 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.97 155.01 16.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 110.706 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.455 ' CZ ' ' NH2' ' A' ' 113' ' ' ARG . 47.0 m-85 -143.69 132.49 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.934 0.397 . . . . 0.0 111.124 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -130.83 124.8 4.31 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.377 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -100.5 130.65 10.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.494 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -122.09 120.69 35.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.825 0.345 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.82 135.31 42.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.98 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 24.4 t -129.25 -47.26 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.833 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -117.94 146.22 38.54 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.589 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.4 67.9 0.7 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.434 2.09 . . . . 0.0 112.183 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -167.21 -40.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.277 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -167.78 164.14 14.2 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.943 0.401 . . . . 0.0 111.317 -179.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -134.98 166.04 24.47 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.323 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -86.18 132.95 33.9 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.783 0.325 . . . . 0.0 111.069 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.407 ' HB2' ' HG2' ' A' ' 99' ' ' LYS . 25.9 tt0 -109.98 112.09 23.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.171 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.0 mmt -108.28 111.98 24.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.945 179.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -118.37 163.74 12.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.35 -0.929 . . . . 0.0 113.104 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.403 ' O ' ' CA ' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -128.61 114.81 17.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.673 0.273 . . . . 0.0 110.471 179.701 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.69 129.63 34.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.416 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -132.69 124.81 28.92 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.633 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -141.64 173.19 11.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.924 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -135.23 178.89 18.23 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.451 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 60.47 171.93 0.09 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.807 0.337 . . . . 0.0 110.887 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -176.17 -66.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.929 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.99 -169.95 0.15 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.112 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -106.87 -42.16 5.01 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.921 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 16.8 mmtm -139.87 31.12 2.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -165.72 84.5 0.1 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.528 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -145.34 31.29 1.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.748 0.309 . . . . 0.0 110.868 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.5 m -107.93 71.58 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.096 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -118.08 -176.04 2.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.881 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -61.43 148.65 41.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.844 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.74 28.74 13.0 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.481 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -64.78 -59.54 4.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.837 0.351 . . . . 0.0 111.006 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -144.55 102.37 3.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 -67.69 0.85 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.827 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -175.17 161.29 2.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.236 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -145.11 128.88 17.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.617 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -94.68 131.64 10.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.87 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.52 121.8 66.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.28 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 17.7 mt-30 -108.79 134.6 51.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.037 0.446 . . . . 0.0 111.712 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.3 tt -128.86 112.48 14.17 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.868 179.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -151.1 162.47 40.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.077 0.465 . . . . 0.0 111.658 -178.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.9 122.37 43.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.041 179.102 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.407 ' HG2' ' HB2' ' A' ' 69' ' ' GLU . 0.0 OUTLIER -112.58 132.13 55.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.145 0.498 . . . . 0.0 112.071 -179.039 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.9 pp -122.49 128.39 50.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.807 178.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.426 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -119.96 -179.91 16.5 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.133 -179.201 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -166.08 125.84 1.2 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.763 -0.219 . . . . 0.0 110.664 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.01 163.7 32.7 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.553 2.169 . . . . 0.0 112.489 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 22.8 mm -119.45 -69.87 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.769 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -177.7 149.33 0.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.626 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 66.16 -74.95 0.06 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.972 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -168.72 59.8 0.06 Allowed 'General case' 0 C--O 1.233 0.232 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.335 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.415 HD23 ' CH2' ' A' ' 151' ' ' TRP . 0.1 OUTLIER -144.66 127.15 15.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.092 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -138.53 162.99 33.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.106 0.479 . . . . 0.0 111.722 -179.241 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.417 ' HA ' ' HA ' ' A' ' 149' ' ' VAL . 1.4 pt -114.81 157.06 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.28 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.426 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 96.3 m-85 -153.47 144.82 23.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.081 0.467 . . . . 0.0 111.73 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 38.8 p -142.48 126.96 17.8 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.167 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.455 ' NH2' ' CZ ' ' A' ' 57' ' ' PHE . 1.4 ppt_? -118.27 134.7 54.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.009 0.433 . . . . 0.0 111.78 -179.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.8 tt -133.63 122.9 24.13 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.078 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -177.65 -132.95 1.76 Allowed Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.602 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.437 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.43 165.55 31.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.302 -0.951 . . . . 0.0 113.082 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.451 ' CE ' ' CE2' ' A' ' 30' ' ' TYR . 1.7 ptt? -120.44 140.99 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.922 0.392 . . . . 0.0 110.744 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.8 t -134.32 124.5 45.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.926 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.426 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 54.2 p-90 -139.14 161.01 38.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.925 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 1.9 mmm-85 -138.18 130.59 29.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.861 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -141.74 142.65 33.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.058 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -151.93 162.04 41.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.896 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 8.3 t -93.86 47.2 1.21 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.816 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.8 33.56 3.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.894 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -99.64 -92.91 2.07 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.531 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -109.47 -31.25 7.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.855 0.36 . . . . 0.0 110.824 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -59.57 -36.97 77.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.934 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -94.97 110.98 22.82 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.002 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 15.0 p -143.4 -54.4 0.38 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.999 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.6 t -66.62 -39.86 88.52 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -179.69 166.87 36.38 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.504 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 9.0 p -178.38 67.47 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.897 0.38 . . . . 0.0 111.06 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 3.9 t -101.32 -46.86 4.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.94 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -59.69 -31.22 69.37 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.93 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.2 t -91.61 110.81 22.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.897 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -85.62 177.08 7.83 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.905 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -76.3 175.88 8.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.81 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -144.29 149.29 36.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.022 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.8 p -131.74 141.77 49.61 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.995 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.426 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -119.87 123.0 5.47 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.499 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.4 p -146.11 130.5 11.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.752 0.311 . . . . 0.0 111.029 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 36.2 t -157.22 140.65 11.23 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.293 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.437 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.4 Cg_endo -80.65 148.15 17.83 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.73 2.286 . . . . 0.0 112.259 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 33.9 m -156.27 159.07 2.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.989 0.423 . . . . 0.0 111.492 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -149.1 123.54 9.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.499 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.36 145.32 40.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.838 0.352 . . . . 0.0 111.425 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.64 133.66 6.22 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.265 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.415 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -169.76 -149.99 6.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.556 -0.831 . . . . 0.0 113.023 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.417 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 13.8 m -135.23 168.78 22.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.813 0.34 . . . . 0.0 111.396 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -131.6 136.61 47.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.881 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . 0.415 ' CH2' HD23 ' A' ' 108' ' ' LEU . 4.6 t-105 -125.14 131.59 53.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.033 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -91.53 137.2 32.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.074 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 62.2 t -112.34 -47.54 5.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.899 0.38 . . . . 0.0 110.86 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.08 -164.04 1.06 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.574 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.15 37.02 1.36 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.781 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . 0.439 ' HB3' ' CE2' ' A' ' 190' ' ' TYR . 0.4 OUTLIER 173.67 -28.39 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.405 179.953 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 7.5 mt -101.36 130.5 50.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.838 0.351 . . . . 0.0 110.988 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.47 160.18 38.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.187 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.1 m -100.96 153.34 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.45 124.99 29.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.294 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.1 tt -123.95 116.51 23.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.112 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . 0.415 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 42.1 mt-10 -136.32 145.17 45.16 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.143 0.497 . . . . 0.0 111.45 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -123.48 166.01 16.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.625 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 8.5 mm-40 -99.42 -179.11 4.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . 0.404 ' CE3' ' HA ' ' A' ' 165' ' ' TRP . 0.2 OUTLIER -61.28 111.55 1.79 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.977 180.0 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 11.0 p -130.69 139.01 52.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.041 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 19.0 p30 -105.96 157.79 17.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.924 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -144.23 -47.43 0.26 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.861 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 3.3 mp -60.7 -60.23 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.157 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -75.53 159.14 51.02 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.385 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 6.1 p30 -109.41 151.91 26.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.821 0.344 . . . . 0.0 110.944 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -95.27 153.34 17.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -105.51 64.91 0.29 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.489 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.2 p -148.69 -177.61 5.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.761 0.315 . . . . 0.0 110.919 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 16.1 m -85.05 136.32 23.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.111 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -163.37 163.14 35.4 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.532 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.9 m -109.9 -65.81 1.12 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.825 0.345 . . . . 0.0 110.881 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -119.07 78.98 17.62 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.888 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.67 84.96 0.77 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.484 2.122 . . . . 0.0 112.303 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -140.78 145.89 36.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.961 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 60.23 -178.97 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -137.68 -106.91 0.78 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.465 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 14.2 mtm -131.38 101.61 5.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.808 0.337 . . . . 0.0 110.972 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 5.9 mp -114.64 135.31 54.29 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.9 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -128.6 141.6 51.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.854 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.98 146.37 50.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.814 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . 0.4 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -163.42 -176.77 35.73 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.584 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.46 142.66 42.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.729 0.3 . . . . 0.0 110.825 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 189' ' ' SER . . . . . 0.456 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 29.6 t -135.96 161.03 36.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.152 0.501 . . . . 0.0 111.857 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . 0.439 ' CE2' ' HB3' ' A' ' 156' ' ' ASP . 7.0 t80 -125.01 135.16 52.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.363 179.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.403 ' O ' ' CE1' ' A' ' 190' ' ' TYR . 8.4 ptt180 -90.92 136.96 32.72 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.113 -179.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -142.01 151.52 42.54 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.837 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -144.28 171.01 25.86 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.558 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 56.8 mt-30 -90.46 132.72 35.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.874 0.369 . . . . 0.0 110.965 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -102.79 162.9 12.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.809 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -121.38 -65.47 1.13 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -95.41 115.56 27.6 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.065 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -129.84 69.43 81.62 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.148 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.42 91.98 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.588 2.192 . . . . 0.0 112.259 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 27.1 t -127.79 -52.27 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.158 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 5.5 m -120.81 113.42 39.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.133 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -74.08 -60.77 1.41 Allowed Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.161 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -72.61 160.58 46.18 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.478 2.119 . . . . 0.0 112.421 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -100.87 166.63 12.11 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.12 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.98 111.77 2.3 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.605 2.203 . . . . 0.0 112.275 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -125.95 78.88 69.58 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.165 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.66 -35.76 9.48 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.533 2.156 . . . . 0.0 112.282 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -99.4 168.63 9.29 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.145 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -52.08 -51.45 11.13 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.461 2.107 . . . . 0.0 112.323 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.858 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.843 0.354 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 6.0 mtt180 -150.59 -73.59 0.16 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.839 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.9 pt -140.92 129.46 24.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.162 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.9 mtm -115.57 147.56 40.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.867 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.6 mttm -135.08 117.38 15.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.92 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -113.75 130.17 56.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.5 pt -106.33 179.57 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.13 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -102.96 133.71 47.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.896 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 10.9 m -85.49 88.5 2.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.102 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -151.05 175.51 12.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -57.7 99.98 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.914 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -86.86 55.36 3.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.412 ' N ' ' CD ' ' A' ' 14' ' ' PRO . . . -86.82 -52.57 0.42 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.088 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 13' ' ' ALA . 31.4 Cg_exo -59.16 84.55 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.509 2.14 . . . . 0.0 112.125 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 19.1 mmtt -88.52 99.73 12.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.914 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -83.94 65.54 8.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.774 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -98.73 141.62 31.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.946 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 t -150.51 172.52 15.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.812 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.418 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 17.6 t90 -142.74 129.92 20.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.0 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.42 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 10.5 m-85 -119.69 135.91 54.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.833 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.57 139.98 35.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.073 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -171.1 -159.2 16.59 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -148.1 147.48 18.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.61 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.401 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 3.0 mttp -123.63 161.14 25.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.988 0.423 . . . . 0.0 111.031 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 2.5 tt -141.35 143.24 33.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.695 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.77 -163.37 27.18 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.55 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -104.8 140.25 38.37 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.88 0.372 . . . . 0.0 110.811 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.7 t -121.56 127.82 51.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.949 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -110.07 141.2 43.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.91 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -67.12 150.96 48.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.837 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -99.06 107.05 19.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.867 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 25.0 p30 -144.37 160.46 41.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.927 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 41.2 m -69.37 -47.53 64.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.988 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 94.99 44.58 3.28 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.508 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -98.73 32.24 2.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.92 0.39 . . . . 0.0 110.959 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -96.27 132.7 41.47 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.825 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.95 -94.13 0.9 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.486 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -86.0 126.85 34.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.769 0.319 . . . . 0.0 110.898 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -152.46 97.2 0.17 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.52 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -122.23 105.81 10.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.835 0.35 . . . . 0.0 110.906 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.74 124.01 28.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -86.09 92.21 8.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.875 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -102.27 131.02 49.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.904 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -127.02 70.66 1.29 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.864 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -129.98 160.12 22.8 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.53 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.21 -45.69 1.27 Allowed 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.6 2.2 . . . . 0.0 112.303 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.0 m -146.73 153.5 40.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.918 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.83 154.22 45.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -99.1 166.74 11.1 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.959 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -100.97 155.64 17.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.903 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -78.58 77.06 5.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.906 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 3.5 pp -90.97 134.9 34.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.85 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.02 143.5 14.89 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.612 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -129.24 153.68 47.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.721 0.296 . . . . 0.0 110.876 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.04 172.18 35.14 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.769 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -114.12 131.27 56.47 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.744 0.307 . . . . 0.0 110.887 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -118.72 128.22 54.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.073 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.97 126.39 3.23 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.39 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -127.5 136.14 9.12 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.608 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.45 ' CZ ' ' CB ' ' A' ' 68' ' ' PHE . 42.1 p90 -134.25 130.62 37.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -100.91 136.8 40.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 34.5 t -111.92 -34.23 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.188 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 7.3 p-10 -128.63 153.79 79.59 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.87 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.63 65.4 1.21 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.54 2.16 . . . . 0.0 112.162 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -159.07 -44.99 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.001 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -174.35 164.08 3.83 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 167.69 21.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.45 ' CB ' ' CZ ' ' A' ' 60' ' ' TYR . 0.3 OUTLIER -85.56 131.86 34.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 110.749 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -113.09 119.86 39.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.089 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.17 123.48 47.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.555 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 148.43 17.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.571 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -130.04 115.05 16.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.802 0.334 . . . . 0.0 110.614 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.38 120.84 33.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.993 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -127.69 115.2 18.36 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 3.4 mp -106.33 124.51 49.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.821 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -74.85 -129.38 0.21 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.445 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 22.7 tpt180 59.95 104.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.847 0.356 . . . . 0.0 110.957 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.25 170.13 16.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.933 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -137.12 131.54 32.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.125 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -107.63 125.34 51.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.92 106.08 8.38 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.986 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.7 -72.89 0.89 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.407 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 4.1 t -83.61 -165.62 1.16 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.84 0.353 . . . . 0.0 110.844 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 35.7 m -91.04 49.64 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.145 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -178.63 136.72 0.15 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.839 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -124.5 -44.56 1.98 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.93 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.22 -37.54 3.75 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.525 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -149.92 156.09 41.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.894 0.378 . . . . 0.0 111.109 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -117.4 -58.03 2.08 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.792 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -148.6 165.58 30.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.759 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -163.33 156.99 19.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.335 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -152.11 130.8 12.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.418 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -99.31 130.53 10.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.105 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.51 121.67 65.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 179.269 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -108.89 142.83 38.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.145 0.498 . . . . 0.0 111.8 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -132.3 110.62 10.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.738 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.401 HG21 ' HA3' ' A' ' 115' ' ' GLY . 2.8 p -150.85 167.39 27.64 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 120.932 0.396 . . . . 0.0 111.677 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -102.45 120.89 41.29 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.132 179.131 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -106.03 132.34 52.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.042 0.449 . . . . 0.0 111.909 -179.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.8 pp -135.87 128.35 30.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.281 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -150.25 -173.3 20.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.919 -179.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 30.4 p90 -166.17 143.12 4.31 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.585 0.231 . . . . 0.0 111.012 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.419 ' HA ' ' CB ' ' A' ' 109' ' ' ASP . 98.5 Cg_endo -85.45 166.35 10.62 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.778 2.319 . . . . 0.0 112.941 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.416 HG23 HD12 ' A' ' 104' ' ' ILE . 25.9 mt -138.4 37.13 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.779 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER 63.63 173.71 0.17 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.64 -179.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 63.41 20.74 12.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.192 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 33.0 m-20 61.93 46.23 6.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.137 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -137.43 130.31 30.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.302 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.419 ' CB ' ' HA ' ' A' ' 103' ' ' PRO . 4.6 p-10 -144.76 158.4 43.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.966 0.413 . . . . 0.0 111.678 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.405 ' CG2' HG13 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 147.93 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.467 179.472 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.431 ' CZ ' ' HD3' ' A' ' 160' ' ' ARG . 17.7 p90 -142.33 143.32 32.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.11 0.481 . . . . 0.0 111.599 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 46.7 p -138.56 126.96 23.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.132 179.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.421 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 0.0 OUTLIER -121.2 138.48 54.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.982 0.42 . . . . 0.0 111.608 -179.241 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.44 ' HB2' ' CD2' ' A' ' 145' ' ' PHE . 7.8 tt -129.53 122.91 30.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.349 179.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' A' ' 97' ' ' THR . . . -177.44 -141.76 4.22 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.723 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.458 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.19 169.13 25.89 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.434 -0.889 . . . . 0.0 112.843 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 14.7 tmm? -125.92 141.71 51.85 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 120.888 0.375 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -127.03 130.53 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.764 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.426 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 4.2 p-90 -137.79 173.72 11.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 111.035 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.99 134.76 40.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.831 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -87.95 156.13 19.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.118 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -145.01 145.82 31.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.817 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -60.5 -179.93 0.14 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.922 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.48 -34.46 9.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.988 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 179.98 -173.81 45.32 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.51 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -115.36 80.78 1.48 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.848 0.356 . . . . 0.0 110.797 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 26.4 t80 -117.78 -58.45 2.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.882 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -100.72 156.43 17.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.125 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 30.9 t -171.76 99.33 0.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -144.35 31.28 1.22 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.908 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -142.5 -157.56 7.2 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.509 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 11.2 p -116.06 58.84 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.954 0.407 . . . . 0.0 111.016 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 40.1 t -116.7 33.99 5.3 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.934 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 34.1 mtt180 -60.78 -53.68 54.4 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.951 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 1.6 m -115.53 33.15 5.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.934 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -60.08 155.24 17.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.893 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 8.7 m80 -141.01 114.9 9.07 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.885 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -116.51 154.06 31.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.965 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.01 149.98 50.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.987 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.426 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -105.21 144.66 15.81 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.464 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.7 p -145.97 132.26 13.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.637 0.256 . . . . 0.0 111.074 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.5 p -157.11 131.85 5.28 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.368 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.458 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.5 Cg_exo -73.66 150.34 44.99 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.65 2.234 . . . . 0.0 111.791 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.1 m -156.28 163.53 1.41 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.26 0 CA-C-O 121.116 0.484 . . . . 0.0 111.84 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.44 ' CD2' ' HB2' ' A' ' 114' ' ' LEU . 10.9 t80 -137.07 118.76 15.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.245 179.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -103.63 126.72 50.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.929 0.395 . . . . 0.0 111.327 -179.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.57 124.88 3.61 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.176 179.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.75 -160.57 11.03 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.693 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.405 HG13 ' CG2' ' A' ' 110' ' ' ILE . 6.0 m -134.75 163.39 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.659 0.266 . . . . 0.0 110.915 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -127.71 142.54 51.3 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 120.918 0.39 . . . . 0.0 111.099 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -126.57 119.16 26.42 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.66 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.59 137.23 32.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.388 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t -114.22 -51.53 5.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.511 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 19.3 p -108.1 -175.55 2.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.3 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 12.5 mtm180 -91.84 45.22 1.21 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.917 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 173.61 -26.81 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.678 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 21.5 mt -115.35 123.26 70.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.887 0.375 . . . . 0.0 111.686 -179.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -135.63 155.93 49.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.994 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 1.7 t -117.63 140.56 49.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.094 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.431 ' HD3' ' CZ ' ' A' ' 111' ' ' TYR . 0.0 OUTLIER -134.59 151.58 51.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.328 0.585 . . . . 0.0 112.123 -179.33 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -113.12 124.8 53.43 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.725 179.093 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -106.89 145.13 32.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.985 0.421 . . . . 0.0 111.622 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.45 ' CE2' ' CD2' ' A' ' 184' ' ' LEU . 0.8 OUTLIER -131.12 126.48 35.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.383 179.673 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? -54.63 -66.67 0.36 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.17 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -155.8 150.74 26.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.888 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.411 HG23 ' CE1' ' A' ' 163' ' ' TYR . 21.3 t -141.16 104.19 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.09 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.8 t-20 -64.23 125.39 24.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -111.94 -179.0 3.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.932 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 1.4 pt -71.11 92.18 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.064 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -142.78 66.25 0.47 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.441 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -158.2 163.02 37.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.797 0.332 . . . . 0.0 110.95 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -100.49 -54.39 2.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.11 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -78.87 -137.62 1.34 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.522 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.4 t -131.45 131.13 43.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.87 0.367 . . . . 0.0 110.901 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.4 t -109.04 -64.56 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.181 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -131.81 -128.6 2.95 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.506 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.95 -64.18 0.23 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.866 0.365 . . . . 0.0 110.899 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 12.4 mtt180 -123.7 102.8 35.04 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.822 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -68.32 148.26 73.63 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 122.323 2.015 . . . . 0.0 112.385 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -171.9 94.44 0.15 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -170.75 151.47 3.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 139.25 -164.01 25.94 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.575 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 8.3 tmm? -147.23 124.92 11.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.879 0.371 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . 0.45 ' CD2' ' CE2' ' A' ' 163' ' ' TYR . 2.5 mp -114.04 137.33 51.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.771 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.3 p -136.76 155.78 49.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.068 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -119.33 133.06 55.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.461 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . 0.401 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -145.67 162.37 28.26 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.207 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.73 133.94 67.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.773 0.32 . . . . 0.0 110.402 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -136.14 175.09 9.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.943 0.401 . . . . 0.0 111.378 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -139.84 155.8 47.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.636 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.42 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -99.66 148.73 24.04 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.933 -179.915 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -95.35 136.63 35.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.831 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -154.76 175.21 32.92 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.645 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -123.02 83.42 2.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.836 0.351 . . . . 0.0 110.853 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -82.16 144.3 30.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.919 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -112.6 112.25 23.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.809 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -137.14 -54.94 0.71 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.184 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -110.99 96.37 29.28 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.189 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -54.23 88.13 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.523 2.149 . . . . 0.0 112.286 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 30.3 m -80.81 157.25 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.157 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 13.3 m -130.26 47.54 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.083 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -103.55 92.3 4.0 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.061 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.18 -27.08 29.67 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.531 2.154 . . . . 0.0 112.366 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.97 140.74 90.25 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.099 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.91 171.45 0.35 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.423 2.082 . . . . 0.0 112.33 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -90.35 -52.66 0.31 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_exo -56.09 84.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.614 2.209 . . . . 0.0 112.41 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . 0.465 ' CB ' ' HD3' ' A' ' 209' ' ' PRO . . . -107.83 -57.83 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.454 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . 0.465 ' HD3' ' CB ' ' A' ' 208' ' ' ALA . 40.3 Cg_exo -57.05 -163.42 0.02 OUTLIER 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.327 2.018 . . . . 0.0 112.313 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.904 179.948 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.779 0.323 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -126.39 -46.28 1.63 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 24.1 pt -138.08 150.03 24.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.106 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -117.17 149.39 40.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.945 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.07 81.42 1.72 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.801 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -87.55 101.72 13.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.14 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 tt -72.04 -33.03 45.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.058 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -166.44 117.29 0.97 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.3 m -131.68 179.78 4.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.187 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -90.71 -24.78 20.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.047 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -56.98 150.82 16.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.977 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.29 104.31 3.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -91.68 122.35 65.76 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.986 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -68.87 -28.17 30.04 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.421 2.081 . . . . 0.0 112.394 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.18 53.86 2.02 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.889 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.3 p30 -89.31 15.95 8.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.481 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -67.13 138.45 57.07 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.804 0.335 . . . . 0.0 110.963 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -142.02 174.99 10.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.833 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.419 ' CZ2' ' HB3' ' A' ' 192' ' ' PHE . 13.3 p-90 -143.79 148.17 35.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.955 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.8 m-85 -119.97 140.0 51.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.709 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.35 139.98 47.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.384 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.15 -158.47 19.82 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.499 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -155.86 150.45 21.81 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.533 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.401 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 9.1 ptmm? -131.71 154.04 49.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.914 0.388 . . . . 0.0 111.07 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -128.29 148.89 50.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.675 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -167.36 -144.66 4.21 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.564 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 9.9 m-90 -116.85 144.12 44.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.852 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.2 m -145.37 138.9 26.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -154.39 109.46 3.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.913 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 14.3 p90 -112.83 35.82 3.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 47.0 t-80 -135.36 95.7 3.33 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -113.64 141.23 47.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.797 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 2.2 m -97.55 80.05 2.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.976 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.78 163.69 35.66 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.508 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -74.6 84.91 2.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.842 0.354 . . . . 0.0 110.859 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -113.87 86.65 2.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -91.77 47.46 2.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.55 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 53.9 t-20 -109.63 112.11 23.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.913 0.387 . . . . 0.0 110.866 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -59.38 -27.71 63.6 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.606 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -87.54 129.67 35.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.848 0.356 . . . . 0.0 110.867 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.6 mt-30 -160.13 115.41 2.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.81 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -84.15 -66.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -63.38 173.4 1.58 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.928 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 11.5 p30 -70.49 162.68 28.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.8 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -140.19 -141.61 4.06 Favored Glycine 0 CA--C 1.518 0.258 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.348 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.57 -20.67 53.47 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.453 2.102 . . . . 0.0 112.241 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.2 t -127.7 120.32 27.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.926 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -98.8 -59.1 1.8 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.844 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -99.82 164.66 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -74.59 132.36 41.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -117.39 155.22 29.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.875 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -134.09 151.59 51.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.98 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -136.28 145.04 16.94 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.515 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.38 144.4 34.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.55 130.85 3.36 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.747 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.91 145.67 24.75 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.689 0.28 . . . . 0.0 110.773 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -135.62 133.35 38.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.023 0.44 . . . . 0.0 111.425 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.82 125.04 1.89 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.849 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -134.39 164.36 24.58 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.934 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -143.91 134.04 24.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.897 0.38 . . . . 0.0 110.657 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -90.4 137.14 32.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 41.6 t -137.09 -47.8 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.798 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.414 ' O ' ' N ' ' A' ' 65' ' ' TYR . 81.4 m-20 -88.69 134.49 33.85 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.423 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 63' ' ' ASN . 22.5 Cg_exo -64.65 64.39 0.27 Allowed 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.516 2.144 . . . . 0.0 112.256 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.414 ' N ' ' O ' ' A' ' 63' ' ' ASN . 1.3 t80 179.62 -33.04 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.505 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -164.35 164.1 22.29 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.965 0.412 . . . . 0.0 111.325 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.75 177.1 18.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.294 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -98.04 142.37 29.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.653 0.263 . . . . 0.0 110.703 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -132.96 121.29 22.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.917 0.389 . . . . 0.0 111.07 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.16 129.32 53.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.421 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.01 156.91 15.35 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.636 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.41 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 40.0 m-85 -130.48 115.04 16.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.774 0.321 . . . . 0.0 110.463 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.83 120.48 30.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.186 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 -139.04 119.42 13.78 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.889 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -115.75 157.08 24.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.783 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -101.55 -56.98 0.84 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.468 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.4 mtp180 -121.07 145.97 47.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.842 0.353 . . . . 0.0 110.891 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.7 ptp -130.35 -49.62 1.09 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.967 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -172.84 -44.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.061 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -102.5 139.55 37.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.922 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 27.3 mtmt -99.21 148.85 23.68 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.82 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -68.87 109.68 3.02 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.512 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -157.61 -58.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.771 0.32 . . . . 0.0 110.913 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.2 t -96.35 48.18 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.082 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -111.88 -176.26 2.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.92 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 p-10 -112.21 38.71 2.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.868 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 98.67 177.99 32.39 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.554 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -60.25 163.94 4.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 0.0 111.132 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -137.93 159.6 41.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.85 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 16.4 mtmt -89.91 125.89 35.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -174.66 143.33 0.77 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.247 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -175.18 136.68 0.38 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.645 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.36 128.47 8.5 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.666 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.66 117.96 51.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.641 0.258 . . . . 0.0 110.324 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -110.55 142.53 42.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.116 0.484 . . . . 0.0 111.72 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.5 tt -129.06 110.23 11.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.483 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.1 p -148.2 174.66 11.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.235 0.541 . . . . 0.0 111.769 -178.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -111.55 135.24 52.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.304 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.66 132.13 55.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.918 0.389 . . . . 0.0 111.448 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -132.18 131.69 42.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.587 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.38 -174.3 34.85 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.569 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.438 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -165.36 150.8 8.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.73 0.3 . . . . 0.0 110.925 -179.882 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.438 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 37.6 Cg_exo -60.74 165.44 11.74 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.709 2.272 . . . . 0.0 112.108 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -124.97 -31.06 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.558 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.1 m -139.06 -65.95 0.48 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.805 0.336 . . . . 0.0 110.82 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -156.82 -50.49 0.07 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.79 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -125.15 30.91 5.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.819 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.89 117.63 10.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.014 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.411 ' HB3' ' HA ' ' A' ' 103' ' ' PRO . 3.0 p30 -131.64 160.26 35.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.032 0.444 . . . . 0.0 112.016 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.429 ' CG2' HG11 ' A' ' 149' ' ' VAL . 1.4 pp -116.07 141.25 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.133 179.332 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -156.69 160.28 39.18 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.103 0.478 . . . . 0.0 111.925 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 9.3 t -138.4 151.07 47.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.02 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 3.7 ppt_? -120.5 127.99 52.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.514 -179.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.6 tt -125.75 122.67 36.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.127 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -179.59 -141.52 4.59 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.512 -0.851 . . . . 0.0 112.669 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.402 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.11 168.65 25.64 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.796 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 8.3 ptp -126.56 142.48 51.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.879 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -124.45 144.05 35.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.807 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.7 t90 -144.74 148.47 34.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.808 0.337 . . . . 0.0 110.974 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.09 131.44 50.1 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.946 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -135.58 147.23 48.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.103 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -150.77 157.95 43.56 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.952 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 2.4 t -129.07 33.84 4.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.959 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 4.3 tttm -120.42 83.87 2.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.838 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -143.61 -92.25 0.15 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.536 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 20.0 p30 -83.37 -175.58 5.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.88 0.371 . . . . 0.0 110.894 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 23.4 t80 -155.82 94.82 1.59 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.917 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -89.22 -67.89 0.81 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.33 -68.26 0.25 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 41.3 p -85.86 78.89 9.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.766 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -129.2 126.98 5.39 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.51 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 5.3 m -158.04 104.79 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.824 0.345 . . . . 0.0 111.266 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.5 m -160.5 124.0 3.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.842 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 6.8 ttp85 -136.57 -66.26 0.54 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.33 31.37 6.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.878 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -110.15 88.56 2.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.898 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -92.71 131.32 37.88 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.88 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -117.53 149.36 40.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.829 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.3 m -140.91 137.85 33.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.978 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -97.61 99.31 2.22 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.536 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p -125.14 125.02 68.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.667 0.27 . . . . 0.0 110.964 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.0 p -157.05 148.65 17.12 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.335 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.402 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 72.4 Cg_endo -76.55 158.47 36.08 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.665 2.243 . . . . 0.0 112.084 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.0 m -155.92 154.41 6.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.031 0.443 . . . . 0.0 111.52 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 59.4 t80 -149.15 118.66 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.416 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -129.37 147.48 51.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.94 0.4 . . . . 0.0 111.345 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.22 145.37 17.19 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.078 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.424 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -164.77 -171.03 30.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.799 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.429 HG11 ' CG2' ' A' ' 110' ' ' ILE . 3.4 m -129.56 148.95 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.746 0.308 . . . . 0.0 111.107 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -110.83 127.15 55.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 5.3 t90 -128.61 120.29 26.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.757 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.57 132.92 34.46 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.354 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.1 t -107.22 -66.34 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.756 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.94 174.57 11.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.843 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.25 -25.49 61.64 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.005 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -135.11 27.64 3.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.186 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.425 HD11 HG22 ' A' ' 157' ' ' ILE . 18.6 mt -151.96 116.44 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.209 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -112.68 168.56 9.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.254 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.3 m -135.92 146.63 47.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.348 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 147.69 46.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.201 0.524 . . . . 0.0 111.902 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.2 tt -119.68 124.1 45.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.776 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -114.42 144.48 43.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.084 0.469 . . . . 0.0 111.592 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.424 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 18.7 p90 -134.14 155.17 50.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.494 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -105.0 -70.18 0.79 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.972 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -131.25 149.14 52.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.5 t -137.23 127.91 39.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -146.9 29.86 0.98 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.877 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -100.32 -59.36 1.72 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.958 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 14.8 pt -71.48 -30.42 39.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.086 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -128.81 127.35 5.57 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.514 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 41.1 m-20 -98.13 36.29 1.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.903 0.383 . . . . 0.0 110.934 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -96.79 101.89 13.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.077 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -159.64 129.89 2.32 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.488 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.39 -59.16 1.76 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.775 0.321 . . . . 0.0 110.824 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -141.95 78.61 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -139.3 -77.47 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.534 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 43.9 p -136.73 119.54 16.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.778 0.323 . . . . 0.0 110.93 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.75 -60.59 1.9 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.51 147.08 45.54 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.58 2.186 . . . . 0.0 112.248 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -91.05 104.83 17.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.957 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 10.5 m-20 -132.03 -67.12 0.68 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.909 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 68.79 151.37 0.38 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.452 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -134.71 100.05 4.5 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.91 0.386 . . . . 0.0 110.995 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.6 mp -114.62 155.19 27.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.534 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 47.4 m -151.86 155.74 38.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.901 0.382 . . . . 0.0 111.264 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -118.26 135.77 54.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.366 179.589 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . 0.401 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -147.92 167.24 28.84 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 119.967 -1.111 . . . . 0.0 113.139 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.3 m -123.74 145.07 31.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 67.4 p -152.29 174.98 13.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.055 0.455 . . . . 0.0 111.593 -179.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -145.16 152.37 39.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.541 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.4 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -95.81 144.32 26.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.878 -179.972 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . 0.419 ' HB3' ' CZ2' ' A' ' 19' ' ' TRP . 0.5 OUTLIER -149.59 135.48 18.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.789 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -142.36 128.21 3.45 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.544 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -120.78 144.67 48.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.863 0.363 . . . . 0.0 110.859 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -99.34 29.87 3.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.858 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -149.06 -69.89 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.884 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -69.78 67.71 0.26 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.105 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . 0.408 ' CB ' ' CD ' ' A' ' 199' ' ' PRO . . . -81.98 -62.22 0.33 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.398 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . 0.408 ' CD ' ' CB ' ' A' ' 198' ' ' ALA . 61.5 Cg_endo -74.11 -46.43 0.3 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.416 2.077 . . . . 0.0 112.609 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 11.4 p -121.39 145.72 27.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.19 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 11.0 p -139.33 123.29 19.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.048 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -74.13 113.16 20.77 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.078 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -55.57 106.71 0.2 Allowed 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.421 2.08 . . . . 0.0 112.283 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -84.61 139.53 38.1 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.106 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.71 148.48 44.94 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.437 2.091 . . . . 0.0 112.355 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -88.78 -52.98 0.36 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.182 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_exo -55.54 96.92 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.454 2.103 . . . . 0.0 112.36 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -145.51 165.96 19.43 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.041 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -67.8 -25.48 39.43 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.611 2.207 . . . . 0.0 112.251 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.941 179.99 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 120.822 0.344 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.6 ttp180 -153.94 37.82 0.45 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.862 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.6 mp -101.99 -64.0 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.083 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.9 ttt -134.08 118.7 18.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.843 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.0 mtpm? -90.44 57.62 3.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.831 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -110.3 119.46 39.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.108 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 32.3 pt -73.44 174.19 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.107 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 36.3 p90 -162.0 154.35 19.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.942 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 15.7 m -80.04 150.08 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.183 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.57 -42.99 2.72 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.918 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -74.83 132.69 41.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.991 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.02 -68.33 0.38 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.055 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -102.56 132.28 21.5 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.118 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.03 61.66 5.73 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.478 2.119 . . . . 0.0 112.306 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.5 mmtt -135.23 84.88 2.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.903 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -68.92 -58.38 4.22 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.817 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -79.47 111.49 15.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.928 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.8 m -118.13 149.9 40.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.839 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.424 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 27.0 m-90 -131.78 131.93 43.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.986 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -128.26 135.96 50.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.722 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.14 141.25 34.17 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.49 -166.6 33.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.546 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -156.01 150.07 21.28 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.414 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -126.85 160.05 32.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.902 0.382 . . . . 0.0 111.157 -179.904 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.66 140.88 46.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.609 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -152.59 -175.04 23.7 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.499 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 5.6 m0 -95.83 144.29 26.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.826 0.346 . . . . 0.0 110.882 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -100.6 156.23 17.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.52 114.54 26.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.891 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 38.7 t80 -106.11 -50.45 3.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.2 t60 -113.81 179.97 3.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.846 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -103.75 -59.73 1.68 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.994 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.0 m -72.46 -56.88 4.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.898 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 96.97 -161.02 21.68 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.582 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -127.43 130.63 49.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.784 0.326 . . . . 0.0 110.918 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -143.56 152.02 40.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.858 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.48 136.78 13.06 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.562 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -98.85 -52.92 3.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.871 0.367 . . . . 0.0 110.872 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -150.0 -113.99 0.67 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.534 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -81.3 88.97 6.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.877 0.37 . . . . 0.0 110.914 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -125.44 113.46 17.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.894 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -71.77 78.69 0.85 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -123.7 83.97 2.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.876 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 -91.21 89.37 7.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.2 139.66 22.85 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.368 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -74.02 173.18 14.51 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.485 2.123 . . . . 0.0 112.371 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 70.6 m -73.6 78.91 1.48 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.909 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 2.0 mmm180 -151.8 160.66 43.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 29.2 m-20 -100.27 161.01 13.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.863 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.09 -58.59 3.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -163.57 135.54 5.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.872 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.0 pp -131.02 154.82 47.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.801 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -135.52 134.5 7.29 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.645 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.11 144.54 33.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.34 117.78 1.2 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.619 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.73 136.1 35.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.75 0.31 . . . . 0.0 110.667 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 22.4 m-85 -125.93 132.8 52.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.974 0.416 . . . . 0.0 111.186 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.57 125.04 1.78 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.201 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.401 ' HA3' ' HA ' ' A' ' 69' ' ' GLU . . . -155.87 -173.42 24.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.858 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 60' ' ' TYR . 1.9 p90 -147.96 158.31 43.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.756 0.312 . . . . 0.0 110.8 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 32.8 mt-30 -107.61 127.3 53.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.994 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 61.0 t -139.66 -41.42 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.069 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.437 ' CB ' ' HD2' ' A' ' 64' ' ' PRO . 6.5 m-80 -52.32 167.13 0.37 Allowed Pre-proline 0 CA--C 1.531 0.22 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.988 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.437 ' HD2' ' CB ' ' A' ' 63' ' ' ASN . 7.6 Cg_endo -49.9 -45.33 32.92 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.824 2.349 . . . . 0.0 112.97 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 27.3 t80 -150.0 50.82 0.91 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.863 0.364 . . . . 0.0 111.666 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.401 ' O ' ' HB2' ' A' ' 63' ' ' ASN . 3.6 pp -179.84 164.12 1.17 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.7 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -137.97 175.66 21.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.615 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -115.36 138.16 51.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.823 0.344 . . . . 0.0 110.648 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.401 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . 1.2 pt-20 -140.13 143.14 36.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.002 0.43 . . . . 0.0 111.198 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -110.68 142.25 42.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.531 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 158.24 14.6 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.617 -0.802 . . . . 0.0 112.441 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -130.83 114.79 15.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.678 0.275 . . . . 0.0 110.77 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.407 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.4 t0 -90.35 119.36 30.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.914 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -135.3 124.08 23.9 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 4.4 mt -98.89 -67.75 0.83 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.998 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 84.58 103.5 0.61 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.544 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.3 ttt-85 60.01 -176.7 0.1 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.743 0.306 . . . . 0.0 110.851 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -139.98 -78.27 0.31 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.957 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -178.5 -50.11 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.009 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -69.02 156.42 38.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 2.9 tttt -73.71 170.16 15.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.942 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 179.1 -176.77 48.14 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.503 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 5.3 t -120.5 105.45 10.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.832 0.349 . . . . 0.0 110.862 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.6 m -99.51 118.95 46.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.072 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -130.32 -77.45 0.54 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.994 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -99.94 -59.85 1.64 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.933 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -169.67 110.58 0.38 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.456 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -105.75 -39.25 6.12 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.809 0.337 . . . . 0.0 111.103 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -164.5 57.56 0.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.877 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -91.46 137.78 32.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.874 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -155.4 176.41 12.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.219 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.43 127.93 8.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.458 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.407 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -88.74 133.65 11.94 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.991 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.83 117.74 45.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -108.98 149.03 29.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.236 0.541 . . . . 0.0 111.875 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.6 tt -135.11 113.78 11.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.629 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 t -154.11 166.33 33.41 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.099 0.476 . . . . 0.0 111.638 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.34 134.57 50.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.481 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.59 130.18 54.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.315 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -135.25 124.27 24.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.537 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -166.89 -169.77 30.91 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.693 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -165.1 157.62 13.67 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.727 0.299 . . . . 0.0 111.112 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 109' ' ' ASP . 90.5 Cg_endo -78.44 170.97 17.6 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.787 2.325 . . . . 0.0 112.634 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 14.2 mm -102.4 -29.88 3.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.918 0.389 . . . . 0.0 110.539 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.22 -60.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.519 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 176.74 46.17 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.753 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 176.63 -31.65 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.219 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -105.45 120.46 41.67 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 7.5 t0 -125.39 147.68 49.08 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.382 0.611 . . . . 0.0 112.385 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -129.33 123.54 58.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.763 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -143.04 168.84 18.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.027 0.441 . . . . 0.0 111.559 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 31.0 p -141.15 140.26 34.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.548 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.7 ptt-85 -111.64 127.93 55.9 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.205 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.5 tt -124.83 125.02 43.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.623 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 176.94 -132.74 2.1 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.422 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.03 169.18 32.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.982 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.0 tmm? -125.94 144.47 50.67 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 120.682 0.277 . . . . 0.0 110.639 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.63 129.65 64.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.404 ' CZ2' ' HB3' ' A' ' 73' ' ' ASP . 0.2 OUTLIER -126.13 135.31 51.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 -179.934 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 55.3 mtt180 -130.68 148.37 52.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.886 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.0 162.65 33.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.07 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -147.57 128.22 14.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.996 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -108.15 53.96 0.67 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.84 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -100.16 87.15 3.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -134.86 -172.49 12.78 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.518 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -111.26 91.29 3.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.873 0.368 . . . . 0.0 110.92 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -157.38 76.17 0.82 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -77.85 177.62 8.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.07 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 32.3 m -126.98 -65.61 0.94 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.904 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 43.2 p -146.7 -70.16 0.25 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.95 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -165.3 48.22 0.28 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.428 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 14.7 m -125.03 133.93 68.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.846 0.355 . . . . 0.0 111.118 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -110.38 121.64 45.78 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.955 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.67 152.55 42.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.774 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -122.32 130.68 53.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.943 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -124.06 119.2 28.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.848 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -123.33 125.08 44.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 20.2 m-20 -121.23 117.84 28.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.944 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 6.9 p -139.6 126.81 21.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.938 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -117.08 113.03 2.63 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.459 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.2 p -131.3 123.53 53.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.791 0.329 . . . . 0.0 111.036 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 38.1 m -157.24 148.18 16.47 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.387 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.422 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.5 Cg_endo -78.0 147.96 24.4 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.766 2.311 . . . . 0.0 112.049 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.11 158.38 3.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.988 0.423 . . . . 0.0 111.52 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -145.88 119.93 9.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.418 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -120.97 163.95 17.47 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.904 0.383 . . . . 0.0 111.396 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -140.7 148.42 20.06 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.246 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.37 -171.99 31.3 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.705 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.8 m -131.98 167.05 27.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.669 0.271 . . . . 0.0 111.08 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -134.64 151.49 51.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.946 0.403 . . . . 0.0 111.291 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -133.06 117.61 17.77 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.582 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -81.68 122.46 27.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.422 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 56.4 t -116.17 -63.24 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.957 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 1.1 m -80.61 174.17 11.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.925 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.04 -34.81 73.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.029 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -147.36 38.75 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.108 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.4 mt -148.87 100.84 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.072 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -113.25 167.91 10.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.288 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.4 t -123.27 143.3 50.15 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.261 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.09 147.19 45.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.13 0.49 . . . . 0.0 111.783 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -113.95 126.11 54.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.806 179.043 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.7 138.51 45.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.385 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -134.19 156.18 48.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.664 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -124.57 46.73 2.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.929 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . 0.417 ' CE3' ' HA ' ' A' ' 165' ' ' TRP . 0.0 OUTLIER -81.79 86.07 6.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 11.1 p -70.55 144.21 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.029 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 70.2 m-20 -89.84 139.98 30.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.937 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -133.8 118.59 18.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.89 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 10.8 pt -82.4 -179.87 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.078 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -137.63 35.78 2.02 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.482 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -107.65 -40.01 5.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.887 0.375 . . . . 0.0 110.903 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -112.7 143.31 44.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -141.47 28.69 2.31 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.402 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.4 m -101.79 34.65 2.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.766 0.317 . . . . 0.0 110.899 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 13.7 m -133.13 169.05 22.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.153 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -63.91 -153.97 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.562 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 2.7 t -121.39 122.33 39.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.794 0.33 . . . . 0.0 110.838 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 6.6 mtt-85 -84.21 154.68 63.51 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.99 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.92 106.09 0.73 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.623 2.215 . . . . 0.0 112.238 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -99.63 35.97 1.88 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.912 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -80.44 -46.43 15.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.939 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 64.12 141.15 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.458 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 2.9 tpp -162.0 142.91 10.62 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.816 0.341 . . . . 0.0 111.017 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 4.2 mp -125.88 157.35 37.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.629 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.22 155.46 37.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.01 0.433 . . . . 0.0 111.285 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -115.24 131.87 56.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.169 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . 0.414 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -146.15 168.06 27.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.367 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -127.59 141.01 47.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -144.57 174.98 10.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.043 0.449 . . . . 0.0 111.522 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -146.15 155.67 42.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.712 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 1.6 ptp180 -110.08 149.06 30.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -77.18 120.58 22.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.927 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -154.51 134.81 4.42 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.428 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.05 86.08 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.758 0.313 . . . . 0.0 110.787 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -98.88 -177.78 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.001 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -78.79 -64.18 1.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.981 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -98.01 169.58 9.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.13 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -143.99 77.1 14.86 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.048 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -80.73 3.91 7.36 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.657 2.238 . . . . 0.0 112.879 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 10.7 p -74.39 64.02 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.875 0.369 . . . . 0.0 111.093 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 7.8 m -100.58 125.96 54.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.161 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -70.6 111.39 9.43 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.159 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.94 61.94 1.85 Allowed 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.402 2.068 . . . . 0.0 112.329 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . 0.41 ' CB ' ' CD ' ' A' ' 205' ' ' PRO . . . -81.03 -62.0 0.37 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.189 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . 0.41 ' CD ' ' CB ' ' A' ' 204' ' ' ALA . 74.0 Cg_endo -75.33 157.51 41.36 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.499 2.132 . . . . 0.0 112.439 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . 0.412 ' N ' ' CD ' ' A' ' 207' ' ' PRO . . . -87.14 -53.0 0.41 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.211 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 206' ' ' ALA . 75.5 Cg_exo -50.69 120.37 6.41 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.6 2.2 . . . . 0.0 112.361 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -99.47 105.92 36.32 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.079 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.35 148.66 74.29 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.473 2.115 . . . . 0.0 112.284 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.192 -0.909 . . . . 0.0 110.891 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.297 0 CA-C-O 120.815 0.34 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -123.58 28.84 6.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.945 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.6 mp -145.78 109.72 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.183 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -168.55 142.57 3.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.901 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.7 mmtt -92.21 -69.29 0.75 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.968 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -90.36 156.7 18.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.124 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.9 mt -123.3 -43.79 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.004 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -140.1 117.39 11.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.805 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.6 m -84.19 -31.14 7.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.092 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -71.41 135.54 47.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.848 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 19.9 m-20 -60.35 113.67 2.52 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -118.6 -50.01 2.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.051 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.67 151.07 93.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.096 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.89 -175.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.582 2.188 . . . . 0.0 112.369 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -88.57 174.23 8.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.904 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -70.01 -62.48 1.37 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.871 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -68.58 165.75 18.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.887 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.7 t -161.93 151.97 16.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.92 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -118.29 130.74 56.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.857 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -126.06 135.88 52.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.799 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.23 153.85 44.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.17 -165.28 37.91 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.42 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -160.54 151.51 22.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.532 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.402 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -133.05 157.91 44.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 0.0 111.034 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -127.46 146.19 50.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.7 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -147.85 -172.06 17.5 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.546 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 5.0 p-90 -132.93 131.13 40.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.848 0.356 . . . . 0.0 110.94 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 10.6 t -159.97 121.24 3.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -159.3 128.19 5.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.936 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -67.3 87.7 0.18 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.905 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -130.35 167.21 18.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.853 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -126.71 -176.01 3.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.841 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 51.1 m -110.97 -68.84 0.9 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.956 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.79 104.59 0.72 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.488 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -79.82 83.1 5.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.927 0.394 . . . . 0.0 110.897 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -112.06 -34.29 6.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.89 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -134.6 108.6 0.72 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.46 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -76.27 -31.15 58.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.864 0.364 . . . . 0.0 110.871 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -70.82 -173.73 15.14 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.536 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.18 149.06 23.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.834 0.35 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -94.53 149.65 21.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.935 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -99.57 101.33 12.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -138.67 137.39 36.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.7 t30 -143.51 31.59 1.33 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.954 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -105.23 -148.48 17.52 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.529 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.57 160.67 48.36 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.539 2.159 . . . . 0.0 112.245 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 63.1 m -131.75 84.99 2.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -73.32 146.32 45.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.927 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.4 p30 -105.55 158.94 16.33 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.953 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -80.64 -178.21 6.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.87 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -97.24 129.28 44.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.934 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -98.81 172.84 7.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.81 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.66 132.29 10.64 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.488 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.14 52.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.69 0.281 . . . . 0.0 110.948 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.5 135.46 7.44 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.737 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -103.75 135.64 44.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.781 0.324 . . . . 0.0 110.882 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -119.41 133.69 55.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.206 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -157.27 125.55 1.59 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.389 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -146.18 -178.65 21.78 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.69 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 14.3 p90 -153.35 160.81 42.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.843 0.354 . . . . 0.0 110.927 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -102.38 137.09 41.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.798 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.3 t -129.21 21.02 2.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.232 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 175.73 144.51 0.23 Allowed Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.603 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -69.31 63.74 1.53 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.429 2.086 . . . . 0.0 112.119 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -160.98 -43.29 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.084 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -171.62 164.02 6.68 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.093 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.23 169.8 21.05 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.439 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.6 m-85 -98.75 138.74 35.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.63 0.253 . . . . 0.0 110.817 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -125.95 129.55 49.49 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.952 0.406 . . . . 0.0 110.965 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.11 129.31 55.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.424 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.27 17.43 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.362 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -125.61 114.85 19.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.748 0.309 . . . . 0.0 110.676 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.449 ' HB2' ' HA3' ' A' ' 93' ' ' GLY . 0.3 OUTLIER -87.15 118.28 26.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.758 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -132.63 137.43 47.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.968 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.14 -31.62 8.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 129.13 -100.65 0.51 Allowed Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.472 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 21.6 mmt180 -120.6 -55.35 2.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.763 0.316 . . . . 0.0 110.892 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.1 ttm -114.91 128.8 56.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -59.31 -69.02 0.22 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.018 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.447 ' N ' ' CD1' ' A' ' 80' ' ' TYR . 1.5 p90 -144.48 -55.52 0.34 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.912 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.6 mttp -166.08 170.78 13.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.866 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 176.92 167.94 36.14 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.473 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -68.89 163.81 23.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.75 0.31 . . . . 0.0 110.81 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.6 p -94.58 45.63 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.999 0.428 . . . . 0.0 111.067 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -102.84 -176.91 3.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.985 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 -79.42 122.9 26.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.943 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 160.0 158.2 9.06 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.645 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -129.37 -163.53 1.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.674 0.273 . . . . 0.0 110.966 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -109.54 -54.48 2.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.828 0.347 . . . . 0.0 110.825 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 46.08 40.76 7.56 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.313 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.28 163.87 13.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.41 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -168.68 127.7 1.12 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.374 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.449 ' HA3' ' HB2' ' A' ' 73' ' ' ASP . . . -83.92 133.73 12.12 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.017 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.85 117.98 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.8 0.333 . . . . 0.0 110.208 179.355 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 -108.98 138.11 45.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.109 0.481 . . . . 0.0 111.728 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.7 tt -127.6 107.24 9.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.696 179.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 27.0 p -144.68 162.05 37.65 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 121.158 0.504 . . . . 0.0 111.796 -178.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -92.92 126.5 38.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.006 178.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -104.87 130.98 52.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.029 0.442 . . . . 0.0 111.845 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.8 pp -136.29 123.78 22.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.21 177.46 34.06 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.507 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.415 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.19 153.95 9.4 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.733 0.302 . . . . 0.0 111.344 -179.925 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.415 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 38.1 Cg_exo -60.6 172.04 3.04 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.76 2.306 . . . . 0.0 112.05 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.434 ' N ' ' O ' ' A' ' 108' ' ' LEU . 0.9 OUTLIER -125.26 -38.36 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.477 -179.934 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 56.6 p -140.34 -55.96 0.53 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -159.3 -63.28 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.206 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -113.22 29.8 7.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.219 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.434 ' O ' ' N ' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -138.21 121.33 16.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.031 179.73 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -135.03 160.09 39.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.722 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.408 ' CG2' HG13 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.93 144.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.209 179.359 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -142.26 141.82 32.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.008 0.432 . . . . 0.0 111.527 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 9.6 t -137.15 126.91 25.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.199 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.4 ' NH2' ' N ' ' A' ' 148' ' ' GLY . 0.0 OUTLIER -114.41 131.6 56.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.913 0.387 . . . . 0.0 111.511 -179.358 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.0 tt -128.06 122.93 33.35 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.451 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -175.82 -135.45 2.12 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.622 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.441 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.12 161.7 26.4 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.899 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.47 138.63 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.716 0.293 . . . . 0.0 110.705 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -129.57 134.68 63.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.427 ' CZ2' ' HB2' ' A' ' 73' ' ' ASP . 0.9 OUTLIER -138.54 131.97 30.41 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.975 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 2.0 tpp180 -104.4 134.02 48.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.872 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -108.69 134.78 50.95 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.159 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -113.91 146.66 39.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -137.75 134.08 34.86 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 34.1 mttt -137.09 150.63 48.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 179.99 174.9 46.26 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.499 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -113.03 78.57 1.14 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.856 0.36 . . . . 0.0 110.867 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -172.75 106.1 0.16 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -141.36 170.59 15.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.074 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.3 t -99.85 -65.46 0.96 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.904 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.4 t -173.56 -50.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.92 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -105.58 -80.28 1.35 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.433 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 32.9 m -113.77 120.69 64.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.784 0.326 . . . . 0.0 111.141 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.6 m -65.39 169.79 5.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.009 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.24 -31.19 62.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 56.1 m -65.39 145.69 55.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.866 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -122.36 166.19 15.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.935 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -105.69 127.75 53.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -118.28 151.73 37.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.902 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 42.9 p -125.68 123.34 38.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.871 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -84.98 108.22 3.15 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.418 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.8 p -136.42 128.35 44.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.621 0.248 . . . . 0.0 110.993 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -157.1 144.72 13.92 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.337 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.441 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 90.9 Cg_endo -80.73 139.99 12.76 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.752 2.302 . . . . 0.0 112.115 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 30.3 m -157.04 162.84 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 121.002 0.43 . . . . 0.0 111.504 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.9 p90 -142.35 121.12 12.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.45 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -105.74 141.16 37.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.976 0.417 . . . . 0.0 111.402 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.59 135.03 7.88 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.994 179.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.424 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -159.68 -171.99 26.26 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.895 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.408 HG13 ' CG2' ' A' ' 110' ' ' ILE . 4.4 m -131.12 150.98 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.663 0.268 . . . . 0.0 111.138 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -122.32 133.99 54.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.169 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 9.4 m95 -121.76 122.17 38.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.649 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.412 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -78.77 137.01 37.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.406 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 72.8 t -101.71 -30.08 3.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.682 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.66 -70.62 0.69 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.792 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 177.75 -36.23 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.958 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -103.89 -26.96 12.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.326 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 5.2 mt -116.73 122.83 70.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.809 0.338 . . . . 0.0 111.226 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.412 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -132.5 161.85 32.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.375 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 9.7 t -117.72 143.98 45.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.965 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -137.0 150.87 48.39 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.204 0.526 . . . . 0.0 112.158 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.7 tt -114.39 123.87 50.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.585 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -107.83 139.54 42.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.986 0.422 . . . . 0.0 111.557 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.424 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 36.3 p90 -134.14 160.15 38.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.723 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -58.1 -49.99 75.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.058 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 21.1 t-105 -179.59 -39.27 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.696 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 16.6 m -137.07 167.83 22.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.153 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -109.77 -37.67 5.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.832 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -100.06 140.12 34.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.824 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 31.2 mt -138.84 157.69 29.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.094 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -69.36 130.56 23.89 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.776 -0.725 . . . . 0.0 112.582 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -112.81 -54.89 2.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.879 0.371 . . . . 0.0 110.905 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.13 80.29 0.96 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.096 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -172.06 -71.31 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.505 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.0 p -132.76 108.39 8.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.929 0.395 . . . . 0.0 110.981 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 10.7 p -159.6 146.96 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.0 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -168.11 -70.8 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.705 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 17.3 p -112.1 -18.77 12.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.599 0.238 . . . . 0.0 111.471 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 48.1 ttt180 -108.49 100.83 40.07 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.666 -0.243 . . . . 0.0 111.113 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -63.4 -158.82 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.568 2.179 . . . . 0.0 112.103 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -111.13 97.55 6.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.88 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -95.86 149.24 21.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.929 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -145.27 160.74 28.11 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.497 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 50.2 mtt -108.33 96.92 6.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.904 0.383 . . . . 0.0 111.011 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 6.3 mp -132.94 126.4 31.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.65 179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 11.0 p -142.53 158.91 43.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.73 134.64 54.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . 0.402 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -149.29 172.62 29.31 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.004 -1.093 . . . . 0.0 113.404 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.65 141.37 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.677 0.275 . . . . 0.0 110.388 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 32.8 p -139.55 171.48 14.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.42 . . . . 0.0 111.268 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -148.03 157.51 43.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.776 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.87 147.71 22.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.95 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -137.3 168.96 18.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.952 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -147.1 174.56 26.86 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.606 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -103.36 -177.45 3.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.816 0.341 . . . . 0.0 110.875 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -73.79 134.88 43.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.846 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -72.05 -31.3 66.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.943 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -97.4 47.45 1.03 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.116 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -119.62 83.82 28.9 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.081 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.13 149.69 20.97 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.559 2.173 . . . . 0.0 112.287 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 12.4 p -116.15 -38.01 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.147 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 16.6 m -132.84 94.05 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.218 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -89.91 -53.39 0.32 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.157 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -52.87 176.63 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.507 2.138 . . . . 0.0 112.307 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -100.78 123.83 44.24 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.068 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.01 122.06 7.8 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.405 2.07 . . . . 0.0 112.408 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . 0.412 ' CB ' ' CD ' ' A' ' 207' ' ' PRO . . . -77.2 -61.42 0.68 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.108 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . 0.412 ' CD ' ' CB ' ' A' ' 206' ' ' ALA . 74.5 Cg_endo -75.16 65.44 6.2 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.495 2.13 . . . . 0.0 112.355 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -140.4 147.82 51.21 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.131 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.67 -177.95 2.78 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.513 2.142 . . . . 0.0 112.338 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 . . . . . 0 C--O 1.248 0.975 0 CA-C-O 118.243 -0.884 . . . . 0.0 110.965 179.927 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 120.846 0.355 . . . . 0.0 111.052 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.2 ptp85 -159.79 172.92 16.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.823 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.416 HD13 ' CZ ' ' A' ' 8' ' ' PHE . 6.6 pt -138.45 163.43 28.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.086 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.9 tmm? -114.98 41.89 2.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.917 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.53 157.95 25.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -90.74 -49.41 6.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.148 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -87.67 135.26 25.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.081 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.416 ' CZ ' HD13 ' A' ' 3' ' ' ILE . 1.8 m-85 -99.03 137.29 37.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.921 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.5 m -74.95 111.07 10.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -118.49 61.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.847 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 15.0 p30 -89.01 53.16 2.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.975 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -153.6 173.25 16.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.152 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.33 87.95 36.79 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.053 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_exo -66.25 65.07 0.48 Allowed 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.774 2.316 . . . . 0.0 112.274 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -110.99 -27.87 8.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.025 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -85.97 54.85 3.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.966 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -108.05 -177.8 3.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.882 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.7 p -122.9 135.46 54.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.885 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -121.94 145.39 48.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.401 ' CE2' ' HG3' ' A' ' 191' ' ' ARG . 89.6 m-85 -142.16 135.98 29.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.401 ' HB2' ' CE1' ' A' ' 190' ' ' TYR . . . -144.41 140.02 28.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.08 -161.11 26.09 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.384 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.85 147.27 17.1 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.56 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.72 153.81 35.07 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.923 0.392 . . . . 0.0 110.906 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 55.7 tp -136.7 138.61 41.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.649 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.72 -161.66 24.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.604 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -87.03 140.26 29.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.812 0.339 . . . . 0.0 110.868 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.6 p -91.84 170.88 9.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 -155.71 127.39 7.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.958 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -109.83 -172.92 2.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.813 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 5.0 p-80 -106.35 154.24 21.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.842 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -129.43 144.15 51.13 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.858 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 68.7 p -103.49 -66.61 0.93 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.845 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 103.03 76.09 1.12 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.531 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -107.36 -62.62 1.4 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.946 0.403 . . . . 0.0 110.879 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -129.58 75.58 1.66 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.852 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.56 158.98 23.99 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.586 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -120.73 166.13 14.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.859 0.361 . . . . 0.0 110.835 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -135.78 48.01 0.95 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.486 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -122.23 166.93 13.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.772 0.32 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -85.63 89.23 7.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.951 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 26.6 p30 -103.18 174.0 6.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -88.11 120.62 29.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.949 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 7.1 t30 -130.89 163.39 27.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.903 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.74 -102.65 1.37 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.529 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.55 159.46 6.43 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.474 2.116 . . . . 0.0 112.338 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.4 p -135.27 105.71 6.4 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.41 90.68 2.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 20.5 m-20 -110.48 -31.01 7.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -78.01 137.05 38.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 15.0 mt-30 -132.3 144.51 50.63 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -110.91 139.57 46.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.077 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.88 132.78 5.55 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.33 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -117.78 142.86 46.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.806 0.336 . . . . 0.0 111.137 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -143.17 134.73 6.07 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.67 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.9 140.28 30.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.304 . . . . 0.0 110.837 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -126.45 134.31 51.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.935 0.398 . . . . 0.0 111.126 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -161.62 126.42 1.58 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.254 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -158.55 -166.2 17.24 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.653 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -151.21 146.56 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.879 0.371 . . . . 0.0 110.989 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -110.2 129.3 55.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.756 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 36.4 t -118.27 -39.32 2.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.078 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -84.53 149.26 54.15 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.848 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_exo -51.54 -26.72 22.96 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.555 2.17 . . . . 0.0 112.347 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -148.81 43.23 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.921 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -159.12 115.79 2.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.932 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 158.38 23.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.483 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -105.28 129.03 53.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.632 0.253 . . . . 0.0 110.62 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -122.54 128.46 50.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.86 0.362 . . . . 0.0 111.149 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.3 ttt -108.96 127.0 53.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.538 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 163.92 12.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.742 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.403 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 95.5 m-85 -138.18 114.85 10.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.24 120.27 25.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.023 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -136.13 123.89 22.51 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.832 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -118.27 -36.37 3.58 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.073 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 78.1 -162.05 49.58 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.393 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.5 tpt180 -165.6 149.03 7.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.909 0.385 . . . . 0.0 110.95 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 30.6 ttm -100.65 33.43 2.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.862 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -91.4 159.52 15.94 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.175 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -115.71 -174.58 2.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.774 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.43 28.08 2.71 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.042 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -110.56 26.25 13.49 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.394 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 52.2 p -158.07 -176.2 5.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.735 0.302 . . . . 0.0 110.824 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.6 m -138.75 120.89 17.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 120.953 0.406 . . . . 0.0 111.125 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -137.41 -81.52 0.36 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 -143.11 26.11 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.05 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 87.06 -138.11 15.21 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.48 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -122.43 -73.39 0.65 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.896 0.379 . . . . 0.0 111.159 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -80.68 77.55 7.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -113.23 -30.54 6.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.0 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -96.42 129.39 43.79 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.974 0.416 . . . . 0.0 111.366 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -168.77 124.86 0.95 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.302 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -115.1 141.01 16.76 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.203 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.11 128.11 67.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.175 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 145.29 35.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.135 0.493 . . . . 0.0 111.855 -178.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -140.08 116.14 10.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.742 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -153.01 165.43 35.6 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.211 0.529 . . . . 0.0 111.809 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -99.19 133.42 43.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.358 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 9.5 pttt -112.79 132.33 55.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.515 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -136.08 122.33 20.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.534 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.31 -176.73 37.14 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.663 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.409 ' HB2' ' HD2' ' A' ' 103' ' ' PRO . 30.3 p90 -166.18 157.61 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 120.657 0.265 . . . . 0.0 111.009 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.409 ' HD2' ' HB2' ' A' ' 102' ' ' TYR . 19.9 Cg_endo -60.4 167.48 7.87 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.599 2.2 . . . . 0.0 111.813 179.623 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.409 ' CG2' ' HB2' ' A' ' 108' ' ' LEU . 0.8 OUTLIER -128.72 -5.36 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.568 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 24.3 m -164.04 -64.22 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.832 0.348 . . . . 0.0 110.878 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -168.11 -42.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.979 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -127.61 27.12 5.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.072 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.409 ' HB2' ' CG2' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -142.63 117.88 10.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.936 179.875 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -127.43 155.91 42.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.983 0.42 . . . . 0.0 111.925 -178.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.425 ' CG2' HG12 ' A' ' 149' ' ' VAL . 1.5 pp -125.18 136.35 61.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.369 179.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 37.8 p90 -150.14 159.35 44.49 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.106 0.479 . . . . 0.0 111.494 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 36.8 p -130.86 149.22 52.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.479 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.1 ppt_? -123.75 127.85 48.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.87 0.367 . . . . 0.0 111.394 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -127.89 122.74 33.29 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.205 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -179.47 -133.18 1.91 Allowed Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.735 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.402 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.1 169.12 33.64 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.809 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -126.02 143.7 51.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.823 0.344 . . . . 0.0 110.906 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.3 t -124.89 125.23 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.839 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 19.7 m0 -102.76 157.16 17.15 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.904 -179.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 6.6 mtm105 -146.73 149.28 33.11 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.028 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -119.43 148.02 43.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.114 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -117.88 139.26 51.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.924 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.18 131.97 56.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.817 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -175.24 -40.59 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.929 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -56.72 -100.21 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.569 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -118.96 94.89 4.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.723 0.296 . . . . 0.0 110.926 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -176.65 165.71 2.59 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.863 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -59.79 96.91 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.03 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.7 m -153.18 99.92 2.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.876 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 9.1 t -119.25 -44.01 2.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.912 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -76.91 126.86 8.15 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.457 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 27.8 m -98.42 31.09 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.823 0.344 . . . . 0.0 111.173 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.6 t -124.91 -49.83 1.72 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.931 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.07 128.15 42.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.969 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.1 m -152.47 97.4 2.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.939 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -70.19 118.81 13.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.834 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 22.7 p80 -113.34 179.95 3.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.881 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -87.97 118.12 27.3 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.907 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 4.2 t -106.35 135.59 47.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.86 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -112.95 141.98 17.16 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.457 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.5 p -146.07 129.97 10.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.749 0.309 . . . . 0.0 111.286 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 54.4 p -157.02 130.6 4.69 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.402 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.9 Cg_endo -78.23 146.94 22.84 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.548 2.165 . . . . 0.0 112.152 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.6 m -156.09 151.11 9.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.872 0.368 . . . . 0.0 111.442 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.2 p90 -149.08 124.27 10.15 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.501 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -134.91 167.04 21.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.979 0.418 . . . . 0.0 111.447 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -133.76 146.14 18.12 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.007 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -155.39 -179.83 30.82 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.901 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.425 HG12 ' CG2' ' A' ' 110' ' ' ILE . 11.4 m -128.42 153.31 37.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.828 0.347 . . . . 0.0 110.994 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -122.12 139.74 53.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.203 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -128.48 118.48 23.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.804 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.411 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -82.24 137.01 34.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.23 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 84.6 t -107.24 -70.01 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.3 -79.49 0.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.735 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.66 -40.98 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.091 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -108.39 -23.36 11.92 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.439 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.3 mt -104.5 128.82 57.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.801 0.334 . . . . 0.0 111.274 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.411 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.04 155.67 46.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.383 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 6.4 t -102.5 145.73 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.299 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.24 139.09 40.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.068 0.461 . . . . 0.0 111.823 -179.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -115.74 130.48 56.87 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.754 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.25 142.58 39.91 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.047 0.451 . . . . 0.0 111.626 -179.256 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.451 ' CE2' ' CD2' ' A' ' 184' ' ' LEU . 0.1 OUTLIER -134.14 130.68 37.68 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.372 179.582 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 5.6 mp0 -98.21 -79.85 0.46 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.12 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -92.3 124.39 36.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.927 0.394 . . . . 0.0 111.009 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 31.3 m -80.76 142.73 13.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.093 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -116.5 142.68 46.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.927 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -122.99 138.69 54.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.954 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 20.9 pt -70.04 -28.47 36.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.192 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -58.5 -54.79 34.88 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.492 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -129.48 102.09 6.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.84 0.352 . . . . 0.0 110.847 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.86 -37.81 67.26 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -162.85 74.79 0.18 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.531 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.0 t -99.75 31.88 3.07 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.852 0.358 . . . . 0.0 110.905 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 3.1 m -140.67 179.48 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.108 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -105.73 49.91 0.86 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.561 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -104.32 150.82 24.13 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.845 0.355 . . . . 0.0 110.829 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . 0.419 ' N ' ' CD ' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -82.32 -52.05 0.73 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.957 -179.984 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . 0.419 ' CD ' ' N ' ' A' ' 178' ' ' ARG . 71.2 Cg_exo -50.88 119.31 5.11 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.502 2.135 . . . . 0.0 112.209 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.48 144.52 37.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.018 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 60.97 173.63 0.1 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -103.64 -131.45 7.24 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.429 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 20.7 tpp -162.0 128.52 3.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.841 0.353 . . . . 0.0 110.973 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . 0.451 ' CD2' ' CE2' ' A' ' 163' ' ' TYR . 0.7 OUTLIER -129.54 129.18 44.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.696 179.821 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.9 m -125.43 151.01 46.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.104 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.47 128.44 52.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.414 179.712 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -145.7 167.24 27.67 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.997 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.7 m -129.56 137.34 57.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.659 0.266 . . . . 0.0 110.588 179.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.7 p -139.88 175.06 9.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.953 0.406 . . . . 0.0 111.318 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . 0.401 ' CE1' ' HB2' ' A' ' 21' ' ' ALA . 3.8 p90 -141.66 159.92 41.23 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.812 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.401 ' HG3' ' CE2' ' A' ' 20' ' ' TYR . 0.4 OUTLIER -103.86 155.48 18.59 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.851 179.967 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -82.91 134.94 35.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.886 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -112.6 -167.65 17.37 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.549 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.98 142.48 27.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.762 0.315 . . . . 0.0 110.925 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -86.38 -43.99 12.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -88.53 131.02 35.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.913 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -111.32 145.96 37.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.096 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -168.82 75.61 0.77 Allowed Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.079 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.29 93.39 0.57 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.532 2.155 . . . . 0.0 112.337 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 21.6 t -114.97 48.69 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.048 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 5.7 m -119.21 135.47 59.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.177 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . 0.404 ' CB ' ' CD ' ' A' ' 203' ' ' PRO . . . -67.58 -61.38 4.5 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . 0.404 ' CD ' ' CB ' ' A' ' 202' ' ' ALA . 49.5 Cg_endo -69.28 124.13 10.97 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.564 2.176 . . . . 0.0 112.24 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -77.06 148.27 78.19 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.027 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.54 150.76 51.98 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.562 2.175 . . . . 0.0 112.336 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -88.92 158.59 47.15 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.011 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -51.92 -61.46 0.51 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.534 2.156 . . . . 0.0 112.352 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -109.29 166.61 10.47 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.48 169.08 19.39 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.587 2.191 . . . . 0.0 112.281 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.815 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.34 0 CA-C-O 120.853 0.359 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 12.4 ptm180 -103.07 -33.32 9.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.993 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.6 tt -169.51 138.44 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.06 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.9 ptp -153.73 130.67 10.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -130.48 -46.38 1.08 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.739 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -66.64 101.98 0.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.098 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 mt -78.17 -58.85 3.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.077 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -157.64 156.47 31.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.901 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.3 m -64.77 118.61 7.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.079 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.6 tp -161.99 -67.75 0.05 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.878 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -86.15 122.25 29.89 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.91 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -78.12 -57.24 3.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.089 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -114.87 145.89 34.94 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.087 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -54.97 -33.22 81.98 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.53 2.153 . . . . 0.0 112.227 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.4 55.49 1.73 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.957 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -79.23 -30.04 43.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.712 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 70.2 m-80 -66.0 -174.69 0.26 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.94 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.6 p -108.88 156.2 19.95 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.775 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.413 ' CZ2' ' HB2' ' A' ' 192' ' ' PHE . 70.2 p-90 -149.6 132.3 15.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.987 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.5 m-85 -114.38 141.15 48.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.55 141.64 28.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.884 0.373 . . . . 0.0 111.278 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.442 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.21 -166.55 30.21 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.879 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -134.3 141.76 13.12 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.466 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.494 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 6.3 ptpt -128.84 149.72 50.63 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.078 0.466 . . . . 0.0 111.412 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 47.4 tp -126.46 150.11 48.89 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.511 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -172.8 -160.66 21.79 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.342 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -78.92 147.41 33.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 0.0 110.917 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.6 t -102.64 -61.54 1.38 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.931 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -147.34 125.87 12.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -106.02 33.95 3.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.936 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -128.04 153.28 46.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -82.75 79.44 9.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.1 m -67.78 146.82 53.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 102.17 -144.58 16.3 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.464 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -72.31 158.4 35.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.852 0.358 . . . . 0.0 110.886 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -128.84 -45.84 1.28 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.859 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -109.27 -35.04 2.38 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.561 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 25.2 m120 -90.6 112.34 24.0 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 176.98 155.81 14.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.499 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -120.62 159.08 26.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.834 0.35 . . . . 0.0 110.899 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -157.35 100.99 1.85 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.923 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -95.98 -57.15 2.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.936 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -136.41 96.88 3.45 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.91 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -118.87 142.97 47.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.917 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -135.95 75.83 0.39 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.569 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -52.33 102.71 0.07 OUTLIER 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.645 2.23 . . . . 0.0 112.288 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 74.5 p -94.72 -41.36 9.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.957 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 43.0 mtt180 -137.13 83.31 1.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -97.86 37.48 1.4 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.971 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -111.22 83.01 1.69 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.851 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 56.9 mt-30 -61.85 111.47 1.9 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.865 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 3.6 pp -126.73 142.4 51.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -125.4 143.88 14.78 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.413 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -118.05 170.02 9.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.688 0.28 . . . . 0.0 110.932 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.58 157.34 27.67 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.783 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -108.97 140.58 42.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 110.876 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.401 ' CD1' ' OE2' ' A' ' 69' ' ' GLU . 3.0 m-85 -126.48 128.76 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.031 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.65 124.99 2.2 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.254 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.13 172.26 23.0 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.763 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -140.11 160.49 39.83 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.827 0.346 . . . . 0.0 110.786 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -113.35 130.38 56.29 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.908 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 42.0 t -131.87 -45.43 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.07 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 68.4 m-80 -86.34 156.1 56.94 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.789 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_endo -61.55 -24.37 77.96 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.596 2.197 . . . . 0.0 112.283 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -150.15 45.85 0.9 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.706 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -162.81 115.76 1.63 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.831 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -121.23 161.56 15.25 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.584 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -114.08 134.7 54.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.779 0.323 . . . . 0.0 110.696 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.401 ' OE2' ' CD1' ' A' ' 57' ' ' PHE . 2.0 tt0 -129.95 129.93 44.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.918 0.389 . . . . 0.0 111.085 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 ttm -108.01 135.43 49.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.422 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 158.52 14.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.512 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 19.9 m-85 -138.0 115.02 10.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.646 0.26 . . . . 0.0 110.657 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.412 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.2 t0 -87.97 121.09 29.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.88 0.372 . . . . 0.0 110.924 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 21.3 t-105 -136.76 132.75 35.21 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.977 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 6.0 tt -83.5 -66.0 0.94 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.939 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 155.76 -138.9 6.26 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.497 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.5 ttm105 -84.3 -52.19 6.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.8 0.333 . . . . 0.0 110.879 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.17 90.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.815 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -127.21 -43.39 1.64 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.18 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 62.5 m-85 -57.05 95.24 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -110.99 157.01 20.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.862 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.83 107.04 0.25 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.551 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.4 t -146.05 -47.41 0.2 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.818 0.342 . . . . 0.0 110.886 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.5 t -96.85 -45.75 12.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.125 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 6.6 t0 -168.39 138.08 2.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.895 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -81.65 98.67 8.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.914 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -140.55 46.55 0.92 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.451 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -140.89 138.37 33.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.869 0.366 . . . . 0.0 111.158 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 39.9 m-85 -143.85 -68.03 0.33 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.9 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.11 132.14 55.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.774 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -151.67 154.37 36.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.212 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 -175.05 130.3 0.3 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.534 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.412 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -85.26 135.76 13.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.926 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.42 120.33 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 179.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -108.95 148.51 30.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.154 0.502 . . . . 0.0 111.744 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 tt -138.13 114.04 9.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.703 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 8.6 p -149.72 164.45 35.22 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 121.054 0.455 . . . . 0.0 111.764 -178.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -97.52 132.28 43.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.314 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.86 132.23 53.66 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.036 0.446 . . . . 0.0 111.643 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.4 pp -135.93 124.07 23.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.431 179.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.96 -169.86 30.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.711 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.437 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 2.9 t80 -160.62 145.17 10.59 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.69 0.281 . . . . 0.0 111.12 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.437 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 95.3 Cg_endo -86.48 172.09 7.1 Favored 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.884 2.389 . . . . 0.0 112.479 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 17.7 mt -142.28 62.67 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 121.032 0.444 . . . . 0.0 111.262 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 8.1 p 56.71 172.99 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.511 179.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.6 t70 60.77 -87.13 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.043 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -179.87 36.79 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.075 0.464 . . . . 0.0 110.739 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.41 HD22 ' CE2' ' A' ' 151' ' ' TRP . 0.0 OUTLIER -121.67 115.77 23.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.149 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.415 ' CB ' ' HA ' ' A' ' 103' ' ' PRO . 11.4 p-10 -131.38 155.11 47.83 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.031 0.443 . . . . 0.0 111.893 -179.19 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.418 ' CG2' ' CG1' ' A' ' 149' ' ' VAL . 1.0 OUTLIER -119.91 146.82 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.271 179.351 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.42 ' CE2' ' HB2' ' A' ' 150' ' ' GLU . 4.4 p90 -162.44 164.01 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.103 0.478 . . . . 0.0 111.763 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 17.4 m -140.54 139.77 35.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.497 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.405 ' HB3' ' NH1' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -114.96 127.99 56.01 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.152 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -127.79 122.91 33.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.44 179.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -178.89 -134.54 2.15 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.536 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -149.42 163.06 29.19 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.751 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.9 ppp? -117.64 145.03 44.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 110.917 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.7 t -127.05 141.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.861 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.5 t90 -131.65 148.88 52.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.003 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 20.1 ttt180 -118.54 152.23 36.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -163.19 149.19 11.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.001 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -107.37 131.1 54.62 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.964 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -98.45 101.09 12.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.855 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.71 169.95 15.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.831 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -129.22 -174.16 13.63 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.455 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -70.08 -31.77 69.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.812 0.339 . . . . 0.0 110.894 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -85.3 158.85 20.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -115.34 76.31 0.99 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.135 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.1 m -84.14 120.63 26.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.922 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 23.4 p -143.05 123.69 14.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.865 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -135.49 -96.67 0.51 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.519 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 16.8 m -142.87 30.82 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 111.19 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 18.7 t -120.47 166.8 13.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.905 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.03 155.48 17.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.939 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.93 165.95 23.46 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.809 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -87.65 143.2 27.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.841 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -116.68 112.73 21.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.898 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -116.0 132.52 56.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.958 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 69.7 p -136.71 129.78 31.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -89.53 135.23 12.84 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.433 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p -132.65 136.12 56.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.714 0.293 . . . . 0.0 111.015 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.02 117.33 2.84 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.347 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.42 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 6.3 Cg_exo -73.65 137.62 25.3 Favored 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 122.605 2.203 . . . . 0.0 111.85 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 26.4 m -156.96 164.03 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.862 0.363 . . . . 0.0 111.386 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -148.59 122.37 9.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.796 179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.52 142.85 45.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.173 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.34 142.12 13.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.299 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.412 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -170.55 -157.69 13.12 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.107 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.418 ' CG1' ' CG2' ' A' ' 110' ' ' ILE . 4.9 m -129.83 163.25 35.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 111.127 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.42 ' HB2' ' CE2' ' A' ' 111' ' ' TYR . 0.7 OUTLIER -133.19 129.38 37.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . 0.41 ' CE2' HD22 ' A' ' 108' ' ' LEU . 1.4 t-105 -118.43 132.55 56.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.792 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.427 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -99.36 134.43 42.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 0.0 111.528 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.413 ' O ' ' CG1' ' A' ' 153' ' ' VAL . 47.8 t -116.06 39.92 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.751 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 59.08 -175.84 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.218 179.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 60.8 26.26 16.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.126 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 56.33 22.83 6.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.245 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 5.7 mt -125.47 109.65 22.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.073 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.427 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -115.88 154.26 30.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.342 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.99 151.53 22.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.247 179.499 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 2.1 ptm180 -136.93 132.76 34.89 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.9 0.381 . . . . 0.0 111.897 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.419 HD23 ' CE1' ' A' ' 163' ' ' TYR . 1.1 tt -123.61 120.79 33.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.734 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . 0.412 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 0.7 OUTLIER -116.34 145.12 43.44 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.606 -179.043 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.457 ' N ' ' CD1' ' A' ' 163' ' ' TYR . 2.1 m-85 -126.76 165.81 18.58 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.551 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -120.38 145.38 47.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.938 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 5.6 t-105 -97.12 135.41 39.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 17.2 m -140.22 31.97 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.1 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -117.3 153.92 32.12 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -98.0 -62.9 1.18 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.898 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 2.3 pp -154.93 -46.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.163 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -130.71 -178.25 15.34 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.35 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -95.87 129.79 43.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.842 0.353 . . . . 0.0 110.933 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -93.71 -45.52 7.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.007 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -78.96 162.69 48.77 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.509 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.2 p -105.49 -30.69 9.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.899 0.38 . . . . 0.0 110.915 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 12.3 p -116.08 141.73 32.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.036 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -145.32 110.93 0.57 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.508 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.97 -54.58 1.72 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.833 0.349 . . . . 0.0 110.844 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 1.1 mtp180 -93.67 143.13 26.07 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.939 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.85 128.0 14.46 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.489 2.126 . . . . 0.0 112.185 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -107.41 -33.26 7.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.825 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -145.96 151.35 37.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.834 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 120.16 151.58 8.78 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.391 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 8.9 ttm -143.05 122.1 12.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.78 0.324 . . . . 0.0 110.971 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 6.7 mp -114.71 133.36 55.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.779 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.2 m -132.59 145.8 51.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.91 137.84 49.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.568 179.705 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -158.8 -176.65 31.09 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.449 -0.881 . . . . 0.0 113.042 -179.569 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -126.16 141.86 44.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.637 0.256 . . . . 0.0 110.52 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 189' ' ' SER . . . . . 0.442 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 1.4 t -137.93 159.72 41.24 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.112 0.482 . . . . 0.0 111.576 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -117.81 146.42 43.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.41 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.26 143.64 45.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . 0.413 ' HB2' ' CZ2' ' A' ' 19' ' ' TRP . 60.3 m-85 -148.29 123.99 10.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.878 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -149.38 167.07 29.64 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.538 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -116.51 170.47 8.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -98.23 169.16 9.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -59.91 -169.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.859 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -97.69 35.38 1.68 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.031 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -124.05 136.15 27.19 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.992 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.4 -167.82 0.47 Allowed 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.489 2.126 . . . . 0.0 112.253 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 10.6 m -92.91 -30.58 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.088 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 29.3 t -74.13 -32.89 33.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.981 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -89.21 157.49 47.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.08 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.04 134.97 30.89 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.517 2.145 . . . . 0.0 112.222 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . 0.414 ' N ' ' CD ' ' A' ' 205' ' ' PRO . . . -78.54 -52.65 1.35 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.174 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . 0.414 ' CD ' ' N ' ' A' ' 204' ' ' ALA . 31.6 Cg_exo -59.13 -159.64 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.482 2.121 . . . . 0.0 112.115 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -103.34 139.71 20.37 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.963 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.84 90.05 0.74 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.471 2.114 . . . . 0.0 112.35 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -89.17 145.17 33.7 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.093 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.38 94.9 0.84 Allowed 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.53 2.153 . . . . 0.0 112.338 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.24 -0.886 . . . . 0.0 110.887 179.975 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 120.789 0.328 . . . . 0.0 111.052 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.79 31.25 6.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.905 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 30.6 mt -144.74 145.53 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.155 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -167.69 128.93 1.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.83 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -72.56 131.24 42.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.827 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -110.98 96.25 6.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.18 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 tt -148.68 36.47 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.979 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -117.28 -40.25 3.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.859 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.2 m -137.14 142.25 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.078 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -139.44 -47.39 0.47 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.945 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -71.43 120.39 16.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.941 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -138.02 36.88 2.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.031 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -90.24 112.05 50.43 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.077 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -54.87 -176.6 0.04 OUTLIER 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.304 2.003 . . . . 0.0 112.324 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 27.8 mttm -95.94 80.94 3.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.939 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -87.72 152.72 21.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.827 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -103.8 100.51 10.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.872 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.98 130.09 55.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.822 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -121.19 146.97 46.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.415 ' CD1' ' HB2' ' A' ' 189' ' ' SER . 0.1 OUTLIER -142.35 135.81 29.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.724 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 145.22 31.03 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.336 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.72 -168.9 38.65 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.566 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -137.0 147.04 19.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.546 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.423 ' HE3' ' CE2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -121.2 153.14 37.98 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 -179.924 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.1 tt -133.43 139.34 46.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.723 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -165.1 -172.37 32.48 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.577 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -92.09 153.61 19.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.773 0.321 . . . . 0.0 110.85 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 25.2 p -111.82 112.1 23.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.973 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.89 94.71 7.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.934 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -136.9 -47.67 0.6 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.95 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -67.12 154.86 40.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.918 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -176.61 -41.47 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.864 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 49.7 p -110.99 165.46 11.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.995 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 96.69 39.49 4.13 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.439 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -138.23 31.6 2.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.749 0.309 . . . . 0.0 110.851 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -64.46 142.04 58.56 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.827 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -170.98 66.05 0.15 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -67.26 -31.48 71.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.868 0.366 . . . . 0.0 110.822 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -68.76 -140.11 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.492 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -119.09 144.33 46.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.345 . . . . 0.0 110.903 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -126.99 89.57 3.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.935 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -100.09 -29.72 12.35 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.94 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -58.64 160.97 5.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.874 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -136.32 151.92 50.13 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.967 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -114.55 171.07 13.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.493 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -52.79 -61.9 0.42 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.518 2.146 . . . . 0.0 112.308 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -149.45 173.53 13.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.835 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 2.8 mtt85 -84.15 143.41 29.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.844 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -86.35 106.3 17.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.909 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.25 168.47 10.21 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.908 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -149.05 92.13 1.93 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.941 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.8 pp -94.54 161.67 14.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.735 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.34 140.33 11.72 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.628 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -127.97 159.63 34.38 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.812 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.417 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -158.44 155.66 26.68 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.802 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -113.59 126.69 55.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.797 0.332 . . . . 0.0 110.856 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.423 ' CE2' ' HE3' ' A' ' 24' ' ' LYS . 38.9 p90 -115.59 133.46 56.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.111 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.1 125.15 1.78 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.132 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -150.41 -176.98 23.93 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.747 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -155.06 154.48 32.52 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.896 0.379 . . . . 0.0 111.006 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -102.89 137.33 41.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.567 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 24.0 t -122.54 -49.17 2.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.004 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -96.18 142.62 24.82 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.491 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.412 ' O ' ' CG ' ' A' ' 65' ' ' TYR . 45.3 Cg_endo -68.15 64.14 1.03 Allowed 'Trans proline' 0 C--N 1.343 0.264 0 C-N-CA 122.399 2.066 . . . . 0.0 111.996 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.412 ' CG ' ' O ' ' A' ' 64' ' ' PRO . 9.0 m-85 -168.24 -37.77 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.414 -179.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -169.55 164.08 10.32 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.976 0.417 . . . . 0.0 111.159 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.49 176.76 18.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.398 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.405 ' CE2' ' HG ' ' A' ' 96' ' ' LEU . 1.2 t80 -103.85 138.24 40.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.634 0.254 . . . . 0.0 110.724 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -134.51 125.9 28.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.852 0.358 . . . . 0.0 111.116 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.1 mtt -107.27 133.38 51.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.434 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.87 159.4 13.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.615 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.417 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -131.53 114.88 15.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.679 0.276 . . . . 0.0 110.613 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -86.18 120.51 27.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.998 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 42.8 t90 -139.09 142.21 38.14 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.917 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 4.8 mp -114.6 -175.79 2.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -107.31 -158.44 20.86 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.503 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.1 tpt180 60.55 108.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.767 0.318 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -96.18 152.21 18.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.796 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.16 134.63 49.1 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.151 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 28.0 m-85 -114.66 31.72 6.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.967 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.2 mptt -98.6 84.56 3.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -147.82 78.37 0.23 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.542 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.4 m -135.65 -70.18 0.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.782 0.325 . . . . 0.0 110.924 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 17.3 m -140.69 32.37 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.165 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -160.87 118.44 2.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.929 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -90.13 128.28 36.3 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 171.49 40.9 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.499 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -118.31 156.13 29.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.848 0.356 . . . . 0.0 111.055 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -85.38 107.72 17.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.989 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 3.3 mmmt -138.77 124.04 19.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.869 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -168.32 176.97 5.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.2 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 -154.54 127.75 8.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.566 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -98.21 130.22 10.16 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.968 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.77 118.96 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 15.8 mt-30 -108.86 144.4 36.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.241 0.543 . . . . 0.0 111.937 -178.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.405 ' HG ' ' CE2' ' A' ' 68' ' ' PHE . 1.3 tt -133.45 112.19 11.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.266 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.422 ' CB ' ' HA3' ' A' ' 115' ' ' GLY . 6.0 p -147.03 178.05 8.67 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.219 0.533 . . . . 0.0 111.984 -178.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -117.27 135.81 53.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.039 179.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -110.65 131.98 54.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.021 0.439 . . . . 0.0 111.379 -179.387 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -135.45 125.71 26.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.259 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.429 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -168.14 -169.82 32.09 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.944 -179.538 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.425 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 24.5 p90 -156.51 152.43 22.85 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.819 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.421 ' HA ' ' CB ' ' A' ' 109' ' ' ASP . 83.8 Cg_endo -83.1 165.52 14.89 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.721 2.281 . . . . 0.0 112.803 -179.617 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.504 ' N ' ' O ' ' A' ' 108' ' ' LEU . 9.6 mt -142.09 139.89 30.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.411 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 88.1 m 64.06 -76.02 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.028 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.7 t0 178.38 -34.78 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.087 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.34 19.86 11.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.415 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.504 ' O ' ' N ' ' A' ' 104' ' ' ILE . 0.1 OUTLIER -138.15 113.38 9.36 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.814 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.421 ' CB ' ' HA ' ' A' ' 103' ' ' PRO . 9.5 m-20 -129.27 145.59 51.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.987 0.422 . . . . 0.0 111.809 -179.234 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.425 HD13 ' CZ ' ' A' ' 102' ' ' TYR . 1.3 pt -114.9 142.17 28.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.657 179.314 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.429 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 33.4 m-85 -149.12 158.33 44.1 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.058 0.456 . . . . 0.0 111.695 -179.35 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.6 m -130.89 141.92 50.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.457 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 36.8 ttp180 -120.83 127.94 52.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.278 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -136.34 122.92 20.92 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.929 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.422 ' HA3' ' CB ' ' A' ' 97' ' ' THR . . . -177.12 -140.71 3.73 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.583 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.7 167.74 25.48 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.868 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 9.0 ttp -130.2 141.1 50.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 0.0 110.735 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.4 t -125.69 115.63 43.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.826 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -110.97 133.81 53.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.888 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 3.2 tpt180 -102.84 144.77 30.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.932 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -112.91 143.81 43.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.061 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -126.64 127.29 44.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 10.3 m -159.67 37.06 0.19 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.967 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 6.3 tptt -137.31 119.16 15.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.847 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -169.75 -49.2 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.481 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 23.2 t30 -92.08 171.96 8.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.89 0.376 . . . . 0.0 110.905 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -69.33 -31.43 69.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.938 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -73.72 171.4 13.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.067 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 29.1 t -152.22 165.54 34.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.842 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.54 56.05 0.68 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.89 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -153.36 -145.35 4.13 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.546 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 12.3 p -110.86 -42.86 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.818 0.342 . . . . 0.0 111.14 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 84.6 p -135.08 -46.99 0.71 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.927 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -154.47 119.56 5.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.856 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 54.4 p -62.31 106.53 0.76 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.991 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -61.43 141.4 57.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.871 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 50.9 p-80 -60.5 142.51 55.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.907 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -122.78 135.5 54.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.878 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.1 p -135.27 130.53 35.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -105.54 89.04 0.6 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.341 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.1 p -118.65 126.12 74.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.705 0.288 . . . . 0.0 110.97 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -157.16 148.49 16.84 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.831 0.348 . . . . 0.0 111.464 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.443 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -79.81 145.66 18.11 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.752 2.302 . . . . 0.0 112.222 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.7 m -156.71 157.1 4.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.927 0.394 . . . . 0.0 111.404 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -149.13 127.19 11.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.476 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -124.01 143.85 50.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.245 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -130.02 146.95 17.85 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.09 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -167.72 -164.39 23.31 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.936 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.413 ' CG1' ' CG2' ' A' ' 110' ' ' ILE . 6.7 m -128.65 166.89 25.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.685 0.279 . . . . 0.0 111.134 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -135.4 149.1 49.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.92 0.391 . . . . 0.0 111.196 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 5.2 m0 -131.39 123.07 27.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.735 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.86 130.2 34.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.225 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.02 -70.44 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.052 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -96.65 -176.68 3.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.962 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 7.3 ttm180 -72.51 117.13 13.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.909 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 62.06 23.78 14.07 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.153 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.42 HG12 ' CD2' ' A' ' 190' ' ' TYR . 22.8 mt -137.47 106.27 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.754 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -132.99 160.86 35.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.984 0.421 . . . . 0.0 111.59 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 24.5 m -119.35 145.45 46.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.973 179.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.403 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 147.42 46.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.179 0.514 . . . . 0.0 111.976 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.425 HD23 ' CZ ' ' A' ' 163' ' ' TYR . 1.3 tt -113.92 123.57 50.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.533 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -107.5 143.88 35.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.044 0.45 . . . . 0.0 111.616 -179.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.433 ' CD1' HD23 ' A' ' 184' ' ' LEU . 45.4 m-85 -130.94 163.53 27.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.504 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -111.89 -70.04 0.83 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 15.8 t-105 -103.61 108.06 19.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 14.4 m -142.65 157.03 18.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.151 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.57 -68.6 0.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 14.4 p-10 -130.6 113.95 14.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 3.1 pt -84.75 153.42 3.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.139 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -172.03 -118.76 0.49 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.581 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -110.71 31.6 5.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.799 0.333 . . . . 0.0 110.958 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -145.93 -179.83 6.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.098 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -158.92 66.41 0.28 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.523 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.6 m -149.37 91.19 1.8 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 6.1 m -125.94 -46.15 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -179.73 146.47 7.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.462 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.5 -53.89 0.21 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.871 0.367 . . . . 0.0 110.968 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . 0.404 ' CB ' ' CD ' ' A' ' 179' ' ' PRO . 2.0 mtm180 -71.76 -61.16 2.13 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.859 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . 0.404 ' CD ' ' CB ' ' A' ' 178' ' ' ARG . 60.1 Cg_endo -72.83 -44.6 0.61 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.588 2.192 . . . . 0.0 112.352 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -76.49 147.07 38.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.91 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -100.72 81.8 2.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -124.18 -165.65 12.28 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.387 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 2.1 mtm -155.01 111.74 3.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.785 0.326 . . . . 0.0 110.984 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . 0.433 HD23 ' CD1' ' A' ' 163' ' ' TYR . 0.5 OUTLIER -112.65 126.53 55.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.605 179.772 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -135.71 152.37 51.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.973 0.416 . . . . 0.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.13 128.72 54.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.3 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -143.2 167.31 26.48 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.16 -1.019 . . . . 0.0 113.082 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -128.42 139.49 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.687 0.28 . . . . 0.0 110.374 179.445 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 189' ' ' SER . . . . . 0.415 ' HB2' ' CD1' ' A' ' 20' ' ' TYR . 0.3 OUTLIER -136.27 168.7 18.93 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 111.723 -179.125 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . 0.452 ' CD1' ' N ' ' A' ' 190' ' ' TYR . 2.7 m-85 -131.71 157.99 42.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.366 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 38.0 mtm180 -94.09 132.54 38.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.943 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -106.22 114.22 28.21 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.933 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -135.49 163.97 24.9 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.52 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -103.59 110.47 22.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.837 0.351 . . . . 0.0 110.866 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -80.24 164.41 23.26 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.91 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -127.69 128.77 46.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.933 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -79.07 -30.92 44.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.168 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -101.58 96.18 6.05 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.043 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.45 92.1 0.35 Allowed 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.447 2.098 . . . . 0.0 112.271 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 12.7 m -85.61 -25.41 6.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.222 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 14.6 p -92.26 15.45 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.385 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -140.13 63.32 23.47 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 120.78 0.324 . . . . 0.0 111.066 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.75 -169.38 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.558 2.172 . . . . 0.0 112.33 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -120.27 115.65 32.74 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.012 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.64 155.24 69.53 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.501 2.134 . . . . 0.0 112.255 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . 0.412 ' N ' ' HD2' ' A' ' 207' ' ' PRO . . . -69.98 -61.61 2.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.168 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . 0.412 ' HD2' ' N ' ' A' ' 206' ' ' ALA . 36.2 Cg_endo -65.23 140.4 64.47 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.483 2.122 . . . . 0.0 112.236 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -100.87 162.82 19.43 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.073 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -53.8 -43.89 54.03 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.455 2.103 . . . . 0.0 112.173 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.253 -0.88 . . . . 0.0 110.85 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 120.805 0.336 . . . . 0.0 111.004 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.42 -31.3 9.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.897 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.8 pt -90.99 133.8 31.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.123 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.2 tpp -162.06 -52.11 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.844 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.65 107.27 19.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.859 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.39 -62.45 1.39 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.083 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 31.7 mt -123.08 157.22 28.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.078 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -122.15 159.05 28.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.942 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.56 128.34 37.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.106 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -143.4 168.89 18.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -88.44 150.65 23.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.859 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.54 158.31 27.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.096 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.419 ' N ' ' CD ' ' A' ' 14' ' ' PRO . . . -87.63 -52.63 0.4 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.026 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.419 ' CD ' ' N ' ' A' ' 13' ' ' ALA . 53.0 Cg_exo -54.93 97.91 0.05 OUTLIER 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.542 2.161 . . . . 0.0 112.224 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.89 34.07 4.12 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.902 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -88.98 -33.48 17.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.933 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -86.88 137.45 32.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.008 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.4 p -148.39 168.87 21.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.838 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 25.9 m-90 -117.28 132.45 56.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.055 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.417 ' CZ ' ' HG3' ' A' ' 191' ' ' ARG . 5.1 m-85 -120.41 135.87 54.91 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.522 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.22 140.26 43.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.488 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 179.14 -163.78 31.57 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.414 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -162.73 161.33 33.67 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.552 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.433 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 0.1 OUTLIER -135.32 160.9 36.97 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.005 0.431 . . . . 0.0 111.044 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.9 tt -130.85 149.17 52.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.735 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -157.89 177.6 34.57 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.463 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . 0.421 ' CD1' ' N ' ' A' ' 27' ' ' TRP . 2.5 p-90 -142.81 141.49 31.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.835 0.35 . . . . 0.0 110.961 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.3 t -101.09 117.78 35.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.93 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -140.96 151.48 44.21 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.746 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -138.32 100.88 4.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.961 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -91.85 160.66 15.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.817 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -110.3 155.41 22.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -94.53 122.55 37.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.28 28.35 8.63 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.586 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 18.9 t80 -144.2 135.1 25.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.787 0.327 . . . . 0.0 110.95 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 11.6 p90 -165.48 148.35 7.87 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -157.36 125.35 1.56 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.511 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -114.49 30.5 7.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.711 0.291 . . . . 0.0 110.901 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -106.87 159.68 14.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.75 117.89 17.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.775 0.321 . . . . 0.0 110.817 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 -141.46 87.24 2.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.881 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -67.83 -37.87 82.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.928 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -141.19 88.46 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.911 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -136.57 -62.45 0.65 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.841 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.6 126.18 1.73 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.464 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.92 92.46 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.471 2.114 . . . . 0.0 112.232 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.1 m -99.52 -39.89 8.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.985 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -72.77 132.38 43.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.881 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -114.85 98.92 7.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -82.12 112.5 19.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -150.81 77.86 1.29 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.947 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.7 mp -90.3 129.56 36.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.82 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -134.52 127.46 4.49 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.502 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -132.37 132.64 43.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.752 0.311 . . . . 0.0 110.914 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.37 158.08 26.79 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.753 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -126.85 134.72 50.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.51 0.195 . . . . 0.0 110.793 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.433 ' CE2' ' HG2' ' A' ' 24' ' ' LYS . 6.3 p90 -142.37 165.39 27.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.176 0.512 . . . . 0.0 111.738 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -140.13 141.87 11.96 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.79 179.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -114.59 143.26 17.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.896 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.425 ' CZ ' ' HB3' ' A' ' 68' ' ' PHE . 1.8 p90 -144.62 121.3 11.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.898 0.38 . . . . 0.0 110.631 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 -93.3 137.11 32.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.976 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.4 t -123.86 -45.06 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.728 179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.428 ' O ' ' N ' ' A' ' 65' ' ' TYR . 0.8 OUTLIER -102.73 132.59 21.11 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.364 179.605 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -59.04 77.42 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.552 2.168 . . . . 0.0 112.361 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.428 ' N ' ' O ' ' A' ' 63' ' ' ASN . 0.6 OUTLIER 178.28 -36.16 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.126 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -171.31 164.06 7.09 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.861 0.362 . . . . 0.0 110.99 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 172.16 20.33 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.425 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . 0.9 OUTLIER -96.87 141.46 30.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.684 0.278 . . . . 0.0 110.611 179.902 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.77 120.24 28.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.976 0.417 . . . . 0.0 111.281 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.3 mtt -106.17 139.03 41.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.859 179.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.427 ' CA ' ' HB3' ' A' ' 57' ' ' PHE . . . -133.0 166.63 23.61 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.643 -179.278 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -136.92 115.43 11.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.363 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -81.52 129.73 34.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.18 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . 0.401 ' CZ3' ' O ' ' A' ' 91' ' ' ALA . 46.0 m95 -135.67 135.78 40.4 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.737 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 8.1 tt -146.11 162.95 36.8 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.936 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 168.68 112.8 0.27 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.498 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 8.5 mmm180 -145.25 157.85 43.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.783 0.325 . . . . 0.0 110.957 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.1 mtp -101.6 97.77 8.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.816 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -160.42 32.19 0.16 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.151 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -120.62 140.93 50.84 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 4.2 mtmm -95.95 92.13 6.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.959 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -114.2 169.39 12.88 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.507 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 25.4 t -168.94 -51.42 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.905 0.384 . . . . 0.0 110.893 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.0 m -132.29 126.86 56.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.101 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -176.09 172.97 2.29 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 62.4 m-20 -127.15 112.14 14.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.961 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 121.04 105.9 2.0 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.523 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -125.16 70.01 1.15 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.906 0.384 . . . . 0.0 111.089 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -110.37 152.89 25.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.925 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.77 -177.31 5.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.926 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.401 ' O ' ' CZ3' ' A' ' 74' ' ' TRP . . . -123.93 163.69 20.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.065 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -157.19 124.99 5.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.519 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -105.53 140.56 15.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.429 -0.891 . . . . 0.0 112.913 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.81 122.62 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.201 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -108.53 143.85 36.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.115 0.483 . . . . 0.0 111.9 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -137.48 113.88 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.849 179.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.2 t -155.1 166.82 32.37 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 111.784 -179.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.1 139.45 39.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.32 179.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.9 ttpp -118.92 132.25 56.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.897 0.379 . . . . 0.0 111.598 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.8 pp -134.03 126.58 30.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.737 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 102' ' ' TYR . . . -167.99 -177.81 39.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.514 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.407 ' CG ' ' O ' ' A' ' 101' ' ' GLY . 6.5 m-85 -166.1 158.89 12.51 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.777 0.322 . . . . 0.0 110.987 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -61.13 171.98 3.51 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.741 2.294 . . . . 0.0 111.944 179.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.422 ' N ' ' O ' ' A' ' 108' ' ' LEU . 0.6 OUTLIER -124.73 -37.1 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.445 -179.906 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 14.7 p -140.4 -46.7 0.42 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.942 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -169.51 -67.76 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.143 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -108.31 26.4 10.49 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.367 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.422 ' O ' ' N ' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -136.28 122.74 20.75 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.828 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -135.15 156.19 49.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.071 0.462 . . . . 0.0 111.996 -179.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.406 ' CG2' HG11 ' A' ' 149' ' ' VAL . 1.6 pp -121.34 138.86 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.394 179.309 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 48.1 p90 -151.28 163.51 38.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.071 0.463 . . . . 0.0 111.557 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 18.5 p -137.63 145.69 43.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.53 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -119.76 127.78 53.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.883 0.373 . . . . 0.0 111.315 -179.756 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -126.98 123.64 37.59 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.328 179.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 178.39 -132.49 1.94 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.42 -179.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.89 168.61 33.95 Favored Glycine 0 C--N 1.331 0.3 0 C-N-CA 120.285 -0.96 . . . . 0.0 112.9 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.95 140.98 52.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.711 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.5 t -133.91 118.16 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.657 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 64.5 p-90 -137.1 176.12 8.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.833 0.349 . . . . 0.0 111.049 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -148.62 150.86 34.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.825 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -162.58 165.64 25.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.089 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -86.58 156.88 19.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.874 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 3.5 t -149.5 -47.44 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.886 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 7.4 mtmt -101.94 117.15 34.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.886 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -109.72 -77.1 0.93 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.45 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -126.42 34.11 4.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.866 0.365 . . . . 0.0 110.795 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 60.1 m-85 -98.47 35.76 1.74 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -113.28 -171.06 1.8 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 38.2 t -159.79 -45.69 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.961 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 4.0 p -92.42 -32.09 15.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.016 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -100.87 120.05 6.74 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.449 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 11.1 p -123.66 -43.6 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 120.751 0.31 . . . . 0.0 111.078 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 96.6 p -93.88 -39.43 10.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.85 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.01 106.8 17.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.948 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 61.7 p -145.66 157.81 43.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -132.15 168.04 18.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.849 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.49 153.25 22.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -96.49 150.75 20.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.835 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.9 t -140.07 138.36 35.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.033 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -112.32 128.21 8.41 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.354 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.8 p -146.14 130.84 11.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.744 0.307 . . . . 0.0 111.194 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.21 141.29 11.67 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.397 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.418 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 92.2 Cg_endo -78.69 149.95 23.96 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.603 2.202 . . . . 0.0 112.02 179.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.8 m -156.3 157.93 3.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.04 0.448 . . . . 0.0 111.702 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -149.08 118.9 7.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.303 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -127.76 159.21 35.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.986 0.422 . . . . 0.0 111.537 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -130.95 151.82 19.75 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.036 179.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -162.73 -177.71 35.96 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.346 -0.931 . . . . 0.0 112.979 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.406 HG11 ' CG2' ' A' ' 110' ' ' ILE . 4.2 m -127.82 154.27 38.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 0.0 111.005 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -124.75 140.46 52.91 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.938 0.399 . . . . 0.0 111.116 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 1.9 t90 -131.63 127.77 37.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.779 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.62 137.2 34.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.329 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 76.0 t -104.75 -67.12 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.664 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.46 -77.24 0.2 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.875 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 5.6 ttp180 -173.93 -37.56 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.136 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -105.78 -24.85 12.4 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.498 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 33.4 mt -112.79 135.66 51.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.927 0.394 . . . . 0.0 111.288 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -136.35 164.35 28.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.233 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -118.53 144.8 45.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.151 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.415 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 0.0 OUTLIER -137.16 152.07 49.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.276 0.56 . . . . 0.0 112.051 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -117.97 125.36 50.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.551 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -117.72 137.54 52.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.049 0.452 . . . . 0.0 111.595 -179.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -134.19 152.29 51.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.489 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -94.7 114.89 26.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 65.0 p-90 -103.78 132.45 50.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.99 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.9 m -140.07 -47.1 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -121.8 111.64 17.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.879 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -96.67 40.45 1.13 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.894 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -149.98 113.27 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.076 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -84.2 171.31 48.06 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.394 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.23 171.97 10.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.815 0.341 . . . . 0.0 110.805 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -135.64 121.9 20.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.032 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -149.71 -55.14 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.463 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.7 m -144.95 -55.64 0.32 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.897 0.379 . . . . 0.0 110.822 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 6.0 m -156.38 149.36 11.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.047 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -140.35 -172.73 13.01 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.426 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 16.1 m -143.2 -67.26 0.36 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.806 0.336 . . . . 0.0 110.887 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 16.9 ttt85 -132.06 119.91 17.0 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.79 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -55.26 87.3 0.04 OUTLIER 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.436 2.091 . . . . 0.0 112.316 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 58.24 -178.46 0.07 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.96 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -149.59 -59.32 0.21 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.834 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 95.54 -99.29 2.37 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.567 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -143.67 121.23 11.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.738 0.304 . . . . 0.0 110.925 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 4.3 mp -120.08 142.45 48.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.681 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 72.0 m -148.71 153.25 37.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.975 0.416 . . . . 0.0 111.226 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.73 136.07 53.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.23 179.706 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.92 170.33 28.59 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.056 -1.069 . . . . 0.0 113.196 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.6 m -132.09 148.09 32.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.602 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 189' ' ' SER . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 160' ' ' ARG . 89.4 p -151.79 175.06 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.054 0.455 . . . . 0.0 111.466 -179.701 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -145.92 156.54 43.59 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.621 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.417 ' HG3' ' CZ ' ' A' ' 20' ' ' TYR . 8.4 ttm180 -99.45 146.63 26.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.92 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -81.37 106.13 13.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.939 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -143.03 148.88 20.77 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.525 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -109.8 126.94 54.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.794 0.33 . . . . 0.0 110.835 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -105.75 -43.26 4.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.907 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -115.48 97.09 5.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.942 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -97.61 50.24 1.05 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.093 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -74.54 165.62 52.08 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.119 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -66.95 94.93 0.35 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.514 2.143 . . . . 0.0 112.282 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 21.7 t -117.69 158.7 18.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.136 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 20.5 m -104.12 55.51 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.04 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -101.28 106.34 44.79 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.152 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -55.02 168.0 1.41 Allowed 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.462 2.108 . . . . 0.0 112.315 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -126.91 127.08 24.47 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.054 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -53.34 106.17 0.15 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.464 2.11 . . . . 0.0 112.272 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -67.71 163.61 47.24 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.079 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.26 132.6 30.09 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.512 2.142 . . . . 0.0 112.17 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . 0.473 ' CB ' ' HD3' ' A' ' 209' ' ' PRO . . . -160.12 -59.72 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.429 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . 0.473 ' HD3' ' CB ' ' A' ' 208' ' ' ALA . 53.9 Cg_exo -52.23 90.35 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.245 1.964 . . . . 0.0 112.364 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.943 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.839 0.352 . . . . 0.0 111.02 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.67 31.47 3.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.81 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.2 pt -149.53 140.9 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.238 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -147.44 166.0 28.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.909 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -136.34 -50.96 0.69 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.813 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -112.79 123.49 50.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.078 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 22.5 mt -135.74 142.69 38.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.148 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -99.69 121.37 41.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.019 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.9 m -74.49 154.27 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.148 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -127.22 -61.78 1.14 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.911 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -83.44 58.69 4.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.886 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -171.69 114.62 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.035 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.14 128.99 93.96 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.008 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -55.02 -31.78 76.13 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.451 2.101 . . . . 0.0 112.223 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 15.2 mtmm -132.1 111.61 11.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.04 -45.36 23.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.841 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -91.44 111.97 23.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.935 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 39.9 p -129.54 136.16 49.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.869 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.418 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.2 t-105 -135.66 135.07 39.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.415 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 7.9 m-85 -121.98 145.05 48.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.77 141.6 28.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.256 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.55 -166.67 34.06 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.552 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.38 146.71 18.42 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.544 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -127.93 149.32 50.37 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 120.858 0.361 . . . . 0.0 111.082 -179.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 2.0 tt -132.55 145.55 51.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.668 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -153.31 171.13 32.22 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.593 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . 0.408 ' CZ2' ' HB3' ' A' ' 50' ' ' ASP . 0.6 OUTLIER -113.92 149.71 34.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.783 0.325 . . . . 0.0 110.795 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.7 m -114.1 167.44 10.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.32 92.24 3.75 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.919 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 13.4 p90 -103.7 137.05 42.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.943 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 25.1 t-80 -82.93 -66.34 0.9 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.92 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.01 139.06 42.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.789 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.7 m -76.48 -36.94 57.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.933 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.38 125.19 4.53 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.588 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -143.19 142.57 31.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.79 0.328 . . . . 0.0 110.907 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -102.12 -48.46 4.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.783 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.31 91.36 1.35 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.473 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -93.14 113.64 25.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.818 0.342 . . . . 0.0 110.97 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -154.87 -134.8 1.95 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.502 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -127.48 79.9 1.92 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.792 0.329 . . . . 0.0 110.971 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.92 140.83 40.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.933 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -69.71 106.79 3.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.884 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -138.91 96.42 3.12 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.91 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 12.3 m-80 -89.18 120.64 30.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.826 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -173.79 -62.95 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.628 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -59.94 -25.71 80.3 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.582 2.188 . . . . 0.0 112.257 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.0 p -127.58 35.16 4.55 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.893 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -136.61 -51.68 0.69 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.931 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -109.28 -177.01 3.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.906 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.408 ' HB3' ' CZ2' ' A' ' 27' ' ' TRP . 21.4 m-20 -116.97 -179.81 3.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.89 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -140.57 111.92 7.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.874 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 1.7 pp -118.14 165.86 13.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.918 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.94 137.96 9.78 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.396 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -136.57 173.13 12.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.915 0.388 . . . . 0.0 111.052 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.87 156.6 26.06 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.626 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.95 160.17 14.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.822 0.344 . . . . 0.0 111.011 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -147.77 126.39 12.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.984 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.43 137.05 5.69 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.299 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.414 ' HA3' ' HB3' ' A' ' 69' ' ' GLU . . . -171.39 -165.84 29.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.649 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.418 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 6.0 p90 -143.57 161.01 39.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.994 0.426 . . . . 0.0 111.039 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -118.94 136.61 53.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.59 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 26.0 t -121.58 -41.91 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.151 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 7.0 m-20 -92.82 160.82 33.31 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.805 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -67.75 -14.28 41.24 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.559 2.173 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -149.39 28.23 0.81 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.788 0.327 . . . . 0.0 111.099 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.41 115.84 7.59 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -128.87 156.41 21.12 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.32 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -128.99 128.43 43.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.621 0.248 . . . . 0.0 110.769 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.414 ' HB3' ' HA3' ' A' ' 59' ' ' GLY . 1.4 pm0 -147.44 153.46 39.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.149 0.499 . . . . 0.0 111.505 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 4.0 ptt? -118.15 138.21 52.45 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.186 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.86 175.63 18.73 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.689 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -134.71 114.94 13.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.661 0.267 . . . . 0.0 110.621 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -78.27 121.64 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.084 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 6.1 m95 -139.04 117.08 11.7 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.878 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 6.8 tp -74.09 -57.59 3.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.949 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 153.18 176.05 25.26 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.476 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.26 88.45 4.92 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.823 0.344 . . . . 0.0 110.932 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -105.4 -178.6 3.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -159.47 141.04 13.07 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.986 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.415 ' CD1' ' HB3' ' A' ' 83' ' ' SER . 0.3 OUTLIER -93.33 142.87 26.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.976 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -120.29 -42.02 2.59 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.86 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -99.51 36.52 4.02 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.471 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.415 ' HB3' ' CD1' ' A' ' 80' ' ' TYR . 8.5 t -154.66 79.82 1.08 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.814 0.34 . . . . 0.0 110.894 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 m -81.97 120.55 33.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.142 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.71 152.16 37.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.859 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -90.57 137.19 32.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 103.85 61.48 0.68 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.516 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -61.77 111.45 1.87 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.867 0.365 . . . . 0.0 111.112 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -126.45 143.36 51.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -97.58 139.68 33.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.83 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.11 159.39 18.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.233 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -164.5 129.64 2.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.631 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.85 141.54 15.32 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.898 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -112.05 126.0 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.249 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -108.86 146.84 33.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.224 0.535 . . . . 0.0 112.03 -178.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.0 tt -139.13 116.1 10.92 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.347 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.412 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 0.9 OUTLIER -154.32 170.03 22.28 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.191 0.519 . . . . 0.0 112.054 -178.694 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -108.95 149.64 28.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.134 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.82 132.23 53.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.966 0.412 . . . . 0.0 111.704 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 4.0 pp -133.34 125.11 28.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.18 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -163.06 -169.82 27.04 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.872 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.423 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -157.35 145.3 14.07 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.674 0.273 . . . . 0.0 110.923 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.435 ' HA ' ' CB ' ' A' ' 109' ' ' ASP . 84.7 Cg_endo -82.59 167.83 14.77 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.764 2.309 . . . . 0.0 112.643 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 5.3 mm -115.64 -32.21 1.92 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.204 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.956 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -170.65 46.89 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.847 0.356 . . . . 0.0 111.208 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 50.7 32.0 6.5 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.858 0.361 . . . . 0.0 111.133 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 38.5 t0 -153.78 -41.98 0.09 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.707 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -119.72 118.22 30.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.915 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.435 ' CB ' ' HA ' ' A' ' 103' ' ' PRO . 5.8 p-10 -134.35 152.48 51.83 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.12 0.486 . . . . 0.0 112.09 -178.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.42 ' CG2' ' CG1' ' A' ' 149' ' ' VAL . 1.3 pt -114.82 147.63 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 179.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -157.77 166.19 33.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.1 0.476 . . . . 0.0 111.823 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 27.4 m -142.28 132.29 24.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.513 179.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 52.6 mtt180 -109.92 128.91 55.66 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.188 -179.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -132.98 125.52 29.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.715 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.412 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . -179.98 -135.51 2.49 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.477 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.432 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -152.19 169.04 31.45 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.48 -0.867 . . . . 0.0 112.792 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.5 ptp -128.13 140.91 51.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.849 0.357 . . . . 0.0 110.995 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -130.63 111.88 21.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.715 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.5 p-90 -128.47 176.13 7.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.927 0.394 . . . . 0.0 111.055 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -119.82 127.6 52.92 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.833 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -88.52 152.11 22.08 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.143 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -126.4 158.79 35.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.854 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 9.2 p -176.75 -40.27 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.971 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.77 -174.45 2.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -161.45 -151.65 6.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.561 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 7.1 m-20 -82.95 150.86 26.17 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.916 0.388 . . . . 0.0 110.863 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -80.96 -63.15 1.47 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.893 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -144.25 -56.21 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.109 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 16.1 m -150.21 120.84 7.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.844 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -163.0 169.53 19.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.877 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -131.43 -60.0 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.499 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 11.1 p -134.4 140.44 45.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.771 0.32 . . . . 0.0 111.093 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -138.25 171.27 14.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.807 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 2.8 ptm85 -79.65 -30.57 41.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.897 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.2 t -82.59 110.43 17.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.888 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -84.45 161.03 20.44 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.071 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -66.19 171.36 4.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.971 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -77.64 136.23 38.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.799 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 14.9 p -124.9 135.34 52.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.007 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -113.83 131.22 9.81 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.406 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.9 p -146.04 128.27 8.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.732 0.301 . . . . 0.0 111.055 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.17 147.4 15.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.247 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.432 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.3 Cg_endo -78.1 151.89 27.38 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.749 2.3 . . . . 0.0 112.209 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.8 m -156.38 157.29 3.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.379 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -149.13 123.78 9.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.628 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -118.34 124.83 48.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -125.59 137.33 10.22 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.306 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -170.87 -150.76 7.17 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.435 -0.888 . . . . 0.0 113.076 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.42 ' CG1' ' CG2' ' A' ' 110' ' ' ILE . 9.0 m -131.3 168.21 24.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.822 0.344 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -134.79 136.74 42.8 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -119.56 128.72 54.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.81 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.73 131.7 40.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.916 0.388 . . . . 0.0 111.456 -179.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 59.5 t -116.09 -69.21 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.66 -167.32 0.45 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.989 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 6.3 ttm180 -81.6 -35.89 29.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.988 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -135.85 33.31 2.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.124 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.2 mt -148.14 124.45 2.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.063 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -136.87 162.8 32.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.439 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 1.7 m -109.73 150.6 28.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.202 179.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.07 136.58 38.49 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.077 0.465 . . . . 0.0 111.864 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.422 HD22 ' CE1' ' A' ' 163' ' ' TYR . 1.4 tt -119.17 120.76 38.04 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.505 178.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -117.39 145.13 44.29 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.115 0.483 . . . . 0.0 111.819 -178.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.422 ' CE1' HD22 ' A' ' 161' ' ' LEU . 0.0 OUTLIER -134.05 166.09 23.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.202 179.428 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -112.46 -32.44 6.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.937 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . 0.431 ' CG ' ' HB2' ' A' ' 181' ' ' ASN . 71.7 t90 -153.37 102.17 2.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.987 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 10.9 p -178.51 -39.39 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.034 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 10.9 p-10 -72.71 -36.49 67.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -134.88 139.49 45.05 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.867 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . 0.406 ' CD1' ' N ' ' A' ' 170' ' ' GLY . 2.7 pp -129.83 -42.81 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.187 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . 0.406 ' N ' ' CD1' ' A' ' 169' ' ' ILE . . . -138.92 129.65 4.54 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.468 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -113.95 -40.33 3.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.824 0.345 . . . . 0.0 110.899 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -163.65 -53.69 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.065 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -110.52 156.3 15.64 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.4 p -111.57 108.67 18.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.852 0.358 . . . . 0.0 110.892 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -138.04 141.78 37.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.061 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -117.32 136.1 12.35 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.429 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -144.05 -48.59 0.28 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.866 0.365 . . . . 0.0 110.935 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 3.8 ptp85 -84.47 113.86 51.46 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.736 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -50.96 -46.79 28.8 Favored 'Trans proline' 0 C--N 1.347 0.451 0 C-N-CA 122.407 2.071 . . . . 0.0 112.319 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.51 152.75 20.79 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.89 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . 0.431 ' HB2' ' CG ' ' A' ' 165' ' ' TRP . 30.2 p-10 -145.09 -46.69 0.23 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.97 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -74.06 110.36 3.08 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.58 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -162.0 113.78 1.69 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.75 0.309 . . . . 0.0 110.956 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 2.0 mp -129.9 157.17 43.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.615 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -156.13 149.23 24.33 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 111.401 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.96 136.0 53.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.439 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -151.85 169.78 31.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.405 -0.903 . . . . 0.0 112.911 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.2 140.05 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.688 0.28 . . . . 0.0 110.714 179.663 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 90.3 p -144.77 175.0 10.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.93 0.395 . . . . 0.0 111.343 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -142.57 159.61 41.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.736 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.415 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -101.74 138.08 39.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.956 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -148.8 166.61 27.95 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -166.94 -178.13 39.17 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.49 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -129.64 98.77 4.93 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.836 0.35 . . . . 0.0 110.897 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -102.38 -47.71 4.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.953 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.69 127.2 32.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.785 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -80.9 -177.19 6.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.105 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -170.32 91.56 0.5 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.071 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.14 176.47 5.43 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.508 2.139 . . . . 0.0 112.304 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 11.9 p -153.74 145.03 14.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.053 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 30.0 m -96.64 26.93 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.321 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -140.12 84.15 15.12 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.004 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_exo -50.92 -27.63 21.45 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.579 2.186 . . . . 0.0 112.341 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -116.27 147.78 40.21 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.01 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.42 136.43 28.68 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.58 2.187 . . . . 0.0 112.352 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -78.88 151.59 76.56 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.046 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -69.44 -42.31 3.85 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.596 2.197 . . . . 0.0 112.222 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -129.14 72.6 81.98 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.072 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.16 173.68 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.631 2.221 . . . . 0.0 112.278 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.184 -0.912 . . . . 0.0 110.885 -179.993 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.786 0.327 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 9.1 mtp-105 -115.7 167.28 11.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.1 mt -126.7 141.98 44.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.089 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -108.0 141.36 39.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.994 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 13.3 mmmt -128.09 156.35 42.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.968 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -104.92 -174.03 2.44 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.061 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 20.7 tt -102.48 116.8 46.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.116 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -121.17 30.08 7.0 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.978 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 m -71.77 88.99 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.5 pp -141.87 107.59 5.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.876 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -73.53 142.56 46.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.951 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -150.12 93.57 2.02 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.124 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -112.31 74.56 1.52 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.162 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.34 -45.68 1.21 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.565 2.176 . . . . 0.0 112.351 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -76.12 -43.32 43.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -84.25 124.09 30.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.926 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -85.92 171.32 11.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.835 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -132.6 179.47 6.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.913 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.431 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.0 OUTLIER -151.09 130.02 12.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.859 -179.924 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.5 m-85 -131.22 135.79 47.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.751 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.43 140.43 21.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.864 0.364 . . . . 0.0 111.341 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.86 173.74 43.42 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.696 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -125.5 141.25 12.84 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.297 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.479 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.4 OUTLIER -130.66 149.08 52.48 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.093 0.473 . . . . 0.0 111.434 -179.787 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 31.9 tp -127.53 153.83 45.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -154.22 160.66 29.61 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.492 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 41.9 p90 -143.01 154.86 44.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.948 0.404 . . . . 0.0 110.918 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 8.2 m -77.7 165.7 23.9 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.921 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.91 126.62 30.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.908 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -110.07 174.52 5.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.848 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 -126.65 167.1 16.16 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.892 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -85.17 -56.48 3.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.951 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.4 m -82.43 -65.93 0.95 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.45 176.69 51.5 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.506 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -136.95 113.52 10.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.791 0.329 . . . . 0.0 110.903 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -166.11 35.83 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.17 -177.82 6.51 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.5 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -92.38 146.8 23.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.825 0.345 . . . . 0.0 110.853 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -165.74 -75.41 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.442 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -137.51 149.72 46.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.796 0.331 . . . . 0.0 110.914 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 -132.64 31.6 3.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 -86.29 -43.65 12.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.816 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -82.95 175.42 10.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.867 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 24.4 m120 -91.72 107.13 18.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.84 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -101.85 171.7 22.02 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.535 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -52.25 125.63 18.06 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.606 2.204 . . . . 0.0 112.268 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.1 t -134.69 31.66 3.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.906 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -101.79 169.77 8.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.95 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -104.7 114.28 28.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.857 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -72.66 90.05 1.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -118.3 158.63 24.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.37 168.22 20.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.886 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -123.54 136.64 10.49 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.393 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -119.97 149.1 42.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 111.177 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -153.69 152.11 23.76 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.398 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.84 148.04 28.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.776 0.322 . . . . 0.0 111.049 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.43 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 35.9 p90 -135.38 118.17 16.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -143.2 129.02 3.58 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.069 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -137.09 169.12 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.963 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.431 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 29.8 p90 -134.34 134.59 41.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.35 . . . . 0.0 110.846 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 -86.92 137.1 32.66 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.808 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 36.7 t -140.76 -48.16 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.832 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 8.1 m120 -85.13 141.25 37.25 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.225 179.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.02 60.28 1.81 Allowed 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.269 1.98 . . . . 0.0 112.225 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER 178.64 -32.16 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.563 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -161.35 164.11 30.27 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.934 0.397 . . . . 0.0 111.355 -179.406 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 174.5 20.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.369 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -83.61 144.52 29.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.655 0.264 . . . . 0.0 110.703 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -128.05 125.23 38.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.884 0.373 . . . . 0.0 111.137 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.8 tpp -106.45 127.51 53.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.569 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.92 148.28 17.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.672 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -127.23 120.03 27.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.696 0.284 . . . . 0.0 110.648 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -97.62 122.71 41.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.899 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -139.03 119.34 13.7 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.876 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -102.94 175.98 5.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -101.31 113.39 4.66 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.467 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 30.3 ttt180 -143.31 112.65 6.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.793 0.33 . . . . 0.0 110.841 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.28 166.98 22.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.918 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.11 157.71 16.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.0 p90 -159.48 143.17 14.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.848 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.89 86.85 1.77 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.899 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -95.39 -98.58 1.75 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.519 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.3 m -170.2 166.49 8.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.769 0.319 . . . . 0.0 110.925 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.7 m -107.14 97.26 5.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.104 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -135.3 -69.76 0.5 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.883 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 24.6 m-20 -112.96 139.71 48.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.85 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 97.33 173.19 33.97 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.448 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -140.09 21.47 2.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.747 0.308 . . . . 0.0 111.404 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 3.8 t80 53.44 85.49 0.05 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.127 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.3 127.89 7.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.888 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -156.6 113.14 3.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.183 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -170.42 126.46 0.77 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.747 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.62 139.29 14.32 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.911 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.65 122.77 61.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.712 0.291 . . . . 0.0 110.292 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.02 136.97 47.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.111 0.481 . . . . 0.0 111.721 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.9 tt -121.08 104.73 10.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.624 -0.717 . . . . 0.0 109.291 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.6 p -145.93 171.37 14.94 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.251 0.548 . . . . 0.0 112.078 -178.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -106.09 131.07 53.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.373 -0.83 . . . . 0.0 109.864 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 19.6 ttpt -116.55 132.12 56.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.148 0.499 . . . . 0.0 111.682 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -127.65 131.33 49.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.626 -0.716 . . . . 0.0 109.587 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.426 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -132.28 175.43 19.86 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 -179.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -166.1 134.4 2.36 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.698 -0.251 . . . . 0.0 110.701 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -76.71 169.01 22.57 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 122.588 2.192 . . . . 0.0 112.39 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 26.2 mm -116.22 -52.79 4.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.99 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 18.0 p -134.48 -47.31 0.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.836 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.2 t0 178.67 -37.1 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.077 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -118.25 16.32 13.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.663 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -137.07 125.23 23.03 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -139.75 161.84 36.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.131 0.491 . . . . 0.0 111.811 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 2.6 tt -114.51 144.93 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.037 179.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.426 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 60.7 m-85 -141.68 138.21 32.3 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.362 . . . . 0.0 111.445 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.87 128.18 30.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.715 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 18.6 mtm105 -118.38 127.91 54.13 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.264 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -134.38 122.78 23.06 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.491 179.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -178.93 -137.86 3.02 Favored Glycine 0 C--N 1.332 0.332 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.456 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.468 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -139.14 160.72 25.9 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.923 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 8.4 ptp -120.7 137.28 54.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.759 0.314 . . . . 0.0 110.775 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -131.62 113.2 22.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.842 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.7 p-90 -138.68 170.07 16.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.917 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 12.8 ttp180 -121.65 138.84 54.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.875 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -113.26 129.31 56.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.153 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -96.09 130.88 43.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.928 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 15.5 p -76.13 177.55 7.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.832 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 20.4 mttp -77.14 -71.98 0.38 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.897 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -168.27 -166.55 27.53 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.557 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 24.1 p30 -67.47 154.07 42.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.788 0.327 . . . . 0.0 110.938 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -169.4 112.74 0.51 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.872 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -108.46 140.42 41.8 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.079 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -124.19 -70.09 0.78 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.935 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 40.1 p -147.27 -48.32 0.18 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.949 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -164.66 79.47 0.13 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.517 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 12.5 p -108.6 121.16 61.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.807 0.337 . . . . 0.0 111.07 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.84 45.08 1.0 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.31 104.21 9.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.818 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 23.5 m -145.63 31.66 1.07 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.95 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -112.42 159.65 18.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.79 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -76.39 132.64 39.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.894 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -75.43 144.6 42.08 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 52.9 p -124.51 114.88 20.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.908 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -93.56 105.73 3.33 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.493 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.7 p -140.78 122.8 15.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.702 0.287 . . . . 0.0 110.969 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -157.12 149.22 17.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.777 0.322 . . . . 0.0 111.557 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.468 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 87.5 Cg_endo -80.59 140.9 13.54 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.923 2.416 . . . . 0.0 112.126 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 31.2 m -156.91 160.56 2.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.004 0.431 . . . . 0.0 111.583 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -149.06 130.28 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.377 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -116.51 155.37 28.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.895 0.378 . . . . 0.0 111.502 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.34 136.49 7.93 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.22 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -162.85 -165.24 19.59 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.854 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -133.72 170.72 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.554 0.216 . . . . 0.0 110.95 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -146.72 149.7 33.93 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.941 0.401 . . . . 0.0 111.266 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 24.8 p90 -137.04 132.18 33.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.631 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.04 135.52 34.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.52 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.0 t -116.18 -63.05 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.823 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -105.22 -171.98 2.01 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.834 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -75.07 113.81 12.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.989 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 33.2 m-20 62.94 32.83 15.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.167 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.42 HG12 ' CE2' ' A' ' 190' ' ' TYR . 45.1 mt -147.79 105.44 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.941 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -126.76 167.62 15.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.357 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.73 144.71 40.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.172 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.61 132.47 44.07 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.124 0.488 . . . . 0.0 111.89 -179.307 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -115.55 117.08 29.35 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.498 178.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.8 mm-40 -107.04 145.03 32.85 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.127 0.489 . . . . 0.0 111.634 -178.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.425 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 48.9 t80 -133.95 158.28 43.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.455 179.656 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -107.27 123.68 48.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.008 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -123.69 107.89 11.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.723 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 31.2 m -65.27 174.45 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.071 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -155.11 -55.64 0.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.9 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -153.97 32.22 0.44 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 2.3 pt -70.35 -28.68 36.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.207 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -125.98 -159.34 10.24 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.47 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -124.47 -44.5 1.99 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.778 0.323 . . . . 0.0 110.918 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -61.02 -174.97 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.015 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -150.34 -92.04 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.586 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 59.8 m -143.35 106.71 4.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.928 0.394 . . . . 0.0 110.919 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 6.4 m -140.61 31.32 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.111 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -161.86 -83.59 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.551 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.45 135.68 46.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.862 0.363 . . . . 0.0 110.877 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . 0.427 ' N ' ' CD ' ' A' ' 179' ' ' PRO . 0.3 OUTLIER -70.07 -51.76 13.8 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.98 179.963 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . 0.427 ' CD ' ' N ' ' A' ' 178' ' ' ARG . 51.4 Cg_exo -55.12 129.72 36.83 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.45 2.1 . . . . 0.0 112.313 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -111.74 148.31 33.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.855 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 23.3 p-10 -87.74 80.86 7.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.912 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -78.04 176.62 53.88 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.52 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 17.8 ttp -118.6 129.58 55.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.922 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . 0.425 ' HG ' ' CD1' ' A' ' 163' ' ' TYR . 2.5 mp -132.8 125.07 29.25 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.687 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 28.9 t -128.53 145.38 51.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.115 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.42 136.59 46.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.584 179.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . 0.479 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -154.63 -176.86 27.38 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.942 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -126.64 135.9 62.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.647 0.261 . . . . 0.0 110.442 179.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 189' ' ' SER . . . . . 0.43 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 43.3 p -130.84 165.37 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.208 0.528 . . . . 0.0 111.721 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . 0.447 ' N ' ' CD1' ' A' ' 190' ' ' TYR . 2.2 m-85 -124.96 143.19 51.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.471 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 8.6 mtp180 -108.14 147.33 31.42 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.905 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -104.63 129.25 52.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.82 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -126.13 164.58 19.65 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.49 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -68.62 -31.07 69.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.75 0.31 . . . . 0.0 110.873 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -108.02 161.18 15.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.821 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -97.91 -33.78 11.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.861 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -140.84 173.3 11.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.159 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -120.64 129.36 25.35 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.013 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.98 151.86 25.74 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.377 2.051 . . . . 0.0 112.345 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 3.6 m -109.34 90.47 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.135 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 23.1 m -114.06 -35.6 2.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.24 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -107.71 108.27 61.32 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.088 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.84 -44.13 2.2 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.37 2.047 . . . . 0.0 112.226 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -117.35 92.86 41.4 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.981 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.72 -49.36 1.62 Allowed 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.566 2.177 . . . . 0.0 112.416 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -136.65 109.08 9.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.157 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_exo -51.85 153.93 10.77 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.468 2.112 . . . . 0.0 112.277 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . 0.474 ' CB ' ' HD3' ' A' ' 209' ' ' PRO . . . -160.12 -59.71 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.327 179.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . 0.474 ' HD3' ' CB ' ' A' ' 208' ' ' ALA . 68.2 Cg_exo -51.17 93.09 0.03 OUTLIER 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.285 1.99 . . . . 0.0 112.314 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.142 -0.932 . . . . 0.0 110.955 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.312 0 CA-C-O 120.838 0.351 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -170.27 98.06 0.27 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.977 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.6 mp -131.89 100.95 4.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.073 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -134.4 130.25 36.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.868 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -78.72 100.8 7.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.932 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.85 71.97 6.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.025 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.6 tp -178.14 -39.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.994 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -153.49 145.24 23.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 138.03 37.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.15 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.3 mp -120.99 -42.86 2.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.931 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -60.52 151.54 28.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -103.65 118.68 37.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.183 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.92 84.91 33.36 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.01 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -70.07 -37.59 8.22 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.625 2.216 . . . . 0.0 112.33 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.65 118.58 15.26 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.964 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -83.69 109.69 17.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.875 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -104.17 131.8 51.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.932 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -137.03 148.66 46.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.735 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 10.3 t90 -111.09 132.91 53.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.088 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.427 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 2.7 t80 -122.57 135.79 54.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.383 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.59 146.93 25.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.953 0.406 . . . . 0.0 111.5 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.01 -172.84 45.44 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.482 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.65 148.57 20.24 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.489 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.27 151.0 47.21 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.072 0.463 . . . . 0.0 111.354 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 18.7 tp -122.12 145.53 48.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.29 179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -144.53 178.9 22.13 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.794 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . 0.407 ' CD1' ' HB3' ' A' ' 52' ' ' LEU . 0.5 OUTLIER -106.11 159.94 15.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.792 0.33 . . . . 0.0 110.834 -179.904 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.98 -60.71 1.49 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.825 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 68.6 mt-30 -104.42 146.14 29.27 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.881 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.419 ' CE2' ' HE2' ' A' ' 183' ' ' MET . 18.0 p90 -143.81 -179.89 6.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.924 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -137.06 99.41 4.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.878 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -65.07 -67.49 0.43 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.026 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 82.6 p -78.52 -66.71 0.82 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.948 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 92.14 154.01 30.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -84.34 -179.97 7.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.851 0.358 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 18.0 m-85 -141.81 96.16 2.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -121.01 -166.1 12.89 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.527 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -79.81 -32.56 40.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.818 0.342 . . . . 0.0 110.894 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -153.14 104.43 0.26 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.515 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -126.07 31.69 5.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.816 0.341 . . . . 0.0 110.876 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -141.87 -46.12 0.35 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.981 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -58.5 -57.45 12.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.897 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 66.1 m-20 -64.47 -30.72 71.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.915 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -98.1 30.47 3.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.907 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -97.63 -99.07 2.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.508 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -79.96 55.24 5.56 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.521 2.148 . . . . 0.0 112.498 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.9 m -164.98 -46.51 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.776 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.7 tpm_? -64.63 140.09 58.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.93 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 53.2 m-20 -105.33 146.42 29.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.768 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -101.42 162.48 12.87 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.838 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -116.78 106.72 13.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.85 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.407 ' HB3' ' CD1' ' A' ' 27' ' ' TRP . 0.7 OUTLIER -134.32 164.43 27.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.06 -179.902 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -141.14 145.79 16.61 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.417 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -114.93 142.18 46.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.718 0.294 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.5 143.83 11.13 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.293 -0.956 . . . . 0.0 112.895 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -98.07 164.46 12.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.648 0.261 . . . . 0.0 110.668 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.439 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 52.2 p90 -152.38 141.03 20.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.062 0.458 . . . . 0.0 111.409 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -133.55 124.92 3.81 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.044 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -97.39 145.73 17.96 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.893 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -131.93 112.26 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.698 0.285 . . . . 0.0 110.574 179.783 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 5.1 mm100 -90.8 137.0 32.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.101 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.6 t -148.87 23.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.948 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.1 m-20 173.22 137.48 0.12 Allowed Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.352 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -67.78 67.97 0.84 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.386 2.057 . . . . 0.0 112.276 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -169.07 -40.59 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.334 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -168.62 164.04 12.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.924 0.393 . . . . 0.0 111.256 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.67 159.19 26.82 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.313 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -82.9 127.57 33.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 110.566 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -114.64 127.08 55.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.966 0.412 . . . . 0.0 111.317 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.2 mtm -104.21 128.44 51.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.962 179.364 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.93 157.7 14.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.951 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -132.68 120.19 21.38 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.731 0.301 . . . . 0.0 110.508 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.418 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.8 OUTLIER -94.54 127.14 40.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.688 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t90 -139.1 125.2 20.01 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.944 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.5 mt -86.53 157.41 19.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.889 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -95.55 113.24 4.58 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.537 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 2.5 ppt_? -170.4 167.07 8.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.835 0.35 . . . . 0.0 110.888 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 15.3 mmm -131.72 166.63 21.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.903 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -98.48 166.78 11.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.081 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -142.45 -49.17 0.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.931 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.03 106.71 17.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.946 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.39 68.49 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.553 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 17.1 m -84.1 -67.81 0.76 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.822 0.344 . . . . 0.0 110.939 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 14.1 t -142.36 34.21 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.084 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -135.75 167.58 20.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.925 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 86.3 m-20 -60.02 164.46 3.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.898 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -101.73 -129.93 6.85 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.529 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -149.95 -52.57 0.15 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.819 0.343 . . . . 0.0 111.123 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -108.35 137.09 46.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.02 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 15.7 mttp -161.67 112.8 1.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.866 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -173.94 169.95 3.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.259 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -149.97 137.86 20.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.547 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.418 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -81.66 128.08 8.27 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.795 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.2 m -133.21 117.77 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.716 0.293 . . . . 0.0 110.257 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -123.92 149.74 45.53 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.107 0.48 . . . . 0.0 111.791 -179.269 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.63 120.1 30.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.517 179.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.408 ' CB ' ' HA3' ' A' ' 115' ' ' GLY . 4.3 p -148.28 171.81 15.38 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-O 121.088 0.471 . . . . 0.0 111.789 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.37 123.04 47.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.987 178.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.5 tttt -114.74 132.33 56.48 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.107 0.479 . . . . 0.0 111.7 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.6 pp -126.83 125.69 42.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.341 179.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.418 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -145.45 160.08 28.02 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.419 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.483 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.2 OUTLIER -166.27 148.49 6.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.676 0.274 . . . . 0.0 111.483 -179.758 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.483 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 73.3 Cg_endo -75.38 172.04 17.1 Favored 'Trans proline' 0 C--N 1.348 0.505 0 C-N-CA 122.807 2.338 . . . . 0.0 112.332 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 29.4 mt -132.08 -70.05 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.14 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.16 -67.95 0.72 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.906 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -161.11 -51.04 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.882 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 -121.24 25.36 9.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.087 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -125.14 112.77 16.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.085 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 0.6 OUTLIER -124.39 155.14 39.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.258 0.552 . . . . 0.0 112.045 -178.999 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.415 ' CG2' HG11 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 151.76 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.937 178.984 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.418 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 20.1 m-85 -146.86 146.1 30.08 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.948 0.404 . . . . 0.0 111.706 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.3 m -142.54 129.87 21.1 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.325 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.24 130.22 52.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 121.02 0.438 . . . . 0.0 111.752 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.1 tt -133.59 122.94 24.25 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.252 179.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.408 ' HA3' ' CB ' ' A' ' 97' ' ' THR . . . -175.87 -140.8 3.57 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.576 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.53 161.52 27.37 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.888 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -119.53 146.55 45.37 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.847 0.356 . . . . 0.0 110.753 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -129.82 144.08 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.985 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -130.23 141.55 50.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.913 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 5.4 mmm180 -137.22 151.21 48.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.917 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -101.9 168.63 9.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.053 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -124.78 134.4 52.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.958 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -75.65 141.94 42.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.905 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.72 122.64 28.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.847 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -164.42 91.53 0.11 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.486 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -60.32 -47.94 83.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.802 0.334 . . . . 0.0 110.895 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -124.54 124.48 42.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -124.99 148.85 48.25 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.104 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.1 m -109.16 -48.72 3.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.4 p -134.57 174.97 9.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.989 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -67.32 -163.53 1.98 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.506 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 7.7 m -141.49 126.43 17.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.837 0.351 . . . . 0.0 111.126 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -85.92 -37.25 19.28 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -67.1 81.52 0.12 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.852 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.7 m -87.42 100.47 12.76 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.941 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -140.57 104.02 4.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 70.2 m80 -148.96 -179.02 6.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.867 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -135.46 131.17 35.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.868 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.5 t -114.06 143.72 44.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -94.93 143.95 16.9 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.563 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.6 p -146.1 132.1 13.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.752 0.31 . . . . 0.0 110.962 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.428 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 1.5 t -157.08 130.19 4.48 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.228 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 142' ' ' SER . 5.7 Cg_exo -73.8 147.31 39.37 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.639 2.226 . . . . 0.0 112.009 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.2 m -156.49 153.79 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.918 0.389 . . . . 0.0 111.46 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -149.1 124.05 10.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.658 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -117.75 145.81 44.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 0.0 111.339 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.49 132.72 5.91 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.226 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -163.32 -154.49 7.72 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.962 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.415 HG11 ' CG2' ' A' ' 110' ' ' ILE . 12.9 m -137.3 170.88 17.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.631 0.253 . . . . 0.0 110.949 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -147.25 150.75 35.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.953 0.406 . . . . 0.0 111.267 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . 0.423 ' CE2' ' HB ' ' A' ' 159' ' ' THR . 37.1 p90 -126.74 138.61 53.41 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.811 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.404 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -91.65 137.24 32.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.411 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 52.3 t -108.94 -47.58 7.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.48 179.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -109.69 -165.07 0.98 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.282 179.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 4.1 ttm180 -100.56 41.86 1.15 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.758 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.2 t0 178.13 -28.64 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.788 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 27.2 mt -114.95 134.29 58.47 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.982 0.42 . . . . 0.0 111.554 -179.518 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . 0.404 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.11 161.15 38.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.057 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' THR . . . . . 0.423 ' HB ' ' CE2' ' A' ' 151' ' ' TRP . 9.7 m -106.26 150.78 25.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.227 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? -137.09 142.23 42.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.172 0.511 . . . . 0.0 111.834 -179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.4 tt -123.65 117.89 26.02 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.601 178.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -107.82 141.11 39.89 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.979 0.419 . . . . 0.0 111.635 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.429 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 27.2 p90 -134.33 166.08 23.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.653 179.615 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -77.96 128.93 34.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.005 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.06 103.81 2.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.86 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 12.4 p -166.97 122.64 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.091 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 20.4 m-80 -83.85 -34.95 24.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.848 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.09 138.88 35.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.842 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 1.7 pp -111.47 -30.25 2.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.14 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 179.95 62.95 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.492 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -116.16 -51.68 2.62 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.762 0.315 . . . . 0.0 110.828 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -60.96 -177.76 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.119 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 178.02 -36.33 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.476 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.0 t -113.04 -46.34 3.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.875 0.369 . . . . 0.0 110.924 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.6 m -87.17 -30.67 5.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.166 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -83.31 77.66 2.1 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.412 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 19.3 p -125.69 79.44 1.82 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.882 0.372 . . . . 0.0 110.865 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.55 93.24 43.21 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -67.99 95.62 0.43 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.451 2.101 . . . . 0.0 112.313 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 22.4 p30 -120.09 174.8 6.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.911 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -113.35 151.8 30.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.862 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 160.07 137.92 2.33 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.495 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' MET . . . . . 0.419 ' HE2' ' CE2' ' A' ' 30' ' ' TYR . 0.0 OUTLIER -154.23 171.6 18.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.768 0.318 . . . . 0.0 110.861 -179.986 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.9 mp -94.42 127.8 40.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.908 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 51.0 m -140.98 150.09 42.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.132 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.65 138.04 54.5 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.521 179.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -157.06 176.31 34.33 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.955 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -125.9 137.78 56.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.737 0.304 . . . . 0.0 110.496 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 189' ' ' SER . . . . . 0.439 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 3.6 p -138.59 171.57 14.17 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.377 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -148.0 156.62 42.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.642 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.427 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -123.94 157.03 35.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.038 -179.918 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -141.43 160.93 39.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.777 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -112.2 113.15 3.21 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.488 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -135.26 121.58 20.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.845 0.355 . . . . 0.0 110.891 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -95.48 170.6 9.24 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -63.89 125.81 25.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.847 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -112.2 120.78 42.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.132 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . 0.428 ' CB ' ' CD ' ' A' ' 199' ' ' PRO . . . -173.06 -63.15 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.229 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . 0.428 ' CD ' ' CB ' ' A' ' 198' ' ' ALA . 59.7 Cg_endo -72.34 140.17 33.18 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.454 2.103 . . . . 0.0 112.327 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 21.5 t -60.09 95.77 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.143 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 14.6 p -115.66 26.72 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.216 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . 0.407 ' CB ' ' CD ' ' A' ' 203' ' ' PRO . . . -79.76 -61.8 0.44 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.208 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . 0.407 ' CD ' ' CB ' ' A' ' 202' ' ' ALA . 73.7 Cg_endo -75.16 151.14 38.47 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.513 2.142 . . . . 0.0 112.397 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -119.13 83.56 24.8 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.006 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.54 -17.37 38.61 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.642 2.228 . . . . 0.0 112.483 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -55.18 147.74 34.03 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.198 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -52.82 -176.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.481 2.12 . . . . 0.0 112.303 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -129.78 98.96 21.02 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.992 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.98 147.27 73.72 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.454 2.103 . . . . 0.0 112.264 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.841 -179.964 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 120.775 0.322 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.3 ttt85 -103.55 142.3 34.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.5 pp -67.57 134.85 29.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.134 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -137.27 31.56 2.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.872 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -123.04 170.14 10.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.818 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.7 113.64 19.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.026 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.3 mp -95.44 111.69 26.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.17 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -92.04 -31.77 15.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.907 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 11.6 p -117.47 127.8 74.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.06 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -167.54 -49.47 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.845 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -89.11 -38.01 14.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.947 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -107.22 99.99 9.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.165 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -87.53 165.33 31.01 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.992 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.87 83.86 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.498 2.132 . . . . 0.0 112.18 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.2 tttp -89.43 -7.71 54.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.349 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 -89.19 45.33 1.28 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.766 0.317 . . . . 0.0 111.309 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.405 ' HB3' ' CZ3' ' A' ' 19' ' ' TRP . 3.7 m-20 -108.22 156.93 18.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.82 0.343 . . . . 0.0 110.974 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 t -147.02 145.93 29.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.843 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.417 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 2.7 m-90 -132.3 129.97 40.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.037 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.421 ' CZ ' ' HB3' ' A' ' 191' ' ' ARG . 0.2 OUTLIER -121.67 135.85 54.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.683 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.05 139.82 23.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.396 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.9 -158.56 20.49 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.417 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.79 149.65 21.52 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.534 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -130.61 154.91 47.37 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.055 0.455 . . . . 0.0 111.135 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.4 tt -127.04 141.7 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.641 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -148.76 171.86 29.01 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.592 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 2.1 m95 -99.16 133.42 43.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.773 0.32 . . . . 0.0 110.871 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.8 m -162.13 121.81 2.42 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.889 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -140.27 83.09 1.89 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -163.81 85.38 0.48 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.8 m80 -105.28 -38.93 6.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.869 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -156.65 156.11 32.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.872 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.37 117.16 27.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.932 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.49 -177.22 54.17 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.48 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -136.09 138.7 42.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.87 0.367 . . . . 0.0 110.921 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.1 t80 -108.19 37.21 2.54 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.7 141.66 15.3 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.464 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -120.17 164.09 16.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.824 0.345 . . . . 0.0 110.831 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -101.4 144.85 16.64 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.499 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -126.43 -62.62 1.14 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.872 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -130.78 -56.33 1.06 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.912 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -81.8 178.51 8.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.846 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -132.21 -47.85 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.777 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 7.5 m-80 -77.95 151.92 33.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.969 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -116.35 156.03 15.88 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.518 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.11 -61.34 0.52 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.543 2.162 . . . . 0.0 112.261 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.8 m -79.31 162.39 25.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.922 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.3 ttt-85 -84.13 -178.39 6.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.751 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -89.51 -42.19 11.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.847 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -93.42 151.53 19.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.852 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -157.63 135.29 10.59 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -88.05 167.75 13.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.91 138.54 14.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.534 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -131.26 138.7 49.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.689 0.28 . . . . 0.0 110.863 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.62 156.32 26.8 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.336 -0.935 . . . . 0.0 112.921 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.45 133.84 49.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.717 0.294 . . . . 0.0 110.844 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -119.75 127.17 52.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.967 0.413 . . . . 0.0 111.075 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.56 124.85 2.18 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.139 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -128.5 173.38 19.17 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.798 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.417 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 21.7 p90 -154.02 131.75 11.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 110.781 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -94.48 137.03 34.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.883 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.3 t -119.68 -45.2 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.886 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -109.25 146.53 34.11 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.613 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.41 ' O ' ' CD2' ' A' ' 65' ' ' TYR . 41.1 Cg_endo -67.53 65.37 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.545 2.164 . . . . 0.0 112.148 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.41 ' CD2' ' O ' ' A' ' 64' ' ' PRO . 9.9 m-85 -164.82 -42.28 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.178 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -170.29 164.17 8.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.191 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.03 175.17 19.61 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.44 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -95.7 134.71 38.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.417 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 0.0 OUTLIER -114.67 128.41 56.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -114.15 119.76 38.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.33 179.437 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 154.59 16.48 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.481 -0.866 . . . . 0.0 112.783 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 -130.09 114.83 16.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.579 0.228 . . . . 0.0 110.659 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.32 125.77 35.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.115 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 10.8 m95 -139.18 140.66 37.89 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.844 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -169.24 46.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.968 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -168.52 152.34 20.17 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.674 -0.775 . . . . 0.0 112.508 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 19.9 mtp180 -114.3 115.92 28.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.878 0.371 . . . . 0.0 110.825 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 63.6 mtp -61.5 160.82 10.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.945 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -109.36 167.91 9.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.984 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . 0.417 ' CE2' ' HG2' ' A' ' 81' ' ' LYS . 47.8 p90 -67.13 -31.01 71.17 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.843 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . 0.417 ' HG2' ' CE2' ' A' ' 80' ' ' TYR . 41.0 mmtt -66.41 169.62 7.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.83 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -173.98 162.45 33.08 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.582 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -76.71 160.97 28.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.808 0.337 . . . . 0.0 110.955 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.8 t -127.96 31.58 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.126 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -151.56 -67.09 0.18 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.853 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -95.51 89.44 5.4 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.902 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -144.36 54.43 0.57 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.56 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -69.73 -46.86 64.96 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.817 0.342 . . . . 0.0 111.068 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 18.8 p90 -148.01 161.17 41.91 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.898 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.14 -167.59 1.93 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.837 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.0 142.89 51.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.124 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 12.1 pm0 -175.01 157.42 2.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.734 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -82.26 130.94 10.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.586 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.47 119.74 55.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.786 0.327 . . . . 0.0 110.446 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 139.87 43.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.534 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.7 tt -130.25 110.88 11.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.972 179.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.49 168.94 22.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.993 0.425 . . . . 0.0 111.565 -179.147 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.401 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -104.1 125.91 50.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.197 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.424 ' HD2' ' CD1' ' A' ' 111' ' ' TYR . 0.6 OUTLIER -104.25 132.21 50.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.997 0.427 . . . . 0.0 111.752 -179.165 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.8 pp -134.82 115.74 14.01 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.388 179.114 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.05 41.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.672 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -166.28 167.05 8.83 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.713 0.292 . . . . 0.0 111.116 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -53.3 167.87 0.73 Allowed 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.488 2.125 . . . . 0.0 111.941 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.4 ' CG2' ' HB2' ' A' ' 108' ' ' LEU . 1.0 OUTLIER -121.13 -34.38 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 120.693 0.282 . . . . 0.0 111.679 -179.818 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -157.6 -53.45 0.07 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.761 0.315 . . . . 0.0 110.991 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -175.22 109.89 0.11 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.092 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 71.35 22.33 4.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.539 179.657 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.44 ' CD2' ' CE2' ' A' ' 151' ' ' TRP . 0.1 OUTLIER -142.81 117.38 9.75 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.582 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.408 ' HB2' ' CG ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -125.41 152.95 44.16 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.225 0.536 . . . . 0.0 112.009 -178.903 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.93 130.88 73.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.044 179.291 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.424 ' CD1' ' HD2' ' A' ' 99' ' ' LYS . 53.1 p90 -144.06 153.62 42.38 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.915 0.388 . . . . 0.0 111.526 -179.446 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 2.1 t -136.94 133.11 35.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.69 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 5.8 ptp180 -111.42 128.36 55.96 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.145 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -124.64 123.61 40.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.619 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 178.82 -132.46 1.9 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.547 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.463 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -148.24 169.08 28.94 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.821 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.07 139.86 51.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.795 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -126.17 132.9 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.809 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 85.3 t90 -134.23 140.38 46.43 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.864 0.364 . . . . 0.0 110.95 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.97 164.03 14.34 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.769 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -100.07 152.92 19.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.124 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -62.95 131.46 48.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.041 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 1.6 m -102.29 139.09 38.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.948 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 19.3 tttt -145.6 131.1 18.74 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.854 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -122.5 28.59 5.7 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.5 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -103.8 32.26 4.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.857 0.361 . . . . 0.0 110.863 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -81.53 111.17 17.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.882 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -98.89 31.19 3.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.963 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -174.78 136.87 0.43 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.95 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -127.48 38.55 4.04 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.811 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -142.3 28.43 2.21 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.509 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.2 m -157.48 -46.87 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.86 0.362 . . . . 0.0 111.17 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.1 t -97.63 179.89 4.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.898 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -150.08 162.37 40.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.875 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.88 105.34 13.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.886 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -83.28 93.26 7.67 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.886 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -93.56 113.35 25.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.906 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -141.43 163.41 33.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.7 p -138.59 146.17 41.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.875 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -122.34 102.5 0.79 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.53 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.2 p -136.11 123.61 34.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.697 0.284 . . . . 0.0 111.054 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.27 150.12 18.33 Favored Pre-proline 0 C--N 1.331 -0.217 0 CA-C-O 120.922 0.392 . . . . 0.0 111.421 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.463 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -78.77 141.14 16.91 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.758 2.306 . . . . 0.0 112.133 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.5 m -156.86 160.66 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.855 0.36 . . . . 0.0 111.418 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.6 p90 -141.6 122.47 14.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.472 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -111.8 138.2 48.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.962 0.41 . . . . 0.0 111.473 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -127.66 138.22 10.32 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.818 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -163.71 -165.71 21.34 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.078 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 17.2 m -135.47 167.05 26.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.659 0.266 . . . . 0.0 111.149 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.408 ' CG ' ' HB2' ' A' ' 109' ' ' ASP . 13.4 pt-20 -136.34 141.09 43.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.999 0.428 . . . . 0.0 111.172 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . 0.44 ' CE2' ' CD2' ' A' ' 108' ' ' LEU . 0.0 OUTLIER -122.31 123.07 40.57 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.628 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.16 131.86 35.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 48.8 t -100.56 -64.01 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.013 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 9.0 t -176.59 173.9 1.95 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.981 0.42 . . . . 0.0 111.826 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 65.62 -86.09 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.378 179.683 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -174.44 32.59 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.839 0.352 . . . . 0.0 110.653 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 28.3 mt -140.05 117.88 10.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.875 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.25 163.77 14.8 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.385 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.9 t -110.8 143.24 41.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.098 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 146.64 45.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.28 0.562 . . . . 0.0 111.855 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -116.63 124.8 50.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.698 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -116.51 141.01 48.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.029 0.442 . . . . 0.0 111.524 -179.181 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 14.2 p90 -134.22 157.61 45.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.468 179.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 -83.52 -68.58 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 8.2 t90 -140.55 103.13 4.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.811 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.3 t -123.89 121.96 63.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.211 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -132.47 30.72 4.11 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.821 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -77.4 136.14 38.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.884 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 23.0 mt -107.08 -26.85 3.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.24 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -56.32 114.6 5.25 Favored Glycine 0 C--N 1.33 0.217 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.52 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 6.9 t0 -97.28 39.07 1.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.865 0.364 . . . . 0.0 110.889 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -91.1 -31.23 16.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.083 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -149.58 92.34 0.14 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.498 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.0 m -86.3 -31.62 21.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.9 0.381 . . . . 0.0 110.96 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.0 100.96 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.147 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -103.65 -108.24 3.25 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.52 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 84.4 m -128.26 -70.37 0.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.794 0.33 . . . . 0.0 110.908 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 16.5 mmt180 -132.13 97.77 17.94 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.871 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.94 134.86 33.32 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.438 2.092 . . . . 0.0 112.231 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -127.43 31.94 5.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.946 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -95.66 79.33 3.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 92.17 -129.76 9.99 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.448 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 2.3 ttt -124.32 97.68 5.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 5.9 mp -122.23 142.02 50.88 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.741 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.99 155.58 41.69 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.996 0.427 . . . . 0.0 111.221 -179.768 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.53 139.08 50.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.355 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -153.53 171.1 32.35 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.281 -0.961 . . . . 0.0 113.166 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.5 137.23 57.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.694 0.283 . . . . 0.0 110.489 179.584 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 77.9 p -140.77 174.95 10.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.992 0.425 . . . . 0.0 111.294 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -137.41 157.1 47.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.585 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.421 ' HB3' ' CZ ' ' A' ' 20' ' ' TYR . 0.4 OUTLIER -113.88 124.8 53.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.916 -179.968 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -65.45 89.03 0.09 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.854 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -124.13 138.46 11.33 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.47 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -144.55 31.49 1.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.8 0.333 . . . . 0.0 110.815 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.62 158.46 29.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.865 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -129.72 144.46 51.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.923 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -65.73 124.0 21.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.033 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . 0.438 ' CB ' ' CD ' ' A' ' 199' ' ' PRO . . . -173.08 -63.54 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.247 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . 0.438 ' CD ' ' CB ' ' A' ' 198' ' ' ALA . 19.4 Cg_endo -59.35 -67.46 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.455 2.103 . . . . 0.0 112.27 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 7.0 m -153.05 179.62 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.142 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 13.5 m -125.85 179.63 3.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.068 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . 0.414 ' CB ' ' CD ' ' A' ' 203' ' ' PRO . . . -59.41 -61.28 8.17 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.07 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . 0.414 ' CD ' ' CB ' ' A' ' 202' ' ' ALA . 59.7 Cg_endo -72.16 141.95 37.03 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.611 2.208 . . . . 0.0 112.315 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -125.42 146.63 55.06 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.981 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -72.89 132.32 18.25 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.466 2.111 . . . . 0.0 112.353 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -126.76 87.29 56.85 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.019 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.15 -61.55 0.49 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.555 2.17 . . . . 0.0 112.282 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -94.66 149.4 36.42 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.073 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.57 -28.3 36.14 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.55 2.167 . . . . 0.0 112.289 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.157 -0.925 . . . . 0.0 110.906 179.912 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.395 0 CA-C-O 120.864 0.364 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.0 tpt180 -138.78 -62.03 0.56 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 4.9 tp -120.3 -40.39 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.266 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 6.0 mtt -129.41 92.71 3.4 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.021 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.74 -34.53 3.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.038 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -88.92 60.25 5.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.088 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 26.1 mm -102.0 -63.24 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.044 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -173.0 126.62 0.46 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.937 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 12.5 p -141.98 -45.81 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.183 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -149.05 -56.02 0.19 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.921 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 59.5 t30 -62.4 123.92 19.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.993 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -126.99 134.83 50.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.066 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -87.71 144.25 34.92 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.185 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -74.27 -168.1 0.45 Allowed 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.584 2.189 . . . . 0.0 112.329 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.23 111.13 23.57 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.886 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -64.3 152.73 40.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 22.7 m-20 -107.99 151.84 25.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 68.9 p -117.61 157.73 25.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.81 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.9 m95 -139.88 138.54 35.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.979 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.7 m-85 -131.8 135.88 47.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.685 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.71 146.03 30.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.322 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.36 -177.62 48.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.9 150.29 21.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.441 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.448 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -135.57 153.68 51.61 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 111.21 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.9 tp -124.03 147.93 47.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.541 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -151.42 175.74 30.16 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.481 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 4.0 m-90 -124.79 144.99 49.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.741 0.305 . . . . 0.0 110.885 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.9 t -102.5 168.8 9.06 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.932 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 1.1 mm100 -72.13 160.02 33.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.889 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 40.1 p90 -103.16 132.21 49.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.868 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -60.82 178.36 0.24 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -115.71 106.45 13.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.921 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 71.4 p -93.72 -48.12 6.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.85 -61.59 3.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.528 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -96.82 135.54 38.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.785 0.326 . . . . 0.0 110.832 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.5 p90 -149.34 -47.16 0.14 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.888 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -103.34 126.4 8.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.512 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -65.53 -57.51 8.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 110.924 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -137.36 -45.09 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.477 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -124.14 174.36 7.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 110.916 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -158.53 126.25 5.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.938 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -108.22 157.01 18.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.905 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -123.4 30.49 6.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.003 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -104.37 30.41 5.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.761 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -141.88 -136.91 3.31 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.432 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -67.99 167.02 22.77 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.505 2.136 . . . . 0.0 112.187 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 61.9 p -131.27 121.27 24.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.027 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -71.86 119.01 15.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -105.82 158.16 16.94 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.973 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -65.85 152.21 44.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.957 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.14 117.07 7.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.756 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.77 147.26 25.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.848 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -136.38 130.63 5.34 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.449 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.88 133.42 51.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.767 0.317 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.407 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -139.73 137.95 8.85 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.881 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -99.5 144.76 28.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.803 0.335 . . . . 0.0 110.563 179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.425 ' CE2' ' HD3' ' A' ' 24' ' ' LYS . 51.3 m-85 -136.16 133.52 37.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.035 0.445 . . . . 0.0 111.345 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.73 126.52 2.22 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.963 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -125.58 169.45 17.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.839 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.408 ' CE2' ' HB3' ' A' ' 68' ' ' PHE . 42.6 p90 -147.12 135.53 21.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -88.45 137.01 32.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.846 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 32.5 t -130.13 -46.78 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.921 0.391 . . . . 0.0 110.931 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -106.82 143.23 26.64 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.47 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.42 ' O ' ' CG ' ' A' ' 65' ' ' TYR . 46.6 Cg_endo -68.39 63.16 1.13 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.436 2.091 . . . . 0.0 112.139 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.42 ' CG ' ' O ' ' A' ' 64' ' ' PRO . 8.3 m-85 -168.49 -38.31 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.434 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -161.78 164.14 29.07 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.906 0.384 . . . . 0.0 111.148 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.43 159.53 22.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.472 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.408 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . 0.8 OUTLIER -82.09 144.86 30.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.554 0.216 . . . . 0.0 110.706 179.928 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.93 127.29 33.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.422 . . . . 0.0 111.074 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.0 ptp -109.26 133.21 53.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.86 17.34 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.766 -179.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.407 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 14.6 m-85 -129.93 118.13 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.615 0.245 . . . . 0.0 110.55 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.0 122.0 37.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.133 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 -139.06 125.38 20.29 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.083 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.5 mp -100.41 -32.69 10.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.873 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 78.72 -151.75 36.23 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.506 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.37 133.11 51.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.786 0.327 . . . . 0.0 110.814 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.5 -58.81 0.09 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.934 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -78.54 135.56 37.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.092 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -91.54 50.41 1.72 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.895 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 4.8 tttt -142.96 116.79 9.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.892 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -149.02 167.66 29.44 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.536 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 35.9 m -82.32 109.56 16.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.835 0.35 . . . . 0.0 110.814 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.2 t -129.71 31.48 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.098 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -107.87 -72.88 0.71 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.926 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -133.87 103.6 5.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.911 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 98.04 163.08 30.96 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.471 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -137.79 175.64 9.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.792 0.329 . . . . 0.0 111.049 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 25.8 p90 -159.37 164.02 35.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.012 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 18.7 mmtt -121.66 -178.4 3.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.852 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -147.9 108.33 4.12 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.072 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -147.7 125.01 11.54 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.608 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.78 135.37 12.11 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.937 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.32 117.98 46.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.798 0.333 . . . . 0.0 110.123 179.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . 0.401 ' CG ' ' CB ' ' A' ' 117' ' ' MET . 8.2 mt-30 -108.86 145.39 35.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.192 0.52 . . . . 0.0 111.925 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.3 tt -130.02 110.32 11.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.256 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.8 p -150.22 170.04 19.9 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.233 0.54 . . . . 0.0 111.984 -178.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.51 45.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.014 178.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -118.85 131.95 56.1 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.062 0.458 . . . . 0.0 111.581 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -131.85 121.67 24.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.96 179.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.423 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -115.95 -177.02 18.34 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.088 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -166.07 122.58 0.99 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 115.803 -0.198 . . . . 0.0 110.71 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -69.12 168.75 19.81 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.435 2.09 . . . . 0.0 112.391 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 27.6 mm -117.22 -43.32 3.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.894 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 29.6 p -147.63 -82.71 0.12 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.823 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -155.31 21.83 0.42 Allowed 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.205 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -175.61 24.69 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.609 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.435 HD23 ' CD1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER -154.38 124.48 6.81 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.588 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -143.07 159.64 41.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.101 0.477 . . . . 0.0 111.628 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.414 ' HA ' ' HA ' ' A' ' 149' ' ' VAL . 1.3 pt -114.64 154.81 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.316 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.423 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 91.5 m-85 -143.04 138.57 30.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.664 -179.508 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 31.6 m -125.2 127.63 47.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.313 179.393 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -116.54 127.88 54.92 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.38 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -137.96 122.58 18.59 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.511 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 179.26 -137.7 3.24 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.524 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.428 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.93 162.34 27.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.945 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.401 ' CB ' ' CG ' ' A' ' 95' ' ' GLN . 2.2 ptt? -119.63 142.31 48.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.801 0.334 . . . . 0.0 110.771 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -133.88 123.81 45.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.688 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.417 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 61.8 p-90 -133.21 161.61 33.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.003 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.08 150.27 50.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.921 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -173.53 150.95 1.85 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.069 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -125.57 120.61 31.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 2.4 p -119.12 31.38 6.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 5.3 mttp -121.73 137.59 54.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.84 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -144.83 -100.42 0.3 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.49 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 17.5 m-80 -77.6 83.51 3.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.799 0.333 . . . . 0.0 110.845 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -146.23 32.67 0.99 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.875 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -68.66 119.95 13.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.213 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 4.0 p -86.13 -56.65 3.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.2 p -146.7 -48.27 0.19 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.93 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -169.45 41.05 0.21 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.523 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 9.6 p -73.97 149.17 7.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.878 0.37 . . . . 0.0 111.076 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 88.4 p -135.01 165.37 25.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.899 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 24.2 mtt85 -91.84 99.78 12.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.931 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 1.3 m -95.89 -37.08 10.86 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.868 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.07 127.65 21.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.817 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 42.2 m80 -73.36 -179.72 3.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.012 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -124.62 130.5 52.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.914 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 8.8 m -129.44 121.73 27.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.927 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.417 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -70.18 147.29 44.13 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.43 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.9 p -146.13 133.58 15.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.705 0.288 . . . . 0.0 111.012 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -157.01 137.38 8.99 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.329 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.428 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 89.4 Cg_endo -81.09 143.47 14.26 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 122.682 2.254 . . . . 0.0 112.084 179.75 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 29.2 m -157.08 163.53 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 111.516 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -149.04 126.36 11.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.574 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -111.91 152.48 27.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.906 0.384 . . . . 0.0 111.267 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.0 131.45 4.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.239 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.426 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -161.03 -160.05 10.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.824 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 5.5 m -134.41 167.72 25.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.628 0.252 . . . . 0.0 110.951 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -134.8 137.05 43.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.007 0.432 . . . . 0.0 111.189 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . 0.435 ' CD1' HD23 ' A' ' 108' ' ' LEU . 1.4 t90 -114.91 123.32 48.85 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.574 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.81 130.74 36.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.523 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 39.3 t -115.99 -57.44 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.852 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.22 -165.39 1.34 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.743 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.19 -28.64 23.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.076 -179.857 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -139.51 18.66 2.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.312 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.1 mt -137.62 116.64 14.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.566 -0.288 . . . . 0.0 111.008 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.32 168.55 18.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.952 0.406 . . . . 0.0 111.242 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 29.1 p -113.43 153.18 29.04 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.135 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 14.8 ptp180 -137.19 141.66 42.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 111.892 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -121.54 118.16 28.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.656 178.853 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -108.34 143.66 36.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.97 0.414 . . . . 0.0 111.768 -178.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.426 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.2 p90 -134.25 162.88 30.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.509 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -78.22 -44.16 26.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.782 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -177.13 164.15 2.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.935 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 11.5 p -58.65 142.5 14.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.138 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 2.5 t30 -110.78 161.71 15.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.865 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -130.78 -175.04 3.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 2.6 pp -124.11 -37.05 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.247 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -95.94 28.34 13.04 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.525 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -91.65 -51.01 5.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.804 0.335 . . . . 0.0 110.883 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -82.1 -175.69 5.77 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.033 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -131.89 -133.25 3.43 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.445 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.8 m -76.02 -64.83 1.01 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.794 0.33 . . . . 0.0 110.814 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 31.9 m -92.92 116.96 35.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.149 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -117.35 96.25 0.69 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.54 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -100.09 -66.93 0.88 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.74 0.305 . . . . 0.0 110.813 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . 0.438 ' N ' ' CD ' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -73.45 -51.07 5.8 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.025 -179.917 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . 0.438 ' CD ' ' N ' ' A' ' 178' ' ' ARG . 32.5 Cg_exo -57.86 84.95 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.516 2.144 . . . . 0.0 112.301 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -162.79 87.57 0.59 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 10.7 t-20 -127.36 102.13 6.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.843 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -148.17 113.21 0.61 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.563 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 1.5 tpp -130.02 97.18 4.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.794 0.33 . . . . 0.0 110.815 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.5 mp -111.28 116.2 30.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.973 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 30.2 t -118.52 147.42 43.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.768 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -126.52 139.36 53.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.709 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . 0.448 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -156.67 -177.03 29.43 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.414 -0.898 . . . . 0.0 113.063 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.3 m -130.82 142.84 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.675 0.274 . . . . 0.0 110.598 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 89.0 p -143.24 170.83 15.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.998 0.427 . . . . 0.0 111.449 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 44.3 p90 -138.66 154.88 48.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.58 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.13 154.25 40.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -96.68 96.14 8.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.958 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -82.46 -168.4 42.07 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.51 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -97.85 120.79 38.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.824 0.345 . . . . 0.0 110.888 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -70.98 178.05 3.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.901 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -130.61 165.84 21.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -122.89 33.13 5.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.084 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -103.09 104.86 42.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.003 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -68.28 -42.8 5.16 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.504 2.136 . . . . 0.0 112.283 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 11.5 p -137.64 120.7 20.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.213 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 16.9 t -103.72 34.91 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.986 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -122.23 84.79 46.53 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.018 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.14 -70.07 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.561 2.174 . . . . 0.0 112.254 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . 0.407 ' CB ' ' CD ' ' A' ' 205' ' ' PRO . . . -73.21 -61.19 1.54 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.139 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . 0.407 ' CD ' ' CB ' ' A' ' 204' ' ' ALA . 59.7 Cg_endo -72.3 -173.77 1.22 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.499 2.133 . . . . 0.0 112.374 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -112.61 152.45 44.7 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.153 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -69.34 -46.21 1.49 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.563 2.176 . . . . 0.0 112.229 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -149.92 146.31 20.23 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.113 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.23 125.84 19.69 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.57 2.18 . . . . 0.0 112.328 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.234 -0.888 . . . . 0.0 110.91 179.963 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 120.856 0.36 . . . . 0.0 111.046 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -97.92 123.37 41.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.6 tp -150.8 147.15 15.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.151 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -119.9 -55.71 2.07 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.415 ' HE2' ' CD2' ' A' ' 8' ' ' PHE . 28.5 tttt -158.9 135.5 9.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.935 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.1 -43.19 2.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.2 mm -67.88 122.39 18.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.164 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.415 ' CD2' ' HE2' ' A' ' 5' ' ' LYS . 0.2 OUTLIER -134.7 171.48 14.3 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 -179.895 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 9.0 p -130.31 105.57 11.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.115 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.2 pp -175.07 141.33 0.57 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.88 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -62.45 155.17 26.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.01 85.59 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.125 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.406 ' N ' ' CD ' ' A' ' 14' ' ' PRO . . . -76.86 -52.5 1.99 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.145 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.406 ' CD ' ' N ' ' A' ' 13' ' ' ALA . 47.8 Cg_exo -55.81 86.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.58 2.187 . . . . 0.0 112.248 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.2 pttt -95.96 55.89 1.63 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.854 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.74 147.07 43.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 16.4 m-20 -80.67 165.45 21.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 t -147.72 179.8 7.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.853 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -151.1 129.87 12.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.009 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.408 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 28.5 m-85 -127.24 135.92 51.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.718 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.15 146.29 30.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.359 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.45 168.73 38.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.566 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.75 143.7 14.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.446 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.449 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 2.8 pttp -131.97 146.52 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.095 0.474 . . . . 0.0 111.286 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 23.1 tp -121.14 152.03 39.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -169.66 -164.35 25.23 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.514 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 24.2 p90 -122.5 119.28 30.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.804 0.335 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -160.22 148.66 16.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.871 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -135.82 107.81 7.15 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.822 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -134.35 79.97 1.83 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.887 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 9.9 p80 -112.13 130.27 55.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.943 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -100.46 104.95 16.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.897 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.05 -53.92 2.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 96.53 -28.13 14.6 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.556 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -60.25 161.33 7.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.821 0.343 . . . . 0.0 110.887 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -133.88 168.4 18.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -131.45 28.35 3.62 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.476 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -97.29 133.9 41.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.881 0.372 . . . . 0.0 110.875 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.58 -61.33 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.511 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -112.31 166.12 11.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.808 0.337 . . . . 0.0 110.871 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -67.45 117.49 9.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.828 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -79.19 156.06 28.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.773 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -106.37 -42.06 5.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.903 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -86.17 154.18 21.51 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.873 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.57 153.78 31.98 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.559 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.17 122.64 9.2 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.561 2.174 . . . . 0.0 112.347 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 21.3 p -135.17 102.73 5.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.14 136.93 34.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.935 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 19.4 m-80 -82.79 153.38 25.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.894 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -93.63 92.92 7.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 13.2 mm100 -78.68 129.94 35.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.929 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 3.6 pp -99.81 139.51 35.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -137.67 159.94 25.07 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.507 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -110.87 151.01 28.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.817 0.341 . . . . 0.0 111.078 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -143.36 122.92 1.97 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.82 135.93 35.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.682 0.277 . . . . 0.0 110.895 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.422 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 24.9 p90 -124.99 127.46 47.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.212 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.8 124.97 1.76 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.011 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -148.22 -172.59 18.32 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.759 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -150.63 156.03 40.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.871 0.367 . . . . 0.0 110.853 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -99.25 137.21 38.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.83 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.6 t -126.76 -48.16 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.765 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -93.57 141.09 23.4 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.46 179.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.77 64.63 0.89 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.497 2.131 . . . . 0.0 112.074 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 179.82 -32.94 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.614 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -162.24 164.1 27.86 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.88 0.371 . . . . 0.0 111.434 -179.51 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.91 177.0 19.43 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.249 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -99.74 134.59 42.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.619 0.247 . . . . 0.0 110.841 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.8 tp10 -124.03 131.51 53.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.989 0.424 . . . . 0.0 111.076 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 6.9 tpt -111.44 130.28 55.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.544 179.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.84 153.32 17.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.558 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 34.2 m-85 -134.19 114.95 13.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.829 0.347 . . . . 0.0 110.746 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.6 122.22 33.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.017 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -137.71 150.6 47.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 3.5 mt -122.98 135.89 54.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.909 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -107.73 -165.19 21.63 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.561 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 9.2 mtp180 60.88 93.23 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.839 0.352 . . . . 0.0 110.904 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -94.34 155.9 16.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.877 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -84.8 153.89 22.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.077 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -144.9 85.14 1.74 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.839 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -110.28 -31.51 7.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.998 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -128.31 170.79 19.58 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.558 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 84.3 p -92.88 -52.52 4.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.787 0.327 . . . . 0.0 110.829 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.1 m -66.22 76.69 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.244 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -176.71 110.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.86 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -65.98 -65.58 0.66 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -178.59 141.39 4.96 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.492 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.4 115.17 27.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.767 0.318 . . . . 0.0 111.047 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -86.51 106.88 17.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 1.1 tptm -67.89 -66.8 0.52 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.818 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . 179.49 164.97 1.04 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.1 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -114.67 131.7 56.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.607 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.23 128.42 9.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.074 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.43 117.85 48.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -112.16 145.62 39.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.182 0.515 . . . . 0.0 112.016 -178.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -134.93 112.81 10.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.249 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.7 p -150.81 172.99 14.74 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.228 0.537 . . . . 0.0 112.027 -178.448 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.12 131.41 48.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.83 178.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.424 ' HD2' ' CD1' ' A' ' 111' ' ' TYR . 3.4 ttpt -118.79 132.11 56.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.101 0.477 . . . . 0.0 111.738 -179.035 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -134.95 133.64 39.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.916 179.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.429 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -147.62 -179.41 23.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.182 -1.009 . . . . 0.0 113.102 -179.437 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -166.3 128.84 1.44 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.734 -0.233 . . . . 0.0 110.654 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -67.4 171.31 11.91 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.391 2.061 . . . . 0.0 112.116 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 18.6 mm -114.65 -42.42 3.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.608 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 49.5 m -145.24 -48.53 0.23 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.675 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 177.7 -37.47 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.995 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 64.3 m-20 -114.79 21.82 14.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.523 -179.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -147.22 127.28 13.69 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 179.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.403 ' OD1' ' CE2' ' A' ' 111' ' ' TYR . 8.8 t70 -144.46 155.7 43.85 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.065 0.46 . . . . 0.0 111.751 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.0 tt -114.51 132.36 63.87 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.022 179.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.429 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 25.5 m-85 -133.14 147.64 52.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.975 0.417 . . . . 0.0 111.734 -179.307 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.49 129.55 23.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.446 179.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -121.33 129.13 52.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.424 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.4 tt -134.85 122.7 22.4 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.488 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -176.94 -136.98 2.54 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.467 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.12 161.62 27.58 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.801 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.11 142.96 48.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.777 0.322 . . . . 0.0 110.706 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.5 t -130.36 138.42 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.89 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.428 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 70.5 p-90 -146.22 157.65 43.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.963 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.58 149.12 50.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.817 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -109.82 124.06 50.65 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.001 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -151.9 147.95 27.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.917 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.58 153.54 33.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.859 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 2.7 tttt -172.49 113.45 0.28 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.862 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -170.48 -145.92 4.94 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.411 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 -95.17 113.87 25.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.911 0.386 . . . . 0.0 110.819 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -155.21 -167.88 2.69 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.856 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -127.14 109.1 11.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.117 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.2 m -92.81 117.04 29.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.906 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 36.2 p -111.84 -64.64 1.26 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -97.01 -77.0 1.33 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.545 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.2 m -144.6 163.86 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.77 0.319 . . . . 0.0 111.116 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 36.9 p -119.89 -55.34 2.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.881 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 30.5 mtt180 -136.58 150.19 48.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.84 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 73.9 m -100.96 -55.62 2.52 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.935 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -117.49 -176.6 3.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.963 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 12.0 m80 -108.41 141.98 39.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.834 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -91.04 137.35 32.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.838 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 65.8 p -138.4 128.17 25.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.857 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.428 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -118.84 138.88 13.97 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p -144.64 135.42 20.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.764 0.316 . . . . 0.0 111.027 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.2 p -156.41 129.61 4.45 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.301 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.418 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 84.5 Cg_endo -77.92 142.57 19.95 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.595 2.197 . . . . 0.0 112.11 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.8 m -157.07 162.4 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.015 0.436 . . . . 0.0 111.455 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.01 124.04 11.39 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.484 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.03 137.12 52.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.862 0.363 . . . . 0.0 111.458 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.04 134.26 7.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.07 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -159.39 -157.31 8.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.919 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -135.18 167.78 24.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.805 0.336 . . . . 0.0 111.207 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -131.42 140.24 49.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.969 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -124.38 125.77 44.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.771 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -88.1 137.11 32.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.423 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 99.2 t -108.88 -69.4 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.95 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 47.1 p -88.26 -81.96 0.24 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.045 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -159.42 -60.88 0.07 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.821 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -103.03 26.42 8.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.957 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 157' ' ' ILE . 18.0 mt -150.98 101.06 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.954 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -117.76 162.45 18.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.213 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 61.1 p -100.99 150.83 22.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.145 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 4.6 ttt85 -137.14 133.12 34.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.062 0.458 . . . . 0.0 111.951 -179.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.11 119.23 33.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.448 178.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -110.04 145.22 37.42 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.189 0.519 . . . . 0.0 111.907 -178.569 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.43 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 8.4 t80 -131.79 147.87 52.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.232 179.474 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -71.32 -79.14 0.07 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.388 -179.586 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . 0.412 ' O ' ' CD2' ' A' ' 163' ' ' TYR . 0.4 OUTLIER -80.4 -177.14 6.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.843 0.354 . . . . 0.0 111.171 -179.782 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.3 t -123.18 159.12 27.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.07 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -70.63 71.62 0.49 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.96 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -140.57 143.99 35.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.978 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 8.5 tp -162.44 115.74 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.087 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -89.84 -104.22 1.15 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.622 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -104.75 171.1 7.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.903 0.382 . . . . 0.0 110.795 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -112.72 164.26 13.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.069 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -168.68 -91.57 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.454 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.9 t -99.22 130.22 45.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.769 0.319 . . . . 0.0 110.951 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 28.7 t -128.12 131.96 68.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.043 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -135.44 -80.19 0.12 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.521 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -94.6 106.65 18.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.752 0.311 . . . . 0.0 110.861 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . 0.403 ' CB ' ' CD ' ' A' ' 179' ' ' PRO . 11.4 mtt-85 -72.47 -61.28 1.79 Allowed Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.986 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . 0.403 ' CD ' ' CB ' ' A' ' 178' ' ' ARG . 56.9 Cg_endo -70.66 69.99 2.1 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.443 2.095 . . . . 0.0 112.314 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -119.59 -51.75 2.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.906 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 28.1 m120 -120.5 115.63 23.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 160.6 63.19 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.553 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 5.8 ptt? -117.16 131.54 56.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.781 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . 0.43 ' HG ' ' CD1' ' A' ' 163' ' ' TYR . 2.4 mp -114.95 127.82 55.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 88.1 p -121.13 146.5 46.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.084 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -125.48 141.04 52.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.647 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -161.7 -176.96 34.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.952 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -128.74 140.54 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.621 0.248 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 189' ' ' SER . . . . . 0.422 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 97.1 p -139.51 175.0 9.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.055 0.455 . . . . 0.0 111.464 -179.497 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 14.8 p90 -146.85 151.43 37.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.653 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . 0.408 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 25.0 ptt-85 -128.56 152.4 48.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.927 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -71.11 94.26 1.11 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.927 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -75.55 163.83 53.85 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.513 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -141.67 144.18 33.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.899 0.381 . . . . 0.0 110.804 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 41.3 mm-40 -64.99 111.85 3.05 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.897 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.76 -32.5 69.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.818 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -93.91 117.31 29.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.048 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -139.02 84.73 16.69 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.178 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -54.07 88.27 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.684 2.256 . . . . 0.0 112.229 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 11.0 m -152.59 179.64 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.076 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 21.5 t -142.23 80.86 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.079 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -114.88 127.65 26.63 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.988 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -55.51 -64.21 0.15 Allowed 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.379 2.053 . . . . 0.0 112.395 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -127.17 113.65 21.64 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.26 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.28 141.74 36.17 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.407 2.071 . . . . 0.0 112.259 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -140.3 134.51 15.5 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.21 -43.63 0.23 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.427 2.085 . . . . 0.0 112.421 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -109.84 93.95 16.01 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.099 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -69.26 -41.98 4.37 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.478 2.119 . . . . 0.0 112.25 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.264 -0.874 . . . . 0.0 110.932 -179.943 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.836 0.351 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 44.0 mtt85 -81.96 73.97 8.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.747 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.7 tt -148.54 128.89 4.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.112 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -166.83 -44.36 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.948 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -99.24 30.83 3.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.926 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -70.6 -76.1 0.11 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.999 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -65.65 145.4 13.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.11 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -138.73 -47.28 0.5 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 26.8 t -99.5 135.95 32.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.092 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 mp -63.44 101.5 0.33 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.981 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -80.52 138.85 36.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.833 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -95.35 77.07 3.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.104 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.403 ' CB ' ' CD ' ' A' ' 14' ' ' PRO . . . -74.3 -61.13 1.26 Allowed Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.173 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.403 ' CD ' ' CB ' ' A' ' 13' ' ' ALA . 61.2 Cg_endo -73.12 87.01 1.06 Allowed 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.447 2.098 . . . . 0.0 112.357 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -153.01 94.89 1.9 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.75 113.05 2.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.825 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -106.0 116.52 32.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.0 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.2 t -136.69 156.01 49.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.771 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -150.66 130.03 12.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.988 -179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -138.91 136.32 35.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.778 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 143.18 38.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.354 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.12 -157.9 10.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.541 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.22 145.87 15.32 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.597 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.91 156.08 32.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.939 0.4 . . . . 0.0 111.107 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -135.66 138.76 43.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.611 179.709 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -131.82 155.01 21.21 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.542 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -133.24 99.99 4.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.796 0.331 . . . . 0.0 110.855 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 m -161.58 102.37 1.2 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.845 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 14.2 mm-40 -148.52 99.06 2.97 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.955 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 11.4 m-85 -117.97 94.76 4.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -154.1 -48.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.901 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -67.64 119.56 12.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.91 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.3 163.67 12.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.48 48.55 3.69 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.479 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -100.92 112.8 25.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.337 . . . . 0.0 110.824 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 4.4 p90 -161.19 -44.27 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.997 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -163.54 132.37 2.72 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.512 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 24.1 p30 -87.08 148.26 25.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.695 0.283 . . . . 0.0 110.945 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -93.76 -154.53 31.14 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.529 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.66 161.52 9.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.802 0.334 . . . . 0.0 110.829 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -148.06 86.68 1.57 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -99.35 -68.15 0.82 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -129.74 -54.0 1.15 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -63.66 91.77 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.837 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -102.68 96.43 1.39 Allowed Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.553 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -67.89 168.1 19.66 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.55 2.167 . . . . 0.0 112.339 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.19 44.32 1.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.97 -31.27 56.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.834 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -73.91 160.45 31.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.826 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.51 168.9 14.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.923 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 10.2 tm0? -140.73 161.02 38.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.912 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -105.37 150.16 25.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.862 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -108.94 143.6 16.31 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.374 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -132.76 156.72 46.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.843 0.354 . . . . 0.0 111.157 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.58 154.64 25.71 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.451 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -95.43 124.7 39.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.74 0.305 . . . . 0.0 110.946 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -111.69 119.06 37.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.039 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.75 124.94 2.84 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.058 179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.17 165.59 25.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.771 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.424 ' CZ ' ' HB2' ' A' ' 68' ' ' PHE . 4.9 p90 -154.26 134.78 13.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.994 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 11.1 mt-30 -103.41 137.07 42.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.714 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 53.9 t -108.25 -30.06 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.259 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -147.22 153.18 44.42 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.852 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_exo -64.49 70.36 0.23 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.646 2.231 . . . . 0.0 112.176 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -159.74 -45.72 0.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -178.22 149.15 0.52 Allowed 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.946 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -123.71 169.83 15.92 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.394 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . 0.424 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 50.9 m-85 -83.98 134.49 34.64 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.682 0.277 . . . . 0.0 110.853 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.66 112.08 19.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.741 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.4 mtp -104.43 118.1 35.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.552 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.0 152.32 17.28 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -130.7 115.02 16.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.846 0.355 . . . . 0.0 110.576 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -81.66 123.13 28.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.023 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -130.89 109.03 10.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.861 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -120.04 172.27 7.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -102.78 104.43 2.57 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.514 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.24 109.12 20.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.86 0.362 . . . . 0.0 110.905 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 50.2 mtp -72.71 106.42 4.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.907 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -174.05 121.02 0.29 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.019 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 2.3 p90 -170.9 147.68 2.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 4.8 mttt -128.06 140.57 51.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.92 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -76.72 -59.52 3.21 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.564 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.66 173.18 3.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.898 0.38 . . . . 0.0 110.81 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 5.5 m -65.8 102.88 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.161 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -149.41 158.62 44.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.859 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.3 m120 -102.04 176.28 5.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 163.32 -87.71 0.1 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.458 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -114.75 136.22 53.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.795 0.331 . . . . 0.0 111.086 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -123.0 -49.46 1.96 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -123.27 134.55 54.07 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -158.48 116.21 2.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.051 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -175.02 141.68 0.59 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.722 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -95.92 134.01 11.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.753 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.68 117.86 54.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.755 0.312 . . . . 0.0 110.447 179.536 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -109.01 137.89 46.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.074 0.464 . . . . 0.0 111.744 -179.1 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.617 179.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 p -149.36 166.28 29.51 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.072 0.463 . . . . 0.0 111.796 -178.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.65 127.7 52.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.1 179.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.84 132.14 56.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.031 0.443 . . . . 0.0 111.749 -179.145 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 4.0 pp -130.09 130.14 44.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.316 179.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -154.03 -173.52 23.17 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.442 -0.885 . . . . 0.0 113.032 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -166.15 148.95 6.4 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 120.596 0.236 . . . . 0.0 110.885 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.414 ' HA ' ' CB ' ' A' ' 109' ' ' ASP . 89.1 Cg_endo -81.23 170.65 14.69 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.73 2.287 . . . . 0.0 112.7 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 16.8 mm -102.91 -42.19 8.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.631 179.726 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.99 -60.53 0.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.776 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 177.02 46.51 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.776 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 21.4 p-10 178.79 -29.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.426 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -112.61 128.82 56.48 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.561 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.414 ' CB ' ' HA ' ' A' ' 103' ' ' PRO . 2.7 p30 -144.91 157.89 43.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.887 0.375 . . . . 0.0 111.603 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.408 ' CG2' ' CG1' ' A' ' 149' ' ' VAL . 1.1 pt -120.81 144.5 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.471 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 4.7 p90 -148.05 149.07 31.42 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 121.225 0.536 . . . . 0.0 111.83 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 21.4 p -130.64 133.2 45.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.988 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.402 ' NE ' ' CB ' ' A' ' 146' ' ' ALA . 0.2 OUTLIER -115.46 130.73 56.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.063 0.459 . . . . 0.0 111.707 -179.261 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.44 ' HB2' ' CD2' ' A' ' 145' ' ' PHE . 7.9 tt -126.26 122.63 36.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.153 179.267 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -178.29 -142.09 4.56 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.294 -0.955 . . . . 0.0 112.869 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.446 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.73 169.08 25.35 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.771 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.4 tmm? -127.57 137.84 52.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.849 0.357 . . . . 0.0 110.948 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -127.29 127.7 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.674 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 2.9 p-90 -142.78 162.64 34.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.798 0.333 . . . . 0.0 110.987 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 18.3 mtp180 -126.44 156.13 41.12 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.971 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -129.62 153.68 47.85 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.026 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -135.63 149.34 49.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.911 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 5.5 p -175.07 70.25 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.89 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 3.1 ttpp -126.51 82.83 2.11 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.857 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -114.3 -162.99 14.5 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.467 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -117.14 93.37 4.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.86 0.362 . . . . 0.0 110.878 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -156.81 -50.89 0.07 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.852 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -118.62 -42.9 2.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.118 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 25.3 m -112.85 125.97 54.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.2 m -120.83 -53.92 2.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.952 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -89.07 -179.82 45.56 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.494 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.88 136.52 34.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.862 0.363 . . . . 0.0 111.173 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 3.1 p -132.59 -64.09 0.77 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.915 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -159.46 41.67 0.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.891 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 1.1 p -102.75 131.88 49.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.942 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.15 174.38 6.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 72.2 m-70 -67.11 144.52 56.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -121.52 120.55 35.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.93 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 30.0 p -119.66 160.0 23.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.96 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -122.72 129.65 7.57 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.485 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.0 p -146.04 128.86 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.696 0.284 . . . . 0.0 110.994 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.463 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -157.18 141.38 11.75 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.436 -179.978 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 142' ' ' SER . 5.8 Cg_exo -73.91 153.41 47.54 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.869 2.379 . . . . 0.0 111.858 179.719 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.0 m -156.74 162.92 1.48 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.181 0 CA-C-O 121.221 0.534 . . . . 0.0 111.764 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' PHE . . . . . 0.44 ' CD2' ' HB2' ' A' ' 114' ' ' LEU . 10.2 t80 -143.05 118.84 10.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.256 179.619 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.402 ' CB ' ' NE ' ' A' ' 113' ' ' ARG . . . -117.15 140.96 48.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.991 0.424 . . . . 0.0 111.16 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.07 134.89 7.16 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.152 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.03 -167.5 21.58 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.81 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.417 HG21 ' CZ2' ' A' ' 151' ' ' TRP . 4.1 m -127.18 160.02 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.869 0.366 . . . . 0.0 111.042 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.433 ' HG2' ' HB3' ' A' ' 160' ' ' ARG . 1.4 tm-20 -120.85 136.39 54.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' TRP . . . . . 0.417 ' CZ2' HG21 ' A' ' 149' ' ' VAL . 37.5 m95 -120.78 120.27 35.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.469 179.525 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.43 119.0 32.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.571 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 40.5 t -116.17 97.26 5.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.807 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 6.4 m 63.97 131.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.739 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.23 89.23 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.027 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -177.87 -57.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.02 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 3.5 mp -141.74 133.61 27.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.144 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.77 161.82 17.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.946 0.403 . . . . 0.0 111.35 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -131.39 144.02 50.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.173 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.433 ' HB3' ' HG2' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -137.1 155.12 50.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.243 0.544 . . . . 0.0 112.009 -179.288 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.408 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.4 OUTLIER -120.41 121.45 38.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.635 179.006 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -107.41 145.05 33.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.116 0.484 . . . . 0.0 111.787 -178.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' TYR . . . . . 0.408 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 5.7 m-85 -129.86 151.36 50.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.491 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.58 97.14 6.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.029 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -179.95 -167.81 0.1 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.845 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.6 t -118.04 130.43 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.172 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -169.95 148.86 3.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.849 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -70.37 -173.21 0.68 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.848 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 1.1 pp -96.95 -28.75 3.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.172 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -175.78 68.17 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.464 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -164.54 32.04 0.07 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.882 0.372 . . . . 0.0 110.901 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -169.71 -173.26 1.58 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.096 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -164.74 119.82 0.9 Allowed Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.562 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.8 t -78.39 90.76 4.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.858 0.361 . . . . 0.0 110.783 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 5.7 m -146.47 129.63 9.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.14 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -151.46 -119.21 0.84 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 66.4 p -103.97 -74.14 0.65 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.775 0.321 . . . . 0.0 111.007 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -98.07 152.44 38.04 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.847 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.39 155.66 9.37 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.592 2.194 . . . . 0.0 112.355 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -120.31 45.86 2.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.849 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -64.14 110.67 2.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -108.93 -75.9 0.9 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.579 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 2.7 ttm -148.08 100.62 3.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.883 0.373 . . . . 0.0 110.865 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' LEU . . . . . 0.403 ' CD1' ' N ' ' A' ' 184' ' ' LEU . 0.5 OUTLIER -121.45 137.19 54.82 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.717 179.921 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.9 m -131.87 151.52 51.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.93 0.395 . . . . 0.0 111.282 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -120.22 134.46 55.25 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.347 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -146.41 165.36 28.29 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.231 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.22 139.83 50.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.376 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.56 168.58 19.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.103 0.478 . . . . 0.0 111.694 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -123.47 146.61 47.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.466 179.624 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -104.34 153.55 20.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.958 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -135.22 145.92 48.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.81 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -145.53 -170.17 14.22 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -82.65 -42.54 18.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.823 0.344 . . . . 0.0 110.913 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -111.78 159.19 18.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.967 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -122.47 -43.48 2.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -135.27 106.27 6.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.041 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -103.94 90.95 3.25 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.109 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -68.73 -168.0 0.21 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.57 2.18 . . . . 0.0 112.203 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 17.2 m -93.01 -31.04 4.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.122 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 21.1 t -72.05 134.39 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.156 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -88.7 -53.2 0.36 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.162 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -52.23 132.64 44.71 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.542 2.161 . . . . 0.0 112.307 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -127.01 82.05 68.79 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.079 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.44 -45.17 2.72 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.537 2.158 . . . . 0.0 112.358 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -132.8 142.33 44.35 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.072 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.95 -45.38 0.48 Allowed 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.53 2.153 . . . . 0.0 112.292 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -159.97 131.72 4.1 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.116 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.62 -62.12 0.36 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.425 2.083 . . . . 0.0 112.278 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.169 -0.92 . . . . 0.0 110.893 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.816 0.341 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.437 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.8 t-105 -146.62 129.9 16.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.42 ' CE1' ' HA3' ' A' ' 59' ' ' GLY . 6.1 p90 -136.92 139.65 41.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.795 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.08 149.49 52.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.197 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.75 -164.44 22.37 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.471 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.16 138.59 6.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.583 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 2.0 pttp -120.18 150.92 39.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.985 0.421 . . . . 0.0 111.033 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.0 tp -129.27 139.66 51.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.595 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.531 -179.945 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.304 -0.318 . . . . 0.0 112.304 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -99.95 144.52 28.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.768 0.318 . . . . 0.0 110.996 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.414 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -147.75 122.97 1.63 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.88 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.809 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.87 125.71 39.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.635 0.255 . . . . 0.0 110.459 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.435 ' HB2' ' NH2' ' A' ' 160' ' ' ARG . 2.8 m-85 -115.24 145.93 41.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.045 0.45 . . . . 0.0 111.583 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -144.92 124.84 2.23 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.786 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 20' ' ' TYR . . . -123.13 146.98 16.64 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.035 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.443 ' CZ ' ' HB2' ' A' ' 68' ' ' PHE . 53.4 p90 -153.53 126.04 8.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.851 0.358 . . . . 0.0 110.771 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.811 0.338 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -127.24 155.09 19.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.435 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.443 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 2.4 m-85 -82.79 141.56 32.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.617 0.246 . . . . 0.0 110.564 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.577 ' HB3' HG23 ' A' ' 97' ' ' THR . 14.2 tp10 -125.67 118.67 26.13 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.88 0.371 . . . . 0.0 111.133 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 10.3 mtt -108.19 124.72 50.7 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.5 179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 163.05 12.47 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.541 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.809 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 57.4 m-85 -137.54 114.91 11.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.684 0.278 . . . . 0.0 110.76 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.43 114.96 22.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.059 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 17.0 t90 . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.097 179.868 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.741 0.305 . . . . 0.0 110.715 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -85.59 135.3 13.29 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.639 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.1 OUTLIER -123.81 122.03 63.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -108.88 142.25 39.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.189 0.519 . . . . 0.0 111.878 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -128.6 114.5 16.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.617 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.828 HG21 ' HD2' ' A' ' 113' ' ' ARG . 0.9 OUTLIER -153.69 165.2 36.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.066 0.46 . . . . 0.0 111.739 -179.007 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.02 129.73 51.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.307 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.53 132.2 55.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.051 0.453 . . . . 0.0 111.517 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.518 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.8 pp -132.76 127.8 35.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.279 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.24 -171.66 23.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.971 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.434 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.09 147.06 5.64 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.897 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.434 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 90.6 Cg_endo . . . . . 0 C--N 1.345 0.387 0 C-N-CA 122.745 2.297 . . . . 0.0 112.617 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.46 0.055 0 CA-C-O 120.617 0.246 . . . . 0.0 110.367 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 4.0 p30 -141.41 152.84 44.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.041 0.448 . . . . 0.0 111.763 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.98 HG22 ' CG1' ' A' ' 149' ' ' VAL . 1.1 pt -116.93 146.24 21.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.318 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -153.59 156.34 37.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.111 0.481 . . . . 0.0 111.693 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 68.2 p -136.37 135.72 39.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.246 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.828 ' HD2' HG21 ' A' ' 97' ' ' THR . 0.0 OUTLIER -116.35 128.33 55.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.998 0.427 . . . . 0.0 111.518 -179.564 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.6 tt -126.78 124.45 39.73 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.445 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.408 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.71 -133.56 2.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.462 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -153.24 168.68 32.02 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.404 -0.903 . . . . 0.0 112.939 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -119.17 141.99 48.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.785 0.326 . . . . 0.0 110.731 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.524 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.9 t -135.03 112.01 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.73 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 40.7 p-90 . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 120.914 0.388 . . . . 0.0 111.115 -179.737 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.674 0.274 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.1 134.76 7.04 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.349 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.483 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 96.4 Cg_endo -79.99 142.32 15.48 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.633 2.222 . . . . 0.0 112.12 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.9 m -156.84 158.48 3.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.968 0.413 . . . . 0.0 111.46 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -149.04 124.04 10.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.582 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.567 ' HB3' ' NH1' ' A' ' 113' ' ' ARG . . . -119.7 168.86 10.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.933 0.396 . . . . 0.0 111.23 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.57 138.77 6.58 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.382 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -160.77 -159.7 10.14 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.756 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.98 ' CG1' HG22 ' A' ' 110' ' ' ILE . 5.7 m -130.66 166.91 27.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.702 0.287 . . . . 0.0 110.933 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -136.03 148.09 48.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.873 0.368 . . . . 0.0 111.178 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 10.1 m0 -131.29 128.68 40.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.791 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.53 122.53 40.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.303 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 45.5 t . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 179.789 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.816 0.341 . . . . 0.0 111.221 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.82 167.72 10.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.189 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' THR . . . . . 0.889 HG22 HG12 ' A' ' 188' ' ' VAL . 22.3 p -125.52 144.41 50.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.354 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.435 ' NH2' ' HB2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 153.45 50.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.127 0.489 . . . . 0.0 111.87 -179.504 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.423 HD23 ' N ' ' A' ' 162' ' ' GLU . 1.5 tt -126.55 124.38 39.86 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.913 179.014 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.423 ' N ' HD23 ' A' ' 161' ' ' LEU . 2.8 mt-10 -106.83 145.15 32.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.162 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.677 ' CG ' HD23 ' A' ' 184' ' ' LEU . 0.7 OUTLIER -131.16 166.02 22.04 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.625 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 164' ' ' GLN . . . . . 0.531 ' HG2' HD11 ' A' ' 184' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.067 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.677 HD23 ' CG ' ' A' ' 163' ' ' TYR . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.648 0.261 . . . . 0.0 110.817 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 12.7 p -171.07 166.73 7.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.97 0.414 . . . . 0.0 111.547 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.64 140.15 49.72 Favored 'General case' 0 N--CA 1.462 0.134 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.275 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -154.06 171.21 32.69 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 119.945 -1.122 . . . . 0.0 113.48 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 188' ' ' VAL . . . . . 0.889 HG12 HG22 ' A' ' 159' ' ' THR . 0.6 OUTLIER -130.48 139.85 50.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.683 -0.259 . . . . 0.0 110.359 179.456 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 83.6 p -134.95 175.08 9.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.041 0.448 . . . . 0.0 111.497 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -145.38 149.81 35.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.696 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.942 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 t . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.886 0.374 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -121.29 132.32 54.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -129.76 135.97 49.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.974 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.45 141.63 29.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.232 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.23 -172.14 41.49 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.586 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.08 148.24 19.71 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.98 152.52 51.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.937 0.398 . . . . 0.0 111.278 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 1.043 HD12 ' HB2' ' A' ' 54' ' ' ALA . 0.6 OUTLIER -130.35 148.75 52.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.443 179.716 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.226 0 C-N-CA 120.542 -0.837 . . . . 0.0 112.772 -179.883 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.458 -0.257 . . . . 0.0 112.458 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 1.043 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -116.52 161.08 19.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.762 0.315 . . . . 0.0 110.938 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -163.81 146.64 11.77 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.681 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.727 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -96.25 160.99 14.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.73 0.3 . . . . 0.0 110.898 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.429 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 19.6 p90 -151.6 139.52 19.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.988 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -136.33 125.05 3.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.349 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -98.13 129.98 10.08 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.581 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -129.14 110.24 11.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.82 0.343 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.805 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.652 0.263 . . . . 0.0 111.095 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 165.22 22.11 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 -81.83 132.49 35.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.775 0.322 . . . . 0.0 110.624 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -112.08 115.92 29.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.172 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -105.53 115.48 30.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.17 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.8 157.25 15.17 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.803 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.727 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 34.1 m-85 -128.95 129.56 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.738 0.304 . . . . 0.0 110.718 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.405 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.9 OUTLIER -96.34 121.01 37.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.754 -179.979 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.233 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.785 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 17.8 tt0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.816 0.341 . . . . 0.0 110.567 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.405 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -84.3 141.27 19.73 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.718 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.89 121.03 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.746 0.308 . . . . 0.0 110.31 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' GLN . . . . . 0.409 ' HG3' ' CB ' ' A' ' 117' ' ' MET . 3.4 mp0 -108.91 136.09 49.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.055 0.455 . . . . 0.0 111.817 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.456 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.6 tt -122.18 106.57 11.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.58 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.572 HG22 ' HA3' ' A' ' 115' ' ' GLY . 7.5 p -145.45 168.77 19.75 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.044 0.449 . . . . 0.0 111.644 -178.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.68 121.97 45.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.009 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.34 132.42 56.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.146 0.498 . . . . 0.0 111.885 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.6 ' HG ' HG23 ' A' ' 112' ' ' THR . 3.4 pp -126.96 127.39 44.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.814 179.096 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -120.2 -177.49 16.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.323 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.428 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 24.3 t80 -166.11 123.12 1.02 Allowed Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.455 0.169 . . . . 0.0 110.738 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.428 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 83.7 Cg_endo . . . . . 0 C--N 1.347 0.464 0 C-N-CA 122.457 2.105 . . . . 0.0 112.671 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.485 HD23 ' N ' ' A' ' 108' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.773 0.321 . . . . 0.0 110.164 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.04 163.27 23.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.066 0.46 . . . . 0.0 111.451 -179.177 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.989 HG22 HG12 ' A' ' 149' ' ' VAL . 1.6 pt -114.79 158.93 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.343 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -156.09 138.74 15.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.028 0.442 . . . . 0.0 111.604 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.6 HG23 ' HG ' ' A' ' 100' ' ' LEU . 1.8 t -132.99 126.94 33.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.243 179.389 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.439 ' CD ' ' HB3' ' A' ' 146' ' ' ALA . 0.5 OUTLIER -118.47 130.46 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.954 0.407 . . . . 0.0 111.43 -179.416 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -131.52 122.84 26.82 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.438 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.572 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -176.37 -140.18 3.44 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.591 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.482 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -138.6 163.31 25.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.832 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.409 ' CB ' ' HG3' ' A' ' 95' ' ' GLN . 1.1 ptt? -122.26 135.65 54.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.764 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.17 119.81 49.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 19.4 t90 . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.021 -179.94 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.416 ' O ' HG13 ' A' ' 141' ' ' VAL . 11.1 p . . . . . 0 C--O 1.231 0.132 0 CA-C-O 120.733 0.301 . . . . 0.0 111.152 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t -157.1 143.18 12.94 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.291 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.482 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 98.9 Cg_endo -79.55 147.45 19.9 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.658 2.239 . . . . 0.0 112.113 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.7 m -156.98 161.83 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.951 0.405 . . . . 0.0 111.528 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.8 p90 -149.01 119.44 7.37 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.572 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.439 ' HB3' ' CD ' ' A' ' 113' ' ' ARG . . . -109.79 129.07 55.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.935 0.398 . . . . 0.0 111.321 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.4 124.98 4.05 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.224 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.421 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -158.56 -152.16 6.33 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.309 -0.948 . . . . 0.0 113.04 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.989 HG12 HG22 ' A' ' 110' ' ' ILE . 6.1 m -135.48 167.31 25.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 111.317 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -136.8 137.4 39.75 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -119.93 127.25 52.49 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.731 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -88.43 124.34 33.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.479 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.535 ' O ' HG12 ' A' ' 153' ' ' VAL . 53.1 t . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.824 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 6.5 mt . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -131.69 158.82 40.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.314 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.0 141.63 33.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.201 179.558 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -124.29 122.95 39.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.11 0.481 . . . . 0.0 111.881 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.415 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 1.4 tt -117.41 116.69 27.67 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.536 178.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.421 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 0.2 OUTLIER -109.48 145.02 36.92 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -178.922 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.421 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.4 p90 -133.99 165.77 24.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.557 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.877 -179.989 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 7.2 mp . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.65 0.262 . . . . 0.0 110.776 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 67.2 m -152.44 150.89 30.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.949 0.404 . . . . 0.0 111.298 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -116.31 145.18 43.38 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.454 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -160.64 173.66 37.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.921 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 2.1 m -127.49 138.16 55.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.759 0.314 . . . . 0.0 110.652 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 189' ' ' SER . . . . . 0.429 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 60.7 p -139.86 170.59 15.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.258 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 1.9 p90 -147.95 160.02 43.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.929 179.969 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.796 0.331 . . . . 0.0 110.933 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.429 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.2 OUTLIER -141.83 154.58 45.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.885 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.444 ' CE1' ' HB3' ' A' ' 191' ' ' ARG . 1.2 m-85 -145.71 135.92 23.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.801 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.34 140.0 27.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.222 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.7 -171.55 41.27 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.424 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.04 150.46 22.69 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.368 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.32 154.57 48.4 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.898 0.38 . . . . 0.0 111.114 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.699 HD12 ' O ' ' A' ' 53' ' ' GLY . 49.4 tp -128.17 139.6 52.39 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.528 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.385 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.545 -179.929 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.699 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.45 -0.389 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.402 ' HB3' ' O ' ' A' ' 74' ' ' TRP . . . -101.19 139.88 36.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.02 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -145.57 126.85 2.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.424 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.498 ' HB3' ' CB ' ' A' ' 72' ' ' TYR . . . -94.89 141.82 28.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.747 0.308 . . . . 0.0 110.97 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -123.8 126.16 45.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.957 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -154.65 124.99 1.62 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -157.98 -168.31 20.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.429 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 8.8 p90 -154.97 161.08 41.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.782 0.325 . . . . 0.0 110.807 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.993 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.754 0.311 . . . . 0.0 110.798 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 153.49 19.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.525 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.07 128.37 42.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.66 0.266 . . . . 0.0 110.439 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -122.2 130.16 52.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.984 0.421 . . . . 0.0 111.417 -179.679 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 19.1 mtt -118.97 127.17 53.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.328 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.73 158.2 14.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.495 -0.859 . . . . 0.0 112.699 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.498 ' CB ' ' HB3' ' A' ' 56' ' ' ALA . 0.7 OUTLIER -129.18 114.94 16.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.781 0.324 . . . . 0.0 110.78 179.947 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -83.41 115.55 22.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.889 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' TRP . . . . . 0.402 ' O ' ' HB3' ' A' ' 54' ' ' ALA . 1.7 t90 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.931 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.769 0.319 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.414 ' HA2' ' CB ' ' A' ' 119' ' ' TRP . . . -99.68 142.64 16.07 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.122 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.76 122.1 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 117' ' ' MET . 2.2 mt-30 -108.8 140.32 42.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.065 0.459 . . . . 0.0 111.678 -179.125 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.4 tt -128.43 116.21 19.39 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.751 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.885 HG21 ' HD2' ' A' ' 113' ' ' ARG . 0.6 OUTLIER -153.97 164.38 38.52 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.035 0.445 . . . . 0.0 111.84 -178.851 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.25 124.98 46.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.285 179.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -102.76 132.53 48.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.029 0.442 . . . . 0.0 111.71 -179.255 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.587 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -134.95 124.16 24.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.347 179.296 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -156.3 -175.84 27.73 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.821 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -166.02 159.97 12.85 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.656 0.265 . . . . 0.0 110.993 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo . . . . . 0 C--N 1.345 0.352 0 C-N-CA 122.631 2.22 . . . . 0.0 112.132 179.832 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.073 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -136.76 160.01 40.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 111.812 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.063 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -115.09 147.27 18.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.219 179.436 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -149.06 145.13 27.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.114 0.483 . . . . 0.0 111.51 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.502 HG22 ' CA ' ' A' ' 147' ' ' GLY . 0.6 OUTLIER -137.81 129.82 28.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.179 179.554 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.885 ' HD2' HG21 ' A' ' 97' ' ' THR . 0.6 OUTLIER -111.93 133.11 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.081 0.467 . . . . 0.0 111.522 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.515 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.8 tt -124.34 122.86 38.87 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.296 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.416 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 179.91 -134.07 2.16 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.815 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.524 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -151.43 169.1 30.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.933 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.406 ' HB3' ' HG2' ' A' ' 95' ' ' GLN . 0.6 OUTLIER -122.68 138.82 54.49 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 111.24 -179.791 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.1 125.89 60.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.503 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' TRP . . . . . 0.414 ' CB ' ' HA2' ' A' ' 93' ' ' GLY . 1.1 p-90 . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 111.244 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.9 p . . . . . 0 C--O 1.233 0.187 0 CA-C-O 120.645 0.26 . . . . 0.0 111.132 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -157.07 142.67 12.64 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.496 -179.842 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.524 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 4.7 Cg_exo -73.93 153.4 47.47 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.834 2.356 . . . . 0.0 111.768 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.8 m -156.33 161.19 2.0 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 121.084 0.469 . . . . 0.0 111.717 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.515 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.5 t80 -142.94 118.96 10.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.237 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.49 136.38 52.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.014 0.435 . . . . 0.0 111.397 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.502 ' CA ' HG22 ' A' ' 112' ' ' THR . . . -133.73 125.74 4.05 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.004 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -157.96 -164.99 14.67 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.354 -0.927 . . . . 0.0 112.873 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 1.063 HG12 HG22 ' A' ' 110' ' ' ILE . 6.8 m -131.75 162.68 39.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.806 0.336 . . . . 0.0 111.046 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.51 140.11 51.36 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.188 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 18.8 m95 -123.22 120.02 31.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.808 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.51 126.71 35.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.391 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.009 179.801 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 17.7 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.771 0.32 . . . . 0.0 111.035 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -116.47 168.83 9.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.008 0.432 . . . . 0.0 111.362 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' THR . . . . . 0.416 ' HB ' HG12 ' A' ' 188' ' ' VAL . 5.8 t -126.77 144.41 50.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.198 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 150.19 47.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.232 0.539 . . . . 0.0 112.016 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.791 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.9 OUTLIER -115.56 122.35 45.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.482 178.943 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -111.94 145.09 40.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.05 0.452 . . . . 0.0 111.7 -178.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.791 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 17.5 m-85 -128.71 147.05 50.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.657 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.978 -179.938 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.785 0.326 . . . . 0.0 110.784 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 9.5 t -138.51 147.88 43.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.389 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.8 131.97 54.01 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.407 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.85 168.63 28.71 Favored Glycine 0 N--CA 1.453 -0.213 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.236 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 188' ' ' VAL . . . . . 0.416 HG12 ' HB ' ' A' ' 159' ' ' THR . 1.1 m -127.99 143.51 40.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.671 0.272 . . . . 0.0 110.472 179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.42 172.98 11.96 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 121.006 0.431 . . . . 0.0 111.468 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.7 p90 -138.05 160.03 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 191' ' ' ARG . . . . . 0.444 ' HB3' ' CE1' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.4 m . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.749 0.309 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 3.9 m-90 -135.64 148.4 48.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.106 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.432 ' CZ ' ' HA3' ' A' ' 59' ' ' GLY . 6.6 p90 -159.95 149.0 17.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.69 153.75 46.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.171 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.87 -171.18 38.07 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.463 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -143.7 147.64 19.06 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.39 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 3.1 pptp? -134.59 146.94 50.09 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.911 0.386 . . . . 0.0 111.043 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.807 HD12 ' HB2' ' A' ' 54' ' ' ALA . 1.9 tt -121.5 146.29 47.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.653 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.486 -179.882 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.436 -0.266 . . . . 0.0 112.436 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.807 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -125.07 148.48 48.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.662 0.268 . . . . 0.0 110.837 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.04 147.85 18.48 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.322 -0.942 . . . . 0.0 112.937 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.83 128.76 53.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.635 0.255 . . . . 0.0 110.643 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -120.3 143.96 48.07 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 0.0 111.397 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -128.15 124.89 4.92 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.045 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.432 ' HA3' ' CZ ' ' A' ' 20' ' ' TYR . . . -100.3 139.72 14.56 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.987 -179.492 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -135.39 114.11 11.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.702 0.287 . . . . 0.0 110.593 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.256 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.9 pp . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 120.862 0.363 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -107.14 177.02 21.46 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.548 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -90.55 142.77 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.833 0.349 . . . . 0.0 110.654 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.401 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 0.6 OUTLIER -122.49 111.96 17.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.151 -179.738 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.9 mtt -100.39 114.82 28.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.888 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 152.16 17.28 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.392 -0.909 . . . . 0.0 113.261 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.46 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 38.6 m-85 -130.3 114.96 16.28 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.5 122.94 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.763 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' TRP . . . . . 0.437 ' CD1' ' HA2' ' A' ' 55' ' ' GLY . 17.9 p-90 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.646 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.186 0 CA-C-O 120.726 0.298 . . . . 0.0 110.679 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.48 124.5 8.1 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.783 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.09 117.8 56.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.343 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.08 139.76 46.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.124 0.488 . . . . 0.0 111.831 -178.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.407 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -129.98 110.97 12.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.556 179.377 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.444 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.5 p -150.02 178.12 9.24 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.083 0.468 . . . . 0.0 111.812 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.2 44.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.033 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.401 ' HB2' ' HB2' ' A' ' 69' ' ' GLU . 8.8 tttt -126.57 132.01 51.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.096 0.475 . . . . 0.0 111.841 -179.286 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.488 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.6 pp -134.55 123.96 24.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.981 179.274 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.435 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -126.24 -175.04 14.02 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.437 -0.887 . . . . 0.0 113.302 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.406 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 0.8 OUTLIER -166.15 122.96 1.0 Allowed Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 115.674 -0.263 . . . . 0.0 110.576 -179.881 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.406 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 58.3 Cg_endo . . . . . 0 C--N 1.347 0.462 0 C-N-CA 122.485 2.123 . . . . 0.0 112.672 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.603 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.675 0.274 . . . . 0.0 110.443 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -145.07 159.28 43.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.009 0.433 . . . . 0.0 111.522 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.025 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.63 148.58 17.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.351 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.435 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 5.7 m-85 -138.13 144.46 40.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.049 0.452 . . . . 0.0 111.736 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -128.91 127.1 41.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.356 179.416 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.25 130.07 56.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.338 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.505 HD12 ' CD2' ' A' ' 145' ' ' PHE . 7.2 tt -137.4 122.95 19.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.636 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.444 ' HA3' HG22 ' A' ' 97' ' ' THR . . . 179.51 -143.05 5.5 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.514 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -146.23 163.86 28.37 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.929 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.57 144.37 49.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.807 0.337 . . . . 0.0 110.94 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.2 t -129.44 135.73 60.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 6.2 m95 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.795 179.994 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.428 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.4 p . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.66 0.267 . . . . 0.0 110.948 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -157.14 152.91 22.63 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.803 0.335 . . . . 0.0 111.577 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.514 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 71.6 Cg_endo -77.04 162.1 32.17 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.769 2.313 . . . . 0.0 112.094 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.6 m -155.96 159.05 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.003 0.43 . . . . 0.0 111.503 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.505 ' CD2' HD12 ' A' ' 114' ' ' LEU . 10.5 t80 -147.24 118.89 7.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.486 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -115.78 122.54 45.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.25 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.405 ' O ' ' CD1' ' A' ' 163' ' ' TYR . . . -126.32 132.21 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.218 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.426 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -166.52 -153.76 7.98 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.817 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 1.025 HG12 HG22 ' A' ' 110' ' ' ILE . 6.0 m -134.7 170.53 19.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.63 0.253 . . . . 0.0 111.016 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -138.3 144.6 40.52 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.904 0.383 . . . . 0.0 111.317 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' TRP . . . . . 0.603 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.2 OUTLIER -127.24 133.51 50.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.566 179.745 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.71 137.2 36.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 179.706 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 32.0 mt . . . . . 0 C--O 1.232 0.165 0 CA-C-O 120.943 0.402 . . . . 0.0 111.651 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -140.03 155.53 47.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.089 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.8 m -101.02 149.97 23.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.481 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.401 ' NH1' ' HB3' ' A' ' 162' ' ' GLU . 0.0 OUTLIER -137.06 134.2 36.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.068 0.461 . . . . 0.0 111.8 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.4 tt -117.56 119.57 35.43 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.792 179.038 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.401 ' HB3' ' NH1' ' A' ' 160' ' ' ARG . 4.8 pt-20 -112.42 143.89 42.79 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.989 0.423 . . . . 0.0 111.703 -179.11 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.426 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 6.4 p90 -134.21 162.83 31.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.516 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.938 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.431 HD12 ' N ' ' A' ' 184' ' ' LEU . 3.7 mp . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.642 0.258 . . . . 0.0 110.703 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.8 m -141.51 151.55 43.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.926 0.394 . . . . 0.0 111.345 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -114.81 132.06 56.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.342 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -149.25 167.5 29.58 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.326 -0.94 . . . . 0.0 113.002 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.2 m -127.57 139.81 50.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.65 0.262 . . . . 0.0 110.706 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 80.6 p -140.11 173.98 10.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.999 0.428 . . . . 0.0 111.241 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -148.0 151.28 35.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.724 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.93 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.677 0.275 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 64.4 p-90 -150.33 148.74 29.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.974 0.416 . . . . 0.0 111.165 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.415 ' HB3' ' HA ' ' A' ' 191' ' ' ARG . 9.5 p90 -130.91 143.35 50.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.652 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.62 149.64 52.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.234 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.47 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.62 -159.98 19.1 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.779 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -132.19 142.36 13.8 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.349 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.423 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -127.67 140.34 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.97 0.414 . . . . 0.0 111.127 -179.86 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.684 HD13 ' HB2' ' A' ' 54' ' ' ALA . 19.2 tp -128.08 141.01 51.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.461 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.652 ' H ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.364 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.624 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.567 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.684 ' HB2' HD13 ' A' ' 25' ' ' LEU . . . -134.94 136.03 41.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.799 0.333 . . . . 0.0 110.878 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.403 ' CA ' ' O ' ' A' ' 72' ' ' TYR . . . -156.07 166.56 33.09 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.693 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.97 155.01 16.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 110.706 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.455 ' CZ ' ' NH2' ' A' ' 113' ' ' ARG . 47.0 m-85 -143.69 132.49 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.934 0.397 . . . . 0.0 111.124 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -130.83 124.8 4.31 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.377 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -100.5 130.65 10.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.494 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -122.09 120.69 35.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.825 0.345 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.98 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.943 0.401 . . . . 0.0 111.317 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -134.98 166.04 24.47 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.323 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -86.18 132.95 33.9 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.783 0.325 . . . . 0.0 111.069 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.727 ' HB3' HG23 ' A' ' 97' ' ' THR . 25.9 tt0 -109.98 112.09 23.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.171 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.0 mmt -108.28 111.98 24.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.945 179.27 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -118.37 163.74 12.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.35 -0.929 . . . . 0.0 113.104 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.403 ' O ' ' CA ' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -128.61 114.81 17.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.673 0.273 . . . . 0.0 110.471 179.701 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.69 129.63 34.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.416 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.633 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.631 0.253 . . . . 0.0 110.617 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -94.68 131.64 10.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.87 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -113.52 121.8 66.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.28 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 17.7 mt-30 -108.79 134.6 51.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.037 0.446 . . . . 0.0 111.712 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.485 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -128.86 112.48 14.17 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.868 179.478 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.727 HG23 ' HB3' ' A' ' 69' ' ' GLU . 0.9 OUTLIER -151.1 162.47 40.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.077 0.465 . . . . 0.0 111.658 -178.932 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.9 122.37 43.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.041 179.102 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.417 ' HG2' ' HB2' ' A' ' 69' ' ' GLU . 0.0 OUTLIER -112.58 132.13 55.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.145 0.498 . . . . 0.0 112.071 -179.039 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.504 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.9 pp -122.49 128.39 50.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.807 178.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.442 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -119.96 -179.91 16.5 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.133 -179.201 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -166.08 125.84 1.2 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.763 -0.219 . . . . 0.0 110.664 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo . . . . . 0 C--N 1.346 0.405 0 C-N-CA 122.553 2.169 . . . . 0.0 112.489 -179.785 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.09 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -138.53 162.99 33.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.106 0.479 . . . . 0.0 111.722 -179.241 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.966 HG22 HG12 ' A' ' 149' ' ' VAL . 1.4 pt -114.81 157.06 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.28 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.442 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 96.3 m-85 -153.47 144.82 23.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.081 0.467 . . . . 0.0 111.73 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 38.8 p -142.48 126.96 17.8 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.167 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.503 ' HD3' HG21 ' A' ' 97' ' ' THR . 1.4 ppt_? -118.27 134.7 54.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.009 0.433 . . . . 0.0 111.78 -179.348 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.8 tt -133.63 122.9 24.13 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.078 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.403 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . -177.65 -132.95 1.76 Allowed Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.602 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.528 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.43 165.55 31.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.302 -0.951 . . . . 0.0 113.082 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.7 ptt? -120.44 140.99 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.922 0.392 . . . . 0.0 110.744 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.478 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.8 t -134.32 124.5 45.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.926 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 54.2 p-90 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.925 179.926 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.4 p . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.752 0.311 . . . . 0.0 111.029 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 36.2 t -157.22 140.65 11.23 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.293 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.528 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.4 Cg_endo -80.65 148.15 17.83 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.73 2.286 . . . . 0.0 112.259 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 33.9 m -156.27 159.07 2.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.989 0.423 . . . . 0.0 111.492 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -149.1 123.54 9.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.499 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.36 145.32 40.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.838 0.352 . . . . 0.0 111.425 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.64 133.66 6.22 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.265 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -169.76 -149.99 6.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.556 -0.831 . . . . 0.0 113.023 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.966 HG12 HG22 ' A' ' 110' ' ' ILE . 13.8 m -135.23 168.78 22.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.813 0.34 . . . . 0.0 111.396 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.407 ' HB2' ' CD2' ' A' ' 111' ' ' TYR . 9.2 tt0 -131.6 136.61 47.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -125.14 131.59 53.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.033 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -91.53 137.2 32.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.074 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 62.2 t . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.899 0.38 . . . . 0.0 110.86 179.942 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.351 . . . . 0.0 110.988 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.47 160.18 38.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.187 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.1 m -100.96 153.34 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.45 124.99 29.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.294 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.1 tt -123.95 116.51 23.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.112 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.432 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 42.1 mt-10 -136.32 145.17 45.16 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.143 0.497 . . . . 0.0 111.45 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -123.48 166.01 16.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.625 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 8.5 mm-40 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 179.963 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 5.9 mp . . . . . 0 CA--C 1.526 0.057 0 CA-C-O 120.79 0.329 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -128.6 141.6 51.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.854 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.98 146.37 50.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.814 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 187' ' ' GLY . . . . . 0.423 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -163.42 -176.77 35.73 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.584 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.46 142.66 42.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.729 0.3 . . . . 0.0 110.825 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 189' ' ' SER . . . . . 0.47 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 29.6 t -135.96 161.03 36.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.152 0.501 . . . . 0.0 111.857 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 190' ' ' TYR . . . . . 0.403 ' CE1' ' O ' ' A' ' 191' ' ' ARG . 7.0 t80 -125.01 135.16 52.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.363 179.797 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 191' ' ' ARG . . . . . 0.415 ' HA ' ' HB3' ' A' ' 20' ' ' TYR . 8.4 ptt180 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.113 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 t . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.741 0.305 . . . . 0.0 110.812 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.434 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 17.6 t90 -142.74 129.92 20.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.0 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.44 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 10.5 m-85 -119.69 135.91 54.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.833 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.57 139.98 35.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.073 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -171.1 -159.2 16.59 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -148.1 147.48 18.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.61 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.409 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 3.0 mttp -123.63 161.14 25.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.988 0.423 . . . . 0.0 111.031 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 2.5 tt -141.35 143.24 33.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.695 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.55 -179.998 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.612 -0.195 . . . . 0.0 112.612 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -129.24 153.68 47.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.721 0.296 . . . . 0.0 110.876 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.04 172.18 35.14 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.769 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.617 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -114.12 131.27 56.47 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.744 0.307 . . . . 0.0 110.887 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.402 ' CD1' ' HG3' ' A' ' 24' ' ' LYS . 30.0 m-85 -118.72 128.22 54.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.073 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.97 126.39 3.23 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.39 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -127.5 136.14 9.12 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.608 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.45 ' CZ ' ' CB ' ' A' ' 68' ' ' PHE . 42.1 p90 -134.25 130.62 37.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.993 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.766 0.317 . . . . 0.0 110.941 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 167.69 21.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.45 ' CB ' ' CZ ' ' A' ' 60' ' ' TYR . 0.3 OUTLIER -85.56 131.86 34.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 110.749 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 3.3 tm-20 -113.09 119.86 39.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.089 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.17 123.48 47.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.555 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 148.43 17.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.571 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.617 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 40.8 m-85 -130.04 115.05 16.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.802 0.334 . . . . 0.0 110.614 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.38 120.84 33.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.993 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.224 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.697 0.284 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -99.31 130.53 10.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.105 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.51 121.67 65.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 179.269 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -108.89 142.83 38.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.145 0.498 . . . . 0.0 111.8 -178.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -132.3 110.62 10.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.738 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.481 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.8 p -150.85 167.39 27.64 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 120.932 0.396 . . . . 0.0 111.677 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -102.45 120.89 41.29 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.132 179.131 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.404 ' HB2' ' HB2' ' A' ' 69' ' ' GLU . 2.1 ttpm? -106.03 132.34 52.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.042 0.449 . . . . 0.0 111.909 -179.025 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.492 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.8 pp -135.87 128.35 30.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.281 179.305 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -150.25 -173.3 20.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.919 -179.646 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.816 ' CE2' HD11 ' A' ' 110' ' ' ILE . 30.4 p90 -166.17 143.12 4.31 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.585 0.231 . . . . 0.0 111.012 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo . . . . . 0 C--N 1.345 0.371 0 C-N-CA 122.778 2.319 . . . . 0.0 112.941 -179.763 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.487 HD23 ' CD1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.681 0.277 . . . . 0.0 110.302 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -144.76 158.4 43.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.966 0.413 . . . . 0.0 111.678 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.928 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 147.93 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.467 179.472 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.448 ' CZ ' ' HD3' ' A' ' 160' ' ' ARG . 17.7 p90 -142.33 143.32 32.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.11 0.481 . . . . 0.0 111.599 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 46.7 p -138.56 126.96 23.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.132 179.399 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.76 ' HG2' ' HB3' ' A' ' 146' ' ' ALA . 0.0 OUTLIER -121.2 138.48 54.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.982 0.42 . . . . 0.0 111.608 -179.241 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.49 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.8 tt -129.53 122.91 30.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.349 179.589 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.481 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -177.44 -141.76 4.22 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.723 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.526 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.19 169.13 25.89 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.434 -0.889 . . . . 0.0 112.843 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 14.7 tmm? -125.92 141.71 51.85 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 120.888 0.375 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -127.03 130.53 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.764 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 4.2 p-90 . . . . . 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 111.035 -179.85 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.637 0.256 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.437 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 4.5 p -157.11 131.85 5.28 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.368 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.526 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.5 Cg_exo -73.66 150.34 44.99 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.65 2.234 . . . . 0.0 111.791 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.1 m -156.28 163.53 1.41 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.26 0 CA-C-O 121.116 0.484 . . . . 0.0 111.84 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.49 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.9 t80 -137.07 118.76 15.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.245 179.629 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.76 ' HB3' ' HG2' ' A' ' 113' ' ' ARG . . . -103.63 126.72 50.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.929 0.395 . . . . 0.0 111.327 -179.636 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.57 124.88 3.61 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.176 179.817 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.75 -160.57 11.03 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.693 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.928 HG12 HG22 ' A' ' 110' ' ' ILE . 6.0 m -134.75 163.39 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.659 0.266 . . . . 0.0 110.915 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -127.71 142.54 51.3 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 120.918 0.39 . . . . 0.0 111.099 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' TRP . . . . . 0.487 ' CD1' HD23 ' A' ' 108' ' ' LEU . 7.6 t90 -126.57 119.16 26.42 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.66 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.59 137.23 32.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.388 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.511 179.631 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 21.5 mt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.887 0.375 . . . . 0.0 111.686 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -135.63 155.93 49.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.994 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 1.7 t -117.63 140.56 49.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.094 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.448 ' HD3' ' CZ ' ' A' ' 111' ' ' TYR . 0.0 OUTLIER -134.59 151.58 51.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.328 0.585 . . . . 0.0 112.123 -179.33 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -113.12 124.8 53.43 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.725 179.093 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -106.89 145.13 32.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.985 0.421 . . . . 0.0 111.622 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.672 ' CE2' HD21 ' A' ' 184' ' ' LEU . 0.8 OUTLIER -131.12 126.48 35.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.383 179.673 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.17 -179.787 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.672 HD21 ' CE2' ' A' ' 163' ' ' TYR . 2.5 mp . . . . . 0 N--CA 1.457 -0.089 0 CA-C-O 120.732 0.301 . . . . 0.0 110.771 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.3 p -136.76 155.78 49.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.068 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -119.33 133.06 55.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.461 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 187' ' ' GLY . . . . . 0.409 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -145.67 162.37 28.26 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.207 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.73 133.94 67.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.773 0.32 . . . . 0.0 110.402 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -136.14 175.09 9.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.943 0.401 . . . . 0.0 111.378 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -139.84 155.8 47.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.636 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 191' ' ' ARG . . . . . 0.44 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.933 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.498 HG22 ' H ' ' A' ' 19' ' ' TRP . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.72 0.295 . . . . 0.0 110.833 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.498 ' H ' HG22 ' A' ' 18' ' ' THR . 13.3 p-90 -143.79 148.17 35.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.955 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.8 m-85 -119.97 140.0 51.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.709 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.35 139.98 47.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.384 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.15 -158.47 19.82 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.499 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -155.86 150.45 21.81 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.533 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 9.1 ptmm? -131.71 154.04 49.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.914 0.388 . . . . 0.0 111.07 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -128.29 148.89 50.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.675 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.564 -179.932 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.38 144.4 34.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.426 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.55 130.85 3.36 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.747 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.765 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.91 145.67 24.75 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.689 0.28 . . . . 0.0 110.773 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -135.62 133.35 38.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.023 0.44 . . . . 0.0 111.425 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.82 125.04 1.89 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.849 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -134.39 164.36 24.58 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.934 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.404 ' CB ' ' HB3' ' A' ' 19' ' ' TRP . 48.5 p90 -143.91 134.04 24.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.897 0.38 . . . . 0.0 110.657 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.965 0.412 . . . . 0.0 111.325 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.75 177.1 18.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.294 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -98.04 142.37 29.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.653 0.263 . . . . 0.0 110.703 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -132.96 121.29 22.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.917 0.389 . . . . 0.0 111.07 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.16 129.32 53.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.421 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.01 156.91 15.35 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.636 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.765 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 40.0 m-85 -130.48 115.04 16.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.774 0.321 . . . . 0.0 110.463 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.83 120.48 30.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.186 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 . . . . . 0 C--N 1.331 -0.236 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.889 179.825 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.807 0.336 . . . . 0.0 110.645 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.36 128.47 8.5 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.666 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.66 117.96 51.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.641 0.258 . . . . 0.0 110.324 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -110.55 142.53 42.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.116 0.484 . . . . 0.0 111.72 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.5 tt -129.06 110.23 11.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.483 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.523 HG22 ' HA3' ' A' ' 115' ' ' GLY . 5.1 p -148.2 174.66 11.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.235 0.541 . . . . 0.0 111.769 -178.765 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -111.55 135.24 52.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.304 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.66 132.13 55.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.918 0.389 . . . . 0.0 111.448 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -132.18 131.69 42.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.587 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.38 -174.3 34.85 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.569 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.46 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -165.36 150.8 8.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.73 0.3 . . . . 0.0 110.925 -179.882 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.46 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 37.6 Cg_exo . . . . . 0 C--N 1.348 0.507 0 C-N-CA 122.709 2.272 . . . . 0.0 112.108 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.449 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.052 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.405 ' HB3' ' HA ' ' A' ' 103' ' ' PRO . 3.0 p30 -131.64 160.26 35.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.032 0.444 . . . . 0.0 112.016 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.968 HG22 HG12 ' A' ' 149' ' ' VAL . 1.4 pp -116.07 141.25 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.133 179.332 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -156.69 160.28 39.18 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.103 0.478 . . . . 0.0 111.925 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 9.3 t -138.4 151.07 47.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.02 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.517 ' NE ' ' HB3' ' A' ' 146' ' ' ALA . 3.7 ppt_? -120.5 127.99 52.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.514 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.6 tt -125.75 122.67 36.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.127 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.523 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -179.59 -141.52 4.59 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.512 -0.851 . . . . 0.0 112.669 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.491 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.11 168.65 25.64 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.796 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.462 ' HE3' HG11 ' A' ' 144' ' ' VAL . 8.3 ptp -126.56 142.48 51.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.879 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -124.45 144.05 35.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.807 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.7 t90 . . . . . 0 C--N 1.329 -0.307 0 CA-C-O 120.808 0.337 . . . . 0.0 110.974 -179.882 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 141' ' ' VAL . 9.1 p . . . . . 0 N--CA 1.457 -0.094 0 CA-C-O 120.667 0.27 . . . . 0.0 110.964 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.0 p -157.05 148.65 17.12 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.335 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.491 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 72.4 Cg_endo -76.55 158.47 36.08 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.665 2.243 . . . . 0.0 112.084 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.462 HG11 ' HE3' ' A' ' 117' ' ' MET . 35.0 m -155.92 154.41 6.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.031 0.443 . . . . 0.0 111.52 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 59.4 t80 -149.15 118.66 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.416 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.517 ' HB3' ' NE ' ' A' ' 113' ' ' ARG . . . -129.37 147.48 51.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.94 0.4 . . . . 0.0 111.345 -179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.22 145.37 17.19 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.078 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -164.77 -171.03 30.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.799 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.968 HG12 HG22 ' A' ' 110' ' ' ILE . 3.4 m -129.56 148.95 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.746 0.308 . . . . 0.0 111.107 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -110.83 127.15 55.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' TRP . . . . . 0.449 ' NE1' HD22 ' A' ' 108' ' ' LEU . 5.3 t90 -128.61 120.29 26.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.757 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.57 132.92 34.46 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.354 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.1 t . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.756 179.746 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 18.6 mt . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.766 0.317 . . . . 0.0 111.209 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -112.68 168.56 9.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.254 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.3 m -135.92 146.63 47.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.348 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 147.69 46.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.201 0.524 . . . . 0.0 111.902 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.2 tt -119.68 124.1 45.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.776 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -114.42 144.48 43.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.084 0.469 . . . . 0.0 111.592 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.43 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 18.7 p90 -134.14 155.17 50.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.494 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.972 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.622 HD12 ' N ' ' A' ' 184' ' ' LEU . 3.6 mp . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.712 0.291 . . . . 0.0 110.534 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 47.4 m -151.86 155.74 38.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.901 0.382 . . . . 0.0 111.264 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -118.26 135.77 54.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.366 179.589 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -147.92 167.24 28.84 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 119.967 -1.111 . . . . 0.0 113.139 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.3 m -123.74 145.07 31.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 67.4 p -152.29 174.98 13.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.055 0.455 . . . . 0.0 111.593 -179.221 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -145.16 152.37 39.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.541 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 191' ' ' ARG . . . . . 0.419 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.878 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.8 m . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.871 0.367 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.44 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 27.0 m-90 -131.78 131.93 43.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.986 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -128.26 135.96 50.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.722 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.14 141.25 34.17 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.49 -166.6 33.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.546 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -156.01 150.07 21.28 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.42 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -126.85 160.05 32.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.902 0.382 . . . . 0.0 111.157 -179.904 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.66 140.88 46.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.609 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.499 -179.888 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.645 -0.182 . . . . 0.0 112.645 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.11 144.54 33.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.34 117.78 1.2 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.619 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.73 136.1 35.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.75 0.31 . . . . 0.0 110.667 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 22.4 m-85 -125.93 132.8 52.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.974 0.416 . . . . 0.0 111.186 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.57 125.04 1.78 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.201 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 69' ' ' GLU . . . -155.87 -173.42 24.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.858 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.44 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 1.9 p90 -147.96 158.31 43.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.756 0.312 . . . . 0.0 110.8 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 32.8 mt-30 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.994 -179.787 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.6 pp . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.823 0.345 . . . . 0.0 110.7 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -137.97 175.66 21.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.615 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -115.36 138.16 51.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.823 0.344 . . . . 0.0 110.648 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.418 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . 1.2 pt-20 -140.13 143.14 36.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.002 0.43 . . . . 0.0 111.198 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -110.68 142.25 42.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.531 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 158.24 14.6 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.617 -0.802 . . . . 0.0 112.441 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -130.83 114.79 15.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.678 0.275 . . . . 0.0 110.77 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.412 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.4 t0 -90.35 119.36 30.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.914 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 2.2 t90 . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.955 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.782 0.325 . . . . 0.0 110.458 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.412 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -88.74 133.65 11.94 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.991 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.83 117.74 45.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -108.98 149.03 29.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.236 0.541 . . . . 0.0 111.875 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.6 tt -135.11 113.78 11.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.629 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 t -154.11 166.33 33.41 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.099 0.476 . . . . 0.0 111.638 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.34 134.57 50.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.481 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.59 130.18 54.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.315 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.557 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -135.25 124.27 24.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.537 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -166.89 -169.77 30.91 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.693 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -165.1 157.62 13.67 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.727 0.299 . . . . 0.0 111.112 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 109' ' ' ASP . 90.5 Cg_endo . . . . . 0 C--N 1.346 0.413 0 C-N-CA 122.787 2.325 . . . . 0.0 112.634 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.045 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 7.5 t0 -125.39 147.68 49.08 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.382 0.611 . . . . 0.0 112.385 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -129.33 123.54 58.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.763 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -143.04 168.84 18.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.027 0.441 . . . . 0.0 111.559 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.427 HG22 ' HA3' ' A' ' 147' ' ' GLY . 31.0 p -141.15 140.26 34.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.548 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.7 ptt-85 -111.64 127.93 55.9 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.205 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.5 tt -124.83 125.02 43.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.623 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 176.94 -132.74 2.1 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.512 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.03 169.18 32.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.982 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.0 tmm? -125.94 144.47 50.67 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 120.682 0.277 . . . . 0.0 110.639 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.63 129.65 64.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' TRP . . . . . 0.402 ' CZ2' ' HB3' ' A' ' 73' ' ' ASP . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.2 p . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.791 0.329 . . . . 0.0 111.036 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 38.1 m -157.24 148.18 16.47 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.387 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.512 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.5 Cg_endo -78.0 147.96 24.4 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.766 2.311 . . . . 0.0 112.049 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.11 158.38 3.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.988 0.423 . . . . 0.0 111.52 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -145.88 119.93 9.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.418 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -120.97 163.95 17.47 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.904 0.383 . . . . 0.0 111.396 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.427 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -140.7 148.42 20.06 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.246 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.37 -171.99 31.3 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.705 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.8 m -131.98 167.05 27.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.669 0.271 . . . . 0.0 111.08 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -134.64 151.49 51.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.946 0.403 . . . . 0.0 111.291 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -133.06 117.61 17.77 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.582 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 158' ' ' ALA . . . -81.68 122.46 27.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.422 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 56.4 t . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.957 179.706 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.4 mt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.925 0.393 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.432 ' HB2' ' HA ' ' A' ' 152' ' ' ALA . . . -113.25 167.91 10.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.288 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.4 t -123.27 143.3 50.15 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.261 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.09 147.19 45.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.13 0.49 . . . . 0.0 111.783 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -113.95 126.11 54.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.806 179.043 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.7 138.51 45.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.385 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -134.19 156.18 48.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.664 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.929 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.605 ' N ' HD12 ' A' ' 184' ' ' LEU . 4.2 mp . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.67 0.272 . . . . 0.0 110.629 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.22 155.46 37.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.01 0.433 . . . . 0.0 111.285 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -115.24 131.87 56.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.169 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 187' ' ' GLY . . . . . 0.42 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -146.15 168.06 27.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.367 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -127.59 141.01 47.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -144.57 174.98 10.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.043 0.449 . . . . 0.0 111.522 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -146.15 155.67 42.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.712 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 1.6 ptp180 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.977 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.763 0.316 . . . . 0.0 110.92 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -118.29 130.74 56.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.857 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -126.06 135.88 52.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.799 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.23 153.85 44.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.17 -165.28 37.91 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.42 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -160.54 151.51 22.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.532 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -133.05 157.91 44.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 0.0 111.034 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -127.46 146.19 50.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.7 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.546 -179.929 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.14 52.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.69 0.281 . . . . 0.0 110.948 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.5 135.46 7.44 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.737 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.487 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -103.75 135.64 44.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.781 0.324 . . . . 0.0 110.882 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -119.41 133.69 55.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.206 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -157.27 125.55 1.59 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.389 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -146.18 -178.65 21.78 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.69 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 14.3 p90 -153.35 160.81 42.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.843 0.354 . . . . 0.0 110.927 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.798 179.859 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.821 0.343 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.23 169.8 21.05 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.439 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.6 m-85 -98.75 138.74 35.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.63 0.253 . . . . 0.0 110.817 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -125.95 129.55 49.49 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.952 0.406 . . . . 0.0 110.965 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.11 129.31 55.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.424 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.27 17.43 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.362 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.487 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 81.5 m-85 -125.61 114.85 19.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.748 0.309 . . . . 0.0 110.676 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.448 ' HB2' ' CZ2' ' A' ' 119' ' ' TRP . 0.3 OUTLIER -87.15 118.28 26.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.758 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.968 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.695 0.283 . . . . 0.0 110.374 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.439 ' HA3' ' HB2' ' A' ' 73' ' ' ASP . . . -83.92 133.73 12.12 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.017 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.85 117.98 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.8 0.333 . . . . 0.0 110.208 179.355 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 -108.98 138.11 45.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.109 0.481 . . . . 0.0 111.728 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.441 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.7 tt -127.6 107.24 9.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.696 179.209 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.651 HG22 ' HA3' ' A' ' 115' ' ' GLY . 27.0 p -144.68 162.05 37.65 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 121.158 0.504 . . . . 0.0 111.796 -178.702 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -92.92 126.5 38.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.006 178.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -104.87 130.98 52.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.029 0.442 . . . . 0.0 111.845 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.51 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.8 pp -136.29 123.78 22.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 179.036 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.21 177.46 34.06 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.507 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.439 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.19 153.95 9.4 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.733 0.302 . . . . 0.0 111.344 -179.925 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.439 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 38.1 Cg_exo . . . . . 0 C--N 1.347 0.483 0 C-N-CA 122.76 2.306 . . . . 0.0 112.05 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.498 HD23 ' N ' ' A' ' 108' ' ' LEU . 0.0 OUTLIER . . . . . 0 CA--C 1.524 -0.048 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -135.03 160.09 39.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.722 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.914 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.93 144.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.209 179.359 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -142.26 141.82 32.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.008 0.432 . . . . 0.0 111.527 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.443 HG23 ' HG ' ' A' ' 100' ' ' LEU . 9.6 t -137.15 126.91 25.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.199 179.347 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.403 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 0.0 OUTLIER -114.41 131.6 56.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.913 0.387 . . . . 0.0 111.511 -179.358 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.0 tt -128.06 122.93 33.35 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.451 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.651 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -175.82 -135.45 2.12 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.622 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.509 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.12 161.7 26.4 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.899 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.47 138.63 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.716 0.293 . . . . 0.0 110.705 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -129.57 134.68 63.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' TRP . . . . . 0.448 ' CZ2' ' HB2' ' A' ' 73' ' ' ASP . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.8 p . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.621 0.248 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -157.1 144.72 13.92 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.337 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.509 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 90.9 Cg_endo -80.73 139.99 12.76 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.752 2.302 . . . . 0.0 112.115 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 143' ' ' PRO . 30.3 m -157.04 162.84 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 121.002 0.43 . . . . 0.0 111.504 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.9 p90 -142.35 121.12 12.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.45 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -105.74 141.16 37.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.976 0.417 . . . . 0.0 111.402 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.59 135.03 7.88 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.994 179.542 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -159.68 -171.99 26.26 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.895 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.914 HG12 HG22 ' A' ' 110' ' ' ILE . 4.4 m -131.12 150.98 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.663 0.268 . . . . 0.0 111.138 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -122.32 133.99 54.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.169 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 9.4 m95 -121.76 122.17 38.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.649 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.413 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -78.77 137.01 37.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.406 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 72.8 t . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.682 179.758 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 5.2 mt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.809 0.338 . . . . 0.0 111.226 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -132.5 161.85 32.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.375 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 9.7 t -117.72 143.98 45.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.965 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -137.0 150.87 48.39 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.204 0.526 . . . . 0.0 112.158 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.7 tt -114.39 123.87 50.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.585 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -107.83 139.54 42.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.986 0.422 . . . . 0.0 111.557 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.429 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 36.3 p90 -134.14 160.15 38.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.723 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.058 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 6.3 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.693 0.283 . . . . 0.0 110.65 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 11.0 p -142.53 158.91 43.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.73 134.64 54.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -149.29 172.62 29.31 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.004 -1.093 . . . . 0.0 113.404 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.65 141.37 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.677 0.275 . . . . 0.0 110.388 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 32.8 p -139.55 171.48 14.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.42 . . . . 0.0 111.268 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -148.03 157.51 43.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.776 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.95 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.7 p . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.818 0.342 . . . . 0.0 110.885 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -121.94 145.39 48.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.405 ' CE2' ' HG3' ' A' ' 191' ' ' ARG . 89.6 m-85 -142.16 135.98 29.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.569 ' HB3' ' CE1' ' A' ' 190' ' ' TYR . . . -144.41 140.02 28.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.08 -161.11 26.09 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.384 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.85 147.27 17.1 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.56 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.72 153.81 35.07 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.923 0.392 . . . . 0.0 110.906 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.462 HD12 ' O ' ' A' ' 53' ' ' GLY . 55.7 tp -136.7 138.61 41.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.649 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.604 -179.827 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.462 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.33 -0.308 . . . . 0.0 112.33 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -117.78 142.86 46.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.806 0.336 . . . . 0.0 111.137 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.419 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -143.17 134.73 6.07 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.67 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.641 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.9 140.28 30.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.304 . . . . 0.0 110.837 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.41 ' CD1' ' HG2' ' A' ' 69' ' ' GLU . 0.2 OUTLIER -126.45 134.31 51.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.935 0.398 . . . . 0.0 111.126 -179.777 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -161.62 126.42 1.58 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.254 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -158.55 -166.2 17.24 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.653 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -151.21 146.56 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.879 0.371 . . . . 0.0 110.989 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.756 179.877 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.785 0.326 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 158.38 23.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.483 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -105.28 129.03 53.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.632 0.253 . . . . 0.0 110.62 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.41 ' HG2' ' CD1' ' A' ' 57' ' ' PHE . 5.0 tt0 -122.54 128.46 50.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.86 0.362 . . . . 0.0 111.149 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.3 ttt -108.96 127.0 53.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.538 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 163.92 12.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.742 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.641 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 95.5 m-85 -138.18 114.85 10.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.24 120.27 25.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.023 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.224 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.832 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.698 0.285 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -115.1 141.01 16.76 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.203 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.11 128.11 67.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.175 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 145.29 35.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.135 0.493 . . . . 0.0 111.855 -178.791 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -140.08 116.14 10.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.742 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -153.01 165.43 35.6 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.211 0.529 . . . . 0.0 111.809 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -99.19 133.42 43.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.358 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 9.5 pttt -112.79 132.33 55.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.515 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.542 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.9 pp -136.08 122.33 20.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.534 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.31 -176.73 37.14 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.663 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.424 ' HB2' ' HD2' ' A' ' 103' ' ' PRO . 30.3 p90 -166.18 157.61 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 120.657 0.265 . . . . 0.0 111.009 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.424 ' HD2' ' HB2' ' A' ' 102' ' ' TYR . 19.9 Cg_endo . . . . . 0 C--N 1.346 0.427 0 C-N-CA 122.599 2.2 . . . . 0.0 111.813 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.077 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -127.43 155.91 42.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.983 0.42 . . . . 0.0 111.925 -178.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.055 HG22 HG12 ' A' ' 149' ' ' VAL . 1.5 pp -125.18 136.35 61.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.369 179.374 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 37.8 p90 -150.14 159.35 44.49 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.106 0.479 . . . . 0.0 111.494 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.407 HG22 ' HA3' ' A' ' 147' ' ' GLY . 36.8 p -130.86 149.22 52.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.479 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.1 ppt_? -123.75 127.85 48.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.87 0.367 . . . . 0.0 111.394 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -127.89 122.74 33.29 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.205 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -179.47 -133.18 1.91 Allowed Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.735 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.1 169.12 33.64 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.809 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -126.02 143.7 51.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.823 0.344 . . . . 0.0 110.906 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.3 t -124.89 125.23 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.839 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 19.7 m0 . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.904 -179.806 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.749 0.309 . . . . 0.0 111.286 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 54.4 p -157.02 130.6 4.69 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.489 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.9 Cg_endo -78.23 146.94 22.84 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.548 2.165 . . . . 0.0 112.152 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.6 m -156.09 151.11 9.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.872 0.368 . . . . 0.0 111.442 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.2 p90 -149.08 124.27 10.15 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.501 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.543 ' HB2' ' HG3' ' A' ' 164' ' ' GLN . . . -134.91 167.04 21.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.979 0.418 . . . . 0.0 111.447 -179.611 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.407 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -133.76 146.14 18.12 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.007 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -155.39 -179.83 30.82 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.901 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 1.055 HG12 HG22 ' A' ' 110' ' ' ILE . 11.4 m -128.42 153.31 37.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.828 0.347 . . . . 0.0 110.994 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -122.12 139.74 53.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.203 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -128.48 118.48 23.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.804 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.413 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -82.24 137.01 34.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.23 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 84.6 t . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 179.839 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.3 mt . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.801 0.334 . . . . 0.0 111.274 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.04 155.67 46.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.383 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 6.4 t -102.5 145.73 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.299 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.24 139.09 40.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.068 0.461 . . . . 0.0 111.823 -179.481 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -115.74 130.48 56.87 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.754 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.25 142.58 39.91 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.047 0.451 . . . . 0.0 111.626 -179.256 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.489 ' CZ ' HD21 ' A' ' 184' ' ' LEU . 0.1 OUTLIER -134.14 130.68 37.68 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.372 179.582 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 164' ' ' GLN . . . . . 0.543 ' HG3' ' HB2' ' A' ' 146' ' ' ALA . 5.6 mp0 . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.12 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.528 ' N ' HD12 ' A' ' 184' ' ' LEU . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.779 0.323 . . . . 0.0 110.696 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.9 m -125.43 151.01 46.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.104 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.47 128.44 52.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.414 179.712 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -145.7 167.24 27.67 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.997 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.7 m -129.56 137.34 57.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.659 0.266 . . . . 0.0 110.588 179.533 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.7 p -139.88 175.06 9.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.953 0.406 . . . . 0.0 111.318 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 190' ' ' TYR . . . . . 0.569 ' CE1' ' HB3' ' A' ' 21' ' ' ALA . 3.8 p90 -141.66 159.92 41.23 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.812 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 191' ' ' ARG . . . . . 0.405 ' HG3' ' CE2' ' A' ' 20' ' ' TYR . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.851 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.6 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.886 0.374 . . . . 0.0 110.775 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 70.2 p-90 -149.6 132.3 15.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.987 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.5 m-85 -114.38 141.15 48.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.55 141.64 28.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.884 0.373 . . . . 0.0 111.278 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.21 -166.55 30.21 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.879 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -134.3 141.76 13.12 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.466 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.515 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 6.3 ptpt -128.84 149.72 50.63 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.078 0.466 . . . . 0.0 111.412 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.79 HD12 ' O ' ' A' ' 53' ' ' GLY . 47.4 tp -126.46 150.11 48.89 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.511 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.567 ' H ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.342 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.79 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.453 -0.22 0 N-CA-C 112.413 -0.275 . . . . 0.0 112.413 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -118.05 170.02 9.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.688 0.28 . . . . 0.0 110.932 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.58 157.34 27.67 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.783 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.533 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -108.97 140.58 42.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 110.876 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.403 ' HE2' ' HZ2' ' A' ' 24' ' ' LYS . 3.0 m-85 -126.48 128.76 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.031 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.65 124.99 2.2 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.254 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.13 172.26 23.0 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.763 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -140.11 160.49 39.83 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.827 0.346 . . . . 0.0 110.786 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 . . . . . 0 C--N 1.331 -0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.908 -179.982 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.664 0.268 . . . . 0.0 110.831 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -121.23 161.56 15.25 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.584 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -114.08 134.7 54.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.779 0.323 . . . . 0.0 110.696 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.401 ' OE2' ' CD1' ' A' ' 57' ' ' PHE . 2.0 tt0 -129.95 129.93 44.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.918 0.389 . . . . 0.0 111.085 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 ttm -108.01 135.43 49.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.422 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 158.52 14.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.512 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.533 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 19.9 m-85 -138.0 115.02 10.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.646 0.26 . . . . 0.0 110.657 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.417 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.2 t0 -87.97 121.09 29.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.88 0.372 . . . . 0.0 110.924 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 21.3 t-105 . . . . . 0 C--N 1.332 -0.193 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.977 -179.958 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.617 0.246 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.417 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -85.26 135.76 13.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.926 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.42 120.33 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 179.431 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -108.95 148.51 30.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.154 0.502 . . . . 0.0 111.744 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 tt -138.13 114.04 9.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.703 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.423 HG22 ' HA3' ' A' ' 115' ' ' GLY . 8.6 p -149.72 164.45 35.22 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 121.054 0.455 . . . . 0.0 111.764 -178.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -97.52 132.28 43.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.314 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.86 132.23 53.66 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.036 0.446 . . . . 0.0 111.643 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.569 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.4 pp -135.93 124.07 23.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.431 179.322 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.96 -169.86 30.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.711 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.456 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 2.9 t80 -160.62 145.17 10.59 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.69 0.281 . . . . 0.0 111.12 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.456 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 95.3 Cg_endo . . . . . 0 C--N 1.347 0.472 0 C-N-CA 122.884 2.389 . . . . 0.0 112.479 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.61 HD22 ' CE2' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.087 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 . . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -131.38 155.11 47.83 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.031 0.443 . . . . 0.0 111.893 -179.19 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.956 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -119.91 146.82 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.271 179.351 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.441 ' CE2' ' HB2' ' A' ' 150' ' ' GLU . 4.4 p90 -162.44 164.01 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.103 0.478 . . . . 0.0 111.763 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.409 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 17.4 m -140.54 139.77 35.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.497 179.737 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.401 ' HB3' ' NH1' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -114.96 127.99 56.01 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.152 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -127.79 122.91 33.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.44 179.803 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.423 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.89 -134.54 2.15 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.536 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -149.42 163.06 29.19 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.751 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.9 ppp? -117.64 145.03 44.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 110.917 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.7 t -127.05 141.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.861 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.5 t90 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.003 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.714 0.293 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.02 117.33 2.84 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.347 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.489 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 6.3 Cg_exo -73.65 137.62 25.3 Favored 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 122.605 2.203 . . . . 0.0 111.85 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 143' ' ' PRO . 26.4 m -156.96 164.03 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.862 0.363 . . . . 0.0 111.386 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -148.59 122.37 9.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.796 179.695 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.52 142.85 45.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.173 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 112' ' ' THR . . . -134.34 142.12 13.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.299 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -170.55 -157.69 13.12 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.107 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.956 HG12 HG22 ' A' ' 110' ' ' ILE . 4.9 m -129.83 163.25 35.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 111.127 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.441 ' HB2' ' CE2' ' A' ' 111' ' ' TYR . 0.7 OUTLIER -133.19 129.38 37.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 151' ' ' TRP . . . . . 0.61 ' CE2' HD22 ' A' ' 108' ' ' LEU . 1.4 t-105 -118.43 132.55 56.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.792 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.425 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -99.36 134.43 42.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 0.0 111.528 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.681 ' O ' HG12 ' A' ' 153' ' ' VAL . 47.8 t . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.751 179.754 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.816 0.341 . . . . 0.0 111.073 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.425 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -115.88 154.26 30.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.342 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.99 151.53 22.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.247 179.499 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 2.1 ptm180 -136.93 132.76 34.89 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.9 0.381 . . . . 0.0 111.897 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.838 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 1.1 tt -123.61 120.79 33.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.734 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.435 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 0.7 OUTLIER -116.34 145.12 43.44 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.606 -179.043 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.838 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 2.1 m-85 -126.76 165.81 18.58 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.551 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.938 -179.998 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.499 HD12 ' N ' ' A' ' 184' ' ' LEU . 6.7 mp . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.826 0.346 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.2 m -132.59 145.8 51.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.91 137.84 49.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.568 179.705 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 187' ' ' GLY . . . . . 0.515 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -158.8 -176.65 31.09 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.449 -0.881 . . . . 0.0 113.042 -179.569 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -126.16 141.86 44.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.637 0.256 . . . . 0.0 110.52 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 189' ' ' SER . . . . . 0.46 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 1.4 t -137.93 159.72 41.24 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.112 0.482 . . . . 0.0 111.576 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -117.81 146.42 43.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.41 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.235 0 CA-C-O 120.813 0.34 . . . . 0.0 110.822 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -121.19 146.97 46.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.421 ' CD1' ' HB2' ' A' ' 189' ' ' SER . 0.1 OUTLIER -142.35 135.81 29.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.724 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 145.22 31.03 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.336 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.72 -168.9 38.65 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.566 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -137.0 147.04 19.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.546 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.435 ' HE3' ' CE2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -121.2 153.14 37.98 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 -179.924 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.1 tt -133.43 139.34 46.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.723 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.383 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.577 -179.989 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.628 -0.189 . . . . 0.0 112.628 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -127.97 159.63 34.38 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.812 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.437 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -158.44 155.66 26.68 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.802 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -113.59 126.69 55.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.797 0.332 . . . . 0.0 110.856 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.435 ' CE2' ' HE3' ' A' ' 24' ' ' LYS . 38.9 p90 -115.59 133.46 56.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.111 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.1 125.15 1.78 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.132 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -150.41 -176.98 23.93 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.747 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -155.06 154.48 32.52 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.896 0.379 . . . . 0.0 111.006 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.567 179.867 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.976 0.417 . . . . 0.0 111.159 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.49 176.76 18.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.398 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.41 ' CE2' ' HG ' ' A' ' 96' ' ' LEU . 1.2 t80 -103.85 138.24 40.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.634 0.254 . . . . 0.0 110.724 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -134.51 125.9 28.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.852 0.358 . . . . 0.0 111.116 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.1 mtt -107.27 133.38 51.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.434 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.87 159.4 13.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.615 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.437 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -131.53 114.88 15.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.679 0.276 . . . . 0.0 110.613 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -86.18 120.51 27.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.998 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 42.8 t90 . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.917 -179.974 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.675 0.274 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -98.21 130.22 10.16 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.968 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.77 118.96 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 15.8 mt-30 -108.86 144.4 36.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.241 0.543 . . . . 0.0 111.937 -178.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.452 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -133.45 112.19 11.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.266 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.515 HG22 ' HA3' ' A' ' 115' ' ' GLY . 6.0 p -147.03 178.05 8.67 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.219 0.533 . . . . 0.0 111.984 -178.641 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -117.27 135.81 53.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.039 179.169 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -110.65 131.98 54.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.021 0.439 . . . . 0.0 111.379 -179.387 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.621 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -135.45 125.71 26.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.259 179.599 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.423 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -168.14 -169.82 32.09 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.944 -179.538 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.823 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 24.5 p90 -156.51 152.43 22.85 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.819 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo . . . . . 0 N--CA 1.463 -0.321 0 C-N-CA 122.721 2.281 . . . . 0.0 112.803 -179.617 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.227 -0.106 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -129.27 145.59 51.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.987 0.422 . . . . 0.0 111.809 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.969 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.9 142.17 28.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.657 179.314 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.423 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 33.4 m-85 -149.12 158.33 44.1 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.058 0.456 . . . . 0.0 111.695 -179.35 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.6 m -130.89 141.92 50.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.457 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 36.8 ttp180 -120.83 127.94 52.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.278 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -136.34 122.92 20.92 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.929 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.515 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -177.12 -140.71 3.73 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.583 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.7 167.74 25.48 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.868 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 9.0 ttp -130.2 141.1 50.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 0.0 110.735 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.4 t -125.69 115.63 43.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.826 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.888 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.409 HG13 ' O ' ' A' ' 141' ' ' VAL . 10.1 p . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.705 0.288 . . . . 0.0 110.97 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -157.16 148.49 16.84 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.831 0.348 . . . . 0.0 111.464 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.511 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -79.81 145.66 18.11 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.752 2.302 . . . . 0.0 112.222 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.7 m -156.71 157.1 4.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.927 0.394 . . . . 0.0 111.404 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -149.13 127.19 11.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.476 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -124.01 143.85 50.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.245 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -130.02 146.95 17.85 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.09 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.409 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -167.72 -164.39 23.31 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.936 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.969 HG12 HG22 ' A' ' 110' ' ' ILE . 6.7 m -128.65 166.89 25.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.685 0.279 . . . . 0.0 111.134 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -135.4 149.1 49.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.92 0.391 . . . . 0.0 111.196 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 5.2 m0 -131.39 123.07 27.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.735 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.86 130.2 34.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.225 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 51.1 t . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.052 179.942 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.442 HG12 ' CD2' ' A' ' 190' ' ' TYR . 22.8 mt . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.697 0.284 . . . . 0.0 110.754 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -132.99 160.86 35.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.984 0.421 . . . . 0.0 111.59 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' THR . . . . . 0.494 ' OG1' HG12 ' A' ' 188' ' ' VAL . 24.5 m -119.35 145.45 46.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.973 179.518 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.408 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 147.42 46.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.179 0.514 . . . . 0.0 111.976 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.817 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 1.3 tt -113.92 123.57 50.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.533 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.409 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 1.1 mt-10 -107.5 143.88 35.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.044 0.45 . . . . 0.0 111.616 -179.074 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.823 ' CE1' HD23 ' A' ' 184' ' ' LEU . 45.4 m-85 -130.94 163.53 27.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.504 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.993 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.823 HD23 ' CE1' ' A' ' 163' ' ' TYR . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.658 0.266 . . . . 0.0 110.605 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -135.71 152.37 51.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.973 0.416 . . . . 0.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.13 128.72 54.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.3 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -143.2 167.31 26.48 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.16 -1.019 . . . . 0.0 113.082 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 188' ' ' VAL . . . . . 0.494 HG12 ' OG1' ' A' ' 159' ' ' THR . 0.4 OUTLIER -128.42 139.49 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.687 0.28 . . . . 0.0 110.374 179.445 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 189' ' ' SER . . . . . 0.421 ' HB2' ' CD1' ' A' ' 20' ' ' TYR . 0.3 OUTLIER -136.27 168.7 18.93 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 111.723 -179.125 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 190' ' ' TYR . . . . . 0.452 ' CD1' ' N ' ' A' ' 190' ' ' TYR . 2.7 m-85 -131.71 157.99 42.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.366 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 38.0 mtm180 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.943 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.511 HG21 ' HD3' ' A' ' 191' ' ' ARG . 1.4 p . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.815 0.341 . . . . 0.0 110.838 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 25.9 m-90 -117.28 132.45 56.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.055 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.429 ' CZ ' ' HG3' ' A' ' 191' ' ' ARG . 5.1 m-85 -120.41 135.87 54.91 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.522 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.22 140.26 43.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.488 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.409 ' HA3' ' HB3' ' A' ' 189' ' ' SER . . . 179.14 -163.78 31.57 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.414 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -162.73 161.33 33.67 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.552 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.458 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 0.1 OUTLIER -135.32 160.9 36.97 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.005 0.431 . . . . 0.0 111.044 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.417 HD12 ' HB2' ' A' ' 54' ' ' ALA . 3.9 tt -130.85 149.17 52.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.735 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.463 179.98 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.417 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -132.37 132.64 43.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.752 0.311 . . . . 0.0 110.914 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.37 158.08 26.79 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.753 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -126.85 134.72 50.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.51 0.195 . . . . 0.0 110.793 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.458 ' CE2' ' HG2' ' A' ' 24' ' ' LYS . 6.3 p90 -142.37 165.39 27.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.176 0.512 . . . . 0.0 111.738 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -140.13 141.87 11.96 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.79 179.67 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -114.59 143.26 17.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.896 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.441 ' CE2' ' HB3' ' A' ' 68' ' ' PHE . 1.8 p90 -144.62 121.3 11.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.898 0.38 . . . . 0.0 110.631 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.976 -179.775 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.861 0.362 . . . . 0.0 110.99 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 172.16 20.33 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.441 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . 0.9 OUTLIER -96.87 141.46 30.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.684 0.278 . . . . 0.0 110.611 179.902 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.77 120.24 28.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.976 0.417 . . . . 0.0 111.281 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.3 mtt -106.17 139.03 41.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.859 179.164 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' GLY . . . . . 0.45 ' CA ' ' HB3' ' A' ' 57' ' ' PHE . . . -133.0 166.63 23.61 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.643 -179.278 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -136.92 115.43 11.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.363 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -81.52 129.73 34.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.18 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 46.0 m95 . . . . . 0 C--N 1.33 -0.264 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.737 179.87 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.713 0.292 . . . . 0.0 110.519 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -105.53 140.56 15.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.429 -0.891 . . . . 0.0 112.913 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -115.81 122.62 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.201 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -108.53 143.85 36.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.115 0.483 . . . . 0.0 111.9 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -137.48 113.88 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.849 179.629 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.413 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 1.2 t -155.1 166.82 32.37 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 111.784 -179.01 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.1 139.45 39.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.32 179.294 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.9 ttpp -118.92 132.25 56.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.897 0.379 . . . . 0.0 111.598 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.8 pp -134.03 126.58 30.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.737 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 102' ' ' TYR . . . -167.99 -177.81 39.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.514 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.407 ' CG ' ' O ' ' A' ' 101' ' ' GLY . 6.5 m-85 -166.1 158.89 12.51 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.777 0.322 . . . . 0.0 110.987 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo . . . . . 0 C--N 1.346 0.442 0 C-N-CA 122.741 2.294 . . . . 0.0 111.944 179.806 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.6 HD22 ' CE2' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 N--CA 1.459 0.019 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -135.15 156.19 49.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.071 0.462 . . . . 0.0 111.996 -179.119 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.944 HG22 HG12 ' A' ' 149' ' ' VAL . 1.6 pp -121.34 138.86 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.394 179.309 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 48.1 p90 -151.28 163.51 38.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.071 0.463 . . . . 0.0 111.557 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.461 HG22 ' HA3' ' A' ' 147' ' ' GLY . 18.5 p -137.63 145.69 43.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.53 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -119.76 127.78 53.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.883 0.373 . . . . 0.0 111.315 -179.756 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -126.98 123.64 37.59 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.328 179.635 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.413 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.39 -132.49 1.94 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.42 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.497 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.89 168.61 33.95 Favored Glycine 0 C--N 1.331 0.3 0 C-N-CA 120.285 -0.96 . . . . 0.0 112.9 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.95 140.98 52.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.711 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.541 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.5 t -133.91 118.16 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.657 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 64.5 p-90 . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 120.833 0.349 . . . . 0.0 111.049 -179.792 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.444 HG23 HG22 ' A' ' 118' ' ' VAL . 10.8 p . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.744 0.307 . . . . 0.0 111.194 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.21 141.29 11.67 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.397 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.497 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 92.2 Cg_endo -78.69 149.95 23.96 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.603 2.202 . . . . 0.0 112.02 179.593 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.8 m -156.3 157.93 3.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.04 0.448 . . . . 0.0 111.702 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -149.08 118.9 7.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.303 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -127.76 159.21 35.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.986 0.422 . . . . 0.0 111.537 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.461 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -130.95 151.82 19.75 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.036 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -162.73 -177.71 35.96 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.346 -0.931 . . . . 0.0 112.979 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.944 HG12 HG22 ' A' ' 110' ' ' ILE . 4.2 m -127.82 154.27 38.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 0.0 111.005 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -124.75 140.46 52.91 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.938 0.399 . . . . 0.0 111.116 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 151' ' ' TRP . . . . . 0.6 ' CE2' HD22 ' A' ' 108' ' ' LEU . 1.9 t90 -131.63 127.77 37.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.779 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.401 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -82.62 137.2 34.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.329 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 76.0 t . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.664 179.819 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 33.4 mt . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.927 0.394 . . . . 0.0 111.288 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -136.35 164.35 28.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.233 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -118.53 144.8 45.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.151 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.408 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 0.0 OUTLIER -137.16 152.07 49.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.276 0.56 . . . . 0.0 112.051 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -117.97 125.36 50.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.551 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -117.72 137.54 52.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.049 0.452 . . . . 0.0 111.595 -179.203 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -134.19 152.29 51.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.489 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 4.3 mp . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.777 0.323 . . . . 0.0 110.681 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 72.0 m -148.71 153.25 37.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.975 0.416 . . . . 0.0 111.226 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.73 136.07 53.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.23 179.706 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.92 170.33 28.59 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.056 -1.069 . . . . 0.0 113.196 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.6 m -132.09 148.09 32.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.602 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 189' ' ' SER . . . . . 0.409 ' HB3' ' HA3' ' A' ' 22' ' ' GLY . 89.4 p -151.79 175.06 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.054 0.455 . . . . 0.0 111.466 -179.701 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -145.92 156.54 43.59 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.621 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 191' ' ' ARG . . . . . 0.511 ' HD3' HG21 ' A' ' 18' ' ' THR . 8.4 ttm180 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.92 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 39.9 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.717 0.294 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.421 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.2 t-105 -135.66 135.07 39.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.432 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 7.9 m-85 -121.98 145.05 48.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.77 141.6 28.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.256 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.55 -166.67 34.06 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.552 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.38 146.71 18.42 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.544 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -127.93 149.32 50.37 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 120.858 0.361 . . . . 0.0 111.082 -179.762 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.465 ' HG ' ' HB2' ' A' ' 54' ' ' ALA . 2.0 tt -132.55 145.55 51.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.668 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.593 179.954 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.396 -0.282 . . . . 0.0 112.396 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.465 ' HB2' ' HG ' ' A' ' 25' ' ' LEU . . . -136.57 173.13 12.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.915 0.388 . . . . 0.0 111.052 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.87 156.6 26.06 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.626 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.656 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.95 160.17 14.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.822 0.344 . . . . 0.0 111.011 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -147.77 126.39 12.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.984 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.43 137.05 5.69 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.299 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.436 ' HA3' ' HB3' ' A' ' 69' ' ' GLU . . . -171.39 -165.84 29.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.649 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.421 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 6.0 p90 -143.57 161.01 39.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.994 0.426 . . . . 0.0 111.039 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.59 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.793 0.33 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -128.87 156.41 21.12 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.32 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -128.99 128.43 43.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.621 0.248 . . . . 0.0 110.769 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.436 ' HB3' ' HA3' ' A' ' 59' ' ' GLY . 1.4 pm0 -147.44 153.46 39.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.149 0.499 . . . . 0.0 111.505 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 4.0 ptt? -118.15 138.21 52.45 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.186 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.86 175.63 18.73 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.689 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.656 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 0.8 OUTLIER -134.71 114.94 13.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.661 0.267 . . . . 0.0 110.621 179.893 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -78.27 121.64 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.084 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 6.1 m95 . . . . . 0 C--N 1.331 -0.216 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.878 179.886 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.699 0.285 . . . . 0.0 110.631 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.85 141.54 15.32 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.898 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -112.05 126.0 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.249 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -108.86 146.84 33.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.224 0.535 . . . . 0.0 112.03 -178.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.425 ' O ' HD23 ' A' ' 96' ' ' LEU . 2.0 tt -139.13 116.1 10.92 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.347 179.527 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.424 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 0.9 OUTLIER -154.32 170.03 22.28 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.191 0.519 . . . . 0.0 112.054 -178.694 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -108.95 149.64 28.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.134 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.82 132.23 53.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.966 0.412 . . . . 0.0 111.704 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.575 ' O ' HD12 ' A' ' 100' ' ' LEU . 4.0 pp -133.34 125.11 28.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.18 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -163.06 -169.82 27.04 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.872 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.442 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -157.35 145.3 14.07 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.674 0.273 . . . . 0.0 110.923 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.442 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 84.7 Cg_endo . . . . . 0 C--N 1.347 0.485 0 C-N-CA 122.764 2.309 . . . . 0.0 112.643 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.456 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 N--CA 1.46 0.064 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 . . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -134.35 152.48 51.83 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.12 0.486 . . . . 0.0 112.09 -178.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.959 HG22 ' CG1' ' A' ' 149' ' ' VAL . 1.3 pt -114.82 147.63 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 179.104 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -157.77 166.19 33.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.1 0.476 . . . . 0.0 111.823 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.41 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 27.4 m -142.28 132.29 24.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.513 179.679 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 52.6 mtt180 -109.92 128.91 55.66 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.188 -179.695 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -132.98 125.52 29.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.715 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.424 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . -179.98 -135.51 2.49 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.477 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.508 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -152.19 169.04 31.45 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.48 -0.867 . . . . 0.0 112.792 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.5 ptp -128.13 140.91 51.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.849 0.357 . . . . 0.0 110.995 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.431 ' O ' HG23 ' A' ' 94' ' ' VAL . 2.1 t -130.63 111.88 21.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.715 179.774 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.5 p-90 . . . . . 0 C--N 1.329 -0.308 0 CA-C-O 120.927 0.394 . . . . 0.0 111.055 -179.831 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.9 p . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.732 0.301 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.17 147.4 15.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.247 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.508 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.3 Cg_endo -78.1 151.89 27.38 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.749 2.3 . . . . 0.0 112.209 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.8 m -156.38 157.29 3.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.379 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -149.13 123.78 9.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.628 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -118.34 124.83 48.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 112' ' ' THR . . . -125.59 137.33 10.22 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.306 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -170.87 -150.76 7.17 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.435 -0.888 . . . . 0.0 113.076 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.959 ' CG1' HG22 ' A' ' 110' ' ' ILE . 9.0 m -131.3 168.21 24.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.822 0.344 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -134.79 136.74 42.8 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' TRP . . . . . 0.456 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.6 OUTLIER -119.56 128.72 54.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.81 179.813 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.73 131.7 40.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.916 0.388 . . . . 0.0 111.456 -179.683 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.422 HG22 ' CZ3' ' A' ' 151' ' ' TRP . 59.5 t . . . . . 0 C--N 1.331 -0.21 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.2 mt . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.784 0.326 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -136.87 162.8 32.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.439 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' THR . . . . . 0.468 HG23 ' CG1' ' A' ' 188' ' ' VAL . 1.7 m -109.73 150.6 28.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.202 179.522 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.07 136.58 38.49 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.077 0.465 . . . . 0.0 111.864 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.703 HD22 ' CE1' ' A' ' 163' ' ' TYR . 1.4 tt -119.17 120.76 38.04 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.505 178.809 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.417 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 5.2 mt-10 -117.39 145.13 44.29 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.115 0.483 . . . . 0.0 111.819 -178.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.703 ' CE1' HD22 ' A' ' 161' ' ' LEU . 0.0 OUTLIER -134.05 166.09 23.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.202 179.428 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.937 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.403 HD12 ' N ' ' A' ' 184' ' ' LEU . 2.0 mp . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.756 0.312 . . . . 0.0 110.615 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -156.13 149.23 24.33 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 111.401 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.96 136.0 53.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.439 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -151.85 169.78 31.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.405 -0.903 . . . . 0.0 112.911 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 188' ' ' VAL . . . . . 0.468 ' CG1' HG23 ' A' ' 159' ' ' THR . 1.0 OUTLIER -131.2 140.05 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.688 0.28 . . . . 0.0 110.714 179.663 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 90.3 p -144.77 175.0 10.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.93 0.395 . . . . 0.0 111.343 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -142.57 159.61 41.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.736 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 191' ' ' ARG . . . . . 0.432 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.75 0.31 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.455 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.0 OUTLIER -151.09 130.02 12.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.859 -179.924 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.5 m-85 -131.22 135.79 47.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.751 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.43 140.43 21.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.864 0.364 . . . . 0.0 111.341 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.86 173.74 43.42 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.696 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -125.5 141.25 12.84 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.297 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.504 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.4 OUTLIER -130.66 149.08 52.48 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.093 0.473 . . . . 0.0 111.434 -179.787 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.803 HD12 ' O ' ' A' ' 53' ' ' GLY . 31.9 tp -127.53 153.83 45.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.492 -179.947 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.803 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.393 -0.283 . . . . 0.0 112.393 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.542 ' HB2' HD13 ' A' ' 25' ' ' LEU . . . -119.97 149.1 42.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 111.177 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -153.69 152.11 23.76 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.398 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.618 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -105.84 148.04 28.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.776 0.322 . . . . 0.0 111.049 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.446 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 35.9 p90 -135.38 118.17 16.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -143.2 129.02 3.58 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.069 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -137.09 169.12 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.963 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.455 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 29.8 p90 -134.34 134.59 41.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.35 . . . . 0.0 110.846 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 . . . . . 0 C--N 1.327 -0.378 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.808 179.99 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.934 0.397 . . . . 0.0 111.355 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 174.5 20.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.369 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.42 ' HB2' ' CE1' ' A' ' 60' ' ' TYR . 2.0 m-85 -83.61 144.52 29.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.655 0.264 . . . . 0.0 110.703 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -128.05 125.23 38.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.884 0.373 . . . . 0.0 111.137 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.8 tpp -106.45 127.51 53.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.569 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.92 148.28 17.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.672 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.618 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 0.1 OUTLIER -127.23 120.03 27.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.696 0.284 . . . . 0.0 110.648 179.878 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -97.62 122.71 41.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.899 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.876 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.865 0.364 . . . . 0.0 110.747 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.62 139.29 14.32 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.911 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.65 122.77 61.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.712 0.291 . . . . 0.0 110.292 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.02 136.97 47.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.111 0.481 . . . . 0.0 111.721 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.404 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.9 tt -121.08 104.73 10.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.624 -0.717 . . . . 0.0 109.291 179.075 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.461 HG22 ' HA3' ' A' ' 115' ' ' GLY . 3.6 p -145.93 171.37 14.94 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.251 0.548 . . . . 0.0 112.078 -178.456 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -106.09 131.07 53.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.373 -0.83 . . . . 0.0 109.864 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 19.6 ttpt -116.55 132.12 56.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.148 0.499 . . . . 0.0 111.682 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -127.65 131.33 49.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.626 -0.716 . . . . 0.0 109.587 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.443 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -132.28 175.43 19.86 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 -179.203 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.47 ' O ' HG22 ' A' ' 110' ' ' ILE . 0.2 OUTLIER -166.1 134.4 2.36 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.698 -0.251 . . . . 0.0 110.701 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 C--N 1.347 0.471 0 C-N-CA 122.588 2.192 . . . . 0.0 112.39 179.998 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.523 -0.061 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -139.75 161.84 36.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.131 0.491 . . . . 0.0 111.811 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.47 HG22 ' O ' ' A' ' 102' ' ' TYR . 2.6 tt -114.51 144.93 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.037 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.443 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 60.7 m-85 -141.68 138.21 32.3 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.362 . . . . 0.0 111.445 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.87 128.18 30.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.715 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.534 ' NH2' ' HB3' ' A' ' 146' ' ' ALA . 18.6 mtm105 -118.38 127.91 54.13 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.264 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -134.38 122.78 23.06 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.491 179.472 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.461 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.93 -137.86 3.02 Favored Glycine 0 C--N 1.332 0.332 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.456 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -139.14 160.72 25.9 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.923 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 8.4 ptp -120.7 137.28 54.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.759 0.314 . . . . 0.0 110.775 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -131.62 113.2 22.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.842 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.7 p-90 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.917 -179.91 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.455 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.7 p . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.702 0.287 . . . . 0.0 110.969 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -157.12 149.22 17.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.777 0.322 . . . . 0.0 111.557 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.536 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 87.5 Cg_endo -80.59 140.9 13.54 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.923 2.416 . . . . 0.0 112.126 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 31.2 m -156.91 160.56 2.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.004 0.431 . . . . 0.0 111.583 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -149.06 130.28 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.377 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.534 ' HB3' ' NH2' ' A' ' 113' ' ' ARG . . . -116.51 155.37 28.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.895 0.378 . . . . 0.0 111.502 -179.717 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.34 136.49 7.93 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.22 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -162.85 -165.24 19.59 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.854 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -133.72 170.72 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.554 0.216 . . . . 0.0 110.95 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -146.72 149.7 33.93 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.941 0.401 . . . . 0.0 111.266 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 24.8 p90 -137.04 132.18 33.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.631 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.04 135.52 34.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.52 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.0 t . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.823 179.662 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.421 HG12 ' CE2' ' A' ' 190' ' ' TYR . 45.1 mt . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.781 0.324 . . . . 0.0 110.941 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -126.76 167.62 15.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.357 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.73 144.71 40.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.172 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.61 132.47 44.07 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.124 0.488 . . . . 0.0 111.89 -179.307 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -115.55 117.08 29.35 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.498 178.86 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.409 ' HG3' ' NZ ' ' A' ' 24' ' ' LYS . 23.8 mm-40 -107.04 145.03 32.85 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.127 0.489 . . . . 0.0 111.634 -178.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.432 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 48.9 t80 -133.95 158.28 43.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.455 179.656 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.008 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.498 HD12 ' N ' ' A' ' 184' ' ' LEU . 2.5 mp . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.774 0.321 . . . . 0.0 110.687 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 28.9 t -128.53 145.38 51.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.115 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.42 136.59 46.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.584 179.635 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 187' ' ' GLY . . . . . 0.504 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -154.63 -176.86 27.38 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.942 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -126.64 135.9 62.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.647 0.261 . . . . 0.0 110.442 179.503 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 189' ' ' SER . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 43.3 p -130.84 165.37 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.208 0.528 . . . . 0.0 111.721 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 190' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 190' ' ' TYR . 2.2 m-85 -124.96 143.19 51.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.471 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 8.6 mtp180 . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.905 -179.813 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.457 -0.087 0 CA-C-O 120.782 0.325 . . . . 0.0 110.735 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 10.3 t90 -111.09 132.91 53.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.088 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.446 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 2.7 t80 -122.57 135.79 54.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.383 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.59 146.93 25.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.953 0.406 . . . . 0.0 111.5 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.407 ' HA3' ' HB3' ' A' ' 189' ' ' SER . . . 178.01 -172.84 45.44 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.482 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.65 148.57 20.24 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.489 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.27 151.0 47.21 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.072 0.463 . . . . 0.0 111.354 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.871 HD12 ' O ' ' A' ' 53' ' ' GLY . 18.7 tp -122.12 145.53 48.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.29 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.794 -179.854 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.871 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.417 -0.273 . . . . 0.0 112.417 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -114.93 142.18 46.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.718 0.294 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.5 143.83 11.13 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.293 -0.956 . . . . 0.0 112.895 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -98.07 164.46 12.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.648 0.261 . . . . 0.0 110.668 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.446 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 52.2 p90 -152.38 141.03 20.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.062 0.458 . . . . 0.0 111.409 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -133.55 124.92 3.81 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.044 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -97.39 145.73 17.96 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.893 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -131.93 112.26 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.698 0.285 . . . . 0.0 110.574 179.783 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 5.1 mm100 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.101 -179.806 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.924 0.393 . . . . 0.0 111.256 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.67 159.19 26.82 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.313 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -82.9 127.57 33.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 110.566 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -114.64 127.08 55.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.966 0.412 . . . . 0.0 111.317 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.2 mtm -104.21 128.44 51.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.962 179.364 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.93 157.7 14.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.951 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -132.68 120.19 21.38 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.731 0.301 . . . . 0.0 110.508 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.424 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.8 OUTLIER -94.54 127.14 40.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.688 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t90 . . . . . 0 C--O 1.233 0.225 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.944 179.909 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.685 0.279 . . . . 0.0 110.547 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.424 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -81.66 128.08 8.27 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.795 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.2 m -133.21 117.77 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.716 0.293 . . . . 0.0 110.257 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' GLN . . . . . 0.408 ' CB ' ' HA ' ' A' ' 117' ' ' MET . 7.6 pt20 -123.92 149.74 45.53 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.107 0.48 . . . . 0.0 111.791 -179.269 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.533 ' O ' HD23 ' A' ' 96' ' ' LEU . 0.3 OUTLIER -124.63 120.1 30.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.517 179.658 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.465 HG22 ' HA3' ' A' ' 115' ' ' GLY . 4.3 p -148.28 171.81 15.38 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-O 121.088 0.471 . . . . 0.0 111.789 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.37 123.04 47.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.987 178.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.5 tttt -114.74 132.33 56.48 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.107 0.479 . . . . 0.0 111.7 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.535 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.6 pp -126.83 125.69 42.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.341 179.347 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.426 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -145.45 160.08 28.02 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.419 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.503 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.2 OUTLIER -166.27 148.49 6.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.676 0.274 . . . . 0.0 111.483 -179.758 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.503 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 73.3 Cg_endo . . . . . 0 C--N 1.348 0.505 0 C-N-CA 122.807 2.338 . . . . 0.0 112.332 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.525 HD23 ' N ' ' A' ' 108' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.083 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.455 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 0.6 OUTLIER -124.39 155.14 39.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.258 0.552 . . . . 0.0 112.045 -178.999 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.862 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 151.76 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.937 178.984 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.426 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 20.1 m-85 -146.86 146.1 30.08 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.948 0.404 . . . . 0.0 111.706 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.3 m -142.54 129.87 21.1 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.325 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.24 130.22 52.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 121.02 0.438 . . . . 0.0 111.752 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.407 ' C ' HD23 ' A' ' 114' ' ' LEU . 6.1 tt -133.59 122.94 24.25 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.252 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.465 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -175.87 -140.8 3.57 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.576 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.475 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.53 161.52 27.37 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.888 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.408 ' HA ' ' CB ' ' A' ' 95' ' ' GLN . 0.2 OUTLIER -119.53 146.55 45.37 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.847 0.356 . . . . 0.0 110.753 -179.943 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -129.82 144.08 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.985 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.913 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.6 p . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.752 0.31 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.463 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 1.5 t -157.08 130.19 4.48 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.228 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.475 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.7 Cg_exo -73.8 147.31 39.37 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.639 2.226 . . . . 0.0 112.009 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.2 m -156.49 153.79 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.918 0.389 . . . . 0.0 111.46 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -149.1 124.05 10.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.658 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -117.75 145.81 44.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 0.0 111.339 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.49 132.72 5.91 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.226 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.441 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -163.32 -154.49 7.72 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.962 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.862 HG12 HG22 ' A' ' 110' ' ' ILE . 12.9 m -137.3 170.88 17.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.631 0.253 . . . . 0.0 110.949 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -147.25 150.75 35.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.953 0.406 . . . . 0.0 111.267 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' TRP . . . . . 0.422 ' CE2' ' HB ' ' A' ' 159' ' ' THR . 37.1 p90 -126.74 138.61 53.41 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.811 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.405 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -91.65 137.24 32.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.411 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 52.3 t . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.48 179.62 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 27.2 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.982 0.42 . . . . 0.0 111.554 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 158' ' ' ALA . . . . . 0.405 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.11 161.15 38.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.057 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' THR . . . . . 0.422 ' HB ' ' CE2' ' A' ' 151' ' ' TRP . 9.7 m -106.26 150.78 25.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.227 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? -137.09 142.23 42.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.172 0.511 . . . . 0.0 111.834 -179.405 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 162' ' ' GLU . 1.4 tt -123.65 117.89 26.02 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.601 178.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.409 ' N ' HD23 ' A' ' 161' ' ' LEU . 1.7 pt-20 -107.82 141.11 39.89 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.979 0.419 . . . . 0.0 111.635 -179.169 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.441 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 27.2 p90 -134.33 166.08 23.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.653 179.615 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.33 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.005 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.9 mp . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.792 0.33 . . . . 0.0 110.908 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 51.0 m -140.98 150.09 42.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.132 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.65 138.04 54.5 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.521 179.742 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -157.06 176.31 34.33 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.955 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -125.9 137.78 56.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.737 0.304 . . . . 0.0 110.496 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 189' ' ' SER . . . . . 0.446 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 3.6 p -138.59 171.57 14.17 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.377 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -148.0 156.62 42.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.642 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 191' ' ' ARG . . . . . 0.446 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.038 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.862 0.363 . . . . 0.0 110.843 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.438 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 2.7 m-90 -132.3 129.97 40.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.037 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.422 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 0.2 OUTLIER -121.67 135.85 54.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.683 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.05 139.82 23.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.396 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.9 -158.56 20.49 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.417 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.79 149.65 21.52 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.534 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -130.61 154.91 47.37 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.055 0.455 . . . . 0.0 111.135 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.4 tt -127.04 141.7 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.641 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.592 -179.93 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.534 -0.226 . . . . 0.0 112.534 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -131.26 138.7 49.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.689 0.28 . . . . 0.0 110.863 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.62 156.32 26.8 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.336 -0.935 . . . . 0.0 112.921 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.45 133.84 49.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.717 0.294 . . . . 0.0 110.844 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -119.75 127.17 52.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.967 0.413 . . . . 0.0 111.075 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.56 124.85 2.18 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.139 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -128.5 173.38 19.17 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.798 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.438 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 21.7 p90 -154.02 131.75 11.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 110.781 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.883 -179.894 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.233 0.219 0 CA-C-O 120.764 0.316 . . . . 0.0 111.191 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.03 175.17 19.61 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.44 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -95.7 134.71 38.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.418 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 0.0 OUTLIER -114.67 128.41 56.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -114.15 119.76 38.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.33 179.437 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 154.59 16.48 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.481 -0.866 . . . . 0.0 112.783 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 -130.09 114.83 16.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.579 0.228 . . . . 0.0 110.659 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.32 125.77 35.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.115 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 10.8 m95 . . . . . 0 C--N 1.331 -0.219 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.844 179.876 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 12.1 pm0 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.761 0.315 . . . . 0.0 110.734 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -82.26 130.94 10.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.586 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.47 119.74 55.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.786 0.327 . . . . 0.0 110.446 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 139.87 43.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.534 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.416 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.7 tt -130.25 110.88 11.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.972 179.537 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.425 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 0.1 OUTLIER -150.49 168.94 22.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.993 0.425 . . . . 0.0 111.565 -179.147 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -104.1 125.91 50.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.197 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.421 ' HE3' ' CG ' ' A' ' 111' ' ' TYR . 0.6 OUTLIER -104.25 132.21 50.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.997 0.427 . . . . 0.0 111.752 -179.165 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.598 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.8 pp -134.82 115.74 14.01 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.388 179.114 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.05 41.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.672 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -166.28 167.05 8.83 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.713 0.292 . . . . 0.0 111.116 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo . . . . . 0 C--N 1.347 0.476 0 C-N-CA 122.488 2.125 . . . . 0.0 111.941 179.635 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.764 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.074 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.413 ' HB2' ' CG ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -125.41 152.95 44.16 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.225 0.536 . . . . 0.0 112.009 -178.903 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.93 130.88 73.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.044 179.291 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.421 ' CG ' ' HE3' ' A' ' 99' ' ' LYS . 53.1 p90 -144.06 153.62 42.38 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.915 0.388 . . . . 0.0 111.526 -179.446 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 2.1 t -136.94 133.11 35.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.69 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 5.8 ptp180 -111.42 128.36 55.96 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.145 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -124.64 123.61 40.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.619 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.425 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.82 -132.46 1.9 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.547 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.548 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -148.24 169.08 28.94 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.821 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.07 139.86 51.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.795 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -126.17 132.9 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.809 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 85.3 t90 . . . . . 0 C--N 1.33 -0.252 0 CA-C-O 120.864 0.364 . . . . 0.0 110.95 -179.822 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.444 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.2 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.697 0.284 . . . . 0.0 111.054 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.27 150.12 18.33 Favored Pre-proline 0 C--N 1.331 -0.217 0 CA-C-O 120.922 0.392 . . . . 0.0 111.421 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.548 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -78.77 141.14 16.91 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.758 2.306 . . . . 0.0 112.133 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.5 m -156.86 160.66 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.855 0.36 . . . . 0.0 111.418 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.6 p90 -141.6 122.47 14.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.472 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -111.8 138.2 48.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.962 0.41 . . . . 0.0 111.473 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -127.66 138.22 10.32 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.818 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -163.71 -165.71 21.34 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.078 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 17.2 m -135.47 167.05 26.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.659 0.266 . . . . 0.0 111.149 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.413 ' CG ' ' HB2' ' A' ' 109' ' ' ASP . 13.4 pt-20 -136.34 141.09 43.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.999 0.428 . . . . 0.0 111.172 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' TRP . . . . . 0.764 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.0 OUTLIER -122.31 123.07 40.57 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.628 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.16 131.86 35.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.013 179.948 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 28.3 mt . . . . . 0 C--O 1.232 0.178 0 CA-C-O 120.809 0.337 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.25 163.77 14.8 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.385 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.9 t -110.8 143.24 41.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.098 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 146.64 45.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.28 0.562 . . . . 0.0 111.855 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -116.63 124.8 50.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.698 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -116.51 141.01 48.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.029 0.442 . . . . 0.0 111.524 -179.181 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 14.2 p90 -134.22 157.61 45.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.468 179.683 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 -179.93 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 5.9 mp . . . . . 0 C--O 1.233 0.194 0 CA-C-O 120.719 0.295 . . . . 0.0 110.741 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.99 155.58 41.69 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.996 0.427 . . . . 0.0 111.221 -179.768 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.53 139.08 50.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.355 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -153.53 171.1 32.35 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.281 -0.961 . . . . 0.0 113.166 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.5 137.23 57.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.694 0.283 . . . . 0.0 110.489 179.584 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 77.9 p -140.77 174.95 10.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.992 0.425 . . . . 0.0 111.294 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -137.41 157.1 47.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.585 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 191' ' ' ARG . . . . . 0.422 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.916 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 68.9 p . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.82 0.343 . . . . 0.0 110.81 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.9 m95 -139.88 138.54 35.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.979 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.7 m-85 -131.8 135.88 47.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.685 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.71 146.03 30.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.322 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.36 -177.62 48.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.9 150.29 21.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.441 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.468 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -135.57 153.68 51.61 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 111.21 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.879 HD12 ' O ' ' A' ' 53' ' ' GLY . 41.9 tp -124.03 147.93 47.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.541 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.481 179.992 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.879 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.88 133.42 51.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.767 0.317 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.425 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -139.73 137.95 8.85 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.881 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.714 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -99.5 144.76 28.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.803 0.335 . . . . 0.0 110.563 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.435 ' CE2' ' HD3' ' A' ' 24' ' ' LYS . 51.3 m-85 -136.16 133.52 37.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.035 0.445 . . . . 0.0 111.345 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.73 126.52 2.22 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.963 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -125.58 169.45 17.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.839 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.422 ' CE2' ' HB3' ' A' ' 68' ' ' PHE . 42.6 p90 -147.12 135.53 21.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.846 -179.935 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.906 0.384 . . . . 0.0 111.148 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.43 159.53 22.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.472 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.422 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . 0.8 OUTLIER -82.09 144.86 30.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.554 0.216 . . . . 0.0 110.706 179.928 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.93 127.29 33.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.422 . . . . 0.0 111.074 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.0 ptp -109.26 133.21 53.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.86 17.34 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.766 -179.683 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.714 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 14.6 m-85 -129.93 118.13 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.615 0.245 . . . . 0.0 110.55 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.0 122.0 37.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.133 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.083 179.885 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.758 0.313 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.78 135.37 12.11 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.937 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -128.32 117.98 46.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.798 0.333 . . . . 0.0 110.123 179.252 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 95' ' ' GLN . . . . . 0.401 ' CG ' ' CB ' ' A' ' 117' ' ' MET . 8.2 mt-30 -108.86 145.39 35.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.192 0.52 . . . . 0.0 111.925 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.3 tt -130.02 110.32 11.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.256 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.8 p -150.22 170.04 19.9 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.233 0.54 . . . . 0.0 111.984 -178.504 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.51 45.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.014 178.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -118.85 131.95 56.1 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.062 0.458 . . . . 0.0 111.581 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.609 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -131.85 121.67 24.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.96 179.12 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.437 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -115.95 -177.02 18.34 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.088 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -166.07 122.58 0.99 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 115.803 -0.198 . . . . 0.0 110.71 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo . . . . . 0 C--N 1.349 0.567 0 C-N-CA 122.435 2.09 . . . . 0.0 112.391 -179.925 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.461 0.087 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -143.07 159.64 41.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.101 0.477 . . . . 0.0 111.628 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 1.031 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.64 154.81 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.316 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.437 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 91.5 m-85 -143.04 138.57 30.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.664 -179.508 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 31.6 m -125.2 127.63 47.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.313 179.393 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -116.54 127.88 54.92 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.38 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -137.96 122.58 18.59 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.511 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 179.26 -137.7 3.24 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.524 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.494 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.93 162.34 27.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.945 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.401 ' CB ' ' CG ' ' A' ' 95' ' ' GLN . 2.2 ptt? -119.63 142.31 48.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.801 0.334 . . . . 0.0 110.771 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.6 t -133.88 123.81 45.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.688 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 61.8 p-90 . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.003 -179.945 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.9 p . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.705 0.288 . . . . 0.0 111.012 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -157.01 137.38 8.99 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.329 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.494 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 89.4 Cg_endo -81.09 143.47 14.26 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 122.682 2.254 . . . . 0.0 112.084 179.75 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 143' ' ' PRO . 29.2 m -157.08 163.53 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 111.516 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -149.04 126.36 11.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.574 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.665 ' HB1' ' CD ' ' A' ' 162' ' ' GLU . . . -111.91 152.48 27.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.906 0.384 . . . . 0.0 111.267 -179.722 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.0 131.45 4.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.239 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -161.03 -160.05 10.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.824 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 1.031 HG12 HG22 ' A' ' 110' ' ' ILE . 5.5 m -134.41 167.72 25.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.628 0.252 . . . . 0.0 110.951 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -134.8 137.05 43.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.007 0.432 . . . . 0.0 111.189 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' TRP . . . . . 0.49 ' CZ3' HG22 ' A' ' 153' ' ' VAL . 1.4 t90 -114.91 123.32 48.85 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.574 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.81 130.74 36.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.523 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.49 HG22 ' CZ3' ' A' ' 151' ' ' TRP . 39.3 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.852 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.1 mt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.703 0.287 . . . . 0.0 111.008 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.32 168.55 18.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.952 0.406 . . . . 0.0 111.242 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' THR . . . . . 0.704 HG22 HG12 ' A' ' 188' ' ' VAL . 29.1 p -113.43 153.18 29.04 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.135 179.614 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 14.8 ptp180 -137.19 141.66 42.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 111.892 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -121.54 118.16 28.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.656 178.853 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.665 ' CD ' ' HB1' ' A' ' 146' ' ' ALA . 0.4 OUTLIER -108.34 143.66 36.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.97 0.414 . . . . 0.0 111.768 -178.832 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.43 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.2 p90 -134.25 162.88 30.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.509 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.782 -179.935 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.5 mp . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.839 0.352 . . . . 0.0 110.973 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 30.2 t -118.52 147.42 43.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.768 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -126.52 139.36 53.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.709 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 187' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -156.67 -177.03 29.43 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.414 -0.898 . . . . 0.0 113.063 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 188' ' ' VAL . . . . . 0.704 HG12 HG22 ' A' ' 159' ' ' THR . 1.3 m -130.82 142.84 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.675 0.274 . . . . 0.0 110.598 179.61 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 89.0 p -143.24 170.83 15.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.998 0.427 . . . . 0.0 111.449 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 44.3 p90 -138.66 154.88 48.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.58 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 t . . . . . 0 N--CA 1.458 -0.059 0 CA-C-O 120.868 0.366 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -151.1 129.87 12.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.009 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.429 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 28.5 m-85 -127.24 135.92 51.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.718 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.15 146.29 30.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.359 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.409 ' HA3' ' CB ' ' A' ' 189' ' ' SER . . . 178.45 168.73 38.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.566 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.75 143.7 14.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.446 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.468 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 2.8 pttp -131.97 146.52 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.095 0.474 . . . . 0.0 111.286 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.853 HD12 ' O ' ' A' ' 53' ' ' GLY . 23.1 tp -121.14 152.03 39.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.514 -179.934 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.853 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.452 -0.258 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -110.87 151.01 28.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.817 0.341 . . . . 0.0 111.078 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -143.36 122.92 1.97 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.404 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.82 135.93 35.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.682 0.277 . . . . 0.0 110.895 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.436 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 24.9 p90 -124.99 127.46 47.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.212 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.8 124.97 1.76 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.011 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -148.22 -172.59 18.32 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.759 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -150.63 156.03 40.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.871 0.367 . . . . 0.0 110.853 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.83 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.88 0.371 . . . . 0.0 111.434 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.91 177.0 19.43 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.249 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -99.74 134.59 42.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.619 0.247 . . . . 0.0 110.841 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.8 tp10 -124.03 131.51 53.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.989 0.424 . . . . 0.0 111.076 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 6.9 tpt -111.44 130.28 55.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.544 179.767 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.84 153.32 17.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.558 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.404 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 34.2 m-85 -134.19 114.95 13.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.829 0.347 . . . . 0.0 110.746 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.6 122.22 33.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.017 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.88 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 . . . . . 0 C--O 1.23 0.039 0 CA-C-O 120.678 0.275 . . . . 0.0 110.607 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.23 128.42 9.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.074 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -127.43 117.85 48.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 179.318 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -112.16 145.62 39.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.182 0.515 . . . . 0.0 112.016 -178.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -134.93 112.81 10.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.249 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.405 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.7 p -150.81 172.99 14.74 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.228 0.537 . . . . 0.0 112.027 -178.448 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.12 131.41 48.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.83 178.901 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.413 ' HD2' ' CD1' ' A' ' 111' ' ' TYR . 3.4 ttpt -118.79 132.11 56.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.101 0.477 . . . . 0.0 111.738 -179.035 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -134.95 133.64 39.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.916 179.177 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.436 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -147.62 -179.41 23.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.182 -1.009 . . . . 0.0 113.102 -179.437 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.408 ' O ' HG22 ' A' ' 110' ' ' ILE . 0.5 OUTLIER -166.3 128.84 1.44 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.734 -0.233 . . . . 0.0 110.654 -179.913 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo . . . . . 0 C--N 1.348 0.523 0 C-N-CA 122.391 2.061 . . . . 0.0 112.116 -179.97 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.051 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.403 ' OD1' ' CE2' ' A' ' 111' ' ' TYR . 8.8 t70 -144.46 155.7 43.85 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.065 0.46 . . . . 0.0 111.751 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.408 HG22 ' O ' ' A' ' 102' ' ' TYR . 3.0 tt -114.51 132.36 63.87 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.022 179.239 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.436 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 25.5 m-85 -133.14 147.64 52.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.975 0.417 . . . . 0.0 111.734 -179.307 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.49 129.55 23.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.446 179.629 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -121.33 129.13 52.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.424 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.4 tt -134.85 122.7 22.4 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.488 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.405 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -176.94 -136.98 2.54 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.467 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.484 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.12 161.62 27.58 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.801 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.11 142.96 48.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.777 0.322 . . . . 0.0 110.706 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.428 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.5 t -130.36 138.42 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.89 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 70.5 p-90 . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.963 -179.99 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.764 0.316 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.2 p -156.41 129.61 4.45 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.301 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.484 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 84.5 Cg_endo -77.92 142.57 19.95 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.595 2.197 . . . . 0.0 112.11 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 143' ' ' PRO . 27.8 m -157.07 162.4 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.015 0.436 . . . . 0.0 111.455 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.01 124.04 11.39 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.484 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.03 137.12 52.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.862 0.363 . . . . 0.0 111.458 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.04 134.26 7.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.07 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -159.39 -157.31 8.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.919 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -135.18 167.78 24.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.805 0.336 . . . . 0.0 111.207 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -131.42 140.24 49.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.969 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -124.38 125.77 44.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.771 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -88.1 137.11 32.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.423 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 99.2 t . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.95 179.848 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 18.0 mt . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.757 0.313 . . . . 0.0 110.954 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -117.76 162.45 18.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.213 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 61.1 p -100.99 150.83 22.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.145 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 4.6 ttt85 -137.14 133.12 34.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.062 0.458 . . . . 0.0 111.951 -179.503 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.11 119.23 33.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.448 178.712 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -110.04 145.22 37.42 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.189 0.519 . . . . 0.0 111.907 -178.569 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.436 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 8.4 t80 -131.79 147.87 52.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.232 179.474 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.388 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.637 ' N ' HD12 ' A' ' 184' ' ' LEU . 2.4 mp . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.801 0.334 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 88.1 p -121.13 146.5 46.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.084 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -125.48 141.04 52.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.647 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 187' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -161.7 -176.96 34.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.952 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -128.74 140.54 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.621 0.248 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 189' ' ' SER . . . . . 0.436 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 97.1 p -139.51 175.0 9.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.055 0.455 . . . . 0.0 111.464 -179.497 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 14.8 p90 -146.85 151.43 37.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.653 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 191' ' ' ARG . . . . . 0.429 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 25.0 ptt-85 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.927 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.682 HG23 ' H ' ' A' ' 61' ' ' GLN . 2.2 t . . . . . 0 C--O 1.233 0.198 0 CA-C-O 120.814 0.34 . . . . 0.0 110.771 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -150.66 130.03 12.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.988 -179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -138.91 136.32 35.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.778 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 143.18 38.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.354 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.12 -157.9 10.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.541 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.22 145.87 15.32 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.597 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.91 156.08 32.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.939 0.4 . . . . 0.0 111.107 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -135.66 138.76 43.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.611 179.709 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.357 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.542 -179.891 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.374 -0.29 . . . . 0.0 112.374 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -132.76 156.72 46.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.843 0.354 . . . . 0.0 111.157 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.58 154.64 25.71 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.451 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.839 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -95.43 124.7 39.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.74 0.305 . . . . 0.0 110.946 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -111.69 119.06 37.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.039 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.75 124.94 2.84 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.058 179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.17 165.59 25.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.771 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.44 ' CZ ' ' HB2' ' A' ' 68' ' ' PHE . 4.9 p90 -154.26 134.78 13.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.994 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.682 ' H ' HG23 ' A' ' 18' ' ' THR . 11.1 mt-30 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.714 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.851 0.358 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -123.71 169.83 15.92 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.394 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 50.9 m-85 -83.98 134.49 34.64 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.682 0.277 . . . . 0.0 110.853 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.66 112.08 19.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.741 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.4 mtp -104.43 118.1 35.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.552 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.0 152.32 17.28 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.839 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 5.1 m-85 -130.7 115.02 16.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.846 0.355 . . . . 0.0 110.576 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -81.66 123.13 28.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.023 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.861 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.8 0.333 . . . . 0.0 110.722 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -95.92 134.01 11.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.753 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -120.68 117.86 54.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.755 0.312 . . . . 0.0 110.447 179.536 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 95' ' ' GLN . . . . . 0.556 ' OE1' HG21 ' A' ' 144' ' ' VAL . 3.4 tt0 -109.01 137.89 46.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.074 0.464 . . . . 0.0 111.744 -179.1 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.617 179.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.504 HG22 ' HA3' ' A' ' 115' ' ' GLY . 3.5 p -149.36 166.28 29.51 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.072 0.463 . . . . 0.0 111.796 -178.669 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.65 127.7 52.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.1 179.126 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.84 132.14 56.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.031 0.443 . . . . 0.0 111.749 -179.145 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.504 ' O ' HD12 ' A' ' 100' ' ' LEU . 4.0 pp -130.09 130.14 44.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.316 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -154.03 -173.52 23.17 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.442 -0.885 . . . . 0.0 113.032 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.664 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 10.2 p90 -166.15 148.95 6.4 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 120.596 0.236 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo . . . . . 0 C--N 1.345 0.383 0 C-N-CA 122.73 2.287 . . . . 0.0 112.7 -179.754 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.639 0.257 . . . . 0.0 110.561 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -144.91 157.89 43.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.887 0.375 . . . . 0.0 111.603 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.95 HG22 HG12 ' A' ' 149' ' ' VAL . 1.1 pt -120.81 144.5 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.471 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 4.7 p90 -148.05 149.07 31.42 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 121.225 0.536 . . . . 0.0 111.83 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 21.4 p -130.64 133.2 45.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.988 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.703 ' NE ' ' HB3' ' A' ' 146' ' ' ALA . 0.2 OUTLIER -115.46 130.73 56.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.063 0.459 . . . . 0.0 111.707 -179.261 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.503 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.9 tt -126.26 122.63 36.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.153 179.267 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.504 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.29 -142.09 4.56 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.294 -0.955 . . . . 0.0 112.869 -179.8 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.519 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.73 169.08 25.35 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.771 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.4 tmm? -127.57 137.84 52.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.849 0.357 . . . . 0.0 110.948 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.46 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.6 t -127.29 127.7 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.674 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 2.9 p-90 . . . . . 0 C--N 1.328 -0.354 0 CA-C-O 120.798 0.333 . . . . 0.0 110.987 -179.912 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.696 0.284 . . . . 0.0 110.994 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.491 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -157.18 141.38 11.75 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.436 -179.978 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.519 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.8 Cg_exo -73.91 153.41 47.54 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.869 2.379 . . . . 0.0 111.858 179.719 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.556 HG21 ' OE1' ' A' ' 95' ' ' GLN . 27.0 m -156.74 162.92 1.48 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.181 0 CA-C-O 121.221 0.534 . . . . 0.0 111.764 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' PHE . . . . . 0.503 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.2 t80 -143.05 118.84 10.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.256 179.619 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.703 ' HB3' ' NE ' ' A' ' 113' ' ' ARG . . . -117.15 140.96 48.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.991 0.424 . . . . 0.0 111.16 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.07 134.89 7.16 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.152 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.03 -167.5 21.58 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.81 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.95 HG12 HG22 ' A' ' 110' ' ' ILE . 4.1 m -127.18 160.02 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.869 0.366 . . . . 0.0 111.042 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.448 ' HG2' ' HB3' ' A' ' 160' ' ' ARG . 1.4 tm-20 -120.85 136.39 54.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 37.5 m95 -120.78 120.27 35.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.469 179.525 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.43 119.0 32.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.571 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 40.5 t . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.807 179.569 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.522 HG23 ' CE1' ' A' ' 190' ' ' TYR . 3.5 mp . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.829 0.347 . . . . 0.0 111.144 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.77 161.82 17.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.946 0.403 . . . . 0.0 111.35 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -131.39 144.02 50.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.173 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.448 ' HB3' ' HG2' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -137.1 155.12 50.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.243 0.544 . . . . 0.0 112.009 -179.288 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.853 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.4 OUTLIER -120.41 121.45 38.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.635 179.006 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -107.41 145.05 33.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.116 0.484 . . . . 0.0 111.787 -178.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' TYR . . . . . 0.867 ' CE2' HD23 ' A' ' 184' ' ' LEU . 5.7 m-85 -129.86 151.36 50.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.491 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.029 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 184' ' ' LEU . . . . . 0.867 HD23 ' CE2' ' A' ' 163' ' ' TYR . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.782 0.325 . . . . 0.0 110.717 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.9 m -131.87 151.52 51.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.93 0.395 . . . . 0.0 111.282 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -120.22 134.46 55.25 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.347 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -146.41 165.36 28.29 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.231 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.22 139.83 50.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.376 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.56 168.58 19.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.103 0.478 . . . . 0.0 111.694 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 190' ' ' TYR . . . . . 0.522 ' CE1' HG23 ' A' ' 157' ' ' ILE . 4.4 m-85 -123.47 146.61 47.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.466 179.624 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.958 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.326 0 CA-C-O 120.878 0.371 . . . . 0.0 111.044 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.99 91.29 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 22.8 mt -134.79 138.85 48.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.131 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.1 tpt -64.58 131.1 46.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.982 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.84 66.42 1.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.847 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -113.47 -73.45 0.66 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.04 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.1 pt -147.05 30.64 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.094 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -120.49 72.59 0.96 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.832 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.404 HG22 ' H ' ' A' ' 9' ' ' VAL . 10.2 m -83.85 130.7 35.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.111 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -110.74 -31.28 7.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.908 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -71.41 -50.7 29.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.908 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -147.5 139.37 24.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.174 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.765 ' HB1' ' HD2' ' A' ' 14' ' ' PRO . . . -64.76 168.15 7.64 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.035 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.765 ' HD2' ' HB1' ' A' ' 13' ' ' ALA . 60.0 Cg_endo -72.38 61.04 3.39 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.529 2.152 . . . . 0.0 112.437 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 3.8 mptt -153.16 128.19 9.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.85 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -89.3 41.08 1.02 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.289 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -108.11 80.84 1.41 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.863 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m -108.03 161.84 14.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.906 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.437 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.8 t-105 -146.62 129.9 16.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.42 ' CE1' ' HA3' ' A' ' 59' ' ' GLY . 6.1 p90 -136.92 139.65 41.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.795 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.08 149.49 52.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.197 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.75 -164.44 22.37 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.471 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.16 138.59 6.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.583 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 2.0 pttp -120.18 150.92 39.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.985 0.421 . . . . 0.0 111.033 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.65 HD21 HD12 ' A' ' 52' ' ' LEU . 3.0 tp -129.27 139.66 51.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.595 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.81 -139.38 3.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.531 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 11.0 m0 -112.42 133.87 54.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.779 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 m -97.77 -48.68 5.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.942 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -130.48 158.14 40.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.02 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 18.6 t80 -176.7 146.24 0.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.864 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.1 t60 -102.77 126.48 49.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -137.31 -47.56 0.58 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -99.0 156.02 17.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.934 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.74 154.94 30.18 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.465 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -144.71 -178.63 6.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.817 0.341 . . . . 0.0 110.937 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -139.79 153.23 47.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.17 40.13 2.53 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.51 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -109.22 140.15 43.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.885 0.374 . . . . 0.0 110.847 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -61.84 -41.46 99.63 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.483 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -79.99 105.89 11.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.84 0.353 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -101.72 -65.48 0.98 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.886 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -109.11 96.87 6.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.96 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 18.2 p-10 -69.13 -37.06 78.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.843 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -131.97 144.42 50.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.799 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -130.45 65.39 0.59 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.52 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.51 -173.39 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.517 2.145 . . . . 0.0 112.248 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.44 25.65 5.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.064 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -142.3 112.01 6.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.899 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -98.78 58.57 1.19 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.854 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -75.67 88.91 2.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.95 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.695 ' C ' HD22 ' A' ' 52' ' ' LEU . 27.3 mt-30 -125.73 95.22 4.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.834 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.695 HD22 ' C ' ' A' ' 51' ' ' GLN . 4.2 mm? -132.23 124.89 29.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.059 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.98 132.09 10.47 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.304 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -99.95 144.52 28.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.768 0.318 . . . . 0.0 110.996 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.414 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -147.75 122.97 1.63 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.88 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.809 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.87 125.71 39.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.635 0.255 . . . . 0.0 110.459 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.435 ' HB2' ' NH2' ' A' ' 160' ' ' ARG . 2.8 m-85 -115.24 145.93 41.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.045 0.45 . . . . 0.0 111.583 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -144.92 124.84 2.23 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.786 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 20' ' ' TYR . . . -123.13 146.98 16.64 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.035 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.443 ' CZ ' ' HB2' ' A' ' 68' ' ' PHE . 53.4 p90 -153.53 126.04 8.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.851 0.358 . . . . 0.0 110.771 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -96.16 137.18 35.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 43.1 t -111.56 -30.27 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.092 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -137.35 153.62 74.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.799 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.26 63.61 1.08 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.596 2.198 . . . . 0.0 112.296 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.667 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.1 OUTLIER -154.36 -45.61 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.971 -179.932 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.667 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.3 OUTLIER -168.79 163.71 11.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.913 -179.881 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -127.24 155.09 19.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.435 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.443 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 2.4 m-85 -82.79 141.56 32.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.617 0.246 . . . . 0.0 110.564 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.577 ' HB3' HG23 ' A' ' 97' ' ' THR . 14.2 tp10 -125.67 118.67 26.13 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.88 0.371 . . . . 0.0 111.133 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 10.3 mtt -108.19 124.72 50.7 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.5 179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 163.05 12.47 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.541 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.809 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 57.4 m-85 -137.54 114.91 11.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.684 0.278 . . . . 0.0 110.76 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.43 114.96 22.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.059 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 17.0 t90 -139.16 148.83 43.72 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.097 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.4 tp 61.86 157.86 0.05 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.897 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 160.52 -28.21 0.32 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.518 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 11.7 ttt180 -112.16 149.63 31.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.762 0.315 . . . . 0.0 110.946 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -107.2 104.85 14.58 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.838 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -171.64 98.46 0.18 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.146 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -153.08 75.89 1.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.889 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.1 tttm -163.59 100.46 0.91 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.876 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -167.11 160.08 33.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.498 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 50.6 m -69.07 -48.15 63.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.329 . . . . 0.0 110.924 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.5 m -140.98 128.82 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.107 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -116.58 -177.7 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -117.83 146.55 43.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.898 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -145.46 39.21 1.18 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.551 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -64.07 -61.04 2.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.81 0.338 . . . . 0.0 111.055 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -112.63 142.48 45.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.905 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 4.4 mtmp? -107.58 138.37 43.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.79 145.57 30.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -158.97 131.91 7.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.715 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -85.59 135.3 13.29 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.639 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.1 OUTLIER -123.81 122.03 63.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -108.88 142.25 39.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.189 0.519 . . . . 0.0 111.878 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -128.6 114.5 16.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.617 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.828 HG21 ' HD2' ' A' ' 113' ' ' ARG . 0.9 OUTLIER -153.69 165.2 36.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.066 0.46 . . . . 0.0 111.739 -179.007 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.02 129.73 51.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.307 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.53 132.2 55.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.051 0.453 . . . . 0.0 111.517 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.518 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.8 pp -132.76 127.8 35.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.279 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.24 -171.66 23.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.971 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.434 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.09 147.06 5.64 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.897 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.434 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 90.6 Cg_endo -81.03 171.7 13.81 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.745 2.297 . . . . 0.0 112.617 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 18.4 mm -106.1 -30.88 2.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.727 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 4.5 m -154.9 -62.35 0.12 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.71 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 177.89 45.64 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.586 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.409 ' OD2' HD21 ' A' ' 108' ' ' LEU . 21.9 p-10 179.07 -30.11 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.49 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.409 HD21 ' OD2' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -112.67 122.33 47.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.617 0.246 . . . . 0.0 110.367 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 4.0 p30 -141.41 152.84 44.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.041 0.448 . . . . 0.0 111.763 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.98 HG22 ' CG1' ' A' ' 149' ' ' VAL . 1.1 pt -116.93 146.24 21.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.318 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -153.59 156.34 37.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.111 0.481 . . . . 0.0 111.693 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 68.2 p -136.37 135.72 39.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.246 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.828 ' HD2' HG21 ' A' ' 97' ' ' THR . 0.0 OUTLIER -116.35 128.33 55.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.998 0.427 . . . . 0.0 111.518 -179.564 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.6 tt -126.78 124.45 39.73 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.445 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.408 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.71 -133.56 2.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.462 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -153.24 168.68 32.02 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.404 -0.903 . . . . 0.0 112.939 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -119.17 141.99 48.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.785 0.326 . . . . 0.0 110.731 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.524 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.9 t -135.03 112.01 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.73 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.428 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 40.7 p-90 -129.14 161.04 30.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.914 0.388 . . . . 0.0 111.115 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 11.6 ptm180 -112.08 155.55 23.67 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.874 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -89.93 157.53 17.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.129 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.86 127.45 32.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.92 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 13.3 t -61.24 164.26 5.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.898 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -72.13 135.89 46.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.913 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.64 -144.78 4.02 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.426 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 24.6 m-20 -87.38 66.6 9.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.927 0.394 . . . . 0.0 110.889 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -105.01 162.34 13.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.813 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -135.22 109.39 8.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.088 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' SER . . . . . 0.474 ' HG ' ' HB3' ' A' ' 133' ' ' SER . 0.6 OUTLIER -139.78 156.14 46.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.5 p -138.1 30.67 2.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.901 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 179.96 -71.46 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.451 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.494 HG13 ' O ' ' A' ' 132' ' ' VAL . 12.3 p -101.0 120.44 50.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.829 0.347 . . . . 0.0 111.018 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.474 ' HB3' ' HG ' ' A' ' 129' ' ' SER . 79.4 p -170.66 164.12 8.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 23.8 mtt180 -111.61 104.57 12.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.877 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 23.9 m -110.83 31.81 5.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -127.68 161.53 28.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 23.7 p-80 -122.6 72.81 1.09 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.899 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -112.47 166.64 11.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.861 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 26.5 p -105.15 119.92 40.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.428 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -79.14 127.51 8.04 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.4 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.9 p -146.02 130.18 11.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.674 0.274 . . . . 0.0 111.136 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.1 134.76 7.04 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.349 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.483 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 96.4 Cg_endo -79.99 142.32 15.48 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.633 2.222 . . . . 0.0 112.12 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.9 m -156.84 158.48 3.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.968 0.413 . . . . 0.0 111.46 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.445 ' CZ ' ' HB2' ' A' ' 181' ' ' ASN . 5.0 p90 -149.04 124.04 10.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.582 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.567 ' HB3' ' NH1' ' A' ' 113' ' ' ARG . . . -119.7 168.86 10.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.933 0.396 . . . . 0.0 111.23 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.57 138.77 6.58 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.382 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -160.77 -159.7 10.14 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.756 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.98 ' CG1' HG22 ' A' ' 110' ' ' ILE . 5.7 m -130.66 166.91 27.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.702 0.287 . . . . 0.0 110.933 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -136.03 148.09 48.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.873 0.368 . . . . 0.0 111.178 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 10.1 m0 -131.29 128.68 40.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.791 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.53 122.53 40.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.303 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 45.5 t -110.32 -64.82 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' THR . . . . . 0.468 HG22 ' H ' ' A' ' 155' ' ' ARG . 1.4 m -81.75 171.2 14.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ARG . . . . . 0.468 ' H ' HG22 ' A' ' 154' ' ' THR . 4.2 mtt-85 -67.14 -26.69 66.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.119 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -143.83 31.45 1.29 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.155 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 15.9 mt -151.1 100.85 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.221 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.82 167.72 10.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.189 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' THR . . . . . 0.889 HG22 HG12 ' A' ' 188' ' ' VAL . 22.3 p -125.52 144.41 50.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.354 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.435 ' NH2' ' HB2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 153.45 50.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.127 0.489 . . . . 0.0 111.87 -179.504 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.423 HD23 ' N ' ' A' ' 162' ' ' GLU . 1.5 tt -126.55 124.38 39.86 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.913 179.014 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.423 ' N ' HD23 ' A' ' 161' ' ' LEU . 2.8 mt-10 -106.83 145.15 32.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.162 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.677 ' CG ' HD23 ' A' ' 184' ' ' LEU . 0.7 OUTLIER -131.16 166.02 22.04 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.625 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 164' ' ' GLN . . . . . 0.531 ' HG2' HD11 ' A' ' 184' ' ' LEU . 0.0 OUTLIER -82.28 -34.35 28.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.067 -179.884 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -108.97 156.97 19.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.98 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.481 HG12 ' H ' ' A' ' 168' ' ' ASN . 23.1 t -117.57 145.06 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.004 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -59.98 -40.75 90.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.956 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ASN . . . . . 0.481 ' H ' HG12 ' A' ' 166' ' ' VAL . 7.6 p30 -114.75 -179.86 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.905 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 169' ' ' ILE . . . . . 0.489 ' O ' HG23 ' A' ' 169' ' ' ILE . 8.4 tt -139.39 119.63 14.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.108 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -77.43 -100.75 0.18 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.494 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -128.15 134.22 49.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.794 0.331 . . . . 0.0 110.86 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -163.76 131.65 3.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.086 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -104.75 -31.49 4.49 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.509 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.0 t -151.35 148.54 28.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.802 0.334 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.449 ' O ' HG23 ' A' ' 175' ' ' VAL . 31.4 m -132.92 119.96 39.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -121.19 90.39 0.46 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.448 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' THR . . . . . 0.65 HG21 ' HA ' ' A' ' 181' ' ' ASN . 2.3 p -137.87 104.45 5.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.849 0.357 . . . . 0.0 110.935 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 178' ' ' ARG . . . . . 0.416 ' N ' ' HD2' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -73.32 -61.02 1.55 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.198 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 179' ' ' PRO . . . . . 0.416 ' HD2' ' N ' ' A' ' 178' ' ' ARG . 36.5 Cg_endo -66.34 -52.22 0.88 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.42 2.08 . . . . 0.0 112.47 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -173.56 170.31 4.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.984 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 181' ' ' ASN . . . . . 0.65 ' HA ' HG21 ' A' ' 177' ' ' THR . 9.7 p30 -96.72 -44.62 7.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.953 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -138.49 -170.68 11.92 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.564 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.98 132.36 25.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.763 0.316 . . . . 0.0 110.852 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.677 HD23 ' CG ' ' A' ' 163' ' ' TYR . 1.0 OUTLIER -89.55 136.55 32.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.817 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 12.7 p -171.07 166.73 7.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.97 0.414 . . . . 0.0 111.547 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.64 140.15 49.72 Favored 'General case' 0 N--CA 1.462 0.134 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.275 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -154.06 171.21 32.69 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 119.945 -1.122 . . . . 0.0 113.48 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 188' ' ' VAL . . . . . 0.889 HG12 HG22 ' A' ' 159' ' ' THR . 0.6 OUTLIER -130.48 139.85 50.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.683 -0.259 . . . . 0.0 110.359 179.456 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 83.6 p -134.95 175.08 9.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.041 0.448 . . . . 0.0 111.497 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -145.38 149.81 35.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.696 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -78.94 156.98 28.29 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.942 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -78.49 90.36 4.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.913 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -118.68 134.59 10.96 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.474 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.77 111.32 3.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.891 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -82.21 156.43 24.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.9 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.77 161.43 25.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.84 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -148.93 131.09 15.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.029 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 198' ' ' ALA . . . . . 0.434 ' O ' HG23 ' A' ' 200' ' ' VAL . . . -144.03 128.26 9.22 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.059 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.75 93.78 0.04 OUTLIER 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.432 2.088 . . . . 0.0 112.276 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 200' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 198' ' ' ALA . 21.2 t -141.98 95.09 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 201' ' ' VAL . . . . . 0.423 ' O ' HG23 ' A' ' 201' ' ' VAL . 14.6 m -79.43 69.89 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.044 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 202' ' ' ALA . . . . . 0.751 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -75.75 -61.03 0.96 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.212 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.751 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 63.5 Cg_endo -73.58 -44.45 0.51 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.577 2.185 . . . . 0.0 112.514 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -70.98 112.05 12.0 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.159 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -77.03 111.79 3.3 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.469 2.113 . . . . 0.0 112.424 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 206' ' ' ALA . . . . . 0.796 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -93.18 -55.05 0.24 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.289 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.796 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 53.8 Cg_exo -52.45 98.99 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.5 2.133 . . . . 0.0 112.39 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.797 ' HB3' ' HD3' ' A' ' 209' ' ' PRO . . . -83.68 -62.88 0.26 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.262 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 209' ' ' PRO . . . . . 0.797 ' HD3' ' HB3' ' A' ' 208' ' ' ALA . 64.0 Cg_endo -74.37 -45.96 0.31 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 122.399 2.066 . . . . 0.0 112.444 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.895 -179.979 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.856 0.36 . . . . 0.0 110.998 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 6.8 ptp180 -132.57 84.61 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.94 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.3 pt -121.63 153.7 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.126 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.4 ttp -138.93 101.34 4.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.963 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.13 139.3 50.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.9 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -98.35 33.69 2.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.024 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.571 HG23 ' O ' ' A' ' 7' ' ' ILE . 5.7 tt -71.91 111.73 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.073 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -159.14 81.76 0.77 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.846 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.4 t -115.98 -59.02 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.065 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -92.86 165.85 12.7 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.843 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 27.8 m120 -89.02 53.33 2.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -94.5 114.62 26.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.095 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.7 147.4 78.27 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.97 -40.62 2.48 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.596 2.198 . . . . 0.0 112.367 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.8 ttmt -131.85 111.15 11.35 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.95 167.41 9.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.02 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -108.07 -71.48 0.76 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.937 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 t -156.7 154.28 29.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.826 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -121.29 132.32 54.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -129.76 135.97 49.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.974 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.45 141.63 29.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.232 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.23 -172.14 41.49 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.586 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.08 148.24 19.71 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.98 152.52 51.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.937 0.398 . . . . 0.0 111.278 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 1.043 HD12 ' HB2' ' A' ' 54' ' ' ALA . 0.6 OUTLIER -130.35 148.75 52.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.443 179.716 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -164.23 -165.35 21.32 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.542 -0.837 . . . . 0.0 112.772 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -143.12 160.36 40.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.925 0.393 . . . . 0.0 111.142 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.66 145.87 46.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.919 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -146.85 117.03 7.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.9 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -119.09 170.47 9.04 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.914 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 8.3 t60 -143.5 124.02 14.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.953 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -134.58 153.24 52.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.949 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 2.7 t -109.71 -29.28 8.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.971 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 102.98 141.03 11.21 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.483 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -116.69 -67.78 0.97 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.893 0.378 . . . . 0.0 110.836 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -129.61 -51.81 1.16 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.883 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.88 119.32 6.37 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.467 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -74.74 -36.88 62.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.339 . . . . 0.0 110.808 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -136.29 -169.63 11.79 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -108.79 170.12 8.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.862 0.363 . . . . 0.0 110.839 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -61.97 -50.38 72.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -92.34 143.54 26.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -60.26 98.09 0.06 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.904 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -129.34 106.12 8.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.915 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.61 138.26 5.86 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.469 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -74.64 -173.93 1.69 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.622 2.215 . . . . 0.0 112.299 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.0 p -144.84 -73.12 0.25 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.2 mmt85 -148.21 29.88 0.87 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.91 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -119.68 162.83 18.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.005 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -98.62 176.77 5.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 1.3 tp-100 -106.31 84.23 2.0 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.839 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.75 144.77 50.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.825 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -154.43 159.2 28.74 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.458 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 1.043 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -116.52 161.08 19.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.762 0.315 . . . . 0.0 110.938 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -163.81 146.64 11.77 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.681 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.727 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -96.25 160.99 14.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.73 0.3 . . . . 0.0 110.898 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.429 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 19.6 p90 -151.6 139.52 19.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.988 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -136.33 125.05 3.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.349 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -98.13 129.98 10.08 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.581 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -129.14 110.24 11.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.82 0.343 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.5 137.02 32.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.805 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 22.6 t -133.6 -49.41 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.966 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -107.05 143.71 27.65 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.591 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.02 73.08 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.329 2.019 . . . . 0.0 112.236 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.429 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.2 OUTLIER -177.05 -38.69 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.206 -179.926 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.429 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.3 OUTLIER -168.35 164.05 12.89 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.095 -179.716 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 165.22 22.11 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 -81.83 132.49 35.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.775 0.322 . . . . 0.0 110.624 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -112.08 115.92 29.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.172 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -105.53 115.48 30.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.17 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.8 157.25 15.17 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.803 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.727 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 34.1 m-85 -128.95 129.56 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.738 0.304 . . . . 0.0 110.718 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.405 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.9 OUTLIER -96.34 121.01 37.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.754 -179.979 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -136.8 118.64 15.16 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.785 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.23 81.09 1.86 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.877 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 155.33 173.38 23.98 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.469 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.61 -173.01 2.4 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.801 0.334 . . . . 0.0 111.002 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.7 mmm -99.12 31.36 3.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.825 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -107.44 56.75 0.63 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.134 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -112.51 -34.8 5.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.986 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 17.8 mttt -59.37 150.27 26.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.861 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -92.83 -149.02 24.24 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -154.85 -46.8 0.09 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 110.912 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.608 HG22 ' O ' ' A' ' 84' ' ' VAL . 12.9 p -135.09 42.82 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -86.08 -176.9 6.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -113.21 -61.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.867 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -69.47 -158.79 1.93 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.484 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -116.0 130.82 56.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.931 0.396 . . . . 0.0 111.075 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' PHE . . . . . 0.419 ' CE2' ' HA ' ' A' ' 123' ' ' SER . 0.7 OUTLIER -116.96 109.4 16.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 -179.982 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.85 135.87 19.96 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -148.75 133.48 17.88 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 17.8 tt0 -175.12 138.98 0.46 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.567 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.405 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -84.3 141.27 19.73 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.718 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.89 121.03 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.746 0.308 . . . . 0.0 110.31 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLN . . . . . 0.409 ' HG3' ' CB ' ' A' ' 117' ' ' MET . 3.4 mp0 -108.91 136.09 49.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.055 0.455 . . . . 0.0 111.817 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.456 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.6 tt -122.18 106.57 11.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.58 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.572 HG22 ' HA3' ' A' ' 115' ' ' GLY . 7.5 p -145.45 168.77 19.75 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.044 0.449 . . . . 0.0 111.644 -178.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.68 121.97 45.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.009 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.34 132.42 56.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.146 0.498 . . . . 0.0 111.885 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.6 ' HG ' HG23 ' A' ' 112' ' ' THR . 3.4 pp -126.96 127.39 44.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.814 179.096 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -120.2 -177.49 16.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.323 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.428 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 24.3 t80 -166.11 123.12 1.02 Allowed Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.455 0.169 . . . . 0.0 110.738 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.428 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 83.7 Cg_endo -78.02 160.64 30.15 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.457 2.105 . . . . 0.0 112.671 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 17.9 mm -116.28 -37.51 2.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -161.62 39.2 0.13 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.065 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 57.56 47.86 15.33 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.935 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.473 ' HB3' HD23 ' A' ' 108' ' ' LEU . 12.4 t70 -177.56 -38.19 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.64 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.485 HD23 ' N ' ' A' ' 108' ' ' LEU . 0.0 OUTLIER -117.53 105.29 11.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.164 179.688 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.04 163.27 23.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.066 0.46 . . . . 0.0 111.451 -179.177 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.989 HG22 HG12 ' A' ' 149' ' ' VAL . 1.6 pt -114.79 158.93 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.343 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -156.09 138.74 15.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.028 0.442 . . . . 0.0 111.604 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.6 HG23 ' HG ' ' A' ' 100' ' ' LEU . 1.8 t -132.99 126.94 33.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.243 179.389 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.439 ' CD ' ' HB3' ' A' ' 146' ' ' ALA . 0.5 OUTLIER -118.47 130.46 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.954 0.407 . . . . 0.0 111.43 -179.416 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -131.52 122.84 26.82 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.438 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.572 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -176.37 -140.18 3.44 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.591 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.482 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -138.6 163.31 25.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.832 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.409 ' CB ' ' HG3' ' A' ' 95' ' ' GLN . 1.1 ptt? -122.26 135.65 54.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.764 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.17 119.81 49.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 19.4 t90 -114.52 143.75 44.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.021 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 14.2 mtp180 -140.18 119.95 13.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.954 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.39 155.21 50.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.087 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -159.24 131.69 6.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.847 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' SER . . . . . 0.419 ' HA ' ' CE2' ' A' ' 89' ' ' PHE . 32.0 t -130.59 96.28 4.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 6.4 mtmt -125.89 88.14 2.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.746 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -84.9 79.11 1.94 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.575 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -112.73 144.58 42.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.892 0.377 . . . . 0.0 110.892 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -82.89 -35.25 26.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.886 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -116.2 -176.04 2.87 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.08 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 39.1 t -106.91 44.21 1.08 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.939 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.8 t -70.6 161.17 31.19 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.914 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -105.36 157.15 16.47 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.588 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.0 m -144.55 163.78 13.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.735 0.302 . . . . 0.0 111.16 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 65.2 m -79.12 -34.01 43.78 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.818 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 12.3 ttt85 -104.02 144.45 31.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -124.35 154.59 40.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.985 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.91 84.85 2.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.79 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 11.5 t-160 -141.64 121.28 13.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.91 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -131.85 148.35 52.54 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 5.1 t -133.4 115.84 15.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -90.4 132.25 11.17 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.486 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.416 ' O ' HG13 ' A' ' 141' ' ' VAL . 11.1 p -146.05 126.13 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.733 0.301 . . . . 0.0 111.152 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t -157.1 143.18 12.94 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.291 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.482 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 98.9 Cg_endo -79.55 147.45 19.9 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.658 2.239 . . . . 0.0 112.113 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.7 m -156.98 161.83 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.951 0.405 . . . . 0.0 111.528 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.8 p90 -149.01 119.44 7.37 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.572 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.439 ' HB3' ' CD ' ' A' ' 113' ' ' ARG . . . -109.79 129.07 55.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.935 0.398 . . . . 0.0 111.321 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.4 124.98 4.05 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.224 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.421 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -158.56 -152.16 6.33 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.309 -0.948 . . . . 0.0 113.04 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.989 HG12 HG22 ' A' ' 110' ' ' ILE . 6.1 m -135.48 167.31 25.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 111.317 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -136.8 137.4 39.75 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -119.93 127.25 52.49 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.731 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -88.43 124.34 33.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.479 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.535 ' O ' HG12 ' A' ' 153' ' ' VAL . 53.1 t -116.07 60.06 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.824 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' THR . . . . . 0.509 HG22 ' O ' ' A' ' 153' ' ' VAL . 14.6 t 45.85 -168.56 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.366 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ARG . . . . . 0.485 ' CG ' HD12 ' A' ' 157' ' ' ILE . 9.5 tpp180 57.6 21.87 7.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.266 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 56.29 24.3 8.09 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.204 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.485 HD12 ' CG ' ' A' ' 155' ' ' ARG . 6.5 mt -129.3 137.48 56.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -131.69 158.82 40.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.314 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.0 141.63 33.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.201 179.558 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -124.29 122.95 39.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.11 0.481 . . . . 0.0 111.881 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.415 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 1.4 tt -117.41 116.69 27.67 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.536 178.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.421 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 0.2 OUTLIER -109.48 145.02 36.92 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -178.922 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.421 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.4 p90 -133.99 165.77 24.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.557 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -178.12 108.16 0.05 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.877 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 24.1 t90 -162.88 118.92 1.83 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.477 ' O ' HG13 ' A' ' 166' ' ' VAL . 10.7 p -124.23 120.28 58.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.079 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -113.88 -37.71 4.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -70.15 67.34 0.3 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.856 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' ILE . . . . . 0.437 ' O ' HD12 ' A' ' 169' ' ' ILE . 2.7 pp -153.25 30.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -96.56 59.74 1.28 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.43 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -97.35 126.72 42.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.778 0.323 . . . . 0.0 110.927 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -131.47 125.87 33.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.11 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -137.01 -63.97 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.564 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 25.6 p -113.51 -42.47 3.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.822 0.344 . . . . 0.0 110.892 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 15.8 m -130.27 166.17 28.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.008 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -111.76 164.18 12.14 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.491 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.4 m -136.79 158.37 44.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.839 0.352 . . . . 0.0 111.024 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -98.49 103.61 19.45 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.81 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.0 137.48 37.77 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.396 2.064 . . . . 0.0 112.314 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -119.73 111.56 18.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.819 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 11.7 p-10 -96.29 150.33 20.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -110.94 -149.35 11.71 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.51 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -155.37 167.03 31.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.837 0.351 . . . . 0.0 110.956 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 7.2 mp -94.8 153.98 17.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.776 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 67.2 m -152.44 150.89 30.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.949 0.404 . . . . 0.0 111.298 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -116.31 145.18 43.38 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.454 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -160.64 173.66 37.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.921 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 2.1 m -127.49 138.16 55.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.759 0.314 . . . . 0.0 110.652 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 189' ' ' SER . . . . . 0.429 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 60.7 p -139.86 170.59 15.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.258 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 1.9 p90 -147.95 160.02 43.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 -95.15 150.15 20.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.929 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -67.63 109.19 3.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.81 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -140.97 -171.03 12.36 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.529 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 -126.33 82.03 2.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.847 0.356 . . . . 0.0 110.903 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -93.6 171.36 8.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.001 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -127.6 164.53 21.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.95 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -132.33 33.5 3.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.167 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -151.83 73.97 7.87 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -78.35 55.86 5.58 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.656 2.237 . . . . 0.0 112.436 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 200' ' ' VAL . . . . . 0.911 HG13 HG23 ' A' ' 201' ' ' VAL . 10.8 p -118.44 -29.15 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.356 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 201' ' ' VAL . . . . . 0.911 HG23 HG13 ' A' ' 200' ' ' VAL . 24.9 t -117.61 148.5 20.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.212 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -114.01 112.42 47.34 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.982 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.16 110.83 2.08 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.47 2.113 . . . . 0.0 112.2 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -112.52 91.5 17.11 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.188 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_exo -51.01 119.61 5.57 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.534 2.156 . . . . 0.0 112.426 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 206' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -77.39 -53.23 1.64 Allowed Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 50.2 Cg_exo -53.12 112.17 0.86 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.484 2.123 . . . . 0.0 112.381 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.767 ' HB3' ' HD3' ' A' ' 209' ' ' PRO . . . -69.99 -61.05 3.13 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.08 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 209' ' ' PRO . . . . . 0.767 ' HD3' ' HB3' ' A' ' 208' ' ' ALA . 60.5 Cg_endo -72.66 144.54 39.86 Favored 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.534 2.156 . . . . 0.0 112.303 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.985 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.303 0 CA-C-O 120.888 0.375 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 10.9 mtp180 -151.57 -47.15 0.11 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.866 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.2 mt -84.97 136.23 23.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.959 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -138.11 40.03 2.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.979 0.419 . . . . 0.0 110.763 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.8 mttt -140.25 115.65 9.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.846 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.91 96.55 1.7 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.066 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.92 157.64 3.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.079 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -158.84 116.31 2.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.735 HG12 HD12 ' A' ' 10' ' ' LEU . 21.4 t -131.42 -66.76 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.145 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.735 HD12 HG12 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -148.89 72.78 1.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.929 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 26.6 m-20 -76.97 -59.73 2.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.021 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -123.99 31.46 5.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.095 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.43 ' HB3' HD23 ' A' ' 10' ' ' LEU . . . -108.75 116.68 55.57 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.034 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.72 -44.69 1.96 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.372 2.048 . . . . 0.0 112.325 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.3 mttm -150.84 119.27 6.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.943 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.94 83.87 0.67 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.799 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -87.84 137.49 32.29 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.939 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -154.66 177.01 11.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.933 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.429 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.2 OUTLIER -141.83 154.58 45.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.885 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.444 ' CE1' ' HB3' ' A' ' 191' ' ' ARG . 1.2 m-85 -145.71 135.92 23.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.801 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.34 140.0 27.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.222 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.7 -171.55 41.27 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.424 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.04 150.46 22.69 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.368 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.32 154.57 48.4 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.898 0.38 . . . . 0.0 111.114 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.699 HD12 ' O ' ' A' ' 53' ' ' GLY . 49.4 tp -128.17 139.6 52.39 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.528 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -146.41 171.31 27.29 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.545 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 1.5 m-90 -78.97 144.51 34.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.765 0.317 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.65 -69.47 0.75 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.829 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 50.4 mt-30 -146.82 155.18 42.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.898 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -117.96 122.17 42.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -70.18 105.75 3.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.926 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 32.0 p-10 -116.29 -38.44 3.57 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.907 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 61.1 m -59.4 -57.93 10.84 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.01 -154.52 26.64 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.393 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -141.62 -69.35 0.37 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.818 0.342 . . . . 0.0 110.858 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 8.2 p90 -156.81 175.23 14.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.931 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -158.43 93.81 0.13 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.534 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 23.1 m-20 -77.21 -52.02 9.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 111.015 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -157.72 -65.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.511 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 76.9 t80 -85.65 139.87 31.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.778 0.323 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -151.32 172.34 16.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.868 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -116.63 81.07 1.57 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.936 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -75.23 -57.32 3.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.887 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -144.94 39.75 1.23 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.913 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -92.03 -91.54 1.43 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.56 -61.74 0.45 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.588 2.192 . . . . 0.0 112.367 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.8 p -138.99 156.53 47.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 4.2 ptp180 -119.25 -40.41 2.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.95 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 21.8 p30 -59.27 162.14 4.87 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.852 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -114.74 -172.11 2.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -55.79 158.0 3.92 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.921 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.439 HD13 HD11 ' A' ' 25' ' ' LEU . 2.5 pp -139.01 164.82 28.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.042 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.699 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -131.47 134.47 7.7 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.488 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.402 ' HB3' ' O ' ' A' ' 74' ' ' TRP . . . -101.19 139.88 36.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.02 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -145.57 126.85 2.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.424 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.498 ' HB3' ' CB ' ' A' ' 72' ' ' TYR . . . -94.89 141.82 28.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.747 0.308 . . . . 0.0 110.97 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -123.8 126.16 45.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.957 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -154.65 124.99 1.62 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -157.98 -168.31 20.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.429 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 8.8 p90 -154.97 161.08 41.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.782 0.325 . . . . 0.0 110.807 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -109.58 135.22 50.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.595 ' O ' HG12 ' A' ' 62' ' ' VAL . 15.9 t -141.46 29.22 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.036 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -162.32 163.53 18.36 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.78 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.37 -40.8 69.99 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.611 2.207 . . . . 0.0 112.328 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 24.7 p90 -148.63 37.59 0.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.899 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -139.39 115.7 10.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.798 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 153.49 19.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.525 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.07 128.37 42.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.66 0.266 . . . . 0.0 110.439 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -122.2 130.16 52.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.984 0.421 . . . . 0.0 111.417 -179.679 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 19.1 mtt -118.97 127.17 53.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.328 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.73 158.2 14.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.495 -0.859 . . . . 0.0 112.699 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.498 ' CB ' ' HB3' ' A' ' 56' ' ' ALA . 0.7 OUTLIER -129.18 114.94 16.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.781 0.324 . . . . 0.0 110.78 179.947 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -83.41 115.55 22.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.889 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' TRP . . . . . 0.402 ' O ' ' HB3' ' A' ' 54' ' ' ALA . 1.7 t90 -139.08 133.85 32.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.931 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.85 69.38 1.12 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.882 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 177.41 -144.97 6.94 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.41 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.0 ttt180 -165.9 156.61 13.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.773 0.32 . . . . 0.0 110.875 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 6.7 ttt -63.39 96.85 0.12 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.897 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -154.45 -174.49 4.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.007 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -58.78 178.79 0.1 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.93 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.7 mttp -60.79 125.5 23.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.881 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -87.46 -94.26 0.94 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.498 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 19.1 m -74.89 177.16 6.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.787 0.327 . . . . 0.0 110.905 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 84' ' ' VAL . 17.1 m -123.99 120.94 60.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.205 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -166.27 163.01 17.7 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.538 ' HB3' ' HB2' ' A' ' 128' ' ' ALA . 2.3 t-20 -134.83 138.79 44.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 129.27 -93.66 0.34 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.488 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -66.55 -30.74 71.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.819 0.342 . . . . 0.0 111.099 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 12.0 t80 60.93 95.01 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.893 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.35 -177.61 0.1 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.888 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.04 160.92 38.64 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.074 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -158.45 125.06 4.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.668 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.414 ' HA2' ' CB ' ' A' ' 119' ' ' TRP . . . -99.68 142.64 16.07 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.122 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.76 122.1 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 117' ' ' MET . 2.2 mt-30 -108.8 140.32 42.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.065 0.459 . . . . 0.0 111.678 -179.125 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.4 tt -128.43 116.21 19.39 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.751 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.885 HG21 ' HD2' ' A' ' 113' ' ' ARG . 0.6 OUTLIER -153.97 164.38 38.52 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.035 0.445 . . . . 0.0 111.84 -178.851 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.25 124.98 46.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.285 179.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -102.76 132.53 48.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.029 0.442 . . . . 0.0 111.71 -179.255 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.587 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -134.95 124.16 24.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.347 179.296 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -156.3 -175.84 27.73 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.821 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -166.02 159.97 12.85 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.656 0.265 . . . . 0.0 110.993 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -73.97 169.79 21.59 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.631 2.22 . . . . 0.0 112.132 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.871 HG23 HG23 ' A' ' 105' ' ' THR . 0.7 OUTLIER -122.26 -39.85 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.495 -0.321 . . . . 0.0 111.367 -179.88 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.871 HG23 HG23 ' A' ' 104' ' ' ILE . 71.8 p -136.78 -59.17 0.72 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.021 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -166.81 -42.95 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.166 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.748 ' C ' HD23 ' A' ' 108' ' ' LEU . 9.0 m-20 -125.35 28.15 6.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.272 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.748 HD23 ' C ' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -143.37 119.09 10.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.081 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -136.76 160.01 40.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 111.812 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.063 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -115.09 147.27 18.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.219 179.436 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -149.06 145.13 27.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.114 0.483 . . . . 0.0 111.51 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.502 HG22 ' CA ' ' A' ' 147' ' ' GLY . 0.6 OUTLIER -137.81 129.82 28.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.179 179.554 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.885 ' HD2' HG21 ' A' ' 97' ' ' THR . 0.6 OUTLIER -111.93 133.11 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.081 0.467 . . . . 0.0 111.522 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.515 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.8 tt -124.34 122.86 38.87 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.296 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.416 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 179.91 -134.07 2.16 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.815 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.524 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -151.43 169.1 30.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.933 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.406 ' HB3' ' HG2' ' A' ' 95' ' ' GLN . 0.6 OUTLIER -122.68 138.82 54.49 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 111.24 -179.791 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.1 125.89 60.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.503 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.414 ' CB ' ' HA2' ' A' ' 93' ' ' GLY . 1.1 p-90 -150.95 179.88 7.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 111.244 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.0 mtm180 -97.93 161.2 13.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.899 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.69 134.2 40.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.992 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -144.8 162.03 37.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.902 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 19.7 p -163.79 -44.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 21.9 mtpt -102.51 112.63 25.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.907 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -177.59 107.66 0.24 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.505 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -142.8 -50.64 0.36 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.817 0.342 . . . . 0.0 110.946 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -112.96 118.01 33.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.538 ' HB2' ' HB3' ' A' ' 86' ' ' ASN . . . -96.63 152.76 18.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.044 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -137.79 165.39 26.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 7.1 p -91.15 98.84 11.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.841 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -105.63 140.2 15.01 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.541 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 21.5 t -66.81 -44.78 88.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.842 0.353 . . . . 0.0 111.123 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.3 m -75.81 166.56 23.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.955 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -128.07 100.56 5.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.935 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 25.5 p -82.34 153.12 25.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.883 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 17.0 mm-40 -80.0 170.84 15.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.914 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -114.38 163.0 15.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.954 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -76.21 141.28 41.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.89 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 78.3 p -135.07 147.69 49.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.968 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -116.42 135.56 12.16 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.329 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.9 p -146.07 127.67 7.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.645 0.26 . . . . 0.0 111.132 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -157.07 142.67 12.64 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.496 -179.842 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.524 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 4.7 Cg_exo -73.93 153.4 47.47 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.834 2.356 . . . . 0.0 111.768 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.8 m -156.33 161.19 2.0 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 121.084 0.469 . . . . 0.0 111.717 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.515 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.5 t80 -142.94 118.96 10.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.237 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.49 136.38 52.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.014 0.435 . . . . 0.0 111.397 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.502 ' CA ' HG22 ' A' ' 112' ' ' THR . . . -133.73 125.74 4.05 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.004 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -157.96 -164.99 14.67 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.354 -0.927 . . . . 0.0 112.873 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 1.063 HG12 HG22 ' A' ' 110' ' ' ILE . 6.8 m -131.75 162.68 39.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.806 0.336 . . . . 0.0 111.046 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.51 140.11 51.36 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.188 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 18.8 m95 -123.22 120.02 31.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.808 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.51 126.71 35.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.391 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 48.4 t -116.14 -68.6 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.009 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' THR . . . . . 0.471 HG22 ' H ' ' A' ' 155' ' ' ARG . 0.2 OUTLIER -75.88 -173.69 2.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.903 -179.986 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ARG . . . . . 0.471 ' H ' HG22 ' A' ' 154' ' ' THR . 5.0 mtt-85 -75.05 -31.81 61.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.957 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -146.26 36.06 1.0 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.114 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 17.7 mt -149.52 100.95 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.035 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -116.47 168.83 9.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.008 0.432 . . . . 0.0 111.362 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' THR . . . . . 0.416 ' HB ' HG12 ' A' ' 188' ' ' VAL . 5.8 t -126.77 144.41 50.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.198 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 150.19 47.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.232 0.539 . . . . 0.0 112.016 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.791 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.9 OUTLIER -115.56 122.35 45.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.482 178.943 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -111.94 145.09 40.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.05 0.452 . . . . 0.0 111.7 -178.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.791 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 17.5 m-85 -128.71 147.05 50.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.657 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -58.87 -53.65 55.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.978 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 3.9 m95 -143.63 134.06 24.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.788 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 23.1 m -85.67 -32.9 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.177 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -85.37 168.38 14.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.835 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -128.88 -52.01 1.23 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.83 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 7.6 pt -69.58 157.53 6.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.105 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -162.92 -87.81 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.546 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -138.05 144.5 41.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.787 0.327 . . . . 0.0 110.899 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -115.75 108.19 16.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.137 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -99.93 -28.52 7.31 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.445 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 68.7 p -125.43 -47.73 1.72 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.724 0.297 . . . . 0.0 110.866 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.484 HG22 ' N ' ' A' ' 176' ' ' GLY . 11.3 p -156.51 158.5 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.119 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' GLY . . . . . 0.484 ' N ' HG22 ' A' ' 175' ' ' VAL . . . -86.59 55.34 4.69 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.413 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.5 m -138.75 59.67 1.62 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.971 0.415 . . . . 0.0 110.861 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 16.1 mtm-85 -79.59 155.24 76.19 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.941 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.05 134.95 50.97 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.512 2.141 . . . . 0.0 112.304 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -100.14 146.79 26.41 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.974 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 60.65 160.68 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.872 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -131.49 -85.22 0.31 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.586 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 4.4 tpp -147.88 149.18 31.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.829 0.347 . . . . 0.0 110.863 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -130.49 136.12 48.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.784 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 9.5 t -138.51 147.88 43.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.389 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.8 131.97 54.01 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.407 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.85 168.63 28.71 Favored Glycine 0 N--CA 1.453 -0.213 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.236 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 188' ' ' VAL . . . . . 0.416 HG12 ' HB ' ' A' ' 159' ' ' THR . 1.1 m -127.99 143.51 40.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.671 0.272 . . . . 0.0 110.472 179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.42 172.98 11.96 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 121.006 0.431 . . . . 0.0 111.468 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.7 p90 -138.05 160.03 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.444 ' HB3' ' CE1' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -113.26 141.88 46.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -91.41 106.65 18.65 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.819 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -122.73 152.89 16.89 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.515 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -90.81 140.42 29.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.773 0.32 . . . . 0.0 110.991 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -124.24 -71.51 0.71 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.928 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.36 91.08 3.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.93 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -81.97 98.81 8.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.051 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 198' ' ' ALA . . . . . 0.746 ' HB3' ' HD3' ' A' ' 199' ' ' PRO . . . -173.11 -63.05 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.171 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.746 ' HD3' ' HB3' ' A' ' 198' ' ' ALA . 57.3 Cg_endo -70.74 72.03 1.96 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.464 2.109 . . . . 0.0 112.298 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 200' ' ' VAL . . . . . 0.495 HG13 ' N ' ' A' ' 201' ' ' VAL . 10.9 p -138.91 -45.67 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.085 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 201' ' ' VAL . . . . . 0.495 ' N ' HG13 ' A' ' 200' ' ' VAL . 20.8 m -127.67 141.15 47.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.103 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -119.48 135.74 24.23 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.071 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -77.52 105.98 2.13 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.584 2.189 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 204' ' ' ALA . . . . . 0.855 ' HB3' ' HD3' ' A' ' 205' ' ' PRO . . . -81.62 -61.93 0.36 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.105 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 205' ' ' PRO . . . . . 0.855 ' HD3' ' HB3' ' A' ' 204' ' ' ALA . 86.5 Cg_endo -77.98 58.27 6.46 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.589 2.193 . . . . 0.0 112.397 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 206' ' ' ALA . . . . . 0.711 ' HB1' ' HD2' ' A' ' 207' ' ' PRO . . . -138.29 172.95 5.85 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.711 ' HD2' ' HB1' ' A' ' 206' ' ' ALA . 55.6 Cg_exo -51.95 -45.55 37.99 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.56 2.174 . . . . 0.0 112.293 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -131.61 140.31 37.94 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.107 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -75.0 -44.07 0.36 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.536 2.157 . . . . 0.0 112.363 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.916 -179.975 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.887 0.375 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.79 178.21 4.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.77 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.6 pt -73.1 81.77 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.102 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 13.8 mtt -127.96 54.56 1.7 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.928 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.09 173.94 11.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.931 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -58.9 179.4 0.09 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.146 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 mp -67.43 -50.28 63.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.092 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -117.03 139.47 50.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.931 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.6 t -106.29 72.23 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.2 pp -161.13 29.21 0.14 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.927 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -89.09 -61.29 1.74 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -167.91 -169.68 1.2 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.088 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -120.99 77.83 31.62 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.074 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -54.99 -36.32 92.18 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.618 2.212 . . . . 0.0 112.204 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.44 112.55 24.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.011 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -88.98 150.75 22.67 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.862 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -89.56 116.06 27.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.933 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.4 m -151.08 132.79 14.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.914 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 3.9 m-90 -135.64 148.4 48.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.106 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.432 ' CZ ' ' HA3' ' A' ' 59' ' ' GLY . 6.6 p90 -159.95 149.0 17.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.69 153.75 46.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.171 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.87 -171.18 38.07 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.463 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -143.7 147.64 19.06 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.39 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 3.1 pptp? -134.59 146.94 50.09 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.911 0.386 . . . . 0.0 111.043 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.807 HD12 ' HB2' ' A' ' 54' ' ' ALA . 1.9 tt -121.5 146.29 47.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.653 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -155.73 175.57 33.52 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.486 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 11.9 m-90 -108.55 159.93 16.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.791 0.329 . . . . 0.0 111.0 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 84.9 p -137.79 58.39 1.69 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.927 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -169.29 -169.75 0.99 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -95.98 148.06 23.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.948 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.2 t60 -147.66 -64.66 0.26 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 68.5 m-20 -146.35 31.9 0.99 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.94 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.5 154.8 19.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.863 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.37 -110.86 3.96 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.566 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 38.0 m-85 -122.46 -178.11 3.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.836 0.35 . . . . 0.0 110.922 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 13.4 m-85 -71.56 168.15 18.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.829 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -158.13 124.49 1.4 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.418 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -114.45 101.78 9.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.928 0.394 . . . . 0.0 110.866 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -160.91 -150.99 6.06 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.509 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -92.8 170.2 9.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.786 0.326 . . . . 0.0 110.886 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -113.16 -170.25 1.64 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -90.99 125.48 35.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.834 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 11.5 m-20 -131.6 -48.18 0.97 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -120.25 85.41 2.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.851 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -157.78 90.13 0.11 Allowed Glycine 0 CA--C 1.518 0.247 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.447 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -70.09 -28.18 23.99 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.49 2.126 . . . . 0.0 112.295 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 9.8 t -71.47 -31.32 67.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.901 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -59.56 107.41 0.58 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -127.35 134.62 49.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.846 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -75.72 151.6 37.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 21.7 mt-30 -109.12 87.98 2.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.813 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.21 139.41 42.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.922 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -139.3 143.09 13.52 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.436 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.807 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -125.07 148.48 48.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.662 0.268 . . . . 0.0 110.837 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.04 147.85 18.48 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.322 -0.942 . . . . 0.0 112.937 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.83 128.76 53.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.635 0.255 . . . . 0.0 110.643 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -120.3 143.96 48.07 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 0.0 111.397 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -128.15 124.89 4.92 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.045 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.432 ' HA3' ' CZ ' ' A' ' 20' ' ' TYR . . . -100.3 139.72 14.56 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.987 -179.492 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -135.39 114.11 11.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.702 0.287 . . . . 0.0 110.593 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.79 126.76 33.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.256 -179.627 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 19.0 t -153.82 -44.22 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.105 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -80.55 173.64 7.4 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.895 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.49 ' O ' HD23 ' A' ' 66' ' ' LEU . 21.4 Cg_exo -65.95 98.69 0.37 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.868 2.379 . . . . 0.0 113.029 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 57.24 44.88 21.33 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.496 179.201 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.49 HD23 ' O ' ' A' ' 64' ' ' PRO . 1.9 pp -176.65 115.72 0.11 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.871 179.671 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -107.14 177.02 21.46 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.548 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -90.55 142.77 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.833 0.349 . . . . 0.0 110.654 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.401 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 0.6 OUTLIER -122.49 111.96 17.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.151 -179.738 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.9 mtt -100.39 114.82 28.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.888 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 152.16 17.28 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.392 -0.909 . . . . 0.0 113.261 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.46 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 38.6 m-85 -130.3 114.96 16.28 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.5 122.94 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.763 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' TRP . . . . . 0.437 ' CD1' ' HA2' ' A' ' 55' ' ' GLY . 17.9 p-90 -139.2 148.09 42.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.646 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.09 176.25 5.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.041 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.24 178.94 39.92 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.523 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 10.3 ttt180 -98.15 30.05 3.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.818 0.342 . . . . 0.0 110.857 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 5.8 mtt -160.38 -172.63 3.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.778 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -167.54 -57.57 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.14 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -157.07 35.95 0.29 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 3.7 mtpm? -98.53 31.06 2.98 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.825 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.22 135.09 12.13 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.42 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 5.3 p -99.67 -39.09 8.44 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.77 0.319 . . . . 0.0 110.874 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -87.98 -31.8 5.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.074 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -135.43 148.8 49.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -84.3 -59.03 2.51 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.88 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.75 119.64 1.21 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.567 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.75 -30.61 14.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.338 . . . . 0.0 111.122 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 64.27 -78.93 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.97 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 3.0 mtmt -158.57 -54.67 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.904 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -176.37 -178.0 0.91 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.082 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -121.33 135.72 55.06 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.679 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.48 124.5 8.1 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.783 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.09 117.8 56.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.343 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.08 139.76 46.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.124 0.488 . . . . 0.0 111.831 -178.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.407 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -129.98 110.97 12.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.556 179.377 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.444 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.5 p -150.02 178.12 9.24 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.083 0.468 . . . . 0.0 111.812 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.2 44.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.033 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.401 ' HB2' ' HB2' ' A' ' 69' ' ' GLU . 8.8 tttt -126.57 132.01 51.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.096 0.475 . . . . 0.0 111.841 -179.286 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.488 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.6 pp -134.55 123.96 24.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.981 179.274 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.435 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -126.24 -175.04 14.02 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.437 -0.887 . . . . 0.0 113.302 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.406 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 0.8 OUTLIER -166.15 122.96 1.0 Allowed Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 115.674 -0.263 . . . . 0.0 110.576 -179.881 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.406 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 58.3 Cg_endo -71.6 167.24 27.0 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.485 2.123 . . . . 0.0 112.672 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 20.4 mm -109.68 -63.96 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.714 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.99 -50.21 2.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.664 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.1 t0 179.05 -36.21 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.165 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.734 ' O ' HD23 ' A' ' 108' ' ' LEU . 1.0 OUTLIER -113.66 16.47 18.62 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -179.468 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.734 HD23 ' O ' ' A' ' 107' ' ' ASP . 0.1 OUTLIER -141.86 125.84 17.23 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.675 0.274 . . . . 0.0 110.443 179.756 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -145.07 159.28 43.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.009 0.433 . . . . 0.0 111.522 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.025 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.63 148.58 17.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.351 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.435 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 5.7 m-85 -138.13 144.46 40.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.049 0.452 . . . . 0.0 111.736 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -128.91 127.1 41.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.356 179.416 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.25 130.07 56.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.338 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.505 HD12 ' CD2' ' A' ' 145' ' ' PHE . 7.2 tt -137.4 122.95 19.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.636 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.444 ' HA3' HG22 ' A' ' 97' ' ' THR . . . 179.51 -143.05 5.5 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.514 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -146.23 163.86 28.37 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.929 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.57 144.37 49.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.807 0.337 . . . . 0.0 110.94 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.2 t -129.44 135.73 60.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 6.2 m95 -123.41 141.08 52.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.795 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 2.0 ptt180 -150.61 126.83 10.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.0 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -88.34 139.61 30.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.065 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 -156.68 156.89 34.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.936 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 30.9 t -126.24 112.12 15.37 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.952 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -143.82 90.95 2.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.789 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -108.84 168.27 13.39 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.479 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -88.05 -37.29 16.41 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.771 0.319 . . . . 0.0 110.885 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -110.26 31.71 5.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.972 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -135.62 171.99 13.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.048 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.2 m -86.28 141.78 29.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.925 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.7 m -84.92 107.79 17.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -69.96 135.3 26.13 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.517 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 8.9 m -120.35 -42.02 2.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.874 0.368 . . . . 0.0 111.125 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 22.5 t -76.45 107.21 8.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.853 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 15.4 mtt180 -68.44 104.97 2.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.929 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 93.4 p -106.12 -50.99 3.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.921 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -131.8 79.68 1.88 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.005 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -140.68 124.75 17.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -125.99 137.35 53.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.835 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 60.0 p -108.79 165.89 11.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.943 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -145.31 140.05 8.78 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.518 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.428 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.4 p -146.02 123.94 4.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 120.66 0.267 . . . . 0.0 110.948 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -157.14 152.91 22.63 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.803 0.335 . . . . 0.0 111.577 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.514 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 71.6 Cg_endo -77.04 162.1 32.17 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.769 2.313 . . . . 0.0 112.094 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.6 m -155.96 159.05 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.003 0.43 . . . . 0.0 111.503 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.505 ' CD2' HD12 ' A' ' 114' ' ' LEU . 10.5 t80 -147.24 118.89 7.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.486 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -115.78 122.54 45.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.25 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.405 ' O ' ' CD1' ' A' ' 163' ' ' TYR . . . -126.32 132.21 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.218 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.426 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -166.52 -153.76 7.98 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.817 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 1.025 HG12 HG22 ' A' ' 110' ' ' ILE . 6.0 m -134.7 170.53 19.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.63 0.253 . . . . 0.0 111.016 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -138.3 144.6 40.52 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.904 0.383 . . . . 0.0 111.317 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' TRP . . . . . 0.603 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.2 OUTLIER -127.24 133.51 50.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.566 179.745 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.71 137.2 36.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.64 -63.68 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 33.6 p -90.55 -169.47 2.4 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.295 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 4.5 mtp180 -96.38 38.89 1.17 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.919 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -179.58 -28.33 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.941 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 32.0 mt -111.7 133.13 58.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-O 120.943 0.402 . . . . 0.0 111.651 -179.311 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -140.03 155.53 47.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.089 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.8 m -101.02 149.97 23.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.481 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.401 ' NH1' ' HB3' ' A' ' 162' ' ' GLU . 0.0 OUTLIER -137.06 134.2 36.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.068 0.461 . . . . 0.0 111.8 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.4 tt -117.56 119.57 35.43 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.792 179.038 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.401 ' HB3' ' NH1' ' A' ' 160' ' ' ARG . 4.8 pt-20 -112.42 143.89 42.79 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.989 0.423 . . . . 0.0 111.703 -179.11 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.426 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 6.4 p90 -134.21 162.83 31.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.516 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -82.52 155.04 24.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.938 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 13.8 t-105 -140.82 -62.33 0.48 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.984 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.464 HG12 ' HB3' ' A' ' 145' ' ' PHE . 11.3 p -65.53 130.03 30.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.086 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 25.8 m120 -127.88 120.66 28.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.951 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 30.3 m120 -111.27 83.27 1.74 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.877 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 4.4 tp -112.15 138.74 39.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.052 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -141.37 -51.61 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.472 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -99.29 159.98 14.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.775 0.321 . . . . 0.0 110.863 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -92.41 166.39 12.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.001 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -133.13 131.31 6.06 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.417 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.7 m -89.55 -62.06 1.56 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.798 0.332 . . . . 0.0 110.761 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 24.5 t -113.12 -40.81 3.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.033 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.31 158.63 31.56 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.464 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 30.8 p -143.6 99.51 3.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.871 0.367 . . . . 0.0 110.999 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' ARG . . . . . 0.404 ' CB ' ' CD ' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -72.98 -60.41 1.85 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.857 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 179' ' ' PRO . . . . . 0.404 ' CD ' ' CB ' ' A' ' 178' ' ' ARG . 63.2 Cg_endo -73.7 135.83 22.35 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.614 2.21 . . . . 0.0 112.301 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.7 101.55 12.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.833 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -66.09 130.06 41.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.896 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 64.12 137.2 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.393 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 1.6 ttp -162.06 109.17 1.35 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.758 0.313 . . . . 0.0 111.213 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.431 HD12 ' N ' ' A' ' 184' ' ' LEU . 3.7 mp -125.11 141.45 52.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.703 179.81 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.8 m -141.51 151.55 43.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.926 0.394 . . . . 0.0 111.345 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -114.81 132.06 56.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.342 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -149.25 167.5 29.58 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.326 -0.94 . . . . 0.0 113.002 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.2 m -127.57 139.81 50.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.65 0.262 . . . . 0.0 110.706 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 80.6 p -140.11 173.98 10.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.999 0.428 . . . . 0.0 111.241 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -148.0 151.28 35.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.724 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 -86.32 153.51 21.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -83.03 119.2 24.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.819 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -108.78 156.57 15.61 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.398 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -77.5 -32.03 53.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.792 0.329 . . . . 0.0 110.871 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -94.57 123.99 38.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.904 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.19 144.94 28.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.945 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -109.24 118.07 35.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.016 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -72.1 154.43 92.33 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.128 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.23 164.23 1.32 Allowed 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.572 2.181 . . . . 0.0 112.271 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.92 103.99 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.142 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 21.3 t -102.05 84.83 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.042 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -124.07 117.76 26.95 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.061 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -73.52 -39.07 2.14 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.415 2.076 . . . . 0.0 112.48 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -89.09 159.45 45.18 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.253 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -53.98 134.83 61.43 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.664 2.243 . . . . 0.0 112.371 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 206' ' ' ALA . . . . . 0.824 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -88.37 -63.5 0.21 Allowed Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.446 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.824 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 73.1 Cg_endo -76.12 161.94 34.86 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.44 2.093 . . . . 0.0 112.539 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.649 ' HB1' ' HD2' ' A' ' 209' ' ' PRO . . . -133.91 170.94 10.0 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.081 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 209' ' ' PRO . . . . . 0.649 ' HD2' ' HB1' ' A' ' 208' ' ' ALA . 51.8 Cg_exo -52.75 -31.23 50.08 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.475 2.117 . . . . 0.0 112.396 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.329 -0.844 . . . . 0.0 110.91 -179.964 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 120.773 0.32 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 39.6 mmt180 -136.94 -57.32 0.72 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.865 HD12 ' HB2' ' A' ' 6' ' ' ALA . 1.4 pt -75.03 113.52 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.095 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.5 tpt -102.49 39.73 1.47 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.873 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.3 tptm -150.0 36.86 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.838 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.865 ' HB2' HD12 ' A' ' 3' ' ' ILE . . . -95.18 -2.24 50.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.702 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.589 HG22 ' O ' ' A' ' 7' ' ' ILE . 22.1 mt -98.09 30.63 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.844 0.354 . . . . 0.0 111.138 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -142.89 22.09 1.94 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.094 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.552 ' C ' HD12 ' A' ' 10' ' ' LEU . 3.7 m -120.12 -32.75 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.348 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.552 HD12 ' C ' ' A' ' 9' ' ' VAL . 7.6 mp -133.47 87.51 2.39 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.843 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 35.1 m120 -75.65 118.2 18.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.978 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -81.8 -76.36 0.26 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.131 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -117.87 92.96 43.07 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.134 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -54.98 152.22 30.48 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.542 2.161 . . . . 0.0 112.255 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -107.21 -44.39 4.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 55.5 m-20 -77.96 101.57 6.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.916 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -87.1 -43.77 12.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.858 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.55 131.8 13.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.683 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 64.4 p-90 -150.33 148.74 29.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.974 0.416 . . . . 0.0 111.165 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.415 ' HB3' ' HA ' ' A' ' 191' ' ' ARG . 9.5 p90 -130.91 143.35 50.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.652 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.62 149.64 52.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.234 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.47 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.62 -159.98 19.1 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.779 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -132.19 142.36 13.8 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.349 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.423 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -127.67 140.34 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.97 0.414 . . . . 0.0 111.127 -179.86 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.684 HD13 ' HB2' ' A' ' 54' ' ' ALA . 19.2 tp -128.08 141.01 51.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.461 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.652 ' H ' HD12 ' A' ' 25' ' ' LEU . . . -173.11 -173.4 39.47 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.624 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 11.0 m0 -100.5 148.16 25.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.875 0.369 . . . . 0.0 110.858 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 32.2 p -117.69 175.37 5.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -151.64 90.69 1.58 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.873 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.451 ' CE2' ' CE ' ' A' ' 117' ' ' MET . 3.8 m-85 -133.82 106.03 7.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.909 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -107.73 121.52 44.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.849 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -136.31 31.71 2.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.2 p -101.27 -31.26 11.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.53 -116.08 5.42 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.483 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -151.67 128.83 11.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.866 0.365 . . . . 0.0 110.836 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -89.11 140.5 29.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.85 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.43 161.38 33.92 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.523 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -62.75 138.85 58.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.86 0.362 . . . . 0.0 110.892 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -110.25 179.86 20.52 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.476 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -74.39 -67.73 0.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -158.31 83.51 0.84 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -118.15 174.01 6.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 12.4 m-80 -129.3 163.24 26.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.932 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -122.08 165.99 15.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -81.95 -150.19 8.02 Favored Glycine 0 CA--C 1.519 0.285 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.493 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.11 171.43 0.18 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.564 2.176 . . . . 0.0 112.331 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.9 p -90.82 -55.12 3.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.938 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -87.33 146.08 26.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.931 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 -121.36 142.1 50.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.916 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -74.72 64.34 1.23 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.756 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -89.98 82.31 6.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.959 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.458 HD12 ' O ' ' A' ' 52' ' ' LEU . 2.9 pp -127.72 144.35 51.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.84 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.567 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -123.81 135.85 9.99 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.473 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.684 ' HB2' HD13 ' A' ' 25' ' ' LEU . . . -134.94 136.03 41.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.799 0.333 . . . . 0.0 110.878 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.403 ' CA ' ' O ' ' A' ' 72' ' ' TYR . . . -156.07 166.56 33.09 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.693 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.97 155.01 16.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 110.706 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.455 ' CZ ' ' NH2' ' A' ' 113' ' ' ARG . 47.0 m-85 -143.69 132.49 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.934 0.397 . . . . 0.0 111.124 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -130.83 124.8 4.31 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.377 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -100.5 130.65 10.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.494 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -122.09 120.69 35.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.825 0.345 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.82 135.31 42.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.98 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 24.4 t -129.25 -47.26 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.833 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -117.94 146.22 38.54 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.589 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.4 67.9 0.7 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.434 2.09 . . . . 0.0 112.183 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.755 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.7 OUTLIER -167.21 -40.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.277 -179.888 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.755 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.4 OUTLIER -167.78 164.14 14.2 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.943 0.401 . . . . 0.0 111.317 -179.765 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -134.98 166.04 24.47 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.323 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -86.18 132.95 33.9 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.783 0.325 . . . . 0.0 111.069 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.727 ' HB3' HG23 ' A' ' 97' ' ' THR . 25.9 tt0 -109.98 112.09 23.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.171 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.0 mmt -108.28 111.98 24.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.945 179.27 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -118.37 163.74 12.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.35 -0.929 . . . . 0.0 113.104 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.403 ' O ' ' CA ' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -128.61 114.81 17.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.673 0.273 . . . . 0.0 110.471 179.701 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.69 129.63 34.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.416 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -132.69 124.81 28.92 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.633 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.513 HD12 ' HA2' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -141.64 173.19 11.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.924 -179.953 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -135.23 178.89 18.23 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.451 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 60.47 171.93 0.09 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.807 0.337 . . . . 0.0 110.887 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -176.17 -66.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.929 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.99 -169.95 0.15 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.112 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -106.87 -42.16 5.01 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.921 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 16.8 mmtm -139.87 31.12 2.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -165.72 84.5 0.1 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.528 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -145.34 31.29 1.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.748 0.309 . . . . 0.0 110.868 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.578 ' O ' HG23 ' A' ' 84' ' ' VAL . 29.5 m -107.93 71.58 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.096 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -118.08 -176.04 2.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.881 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -61.43 148.65 41.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.844 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.74 28.74 13.0 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.481 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -64.78 -59.54 4.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.837 0.351 . . . . 0.0 111.006 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -144.55 102.37 3.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 -67.69 0.85 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.827 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -175.17 161.29 2.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.236 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -145.11 128.88 17.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.617 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -94.68 131.64 10.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.87 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -113.52 121.8 66.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.28 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 17.7 mt-30 -108.79 134.6 51.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.037 0.446 . . . . 0.0 111.712 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.485 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -128.86 112.48 14.17 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.868 179.478 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.727 HG23 ' HB3' ' A' ' 69' ' ' GLU . 0.9 OUTLIER -151.1 162.47 40.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.077 0.465 . . . . 0.0 111.658 -178.932 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.9 122.37 43.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.041 179.102 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.417 ' HG2' ' HB2' ' A' ' 69' ' ' GLU . 0.0 OUTLIER -112.58 132.13 55.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.145 0.498 . . . . 0.0 112.071 -179.039 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.504 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.9 pp -122.49 128.39 50.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.807 178.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.442 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -119.96 -179.91 16.5 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.133 -179.201 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -166.08 125.84 1.2 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.763 -0.219 . . . . 0.0 110.664 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.01 163.7 32.7 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.553 2.169 . . . . 0.0 112.489 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.582 HG22 ' OG1' ' A' ' 105' ' ' THR . 22.8 mm -119.45 -69.87 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.769 179.797 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.582 ' OG1' HG22 ' A' ' 104' ' ' ILE . 0.0 OUTLIER -177.7 149.33 0.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.626 -179.994 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 66.16 -74.95 0.06 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.972 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.802 ' O ' HD23 ' A' ' 108' ' ' LEU . 10.1 p-10 -168.72 59.8 0.06 Allowed 'General case' 0 C--O 1.233 0.232 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.335 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.802 HD23 ' O ' ' A' ' 107' ' ' ASP . 0.1 OUTLIER -144.66 127.15 15.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.092 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -138.53 162.99 33.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.106 0.479 . . . . 0.0 111.722 -179.241 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.966 HG22 HG12 ' A' ' 149' ' ' VAL . 1.4 pt -114.81 157.06 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.28 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.442 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 96.3 m-85 -153.47 144.82 23.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.081 0.467 . . . . 0.0 111.73 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 38.8 p -142.48 126.96 17.8 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.167 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.503 ' HD3' HG21 ' A' ' 97' ' ' THR . 1.4 ppt_? -118.27 134.7 54.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.009 0.433 . . . . 0.0 111.78 -179.348 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.8 tt -133.63 122.9 24.13 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.078 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.403 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . -177.65 -132.95 1.76 Allowed Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.602 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.528 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.43 165.55 31.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.302 -0.951 . . . . 0.0 113.082 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.451 ' CE ' ' CE2' ' A' ' 30' ' ' TYR . 1.7 ptt? -120.44 140.99 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.922 0.392 . . . . 0.0 110.744 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.478 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.8 t -134.32 124.5 45.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.926 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.434 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 54.2 p-90 -139.14 161.01 38.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.925 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.638 ' HD3' HG22 ' A' ' 139' ' ' THR . 1.9 mmm-85 -138.18 130.59 29.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.861 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -141.74 142.65 33.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.058 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -151.93 162.04 41.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.896 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 8.3 t -93.86 47.2 1.21 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.816 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.8 33.56 3.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.894 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -99.64 -92.91 2.07 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.531 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -109.47 -31.25 7.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.855 0.36 . . . . 0.0 110.824 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -59.57 -36.97 77.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.934 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -94.97 110.98 22.82 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.002 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 15.0 p -143.4 -54.4 0.38 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.999 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.6 t -66.62 -39.86 88.52 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -179.69 166.87 36.38 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.504 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.587 HG13 ' O ' ' A' ' 132' ' ' VAL . 9.0 p -178.38 67.47 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.897 0.38 . . . . 0.0 111.06 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 3.9 t -101.32 -46.86 4.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.94 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -59.69 -31.22 69.37 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.93 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.2 t -91.61 110.81 22.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.897 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -85.62 177.08 7.83 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.905 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 50.9 p-80 -76.3 175.88 8.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.81 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -144.29 149.29 36.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.022 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.638 HG22 ' HD3' ' A' ' 120' ' ' ARG . 20.8 p -131.74 141.77 49.61 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.995 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.434 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -119.87 123.0 5.47 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.499 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.4 p -146.11 130.5 11.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.752 0.311 . . . . 0.0 111.029 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 36.2 t -157.22 140.65 11.23 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.293 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.528 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.4 Cg_endo -80.65 148.15 17.83 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.73 2.286 . . . . 0.0 112.259 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 33.9 m -156.27 159.07 2.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.989 0.423 . . . . 0.0 111.492 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -149.1 123.54 9.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.499 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.36 145.32 40.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.838 0.352 . . . . 0.0 111.425 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.64 133.66 6.22 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.265 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -169.76 -149.99 6.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.556 -0.831 . . . . 0.0 113.023 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.966 HG12 HG22 ' A' ' 110' ' ' ILE . 13.8 m -135.23 168.78 22.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.813 0.34 . . . . 0.0 111.396 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.407 ' HB2' ' CD2' ' A' ' 111' ' ' TYR . 9.2 tt0 -131.6 136.61 47.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -125.14 131.59 53.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.033 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.519 ' HB3' ' HB2' ' A' ' 107' ' ' ASP . . . -91.53 137.2 32.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.074 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 62.2 t -112.34 -47.54 5.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.899 0.38 . . . . 0.0 110.86 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.08 -164.04 1.06 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.574 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.15 37.02 1.36 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.781 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ASP . . . . . 0.444 ' HB3' ' CE2' ' A' ' 190' ' ' TYR . 0.4 OUTLIER 173.67 -28.39 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.405 179.953 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 7.5 mt -101.36 130.5 50.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.838 0.351 . . . . 0.0 110.988 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.47 160.18 38.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.187 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.1 m -100.96 153.34 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.45 124.99 29.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.294 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.1 tt -123.95 116.51 23.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.112 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.432 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 42.1 mt-10 -136.32 145.17 45.16 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.143 0.497 . . . . 0.0 111.45 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -123.48 166.01 16.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.625 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 8.5 mm-40 -99.42 -179.11 4.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' TRP . . . . . 0.404 ' CE3' ' HA ' ' A' ' 165' ' ' TRP . 0.2 OUTLIER -61.28 111.55 1.79 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.977 180.0 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 11.0 p -130.69 139.01 52.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.041 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 19.0 p30 -105.96 157.79 17.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.924 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -144.23 -47.43 0.26 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.861 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' ILE . . . . . 0.498 ' H ' HD12 ' A' ' 169' ' ' ILE . 3.3 mp -60.7 -60.23 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.157 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -75.53 159.14 51.02 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.385 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 6.1 p30 -109.41 151.91 26.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.821 0.344 . . . . 0.0 110.944 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -95.27 153.34 17.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -105.51 64.91 0.29 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.489 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.2 p -148.69 -177.61 5.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.761 0.315 . . . . 0.0 110.919 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 16.1 m -85.05 136.32 23.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.111 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -163.37 163.14 35.4 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.532 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.9 m -109.9 -65.81 1.12 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.825 0.345 . . . . 0.0 110.881 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -119.07 78.98 17.62 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.888 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.67 84.96 0.77 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.484 2.122 . . . . 0.0 112.303 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -140.78 145.89 36.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.961 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 60.23 -178.97 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -137.68 -106.91 0.78 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.465 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 14.2 mtm -131.38 101.61 5.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.808 0.337 . . . . 0.0 110.972 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 5.9 mp -114.64 135.31 54.29 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.9 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -128.6 141.6 51.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.854 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.98 146.37 50.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.814 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 187' ' ' GLY . . . . . 0.423 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -163.42 -176.77 35.73 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.584 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.46 142.66 42.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.729 0.3 . . . . 0.0 110.825 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 189' ' ' SER . . . . . 0.47 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 29.6 t -135.96 161.03 36.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.152 0.501 . . . . 0.0 111.857 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 190' ' ' TYR . . . . . 0.444 ' CE2' ' HB3' ' A' ' 156' ' ' ASP . 7.0 t80 -125.01 135.16 52.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.363 179.797 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.415 ' HA ' ' HB3' ' A' ' 20' ' ' TYR . 8.4 ptt180 -90.92 136.96 32.72 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.113 -179.874 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -142.01 151.52 42.54 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.837 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -144.28 171.01 25.86 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.558 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 56.8 mt-30 -90.46 132.72 35.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.874 0.369 . . . . 0.0 110.965 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -102.79 162.9 12.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.809 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -121.38 -65.47 1.13 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -95.41 115.56 27.6 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.065 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -129.84 69.43 81.62 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.148 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.42 91.98 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.588 2.192 . . . . 0.0 112.259 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 27.1 t -127.79 -52.27 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.158 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 5.5 m -120.81 113.42 39.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.133 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 202' ' ' ALA . . . . . 0.745 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -74.08 -60.77 1.41 Allowed Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.161 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.745 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 59.2 Cg_endo -72.61 160.58 46.18 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.478 2.119 . . . . 0.0 112.421 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 204' ' ' ALA . . . . . 0.74 ' HB1' ' HD2' ' A' ' 205' ' ' PRO . . . -100.87 166.63 12.11 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.12 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 205' ' ' PRO . . . . . 0.74 ' HD2' ' HB1' ' A' ' 204' ' ' ALA . 39.5 Cg_endo -66.98 111.77 2.3 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.605 2.203 . . . . 0.0 112.275 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -125.95 78.88 69.58 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.165 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.66 -35.76 9.48 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.533 2.156 . . . . 0.0 112.282 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.594 ' HB1' ' HD2' ' A' ' 209' ' ' PRO . . . -99.4 168.63 9.29 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.145 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 209' ' ' PRO . . . . . 0.594 ' HD2' ' HB1' ' A' ' 208' ' ' ALA . 54.3 Cg_exo -52.08 -51.45 11.13 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.461 2.107 . . . . 0.0 112.323 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.858 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.843 0.354 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 6.0 mtt180 -150.59 -73.59 0.16 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.839 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.9 pt -140.92 129.46 24.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.162 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.9 mtm -115.57 147.56 40.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.867 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.6 mttm -135.08 117.38 15.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.92 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -113.75 130.17 56.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.5 pt -106.33 179.57 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.13 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -102.96 133.71 47.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.896 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 9' ' ' VAL . 10.9 m -85.49 88.5 2.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.102 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -151.05 175.51 12.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -57.7 99.98 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.914 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -86.86 55.36 3.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.756 ' HB3' ' HD3' ' A' ' 14' ' ' PRO . . . -86.82 -52.57 0.42 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.088 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.756 ' HD3' ' HB3' ' A' ' 13' ' ' ALA . 31.4 Cg_exo -59.16 84.55 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.509 2.14 . . . . 0.0 112.125 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 19.1 mmtt -88.52 99.73 12.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.914 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -83.94 65.54 8.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.774 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -98.73 141.62 31.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.946 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 t -150.51 172.52 15.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.812 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.434 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 17.6 t90 -142.74 129.92 20.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.0 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.44 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 10.5 m-85 -119.69 135.91 54.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.833 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.57 139.98 35.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.073 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -171.1 -159.2 16.59 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -148.1 147.48 18.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.61 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.409 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 3.0 mttp -123.63 161.14 25.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.988 0.423 . . . . 0.0 111.031 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 2.5 tt -141.35 143.24 33.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.695 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.77 -163.37 27.18 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.55 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -104.8 140.25 38.37 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.88 0.372 . . . . 0.0 110.811 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.7 t -121.56 127.82 51.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.949 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -110.07 141.2 43.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.91 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -67.12 150.96 48.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.837 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -99.06 107.05 19.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.867 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 25.0 p30 -144.37 160.46 41.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.927 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 41.2 m -69.37 -47.53 64.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.988 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 94.99 44.58 3.28 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.508 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -98.73 32.24 2.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.92 0.39 . . . . 0.0 110.959 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -96.27 132.7 41.47 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.825 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.95 -94.13 0.9 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.486 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -86.0 126.85 34.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.769 0.319 . . . . 0.0 110.898 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -152.46 97.2 0.17 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.52 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -122.23 105.81 10.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.835 0.35 . . . . 0.0 110.906 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.74 124.01 28.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -86.09 92.21 8.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.875 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -102.27 131.02 49.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.904 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -127.02 70.66 1.29 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.864 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -129.98 160.12 22.8 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.53 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.21 -45.69 1.27 Allowed 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.6 2.2 . . . . 0.0 112.303 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.0 m -146.73 153.5 40.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.918 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.83 154.22 45.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -99.1 166.74 11.1 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.959 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -100.97 155.64 17.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.903 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -78.58 77.06 5.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.906 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 3.5 pp -90.97 134.9 34.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.85 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.02 143.5 14.89 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.612 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -129.24 153.68 47.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.721 0.296 . . . . 0.0 110.876 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.04 172.18 35.14 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.769 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.617 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -114.12 131.27 56.47 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.744 0.307 . . . . 0.0 110.887 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.402 ' CD1' ' HG3' ' A' ' 24' ' ' LYS . 30.0 m-85 -118.72 128.22 54.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.073 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.97 126.39 3.23 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.39 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -127.5 136.14 9.12 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.608 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.45 ' CZ ' ' CB ' ' A' ' 68' ' ' PHE . 42.1 p90 -134.25 130.62 37.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -100.91 136.8 40.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 34.5 t -111.92 -34.23 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.188 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 7.3 p-10 -128.63 153.79 79.59 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.87 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.63 65.4 1.21 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.54 2.16 . . . . 0.0 112.162 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -159.07 -44.99 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.001 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -174.35 164.08 3.83 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 167.69 21.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.45 ' CB ' ' CZ ' ' A' ' 60' ' ' TYR . 0.3 OUTLIER -85.56 131.86 34.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 110.749 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 3.3 tm-20 -113.09 119.86 39.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.089 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.17 123.48 47.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.555 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 148.43 17.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.571 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.617 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 40.8 m-85 -130.04 115.05 16.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.802 0.334 . . . . 0.0 110.614 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.38 120.84 33.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.993 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -127.69 115.2 18.36 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.588 HD12 ' N ' ' A' ' 75' ' ' LEU . 3.4 mp -106.33 124.51 49.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.821 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -74.85 -129.38 0.21 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.445 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 22.7 tpt180 59.95 104.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.847 0.356 . . . . 0.0 110.957 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.25 170.13 16.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.933 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -137.12 131.54 32.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.125 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -107.63 125.34 51.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.92 106.08 8.38 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.986 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.7 -72.89 0.89 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.407 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 4.1 t -83.61 -165.62 1.16 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.84 0.353 . . . . 0.0 110.844 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.41 ' O ' HG23 ' A' ' 84' ' ' VAL . 35.7 m -91.04 49.64 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.145 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -178.63 136.72 0.15 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.839 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -124.5 -44.56 1.98 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.93 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.22 -37.54 3.75 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.525 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -149.92 156.09 41.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.894 0.378 . . . . 0.0 111.109 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -117.4 -58.03 2.08 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.792 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -148.6 165.58 30.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.759 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -163.33 156.99 19.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.335 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -152.11 130.8 12.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.418 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -99.31 130.53 10.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.105 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.51 121.67 65.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 179.269 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -108.89 142.83 38.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.145 0.498 . . . . 0.0 111.8 -178.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -132.3 110.62 10.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.738 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.481 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.8 p -150.85 167.39 27.64 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 120.932 0.396 . . . . 0.0 111.677 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -102.45 120.89 41.29 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.132 179.131 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.404 ' HB2' ' HB2' ' A' ' 69' ' ' GLU . 2.1 ttpm? -106.03 132.34 52.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.042 0.449 . . . . 0.0 111.909 -179.025 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.492 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.8 pp -135.87 128.35 30.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.281 179.305 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -150.25 -173.3 20.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.919 -179.646 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.816 ' CE2' HD11 ' A' ' 110' ' ' ILE . 30.4 p90 -166.17 143.12 4.31 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.585 0.231 . . . . 0.0 111.012 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -85.45 166.35 10.62 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.778 2.319 . . . . 0.0 112.941 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.601 ' O ' HG22 ' A' ' 104' ' ' ILE . 25.9 mt -138.4 37.13 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.779 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.482 HG22 ' H ' ' A' ' 106' ' ' ASP . 0.7 OUTLIER 63.63 173.71 0.17 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.64 -179.782 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.482 ' H ' HG22 ' A' ' 105' ' ' THR . 0.6 OUTLIER 63.41 20.74 12.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.192 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.549 ' HB3' ' HB3' ' A' ' 152' ' ' ALA . 33.0 m-20 61.93 46.23 6.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.137 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.487 HD23 ' CD1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER -137.43 130.31 30.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.302 179.639 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -144.76 158.4 43.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.966 0.413 . . . . 0.0 111.678 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.928 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 147.93 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.467 179.472 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.448 ' CZ ' ' HD3' ' A' ' 160' ' ' ARG . 17.7 p90 -142.33 143.32 32.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.11 0.481 . . . . 0.0 111.599 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 46.7 p -138.56 126.96 23.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.132 179.399 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.76 ' HG2' ' HB3' ' A' ' 146' ' ' ALA . 0.0 OUTLIER -121.2 138.48 54.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.982 0.42 . . . . 0.0 111.608 -179.241 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.49 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.8 tt -129.53 122.91 30.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.349 179.589 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.481 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -177.44 -141.76 4.22 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.723 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.526 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.19 169.13 25.89 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.434 -0.889 . . . . 0.0 112.843 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 14.7 tmm? -125.92 141.71 51.85 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 120.888 0.375 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -127.03 130.53 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.764 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.434 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 4.2 p-90 -137.79 173.72 11.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 111.035 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.99 134.76 40.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.831 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.666 ' HB3' ' HB3' ' A' ' 138' ' ' ASP . . . -87.95 156.13 19.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.118 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -145.01 145.82 31.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.817 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -60.5 -179.93 0.14 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.922 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.48 -34.46 9.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.988 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 179.98 -173.81 45.32 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.51 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -115.36 80.78 1.48 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.848 0.356 . . . . 0.0 110.797 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 26.4 t80 -117.78 -58.45 2.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.882 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -100.72 156.43 17.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.125 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 30.9 t -171.76 99.33 0.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -144.35 31.28 1.22 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.908 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -142.5 -157.56 7.2 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.509 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.534 HG13 ' O ' ' A' ' 132' ' ' VAL . 11.2 p -116.06 58.84 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.954 0.407 . . . . 0.0 111.016 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 40.1 t -116.7 33.99 5.3 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.934 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 34.1 mtt180 -60.78 -53.68 54.4 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.951 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 1.6 m -115.53 33.15 5.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.934 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -60.08 155.24 17.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.893 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 8.7 m80 -141.01 114.9 9.07 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.885 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.666 ' HB3' ' HB3' ' A' ' 121' ' ' ALA . 13.5 t70 -116.51 154.06 31.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.965 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.01 149.98 50.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.987 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.434 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -105.21 144.66 15.81 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.464 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.7 p -145.97 132.26 13.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.637 0.256 . . . . 0.0 111.074 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.437 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 4.5 p -157.11 131.85 5.28 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.368 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.526 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.5 Cg_exo -73.66 150.34 44.99 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.65 2.234 . . . . 0.0 111.791 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.1 m -156.28 163.53 1.41 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.26 0 CA-C-O 121.116 0.484 . . . . 0.0 111.84 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.49 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.9 t80 -137.07 118.76 15.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.245 179.629 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.76 ' HB3' ' HG2' ' A' ' 113' ' ' ARG . . . -103.63 126.72 50.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.929 0.395 . . . . 0.0 111.327 -179.636 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.57 124.88 3.61 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.176 179.817 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.75 -160.57 11.03 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.693 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.928 HG12 HG22 ' A' ' 110' ' ' ILE . 6.0 m -134.75 163.39 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.659 0.266 . . . . 0.0 110.915 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -127.71 142.54 51.3 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 120.918 0.39 . . . . 0.0 111.099 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' TRP . . . . . 0.487 ' CD1' HD23 ' A' ' 108' ' ' LEU . 7.6 t90 -126.57 119.16 26.42 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.66 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.549 ' HB3' ' HB3' ' A' ' 107' ' ' ASP . . . -90.59 137.23 32.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.388 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t -114.22 -51.53 5.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.511 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 19.3 p -108.1 -175.55 2.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.3 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 12.5 mtm180 -91.84 45.22 1.21 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.917 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 173.61 -26.81 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.678 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 21.5 mt -115.35 123.26 70.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.887 0.375 . . . . 0.0 111.686 -179.42 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -135.63 155.93 49.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.994 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 1.7 t -117.63 140.56 49.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.094 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.448 ' HD3' ' CZ ' ' A' ' 111' ' ' TYR . 0.0 OUTLIER -134.59 151.58 51.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.328 0.585 . . . . 0.0 112.123 -179.33 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -113.12 124.8 53.43 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.725 179.093 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -106.89 145.13 32.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.985 0.421 . . . . 0.0 111.622 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.672 ' CE2' HD21 ' A' ' 184' ' ' LEU . 0.8 OUTLIER -131.12 126.48 35.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.383 179.673 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? -54.63 -66.67 0.36 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.17 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -155.8 150.74 26.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.888 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.463 HG22 ' CE1' ' A' ' 163' ' ' TYR . 21.3 t -141.16 104.19 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.09 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.8 t-20 -64.23 125.39 24.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -111.94 -179.0 3.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.932 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 1.4 pt -71.11 92.18 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.064 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -142.78 66.25 0.47 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.441 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -158.2 163.02 37.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.797 0.332 . . . . 0.0 110.95 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -100.49 -54.39 2.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.11 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -78.87 -137.62 1.34 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.522 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.4 t -131.45 131.13 43.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.87 0.367 . . . . 0.0 110.901 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.4 t -109.04 -64.56 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.181 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -131.81 -128.6 2.95 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.506 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.95 -64.18 0.23 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.866 0.365 . . . . 0.0 110.899 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 12.4 mtt180 -123.7 102.8 35.04 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.822 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -68.32 148.26 73.63 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 122.323 2.015 . . . . 0.0 112.385 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -171.9 94.44 0.15 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -170.75 151.47 3.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 139.25 -164.01 25.94 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.575 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 8.3 tmm? -147.23 124.92 11.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.879 0.371 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.672 HD21 ' CE2' ' A' ' 163' ' ' TYR . 2.5 mp -114.04 137.33 51.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.771 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.3 p -136.76 155.78 49.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.068 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -119.33 133.06 55.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.461 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 187' ' ' GLY . . . . . 0.409 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -145.67 162.37 28.26 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.207 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.73 133.94 67.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.773 0.32 . . . . 0.0 110.402 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -136.14 175.09 9.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.943 0.401 . . . . 0.0 111.378 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -139.84 155.8 47.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.636 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.44 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -99.66 148.73 24.04 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.933 -179.915 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -95.35 136.63 35.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.831 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -154.76 175.21 32.92 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.645 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -123.02 83.42 2.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.836 0.351 . . . . 0.0 110.853 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -82.16 144.3 30.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.919 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -112.6 112.25 23.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.809 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -137.14 -54.94 0.71 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.184 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 198' ' ' ALA . . . . . 0.428 ' O ' HG13 ' A' ' 200' ' ' VAL . . . -110.99 96.37 29.28 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.189 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -54.23 88.13 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.523 2.149 . . . . 0.0 112.286 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 200' ' ' VAL . . . . . 0.428 HG13 ' O ' ' A' ' 198' ' ' ALA . 30.3 m -80.81 157.25 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.157 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 13.3 m -130.26 47.54 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.083 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -103.55 92.3 4.0 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.061 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.18 -27.08 29.67 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.531 2.154 . . . . 0.0 112.366 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.97 140.74 90.25 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.099 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.91 171.45 0.35 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.423 2.082 . . . . 0.0 112.33 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 206' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -90.35 -52.66 0.31 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 48.0 Cg_exo -56.09 84.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.614 2.209 . . . . 0.0 112.41 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.859 ' HB3' ' HD3' ' A' ' 209' ' ' PRO . . . -107.83 -57.83 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.454 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 209' ' ' PRO . . . . . 0.859 ' HD3' ' HB3' ' A' ' 208' ' ' ALA . 40.3 Cg_exo -57.05 -163.42 0.02 OUTLIER 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.327 2.018 . . . . 0.0 112.313 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.904 179.948 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.779 0.323 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -126.39 -46.28 1.63 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 24.1 pt -138.08 150.03 24.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.106 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -117.17 149.39 40.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.945 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.07 81.42 1.72 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.801 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -87.55 101.72 13.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.14 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 tt -72.04 -33.03 45.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.058 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -166.44 117.29 0.97 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.3 m -131.68 179.78 4.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.187 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -90.71 -24.78 20.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.047 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -56.98 150.82 16.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.977 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.29 104.31 3.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -91.68 122.35 65.76 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.986 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -68.87 -28.17 30.04 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.421 2.081 . . . . 0.0 112.394 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.18 53.86 2.02 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.889 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.3 p30 -89.31 15.95 8.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.481 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -67.13 138.45 57.07 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.804 0.335 . . . . 0.0 110.963 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.498 HG22 ' H ' ' A' ' 19' ' ' TRP . 0.5 OUTLIER -142.02 174.99 10.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.833 -179.961 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.498 ' H ' HG22 ' A' ' 18' ' ' THR . 13.3 p-90 -143.79 148.17 35.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.955 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.8 m-85 -119.97 140.0 51.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.709 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.35 139.98 47.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.384 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.15 -158.47 19.82 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.499 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -155.86 150.45 21.81 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.533 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 9.1 ptmm? -131.71 154.04 49.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.914 0.388 . . . . 0.0 111.07 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -128.29 148.89 50.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.675 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -167.36 -144.66 4.21 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.564 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 9.9 m-90 -116.85 144.12 44.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.852 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.2 m -145.37 138.9 26.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -154.39 109.46 3.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.913 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 14.3 p90 -112.83 35.82 3.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 47.0 t-80 -135.36 95.7 3.33 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -113.64 141.23 47.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.797 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 2.2 m -97.55 80.05 2.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.976 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.78 163.69 35.66 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.508 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -74.6 84.91 2.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.842 0.354 . . . . 0.0 110.859 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -113.87 86.65 2.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -91.77 47.46 2.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.55 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 53.9 t-20 -109.63 112.11 23.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.913 0.387 . . . . 0.0 110.866 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -59.38 -27.71 63.6 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.606 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -87.54 129.67 35.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.848 0.356 . . . . 0.0 110.867 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.6 mt-30 -160.13 115.41 2.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.81 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -84.15 -66.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -63.38 173.4 1.58 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.928 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 11.5 p30 -70.49 162.68 28.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.8 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -140.19 -141.61 4.06 Favored Glycine 0 CA--C 1.518 0.258 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.348 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.57 -20.67 53.47 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.453 2.102 . . . . 0.0 112.241 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.2 t -127.7 120.32 27.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.926 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -98.8 -59.1 1.8 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.844 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -99.82 164.66 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -74.59 132.36 41.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -117.39 155.22 29.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.875 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -134.09 151.59 51.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.98 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -136.28 145.04 16.94 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.515 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.38 144.4 34.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.426 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.55 130.85 3.36 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.747 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.765 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.91 145.67 24.75 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.689 0.28 . . . . 0.0 110.773 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -135.62 133.35 38.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.023 0.44 . . . . 0.0 111.425 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.82 125.04 1.89 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.849 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -134.39 164.36 24.58 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.934 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.404 ' CB ' ' HB3' ' A' ' 19' ' ' TRP . 48.5 p90 -143.91 134.04 24.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.897 0.38 . . . . 0.0 110.657 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -90.4 137.14 32.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 41.6 t -137.09 -47.8 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.798 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.437 ' HA ' ' HD3' ' A' ' 64' ' ' PRO . 81.4 m-20 -88.69 134.49 33.85 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.423 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 63' ' ' ASN . 22.5 Cg_exo -64.65 64.39 0.27 Allowed 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.516 2.144 . . . . 0.0 112.256 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.432 ' N ' ' O ' ' A' ' 63' ' ' ASN . 1.3 t80 179.62 -33.04 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.505 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -164.35 164.1 22.29 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.965 0.412 . . . . 0.0 111.325 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.75 177.1 18.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.294 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -98.04 142.37 29.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.653 0.263 . . . . 0.0 110.703 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -132.96 121.29 22.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.917 0.389 . . . . 0.0 111.07 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.16 129.32 53.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.421 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.01 156.91 15.35 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.636 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.765 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 40.0 m-85 -130.48 115.04 16.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.774 0.321 . . . . 0.0 110.463 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.83 120.48 30.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.186 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 -139.04 119.42 13.78 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.889 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -115.75 157.08 24.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.783 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -101.55 -56.98 0.84 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.468 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.4 mtp180 -121.07 145.97 47.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.842 0.353 . . . . 0.0 110.891 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.7 ptp -130.35 -49.62 1.09 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.967 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -172.84 -44.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.061 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -102.5 139.55 37.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.922 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 27.3 mtmt -99.21 148.85 23.68 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.82 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -68.87 109.68 3.02 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.512 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -157.61 -58.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.771 0.32 . . . . 0.0 110.913 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.567 ' O ' HG12 ' A' ' 84' ' ' VAL . 29.2 t -96.35 48.18 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.082 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -111.88 -176.26 2.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.92 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 p-10 -112.21 38.71 2.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.868 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 98.67 177.99 32.39 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.554 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -60.25 163.94 4.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 0.0 111.132 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -137.93 159.6 41.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.85 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 16.4 mtmt -89.91 125.89 35.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -174.66 143.33 0.77 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.247 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -175.18 136.68 0.38 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.645 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.36 128.47 8.5 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.666 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.66 117.96 51.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.641 0.258 . . . . 0.0 110.324 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -110.55 142.53 42.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.116 0.484 . . . . 0.0 111.72 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.5 tt -129.06 110.23 11.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.483 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.523 HG22 ' HA3' ' A' ' 115' ' ' GLY . 5.1 p -148.2 174.66 11.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.235 0.541 . . . . 0.0 111.769 -178.765 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -111.55 135.24 52.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.304 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.66 132.13 55.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.918 0.389 . . . . 0.0 111.448 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -132.18 131.69 42.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.587 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.38 -174.3 34.85 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.569 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.46 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -165.36 150.8 8.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.73 0.3 . . . . 0.0 110.925 -179.882 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.46 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 37.6 Cg_exo -60.74 165.44 11.74 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.709 2.272 . . . . 0.0 112.108 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.765 HG22 ' O ' ' A' ' 108' ' ' LEU . 0.5 OUTLIER -124.97 -31.06 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.558 -179.923 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.524 ' OG1' HG23 ' A' ' 104' ' ' ILE . 1.1 m -139.06 -65.95 0.48 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.805 0.336 . . . . 0.0 110.82 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -156.82 -50.49 0.07 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.79 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.761 ' C ' HD23 ' A' ' 108' ' ' LEU . 77.5 m-20 -125.15 30.91 5.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.819 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.765 ' O ' HG22 ' A' ' 104' ' ' ILE . 0.0 OUTLIER -140.89 117.63 10.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.014 179.965 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.405 ' HB3' ' HA ' ' A' ' 103' ' ' PRO . 3.0 p30 -131.64 160.26 35.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.032 0.444 . . . . 0.0 112.016 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.968 HG22 HG12 ' A' ' 149' ' ' VAL . 1.4 pp -116.07 141.25 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.133 179.332 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -156.69 160.28 39.18 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.103 0.478 . . . . 0.0 111.925 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 9.3 t -138.4 151.07 47.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.02 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.517 ' NE ' ' HB3' ' A' ' 146' ' ' ALA . 3.7 ppt_? -120.5 127.99 52.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.514 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.6 tt -125.75 122.67 36.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.127 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.523 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -179.59 -141.52 4.59 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.512 -0.851 . . . . 0.0 112.669 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.491 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.11 168.65 25.64 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.796 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.462 ' HE3' HG11 ' A' ' 144' ' ' VAL . 8.3 ptp -126.56 142.48 51.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.879 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -124.45 144.05 35.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.807 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.7 t90 -144.74 148.47 34.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.808 0.337 . . . . 0.0 110.974 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.09 131.44 50.1 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.946 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -135.58 147.23 48.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.103 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -150.77 157.95 43.56 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.952 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 2.4 t -129.07 33.84 4.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.959 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 4.3 tttm -120.42 83.87 2.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.838 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -143.61 -92.25 0.15 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.536 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 20.0 p30 -83.37 -175.58 5.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.88 0.371 . . . . 0.0 110.894 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 23.4 t80 -155.82 94.82 1.59 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.917 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -89.22 -67.89 0.81 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.33 -68.26 0.25 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 41.3 p -85.86 78.89 9.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.766 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' GLY . . . . . 0.505 ' O ' HG13 ' A' ' 132' ' ' VAL . . . -129.2 126.98 5.39 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.51 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.505 HG13 ' O ' ' A' ' 131' ' ' GLY . 5.3 m -158.04 104.79 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.824 0.345 . . . . 0.0 111.266 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.5 m -160.5 124.0 3.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.842 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 6.8 ttp85 -136.57 -66.26 0.54 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.33 31.37 6.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.878 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -110.15 88.56 2.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.898 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -92.71 131.32 37.88 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.88 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -117.53 149.36 40.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.829 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.3 m -140.91 137.85 33.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.978 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -97.61 99.31 2.22 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.536 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 141' ' ' VAL . 9.1 p -125.14 125.02 68.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.667 0.27 . . . . 0.0 110.964 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.0 p -157.05 148.65 17.12 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.335 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.491 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 72.4 Cg_endo -76.55 158.47 36.08 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.665 2.243 . . . . 0.0 112.084 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.462 HG11 ' HE3' ' A' ' 117' ' ' MET . 35.0 m -155.92 154.41 6.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.031 0.443 . . . . 0.0 111.52 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 59.4 t80 -149.15 118.66 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.416 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.517 ' HB3' ' NE ' ' A' ' 113' ' ' ARG . . . -129.37 147.48 51.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.94 0.4 . . . . 0.0 111.345 -179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.22 145.37 17.19 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.078 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -164.77 -171.03 30.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.799 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.968 HG12 HG22 ' A' ' 110' ' ' ILE . 3.4 m -129.56 148.95 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.746 0.308 . . . . 0.0 111.107 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -110.83 127.15 55.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' TRP . . . . . 0.449 ' NE1' HD22 ' A' ' 108' ' ' LEU . 5.3 t90 -128.61 120.29 26.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.757 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.56 ' HB3' ' HB3' ' A' ' 107' ' ' ASP . . . -84.57 132.92 34.46 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.354 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.1 t -107.22 -66.34 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.756 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' THR . . . . . 0.413 HG22 ' H ' ' A' ' 155' ' ' ARG . 0.2 OUTLIER -79.94 174.57 11.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.843 179.874 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ARG . . . . . 0.413 ' H ' HG22 ' A' ' 154' ' ' THR . 0.0 OUTLIER -72.25 -25.49 61.64 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.005 -179.981 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -135.11 27.64 3.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.186 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 18.6 mt -151.96 116.44 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.209 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -112.68 168.56 9.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.254 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.3 m -135.92 146.63 47.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.348 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 147.69 46.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.201 0.524 . . . . 0.0 111.902 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.2 tt -119.68 124.1 45.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.776 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -114.42 144.48 43.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.084 0.469 . . . . 0.0 111.592 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.43 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 18.7 p90 -134.14 155.17 50.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.494 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -105.0 -70.18 0.79 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.972 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -131.25 149.14 52.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.5 t -137.23 127.91 39.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -146.9 29.86 0.98 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.877 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -100.32 -59.36 1.72 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.958 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 14.8 pt -71.48 -30.42 39.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.086 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -128.81 127.35 5.57 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.514 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 41.1 m-20 -98.13 36.29 1.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.903 0.383 . . . . 0.0 110.934 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -96.79 101.89 13.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.077 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -159.64 129.89 2.32 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.488 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.39 -59.16 1.76 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.775 0.321 . . . . 0.0 110.824 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -141.95 78.61 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -139.3 -77.47 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.534 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 43.9 p -136.73 119.54 16.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.778 0.323 . . . . 0.0 110.93 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.75 -60.59 1.9 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.51 147.08 45.54 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.58 2.186 . . . . 0.0 112.248 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -91.05 104.83 17.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.957 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 10.5 m-20 -132.03 -67.12 0.68 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.909 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 68.79 151.37 0.38 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.452 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -134.71 100.05 4.5 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.91 0.386 . . . . 0.0 110.995 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.622 HD12 ' N ' ' A' ' 184' ' ' LEU . 3.6 mp -114.62 155.19 27.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.534 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 47.4 m -151.86 155.74 38.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.901 0.382 . . . . 0.0 111.264 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -118.26 135.77 54.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.366 179.589 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -147.92 167.24 28.84 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 119.967 -1.111 . . . . 0.0 113.139 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.3 m -123.74 145.07 31.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 67.4 p -152.29 174.98 13.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.055 0.455 . . . . 0.0 111.593 -179.221 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -145.16 152.37 39.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.541 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.419 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -95.81 144.32 26.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.878 -179.972 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 192' ' ' PHE . . . . . 0.427 ' HB3' ' CZ2' ' A' ' 19' ' ' TRP . 0.5 OUTLIER -149.59 135.48 18.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.789 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -142.36 128.21 3.45 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.544 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -120.78 144.67 48.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.863 0.363 . . . . 0.0 110.859 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -99.34 29.87 3.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.858 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -149.06 -69.89 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.884 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -69.78 67.71 0.26 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.105 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 198' ' ' ALA . . . . . 0.81 ' HB3' ' HD3' ' A' ' 199' ' ' PRO . . . -81.98 -62.22 0.33 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.398 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.81 ' HD3' ' HB3' ' A' ' 198' ' ' ALA . 61.5 Cg_endo -74.11 -46.43 0.3 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.416 2.077 . . . . 0.0 112.609 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 11.4 p -121.39 145.72 27.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.19 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 201' ' ' VAL . . . . . 0.453 ' O ' HG13 ' A' ' 201' ' ' VAL . 11.0 p -139.33 123.29 19.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.048 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -74.13 113.16 20.77 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.078 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -55.57 106.71 0.2 Allowed 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.421 2.08 . . . . 0.0 112.283 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -84.61 139.53 38.1 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.106 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.71 148.48 44.94 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.437 2.091 . . . . 0.0 112.355 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 206' ' ' ALA . . . . . 0.759 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -88.78 -52.98 0.36 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.182 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.759 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 48.1 Cg_exo -55.54 96.92 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.454 2.103 . . . . 0.0 112.36 179.838 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.722 ' HB1' ' HD2' ' A' ' 209' ' ' PRO . . . -145.51 165.96 19.43 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.041 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 209' ' ' PRO . . . . . 0.722 ' HD2' ' HB1' ' A' ' 208' ' ' ALA . 42.5 Cg_endo -67.8 -25.48 39.43 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.611 2.207 . . . . 0.0 112.251 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.941 179.99 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 120.822 0.344 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.6 ttp180 -153.94 37.82 0.45 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.862 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.6 mp -101.99 -64.0 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.083 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.9 ttt -134.08 118.7 18.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.843 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.0 mtpm? -90.44 57.62 3.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.831 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -110.3 119.46 39.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.108 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 32.3 pt -73.44 174.19 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.107 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 36.3 p90 -162.0 154.35 19.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.942 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 15.7 m -80.04 150.08 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.183 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.57 -42.99 2.72 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.918 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -74.83 132.69 41.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.991 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.02 -68.33 0.38 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.055 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -102.56 132.28 21.5 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.118 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.03 61.66 5.73 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.478 2.119 . . . . 0.0 112.306 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.5 mmtt -135.23 84.88 2.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.903 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -68.92 -58.38 4.22 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.817 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -79.47 111.49 15.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.928 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.8 m -118.13 149.9 40.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.839 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.44 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 27.0 m-90 -131.78 131.93 43.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.986 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -128.26 135.96 50.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.722 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.14 141.25 34.17 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.49 -166.6 33.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.546 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -156.01 150.07 21.28 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.42 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -126.85 160.05 32.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.902 0.382 . . . . 0.0 111.157 -179.904 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.66 140.88 46.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.609 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -152.59 -175.04 23.7 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.499 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 5.6 m0 -95.83 144.29 26.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.826 0.346 . . . . 0.0 110.882 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -100.6 156.23 17.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.52 114.54 26.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.891 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 38.7 t80 -106.11 -50.45 3.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.2 t60 -113.81 179.97 3.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.846 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -103.75 -59.73 1.68 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.994 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.0 m -72.46 -56.88 4.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.898 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 96.97 -161.02 21.68 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.582 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -127.43 130.63 49.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.784 0.326 . . . . 0.0 110.918 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -143.56 152.02 40.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.858 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.48 136.78 13.06 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.562 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -98.85 -52.92 3.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.871 0.367 . . . . 0.0 110.872 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -150.0 -113.99 0.67 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.534 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -81.3 88.97 6.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.877 0.37 . . . . 0.0 110.914 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -125.44 113.46 17.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.894 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -71.77 78.69 0.85 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -123.7 83.97 2.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.876 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 -91.21 89.37 7.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.2 139.66 22.85 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.368 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -74.02 173.18 14.51 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.485 2.123 . . . . 0.0 112.371 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 70.6 m -73.6 78.91 1.48 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.909 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 2.0 mmm180 -151.8 160.66 43.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 29.2 m-20 -100.27 161.01 13.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.863 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.09 -58.59 3.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -163.57 135.54 5.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.872 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.0 pp -131.02 154.82 47.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.801 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -135.52 134.5 7.29 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.645 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.11 144.54 33.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.34 117.78 1.2 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.619 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.73 136.1 35.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.75 0.31 . . . . 0.0 110.667 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 22.4 m-85 -125.93 132.8 52.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.974 0.416 . . . . 0.0 111.186 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.57 125.04 1.78 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.201 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 69' ' ' GLU . . . -155.87 -173.42 24.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.858 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.44 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 1.9 p90 -147.96 158.31 43.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.756 0.312 . . . . 0.0 110.8 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 32.8 mt-30 -107.61 127.3 53.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.994 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 61.0 t -139.66 -41.42 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.069 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.445 ' CB ' ' HD2' ' A' ' 64' ' ' PRO . 6.5 m-80 -52.32 167.13 0.37 Allowed Pre-proline 0 CA--C 1.531 0.22 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.988 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.445 ' HD2' ' CB ' ' A' ' 63' ' ' ASN . 7.6 Cg_endo -49.9 -45.33 32.92 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.824 2.349 . . . . 0.0 112.97 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 27.3 t80 -150.0 50.82 0.91 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.863 0.364 . . . . 0.0 111.666 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.421 ' O ' ' HB2' ' A' ' 63' ' ' ASN . 3.6 pp -179.84 164.12 1.17 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.7 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -137.97 175.66 21.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.615 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -115.36 138.16 51.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.823 0.344 . . . . 0.0 110.648 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.418 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . 1.2 pt-20 -140.13 143.14 36.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.002 0.43 . . . . 0.0 111.198 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -110.68 142.25 42.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.531 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 158.24 14.6 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.617 -0.802 . . . . 0.0 112.441 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -130.83 114.79 15.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.678 0.275 . . . . 0.0 110.77 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.412 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.4 t0 -90.35 119.36 30.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.914 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -135.3 124.08 23.9 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 4.4 mt -98.89 -67.75 0.83 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.998 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 84.58 103.5 0.61 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.544 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.3 ttt-85 60.01 -176.7 0.1 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.743 0.306 . . . . 0.0 110.851 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -139.98 -78.27 0.31 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.957 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -178.5 -50.11 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.009 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -69.02 156.42 38.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 2.9 tttt -73.71 170.16 15.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.942 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 179.1 -176.77 48.14 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.503 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 5.3 t -120.5 105.45 10.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.832 0.349 . . . . 0.0 110.862 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.6 m -99.51 118.95 46.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.072 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -130.32 -77.45 0.54 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.994 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -99.94 -59.85 1.64 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.933 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -169.67 110.58 0.38 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.456 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -105.75 -39.25 6.12 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.809 0.337 . . . . 0.0 111.103 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -164.5 57.56 0.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.877 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -91.46 137.78 32.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.874 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -155.4 176.41 12.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.219 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.43 127.93 8.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.458 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.412 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -88.74 133.65 11.94 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.991 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.83 117.74 45.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -108.98 149.03 29.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.236 0.541 . . . . 0.0 111.875 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.6 tt -135.11 113.78 11.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.629 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 t -154.11 166.33 33.41 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.099 0.476 . . . . 0.0 111.638 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.34 134.57 50.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.481 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.59 130.18 54.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.315 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.557 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -135.25 124.27 24.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.537 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -166.89 -169.77 30.91 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.693 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -165.1 157.62 13.67 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.727 0.299 . . . . 0.0 111.112 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 109' ' ' ASP . 90.5 Cg_endo -78.44 170.97 17.6 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.787 2.325 . . . . 0.0 112.634 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 14.2 mm -102.4 -29.88 3.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.918 0.389 . . . . 0.0 110.539 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.22 -60.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.519 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 176.74 46.17 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.753 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 176.63 -31.65 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.219 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -105.45 120.46 41.67 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 7.5 t0 -125.39 147.68 49.08 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.382 0.611 . . . . 0.0 112.385 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -129.33 123.54 58.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.763 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -143.04 168.84 18.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.027 0.441 . . . . 0.0 111.559 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.427 HG22 ' HA3' ' A' ' 147' ' ' GLY . 31.0 p -141.15 140.26 34.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.548 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.7 ptt-85 -111.64 127.93 55.9 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.205 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.5 tt -124.83 125.02 43.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.623 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 176.94 -132.74 2.1 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.512 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.03 169.18 32.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.982 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.0 tmm? -125.94 144.47 50.67 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 120.682 0.277 . . . . 0.0 110.639 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.63 129.65 64.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.402 ' CZ2' ' HB3' ' A' ' 73' ' ' ASP . 0.2 OUTLIER -126.13 135.31 51.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 -179.934 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.442 ' HA ' HG22 ' A' ' 139' ' ' THR . 55.3 mtt180 -130.68 148.37 52.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.886 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.0 162.65 33.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.07 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -147.57 128.22 14.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.996 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -108.15 53.96 0.67 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.84 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -100.16 87.15 3.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -134.86 -172.49 12.78 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.518 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -111.26 91.29 3.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.873 0.368 . . . . 0.0 110.92 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -157.38 76.17 0.82 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -77.85 177.62 8.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.07 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 32.3 m -126.98 -65.61 0.94 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.904 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 43.2 p -146.7 -70.16 0.25 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.95 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -165.3 48.22 0.28 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.428 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 14.7 m -125.03 133.93 68.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.846 0.355 . . . . 0.0 111.118 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -110.38 121.64 45.78 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.955 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.67 152.55 42.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.774 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -122.32 130.68 53.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.943 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -124.06 119.2 28.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.848 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -123.33 125.08 44.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 20.2 m-20 -121.23 117.84 28.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.944 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.442 HG22 ' HA ' ' A' ' 120' ' ' ARG . 6.9 p -139.6 126.81 21.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.938 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -117.08 113.03 2.63 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.459 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.2 p -131.3 123.53 53.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.791 0.329 . . . . 0.0 111.036 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 38.1 m -157.24 148.18 16.47 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.387 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.512 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.5 Cg_endo -78.0 147.96 24.4 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.766 2.311 . . . . 0.0 112.049 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.11 158.38 3.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.988 0.423 . . . . 0.0 111.52 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -145.88 119.93 9.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.418 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -120.97 163.95 17.47 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.904 0.383 . . . . 0.0 111.396 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.427 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -140.7 148.42 20.06 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.246 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.37 -171.99 31.3 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.705 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.8 m -131.98 167.05 27.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.669 0.271 . . . . 0.0 111.08 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -134.64 151.49 51.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.946 0.403 . . . . 0.0 111.291 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -133.06 117.61 17.77 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.582 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 158' ' ' ALA . . . -81.68 122.46 27.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.422 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 56.4 t -116.17 -63.24 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.957 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' THR . . . . . 0.516 HG22 ' H ' ' A' ' 155' ' ' ARG . 1.1 m -80.61 174.17 11.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.925 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ARG . . . . . 0.516 ' H ' HG22 ' A' ' 154' ' ' THR . 0.0 OUTLIER -60.04 -34.81 73.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.029 -179.885 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -147.36 38.75 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.108 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.4 mt -148.87 100.84 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.072 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.432 ' HB2' ' HA ' ' A' ' 152' ' ' ALA . . . -113.25 167.91 10.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.288 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.4 t -123.27 143.3 50.15 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.261 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.09 147.19 45.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.13 0.49 . . . . 0.0 111.783 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -113.95 126.11 54.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.806 179.043 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.7 138.51 45.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.385 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -134.19 156.18 48.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.664 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -124.57 46.73 2.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.929 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' TRP . . . . . 0.428 ' CE3' ' HA ' ' A' ' 165' ' ' TRP . 0.0 OUTLIER -81.79 86.07 6.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 11.1 p -70.55 144.21 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.029 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 70.2 m-20 -89.84 139.98 30.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.937 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -133.8 118.59 18.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.89 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 10.8 pt -82.4 -179.87 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.078 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -137.63 35.78 2.02 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.482 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -107.65 -40.01 5.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.887 0.375 . . . . 0.0 110.903 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -112.7 143.31 44.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -141.47 28.69 2.31 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.402 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.4 m -101.79 34.65 2.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.766 0.317 . . . . 0.0 110.899 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 13.7 m -133.13 169.05 22.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.153 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -63.91 -153.97 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.562 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 2.7 t -121.39 122.33 39.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.794 0.33 . . . . 0.0 110.838 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 6.6 mtt-85 -84.21 154.68 63.51 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.99 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.92 106.09 0.73 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.623 2.215 . . . . 0.0 112.238 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -99.63 35.97 1.88 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.912 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -80.44 -46.43 15.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.939 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 64.12 141.15 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.458 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' MET . . . . . 0.596 ' C ' HD12 ' A' ' 184' ' ' LEU . 2.9 tpp -162.0 142.91 10.62 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.816 0.341 . . . . 0.0 111.017 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.605 HD12 ' N ' ' A' ' 184' ' ' LEU . 4.2 mp -125.88 157.35 37.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.629 179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.22 155.46 37.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.01 0.433 . . . . 0.0 111.285 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -115.24 131.87 56.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.169 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 187' ' ' GLY . . . . . 0.42 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -146.15 168.06 27.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.367 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -127.59 141.01 47.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -144.57 174.98 10.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.043 0.449 . . . . 0.0 111.522 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -146.15 155.67 42.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.712 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 1.6 ptp180 -110.08 149.06 30.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -77.18 120.58 22.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.927 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -154.51 134.81 4.42 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.428 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.05 86.08 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.758 0.313 . . . . 0.0 110.787 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -98.88 -177.78 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.001 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -78.79 -64.18 1.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.981 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -98.01 169.58 9.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.13 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -143.99 77.1 14.86 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.048 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -80.73 3.91 7.36 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.657 2.238 . . . . 0.0 112.879 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 200' ' ' VAL . . . . . 0.575 ' O ' HG13 ' A' ' 200' ' ' VAL . 10.7 p -74.39 64.02 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.875 0.369 . . . . 0.0 111.093 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 7.8 m -100.58 125.96 54.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.161 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -70.6 111.39 9.43 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.159 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.94 61.94 1.85 Allowed 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.402 2.068 . . . . 0.0 112.329 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 204' ' ' ALA . . . . . 0.813 ' HB3' ' HD3' ' A' ' 205' ' ' PRO . . . -81.03 -62.0 0.37 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.189 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 205' ' ' PRO . . . . . 0.813 ' HD3' ' HB3' ' A' ' 204' ' ' ALA . 74.0 Cg_endo -75.33 157.51 41.36 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.499 2.132 . . . . 0.0 112.439 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 206' ' ' ALA . . . . . 0.76 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -87.14 -53.0 0.41 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.211 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.76 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 75.5 Cg_exo -50.69 120.37 6.41 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.6 2.2 . . . . 0.0 112.361 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -99.47 105.92 36.32 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.079 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.35 148.66 74.29 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.473 2.115 . . . . 0.0 112.284 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.192 -0.909 . . . . 0.0 110.891 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.297 0 CA-C-O 120.815 0.34 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ARG . . . . . 0.595 ' C ' HD12 ' A' ' 3' ' ' ILE . 0.4 OUTLIER -123.58 28.84 6.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.945 179.992 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.595 HD12 ' C ' ' A' ' 2' ' ' ARG . 3.6 mp -145.78 109.72 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.183 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -168.55 142.57 3.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.901 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.7 mmtt -92.21 -69.29 0.75 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.968 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -90.36 156.7 18.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.124 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.9 mt -123.3 -43.79 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.004 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -140.1 117.39 11.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.805 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.6 m -84.19 -31.14 7.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.092 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.594 HD13 ' N ' ' A' ' 11' ' ' ASN . 0.2 OUTLIER -71.41 135.54 47.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.848 -179.977 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.594 ' N ' HD13 ' A' ' 10' ' ' LEU . 19.9 m-20 -60.35 113.67 2.52 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -118.6 -50.01 2.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.051 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.67 151.07 93.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.096 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.89 -175.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.582 2.188 . . . . 0.0 112.369 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -88.57 174.23 8.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.904 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -70.01 -62.48 1.37 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.871 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -68.58 165.75 18.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.887 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.7 t -161.93 151.97 16.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.92 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -118.29 130.74 56.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.857 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -126.06 135.88 52.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.799 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.23 153.85 44.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.17 -165.28 37.91 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.42 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -160.54 151.51 22.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.532 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -133.05 157.91 44.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 0.0 111.034 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -127.46 146.19 50.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.7 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -147.85 -172.06 17.5 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.546 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 5.0 p-90 -132.93 131.13 40.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.848 0.356 . . . . 0.0 110.94 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 10.6 t -159.97 121.24 3.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -159.3 128.19 5.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.936 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -67.3 87.7 0.18 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.905 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -130.35 167.21 18.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.853 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -126.71 -176.01 3.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.841 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 51.1 m -110.97 -68.84 0.9 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.956 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.79 104.59 0.72 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.488 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -79.82 83.1 5.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.927 0.394 . . . . 0.0 110.897 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -112.06 -34.29 6.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.89 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -134.6 108.6 0.72 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.46 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -76.27 -31.15 58.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.864 0.364 . . . . 0.0 110.871 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -70.82 -173.73 15.14 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.536 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.18 149.06 23.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.834 0.35 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -94.53 149.65 21.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.935 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -99.57 101.33 12.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -138.67 137.39 36.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.7 t30 -143.51 31.59 1.33 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.954 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -105.23 -148.48 17.52 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.529 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.57 160.67 48.36 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.539 2.159 . . . . 0.0 112.245 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 63.1 m -131.75 84.99 2.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -73.32 146.32 45.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.927 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.4 p30 -105.55 158.94 16.33 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.953 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -80.64 -178.21 6.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.87 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -97.24 129.28 44.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.934 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.495 HD22 ' N ' ' A' ' 52' ' ' LEU . 3.4 mm? -98.81 172.84 7.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.81 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.66 132.29 10.64 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.488 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.14 52.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.69 0.281 . . . . 0.0 110.948 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.5 135.46 7.44 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.737 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.487 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -103.75 135.64 44.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.781 0.324 . . . . 0.0 110.882 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -119.41 133.69 55.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.206 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -157.27 125.55 1.59 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.389 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -146.18 -178.65 21.78 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.69 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 14.3 p90 -153.35 160.81 42.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.843 0.354 . . . . 0.0 110.927 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -102.38 137.09 41.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.798 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.604 ' O ' HG12 ' A' ' 62' ' ' VAL . 16.3 t -129.21 21.02 2.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.232 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 175.73 144.51 0.23 Allowed Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.603 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -69.31 63.74 1.53 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.429 2.086 . . . . 0.0 112.119 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.444 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.2 OUTLIER -160.98 -43.29 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.084 -179.872 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.444 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.4 OUTLIER -171.62 164.02 6.68 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.093 -179.79 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.23 169.8 21.05 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.439 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.6 m-85 -98.75 138.74 35.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.63 0.253 . . . . 0.0 110.817 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -125.95 129.55 49.49 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.952 0.406 . . . . 0.0 110.965 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.11 129.31 55.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.424 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.27 17.43 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.362 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.487 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 81.5 m-85 -125.61 114.85 19.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.748 0.309 . . . . 0.0 110.676 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.448 ' HB2' ' CZ2' ' A' ' 119' ' ' TRP . 0.3 OUTLIER -87.15 118.28 26.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.758 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -132.63 137.43 47.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.968 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.562 HD13 ' HA ' ' A' ' 79' ' ' ALA . 0.2 OUTLIER -106.14 -31.62 8.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 179.988 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 129.13 -100.65 0.51 Allowed Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.472 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 21.6 mmt180 -120.6 -55.35 2.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.763 0.316 . . . . 0.0 110.892 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.1 ttm -114.91 128.8 56.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.562 ' HA ' HD13 ' A' ' 75' ' ' LEU . . . -59.31 -69.02 0.22 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.018 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 80' ' ' TYR . 1.5 p90 -144.48 -55.52 0.34 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.912 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.6 mttp -166.08 170.78 13.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.866 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 176.92 167.94 36.14 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.473 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -68.89 163.81 23.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.75 0.31 . . . . 0.0 110.81 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 84' ' ' VAL . 11.6 p -94.58 45.63 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.999 0.428 . . . . 0.0 111.067 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -102.84 -176.91 3.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.985 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 -79.42 122.9 26.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.943 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 160.0 158.2 9.06 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.645 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -129.37 -163.53 1.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.674 0.273 . . . . 0.0 110.966 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -109.54 -54.48 2.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.828 0.347 . . . . 0.0 110.825 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 46.08 40.76 7.56 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.313 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.28 163.87 13.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.41 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -168.68 127.7 1.12 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.374 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.439 ' HA3' ' HB2' ' A' ' 73' ' ' ASP . . . -83.92 133.73 12.12 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.017 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.85 117.98 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.8 0.333 . . . . 0.0 110.208 179.355 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 -108.98 138.11 45.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.109 0.481 . . . . 0.0 111.728 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.441 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.7 tt -127.6 107.24 9.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.696 179.209 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.651 HG22 ' HA3' ' A' ' 115' ' ' GLY . 27.0 p -144.68 162.05 37.65 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 121.158 0.504 . . . . 0.0 111.796 -178.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -92.92 126.5 38.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.006 178.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -104.87 130.98 52.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.029 0.442 . . . . 0.0 111.845 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.51 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.8 pp -136.29 123.78 22.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 179.036 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.21 177.46 34.06 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.507 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.439 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.19 153.95 9.4 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.733 0.302 . . . . 0.0 111.344 -179.925 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.439 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 38.1 Cg_exo -60.6 172.04 3.04 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.76 2.306 . . . . 0.0 112.05 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.653 HG23 HG23 ' A' ' 105' ' ' THR . 0.9 OUTLIER -125.26 -38.36 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.477 -179.934 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.653 HG23 HG23 ' A' ' 104' ' ' ILE . 56.6 p -140.34 -55.96 0.53 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -159.3 -63.28 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.206 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.813 ' C ' HD23 ' A' ' 108' ' ' LEU . 1.0 OUTLIER -113.22 29.8 7.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.219 -179.784 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.813 HD23 ' C ' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -138.21 121.33 16.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.031 179.73 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -135.03 160.09 39.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.722 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.914 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.93 144.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.209 179.359 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -142.26 141.82 32.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.008 0.432 . . . . 0.0 111.527 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.443 HG23 ' HG ' ' A' ' 100' ' ' LEU . 9.6 t -137.15 126.91 25.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.199 179.347 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.403 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 0.0 OUTLIER -114.41 131.6 56.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.913 0.387 . . . . 0.0 111.511 -179.358 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.0 tt -128.06 122.93 33.35 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.451 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.651 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -175.82 -135.45 2.12 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.622 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.509 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.12 161.7 26.4 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.899 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.47 138.63 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.716 0.293 . . . . 0.0 110.705 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -129.57 134.68 63.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.448 ' CZ2' ' HB2' ' A' ' 73' ' ' ASP . 0.9 OUTLIER -138.54 131.97 30.41 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.975 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 2.0 tpp180 -104.4 134.02 48.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.872 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -108.69 134.78 50.95 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.159 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -113.91 146.66 39.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -137.75 134.08 34.86 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 34.1 mttt -137.09 150.63 48.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 179.99 174.9 46.26 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.499 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -113.03 78.57 1.14 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.856 0.36 . . . . 0.0 110.867 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -172.75 106.1 0.16 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -141.36 170.59 15.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.074 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.3 t -99.85 -65.46 0.96 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.904 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.4 t -173.56 -50.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.92 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -105.58 -80.28 1.35 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.433 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 132' ' ' VAL . 32.9 m -113.77 120.69 64.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.784 0.326 . . . . 0.0 111.141 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.6 m -65.39 169.79 5.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.009 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.24 -31.19 62.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 56.1 m -65.39 145.69 55.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.866 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -122.36 166.19 15.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.935 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -105.69 127.75 53.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -118.28 151.73 37.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.902 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 42.9 p -125.68 123.34 38.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.871 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -84.98 108.22 3.15 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.418 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.8 p -136.42 128.35 44.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.621 0.248 . . . . 0.0 110.993 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -157.1 144.72 13.92 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.337 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.509 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 90.9 Cg_endo -80.73 139.99 12.76 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.752 2.302 . . . . 0.0 112.115 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 143' ' ' PRO . 30.3 m -157.04 162.84 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 121.002 0.43 . . . . 0.0 111.504 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.9 p90 -142.35 121.12 12.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.45 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -105.74 141.16 37.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.976 0.417 . . . . 0.0 111.402 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.59 135.03 7.88 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.994 179.542 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -159.68 -171.99 26.26 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.895 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.914 HG12 HG22 ' A' ' 110' ' ' ILE . 4.4 m -131.12 150.98 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.663 0.268 . . . . 0.0 111.138 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -122.32 133.99 54.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.169 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 9.4 m95 -121.76 122.17 38.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.649 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.621 ' HB3' ' HB3' ' A' ' 107' ' ' ASP . . . -78.77 137.01 37.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.406 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 72.8 t -101.71 -30.08 3.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.682 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.66 -70.62 0.69 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.792 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 177.75 -36.23 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.958 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -103.89 -26.96 12.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.326 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 5.2 mt -116.73 122.83 70.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.809 0.338 . . . . 0.0 111.226 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -132.5 161.85 32.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.375 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 9.7 t -117.72 143.98 45.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.965 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -137.0 150.87 48.39 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.204 0.526 . . . . 0.0 112.158 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.7 tt -114.39 123.87 50.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.585 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -107.83 139.54 42.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.986 0.422 . . . . 0.0 111.557 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.429 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 36.3 p90 -134.14 160.15 38.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.723 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -58.1 -49.99 75.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.058 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 21.1 t-105 -179.59 -39.27 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.696 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 16.6 m -137.07 167.83 22.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.153 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -109.77 -37.67 5.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.832 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -100.06 140.12 34.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.824 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 169' ' ' ILE . . . . . 0.466 HG22 ' N ' ' A' ' 170' ' ' GLY . 31.2 mt -138.84 157.69 29.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.094 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 170' ' ' GLY . . . . . 0.466 ' N ' HG22 ' A' ' 169' ' ' ILE . . . -69.36 130.56 23.89 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.776 -0.725 . . . . 0.0 112.582 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -112.81 -54.89 2.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.879 0.371 . . . . 0.0 110.905 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.13 80.29 0.96 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.096 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -172.06 -71.31 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.505 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.0 p -132.76 108.39 8.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.929 0.395 . . . . 0.0 110.981 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 10.7 p -159.6 146.96 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.0 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -168.11 -70.8 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.705 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 17.3 p -112.1 -18.77 12.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.599 0.238 . . . . 0.0 111.471 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 48.1 ttt180 -108.49 100.83 40.07 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.666 -0.243 . . . . 0.0 111.113 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -63.4 -158.82 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.568 2.179 . . . . 0.0 112.103 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -111.13 97.55 6.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.88 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -95.86 149.24 21.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.929 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -145.27 160.74 28.11 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.497 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' MET . . . . . 0.434 ' C ' HD12 ' A' ' 184' ' ' LEU . 50.2 mtt -108.33 96.92 6.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.904 0.383 . . . . 0.0 111.011 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.434 HD12 ' C ' ' A' ' 183' ' ' MET . 6.3 mp -132.94 126.4 31.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.65 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 11.0 p -142.53 158.91 43.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.73 134.64 54.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -149.29 172.62 29.31 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.004 -1.093 . . . . 0.0 113.404 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.65 141.37 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.677 0.275 . . . . 0.0 110.388 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 32.8 p -139.55 171.48 14.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.42 . . . . 0.0 111.268 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -148.03 157.51 43.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.776 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.87 147.71 22.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.95 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -137.3 168.96 18.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.952 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -147.1 174.56 26.86 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.606 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -103.36 -177.45 3.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.816 0.341 . . . . 0.0 110.875 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -73.79 134.88 43.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.846 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -72.05 -31.3 66.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.943 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -97.4 47.45 1.03 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.116 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -119.62 83.82 28.9 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.081 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.13 149.69 20.97 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.559 2.173 . . . . 0.0 112.287 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 200' ' ' VAL . . . . . 0.457 HG13 HG22 ' A' ' 201' ' ' VAL . 12.4 p -116.15 -38.01 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.147 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 201' ' ' VAL . . . . . 0.571 ' O ' HG23 ' A' ' 201' ' ' VAL . 16.6 m -132.84 94.05 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.218 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 202' ' ' ALA . . . . . 0.755 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -89.91 -53.39 0.32 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.157 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.755 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 50.8 Cg_exo -52.87 176.63 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.507 2.138 . . . . 0.0 112.307 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -100.78 123.83 44.24 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.068 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.01 122.06 7.8 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.405 2.07 . . . . 0.0 112.408 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 206' ' ' ALA . . . . . 0.814 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -77.2 -61.42 0.68 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.108 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.814 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 74.5 Cg_endo -75.16 65.44 6.2 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.495 2.13 . . . . 0.0 112.355 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -140.4 147.82 51.21 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.131 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.67 -177.95 2.78 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.513 2.142 . . . . 0.0 112.338 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 . . . . . 0 C--O 1.248 0.975 0 CA-C-O 118.243 -0.884 . . . . 0.0 110.965 179.927 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 120.846 0.355 . . . . 0.0 111.052 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.2 ptp85 -159.79 172.92 16.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.823 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.525 HD11 ' CE1' ' A' ' 8' ' ' PHE . 6.6 pt -138.45 163.43 28.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.086 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.9 tmm? -114.98 41.89 2.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.917 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.53 157.95 25.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -90.74 -49.41 6.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.148 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -87.67 135.26 25.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.081 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.525 ' CE1' HD11 ' A' ' 3' ' ' ILE . 1.8 m-85 -99.03 137.29 37.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.921 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 9' ' ' VAL . 27.5 m -74.95 111.07 10.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -118.49 61.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.847 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -89.01 53.16 2.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.975 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -153.6 173.25 16.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.152 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.33 87.95 36.79 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.053 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_exo -66.25 65.07 0.48 Allowed 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.774 2.316 . . . . 0.0 112.274 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -110.99 -27.87 8.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.025 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -85.97 54.85 3.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.966 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -108.05 -177.8 3.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.882 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.7 p -122.9 135.46 54.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.885 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -121.94 145.39 48.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.405 ' CE2' ' HG3' ' A' ' 191' ' ' ARG . 89.6 m-85 -142.16 135.98 29.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.569 ' HB3' ' CE1' ' A' ' 190' ' ' TYR . . . -144.41 140.02 28.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.08 -161.11 26.09 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.384 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.85 147.27 17.1 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.56 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.72 153.81 35.07 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.923 0.392 . . . . 0.0 110.906 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.462 HD12 ' O ' ' A' ' 53' ' ' GLY . 55.7 tp -136.7 138.61 41.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.649 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.72 -161.66 24.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.604 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -87.03 140.26 29.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.812 0.339 . . . . 0.0 110.868 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.6 p -91.84 170.88 9.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 -155.71 127.39 7.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.958 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.419 ' HH ' ' HZ3' ' A' ' 119' ' ' TRP . 0.2 OUTLIER -109.83 -172.92 2.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.813 -179.941 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 5.0 p-80 -106.35 154.24 21.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.842 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -129.43 144.15 51.13 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.858 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 68.7 p -103.49 -66.61 0.93 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.845 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 103.03 76.09 1.12 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.531 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -107.36 -62.62 1.4 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.946 0.403 . . . . 0.0 110.879 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -129.58 75.58 1.66 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.852 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.56 158.98 23.99 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.586 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -120.73 166.13 14.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.859 0.361 . . . . 0.0 110.835 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -135.78 48.01 0.95 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.486 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -122.23 166.93 13.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.772 0.32 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -85.63 89.23 7.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.951 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 26.6 p30 -103.18 174.0 6.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -88.11 120.62 29.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.949 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 7.1 t30 -130.89 163.39 27.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.903 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.74 -102.65 1.37 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.529 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.55 159.46 6.43 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.474 2.116 . . . . 0.0 112.338 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.4 p -135.27 105.71 6.4 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.41 90.68 2.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 20.5 m-20 -110.48 -31.01 7.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -78.01 137.05 38.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 15.0 mt-30 -132.3 144.51 50.63 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.439 HD13 ' HA ' ' A' ' 52' ' ' LEU . 3.9 mm? -110.91 139.57 46.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.077 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.462 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -140.88 132.78 5.55 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.33 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -117.78 142.86 46.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.806 0.336 . . . . 0.0 111.137 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.419 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -143.17 134.73 6.07 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.67 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.641 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.9 140.28 30.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.304 . . . . 0.0 110.837 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.41 ' CD1' ' HG2' ' A' ' 69' ' ' GLU . 0.2 OUTLIER -126.45 134.31 51.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.935 0.398 . . . . 0.0 111.126 -179.777 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -161.62 126.42 1.58 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.254 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -158.55 -166.2 17.24 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.653 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -151.21 146.56 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.879 0.371 . . . . 0.0 110.989 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -110.2 129.3 55.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.756 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 36.4 t -118.27 -39.32 2.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.078 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -84.53 149.26 54.15 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.848 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_exo -51.54 -26.72 22.96 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.555 2.17 . . . . 0.0 112.347 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.465 ' CE2' HD13 ' A' ' 100' ' ' LEU . 0.9 OUTLIER -148.81 43.23 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.921 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -159.12 115.79 2.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.932 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 158.38 23.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.483 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -105.28 129.03 53.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.632 0.253 . . . . 0.0 110.62 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.41 ' HG2' ' CD1' ' A' ' 57' ' ' PHE . 5.0 tt0 -122.54 128.46 50.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.86 0.362 . . . . 0.0 111.149 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.3 ttt -108.96 127.0 53.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.538 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 163.92 12.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.742 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.641 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 95.5 m-85 -138.18 114.85 10.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.24 120.27 25.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.023 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -136.13 123.89 22.51 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.832 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -118.27 -36.37 3.58 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.073 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 78.1 -162.05 49.58 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.393 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.5 tpt180 -165.6 149.03 7.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.909 0.385 . . . . 0.0 110.95 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 30.6 ttm -100.65 33.43 2.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.862 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -91.4 159.52 15.94 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.175 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -115.71 -174.58 2.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.774 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.43 28.08 2.71 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.042 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -110.56 26.25 13.49 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.394 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 52.2 p -158.07 -176.2 5.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.735 0.302 . . . . 0.0 110.824 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.6 m -138.75 120.89 17.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 120.953 0.406 . . . . 0.0 111.125 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -137.41 -81.52 0.36 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -143.11 26.11 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.05 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 87.06 -138.11 15.21 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.48 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -122.43 -73.39 0.65 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.896 0.379 . . . . 0.0 111.159 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -80.68 77.55 7.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -113.23 -30.54 6.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.0 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -96.42 129.39 43.79 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.974 0.416 . . . . 0.0 111.366 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -168.77 124.86 0.95 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.302 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -115.1 141.01 16.76 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.203 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.11 128.11 67.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.175 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 145.29 35.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.135 0.493 . . . . 0.0 111.855 -178.791 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -140.08 116.14 10.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.742 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -153.01 165.43 35.6 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.211 0.529 . . . . 0.0 111.809 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -99.19 133.42 43.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.358 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 9.5 pttt -112.79 132.33 55.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.515 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.542 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.9 pp -136.08 122.33 20.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.534 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.31 -176.73 37.14 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.663 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.424 ' HB2' ' HD2' ' A' ' 103' ' ' PRO . 30.3 p90 -166.18 157.61 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 120.657 0.265 . . . . 0.0 111.009 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.424 ' HD2' ' HB2' ' A' ' 102' ' ' TYR . 19.9 Cg_endo -60.4 167.48 7.87 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.599 2.2 . . . . 0.0 111.813 179.623 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.666 HG22 ' O ' ' A' ' 108' ' ' LEU . 0.8 OUTLIER -128.72 -5.36 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.568 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 24.3 m -164.04 -64.22 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.832 0.348 . . . . 0.0 110.878 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -168.11 -42.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.979 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.485 ' C ' HD23 ' A' ' 108' ' ' LEU . 0.6 OUTLIER -127.61 27.12 5.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.072 179.894 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.666 ' O ' HG22 ' A' ' 104' ' ' ILE . 0.0 OUTLIER -142.63 117.88 10.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.936 179.875 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -127.43 155.91 42.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.983 0.42 . . . . 0.0 111.925 -178.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.055 HG22 HG12 ' A' ' 149' ' ' VAL . 1.5 pp -125.18 136.35 61.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.369 179.374 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 37.8 p90 -150.14 159.35 44.49 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.106 0.479 . . . . 0.0 111.494 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.407 HG22 ' HA3' ' A' ' 147' ' ' GLY . 36.8 p -130.86 149.22 52.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.479 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.1 ppt_? -123.75 127.85 48.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.87 0.367 . . . . 0.0 111.394 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -127.89 122.74 33.29 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.205 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -179.47 -133.18 1.91 Allowed Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.735 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.1 169.12 33.64 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.809 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -126.02 143.7 51.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.823 0.344 . . . . 0.0 110.906 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.3 t -124.89 125.23 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.839 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.419 ' HZ3' ' HH ' ' A' ' 30' ' ' TYR . 19.7 m0 -102.76 157.16 17.15 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.904 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.401 ' NH1' ' HB3' ' A' ' 120' ' ' ARG . 6.6 mtm105 -146.73 149.28 33.11 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.028 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -119.43 148.02 43.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.114 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -117.88 139.26 51.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.924 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.18 131.97 56.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.817 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -175.24 -40.59 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.929 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -56.72 -100.21 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.569 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -118.96 94.89 4.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.723 0.296 . . . . 0.0 110.926 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -176.65 165.71 2.59 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.863 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -59.79 96.91 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.03 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.7 m -153.18 99.92 2.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.876 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 9.1 t -119.25 -44.01 2.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.912 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -76.91 126.86 8.15 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.457 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 27.8 m -98.42 31.09 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.823 0.344 . . . . 0.0 111.173 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.6 t -124.91 -49.83 1.72 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.931 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.07 128.15 42.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.969 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.1 m -152.47 97.4 2.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.939 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -70.19 118.81 13.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.834 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 22.7 p80 -113.34 179.95 3.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.881 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -87.97 118.12 27.3 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.907 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 4.2 t -106.35 135.59 47.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.86 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -112.95 141.98 17.16 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.457 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.5 p -146.07 129.97 10.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.749 0.309 . . . . 0.0 111.286 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 54.4 p -157.02 130.6 4.69 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.489 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.9 Cg_endo -78.23 146.94 22.84 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.548 2.165 . . . . 0.0 112.152 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.6 m -156.09 151.11 9.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.872 0.368 . . . . 0.0 111.442 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.2 p90 -149.08 124.27 10.15 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.501 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.543 ' HB2' ' HG3' ' A' ' 164' ' ' GLN . . . -134.91 167.04 21.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.979 0.418 . . . . 0.0 111.447 -179.611 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.407 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -133.76 146.14 18.12 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.007 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -155.39 -179.83 30.82 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.901 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 1.055 HG12 HG22 ' A' ' 110' ' ' ILE . 11.4 m -128.42 153.31 37.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.828 0.347 . . . . 0.0 110.994 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -122.12 139.74 53.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.203 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -128.48 118.48 23.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.804 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.413 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -82.24 137.01 34.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.23 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 84.6 t -107.24 -70.01 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.3 -79.49 0.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.735 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.66 -40.98 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.091 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -108.39 -23.36 11.92 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.439 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.3 mt -104.5 128.82 57.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.801 0.334 . . . . 0.0 111.274 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.04 155.67 46.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.383 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 6.4 t -102.5 145.73 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.299 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.24 139.09 40.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.068 0.461 . . . . 0.0 111.823 -179.481 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -115.74 130.48 56.87 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.754 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.25 142.58 39.91 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.047 0.451 . . . . 0.0 111.626 -179.256 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.489 ' CZ ' HD21 ' A' ' 184' ' ' LEU . 0.1 OUTLIER -134.14 130.68 37.68 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.372 179.582 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 164' ' ' GLN . . . . . 0.543 ' HG3' ' HB2' ' A' ' 146' ' ' ALA . 5.6 mp0 -98.21 -79.85 0.46 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.12 -179.771 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -92.3 124.39 36.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.927 0.394 . . . . 0.0 111.009 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 31.3 m -80.76 142.73 13.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.093 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -116.5 142.68 46.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.927 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -122.99 138.69 54.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.954 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 20.9 pt -70.04 -28.47 36.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.192 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -58.5 -54.79 34.88 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.492 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -129.48 102.09 6.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.84 0.352 . . . . 0.0 110.847 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.86 -37.81 67.26 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -162.85 74.79 0.18 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.531 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.0 t -99.75 31.88 3.07 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.852 0.358 . . . . 0.0 110.905 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 3.1 m -140.67 179.48 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.108 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -105.73 49.91 0.86 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.561 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -104.32 150.82 24.13 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.845 0.355 . . . . 0.0 110.829 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 178' ' ' ARG . . . . . 0.42 ' HB2' ' HD3' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -82.32 -52.05 0.73 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.957 -179.984 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 179' ' ' PRO . . . . . 0.42 ' HD3' ' HB2' ' A' ' 178' ' ' ARG . 71.2 Cg_exo -50.88 119.31 5.11 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.502 2.135 . . . . 0.0 112.209 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.48 144.52 37.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.018 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 60.97 173.63 0.1 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -103.64 -131.45 7.24 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.429 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 20.7 tpp -162.0 128.52 3.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.841 0.353 . . . . 0.0 110.973 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.528 HD12 ' N ' ' A' ' 184' ' ' LEU . 0.7 OUTLIER -129.54 129.18 44.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.696 179.821 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.9 m -125.43 151.01 46.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.104 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.47 128.44 52.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.414 179.712 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -145.7 167.24 27.67 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.997 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.7 m -129.56 137.34 57.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.659 0.266 . . . . 0.0 110.588 179.533 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.7 p -139.88 175.06 9.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.953 0.406 . . . . 0.0 111.318 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 190' ' ' TYR . . . . . 0.569 ' CE1' ' HB3' ' A' ' 21' ' ' ALA . 3.8 p90 -141.66 159.92 41.23 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.812 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.405 ' HG3' ' CE2' ' A' ' 20' ' ' TYR . 0.4 OUTLIER -103.86 155.48 18.59 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.851 179.967 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -82.91 134.94 35.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.886 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -112.6 -167.65 17.37 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.549 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.98 142.48 27.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.762 0.315 . . . . 0.0 110.925 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -86.38 -43.99 12.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -88.53 131.02 35.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.913 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -111.32 145.96 37.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.096 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -168.82 75.61 0.77 Allowed Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.079 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.29 93.39 0.57 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.532 2.155 . . . . 0.0 112.337 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 200' ' ' VAL . . . . . 0.512 ' O ' HG12 ' A' ' 200' ' ' VAL . 21.6 t -114.97 48.69 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 5.7 m -119.21 135.47 59.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.177 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 202' ' ' ALA . . . . . 0.729 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -67.58 -61.38 4.5 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.729 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 49.5 Cg_endo -69.28 124.13 10.97 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.564 2.176 . . . . 0.0 112.24 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -77.06 148.27 78.19 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.027 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.54 150.76 51.98 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.562 2.175 . . . . 0.0 112.336 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -88.92 158.59 47.15 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.011 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -51.92 -61.46 0.51 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.534 2.156 . . . . 0.0 112.352 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.722 ' HB1' ' HD2' ' A' ' 209' ' ' PRO . . . -109.29 166.61 10.47 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 209' ' ' PRO . . . . . 0.722 ' HD2' ' HB1' ' A' ' 208' ' ' ALA . 53.0 Cg_endo -69.48 169.08 19.39 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.587 2.191 . . . . 0.0 112.281 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.815 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.34 0 CA-C-O 120.853 0.359 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ARG . . . . . 0.679 ' HG3' HG22 ' A' ' 3' ' ' ILE . 12.4 ptm180 -103.07 -33.32 9.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.993 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.679 HG22 ' HG3' ' A' ' 2' ' ' ARG . 5.6 tt -169.51 138.44 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.06 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.9 ptp -153.73 130.67 10.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -130.48 -46.38 1.08 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.739 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -66.64 101.98 0.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.098 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 mt -78.17 -58.85 3.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.077 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -157.64 156.47 31.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.901 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 9' ' ' VAL . 31.3 m -64.77 118.61 7.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.079 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.6 tp -161.99 -67.75 0.05 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.878 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -86.15 122.25 29.89 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.91 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -78.12 -57.24 3.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.089 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -114.87 145.89 34.94 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.087 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -54.97 -33.22 81.98 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.53 2.153 . . . . 0.0 112.227 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.4 55.49 1.73 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.957 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -79.23 -30.04 43.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.712 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 70.2 m-80 -66.0 -174.69 0.26 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.94 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.6 p -108.88 156.2 19.95 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.775 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.423 ' CZ2' ' HB2' ' A' ' 192' ' ' PHE . 70.2 p-90 -149.6 132.3 15.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.987 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.5 m-85 -114.38 141.15 48.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.55 141.64 28.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.884 0.373 . . . . 0.0 111.278 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.21 -166.55 30.21 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.879 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -134.3 141.76 13.12 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.466 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.515 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 6.3 ptpt -128.84 149.72 50.63 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.078 0.466 . . . . 0.0 111.412 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.79 HD12 ' O ' ' A' ' 53' ' ' GLY . 47.4 tp -126.46 150.11 48.89 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.511 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.567 ' H ' HD12 ' A' ' 25' ' ' LEU . . . -172.8 -160.66 21.79 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.342 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -78.92 147.41 33.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 0.0 110.917 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.6 t -102.64 -61.54 1.38 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.931 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -147.34 125.87 12.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -106.02 33.95 3.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.936 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -128.04 153.28 46.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -82.75 79.44 9.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.1 m -67.78 146.82 53.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 102.17 -144.58 16.3 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.464 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -72.31 158.4 35.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.852 0.358 . . . . 0.0 110.886 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -128.84 -45.84 1.28 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.859 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -109.27 -35.04 2.38 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.561 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 25.2 m120 -90.6 112.34 24.0 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 176.98 155.81 14.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.499 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -120.62 159.08 26.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.834 0.35 . . . . 0.0 110.899 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -157.35 100.99 1.85 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.923 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -95.98 -57.15 2.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.936 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -136.41 96.88 3.45 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.91 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -118.87 142.97 47.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.917 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.439 ' O ' HG23 ' A' ' 47' ' ' THR . . . -135.95 75.83 0.39 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.569 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -52.33 102.71 0.07 OUTLIER 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.645 2.23 . . . . 0.0 112.288 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.439 HG23 ' O ' ' A' ' 45' ' ' GLY . 74.5 p -94.72 -41.36 9.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.957 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 43.0 mtt180 -137.13 83.31 1.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -97.86 37.48 1.4 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.971 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -111.22 83.01 1.69 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.851 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 56.9 mt-30 -61.85 111.47 1.9 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.865 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 3.6 pp -126.73 142.4 51.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.79 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -125.4 143.88 14.78 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.413 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -118.05 170.02 9.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.688 0.28 . . . . 0.0 110.932 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.58 157.34 27.67 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.783 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.533 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -108.97 140.58 42.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 110.876 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.403 ' HE2' ' HZ2' ' A' ' 24' ' ' LYS . 3.0 m-85 -126.48 128.76 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.031 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.65 124.99 2.2 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.254 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.13 172.26 23.0 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.763 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -140.11 160.49 39.83 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.827 0.346 . . . . 0.0 110.786 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -113.35 130.38 56.29 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.908 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 42.0 t -131.87 -45.43 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.07 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 68.4 m-80 -86.34 156.1 56.94 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.789 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_endo -61.55 -24.37 77.96 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.596 2.197 . . . . 0.0 112.283 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -150.15 45.85 0.9 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.706 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -162.81 115.76 1.63 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.831 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -121.23 161.56 15.25 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.584 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -114.08 134.7 54.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.779 0.323 . . . . 0.0 110.696 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.401 ' OE2' ' CD1' ' A' ' 57' ' ' PHE . 2.0 tt0 -129.95 129.93 44.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.918 0.389 . . . . 0.0 111.085 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 ttm -108.01 135.43 49.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.422 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 158.52 14.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.512 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.533 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 19.9 m-85 -138.0 115.02 10.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.646 0.26 . . . . 0.0 110.657 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.417 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.2 t0 -87.97 121.09 29.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.88 0.372 . . . . 0.0 110.924 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 21.3 t-105 -136.76 132.75 35.21 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.977 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.45 ' C ' HD23 ' A' ' 75' ' ' LEU . 6.0 tt -83.5 -66.0 0.94 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.939 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 155.76 -138.9 6.26 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.497 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.5 ttm105 -84.3 -52.19 6.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.8 0.333 . . . . 0.0 110.879 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.17 90.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.815 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -127.21 -43.39 1.64 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.18 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 62.5 m-85 -57.05 95.24 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -110.99 157.01 20.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.862 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.83 107.04 0.25 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.551 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.4 t -146.05 -47.41 0.2 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.818 0.342 . . . . 0.0 110.886 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.5 t -96.85 -45.75 12.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.125 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 6.6 t0 -168.39 138.08 2.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.895 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -81.65 98.67 8.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.914 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -140.55 46.55 0.92 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.451 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -140.89 138.37 33.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.869 0.366 . . . . 0.0 111.158 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 39.9 m-85 -143.85 -68.03 0.33 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.9 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.11 132.14 55.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.774 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -151.67 154.37 36.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.212 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 -175.05 130.3 0.3 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.534 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.417 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -85.26 135.76 13.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.926 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.42 120.33 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 179.431 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -108.95 148.51 30.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.154 0.502 . . . . 0.0 111.744 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 tt -138.13 114.04 9.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.703 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.423 HG22 ' HA3' ' A' ' 115' ' ' GLY . 8.6 p -149.72 164.45 35.22 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 121.054 0.455 . . . . 0.0 111.764 -178.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -97.52 132.28 43.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.314 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.86 132.23 53.66 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.036 0.446 . . . . 0.0 111.643 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.569 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.4 pp -135.93 124.07 23.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.431 179.322 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.96 -169.86 30.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.711 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.456 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 2.9 t80 -160.62 145.17 10.59 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.69 0.281 . . . . 0.0 111.12 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.456 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 95.3 Cg_endo -86.48 172.09 7.1 Favored 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.884 2.389 . . . . 0.0 112.479 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.423 ' O ' HG22 ' A' ' 104' ' ' ILE . 17.7 mt -142.28 62.67 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 121.032 0.444 . . . . 0.0 111.262 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 8.1 p 56.71 172.99 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.511 179.625 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.6 t70 60.77 -87.13 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.043 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.867 ' HB3' ' HB3' ' A' ' 152' ' ' ALA . 0.3 OUTLIER -179.87 36.79 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.075 0.464 . . . . 0.0 110.739 -179.991 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.61 HD22 ' CE2' ' A' ' 151' ' ' TRP . 0.0 OUTLIER -121.67 115.77 23.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.149 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -131.38 155.11 47.83 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.031 0.443 . . . . 0.0 111.893 -179.19 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.956 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -119.91 146.82 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.271 179.351 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.441 ' CE2' ' HB2' ' A' ' 150' ' ' GLU . 4.4 p90 -162.44 164.01 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.103 0.478 . . . . 0.0 111.763 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.409 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 17.4 m -140.54 139.77 35.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.497 179.737 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.401 ' HB3' ' NH1' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -114.96 127.99 56.01 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.152 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -127.79 122.91 33.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.44 179.803 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.423 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.89 -134.54 2.15 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.536 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -149.42 163.06 29.19 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.751 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.9 ppp? -117.64 145.03 44.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 110.917 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.7 t -127.05 141.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.861 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.5 t90 -131.65 148.88 52.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.003 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 20.1 ttt180 -118.54 152.23 36.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -163.19 149.19 11.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.001 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -107.37 131.1 54.62 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.964 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -98.45 101.09 12.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.855 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.71 169.95 15.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.831 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -129.22 -174.16 13.63 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.455 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -70.08 -31.77 69.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.812 0.339 . . . . 0.0 110.894 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -85.3 158.85 20.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -115.34 76.31 0.99 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.135 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.1 m -84.14 120.63 26.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.922 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 23.4 p -143.05 123.69 14.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.865 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -135.49 -96.67 0.51 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.519 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 16.8 m -142.87 30.82 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 111.19 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 18.7 t -120.47 166.8 13.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.905 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.03 155.48 17.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.939 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.93 165.95 23.46 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.809 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -87.65 143.2 27.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.841 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -116.68 112.73 21.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.898 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -116.0 132.52 56.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.958 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 69.7 p -136.71 129.78 31.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -89.53 135.23 12.84 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.433 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p -132.65 136.12 56.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.714 0.293 . . . . 0.0 111.015 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.02 117.33 2.84 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.347 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.489 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 6.3 Cg_exo -73.65 137.62 25.3 Favored 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 122.605 2.203 . . . . 0.0 111.85 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 143' ' ' PRO . 26.4 m -156.96 164.03 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.862 0.363 . . . . 0.0 111.386 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -148.59 122.37 9.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.796 179.695 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.52 142.85 45.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.173 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 112' ' ' THR . . . -134.34 142.12 13.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.299 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -170.55 -157.69 13.12 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.107 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.956 HG12 HG22 ' A' ' 110' ' ' ILE . 4.9 m -129.83 163.25 35.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 111.127 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.441 ' HB2' ' CE2' ' A' ' 111' ' ' TYR . 0.7 OUTLIER -133.19 129.38 37.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 151' ' ' TRP . . . . . 0.61 ' CE2' HD22 ' A' ' 108' ' ' LEU . 1.4 t-105 -118.43 132.55 56.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.792 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.867 ' HB3' ' HB3' ' A' ' 107' ' ' ASP . . . -99.36 134.43 42.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 0.0 111.528 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.681 ' O ' HG12 ' A' ' 153' ' ' VAL . 47.8 t -116.06 39.92 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.751 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' THR . . . . . 0.424 HG22 ' H ' ' A' ' 155' ' ' ARG . 0.2 OUTLIER 59.08 -175.84 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.218 179.692 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ARG . . . . . 0.534 ' HB3' HD12 ' A' ' 157' ' ' ILE . 1.3 mtt-85 60.8 26.26 16.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.126 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 56.33 22.83 6.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.245 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.534 HD12 ' HB3' ' A' ' 155' ' ' ARG . 5.7 mt -125.47 109.65 22.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.073 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.425 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -115.88 154.26 30.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.342 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.99 151.53 22.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.247 179.499 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 2.1 ptm180 -136.93 132.76 34.89 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.9 0.381 . . . . 0.0 111.897 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.838 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 1.1 tt -123.61 120.79 33.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.734 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.435 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 0.7 OUTLIER -116.34 145.12 43.44 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.606 -179.043 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.838 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 2.1 m-85 -126.76 165.81 18.58 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.551 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -120.38 145.38 47.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.938 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 5.6 t-105 -97.12 135.41 39.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.585 HG11 ' HB3' ' A' ' 181' ' ' ASN . 17.2 m -140.22 31.97 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.1 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -117.3 153.92 32.12 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -98.0 -62.9 1.18 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.898 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 170' ' ' GLY . 2.3 pp -154.93 -46.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.163 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 170' ' ' GLY . . . . . 0.656 ' N ' HD12 ' A' ' 169' ' ' ILE . . . -130.71 -178.25 15.34 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.35 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -95.87 129.79 43.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.842 0.353 . . . . 0.0 110.933 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -93.71 -45.52 7.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.007 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -78.96 162.69 48.77 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.509 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.2 p -105.49 -30.69 9.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.899 0.38 . . . . 0.0 110.915 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 12.3 p -116.08 141.73 32.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.036 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -145.32 110.93 0.57 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.508 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.97 -54.58 1.72 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.833 0.349 . . . . 0.0 110.844 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 1.1 mtp180 -93.67 143.13 26.07 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.939 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.85 128.0 14.46 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.489 2.126 . . . . 0.0 112.185 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -107.41 -33.26 7.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.825 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' ASN . . . . . 0.585 ' HB3' HG11 ' A' ' 166' ' ' VAL . 63.3 m-80 -145.96 151.35 37.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.834 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 120.16 151.58 8.78 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.391 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 183' ' ' MET . . . . . 0.614 ' C ' HD12 ' A' ' 184' ' ' LEU . 8.9 ttm -143.05 122.1 12.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.78 0.324 . . . . 0.0 110.971 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.614 HD12 ' C ' ' A' ' 183' ' ' MET . 6.7 mp -114.71 133.36 55.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.779 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.2 m -132.59 145.8 51.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.91 137.84 49.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.568 179.705 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 187' ' ' GLY . . . . . 0.515 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -158.8 -176.65 31.09 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.449 -0.881 . . . . 0.0 113.042 -179.569 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -126.16 141.86 44.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.637 0.256 . . . . 0.0 110.52 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 189' ' ' SER . . . . . 0.46 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 1.4 t -137.93 159.72 41.24 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.112 0.482 . . . . 0.0 111.576 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -117.81 146.42 43.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.41 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.26 143.64 45.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 192' ' ' PHE . . . . . 0.423 ' HB2' ' CZ2' ' A' ' 19' ' ' TRP . 60.3 m-85 -148.29 123.99 10.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.878 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -149.38 167.07 29.64 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.538 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -116.51 170.47 8.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -98.23 169.16 9.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -59.91 -169.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.859 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -97.69 35.38 1.68 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.031 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -124.05 136.15 27.19 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.992 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.483 ' HG2' ' HB3' ' A' ' 202' ' ' ALA . 74.2 Cg_endo -75.4 -167.82 0.47 Allowed 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.489 2.126 . . . . 0.0 112.253 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 10.6 m -92.91 -30.58 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.088 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 29.3 t -74.13 -32.89 33.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.981 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 202' ' ' ALA . . . . . 0.483 ' HB3' ' HG2' ' A' ' 199' ' ' PRO . . . -89.21 157.49 47.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.08 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.438 ' HD2' ' HB1' ' A' ' 202' ' ' ALA . 49.9 Cg_endo -69.04 134.97 30.89 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.517 2.145 . . . . 0.0 112.222 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 204' ' ' ALA . . . . . 0.766 ' HB3' ' HD3' ' A' ' 205' ' ' PRO . . . -78.54 -52.65 1.35 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.174 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 205' ' ' PRO . . . . . 0.766 ' HD3' ' HB3' ' A' ' 204' ' ' ALA . 31.6 Cg_exo -59.13 -159.64 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.482 2.121 . . . . 0.0 112.115 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -103.34 139.71 20.37 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.963 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.84 90.05 0.74 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.471 2.114 . . . . 0.0 112.35 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -89.17 145.17 33.7 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.093 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.38 94.9 0.84 Allowed 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.53 2.153 . . . . 0.0 112.338 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.24 -0.886 . . . . 0.0 110.887 179.975 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 120.789 0.328 . . . . 0.0 111.052 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.79 31.25 6.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.905 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 30.6 mt -144.74 145.53 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.155 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -167.69 128.93 1.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.83 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -72.56 131.24 42.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.827 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -110.98 96.25 6.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.18 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 tt -148.68 36.47 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.979 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -117.28 -40.25 3.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.859 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.2 m -137.14 142.25 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.078 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -139.44 -47.39 0.47 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.945 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -71.43 120.39 16.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.941 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -138.02 36.88 2.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.031 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -90.24 112.05 50.43 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.077 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -54.87 -176.6 0.04 OUTLIER 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.304 2.003 . . . . 0.0 112.324 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 27.8 mttm -95.94 80.94 3.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.939 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -87.72 152.72 21.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.827 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -103.8 100.51 10.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.872 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.98 130.09 55.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.822 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -121.19 146.97 46.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.421 ' CD1' ' HB2' ' A' ' 189' ' ' SER . 0.1 OUTLIER -142.35 135.81 29.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.724 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 145.22 31.03 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.336 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.72 -168.9 38.65 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.566 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -137.0 147.04 19.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.546 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.435 ' HE3' ' CE2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -121.2 153.14 37.98 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 -179.924 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.1 tt -133.43 139.34 46.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.723 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -165.1 -172.37 32.48 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.577 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -92.09 153.61 19.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.773 0.321 . . . . 0.0 110.85 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 25.2 p -111.82 112.1 23.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.973 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.89 94.71 7.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.934 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -136.9 -47.67 0.6 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.95 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -67.12 154.86 40.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.918 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -176.61 -41.47 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.864 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 49.7 p -110.99 165.46 11.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.995 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 96.69 39.49 4.13 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.439 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -138.23 31.6 2.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.749 0.309 . . . . 0.0 110.851 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -64.46 142.04 58.56 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.827 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -170.98 66.05 0.15 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -67.26 -31.48 71.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.868 0.366 . . . . 0.0 110.822 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -68.76 -140.11 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.492 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -119.09 144.33 46.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.345 . . . . 0.0 110.903 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -126.99 89.57 3.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.935 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -100.09 -29.72 12.35 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.94 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -58.64 160.97 5.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.874 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -136.32 151.92 50.13 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.967 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -114.55 171.07 13.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.493 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -52.79 -61.9 0.42 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.518 2.146 . . . . 0.0 112.308 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -149.45 173.53 13.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.835 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 2.8 mtt85 -84.15 143.41 29.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.844 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -86.35 106.3 17.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.909 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.25 168.47 10.21 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.908 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 -149.05 92.13 1.93 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.941 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.8 pp -94.54 161.67 14.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.735 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.34 140.33 11.72 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.628 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -127.97 159.63 34.38 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.812 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.437 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -158.44 155.66 26.68 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.802 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -113.59 126.69 55.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.797 0.332 . . . . 0.0 110.856 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.435 ' CE2' ' HE3' ' A' ' 24' ' ' LYS . 38.9 p90 -115.59 133.46 56.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.111 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.1 125.15 1.78 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.132 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -150.41 -176.98 23.93 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.747 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -155.06 154.48 32.52 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.896 0.379 . . . . 0.0 111.006 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -102.89 137.33 41.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.567 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 24.0 t -122.54 -49.17 2.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.004 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -96.18 142.62 24.82 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.491 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.412 ' O ' ' CG ' ' A' ' 65' ' ' TYR . 45.3 Cg_endo -68.15 64.14 1.03 Allowed 'Trans proline' 0 C--N 1.343 0.264 0 C-N-CA 122.399 2.066 . . . . 0.0 111.996 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.412 ' CG ' ' O ' ' A' ' 64' ' ' PRO . 9.0 m-85 -168.24 -37.77 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.414 -179.794 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -169.55 164.08 10.32 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.976 0.417 . . . . 0.0 111.159 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.49 176.76 18.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.398 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.41 ' CE2' ' HG ' ' A' ' 96' ' ' LEU . 1.2 t80 -103.85 138.24 40.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.634 0.254 . . . . 0.0 110.724 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -134.51 125.9 28.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.852 0.358 . . . . 0.0 111.116 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.1 mtt -107.27 133.38 51.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.434 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.87 159.4 13.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.615 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.437 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -131.53 114.88 15.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.679 0.276 . . . . 0.0 110.613 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -86.18 120.51 27.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.998 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 42.8 t90 -139.09 142.21 38.14 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.917 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 4.8 mp -114.6 -175.79 2.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -107.31 -158.44 20.86 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.503 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.1 tpt180 60.55 108.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.767 0.318 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -96.18 152.21 18.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.796 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.16 134.63 49.1 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.151 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 28.0 m-85 -114.66 31.72 6.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.967 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.2 mptt -98.6 84.56 3.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -147.82 78.37 0.23 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.542 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.4 m -135.65 -70.18 0.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.782 0.325 . . . . 0.0 110.924 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 17.3 m -140.69 32.37 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.165 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -160.87 118.44 2.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.929 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -90.13 128.28 36.3 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 171.49 40.9 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.499 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -118.31 156.13 29.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.848 0.356 . . . . 0.0 111.055 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -85.38 107.72 17.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.989 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 3.3 mmmt -138.77 124.04 19.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.869 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -168.32 176.97 5.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.2 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 -154.54 127.75 8.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.566 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -98.21 130.22 10.16 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.968 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.77 118.96 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 15.8 mt-30 -108.86 144.4 36.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.241 0.543 . . . . 0.0 111.937 -178.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.452 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -133.45 112.19 11.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.266 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.515 HG22 ' HA3' ' A' ' 115' ' ' GLY . 6.0 p -147.03 178.05 8.67 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.219 0.533 . . . . 0.0 111.984 -178.641 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -117.27 135.81 53.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.039 179.169 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -110.65 131.98 54.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.021 0.439 . . . . 0.0 111.379 -179.387 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.621 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -135.45 125.71 26.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.259 179.599 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.423 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -168.14 -169.82 32.09 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.944 -179.538 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.823 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 24.5 p90 -156.51 152.43 22.85 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.819 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -83.1 165.52 14.89 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.721 2.281 . . . . 0.0 112.803 -179.617 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.488 ' N ' ' O ' ' A' ' 108' ' ' LEU . 9.6 mt -142.09 139.89 30.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.411 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 88.1 m 64.06 -76.02 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.028 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.7 t0 178.38 -34.78 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.087 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.34 19.86 11.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.415 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.488 ' O ' ' N ' ' A' ' 104' ' ' ILE . 0.1 OUTLIER -138.15 113.38 9.36 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.814 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -129.27 145.59 51.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.987 0.422 . . . . 0.0 111.809 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.969 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.9 142.17 28.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.657 179.314 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.423 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 33.4 m-85 -149.12 158.33 44.1 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.058 0.456 . . . . 0.0 111.695 -179.35 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.6 m -130.89 141.92 50.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.457 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 36.8 ttp180 -120.83 127.94 52.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.278 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -136.34 122.92 20.92 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.929 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.515 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -177.12 -140.71 3.73 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.583 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.7 167.74 25.48 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.868 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 9.0 ttp -130.2 141.1 50.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 0.0 110.735 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.4 t -125.69 115.63 43.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.826 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -110.97 133.81 53.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.888 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 3.2 tpt180 -102.84 144.77 30.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.932 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -112.91 143.81 43.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.061 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -126.64 127.29 44.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 10.3 m -159.67 37.06 0.19 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.967 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 6.3 tptt -137.31 119.16 15.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.847 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -169.75 -49.2 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.481 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 23.2 t30 -92.08 171.96 8.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.89 0.376 . . . . 0.0 110.905 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -69.33 -31.43 69.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.938 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -73.72 171.4 13.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.067 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 29.1 t -152.22 165.54 34.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.842 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.54 56.05 0.68 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.89 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -153.36 -145.35 4.13 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.546 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.452 HG13 ' N ' ' A' ' 133' ' ' SER . 12.3 p -110.86 -42.86 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.818 0.342 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.452 ' N ' HG13 ' A' ' 132' ' ' VAL . 84.6 p -135.08 -46.99 0.71 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.927 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -154.47 119.56 5.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.856 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 54.4 p -62.31 106.53 0.76 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.991 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -61.43 141.4 57.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.871 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 50.9 p-80 -60.5 142.51 55.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.907 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -122.78 135.5 54.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.878 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.1 p -135.27 130.53 35.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -105.54 89.04 0.6 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.341 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.409 HG13 ' O ' ' A' ' 141' ' ' VAL . 10.1 p -118.65 126.12 74.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.705 0.288 . . . . 0.0 110.97 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -157.16 148.49 16.84 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.831 0.348 . . . . 0.0 111.464 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.511 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -79.81 145.66 18.11 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.752 2.302 . . . . 0.0 112.222 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.7 m -156.71 157.1 4.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.927 0.394 . . . . 0.0 111.404 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -149.13 127.19 11.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.476 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -124.01 143.85 50.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.245 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -130.02 146.95 17.85 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.09 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.409 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -167.72 -164.39 23.31 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.936 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.969 HG12 HG22 ' A' ' 110' ' ' ILE . 6.7 m -128.65 166.89 25.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.685 0.279 . . . . 0.0 111.134 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -135.4 149.1 49.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.92 0.391 . . . . 0.0 111.196 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 5.2 m0 -131.39 123.07 27.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.735 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.86 130.2 34.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.225 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.02 -70.44 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.052 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -96.65 -176.68 3.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.962 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 7.3 ttm180 -72.51 117.13 13.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.909 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 62.06 23.78 14.07 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.153 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.442 HG12 ' CD2' ' A' ' 190' ' ' TYR . 22.8 mt -137.47 106.27 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.754 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -132.99 160.86 35.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.984 0.421 . . . . 0.0 111.59 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' THR . . . . . 0.494 ' OG1' HG12 ' A' ' 188' ' ' VAL . 24.5 m -119.35 145.45 46.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.973 179.518 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.408 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 147.42 46.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.179 0.514 . . . . 0.0 111.976 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.817 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 1.3 tt -113.92 123.57 50.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.533 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.409 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 1.1 mt-10 -107.5 143.88 35.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.044 0.45 . . . . 0.0 111.616 -179.074 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.823 ' CE1' HD23 ' A' ' 184' ' ' LEU . 45.4 m-85 -130.94 163.53 27.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.504 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -111.89 -70.04 0.83 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 15.8 t-105 -103.61 108.06 19.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 14.4 m -142.65 157.03 18.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.151 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.57 -68.6 0.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 14.4 p-10 -130.6 113.95 14.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 3.1 pt -84.75 153.42 3.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.139 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -172.03 -118.76 0.49 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.581 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -110.71 31.6 5.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.799 0.333 . . . . 0.0 110.958 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -145.93 -179.83 6.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.098 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -158.92 66.41 0.28 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.523 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.6 m -149.37 91.19 1.8 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 176' ' ' GLY . 6.1 m -125.94 -46.15 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 176' ' ' GLY . . . . . 0.41 ' N ' HG23 ' A' ' 175' ' ' VAL . . . -179.73 146.47 7.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.462 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.5 -53.89 0.21 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.871 0.367 . . . . 0.0 110.968 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 178' ' ' ARG . . . . . 0.404 ' CB ' ' CD ' ' A' ' 179' ' ' PRO . 2.0 mtm180 -71.76 -61.16 2.13 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.859 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 179' ' ' PRO . . . . . 0.404 ' CD ' ' CB ' ' A' ' 178' ' ' ARG . 60.1 Cg_endo -72.83 -44.6 0.61 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.588 2.192 . . . . 0.0 112.352 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -76.49 147.07 38.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.91 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -100.72 81.8 2.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -124.18 -165.65 12.28 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.387 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 2.1 mtm -155.01 111.74 3.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.785 0.326 . . . . 0.0 110.984 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.823 HD23 ' CE1' ' A' ' 163' ' ' TYR . 0.5 OUTLIER -112.65 126.53 55.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.605 179.772 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -135.71 152.37 51.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.973 0.416 . . . . 0.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.13 128.72 54.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.3 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -143.2 167.31 26.48 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.16 -1.019 . . . . 0.0 113.082 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 188' ' ' VAL . . . . . 0.494 HG12 ' OG1' ' A' ' 159' ' ' THR . 0.4 OUTLIER -128.42 139.49 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.687 0.28 . . . . 0.0 110.374 179.445 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 189' ' ' SER . . . . . 0.421 ' HB2' ' CD1' ' A' ' 20' ' ' TYR . 0.3 OUTLIER -136.27 168.7 18.93 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 111.723 -179.125 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 190' ' ' TYR . . . . . 0.452 ' CD1' ' N ' ' A' ' 190' ' ' TYR . 2.7 m-85 -131.71 157.99 42.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.366 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 38.0 mtm180 -94.09 132.54 38.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.943 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -106.22 114.22 28.21 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.933 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -135.49 163.97 24.9 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.52 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -103.59 110.47 22.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.837 0.351 . . . . 0.0 110.866 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -80.24 164.41 23.26 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.91 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -127.69 128.77 46.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.933 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -79.07 -30.92 44.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.168 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -101.58 96.18 6.05 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.043 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.45 92.1 0.35 Allowed 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.447 2.098 . . . . 0.0 112.271 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 12.7 m -85.61 -25.41 6.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.222 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 201' ' ' VAL . . . . . 0.634 HG22 ' O ' ' A' ' 201' ' ' VAL . 14.6 p -92.26 15.45 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.385 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -140.13 63.32 23.47 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 120.78 0.324 . . . . 0.0 111.066 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.75 -169.38 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.558 2.172 . . . . 0.0 112.33 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -120.27 115.65 32.74 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.012 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.64 155.24 69.53 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.501 2.134 . . . . 0.0 112.255 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 206' ' ' ALA . . . . . 0.653 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -69.98 -61.61 2.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.168 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.653 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 36.2 Cg_endo -65.23 140.4 64.47 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.483 2.122 . . . . 0.0 112.236 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.415 ' HB1' ' HD2' ' A' ' 209' ' ' PRO . . . -100.87 162.82 19.43 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.073 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 209' ' ' PRO . . . . . 0.415 ' HD2' ' HB1' ' A' ' 208' ' ' ALA . 51.4 Cg_exo -53.8 -43.89 54.03 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.455 2.103 . . . . 0.0 112.173 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.253 -0.88 . . . . 0.0 110.85 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 120.805 0.336 . . . . 0.0 111.004 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.42 -31.3 9.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.897 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.8 pt -90.99 133.8 31.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.123 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.2 tpp -162.06 -52.11 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.844 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.65 107.27 19.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.859 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.39 -62.45 1.39 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.083 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.448 HG22 ' N ' ' A' ' 8' ' ' PHE . 31.7 mt -123.08 157.22 28.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.078 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' N ' HG22 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -122.15 159.05 28.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.942 179.975 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.56 128.34 37.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.106 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -143.4 168.89 18.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -88.44 150.65 23.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.859 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.54 158.31 27.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.096 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.766 ' HB3' ' HD3' ' A' ' 14' ' ' PRO . . . -87.63 -52.63 0.4 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.026 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.766 ' HD3' ' HB3' ' A' ' 13' ' ' ALA . 53.0 Cg_exo -54.93 97.91 0.05 OUTLIER 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.542 2.161 . . . . 0.0 112.224 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.89 34.07 4.12 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.902 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -88.98 -33.48 17.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.933 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -86.88 137.45 32.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.008 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.511 HG21 ' HD3' ' A' ' 191' ' ' ARG . 1.4 p -148.39 168.87 21.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.838 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 25.9 m-90 -117.28 132.45 56.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.055 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.429 ' CZ ' ' HG3' ' A' ' 191' ' ' ARG . 5.1 m-85 -120.41 135.87 54.91 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.522 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.22 140.26 43.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.488 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.409 ' HA3' ' HB3' ' A' ' 189' ' ' SER . . . 179.14 -163.78 31.57 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.414 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -162.73 161.33 33.67 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.552 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.458 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 0.1 OUTLIER -135.32 160.9 36.97 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.005 0.431 . . . . 0.0 111.044 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.417 HD12 ' HB2' ' A' ' 54' ' ' ALA . 3.9 tt -130.85 149.17 52.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.735 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -157.89 177.6 34.57 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.463 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' TRP . . . . . 0.421 ' CD1' ' N ' ' A' ' 27' ' ' TRP . 2.5 p-90 -142.81 141.49 31.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.835 0.35 . . . . 0.0 110.961 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.3 t -101.09 117.78 35.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.93 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -140.96 151.48 44.21 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.746 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -138.32 100.88 4.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.961 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -91.85 160.66 15.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.817 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -110.3 155.41 22.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -94.53 122.55 37.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.28 28.35 8.63 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.586 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 18.9 t80 -144.2 135.1 25.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.787 0.327 . . . . 0.0 110.95 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 11.6 p90 -165.48 148.35 7.87 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -157.36 125.35 1.56 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.511 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -114.49 30.5 7.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.711 0.291 . . . . 0.0 110.901 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -106.87 159.68 14.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.75 117.89 17.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.775 0.321 . . . . 0.0 110.817 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 -141.46 87.24 2.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.881 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -67.83 -37.87 82.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.928 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -141.19 88.46 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.911 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -136.57 -62.45 0.65 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.841 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.6 126.18 1.73 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.464 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.92 92.46 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.471 2.114 . . . . 0.0 112.232 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.1 m -99.52 -39.89 8.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.985 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -72.77 132.38 43.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.881 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -114.85 98.92 7.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -82.12 112.5 19.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -150.81 77.86 1.29 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.947 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.7 mp -90.3 129.56 36.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.82 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -134.52 127.46 4.49 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.502 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.417 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -132.37 132.64 43.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.752 0.311 . . . . 0.0 110.914 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.37 158.08 26.79 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.753 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -126.85 134.72 50.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.51 0.195 . . . . 0.0 110.793 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.458 ' CE2' ' HG2' ' A' ' 24' ' ' LYS . 6.3 p90 -142.37 165.39 27.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.176 0.512 . . . . 0.0 111.738 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -140.13 141.87 11.96 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.79 179.67 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -114.59 143.26 17.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.896 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.441 ' CE2' ' HB3' ' A' ' 68' ' ' PHE . 1.8 p90 -144.62 121.3 11.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.898 0.38 . . . . 0.0 110.631 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 -93.3 137.11 32.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.976 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.4 t -123.86 -45.06 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.728 179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.428 ' O ' ' N ' ' A' ' 65' ' ' TYR . 0.8 OUTLIER -102.73 132.59 21.11 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.364 179.605 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 63' ' ' ASN . 31.4 Cg_exo -59.04 77.42 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.552 2.168 . . . . 0.0 112.361 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.428 ' N ' ' O ' ' A' ' 63' ' ' ASN . 0.6 OUTLIER 178.28 -36.16 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.126 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -171.31 164.06 7.09 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.861 0.362 . . . . 0.0 110.99 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 172.16 20.33 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.441 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . 0.9 OUTLIER -96.87 141.46 30.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.684 0.278 . . . . 0.0 110.611 179.902 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.77 120.24 28.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.976 0.417 . . . . 0.0 111.281 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.3 mtt -106.17 139.03 41.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.859 179.164 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.45 ' CA ' ' HB3' ' A' ' 57' ' ' PHE . . . -133.0 166.63 23.61 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.643 -179.278 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -136.92 115.43 11.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.363 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -81.52 129.73 34.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.18 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' TRP . . . . . 0.401 ' CZ3' ' O ' ' A' ' 91' ' ' ALA . 46.0 m95 -135.67 135.78 40.4 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.737 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.736 HD23 ' N ' ' A' ' 76' ' ' GLY . 8.1 tt -146.11 162.95 36.8 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.936 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.736 ' N ' HD23 ' A' ' 75' ' ' LEU . . . 168.68 112.8 0.27 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.498 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 8.5 mmm180 -145.25 157.85 43.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.783 0.325 . . . . 0.0 110.957 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.1 mtp -101.6 97.77 8.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.816 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -160.42 32.19 0.16 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.151 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -120.62 140.93 50.84 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 4.2 mtmm -95.95 92.13 6.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.959 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -114.2 169.39 12.88 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.507 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 25.4 t -168.94 -51.42 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.905 0.384 . . . . 0.0 110.893 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.0 m -132.29 126.86 56.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.101 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -176.09 172.97 2.29 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -127.15 112.14 14.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.961 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 121.04 105.9 2.0 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.523 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -125.16 70.01 1.15 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.906 0.384 . . . . 0.0 111.089 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -110.37 152.89 25.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.925 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.77 -177.31 5.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.926 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.401 ' O ' ' CZ3' ' A' ' 74' ' ' TRP . . . -123.93 163.69 20.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.065 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -157.19 124.99 5.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.519 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -105.53 140.56 15.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.429 -0.891 . . . . 0.0 112.913 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -115.81 122.62 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.201 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -108.53 143.85 36.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.115 0.483 . . . . 0.0 111.9 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -137.48 113.88 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.849 179.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.413 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 1.2 t -155.1 166.82 32.37 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 111.784 -179.01 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.1 139.45 39.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.32 179.294 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.9 ttpp -118.92 132.25 56.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.897 0.379 . . . . 0.0 111.598 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.8 pp -134.03 126.58 30.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.737 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 102' ' ' TYR . . . -167.99 -177.81 39.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.514 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.407 ' CG ' ' O ' ' A' ' 101' ' ' GLY . 6.5 m-85 -166.1 158.89 12.51 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.777 0.322 . . . . 0.0 110.987 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -61.13 171.98 3.51 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.741 2.294 . . . . 0.0 111.944 179.806 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.527 HG22 ' O ' ' A' ' 108' ' ' LEU . 0.6 OUTLIER -124.73 -37.1 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.445 -179.906 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 14.7 p -140.4 -46.7 0.42 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.942 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -169.51 -67.76 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.143 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.845 ' HB3' ' HB3' ' A' ' 152' ' ' ALA . 2.6 m-20 -108.31 26.4 10.49 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.367 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.803 HD23 ' C ' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -136.28 122.74 20.75 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.828 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -135.15 156.19 49.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.071 0.462 . . . . 0.0 111.996 -179.119 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.944 HG22 HG12 ' A' ' 149' ' ' VAL . 1.6 pp -121.34 138.86 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.394 179.309 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 48.1 p90 -151.28 163.51 38.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.071 0.463 . . . . 0.0 111.557 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.461 HG22 ' HA3' ' A' ' 147' ' ' GLY . 18.5 p -137.63 145.69 43.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.53 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -119.76 127.78 53.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.883 0.373 . . . . 0.0 111.315 -179.756 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -126.98 123.64 37.59 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.328 179.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.413 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.39 -132.49 1.94 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.42 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.497 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.89 168.61 33.95 Favored Glycine 0 C--N 1.331 0.3 0 C-N-CA 120.285 -0.96 . . . . 0.0 112.9 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.95 140.98 52.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.711 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.541 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.5 t -133.91 118.16 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.657 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 64.5 p-90 -137.1 176.12 8.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.833 0.349 . . . . 0.0 111.049 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -148.62 150.86 34.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.825 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -162.58 165.64 25.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.089 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -86.58 156.88 19.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.874 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 3.5 t -149.5 -47.44 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.886 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 7.4 mtmt -101.94 117.15 34.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.886 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -109.72 -77.1 0.93 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.45 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -126.42 34.11 4.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.866 0.365 . . . . 0.0 110.795 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 60.1 m-85 -98.47 35.76 1.74 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -113.28 -171.06 1.8 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 38.2 t -159.79 -45.69 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.961 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 4.0 p -92.42 -32.09 15.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.016 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -100.87 120.05 6.74 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.449 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.459 HG13 ' N ' ' A' ' 133' ' ' SER . 11.1 p -123.66 -43.6 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 120.751 0.31 . . . . 0.0 111.078 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.459 ' N ' HG13 ' A' ' 132' ' ' VAL . 96.6 p -93.88 -39.43 10.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.85 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.01 106.8 17.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.948 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 61.7 p -145.66 157.81 43.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -132.15 168.04 18.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.849 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.49 153.25 22.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -96.49 150.75 20.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.835 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.9 t -140.07 138.36 35.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.033 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -112.32 128.21 8.41 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.354 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.444 HG23 HG22 ' A' ' 118' ' ' VAL . 10.8 p -146.14 130.84 11.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.744 0.307 . . . . 0.0 111.194 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.21 141.29 11.67 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.397 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.497 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 92.2 Cg_endo -78.69 149.95 23.96 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.603 2.202 . . . . 0.0 112.02 179.593 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.8 m -156.3 157.93 3.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.04 0.448 . . . . 0.0 111.702 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -149.08 118.9 7.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.303 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -127.76 159.21 35.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.986 0.422 . . . . 0.0 111.537 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.461 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -130.95 151.82 19.75 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.036 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -162.73 -177.71 35.96 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.346 -0.931 . . . . 0.0 112.979 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.944 HG12 HG22 ' A' ' 110' ' ' ILE . 4.2 m -127.82 154.27 38.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 0.0 111.005 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -124.75 140.46 52.91 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.938 0.399 . . . . 0.0 111.116 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 151' ' ' TRP . . . . . 0.6 ' CE2' HD22 ' A' ' 108' ' ' LEU . 1.9 t90 -131.63 127.77 37.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.779 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.845 ' HB3' ' HB3' ' A' ' 107' ' ' ASP . . . -82.62 137.2 34.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.329 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 76.0 t -104.75 -67.12 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.664 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.46 -77.24 0.2 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.875 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 5.6 ttp180 -173.93 -37.56 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.136 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -105.78 -24.85 12.4 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.498 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 33.4 mt -112.79 135.66 51.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.927 0.394 . . . . 0.0 111.288 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -136.35 164.35 28.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.233 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -118.53 144.8 45.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.151 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.408 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 0.0 OUTLIER -137.16 152.07 49.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.276 0.56 . . . . 0.0 112.051 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -117.97 125.36 50.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.551 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -117.72 137.54 52.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.049 0.452 . . . . 0.0 111.595 -179.203 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -134.19 152.29 51.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.489 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -94.7 114.89 26.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 65.0 p-90 -103.78 132.45 50.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.99 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.415 HG23 ' N ' ' A' ' 167' ' ' ASN . 5.9 m -140.07 -47.1 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 167' ' ' ASN . . . . . 0.415 ' N ' HG23 ' A' ' 166' ' ' VAL . 1.5 t-20 -121.8 111.64 17.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.879 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -96.67 40.45 1.13 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.894 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 169' ' ' ILE . . . . . 0.568 ' O ' HG23 ' A' ' 169' ' ' ILE . 0.9 OUTLIER -149.98 113.27 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.076 179.987 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -84.2 171.31 48.06 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.394 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.23 171.97 10.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.815 0.341 . . . . 0.0 110.805 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -135.64 121.9 20.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.032 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -149.71 -55.14 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.463 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.442 ' O ' HG13 ' A' ' 175' ' ' VAL . 8.7 m -144.95 -55.64 0.32 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.897 0.379 . . . . 0.0 110.822 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.442 HG13 ' O ' ' A' ' 174' ' ' THR . 6.0 m -156.38 149.36 11.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.047 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -140.35 -172.73 13.01 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.426 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 16.1 m -143.2 -67.26 0.36 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.806 0.336 . . . . 0.0 110.887 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 16.9 ttt85 -132.06 119.91 17.0 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.79 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -55.26 87.3 0.04 OUTLIER 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.436 2.091 . . . . 0.0 112.316 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 58.24 -178.46 0.07 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.96 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -149.59 -59.32 0.21 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.834 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 95.54 -99.29 2.37 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.567 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -143.67 121.23 11.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.738 0.304 . . . . 0.0 110.925 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 4.3 mp -120.08 142.45 48.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.681 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 72.0 m -148.71 153.25 37.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.975 0.416 . . . . 0.0 111.226 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.73 136.07 53.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.23 179.706 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.92 170.33 28.59 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.056 -1.069 . . . . 0.0 113.196 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.6 m -132.09 148.09 32.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.602 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 189' ' ' SER . . . . . 0.409 ' HB3' ' HA3' ' A' ' 22' ' ' GLY . 89.4 p -151.79 175.06 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.054 0.455 . . . . 0.0 111.466 -179.701 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -145.92 156.54 43.59 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.621 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.511 ' HD3' HG21 ' A' ' 18' ' ' THR . 8.4 ttm180 -99.45 146.63 26.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.92 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -81.37 106.13 13.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.939 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -143.03 148.88 20.77 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.525 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -109.8 126.94 54.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.794 0.33 . . . . 0.0 110.835 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -105.75 -43.26 4.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.907 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -115.48 97.09 5.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.942 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -97.61 50.24 1.05 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.093 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 198' ' ' ALA . . . . . 0.709 ' HB1' ' HD2' ' A' ' 199' ' ' PRO . . . -74.54 165.62 52.08 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.119 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.709 ' HD2' ' HB1' ' A' ' 198' ' ' ALA . 40.0 Cg_endo -66.95 94.93 0.35 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.514 2.143 . . . . 0.0 112.282 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 200' ' ' VAL . . . . . 0.476 HG12 ' N ' ' A' ' 201' ' ' VAL . 21.7 t -117.69 158.7 18.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.136 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 201' ' ' VAL . . . . . 0.476 ' N ' HG12 ' A' ' 200' ' ' VAL . 20.5 m -104.12 55.51 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.04 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -101.28 106.34 44.79 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.152 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -55.02 168.0 1.41 Allowed 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.462 2.108 . . . . 0.0 112.315 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -126.91 127.08 24.47 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.054 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -53.34 106.17 0.15 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.464 2.11 . . . . 0.0 112.272 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 206' ' ' ALA . . . . . 0.654 ' HB1' ' HD2' ' A' ' 207' ' ' PRO . . . -67.71 163.61 47.24 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.079 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.654 ' HD2' ' HB1' ' A' ' 206' ' ' ALA . 37.4 Cg_endo -66.26 132.6 30.09 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.512 2.142 . . . . 0.0 112.17 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.892 ' HB3' ' HD3' ' A' ' 209' ' ' PRO . . . -160.12 -59.72 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.429 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 209' ' ' PRO . . . . . 0.892 ' HD3' ' HB3' ' A' ' 208' ' ' ALA . 53.9 Cg_exo -52.23 90.35 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.245 1.964 . . . . 0.0 112.364 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.943 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.839 0.352 . . . . 0.0 111.02 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.67 31.47 3.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.81 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.2 pt -149.53 140.9 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.238 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -147.44 166.0 28.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.909 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -136.34 -50.96 0.69 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.813 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -112.79 123.49 50.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.078 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 22.5 mt -135.74 142.69 38.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.148 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -99.69 121.37 41.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.019 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.9 m -74.49 154.27 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.148 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -127.22 -61.78 1.14 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.911 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -83.44 58.69 4.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.886 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -171.69 114.62 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.035 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.14 128.99 93.96 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.008 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -55.02 -31.78 76.13 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.451 2.101 . . . . 0.0 112.223 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 15.2 mtmm -132.1 111.61 11.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.04 -45.36 23.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.841 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -91.44 111.97 23.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.935 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 39.9 p -129.54 136.16 49.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.869 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.421 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.2 t-105 -135.66 135.07 39.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.432 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 7.9 m-85 -121.98 145.05 48.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.77 141.6 28.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.256 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.55 -166.67 34.06 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.552 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.38 146.71 18.42 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.544 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -127.93 149.32 50.37 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 120.858 0.361 . . . . 0.0 111.082 -179.762 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.751 HD21 HD13 ' A' ' 52' ' ' LEU . 2.0 tt -132.55 145.55 51.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.668 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -153.31 171.13 32.22 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.593 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' TRP . . . . . 0.41 ' CZ2' ' HB3' ' A' ' 50' ' ' ASP . 0.6 OUTLIER -113.92 149.71 34.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.783 0.325 . . . . 0.0 110.795 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.7 m -114.1 167.44 10.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.32 92.24 3.75 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.919 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 13.4 p90 -103.7 137.05 42.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.943 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 25.1 t-80 -82.93 -66.34 0.9 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.92 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.01 139.06 42.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.789 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.7 m -76.48 -36.94 57.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.933 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.38 125.19 4.53 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.588 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -143.19 142.57 31.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.79 0.328 . . . . 0.0 110.907 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -102.12 -48.46 4.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.783 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.31 91.36 1.35 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.473 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -93.14 113.64 25.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.818 0.342 . . . . 0.0 110.97 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -154.87 -134.8 1.95 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.502 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -127.48 79.9 1.92 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.792 0.329 . . . . 0.0 110.971 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.92 140.83 40.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.933 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -69.71 106.79 3.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.884 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -138.91 96.42 3.12 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.91 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 12.3 m-80 -89.18 120.64 30.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.826 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.402 ' N ' ' HD2' ' A' ' 46' ' ' PRO . . . -173.79 -62.95 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.628 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' PRO . . . . . 0.402 ' HD2' ' N ' ' A' ' 45' ' ' GLY . 18.2 Cg_endo -59.94 -25.71 80.3 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.582 2.188 . . . . 0.0 112.257 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.0 p -127.58 35.16 4.55 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.893 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -136.61 -51.68 0.69 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.931 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -109.28 -177.01 3.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.906 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.41 ' HB3' ' CZ2' ' A' ' 27' ' ' TRP . 21.4 m-20 -116.97 -179.81 3.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.89 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -140.57 111.92 7.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.874 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.751 HD13 HD21 ' A' ' 25' ' ' LEU . 1.7 pp -118.14 165.86 13.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.918 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.94 137.96 9.78 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.396 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.465 ' HB2' ' HG ' ' A' ' 25' ' ' LEU . . . -136.57 173.13 12.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.915 0.388 . . . . 0.0 111.052 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.87 156.6 26.06 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.626 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.656 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.95 160.17 14.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.822 0.344 . . . . 0.0 111.011 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -147.77 126.39 12.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.984 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.43 137.05 5.69 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.299 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.436 ' HA3' ' HB3' ' A' ' 69' ' ' GLU . . . -171.39 -165.84 29.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.649 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.421 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 6.0 p90 -143.57 161.01 39.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.994 0.426 . . . . 0.0 111.039 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -118.94 136.61 53.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.59 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 26.0 t -121.58 -41.91 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.151 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.403 ' HB2' ' CB ' ' A' ' 66' ' ' LEU . 7.0 m-20 -92.82 160.82 33.31 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.805 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -67.75 -14.28 41.24 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.559 2.173 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.768 ' CZ ' HD13 ' A' ' 100' ' ' LEU . 4.3 t80 -149.39 28.23 0.81 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.788 0.327 . . . . 0.0 111.099 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.513 HD22 ' O ' ' A' ' 65' ' ' TYR . 0.4 OUTLIER -145.41 115.84 7.59 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.88 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -128.87 156.41 21.12 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.32 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -128.99 128.43 43.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.621 0.248 . . . . 0.0 110.769 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.436 ' HB3' ' HA3' ' A' ' 59' ' ' GLY . 1.4 pm0 -147.44 153.46 39.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.149 0.499 . . . . 0.0 111.505 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 4.0 ptt? -118.15 138.21 52.45 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.186 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.86 175.63 18.73 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.689 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.656 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 0.8 OUTLIER -134.71 114.94 13.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.661 0.267 . . . . 0.0 110.621 179.893 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -78.27 121.64 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.084 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 6.1 m95 -139.04 117.08 11.7 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.878 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 6.8 tp -74.09 -57.59 3.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.949 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 153.18 176.05 25.26 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.476 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.26 88.45 4.92 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.823 0.344 . . . . 0.0 110.932 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -105.4 -178.6 3.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -159.47 141.04 13.07 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.986 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.44 ' CD1' ' HB3' ' A' ' 83' ' ' SER . 0.3 OUTLIER -93.33 142.87 26.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.976 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -120.29 -42.02 2.59 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.86 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -99.51 36.52 4.02 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.471 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.44 ' HB3' ' CD1' ' A' ' 80' ' ' TYR . 8.5 t -154.66 79.82 1.08 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.814 0.34 . . . . 0.0 110.894 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 m -81.97 120.55 33.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.142 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.71 152.16 37.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.859 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -90.57 137.19 32.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 103.85 61.48 0.68 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.516 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -61.77 111.45 1.87 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.867 0.365 . . . . 0.0 111.112 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -126.45 143.36 51.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -97.58 139.68 33.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.83 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.11 159.39 18.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.233 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -164.5 129.64 2.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.631 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.85 141.54 15.32 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.898 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -112.05 126.0 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.249 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -108.86 146.84 33.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.224 0.535 . . . . 0.0 112.03 -178.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.425 ' O ' HD23 ' A' ' 96' ' ' LEU . 2.0 tt -139.13 116.1 10.92 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.347 179.527 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.424 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 0.9 OUTLIER -154.32 170.03 22.28 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.191 0.519 . . . . 0.0 112.054 -178.694 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -108.95 149.64 28.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.134 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.82 132.23 53.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.966 0.412 . . . . 0.0 111.704 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.768 HD13 ' CZ ' ' A' ' 65' ' ' TYR . 4.0 pp -133.34 125.11 28.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.18 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -163.06 -169.82 27.04 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.872 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.442 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -157.35 145.3 14.07 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.674 0.273 . . . . 0.0 110.923 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.442 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 84.7 Cg_endo -82.59 167.83 14.77 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.764 2.309 . . . . 0.0 112.643 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.64 ' O ' HG23 ' A' ' 105' ' ' THR . 5.3 mm -115.64 -32.21 1.92 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.204 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.956 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.64 HG23 ' O ' ' A' ' 104' ' ' ILE . 0.5 OUTLIER -170.65 46.89 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.847 0.356 . . . . 0.0 111.208 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 50.7 32.0 6.5 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.858 0.361 . . . . 0.0 111.133 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.67 ' OD1' ' HB3' ' A' ' 152' ' ' ALA . 38.5 t0 -153.78 -41.98 0.09 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.707 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.456 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER -119.72 118.22 30.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.915 179.699 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -134.35 152.48 51.83 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.12 0.486 . . . . 0.0 112.09 -178.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.959 HG22 ' CG1' ' A' ' 149' ' ' VAL . 1.3 pt -114.82 147.63 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 179.104 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -157.77 166.19 33.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.1 0.476 . . . . 0.0 111.823 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.41 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 27.4 m -142.28 132.29 24.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.513 179.679 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 52.6 mtt180 -109.92 128.91 55.66 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.188 -179.695 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -132.98 125.52 29.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.715 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.424 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . -179.98 -135.51 2.49 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.477 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.508 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -152.19 169.04 31.45 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.48 -0.867 . . . . 0.0 112.792 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.5 ptp -128.13 140.91 51.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.849 0.357 . . . . 0.0 110.995 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.431 ' O ' HG23 ' A' ' 94' ' ' VAL . 2.1 t -130.63 111.88 21.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.715 179.774 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.5 p-90 -128.47 176.13 7.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.927 0.394 . . . . 0.0 111.055 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -119.82 127.6 52.92 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.833 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.636 ' HB3' ' HB3' ' A' ' 138' ' ' ASP . . . -88.52 152.11 22.08 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.143 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -126.4 158.79 35.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.854 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 9.2 p -176.75 -40.27 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.971 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.77 -174.45 2.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -161.45 -151.65 6.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.561 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 7.1 m-20 -82.95 150.86 26.17 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.916 0.388 . . . . 0.0 110.863 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -80.96 -63.15 1.47 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.893 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -144.25 -56.21 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.109 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 16.1 m -150.21 120.84 7.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.844 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -163.0 169.53 19.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.877 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -131.43 -60.0 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.499 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 11.1 p -134.4 140.44 45.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.771 0.32 . . . . 0.0 111.093 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -138.25 171.27 14.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.807 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 2.8 ptm85 -79.65 -30.57 41.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.897 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.2 t -82.59 110.43 17.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.888 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -84.45 161.03 20.44 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.071 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -66.19 171.36 4.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.971 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.636 ' HB3' ' HB3' ' A' ' 121' ' ' ALA . 4.8 t0 -77.64 136.23 38.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.799 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 14.9 p -124.9 135.34 52.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.007 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -113.83 131.22 9.81 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.406 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.9 p -146.04 128.27 8.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.732 0.301 . . . . 0.0 111.055 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.17 147.4 15.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.247 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.508 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.3 Cg_endo -78.1 151.89 27.38 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.749 2.3 . . . . 0.0 112.209 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.8 m -156.38 157.29 3.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.379 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -149.13 123.78 9.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.628 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -118.34 124.83 48.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 112' ' ' THR . . . -125.59 137.33 10.22 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.306 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -170.87 -150.76 7.17 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.435 -0.888 . . . . 0.0 113.076 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.959 ' CG1' HG22 ' A' ' 110' ' ' ILE . 9.0 m -131.3 168.21 24.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.822 0.344 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -134.79 136.74 42.8 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' TRP . . . . . 0.456 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.6 OUTLIER -119.56 128.72 54.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.81 179.813 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.67 ' HB3' ' OD1' ' A' ' 107' ' ' ASP . . . -94.73 131.7 40.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.916 0.388 . . . . 0.0 111.456 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.422 HG22 ' CZ3' ' A' ' 151' ' ' TRP . 59.5 t -116.09 -69.21 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.747 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' THR . . . . . 0.447 HG22 ' H ' ' A' ' 155' ' ' ARG . 0.2 OUTLIER -73.66 -167.32 0.45 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.989 -179.882 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ARG . . . . . 0.447 ' H ' HG22 ' A' ' 154' ' ' THR . 6.3 ttm180 -81.6 -35.89 29.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.988 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -135.85 33.31 2.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.124 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.2 mt -148.14 124.45 2.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.063 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -136.87 162.8 32.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.439 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' THR . . . . . 0.468 HG23 ' CG1' ' A' ' 188' ' ' VAL . 1.7 m -109.73 150.6 28.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.202 179.522 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.07 136.58 38.49 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.077 0.465 . . . . 0.0 111.864 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.703 HD22 ' CE1' ' A' ' 163' ' ' TYR . 1.4 tt -119.17 120.76 38.04 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.505 178.809 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.417 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 5.2 mt-10 -117.39 145.13 44.29 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.115 0.483 . . . . 0.0 111.819 -178.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.703 ' CE1' HD22 ' A' ' 161' ' ' LEU . 0.0 OUTLIER -134.05 166.09 23.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.202 179.428 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -112.46 -32.44 6.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.937 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 165' ' ' TRP . . . . . 0.434 ' CG ' ' HB2' ' A' ' 181' ' ' ASN . 71.7 t90 -153.37 102.17 2.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.987 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 10.9 p -178.51 -39.39 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.034 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 10.9 p-10 -72.71 -36.49 67.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -134.88 139.49 45.05 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.867 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 169' ' ' ILE . . . . . 0.713 HD12 ' N ' ' A' ' 170' ' ' GLY . 2.7 pp -129.83 -42.81 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.187 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 170' ' ' GLY . . . . . 0.713 ' N ' HD12 ' A' ' 169' ' ' ILE . . . -138.92 129.65 4.54 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.468 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -113.95 -40.33 3.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.824 0.345 . . . . 0.0 110.899 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -163.65 -53.69 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.065 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -110.52 156.3 15.64 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.4 p -111.57 108.67 18.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.852 0.358 . . . . 0.0 110.892 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -138.04 141.78 37.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.061 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -117.32 136.1 12.35 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.429 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -144.05 -48.59 0.28 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.866 0.365 . . . . 0.0 110.935 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 3.8 ptp85 -84.47 113.86 51.46 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.736 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -50.96 -46.79 28.8 Favored 'Trans proline' 0 C--N 1.347 0.451 0 C-N-CA 122.407 2.071 . . . . 0.0 112.319 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.51 152.75 20.79 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.89 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 181' ' ' ASN . . . . . 0.434 ' HB2' ' CG ' ' A' ' 165' ' ' TRP . 30.2 p-10 -145.09 -46.69 0.23 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.97 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -74.06 110.36 3.08 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.58 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -162.0 113.78 1.69 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.75 0.309 . . . . 0.0 110.956 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.403 HD12 ' N ' ' A' ' 184' ' ' LEU . 2.0 mp -129.9 157.17 43.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.615 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -156.13 149.23 24.33 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 111.401 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.96 136.0 53.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.439 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -151.85 169.78 31.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.405 -0.903 . . . . 0.0 112.911 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 188' ' ' VAL . . . . . 0.468 ' CG1' HG23 ' A' ' 159' ' ' THR . 1.0 OUTLIER -131.2 140.05 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.688 0.28 . . . . 0.0 110.714 179.663 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 90.3 p -144.77 175.0 10.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.93 0.395 . . . . 0.0 111.343 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -142.57 159.61 41.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.736 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.432 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -101.74 138.08 39.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.956 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -148.8 166.61 27.95 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -166.94 -178.13 39.17 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.49 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -129.64 98.77 4.93 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.836 0.35 . . . . 0.0 110.897 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -102.38 -47.71 4.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.953 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.69 127.2 32.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.785 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -80.9 -177.19 6.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.105 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -170.32 91.56 0.5 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.071 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.14 176.47 5.43 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.508 2.139 . . . . 0.0 112.304 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 200' ' ' VAL . . . . . 0.533 HG22 ' H ' ' A' ' 202' ' ' ALA . 11.9 p -153.74 145.03 14.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.053 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 30.0 m -96.64 26.93 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.321 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 202' ' ' ALA . . . . . 0.533 ' H ' HG22 ' A' ' 200' ' ' VAL . . . -140.12 84.15 15.12 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.004 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_exo -50.92 -27.63 21.45 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.579 2.186 . . . . 0.0 112.341 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -116.27 147.78 40.21 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.01 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.42 136.43 28.68 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.58 2.187 . . . . 0.0 112.352 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -78.88 151.59 76.56 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.046 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -69.44 -42.31 3.85 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.596 2.197 . . . . 0.0 112.222 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -129.14 72.6 81.98 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.072 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.16 173.68 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.631 2.221 . . . . 0.0 112.278 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.184 -0.912 . . . . 0.0 110.885 -179.993 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.786 0.327 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 9.1 mtp-105 -115.7 167.28 11.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.1 mt -126.7 141.98 44.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.089 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -108.0 141.36 39.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.994 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 13.3 mmmt -128.09 156.35 42.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.968 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -104.92 -174.03 2.44 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.061 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.625 HG12 HG22 ' A' ' 9' ' ' VAL . 20.7 tt -102.48 116.8 46.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.116 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.574 ' CE2' HD21 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -121.17 30.08 7.0 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.978 -179.991 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.625 HG22 HG12 ' A' ' 7' ' ' ILE . 20.6 m -71.77 88.99 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.574 HD21 ' CE2' ' A' ' 8' ' ' PHE . 1.5 pp -141.87 107.59 5.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.876 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -73.53 142.56 46.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.951 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -150.12 93.57 2.02 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.124 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -112.31 74.56 1.52 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.162 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.34 -45.68 1.21 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.565 2.176 . . . . 0.0 112.351 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -76.12 -43.32 43.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -84.25 124.09 30.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.926 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -85.92 171.32 11.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.835 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -132.6 179.47 6.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.913 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.455 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.0 OUTLIER -151.09 130.02 12.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.859 -179.924 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.5 m-85 -131.22 135.79 47.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.751 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.43 140.43 21.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.864 0.364 . . . . 0.0 111.341 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.86 173.74 43.42 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.696 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -125.5 141.25 12.84 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.297 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.504 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.4 OUTLIER -130.66 149.08 52.48 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.093 0.473 . . . . 0.0 111.434 -179.787 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 1.064 HD11 HD12 ' A' ' 52' ' ' LEU . 31.9 tp -127.53 153.83 45.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -154.22 160.66 29.61 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.492 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' TRP . . . . . 0.408 ' CH2' HD11 ' A' ' 186' ' ' LEU . 41.9 p90 -143.01 154.86 44.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.948 0.404 . . . . 0.0 110.918 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 8.2 m -77.7 165.7 23.9 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.921 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.91 126.62 30.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.908 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -110.07 174.52 5.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.848 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 -126.65 167.1 16.16 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.892 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -85.17 -56.48 3.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.951 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.4 m -82.43 -65.93 0.95 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.45 176.69 51.5 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.506 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -136.95 113.52 10.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.791 0.329 . . . . 0.0 110.903 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -166.11 35.83 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.17 -177.82 6.51 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.5 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -92.38 146.8 23.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.825 0.345 . . . . 0.0 110.853 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -165.74 -75.41 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.442 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -137.51 149.72 46.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.796 0.331 . . . . 0.0 110.914 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 -132.64 31.6 3.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 -86.29 -43.65 12.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.816 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -82.95 175.42 10.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.867 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 24.4 m120 -91.72 107.13 18.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.84 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -101.85 171.7 22.02 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.535 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -52.25 125.63 18.06 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.606 2.204 . . . . 0.0 112.268 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.1 t -134.69 31.66 3.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.906 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -101.79 169.77 8.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.95 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -104.7 114.28 28.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.857 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -72.66 90.05 1.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -118.3 158.63 24.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 1.064 HD12 HD11 ' A' ' 25' ' ' LEU . 0.3 OUTLIER -76.37 168.22 20.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.886 -179.954 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.803 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -123.54 136.64 10.49 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.393 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.542 ' HB2' HD13 ' A' ' 25' ' ' LEU . . . -119.97 149.1 42.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 111.177 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -153.69 152.11 23.76 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.398 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.618 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -105.84 148.04 28.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.776 0.322 . . . . 0.0 111.049 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.446 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 35.9 p90 -135.38 118.17 16.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -143.2 129.02 3.58 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.069 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -137.09 169.12 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.963 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.455 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 29.8 p90 -134.34 134.59 41.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.35 . . . . 0.0 110.846 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 -86.92 137.1 32.66 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.808 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 36.7 t -140.76 -48.16 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.832 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 8.1 m120 -85.13 141.25 37.25 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.225 179.497 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.02 60.28 1.81 Allowed 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.269 1.98 . . . . 0.0 112.225 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER 178.64 -32.16 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.563 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -161.35 164.11 30.27 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.934 0.397 . . . . 0.0 111.355 -179.406 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 174.5 20.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.369 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.42 ' HB2' ' CE1' ' A' ' 60' ' ' TYR . 2.0 m-85 -83.61 144.52 29.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.655 0.264 . . . . 0.0 110.703 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -128.05 125.23 38.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.884 0.373 . . . . 0.0 111.137 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.8 tpp -106.45 127.51 53.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.569 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.92 148.28 17.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.672 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.618 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 0.1 OUTLIER -127.23 120.03 27.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.696 0.284 . . . . 0.0 110.648 179.878 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -97.62 122.71 41.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.899 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -139.03 119.34 13.7 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.876 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -102.94 175.98 5.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -101.31 113.39 4.66 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.467 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 30.3 ttt180 -143.31 112.65 6.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.793 0.33 . . . . 0.0 110.841 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.28 166.98 22.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.918 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.11 157.71 16.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.0 p90 -159.48 143.17 14.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.848 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.89 86.85 1.77 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.899 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -95.39 -98.58 1.75 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.519 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.3 m -170.2 166.49 8.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.769 0.319 . . . . 0.0 110.925 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.7 m -107.14 97.26 5.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.104 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -135.3 -69.76 0.5 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.883 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 24.6 m-20 -112.96 139.71 48.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.85 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 97.33 173.19 33.97 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.448 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -140.09 21.47 2.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.747 0.308 . . . . 0.0 111.404 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 3.8 t80 53.44 85.49 0.05 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.127 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.3 127.89 7.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.888 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -156.6 113.14 3.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.183 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -170.42 126.46 0.77 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.747 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.62 139.29 14.32 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.911 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.65 122.77 61.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.712 0.291 . . . . 0.0 110.292 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.02 136.97 47.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.111 0.481 . . . . 0.0 111.721 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.404 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.9 tt -121.08 104.73 10.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.624 -0.717 . . . . 0.0 109.291 179.075 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.461 HG22 ' HA3' ' A' ' 115' ' ' GLY . 3.6 p -145.93 171.37 14.94 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.251 0.548 . . . . 0.0 112.078 -178.456 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -106.09 131.07 53.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.373 -0.83 . . . . 0.0 109.864 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 19.6 ttpt -116.55 132.12 56.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.148 0.499 . . . . 0.0 111.682 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -127.65 131.33 49.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.626 -0.716 . . . . 0.0 109.587 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.443 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -132.28 175.43 19.86 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 -179.203 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.47 ' O ' HG22 ' A' ' 110' ' ' ILE . 0.2 OUTLIER -166.1 134.4 2.36 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.698 -0.251 . . . . 0.0 110.701 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -76.71 169.01 22.57 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 122.588 2.192 . . . . 0.0 112.39 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.583 HG22 HG23 ' A' ' 105' ' ' THR . 26.2 mm -116.22 -52.79 4.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.99 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.583 HG23 HG22 ' A' ' 104' ' ' ILE . 18.0 p -134.48 -47.31 0.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.836 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.2 t0 178.67 -37.1 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.077 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.508 ' C ' HD23 ' A' ' 108' ' ' LEU . 6.5 p-10 -118.25 16.32 13.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.663 -179.669 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.508 HD23 ' C ' ' A' ' 107' ' ' ASP . 0.1 OUTLIER -137.07 125.23 23.03 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.379 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -139.75 161.84 36.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.131 0.491 . . . . 0.0 111.811 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.47 HG22 ' O ' ' A' ' 102' ' ' TYR . 2.6 tt -114.51 144.93 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.037 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.443 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 60.7 m-85 -141.68 138.21 32.3 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.362 . . . . 0.0 111.445 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.87 128.18 30.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.715 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.534 ' NH2' ' HB3' ' A' ' 146' ' ' ALA . 18.6 mtm105 -118.38 127.91 54.13 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.264 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -134.38 122.78 23.06 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.491 179.472 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.461 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.93 -137.86 3.02 Favored Glycine 0 C--N 1.332 0.332 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.456 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -139.14 160.72 25.9 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.923 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 8.4 ptp -120.7 137.28 54.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.759 0.314 . . . . 0.0 110.775 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -131.62 113.2 22.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.842 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.7 p-90 -138.68 170.07 16.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.917 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 12.8 ttp180 -121.65 138.84 54.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.875 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -113.26 129.31 56.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.153 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -96.09 130.88 43.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.928 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 15.5 p -76.13 177.55 7.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.832 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 20.4 mttp -77.14 -71.98 0.38 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.897 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -168.27 -166.55 27.53 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.557 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 24.1 p30 -67.47 154.07 42.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.788 0.327 . . . . 0.0 110.938 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -169.4 112.74 0.51 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.872 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -108.46 140.42 41.8 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.079 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -124.19 -70.09 0.78 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.935 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 40.1 p -147.27 -48.32 0.18 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.949 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -164.66 79.47 0.13 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.517 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.467 HG13 ' O ' ' A' ' 132' ' ' VAL . 12.5 p -108.6 121.16 61.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.807 0.337 . . . . 0.0 111.07 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.84 45.08 1.0 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.31 104.21 9.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.818 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 23.5 m -145.63 31.66 1.07 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.95 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -112.42 159.65 18.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.79 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -76.39 132.64 39.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.894 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -75.43 144.6 42.08 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 52.9 p -124.51 114.88 20.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.908 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -93.56 105.73 3.33 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.493 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.455 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.7 p -140.78 122.8 15.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.702 0.287 . . . . 0.0 110.969 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -157.12 149.22 17.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.777 0.322 . . . . 0.0 111.557 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.536 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 87.5 Cg_endo -80.59 140.9 13.54 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.923 2.416 . . . . 0.0 112.126 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 31.2 m -156.91 160.56 2.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.004 0.431 . . . . 0.0 111.583 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -149.06 130.28 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.377 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.534 ' HB3' ' NH2' ' A' ' 113' ' ' ARG . . . -116.51 155.37 28.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.895 0.378 . . . . 0.0 111.502 -179.717 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.34 136.49 7.93 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.22 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -162.85 -165.24 19.59 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.854 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -133.72 170.72 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.554 0.216 . . . . 0.0 110.95 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -146.72 149.7 33.93 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.941 0.401 . . . . 0.0 111.266 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 24.8 p90 -137.04 132.18 33.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.631 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.04 135.52 34.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.52 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.0 t -116.18 -63.05 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.823 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -105.22 -171.98 2.01 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.834 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -75.07 113.81 12.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.989 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 33.2 m-20 62.94 32.83 15.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.167 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.421 HG12 ' CE2' ' A' ' 190' ' ' TYR . 45.1 mt -147.79 105.44 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.941 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -126.76 167.62 15.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.357 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.73 144.71 40.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.172 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.61 132.47 44.07 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.124 0.488 . . . . 0.0 111.89 -179.307 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -115.55 117.08 29.35 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.498 178.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.409 ' HG3' ' NZ ' ' A' ' 24' ' ' LYS . 23.8 mm-40 -107.04 145.03 32.85 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.127 0.489 . . . . 0.0 111.634 -178.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.432 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 48.9 t80 -133.95 158.28 43.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.455 179.656 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -107.27 123.68 48.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.008 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -123.69 107.89 11.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.723 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 31.2 m -65.27 174.45 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.071 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -155.11 -55.64 0.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.9 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -153.97 32.22 0.44 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 2.3 pt -70.35 -28.68 36.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.207 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -125.98 -159.34 10.24 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.47 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -124.47 -44.5 1.99 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.778 0.323 . . . . 0.0 110.918 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -61.02 -174.97 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.015 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -150.34 -92.04 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.586 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 59.8 m -143.35 106.71 4.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.928 0.394 . . . . 0.0 110.919 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 6.4 m -140.61 31.32 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.111 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -161.86 -83.59 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.551 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 177' ' ' THR . . . . . 0.817 HG22 ' HD2' ' A' ' 179' ' ' PRO . 0.2 OUTLIER -105.45 135.68 46.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.862 0.363 . . . . 0.0 110.877 179.977 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 178' ' ' ARG . . . . . 0.427 ' N ' ' CD ' ' A' ' 179' ' ' PRO . 0.3 OUTLIER -70.07 -51.76 13.8 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.98 179.963 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 179' ' ' PRO . . . . . 0.817 ' HD2' HG22 ' A' ' 177' ' ' THR . 51.4 Cg_exo -55.12 129.72 36.83 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.45 2.1 . . . . 0.0 112.313 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -111.74 148.31 33.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.855 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 23.3 p-10 -87.74 80.86 7.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.912 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -78.04 176.62 53.88 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.52 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 17.8 ttp -118.6 129.58 55.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.922 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.498 HD12 ' N ' ' A' ' 184' ' ' LEU . 2.5 mp -132.8 125.07 29.25 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.687 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 28.9 t -128.53 145.38 51.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.115 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 186' ' ' LEU . . . . . 0.408 HD11 ' CH2' ' A' ' 27' ' ' TRP . 0.0 OUTLIER -132.42 136.59 46.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.584 179.635 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 187' ' ' GLY . . . . . 0.504 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -154.63 -176.86 27.38 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.942 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -126.64 135.9 62.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.647 0.261 . . . . 0.0 110.442 179.503 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 189' ' ' SER . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 43.3 p -130.84 165.37 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.208 0.528 . . . . 0.0 111.721 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 190' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 190' ' ' TYR . 2.2 m-85 -124.96 143.19 51.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.471 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 8.6 mtp180 -108.14 147.33 31.42 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.905 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -104.63 129.25 52.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.82 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -126.13 164.58 19.65 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.49 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -68.62 -31.07 69.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.75 0.31 . . . . 0.0 110.873 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -108.02 161.18 15.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.821 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -97.91 -33.78 11.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.861 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -140.84 173.3 11.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.159 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -120.64 129.36 25.35 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.013 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.98 151.86 25.74 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.377 2.051 . . . . 0.0 112.345 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 3.6 m -109.34 90.47 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.135 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 23.1 m -114.06 -35.6 2.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.24 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -107.71 108.27 61.32 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.088 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.84 -44.13 2.2 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.37 2.047 . . . . 0.0 112.226 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -117.35 92.86 41.4 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.981 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.72 -49.36 1.62 Allowed 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.566 2.177 . . . . 0.0 112.416 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -136.65 109.08 9.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.157 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_exo -51.85 153.93 10.77 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.468 2.112 . . . . 0.0 112.277 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.903 ' HB3' ' HD3' ' A' ' 209' ' ' PRO . . . -160.12 -59.71 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.327 179.806 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 209' ' ' PRO . . . . . 0.903 ' HD3' ' HB3' ' A' ' 208' ' ' ALA . 68.2 Cg_exo -51.17 93.09 0.03 OUTLIER 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.285 1.99 . . . . 0.0 112.314 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.142 -0.932 . . . . 0.0 110.955 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.312 0 CA-C-O 120.838 0.351 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -170.27 98.06 0.27 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.977 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.6 mp -131.89 100.95 4.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.073 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -134.4 130.25 36.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.868 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -78.72 100.8 7.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.932 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.85 71.97 6.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.025 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.6 tp -178.14 -39.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.994 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -153.49 145.24 23.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 138.03 37.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.15 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.3 mp -120.99 -42.86 2.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.931 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -60.52 151.54 28.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -103.65 118.68 37.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.183 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.92 84.91 33.36 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.01 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -70.07 -37.59 8.22 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.625 2.216 . . . . 0.0 112.33 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.65 118.58 15.26 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.964 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -83.69 109.69 17.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.875 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -104.17 131.8 51.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.932 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -137.03 148.66 46.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.735 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 10.3 t90 -111.09 132.91 53.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.088 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.446 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 2.7 t80 -122.57 135.79 54.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.383 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.59 146.93 25.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.953 0.406 . . . . 0.0 111.5 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.407 ' HA3' ' HB3' ' A' ' 189' ' ' SER . . . 178.01 -172.84 45.44 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.482 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.65 148.57 20.24 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.489 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.27 151.0 47.21 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.072 0.463 . . . . 0.0 111.354 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.871 HD12 ' O ' ' A' ' 53' ' ' GLY . 18.7 tp -122.12 145.53 48.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.29 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -144.53 178.9 22.13 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.794 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' TRP . . . . . 0.418 ' CD1' ' HB3' ' A' ' 52' ' ' LEU . 0.5 OUTLIER -106.11 159.94 15.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.792 0.33 . . . . 0.0 110.834 -179.904 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.98 -60.71 1.49 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.825 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 68.6 mt-30 -104.42 146.14 29.27 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.881 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 18.0 p90 -143.81 -179.89 6.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.924 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -137.06 99.41 4.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.878 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -65.07 -67.49 0.43 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.026 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 82.6 p -78.52 -66.71 0.82 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.948 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 92.14 154.01 30.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -84.34 -179.97 7.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.851 0.358 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 18.0 m-85 -141.81 96.16 2.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -121.01 -166.1 12.89 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.527 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -79.81 -32.56 40.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.818 0.342 . . . . 0.0 110.894 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -153.14 104.43 0.26 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.515 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -126.07 31.69 5.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.816 0.341 . . . . 0.0 110.876 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -141.87 -46.12 0.35 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.981 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -58.5 -57.45 12.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.897 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 66.1 m-20 -64.47 -30.72 71.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.915 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -98.1 30.47 3.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.907 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -97.63 -99.07 2.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.508 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -79.96 55.24 5.56 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.521 2.148 . . . . 0.0 112.498 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.9 m -164.98 -46.51 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.776 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.7 tpm_? -64.63 140.09 58.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.93 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 53.2 m-20 -105.33 146.42 29.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.768 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -101.42 162.48 12.87 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.838 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -116.78 106.72 13.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.85 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.614 HD12 HD11 ' A' ' 25' ' ' LEU . 0.7 OUTLIER -134.32 164.43 27.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.06 -179.902 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.871 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -141.14 145.79 16.61 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.417 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -114.93 142.18 46.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.718 0.294 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.5 143.83 11.13 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.293 -0.956 . . . . 0.0 112.895 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -98.07 164.46 12.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.648 0.261 . . . . 0.0 110.668 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.446 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 52.2 p90 -152.38 141.03 20.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.062 0.458 . . . . 0.0 111.409 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -133.55 124.92 3.81 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.044 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -97.39 145.73 17.96 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.893 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -131.93 112.26 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.698 0.285 . . . . 0.0 110.574 179.783 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 5.1 mm100 -90.8 137.0 32.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.101 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.629 ' O ' HG12 ' A' ' 62' ' ' VAL . 21.6 t -148.87 23.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.948 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.1 m-20 173.22 137.48 0.12 Allowed Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.352 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -67.78 67.97 0.84 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.386 2.057 . . . . 0.0 112.276 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -169.07 -40.59 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.334 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -168.62 164.04 12.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.924 0.393 . . . . 0.0 111.256 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.67 159.19 26.82 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.313 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -82.9 127.57 33.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 110.566 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -114.64 127.08 55.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.966 0.412 . . . . 0.0 111.317 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.2 mtm -104.21 128.44 51.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.962 179.364 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.93 157.7 14.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.951 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -132.68 120.19 21.38 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.731 0.301 . . . . 0.0 110.508 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.424 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.8 OUTLIER -94.54 127.14 40.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.688 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t90 -139.1 125.2 20.01 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.944 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.5 mt -86.53 157.41 19.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.889 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -95.55 113.24 4.58 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.537 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 2.5 ppt_? -170.4 167.07 8.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.835 0.35 . . . . 0.0 110.888 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 15.3 mmm -131.72 166.63 21.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.903 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -98.48 166.78 11.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.081 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -142.45 -49.17 0.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.931 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.03 106.71 17.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.946 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.39 68.49 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.553 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 17.1 m -84.1 -67.81 0.76 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.822 0.344 . . . . 0.0 110.939 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.556 ' O ' HG12 ' A' ' 84' ' ' VAL . 14.1 t -142.36 34.21 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.084 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -135.75 167.58 20.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.925 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 86.3 m-20 -60.02 164.46 3.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.898 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -101.73 -129.93 6.85 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.529 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -149.95 -52.57 0.15 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.819 0.343 . . . . 0.0 111.123 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -108.35 137.09 46.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.02 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 15.7 mttp -161.67 112.8 1.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.866 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -173.94 169.95 3.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.259 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -149.97 137.86 20.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.547 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.424 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -81.66 128.08 8.27 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.795 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.2 m -133.21 117.77 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.716 0.293 . . . . 0.0 110.257 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLN . . . . . 0.408 ' CB ' ' HA ' ' A' ' 117' ' ' MET . 7.6 pt20 -123.92 149.74 45.53 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.107 0.48 . . . . 0.0 111.791 -179.269 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.533 ' O ' HD23 ' A' ' 96' ' ' LEU . 0.3 OUTLIER -124.63 120.1 30.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.517 179.658 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.465 HG22 ' HA3' ' A' ' 115' ' ' GLY . 4.3 p -148.28 171.81 15.38 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-O 121.088 0.471 . . . . 0.0 111.789 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.37 123.04 47.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.987 178.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.5 tttt -114.74 132.33 56.48 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.107 0.479 . . . . 0.0 111.7 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.535 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.6 pp -126.83 125.69 42.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.341 179.347 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.426 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -145.45 160.08 28.02 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.419 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.503 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.2 OUTLIER -166.27 148.49 6.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.676 0.274 . . . . 0.0 111.483 -179.758 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.503 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 73.3 Cg_endo -75.38 172.04 17.1 Favored 'Trans proline' 0 C--N 1.348 0.505 0 C-N-CA 122.807 2.338 . . . . 0.0 112.332 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 29.4 mt -132.08 -70.05 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.14 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.16 -67.95 0.72 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.906 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -161.11 -51.04 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.882 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.816 ' C ' HD23 ' A' ' 108' ' ' LEU . 14.4 m-20 -121.24 25.36 9.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.087 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.816 HD23 ' C ' ' A' ' 107' ' ' ASP . 0.2 OUTLIER -125.14 112.77 16.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.085 179.794 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.455 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 0.6 OUTLIER -124.39 155.14 39.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.258 0.552 . . . . 0.0 112.045 -178.999 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.862 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 151.76 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.937 178.984 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.426 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 20.1 m-85 -146.86 146.1 30.08 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.948 0.404 . . . . 0.0 111.706 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.3 m -142.54 129.87 21.1 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.325 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.24 130.22 52.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 121.02 0.438 . . . . 0.0 111.752 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.407 ' C ' HD23 ' A' ' 114' ' ' LEU . 6.1 tt -133.59 122.94 24.25 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.252 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.465 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -175.87 -140.8 3.57 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.576 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.475 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.53 161.52 27.37 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.888 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.408 ' HA ' ' CB ' ' A' ' 95' ' ' GLN . 0.2 OUTLIER -119.53 146.55 45.37 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.847 0.356 . . . . 0.0 110.753 -179.943 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -129.82 144.08 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.985 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -130.23 141.55 50.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.913 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 5.4 mmm180 -137.22 151.21 48.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.917 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -101.9 168.63 9.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.053 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -124.78 134.4 52.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.958 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -75.65 141.94 42.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.905 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.72 122.64 28.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.847 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -164.42 91.53 0.11 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.486 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -60.32 -47.94 83.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.802 0.334 . . . . 0.0 110.895 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -124.54 124.48 42.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -124.99 148.85 48.25 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.104 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.1 m -109.16 -48.72 3.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.4 p -134.57 174.97 9.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.989 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -67.32 -163.53 1.98 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.506 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 7.7 m -141.49 126.43 17.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.837 0.351 . . . . 0.0 111.126 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -85.92 -37.25 19.28 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -67.1 81.52 0.12 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.852 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.7 m -87.42 100.47 12.76 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.941 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -140.57 104.02 4.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 70.2 m80 -148.96 -179.02 6.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.867 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -135.46 131.17 35.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.868 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.5 t -114.06 143.72 44.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -94.93 143.95 16.9 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.563 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.6 p -146.1 132.1 13.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.752 0.31 . . . . 0.0 110.962 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.463 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 1.5 t -157.08 130.19 4.48 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.228 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.475 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.7 Cg_exo -73.8 147.31 39.37 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.639 2.226 . . . . 0.0 112.009 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.2 m -156.49 153.79 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.918 0.389 . . . . 0.0 111.46 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -149.1 124.05 10.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.658 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -117.75 145.81 44.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 0.0 111.339 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.49 132.72 5.91 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.226 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.441 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -163.32 -154.49 7.72 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.962 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.862 HG12 HG22 ' A' ' 110' ' ' ILE . 12.9 m -137.3 170.88 17.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.631 0.253 . . . . 0.0 110.949 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -147.25 150.75 35.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.953 0.406 . . . . 0.0 111.267 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' TRP . . . . . 0.422 ' CE2' ' HB ' ' A' ' 159' ' ' THR . 37.1 p90 -126.74 138.61 53.41 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.811 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.405 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -91.65 137.24 32.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.411 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 52.3 t -108.94 -47.58 7.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.48 179.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -109.69 -165.07 0.98 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.282 179.581 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 4.1 ttm180 -100.56 41.86 1.15 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.758 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.2 t0 178.13 -28.64 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.788 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 27.2 mt -114.95 134.29 58.47 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.982 0.42 . . . . 0.0 111.554 -179.518 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' ALA . . . . . 0.405 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.11 161.15 38.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.057 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' THR . . . . . 0.422 ' HB ' ' CE2' ' A' ' 151' ' ' TRP . 9.7 m -106.26 150.78 25.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.227 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? -137.09 142.23 42.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.172 0.511 . . . . 0.0 111.834 -179.405 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 162' ' ' GLU . 1.4 tt -123.65 117.89 26.02 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.601 178.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.409 ' N ' HD23 ' A' ' 161' ' ' LEU . 1.7 pt-20 -107.82 141.11 39.89 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.979 0.419 . . . . 0.0 111.635 -179.169 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.441 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 27.2 p90 -134.33 166.08 23.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.653 179.615 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -77.96 128.93 34.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.005 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.06 103.81 2.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.86 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.453 ' O ' HG13 ' A' ' 166' ' ' VAL . 12.4 p -166.97 122.64 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.091 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 20.4 m-80 -83.85 -34.95 24.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.848 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -81.09 138.88 35.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.842 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 1.7 pp -111.47 -30.25 2.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.14 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 179.95 62.95 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.492 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -116.16 -51.68 2.62 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.762 0.315 . . . . 0.0 110.828 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.427 ' HB1' ' HA3' ' A' ' 176' ' ' GLY . . . -60.96 -177.76 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.119 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 178.02 -36.33 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.476 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.455 HG23 HG13 ' A' ' 175' ' ' VAL . 4.0 t -113.04 -46.34 3.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.875 0.369 . . . . 0.0 110.924 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.455 HG13 HG23 ' A' ' 174' ' ' THR . 27.6 m -87.17 -30.67 5.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.166 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 176' ' ' GLY . . . . . 0.427 ' HA3' ' HB1' ' A' ' 172' ' ' ALA . . . -83.31 77.66 2.1 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.412 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 19.3 p -125.69 79.44 1.82 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.882 0.372 . . . . 0.0 110.865 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.55 93.24 43.21 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -67.99 95.62 0.43 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.451 2.101 . . . . 0.0 112.313 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 22.4 p30 -120.09 174.8 6.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.911 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -113.35 151.8 30.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.862 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 160.07 137.92 2.33 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.495 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 183' ' ' MET . . . . . 0.563 ' HE2' HD12 ' A' ' 184' ' ' LEU . 0.0 OUTLIER -154.23 171.6 18.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.768 0.318 . . . . 0.0 110.861 -179.986 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.563 HD12 ' HE2' ' A' ' 183' ' ' MET . 3.9 mp -94.42 127.8 40.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.908 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 51.0 m -140.98 150.09 42.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.132 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.65 138.04 54.5 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.521 179.742 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -157.06 176.31 34.33 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.955 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -125.9 137.78 56.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.737 0.304 . . . . 0.0 110.496 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 189' ' ' SER . . . . . 0.446 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 3.6 p -138.59 171.57 14.17 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.377 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -148.0 156.62 42.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.642 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.446 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -123.94 157.03 35.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.038 -179.918 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -141.43 160.93 39.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.777 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -112.2 113.15 3.21 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.488 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -135.26 121.58 20.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.845 0.355 . . . . 0.0 110.891 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -95.48 170.6 9.24 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -63.89 125.81 25.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.847 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -112.2 120.78 42.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.132 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 198' ' ' ALA . . . . . 0.779 ' HB3' ' HD3' ' A' ' 199' ' ' PRO . . . -173.06 -63.15 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.229 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.779 ' HD3' ' HB3' ' A' ' 198' ' ' ALA . 59.7 Cg_endo -72.34 140.17 33.18 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.454 2.103 . . . . 0.0 112.327 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 21.5 t -60.09 95.77 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.143 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 201' ' ' VAL . . . . . 0.639 HG22 ' O ' ' A' ' 201' ' ' VAL . 14.6 p -115.66 26.72 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.216 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 202' ' ' ALA . . . . . 0.805 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -79.76 -61.8 0.44 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.208 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.805 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 73.7 Cg_endo -75.16 151.14 38.47 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.513 2.142 . . . . 0.0 112.397 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -119.13 83.56 24.8 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.006 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.54 -17.37 38.61 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.642 2.228 . . . . 0.0 112.483 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -55.18 147.74 34.03 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.198 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -52.82 -176.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.481 2.12 . . . . 0.0 112.303 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -129.78 98.96 21.02 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.992 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.98 147.27 73.72 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.454 2.103 . . . . 0.0 112.264 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.841 -179.964 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 120.775 0.322 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.3 ttt85 -103.55 142.3 34.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.633 HD13 HD11 ' A' ' 7' ' ' ILE . 2.5 pp -67.57 134.85 29.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.134 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -137.27 31.56 2.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.872 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -123.04 170.14 10.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.818 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.7 113.64 19.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.026 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.693 HG21 HD12 ' A' ' 10' ' ' LEU . 3.3 mp -95.44 111.69 26.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.17 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -92.04 -31.77 15.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.907 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 11.6 p -117.47 127.8 74.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.06 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.693 HD12 HG21 ' A' ' 7' ' ' ILE . 0.5 OUTLIER -167.54 -49.47 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.845 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -89.11 -38.01 14.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.947 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -107.22 99.99 9.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.165 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.684 ' HB1' ' HD2' ' A' ' 14' ' ' PRO . . . -87.53 165.33 31.01 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.992 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.684 ' HD2' ' HB1' ' A' ' 13' ' ' ALA . 18.3 Cg_endo -59.87 83.86 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.498 2.132 . . . . 0.0 112.18 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.2 tttp -89.43 -7.71 54.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.349 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 -89.19 45.33 1.28 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.766 0.317 . . . . 0.0 111.309 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.428 ' HB3' ' CZ3' ' A' ' 19' ' ' TRP . 3.7 m-20 -108.22 156.93 18.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.82 0.343 . . . . 0.0 110.974 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 t -147.02 145.93 29.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.843 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.438 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 2.7 m-90 -132.3 129.97 40.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.037 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.422 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 0.2 OUTLIER -121.67 135.85 54.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.683 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.05 139.82 23.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.396 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.9 -158.56 20.49 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.417 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.79 149.65 21.52 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.534 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -130.61 154.91 47.37 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.055 0.455 . . . . 0.0 111.135 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.638 HD21 HD13 ' A' ' 52' ' ' LEU . 1.4 tt -127.04 141.7 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.641 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -148.76 171.86 29.01 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.592 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 2.1 m95 -99.16 133.42 43.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.773 0.32 . . . . 0.0 110.871 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.8 m -162.13 121.81 2.42 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.889 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -140.27 83.09 1.89 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -163.81 85.38 0.48 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.8 m80 -105.28 -38.93 6.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.869 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -156.65 156.11 32.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.872 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.37 117.16 27.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.932 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.49 -177.22 54.17 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.48 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -136.09 138.7 42.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.87 0.367 . . . . 0.0 110.921 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.1 t80 -108.19 37.21 2.54 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.7 141.66 15.3 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.464 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -120.17 164.09 16.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.824 0.345 . . . . 0.0 110.831 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -101.4 144.85 16.64 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.499 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -126.43 -62.62 1.14 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.872 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -130.78 -56.33 1.06 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.912 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -81.8 178.51 8.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.846 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -132.21 -47.85 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.777 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 7.5 m-80 -77.95 151.92 33.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.969 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -116.35 156.03 15.88 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.518 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.11 -61.34 0.52 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.543 2.162 . . . . 0.0 112.261 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.8 m -79.31 162.39 25.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.922 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.3 ttt-85 -84.13 -178.39 6.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.751 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -89.51 -42.19 11.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.847 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -93.42 151.53 19.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.852 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -157.63 135.29 10.59 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.638 HD13 HD21 ' A' ' 25' ' ' LEU . 0.3 OUTLIER -88.05 167.75 13.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.91 138.54 14.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.534 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -131.26 138.7 49.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.689 0.28 . . . . 0.0 110.863 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.62 156.32 26.8 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.336 -0.935 . . . . 0.0 112.921 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.45 133.84 49.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.717 0.294 . . . . 0.0 110.844 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -119.75 127.17 52.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.967 0.413 . . . . 0.0 111.075 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.56 124.85 2.18 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.139 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -128.5 173.38 19.17 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.798 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.438 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 21.7 p90 -154.02 131.75 11.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 110.781 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -94.48 137.03 34.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.883 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.3 t -119.68 -45.2 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.886 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -109.25 146.53 34.11 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.613 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.41 ' O ' ' CD2' ' A' ' 65' ' ' TYR . 41.1 Cg_endo -67.53 65.37 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.545 2.164 . . . . 0.0 112.148 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.41 ' CD2' ' O ' ' A' ' 64' ' ' PRO . 9.9 m-85 -164.82 -42.28 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.178 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -170.29 164.17 8.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.191 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.03 175.17 19.61 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.44 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -95.7 134.71 38.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.418 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 0.0 OUTLIER -114.67 128.41 56.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -114.15 119.76 38.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.33 179.437 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 154.59 16.48 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.481 -0.866 . . . . 0.0 112.783 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 -130.09 114.83 16.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.579 0.228 . . . . 0.0 110.659 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.32 125.77 35.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.115 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 10.8 m95 -139.18 140.66 37.89 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.844 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.539 HD23 ' N ' ' A' ' 75' ' ' LEU . 1.2 pt? -169.24 46.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.968 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -168.52 152.34 20.17 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.674 -0.775 . . . . 0.0 112.508 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 19.9 mtp180 -114.3 115.92 28.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.878 0.371 . . . . 0.0 110.825 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 63.6 mtp -61.5 160.82 10.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.945 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -109.36 167.91 9.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.984 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' TYR . . . . . 0.419 ' CE2' ' HG2' ' A' ' 81' ' ' LYS . 47.8 p90 -67.13 -31.01 71.17 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.843 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' LYS . . . . . 0.419 ' HG2' ' CE2' ' A' ' 80' ' ' TYR . 41.0 mmtt -66.41 169.62 7.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.83 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -173.98 162.45 33.08 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.582 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -76.71 160.97 28.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.808 0.337 . . . . 0.0 110.955 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 84' ' ' VAL . 15.8 t -127.96 31.58 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.126 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -151.56 -67.09 0.18 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.853 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -95.51 89.44 5.4 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.902 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -144.36 54.43 0.57 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.56 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -69.73 -46.86 64.96 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.817 0.342 . . . . 0.0 111.068 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 18.8 p90 -148.01 161.17 41.91 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.898 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.14 -167.59 1.93 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.837 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.0 142.89 51.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.124 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 12.1 pm0 -175.01 157.42 2.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.734 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -82.26 130.94 10.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.586 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.47 119.74 55.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.786 0.327 . . . . 0.0 110.446 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 139.87 43.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.534 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.416 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.7 tt -130.25 110.88 11.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.972 179.537 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.425 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 0.1 OUTLIER -150.49 168.94 22.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.993 0.425 . . . . 0.0 111.565 -179.147 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -104.1 125.91 50.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.197 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.421 ' HE3' ' CG ' ' A' ' 111' ' ' TYR . 0.6 OUTLIER -104.25 132.21 50.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.997 0.427 . . . . 0.0 111.752 -179.165 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.598 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.8 pp -134.82 115.74 14.01 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.388 179.114 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.05 41.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.672 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -166.28 167.05 8.83 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.713 0.292 . . . . 0.0 111.116 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -53.3 167.87 0.73 Allowed 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.488 2.125 . . . . 0.0 111.941 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.615 HG23 ' OG1' ' A' ' 105' ' ' THR . 1.0 OUTLIER -121.13 -34.38 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 120.693 0.282 . . . . 0.0 111.679 -179.818 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.615 ' OG1' HG23 ' A' ' 104' ' ' ILE . 0.2 OUTLIER -157.6 -53.45 0.07 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.761 0.315 . . . . 0.0 110.991 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -175.22 109.89 0.11 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.092 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.592 ' O ' HD23 ' A' ' 108' ' ' LEU . 0.1 OUTLIER 71.35 22.33 4.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.539 179.657 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.764 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.1 OUTLIER -142.81 117.38 9.75 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.582 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.413 ' HB2' ' CG ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -125.41 152.95 44.16 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.225 0.536 . . . . 0.0 112.009 -178.903 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.93 130.88 73.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.044 179.291 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.421 ' CG ' ' HE3' ' A' ' 99' ' ' LYS . 53.1 p90 -144.06 153.62 42.38 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.915 0.388 . . . . 0.0 111.526 -179.446 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 2.1 t -136.94 133.11 35.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.69 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 5.8 ptp180 -111.42 128.36 55.96 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.145 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -124.64 123.61 40.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.619 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.425 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.82 -132.46 1.9 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.547 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.548 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -148.24 169.08 28.94 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.821 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.07 139.86 51.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.795 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -126.17 132.9 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.809 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 85.3 t90 -134.23 140.38 46.43 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.864 0.364 . . . . 0.0 110.95 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.97 164.03 14.34 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.769 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -100.07 152.92 19.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.124 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -62.95 131.46 48.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.041 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 1.6 m -102.29 139.09 38.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.948 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 19.3 tttt -145.6 131.1 18.74 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.854 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -122.5 28.59 5.7 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.5 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -103.8 32.26 4.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.857 0.361 . . . . 0.0 110.863 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -81.53 111.17 17.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.882 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -98.89 31.19 3.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.963 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -174.78 136.87 0.43 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.95 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -127.48 38.55 4.04 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.811 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' GLY . . . . . 0.483 ' O ' HG13 ' A' ' 132' ' ' VAL . . . -142.3 28.43 2.21 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.509 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.483 HG13 ' O ' ' A' ' 131' ' ' GLY . 6.2 m -157.48 -46.87 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.86 0.362 . . . . 0.0 111.17 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.409 ' N ' HG23 ' A' ' 132' ' ' VAL . 1.1 t -97.63 179.89 4.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.898 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -150.08 162.37 40.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.875 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.88 105.34 13.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.886 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -83.28 93.26 7.67 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.886 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -93.56 113.35 25.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.906 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -141.43 163.41 33.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.7 p -138.59 146.17 41.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.875 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -122.34 102.5 0.79 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.53 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.444 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.2 p -136.11 123.61 34.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.697 0.284 . . . . 0.0 111.054 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.27 150.12 18.33 Favored Pre-proline 0 C--N 1.331 -0.217 0 CA-C-O 120.922 0.392 . . . . 0.0 111.421 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.548 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -78.77 141.14 16.91 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.758 2.306 . . . . 0.0 112.133 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.5 m -156.86 160.66 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.855 0.36 . . . . 0.0 111.418 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.6 p90 -141.6 122.47 14.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.472 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -111.8 138.2 48.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.962 0.41 . . . . 0.0 111.473 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -127.66 138.22 10.32 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.818 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -163.71 -165.71 21.34 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.078 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 17.2 m -135.47 167.05 26.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.659 0.266 . . . . 0.0 111.149 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.413 ' CG ' ' HB2' ' A' ' 109' ' ' ASP . 13.4 pt-20 -136.34 141.09 43.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.999 0.428 . . . . 0.0 111.172 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' TRP . . . . . 0.764 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.0 OUTLIER -122.31 123.07 40.57 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.628 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.16 131.86 35.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.786 HG12 HG22 ' A' ' 154' ' ' THR . 48.8 t -100.56 -64.01 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.013 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' THR . . . . . 0.786 HG22 HG12 ' A' ' 153' ' ' VAL . 9.0 t -176.59 173.9 1.95 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.981 0.42 . . . . 0.0 111.826 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 65.62 -86.09 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.378 179.683 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -174.44 32.59 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.839 0.352 . . . . 0.0 110.653 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 28.3 mt -140.05 117.88 10.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.875 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.25 163.77 14.8 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.385 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.9 t -110.8 143.24 41.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.098 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 146.64 45.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.28 0.562 . . . . 0.0 111.855 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -116.63 124.8 50.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.698 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -116.51 141.01 48.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.029 0.442 . . . . 0.0 111.524 -179.181 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 14.2 p90 -134.22 157.61 45.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.468 179.683 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 -83.52 -68.58 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 8.2 t90 -140.55 103.13 4.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.811 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.3 t -123.89 121.96 63.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.211 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -132.47 30.72 4.11 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.821 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -77.4 136.14 38.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.884 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 23.0 mt -107.08 -26.85 3.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.24 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -56.32 114.6 5.25 Favored Glycine 0 C--N 1.33 0.217 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.52 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 6.9 t0 -97.28 39.07 1.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.865 0.364 . . . . 0.0 110.889 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -91.1 -31.23 16.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.083 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -149.58 92.34 0.14 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.498 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.0 m -86.3 -31.62 21.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.9 0.381 . . . . 0.0 110.96 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.0 100.96 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.147 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -103.65 -108.24 3.25 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.52 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 84.4 m -128.26 -70.37 0.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.794 0.33 . . . . 0.0 110.908 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 16.5 mmt180 -132.13 97.77 17.94 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.871 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.94 134.86 33.32 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.438 2.092 . . . . 0.0 112.231 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -127.43 31.94 5.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.946 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' ASN . . . . . 0.508 ' O ' HD11 ' A' ' 184' ' ' LEU . 0.9 OUTLIER -95.66 79.33 3.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 92.17 -129.76 9.99 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.448 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 2.3 ttt -124.32 97.68 5.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.508 HD11 ' O ' ' A' ' 181' ' ' ASN . 5.9 mp -122.23 142.02 50.88 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.741 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.99 155.58 41.69 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.996 0.427 . . . . 0.0 111.221 -179.768 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.53 139.08 50.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.355 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -153.53 171.1 32.35 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.281 -0.961 . . . . 0.0 113.166 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.5 137.23 57.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.694 0.283 . . . . 0.0 110.489 179.584 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 77.9 p -140.77 174.95 10.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.992 0.425 . . . . 0.0 111.294 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -137.41 157.1 47.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.585 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.422 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.4 OUTLIER -113.88 124.8 53.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.916 -179.968 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -65.45 89.03 0.09 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.854 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -124.13 138.46 11.33 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.47 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -144.55 31.49 1.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.8 0.333 . . . . 0.0 110.815 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.62 158.46 29.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.865 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -129.72 144.46 51.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.923 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -65.73 124.0 21.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.033 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 198' ' ' ALA . . . . . 0.653 ' HB3' ' CD ' ' A' ' 199' ' ' PRO . . . -173.08 -63.54 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.247 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.653 ' CD ' ' HB3' ' A' ' 198' ' ' ALA . 19.4 Cg_endo -59.35 -67.46 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.455 2.103 . . . . 0.0 112.27 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 7.0 m -153.05 179.62 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.142 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 13.5 m -125.85 179.63 3.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.068 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 202' ' ' ALA . . . . . 0.753 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -59.41 -61.28 8.17 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.07 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.753 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 59.7 Cg_endo -72.16 141.95 37.03 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.611 2.208 . . . . 0.0 112.315 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -125.42 146.63 55.06 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.981 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -72.89 132.32 18.25 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.466 2.111 . . . . 0.0 112.353 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -126.76 87.29 56.85 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.019 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.15 -61.55 0.49 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.555 2.17 . . . . 0.0 112.282 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -94.66 149.4 36.42 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.073 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.57 -28.3 36.14 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.55 2.167 . . . . 0.0 112.289 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.157 -0.925 . . . . 0.0 110.906 179.912 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.395 0 CA-C-O 120.864 0.364 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.0 tpt180 -138.78 -62.03 0.56 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.406 HG23 ' N ' ' A' ' 4' ' ' MET . 4.9 tp -120.3 -40.39 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.266 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.406 ' N ' HG23 ' A' ' 3' ' ' ILE . 6.0 mtt -129.41 92.71 3.4 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.021 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.74 -34.53 3.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.038 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -88.92 60.25 5.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.088 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 26.1 mm -102.0 -63.24 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.044 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -173.0 126.62 0.46 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.937 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.776 ' O ' HD22 ' A' ' 10' ' ' LEU . 12.5 p -141.98 -45.81 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.183 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.776 HD22 ' O ' ' A' ' 9' ' ' VAL . 0.4 OUTLIER -149.05 -56.02 0.19 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.921 179.925 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 59.5 t30 -62.4 123.92 19.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.993 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -126.99 134.83 50.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.066 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -87.71 144.25 34.92 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.185 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -74.27 -168.1 0.45 Allowed 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.584 2.189 . . . . 0.0 112.329 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.23 111.13 23.57 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.886 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -64.3 152.73 40.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 22.7 m-20 -107.99 151.84 25.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 68.9 p -117.61 157.73 25.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.81 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.9 m95 -139.88 138.54 35.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.979 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.7 m-85 -131.8 135.88 47.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.685 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.71 146.03 30.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.322 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.36 -177.62 48.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.9 150.29 21.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.441 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.468 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -135.57 153.68 51.61 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 111.21 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.879 HD12 ' O ' ' A' ' 53' ' ' GLY . 41.9 tp -124.03 147.93 47.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.541 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -151.42 175.74 30.16 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.481 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 4.0 m-90 -124.79 144.99 49.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.741 0.305 . . . . 0.0 110.885 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.9 t -102.5 168.8 9.06 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.932 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 1.1 mm100 -72.13 160.02 33.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.889 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 40.1 p90 -103.16 132.21 49.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.868 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -60.82 178.36 0.24 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -115.71 106.45 13.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.921 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 71.4 p -93.72 -48.12 6.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.85 -61.59 3.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.528 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -96.82 135.54 38.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.785 0.326 . . . . 0.0 110.832 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.5 p90 -149.34 -47.16 0.14 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.888 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -103.34 126.4 8.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.512 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -65.53 -57.51 8.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 110.924 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -137.36 -45.09 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.477 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -124.14 174.36 7.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 110.916 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -158.53 126.25 5.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.938 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -108.22 157.01 18.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.905 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -123.4 30.49 6.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.003 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -104.37 30.41 5.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.761 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -141.88 -136.91 3.31 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.432 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -67.99 167.02 22.77 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.505 2.136 . . . . 0.0 112.187 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 61.9 p -131.27 121.27 24.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.027 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -71.86 119.01 15.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -105.82 158.16 16.94 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.973 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -65.85 152.21 44.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.957 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.14 117.07 7.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.756 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.77 147.26 25.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.848 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.879 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -136.38 130.63 5.34 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.449 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.88 133.42 51.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.767 0.317 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.425 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -139.73 137.95 8.85 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.881 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.714 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -99.5 144.76 28.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.803 0.335 . . . . 0.0 110.563 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.435 ' CE2' ' HD3' ' A' ' 24' ' ' LYS . 51.3 m-85 -136.16 133.52 37.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.035 0.445 . . . . 0.0 111.345 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.73 126.52 2.22 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.963 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -125.58 169.45 17.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.839 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.422 ' CE2' ' HB3' ' A' ' 68' ' ' PHE . 42.6 p90 -147.12 135.53 21.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -88.45 137.01 32.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.846 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 32.5 t -130.13 -46.78 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.921 0.391 . . . . 0.0 110.931 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -106.82 143.23 26.64 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.47 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.42 ' O ' ' CG ' ' A' ' 65' ' ' TYR . 46.6 Cg_endo -68.39 63.16 1.13 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.436 2.091 . . . . 0.0 112.139 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.655 ' HB3' HD23 ' A' ' 66' ' ' LEU . 8.3 m-85 -168.49 -38.31 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.434 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.655 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.2 OUTLIER -161.78 164.14 29.07 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.906 0.384 . . . . 0.0 111.148 -179.63 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.43 159.53 22.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.472 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.422 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . 0.8 OUTLIER -82.09 144.86 30.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.554 0.216 . . . . 0.0 110.706 179.928 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.93 127.29 33.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.422 . . . . 0.0 111.074 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.0 ptp -109.26 133.21 53.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.86 17.34 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.766 -179.683 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.714 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 14.6 m-85 -129.93 118.13 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.615 0.245 . . . . 0.0 110.55 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.0 122.0 37.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.133 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 -139.06 125.38 20.29 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.083 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.5 mp -100.41 -32.69 10.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.873 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 78.72 -151.75 36.23 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.506 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.37 133.11 51.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.786 0.327 . . . . 0.0 110.814 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.5 -58.81 0.09 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.934 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -78.54 135.56 37.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.092 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -91.54 50.41 1.72 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.895 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 4.8 tttt -142.96 116.79 9.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.892 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -149.02 167.66 29.44 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.536 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 35.9 m -82.32 109.56 16.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.835 0.35 . . . . 0.0 110.814 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.592 ' O ' HG12 ' A' ' 84' ' ' VAL . 16.2 t -129.71 31.48 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.098 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -107.87 -72.88 0.71 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.926 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -133.87 103.6 5.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.911 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 98.04 163.08 30.96 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.471 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -137.79 175.64 9.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.792 0.329 . . . . 0.0 111.049 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 25.8 p90 -159.37 164.02 35.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.012 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 18.7 mmtt -121.66 -178.4 3.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.852 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -147.9 108.33 4.12 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.072 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -147.7 125.01 11.54 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.608 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.78 135.37 12.11 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.937 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -128.32 117.98 46.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.798 0.333 . . . . 0.0 110.123 179.252 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 95' ' ' GLN . . . . . 0.401 ' CG ' ' CB ' ' A' ' 117' ' ' MET . 8.2 mt-30 -108.86 145.39 35.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.192 0.52 . . . . 0.0 111.925 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.3 tt -130.02 110.32 11.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.256 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.8 p -150.22 170.04 19.9 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.233 0.54 . . . . 0.0 111.984 -178.504 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.51 45.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.014 178.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -118.85 131.95 56.1 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.062 0.458 . . . . 0.0 111.581 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.609 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -131.85 121.67 24.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.96 179.12 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.437 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -115.95 -177.02 18.34 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.088 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -166.07 122.58 0.99 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 115.803 -0.198 . . . . 0.0 110.71 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -69.12 168.75 19.81 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.435 2.09 . . . . 0.0 112.391 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.645 HG22 HG23 ' A' ' 105' ' ' THR . 27.6 mm -117.22 -43.32 3.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.894 179.758 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.645 HG23 HG22 ' A' ' 104' ' ' ILE . 29.6 p -147.63 -82.71 0.12 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.823 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -155.31 21.83 0.42 Allowed 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.205 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.882 ' O ' HD23 ' A' ' 108' ' ' LEU . 5.3 p-10 -175.61 24.69 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.609 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.882 HD23 ' O ' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -154.38 124.48 6.81 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.588 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -143.07 159.64 41.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.101 0.477 . . . . 0.0 111.628 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 1.031 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.64 154.81 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.316 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.437 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 91.5 m-85 -143.04 138.57 30.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.664 -179.508 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 31.6 m -125.2 127.63 47.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.313 179.393 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -116.54 127.88 54.92 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.38 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -137.96 122.58 18.59 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.511 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 179.26 -137.7 3.24 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.524 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.494 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.93 162.34 27.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.945 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.401 ' CB ' ' CG ' ' A' ' 95' ' ' GLN . 2.2 ptt? -119.63 142.31 48.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.801 0.334 . . . . 0.0 110.771 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.6 t -133.88 123.81 45.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.688 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.488 ' HZ3' ' HB3' ' A' ' 121' ' ' ALA . 61.8 p-90 -133.21 161.61 33.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.003 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.08 150.27 50.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.921 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.488 ' HB3' ' HZ3' ' A' ' 119' ' ' TRP . . . -173.53 150.95 1.85 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.069 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -125.57 120.61 31.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 2.4 p -119.12 31.38 6.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 5.3 mttp -121.73 137.59 54.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.84 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -144.83 -100.42 0.3 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.49 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 17.5 m-80 -77.6 83.51 3.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.799 0.333 . . . . 0.0 110.845 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -146.23 32.67 0.99 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.875 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -68.66 119.95 13.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.213 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 4.0 p -86.13 -56.65 3.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.2 p -146.7 -48.27 0.19 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.93 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -169.45 41.05 0.21 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.523 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 9.6 p -73.97 149.17 7.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.878 0.37 . . . . 0.0 111.076 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 88.4 p -135.01 165.37 25.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.899 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 24.2 mtt85 -91.84 99.78 12.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.931 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 1.3 m -95.89 -37.08 10.86 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.868 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.07 127.65 21.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.817 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 42.2 m80 -73.36 -179.72 3.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.012 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -124.62 130.5 52.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.914 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 8.8 m -129.44 121.73 27.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.927 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.422 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -70.18 147.29 44.13 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.43 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.9 p -146.13 133.58 15.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.705 0.288 . . . . 0.0 111.012 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -157.01 137.38 8.99 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.329 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.494 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 89.4 Cg_endo -81.09 143.47 14.26 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 122.682 2.254 . . . . 0.0 112.084 179.75 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 143' ' ' PRO . 29.2 m -157.08 163.53 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 111.516 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -149.04 126.36 11.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.574 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.665 ' HB1' ' CD ' ' A' ' 162' ' ' GLU . . . -111.91 152.48 27.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.906 0.384 . . . . 0.0 111.267 -179.722 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.0 131.45 4.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.239 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -161.03 -160.05 10.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.824 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 1.031 HG12 HG22 ' A' ' 110' ' ' ILE . 5.5 m -134.41 167.72 25.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.628 0.252 . . . . 0.0 110.951 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -134.8 137.05 43.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.007 0.432 . . . . 0.0 111.189 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' TRP . . . . . 0.49 ' CZ3' HG22 ' A' ' 153' ' ' VAL . 1.4 t90 -114.91 123.32 48.85 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.574 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.81 130.74 36.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.523 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.49 HG22 ' CZ3' ' A' ' 151' ' ' TRP . 39.3 t -115.99 -57.44 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.852 179.647 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.22 -165.39 1.34 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.743 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.19 -28.64 23.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.076 -179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -139.51 18.66 2.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.312 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.1 mt -137.62 116.64 14.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.566 -0.288 . . . . 0.0 111.008 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.32 168.55 18.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.952 0.406 . . . . 0.0 111.242 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' THR . . . . . 0.704 HG22 HG12 ' A' ' 188' ' ' VAL . 29.1 p -113.43 153.18 29.04 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.135 179.614 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 14.8 ptp180 -137.19 141.66 42.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 111.892 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -121.54 118.16 28.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.656 178.853 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.665 ' CD ' ' HB1' ' A' ' 146' ' ' ALA . 0.4 OUTLIER -108.34 143.66 36.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.97 0.414 . . . . 0.0 111.768 -178.832 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.43 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.2 p90 -134.25 162.88 30.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.509 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -78.22 -44.16 26.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.782 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -177.13 164.15 2.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.935 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 11.5 p -58.65 142.5 14.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.138 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 2.5 t30 -110.78 161.71 15.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.865 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -130.78 -175.04 3.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' ILE . . . . . 0.446 HD12 ' N ' ' A' ' 170' ' ' GLY . 2.6 pp -124.11 -37.05 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.247 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' GLY . . . . . 0.446 ' N ' HD12 ' A' ' 169' ' ' ILE . . . -95.94 28.34 13.04 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.525 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -91.65 -51.01 5.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.804 0.335 . . . . 0.0 110.883 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -82.1 -175.69 5.77 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.033 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -131.89 -133.25 3.43 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.445 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.8 m -76.02 -64.83 1.01 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.794 0.33 . . . . 0.0 110.814 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.522 ' O ' HG23 ' A' ' 175' ' ' VAL . 31.9 m -92.92 116.96 35.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.149 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -117.35 96.25 0.69 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.54 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -100.09 -66.93 0.88 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.74 0.305 . . . . 0.0 110.813 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 178' ' ' ARG . . . . . 0.438 ' N ' ' CD ' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -73.45 -51.07 5.8 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.025 -179.917 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 179' ' ' PRO . . . . . 0.438 ' CD ' ' N ' ' A' ' 178' ' ' ARG . 32.5 Cg_exo -57.86 84.95 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.516 2.144 . . . . 0.0 112.301 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -162.79 87.57 0.59 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -127.36 102.13 6.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.843 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -148.17 113.21 0.61 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.563 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 1.5 tpp -130.02 97.18 4.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.794 0.33 . . . . 0.0 110.815 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.5 mp -111.28 116.2 30.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.973 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 30.2 t -118.52 147.42 43.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.768 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -126.52 139.36 53.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.709 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 187' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -156.67 -177.03 29.43 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.414 -0.898 . . . . 0.0 113.063 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 188' ' ' VAL . . . . . 0.704 HG12 HG22 ' A' ' 159' ' ' THR . 1.3 m -130.82 142.84 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.675 0.274 . . . . 0.0 110.598 179.61 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 89.0 p -143.24 170.83 15.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.998 0.427 . . . . 0.0 111.449 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 44.3 p90 -138.66 154.88 48.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.58 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.13 154.25 40.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -96.68 96.14 8.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.958 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -82.46 -168.4 42.07 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.51 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -97.85 120.79 38.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.824 0.345 . . . . 0.0 110.888 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -70.98 178.05 3.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.901 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -130.61 165.84 21.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -122.89 33.13 5.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.084 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -103.09 104.86 42.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.003 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -68.28 -42.8 5.16 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.504 2.136 . . . . 0.0 112.283 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 200' ' ' VAL . . . . . 0.536 HG22 ' H ' ' A' ' 202' ' ' ALA . 11.5 p -137.64 120.7 20.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.213 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 201' ' ' VAL . . . . . 0.578 ' O ' HG12 ' A' ' 201' ' ' VAL . 16.9 t -103.72 34.91 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.986 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 202' ' ' ALA . . . . . 0.536 ' H ' HG22 ' A' ' 200' ' ' VAL . . . -122.23 84.79 46.53 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.018 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.14 -70.07 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.561 2.174 . . . . 0.0 112.254 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 204' ' ' ALA . . . . . 0.739 ' HB3' ' HD3' ' A' ' 205' ' ' PRO . . . -73.21 -61.19 1.54 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.139 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 205' ' ' PRO . . . . . 0.739 ' HD3' ' HB3' ' A' ' 204' ' ' ALA . 59.7 Cg_endo -72.3 -173.77 1.22 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.499 2.133 . . . . 0.0 112.374 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -112.61 152.45 44.7 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.153 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 207' ' ' PRO . . . . . 0.441 ' HB3' HG23 ' A' ' 200' ' ' VAL . 52.0 Cg_endo -69.34 -46.21 1.49 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.563 2.176 . . . . 0.0 112.229 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -149.92 146.31 20.23 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.113 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.23 125.84 19.69 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.57 2.18 . . . . 0.0 112.328 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.234 -0.888 . . . . 0.0 110.91 179.963 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 120.856 0.36 . . . . 0.0 111.046 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -97.92 123.37 41.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.6 tp -150.8 147.15 15.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.151 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -119.9 -55.71 2.07 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HE2' ' CD2' ' A' ' 8' ' ' PHE . 28.5 tttt -158.9 135.5 9.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.935 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.1 -43.19 2.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.2 mm -67.88 122.39 18.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.164 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.416 ' CD2' ' HE2' ' A' ' 5' ' ' LYS . 0.2 OUTLIER -134.7 171.48 14.3 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 -179.895 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.612 ' O ' HG13 ' A' ' 9' ' ' VAL . 9.0 p -130.31 105.57 11.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.115 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.471 ' O ' HD12 ' A' ' 10' ' ' LEU . 2.2 pp -175.07 141.33 0.57 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.88 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -62.45 155.17 26.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.01 85.59 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.125 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.743 ' HB3' ' HD3' ' A' ' 14' ' ' PRO . . . -76.86 -52.5 1.99 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.145 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.743 ' HD3' ' HB3' ' A' ' 13' ' ' ALA . 47.8 Cg_exo -55.81 86.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.58 2.187 . . . . 0.0 112.248 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.2 pttt -95.96 55.89 1.63 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.854 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.74 147.07 43.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 16.4 m-20 -80.67 165.45 21.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 t -147.72 179.8 7.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.853 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -151.1 129.87 12.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.009 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.429 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 28.5 m-85 -127.24 135.92 51.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.718 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.15 146.29 30.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.359 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.409 ' HA3' ' CB ' ' A' ' 189' ' ' SER . . . 178.45 168.73 38.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.566 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.75 143.7 14.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.446 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.468 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 2.8 pttp -131.97 146.52 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.095 0.474 . . . . 0.0 111.286 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.853 HD12 ' O ' ' A' ' 53' ' ' GLY . 23.1 tp -121.14 152.03 39.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -169.66 -164.35 25.23 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.514 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 24.2 p90 -122.5 119.28 30.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.804 0.335 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -160.22 148.66 16.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.871 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -135.82 107.81 7.15 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.822 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -134.35 79.97 1.83 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.887 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 9.9 p80 -112.13 130.27 55.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.943 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -100.46 104.95 16.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.897 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.05 -53.92 2.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 96.53 -28.13 14.6 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.556 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -60.25 161.33 7.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.821 0.343 . . . . 0.0 110.887 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -133.88 168.4 18.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -131.45 28.35 3.62 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.476 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -97.29 133.9 41.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.881 0.372 . . . . 0.0 110.875 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.58 -61.33 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.511 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -112.31 166.12 11.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.808 0.337 . . . . 0.0 110.871 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -67.45 117.49 9.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.828 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -79.19 156.06 28.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.773 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -106.37 -42.06 5.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.903 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -86.17 154.18 21.51 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.873 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.57 153.78 31.98 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.559 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.17 122.64 9.2 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.561 2.174 . . . . 0.0 112.347 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 21.3 p -135.17 102.73 5.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.14 136.93 34.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.935 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 19.4 m-80 -82.79 153.38 25.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.894 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -93.63 92.92 7.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 13.2 mm100 -78.68 129.94 35.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.929 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 3.6 pp -99.81 139.51 35.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.853 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -137.67 159.94 25.07 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.507 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -110.87 151.01 28.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.817 0.341 . . . . 0.0 111.078 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -143.36 122.92 1.97 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.404 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.82 135.93 35.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.682 0.277 . . . . 0.0 110.895 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.436 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 24.9 p90 -124.99 127.46 47.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.212 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.8 124.97 1.76 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.011 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -148.22 -172.59 18.32 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.759 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -150.63 156.03 40.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.871 0.367 . . . . 0.0 110.853 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -99.25 137.21 38.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.83 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.6 t -126.76 -48.16 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.765 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -93.57 141.09 23.4 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.46 179.585 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.77 64.63 0.89 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.497 2.131 . . . . 0.0 112.074 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.479 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.2 OUTLIER 179.82 -32.94 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.614 -179.938 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.479 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.4 OUTLIER -162.24 164.1 27.86 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.88 0.371 . . . . 0.0 111.434 -179.51 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.91 177.0 19.43 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.249 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -99.74 134.59 42.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.619 0.247 . . . . 0.0 110.841 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.8 tp10 -124.03 131.51 53.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.989 0.424 . . . . 0.0 111.076 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 6.9 tpt -111.44 130.28 55.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.544 179.767 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.84 153.32 17.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.558 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.404 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 34.2 m-85 -134.19 114.95 13.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.829 0.347 . . . . 0.0 110.746 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.6 122.22 33.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.017 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -137.71 150.6 47.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 3.5 mt -122.98 135.89 54.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.909 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -107.73 -165.19 21.63 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.561 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 9.2 mtp180 60.88 93.23 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.839 0.352 . . . . 0.0 110.904 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -94.34 155.9 16.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.877 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -84.8 153.89 22.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.077 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -144.9 85.14 1.74 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.839 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -110.28 -31.51 7.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.998 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -128.31 170.79 19.58 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.558 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 84.3 p -92.88 -52.52 4.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.787 0.327 . . . . 0.0 110.829 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.58 ' O ' HG23 ' A' ' 84' ' ' VAL . 28.1 m -66.22 76.69 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.244 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -176.71 110.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.86 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -65.98 -65.58 0.66 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -178.59 141.39 4.96 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.492 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.4 115.17 27.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.767 0.318 . . . . 0.0 111.047 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -86.51 106.88 17.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 1.1 tptm -67.89 -66.8 0.52 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.818 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.566 ' HB1' ' O ' ' A' ' 120' ' ' ARG . . . 179.49 164.97 1.04 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.1 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -114.67 131.7 56.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.607 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.23 128.42 9.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.074 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -127.43 117.85 48.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 179.318 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -112.16 145.62 39.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.182 0.515 . . . . 0.0 112.016 -178.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -134.93 112.81 10.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.249 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.405 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.7 p -150.81 172.99 14.74 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.228 0.537 . . . . 0.0 112.027 -178.448 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.12 131.41 48.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.83 178.901 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.413 ' HD2' ' CD1' ' A' ' 111' ' ' TYR . 3.4 ttpt -118.79 132.11 56.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.101 0.477 . . . . 0.0 111.738 -179.035 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -134.95 133.64 39.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.916 179.177 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.436 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -147.62 -179.41 23.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.182 -1.009 . . . . 0.0 113.102 -179.437 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.408 ' O ' HG22 ' A' ' 110' ' ' ILE . 0.5 OUTLIER -166.3 128.84 1.44 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.734 -0.233 . . . . 0.0 110.654 -179.913 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -67.4 171.31 11.91 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.391 2.061 . . . . 0.0 112.116 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 18.6 mm -114.65 -42.42 3.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.608 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 49.5 m -145.24 -48.53 0.23 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.675 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 177.7 -37.47 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.995 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.759 ' O ' HD23 ' A' ' 108' ' ' LEU . 64.3 m-20 -114.79 21.82 14.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.523 -179.761 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.759 HD23 ' O ' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -147.22 127.28 13.69 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 179.731 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.403 ' OD1' ' CE2' ' A' ' 111' ' ' TYR . 8.8 t70 -144.46 155.7 43.85 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.065 0.46 . . . . 0.0 111.751 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.408 HG22 ' O ' ' A' ' 102' ' ' TYR . 3.0 tt -114.51 132.36 63.87 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.022 179.239 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.436 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 25.5 m-85 -133.14 147.64 52.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.975 0.417 . . . . 0.0 111.734 -179.307 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.49 129.55 23.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.446 179.629 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -121.33 129.13 52.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.424 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.4 tt -134.85 122.7 22.4 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.488 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.405 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -176.94 -136.98 2.54 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.467 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.484 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.12 161.62 27.58 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.801 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.11 142.96 48.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.777 0.322 . . . . 0.0 110.706 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.428 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.5 t -130.36 138.42 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.89 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.437 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 70.5 p-90 -146.22 157.65 43.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.963 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.566 ' O ' ' HB1' ' A' ' 91' ' ' ALA . 0.0 OUTLIER -134.58 149.12 50.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.817 -179.982 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -109.82 124.06 50.65 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.001 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -151.9 147.95 27.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.917 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.58 153.54 33.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.859 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 2.7 tttt -172.49 113.45 0.28 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.862 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -170.48 -145.92 4.94 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.411 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 -95.17 113.87 25.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.911 0.386 . . . . 0.0 110.819 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -155.21 -167.88 2.69 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.856 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -127.14 109.1 11.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.117 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.2 m -92.81 117.04 29.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.906 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 36.2 p -111.84 -64.64 1.26 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -97.01 -77.0 1.33 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.545 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.2 m -144.6 163.86 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.77 0.319 . . . . 0.0 111.116 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 36.9 p -119.89 -55.34 2.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.881 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 30.5 mtt180 -136.58 150.19 48.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.84 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 73.9 m -100.96 -55.62 2.52 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.935 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -117.49 -176.6 3.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.963 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 12.0 m80 -108.41 141.98 39.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.834 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -91.04 137.35 32.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.838 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 65.8 p -138.4 128.17 25.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.857 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.437 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -118.84 138.88 13.97 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p -144.64 135.42 20.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.764 0.316 . . . . 0.0 111.027 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.2 p -156.41 129.61 4.45 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.301 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.484 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 84.5 Cg_endo -77.92 142.57 19.95 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.595 2.197 . . . . 0.0 112.11 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 143' ' ' PRO . 27.8 m -157.07 162.4 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.015 0.436 . . . . 0.0 111.455 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.01 124.04 11.39 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.484 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.03 137.12 52.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.862 0.363 . . . . 0.0 111.458 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.04 134.26 7.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.07 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -159.39 -157.31 8.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.919 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -135.18 167.78 24.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.805 0.336 . . . . 0.0 111.207 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -131.42 140.24 49.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.969 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -124.38 125.77 44.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.771 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.601 ' HB3' ' HA ' ' A' ' 107' ' ' ASP . . . -88.1 137.11 32.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.423 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 99.2 t -108.88 -69.4 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.95 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 47.1 p -88.26 -81.96 0.24 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.045 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -159.42 -60.88 0.07 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.821 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -103.03 26.42 8.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.957 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 18.0 mt -150.98 101.06 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.954 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -117.76 162.45 18.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.213 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 61.1 p -100.99 150.83 22.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.145 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 4.6 ttt85 -137.14 133.12 34.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.062 0.458 . . . . 0.0 111.951 -179.503 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.11 119.23 33.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.448 178.712 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -110.04 145.22 37.42 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.189 0.519 . . . . 0.0 111.907 -178.569 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.436 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 8.4 t80 -131.79 147.87 52.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.232 179.474 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -71.32 -79.14 0.07 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.388 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' TRP . . . . . 0.412 ' O ' ' CD2' ' A' ' 163' ' ' TYR . 0.4 OUTLIER -80.4 -177.14 6.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.843 0.354 . . . . 0.0 111.171 -179.782 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 167' ' ' ASN . 21.3 t -123.18 159.12 27.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.07 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 167' ' ' ASN . . . . . 0.485 ' N ' HG12 ' A' ' 166' ' ' VAL . 2.8 m-80 -70.63 71.62 0.49 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.96 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -140.57 143.99 35.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.978 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' ILE . . . . . 0.54 ' O ' HG23 ' A' ' 169' ' ' ILE . 8.5 tp -162.44 115.74 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.087 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -89.84 -104.22 1.15 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.622 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -104.75 171.1 7.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.903 0.382 . . . . 0.0 110.795 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -112.72 164.26 13.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.069 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -168.68 -91.57 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.454 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.9 t -99.22 130.22 45.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.769 0.319 . . . . 0.0 110.951 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 28.7 t -128.12 131.96 68.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.043 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -135.44 -80.19 0.12 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.521 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -94.6 106.65 18.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.752 0.311 . . . . 0.0 110.861 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 178' ' ' ARG . . . . . 0.406 ' HB2' ' HD3' ' A' ' 179' ' ' PRO . 11.4 mtt-85 -72.47 -61.28 1.79 Allowed Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.986 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 179' ' ' PRO . . . . . 0.406 ' HD3' ' HB2' ' A' ' 178' ' ' ARG . 56.9 Cg_endo -70.66 69.99 2.1 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.443 2.095 . . . . 0.0 112.314 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -119.59 -51.75 2.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.906 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -120.5 115.63 23.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 160.6 63.19 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.553 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 5.8 ptt? -117.16 131.54 56.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.781 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.637 HD12 ' N ' ' A' ' 184' ' ' LEU . 2.4 mp -114.95 127.82 55.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 88.1 p -121.13 146.5 46.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.084 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -125.48 141.04 52.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.647 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 187' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -161.7 -176.96 34.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.952 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -128.74 140.54 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.621 0.248 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 189' ' ' SER . . . . . 0.436 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 97.1 p -139.51 175.0 9.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.055 0.455 . . . . 0.0 111.464 -179.497 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 14.8 p90 -146.85 151.43 37.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.653 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 191' ' ' ARG . . . . . 0.429 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 25.0 ptt-85 -128.56 152.4 48.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.927 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -71.11 94.26 1.11 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.927 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -75.55 163.83 53.85 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.513 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -141.67 144.18 33.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.899 0.381 . . . . 0.0 110.804 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 41.3 mm-40 -64.99 111.85 3.05 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.897 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.76 -32.5 69.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.818 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -93.91 117.31 29.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.048 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 198' ' ' ALA . . . . . 0.752 ' O ' HG22 ' A' ' 200' ' ' VAL . . . -139.02 84.73 16.69 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.178 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -54.07 88.27 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.684 2.256 . . . . 0.0 112.229 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 200' ' ' VAL . . . . . 0.752 HG22 ' O ' ' A' ' 198' ' ' ALA . 11.0 m -152.59 179.64 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.076 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 21.5 t -142.23 80.86 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.079 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -114.88 127.65 26.63 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.988 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -55.51 -64.21 0.15 Allowed 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.379 2.053 . . . . 0.0 112.395 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -127.17 113.65 21.64 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.26 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.28 141.74 36.17 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.407 2.071 . . . . 0.0 112.259 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -140.3 134.51 15.5 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.21 -43.63 0.23 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.427 2.085 . . . . 0.0 112.421 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -109.84 93.95 16.01 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.099 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -69.26 -41.98 4.37 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.478 2.119 . . . . 0.0 112.25 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.264 -0.874 . . . . 0.0 110.932 -179.943 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.836 0.351 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 44.0 mtt85 -81.96 73.97 8.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.747 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.7 tt -148.54 128.89 4.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.112 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -166.83 -44.36 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.948 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -99.24 30.83 3.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.926 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -70.6 -76.1 0.11 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.999 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.452 HD13 ' H ' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -65.65 145.4 13.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.11 -179.945 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -138.73 -47.28 0.5 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 26.8 t -99.5 135.95 32.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.092 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.579 ' H ' HD12 ' A' ' 10' ' ' LEU . 5.2 mp -63.44 101.5 0.33 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.981 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -80.52 138.85 36.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.833 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.533 ' HB1' ' HD2' ' A' ' 15' ' ' LYS . . . -95.35 77.07 3.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.104 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.761 ' HB3' ' HD3' ' A' ' 14' ' ' PRO . . . -74.3 -61.13 1.26 Allowed Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.173 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.761 ' HD3' ' HB3' ' A' ' 13' ' ' ALA . 61.2 Cg_endo -73.12 87.01 1.06 Allowed 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.447 2.098 . . . . 0.0 112.357 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.533 ' HD2' ' HB1' ' A' ' 12' ' ' ALA . 0.1 OUTLIER -153.01 94.89 1.9 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.964 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.75 113.05 2.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.825 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -106.0 116.52 32.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.0 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.682 HG23 ' H ' ' A' ' 61' ' ' GLN . 2.2 t -136.69 156.01 49.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.771 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -150.66 130.03 12.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.988 -179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -138.91 136.32 35.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.778 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 143.18 38.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.354 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.12 -157.9 10.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.541 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.22 145.87 15.32 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.597 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.91 156.08 32.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.939 0.4 . . . . 0.0 111.107 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.743 HD21 ' HB2' ' A' ' 52' ' ' LEU . 0.7 OUTLIER -135.66 138.76 43.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.611 179.709 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -131.82 155.01 21.21 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.542 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -133.24 99.99 4.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.796 0.331 . . . . 0.0 110.855 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 m -161.58 102.37 1.2 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.845 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 14.2 mm-40 -148.52 99.06 2.97 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.955 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 11.4 m-85 -117.97 94.76 4.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -154.1 -48.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.901 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -67.64 119.56 12.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.91 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.3 163.67 12.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.48 48.55 3.69 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.479 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -100.92 112.8 25.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.337 . . . . 0.0 110.824 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 4.4 p90 -161.19 -44.27 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.997 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -163.54 132.37 2.72 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.512 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 24.1 p30 -87.08 148.26 25.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.695 0.283 . . . . 0.0 110.945 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -93.76 -154.53 31.14 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.529 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.66 161.52 9.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.802 0.334 . . . . 0.0 110.829 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -148.06 86.68 1.57 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -99.35 -68.15 0.82 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -129.74 -54.0 1.15 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -63.66 91.77 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.837 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -102.68 96.43 1.39 Allowed Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.553 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -67.89 168.1 19.66 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.55 2.167 . . . . 0.0 112.339 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.19 44.32 1.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.97 -31.27 56.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.834 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -73.91 160.45 31.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.826 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.51 168.9 14.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.923 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 10.2 tm0? -140.73 161.02 38.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.912 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.743 ' HB2' HD21 ' A' ' 25' ' ' LEU . 0.2 OUTLIER -105.37 150.16 25.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.862 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -108.94 143.6 16.31 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.374 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -132.76 156.72 46.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.843 0.354 . . . . 0.0 111.157 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.58 154.64 25.71 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.451 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.839 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -95.43 124.7 39.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.74 0.305 . . . . 0.0 110.946 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -111.69 119.06 37.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.039 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.75 124.94 2.84 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.058 179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.17 165.59 25.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.771 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.44 ' CZ ' ' HB2' ' A' ' 68' ' ' PHE . 4.9 p90 -154.26 134.78 13.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.994 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.682 ' H ' HG23 ' A' ' 18' ' ' THR . 11.1 mt-30 -103.41 137.07 42.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.714 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 53.9 t -108.25 -30.06 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.259 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -147.22 153.18 44.42 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.852 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_exo -64.49 70.36 0.23 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.646 2.231 . . . . 0.0 112.176 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.683 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.5 OUTLIER -159.74 -45.72 0.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -179.974 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.683 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.5 OUTLIER -178.22 149.15 0.52 Allowed 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.946 -179.935 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -123.71 169.83 15.92 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.394 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 50.9 m-85 -83.98 134.49 34.64 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.682 0.277 . . . . 0.0 110.853 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.66 112.08 19.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.741 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.4 mtp -104.43 118.1 35.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.552 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.0 152.32 17.28 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.839 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 5.1 m-85 -130.7 115.02 16.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.846 0.355 . . . . 0.0 110.576 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -81.66 123.13 28.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.023 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -130.89 109.03 10.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.861 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -120.04 172.27 7.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -102.78 104.43 2.57 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.514 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.24 109.12 20.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.86 0.362 . . . . 0.0 110.905 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 50.2 mtp -72.71 106.42 4.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.907 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -174.05 121.02 0.29 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.019 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 2.3 p90 -170.9 147.68 2.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 4.8 mttt -128.06 140.57 51.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.92 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -76.72 -59.52 3.21 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.564 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.66 173.18 3.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.898 0.38 . . . . 0.0 110.81 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 84' ' ' VAL . 5.5 m -65.8 102.88 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.161 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -149.41 158.62 44.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.859 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.3 m120 -102.04 176.28 5.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 163.32 -87.71 0.1 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.458 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -114.75 136.22 53.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.795 0.331 . . . . 0.0 111.086 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -123.0 -49.46 1.96 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -123.27 134.55 54.07 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -158.48 116.21 2.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.051 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -175.02 141.68 0.59 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.722 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -95.92 134.01 11.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.753 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -120.68 117.86 54.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.755 0.312 . . . . 0.0 110.447 179.536 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 95' ' ' GLN . . . . . 0.556 ' OE1' HG21 ' A' ' 144' ' ' VAL . 3.4 tt0 -109.01 137.89 46.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.074 0.464 . . . . 0.0 111.744 -179.1 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.617 179.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.504 HG22 ' HA3' ' A' ' 115' ' ' GLY . 3.5 p -149.36 166.28 29.51 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.072 0.463 . . . . 0.0 111.796 -178.669 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.65 127.7 52.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.1 179.126 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.84 132.14 56.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.031 0.443 . . . . 0.0 111.749 -179.145 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.504 ' O ' HD12 ' A' ' 100' ' ' LEU . 4.0 pp -130.09 130.14 44.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.316 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -154.03 -173.52 23.17 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.442 -0.885 . . . . 0.0 113.032 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.664 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 10.2 p90 -166.15 148.95 6.4 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 120.596 0.236 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -81.23 170.65 14.69 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.73 2.287 . . . . 0.0 112.7 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 16.8 mm -102.91 -42.19 8.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.631 179.726 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.99 -60.53 0.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.776 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 177.02 46.51 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.776 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.462 ' OD2' HD21 ' A' ' 108' ' ' LEU . 21.4 p-10 178.79 -29.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.426 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.462 HD21 ' OD2' ' A' ' 107' ' ' ASP . 0.1 OUTLIER -112.61 128.82 56.48 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.561 -179.849 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -144.91 157.89 43.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.887 0.375 . . . . 0.0 111.603 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.95 HG22 HG12 ' A' ' 149' ' ' VAL . 1.1 pt -120.81 144.5 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.471 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 4.7 p90 -148.05 149.07 31.42 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 121.225 0.536 . . . . 0.0 111.83 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 21.4 p -130.64 133.2 45.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.988 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.703 ' NE ' ' HB3' ' A' ' 146' ' ' ALA . 0.2 OUTLIER -115.46 130.73 56.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.063 0.459 . . . . 0.0 111.707 -179.261 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.503 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.9 tt -126.26 122.63 36.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.153 179.267 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.504 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.29 -142.09 4.56 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.294 -0.955 . . . . 0.0 112.869 -179.8 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.519 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.73 169.08 25.35 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.771 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.4 tmm? -127.57 137.84 52.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.849 0.357 . . . . 0.0 110.948 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.46 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.6 t -127.29 127.7 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.674 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 2.9 p-90 -142.78 162.64 34.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.798 0.333 . . . . 0.0 110.987 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 18.3 mtp180 -126.44 156.13 41.12 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.971 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -129.62 153.68 47.85 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.026 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -135.63 149.34 49.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.911 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 5.5 p -175.07 70.25 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.89 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 3.1 ttpp -126.51 82.83 2.11 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.857 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -114.3 -162.99 14.5 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.467 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -117.14 93.37 4.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.86 0.362 . . . . 0.0 110.878 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -156.81 -50.89 0.07 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.852 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -118.62 -42.9 2.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.118 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 25.3 m -112.85 125.97 54.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.2 m -120.83 -53.92 2.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.952 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -89.07 -179.82 45.56 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.494 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.88 136.52 34.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.862 0.363 . . . . 0.0 111.173 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 3.1 p -132.59 -64.09 0.77 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.915 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -159.46 41.67 0.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.891 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 1.1 p -102.75 131.88 49.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.942 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.15 174.38 6.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 72.2 m-70 -67.11 144.52 56.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -121.52 120.55 35.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.93 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 30.0 p -119.66 160.0 23.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.96 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -122.72 129.65 7.57 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.485 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.0 p -146.04 128.86 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.696 0.284 . . . . 0.0 110.994 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.491 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -157.18 141.38 11.75 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.436 -179.978 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.519 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.8 Cg_exo -73.91 153.41 47.54 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.869 2.379 . . . . 0.0 111.858 179.719 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.556 HG21 ' OE1' ' A' ' 95' ' ' GLN . 27.0 m -156.74 162.92 1.48 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.181 0 CA-C-O 121.221 0.534 . . . . 0.0 111.764 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' PHE . . . . . 0.503 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.2 t80 -143.05 118.84 10.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.256 179.619 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.703 ' HB3' ' NE ' ' A' ' 113' ' ' ARG . . . -117.15 140.96 48.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.991 0.424 . . . . 0.0 111.16 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.07 134.89 7.16 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.152 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.03 -167.5 21.58 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.81 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.95 HG12 HG22 ' A' ' 110' ' ' ILE . 4.1 m -127.18 160.02 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.869 0.366 . . . . 0.0 111.042 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.448 ' HG2' ' HB3' ' A' ' 160' ' ' ARG . 1.4 tm-20 -120.85 136.39 54.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 37.5 m95 -120.78 120.27 35.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.469 179.525 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.43 119.0 32.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.571 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 40.5 t -116.17 97.26 5.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.807 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 6.4 m 63.97 131.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.739 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.23 89.23 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.027 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 156' ' ' ASP . . . . . 0.869 ' HB3' HD12 ' A' ' 157' ' ' ILE . 3.8 t0 -177.87 -57.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.02 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.869 HD12 ' HB3' ' A' ' 156' ' ' ASP . 3.5 mp -141.74 133.61 27.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.144 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.77 161.82 17.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.946 0.403 . . . . 0.0 111.35 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -131.39 144.02 50.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.173 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.448 ' HB3' ' HG2' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -137.1 155.12 50.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.243 0.544 . . . . 0.0 112.009 -179.288 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.853 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.4 OUTLIER -120.41 121.45 38.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.635 179.006 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -107.41 145.05 33.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.116 0.484 . . . . 0.0 111.787 -178.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' TYR . . . . . 0.867 ' CE2' HD23 ' A' ' 184' ' ' LEU . 5.7 m-85 -129.86 151.36 50.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.491 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.58 97.14 6.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.029 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -179.95 -167.81 0.1 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.845 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.6 t -118.04 130.43 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.172 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -169.95 148.86 3.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.849 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -70.37 -173.21 0.68 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.848 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 169' ' ' ILE . . . . . 0.455 HD13 ' OH ' ' A' ' 102' ' ' TYR . 1.1 pp -96.95 -28.75 3.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.172 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -175.78 68.17 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.464 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -164.54 32.04 0.07 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.882 0.372 . . . . 0.0 110.901 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -169.71 -173.26 1.58 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.096 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -164.74 119.82 0.9 Allowed Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.562 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.494 ' O ' HG23 ' A' ' 174' ' ' THR . 4.8 t -78.39 90.76 4.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.858 0.361 . . . . 0.0 110.783 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 5.7 m -146.47 129.63 9.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.14 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -151.46 -119.21 0.84 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 66.4 p -103.97 -74.14 0.65 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.775 0.321 . . . . 0.0 111.007 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -98.07 152.44 38.04 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.847 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.39 155.66 9.37 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.592 2.194 . . . . 0.0 112.355 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -120.31 45.86 2.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.849 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -64.14 110.67 2.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -108.93 -75.9 0.9 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.579 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 2.7 ttm -148.08 100.62 3.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.883 0.373 . . . . 0.0 110.865 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 184' ' ' LEU . . . . . 0.867 HD23 ' CE2' ' A' ' 163' ' ' TYR . 0.5 OUTLIER -121.45 137.19 54.82 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.717 179.921 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.9 m -131.87 151.52 51.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.93 0.395 . . . . 0.0 111.282 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -120.22 134.46 55.25 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.347 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -146.41 165.36 28.29 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.231 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.22 139.83 50.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.376 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.56 168.58 19.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.103 0.478 . . . . 0.0 111.694 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 190' ' ' TYR . . . . . 0.522 ' CE1' HG23 ' A' ' 157' ' ' ILE . 4.4 m-85 -123.47 146.61 47.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.466 179.624 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -104.34 153.55 20.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.958 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -135.22 145.92 48.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.81 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -145.53 -170.17 14.22 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -82.65 -42.54 18.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.823 0.344 . . . . 0.0 110.913 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -111.78 159.19 18.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.967 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -122.47 -43.48 2.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -135.27 106.27 6.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.041 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -103.94 90.95 3.25 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.109 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -68.73 -168.0 0.21 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.57 2.18 . . . . 0.0 112.203 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 17.2 m -93.01 -31.04 4.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.122 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 21.1 t -72.05 134.39 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.156 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 202' ' ' ALA . . . . . 0.753 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -88.7 -53.2 0.36 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.162 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.753 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 53.2 Cg_exo -52.23 132.64 44.71 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.542 2.161 . . . . 0.0 112.307 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -127.01 82.05 68.79 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.079 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.44 -45.17 2.72 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.537 2.158 . . . . 0.0 112.358 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -132.8 142.33 44.35 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.072 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.95 -45.38 0.48 Allowed 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.53 2.153 . . . . 0.0 112.292 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -159.97 131.72 4.1 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.116 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.62 -62.12 0.36 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.425 2.083 . . . . 0.0 112.278 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.169 -0.92 . . . . 0.0 110.893 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.816 0.341 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.437 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.8 t-105 -146.62 129.9 16.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.42 ' CE1' ' HA3' ' A' ' 59' ' ' GLY . 6.1 p90 -136.92 139.65 41.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.795 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.08 149.49 52.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.197 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.75 -164.44 22.37 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.471 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.16 138.59 6.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.583 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 2.0 pttp -120.18 150.92 39.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.985 0.421 . . . . 0.0 111.033 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.0 tp -129.27 139.66 51.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.595 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.531 -179.945 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.304 -0.318 . . . . 0.0 112.304 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -99.95 144.52 28.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.768 0.318 . . . . 0.0 110.996 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.414 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -147.75 122.97 1.63 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.88 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.809 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.87 125.71 39.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.635 0.255 . . . . 0.0 110.459 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.435 ' HB2' ' NH2' ' A' ' 160' ' ' ARG . 2.8 m-85 -115.24 145.93 41.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.045 0.45 . . . . 0.0 111.583 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -144.92 124.84 2.23 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.786 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 20' ' ' TYR . . . -123.13 146.98 16.64 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.035 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.443 ' CZ ' ' HB2' ' A' ' 68' ' ' PHE . 53.4 p90 -153.53 126.04 8.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.851 0.358 . . . . 0.0 110.771 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.811 0.338 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -127.24 155.09 19.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.435 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.443 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 2.4 m-85 -82.79 141.56 32.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.617 0.246 . . . . 0.0 110.564 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.577 ' HB3' HG23 ' A' ' 97' ' ' THR . 14.2 tp10 -125.67 118.67 26.13 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.88 0.371 . . . . 0.0 111.133 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 10.3 mtt -108.19 124.72 50.7 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.5 179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 163.05 12.47 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.541 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.809 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 57.4 m-85 -137.54 114.91 11.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.684 0.278 . . . . 0.0 110.76 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.43 114.96 22.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.059 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 17.0 t90 . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.097 179.868 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.741 0.305 . . . . 0.0 110.715 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -85.59 135.3 13.29 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.639 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.1 OUTLIER -123.81 122.03 63.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -108.88 142.25 39.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.189 0.519 . . . . 0.0 111.878 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -128.6 114.5 16.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.617 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.828 HG21 ' HD2' ' A' ' 113' ' ' ARG . 0.9 OUTLIER -153.69 165.2 36.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.066 0.46 . . . . 0.0 111.739 -179.007 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.02 129.73 51.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.307 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.53 132.2 55.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.051 0.453 . . . . 0.0 111.517 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.518 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.8 pp -132.76 127.8 35.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.279 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.24 -171.66 23.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.971 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.434 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.09 147.06 5.64 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.897 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.434 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 90.6 Cg_endo . . . . . 0 C--N 1.345 0.387 0 C-N-CA 122.745 2.297 . . . . 0.0 112.617 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.46 0.055 0 CA-C-O 120.617 0.246 . . . . 0.0 110.367 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 4.0 p30 -141.41 152.84 44.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.041 0.448 . . . . 0.0 111.763 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.98 HG22 ' CG1' ' A' ' 149' ' ' VAL . 1.1 pt -116.93 146.24 21.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.318 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -153.59 156.34 37.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.111 0.481 . . . . 0.0 111.693 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 68.2 p -136.37 135.72 39.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.246 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.828 ' HD2' HG21 ' A' ' 97' ' ' THR . 0.0 OUTLIER -116.35 128.33 55.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.998 0.427 . . . . 0.0 111.518 -179.564 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.6 tt -126.78 124.45 39.73 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.445 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.408 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.71 -133.56 2.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.462 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -153.24 168.68 32.02 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.404 -0.903 . . . . 0.0 112.939 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -119.17 141.99 48.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.785 0.326 . . . . 0.0 110.731 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.524 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.9 t -135.03 112.01 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.73 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 40.7 p-90 . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 120.914 0.388 . . . . 0.0 111.115 -179.737 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.674 0.274 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.1 134.76 7.04 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.349 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.483 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 96.4 Cg_endo -79.99 142.32 15.48 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.633 2.222 . . . . 0.0 112.12 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.9 m -156.84 158.48 3.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.968 0.413 . . . . 0.0 111.46 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -149.04 124.04 10.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.582 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.567 ' HB3' ' NH1' ' A' ' 113' ' ' ARG . . . -119.7 168.86 10.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.933 0.396 . . . . 0.0 111.23 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.57 138.77 6.58 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.382 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -160.77 -159.7 10.14 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.756 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.98 ' CG1' HG22 ' A' ' 110' ' ' ILE . 5.7 m -130.66 166.91 27.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.702 0.287 . . . . 0.0 110.933 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -136.03 148.09 48.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.873 0.368 . . . . 0.0 111.178 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 10.1 m0 -131.29 128.68 40.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.791 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.53 122.53 40.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.303 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 45.5 t . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 179.789 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.816 0.341 . . . . 0.0 111.221 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.82 167.72 10.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.189 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . 0.889 HG22 HG12 ' A' ' 188' ' ' VAL . 22.3 p -125.52 144.41 50.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.354 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.435 ' NH2' ' HB2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 153.45 50.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.127 0.489 . . . . 0.0 111.87 -179.504 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.423 HD23 ' N ' ' A' ' 162' ' ' GLU . 1.5 tt -126.55 124.38 39.86 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.913 179.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.423 ' N ' HD23 ' A' ' 161' ' ' LEU . 2.8 mt-10 -106.83 145.15 32.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.162 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.677 ' CG ' HD23 ' A' ' 184' ' ' LEU . 0.7 OUTLIER -131.16 166.02 22.04 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.625 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . 0.531 ' HG2' HD11 ' A' ' 184' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.067 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.677 HD23 ' CG ' ' A' ' 163' ' ' TYR . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.648 0.261 . . . . 0.0 110.817 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 12.7 p -171.07 166.73 7.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.97 0.414 . . . . 0.0 111.547 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.64 140.15 49.72 Favored 'General case' 0 N--CA 1.462 0.134 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.275 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -154.06 171.21 32.69 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 119.945 -1.122 . . . . 0.0 113.48 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . 0.889 HG12 HG22 ' A' ' 159' ' ' THR . 0.6 OUTLIER -130.48 139.85 50.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.683 -0.259 . . . . 0.0 110.359 179.456 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 83.6 p -134.95 175.08 9.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.041 0.448 . . . . 0.0 111.497 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -145.38 149.81 35.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.696 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.942 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 t . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.886 0.374 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -121.29 132.32 54.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -129.76 135.97 49.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.974 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.45 141.63 29.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.232 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.23 -172.14 41.49 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.586 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.08 148.24 19.71 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.98 152.52 51.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.937 0.398 . . . . 0.0 111.278 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 1.043 HD12 ' HB2' ' A' ' 54' ' ' ALA . 0.6 OUTLIER -130.35 148.75 52.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.443 179.716 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.226 0 C-N-CA 120.542 -0.837 . . . . 0.0 112.772 -179.883 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.458 -0.257 . . . . 0.0 112.458 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 1.043 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -116.52 161.08 19.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.762 0.315 . . . . 0.0 110.938 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -163.81 146.64 11.77 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.681 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.727 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -96.25 160.99 14.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.73 0.3 . . . . 0.0 110.898 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.429 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 19.6 p90 -151.6 139.52 19.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.988 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -136.33 125.05 3.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.349 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -98.13 129.98 10.08 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.581 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -129.14 110.24 11.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.82 0.343 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.805 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.652 0.263 . . . . 0.0 111.095 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 165.22 22.11 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 -81.83 132.49 35.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.775 0.322 . . . . 0.0 110.624 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -112.08 115.92 29.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.172 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -105.53 115.48 30.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.17 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.8 157.25 15.17 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.803 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.727 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 34.1 m-85 -128.95 129.56 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.738 0.304 . . . . 0.0 110.718 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.405 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.9 OUTLIER -96.34 121.01 37.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.754 -179.979 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.233 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.785 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 17.8 tt0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.816 0.341 . . . . 0.0 110.567 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.405 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -84.3 141.27 19.73 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.718 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.89 121.03 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.746 0.308 . . . . 0.0 110.31 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . 0.409 ' HG3' ' CB ' ' A' ' 117' ' ' MET . 3.4 mp0 -108.91 136.09 49.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.055 0.455 . . . . 0.0 111.817 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.456 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.6 tt -122.18 106.57 11.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.58 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.572 HG22 ' HA3' ' A' ' 115' ' ' GLY . 7.5 p -145.45 168.77 19.75 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.044 0.449 . . . . 0.0 111.644 -178.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.68 121.97 45.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.009 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.34 132.42 56.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.146 0.498 . . . . 0.0 111.885 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.6 ' HG ' HG23 ' A' ' 112' ' ' THR . 3.4 pp -126.96 127.39 44.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.814 179.096 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -120.2 -177.49 16.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.323 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.428 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 24.3 t80 -166.11 123.12 1.02 Allowed Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.455 0.169 . . . . 0.0 110.738 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.428 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 83.7 Cg_endo . . . . . 0 C--N 1.347 0.464 0 C-N-CA 122.457 2.105 . . . . 0.0 112.671 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.485 HD23 ' N ' ' A' ' 108' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.773 0.321 . . . . 0.0 110.164 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.04 163.27 23.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.066 0.46 . . . . 0.0 111.451 -179.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.989 HG22 HG12 ' A' ' 149' ' ' VAL . 1.6 pt -114.79 158.93 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.343 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -156.09 138.74 15.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.028 0.442 . . . . 0.0 111.604 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.6 HG23 ' HG ' ' A' ' 100' ' ' LEU . 1.8 t -132.99 126.94 33.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.243 179.389 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.439 ' CD ' ' HB3' ' A' ' 146' ' ' ALA . 0.5 OUTLIER -118.47 130.46 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.954 0.407 . . . . 0.0 111.43 -179.416 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -131.52 122.84 26.82 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.438 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.572 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -176.37 -140.18 3.44 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.591 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.482 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -138.6 163.31 25.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.832 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.409 ' CB ' ' HG3' ' A' ' 95' ' ' GLN . 1.1 ptt? -122.26 135.65 54.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.764 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.17 119.81 49.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 19.4 t90 . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.021 -179.94 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.416 ' O ' HG13 ' A' ' 141' ' ' VAL . 11.1 p . . . . . 0 C--O 1.231 0.132 0 CA-C-O 120.733 0.301 . . . . 0.0 111.152 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t -157.1 143.18 12.94 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.291 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.482 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 98.9 Cg_endo -79.55 147.45 19.9 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.658 2.239 . . . . 0.0 112.113 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.7 m -156.98 161.83 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.951 0.405 . . . . 0.0 111.528 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.8 p90 -149.01 119.44 7.37 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.572 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.439 ' HB3' ' CD ' ' A' ' 113' ' ' ARG . . . -109.79 129.07 55.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.935 0.398 . . . . 0.0 111.321 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.4 124.98 4.05 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.224 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.421 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -158.56 -152.16 6.33 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.309 -0.948 . . . . 0.0 113.04 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.989 HG12 HG22 ' A' ' 110' ' ' ILE . 6.1 m -135.48 167.31 25.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 111.317 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -136.8 137.4 39.75 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -119.93 127.25 52.49 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.731 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -88.43 124.34 33.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.479 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.535 ' O ' HG12 ' A' ' 153' ' ' VAL . 53.1 t . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.824 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 6.5 mt . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -131.69 158.82 40.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.314 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.0 141.63 33.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.201 179.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -124.29 122.95 39.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.11 0.481 . . . . 0.0 111.881 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.415 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 1.4 tt -117.41 116.69 27.67 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.536 178.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.421 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 0.2 OUTLIER -109.48 145.02 36.92 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -178.922 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.421 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.4 p90 -133.99 165.77 24.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.557 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.877 -179.989 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 7.2 mp . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.65 0.262 . . . . 0.0 110.776 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 67.2 m -152.44 150.89 30.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.949 0.404 . . . . 0.0 111.298 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -116.31 145.18 43.38 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.454 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -160.64 173.66 37.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.921 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 2.1 m -127.49 138.16 55.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.759 0.314 . . . . 0.0 110.652 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . 0.429 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 60.7 p -139.86 170.59 15.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.258 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 1.9 p90 -147.95 160.02 43.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.929 179.969 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.796 0.331 . . . . 0.0 110.933 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.429 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.2 OUTLIER -141.83 154.58 45.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.885 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.444 ' CE1' ' HB3' ' A' ' 191' ' ' ARG . 1.2 m-85 -145.71 135.92 23.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.801 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.34 140.0 27.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.222 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.7 -171.55 41.27 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.424 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.04 150.46 22.69 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.368 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.32 154.57 48.4 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.898 0.38 . . . . 0.0 111.114 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.699 HD12 ' O ' ' A' ' 53' ' ' GLY . 49.4 tp -128.17 139.6 52.39 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.528 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.385 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.545 -179.929 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.699 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.45 -0.389 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.402 ' HB3' ' O ' ' A' ' 74' ' ' TRP . . . -101.19 139.88 36.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.02 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -145.57 126.85 2.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.424 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.498 ' HB3' ' CB ' ' A' ' 72' ' ' TYR . . . -94.89 141.82 28.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.747 0.308 . . . . 0.0 110.97 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -123.8 126.16 45.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.957 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -154.65 124.99 1.62 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -157.98 -168.31 20.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.429 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 8.8 p90 -154.97 161.08 41.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.782 0.325 . . . . 0.0 110.807 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.993 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.754 0.311 . . . . 0.0 110.798 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 153.49 19.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.525 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.07 128.37 42.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.66 0.266 . . . . 0.0 110.439 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -122.2 130.16 52.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.984 0.421 . . . . 0.0 111.417 -179.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 19.1 mtt -118.97 127.17 53.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.328 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.73 158.2 14.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.495 -0.859 . . . . 0.0 112.699 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.498 ' CB ' ' HB3' ' A' ' 56' ' ' ALA . 0.7 OUTLIER -129.18 114.94 16.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.781 0.324 . . . . 0.0 110.78 179.947 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -83.41 115.55 22.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.889 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . 0.402 ' O ' ' HB3' ' A' ' 54' ' ' ALA . 1.7 t90 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.931 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.769 0.319 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.414 ' HA2' ' CB ' ' A' ' 119' ' ' TRP . . . -99.68 142.64 16.07 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.122 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.76 122.1 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 117' ' ' MET . 2.2 mt-30 -108.8 140.32 42.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.065 0.459 . . . . 0.0 111.678 -179.125 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.4 tt -128.43 116.21 19.39 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.751 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.885 HG21 ' HD2' ' A' ' 113' ' ' ARG . 0.6 OUTLIER -153.97 164.38 38.52 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.035 0.445 . . . . 0.0 111.84 -178.851 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.25 124.98 46.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.285 179.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -102.76 132.53 48.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.029 0.442 . . . . 0.0 111.71 -179.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.587 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -134.95 124.16 24.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.347 179.296 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -156.3 -175.84 27.73 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.821 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -166.02 159.97 12.85 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.656 0.265 . . . . 0.0 110.993 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo . . . . . 0 C--N 1.345 0.352 0 C-N-CA 122.631 2.22 . . . . 0.0 112.132 179.832 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.073 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -136.76 160.01 40.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 111.812 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.063 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -115.09 147.27 18.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.219 179.436 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -149.06 145.13 27.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.114 0.483 . . . . 0.0 111.51 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.502 HG22 ' CA ' ' A' ' 147' ' ' GLY . 0.6 OUTLIER -137.81 129.82 28.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.179 179.554 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.885 ' HD2' HG21 ' A' ' 97' ' ' THR . 0.6 OUTLIER -111.93 133.11 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.081 0.467 . . . . 0.0 111.522 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.515 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.8 tt -124.34 122.86 38.87 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.296 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.416 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 179.91 -134.07 2.16 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.815 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.524 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -151.43 169.1 30.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.933 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.406 ' HB3' ' HG2' ' A' ' 95' ' ' GLN . 0.6 OUTLIER -122.68 138.82 54.49 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 111.24 -179.791 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.1 125.89 60.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.503 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . 0.414 ' CB ' ' HA2' ' A' ' 93' ' ' GLY . 1.1 p-90 . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 111.244 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.9 p . . . . . 0 C--O 1.233 0.187 0 CA-C-O 120.645 0.26 . . . . 0.0 111.132 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -157.07 142.67 12.64 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.496 -179.842 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.524 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 4.7 Cg_exo -73.93 153.4 47.47 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.834 2.356 . . . . 0.0 111.768 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.8 m -156.33 161.19 2.0 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 121.084 0.469 . . . . 0.0 111.717 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.515 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.5 t80 -142.94 118.96 10.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.237 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.49 136.38 52.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.014 0.435 . . . . 0.0 111.397 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.502 ' CA ' HG22 ' A' ' 112' ' ' THR . . . -133.73 125.74 4.05 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.004 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -157.96 -164.99 14.67 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.354 -0.927 . . . . 0.0 112.873 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 1.063 HG12 HG22 ' A' ' 110' ' ' ILE . 6.8 m -131.75 162.68 39.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.806 0.336 . . . . 0.0 111.046 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.51 140.11 51.36 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.188 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 18.8 m95 -123.22 120.02 31.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.808 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.51 126.71 35.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.391 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 C--N 1.33 -0.245 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.009 179.801 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 17.7 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.771 0.32 . . . . 0.0 111.035 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -116.47 168.83 9.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.008 0.432 . . . . 0.0 111.362 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . 0.416 ' HB ' HG12 ' A' ' 188' ' ' VAL . 5.8 t -126.77 144.41 50.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.198 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 150.19 47.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.232 0.539 . . . . 0.0 112.016 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.791 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.9 OUTLIER -115.56 122.35 45.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.482 178.943 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -111.94 145.09 40.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.05 0.452 . . . . 0.0 111.7 -178.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.791 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 17.5 m-85 -128.71 147.05 50.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.657 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.978 -179.938 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.785 0.326 . . . . 0.0 110.784 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 9.5 t -138.51 147.88 43.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.389 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.8 131.97 54.01 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.407 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.85 168.63 28.71 Favored Glycine 0 N--CA 1.453 -0.213 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.236 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . 0.416 HG12 ' HB ' ' A' ' 159' ' ' THR . 1.1 m -127.99 143.51 40.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.671 0.272 . . . . 0.0 110.472 179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.42 172.98 11.96 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 121.006 0.431 . . . . 0.0 111.468 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.7 p90 -138.05 160.03 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . 0.444 ' HB3' ' CE1' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.4 m . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.749 0.309 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 3.9 m-90 -135.64 148.4 48.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.106 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.432 ' CZ ' ' HA3' ' A' ' 59' ' ' GLY . 6.6 p90 -159.95 149.0 17.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.69 153.75 46.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.171 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.87 -171.18 38.07 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.463 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -143.7 147.64 19.06 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.39 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 3.1 pptp? -134.59 146.94 50.09 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.911 0.386 . . . . 0.0 111.043 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.807 HD12 ' HB2' ' A' ' 54' ' ' ALA . 1.9 tt -121.5 146.29 47.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.653 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.486 -179.882 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.436 -0.266 . . . . 0.0 112.436 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.807 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -125.07 148.48 48.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.662 0.268 . . . . 0.0 110.837 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.04 147.85 18.48 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.322 -0.942 . . . . 0.0 112.937 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.83 128.76 53.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.635 0.255 . . . . 0.0 110.643 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -120.3 143.96 48.07 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 0.0 111.397 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -128.15 124.89 4.92 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.045 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.432 ' HA3' ' CZ ' ' A' ' 20' ' ' TYR . . . -100.3 139.72 14.56 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.987 -179.492 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -135.39 114.11 11.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.702 0.287 . . . . 0.0 110.593 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.256 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.9 pp . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 120.862 0.363 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -107.14 177.02 21.46 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.548 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -90.55 142.77 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.833 0.349 . . . . 0.0 110.654 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.401 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 0.6 OUTLIER -122.49 111.96 17.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.151 -179.738 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.9 mtt -100.39 114.82 28.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.888 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 152.16 17.28 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.392 -0.909 . . . . 0.0 113.261 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.46 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 38.6 m-85 -130.3 114.96 16.28 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.5 122.94 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.763 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . 0.437 ' CD1' ' HA2' ' A' ' 55' ' ' GLY . 17.9 p-90 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.646 179.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.186 0 CA-C-O 120.726 0.298 . . . . 0.0 110.679 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.48 124.5 8.1 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.783 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.09 117.8 56.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.08 139.76 46.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.124 0.488 . . . . 0.0 111.831 -178.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.407 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -129.98 110.97 12.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.556 179.377 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.444 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.5 p -150.02 178.12 9.24 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.083 0.468 . . . . 0.0 111.812 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.2 44.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.033 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.401 ' HB2' ' HB2' ' A' ' 69' ' ' GLU . 8.8 tttt -126.57 132.01 51.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.096 0.475 . . . . 0.0 111.841 -179.286 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.488 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.6 pp -134.55 123.96 24.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.981 179.274 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.435 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -126.24 -175.04 14.02 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.437 -0.887 . . . . 0.0 113.302 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.406 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 0.8 OUTLIER -166.15 122.96 1.0 Allowed Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 115.674 -0.263 . . . . 0.0 110.576 -179.881 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.406 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 58.3 Cg_endo . . . . . 0 C--N 1.347 0.462 0 C-N-CA 122.485 2.123 . . . . 0.0 112.672 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.603 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.675 0.274 . . . . 0.0 110.443 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -145.07 159.28 43.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.009 0.433 . . . . 0.0 111.522 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.025 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.63 148.58 17.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.351 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.435 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 5.7 m-85 -138.13 144.46 40.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.049 0.452 . . . . 0.0 111.736 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -128.91 127.1 41.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.356 179.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.25 130.07 56.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.338 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.505 HD12 ' CD2' ' A' ' 145' ' ' PHE . 7.2 tt -137.4 122.95 19.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.636 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.444 ' HA3' HG22 ' A' ' 97' ' ' THR . . . 179.51 -143.05 5.5 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.514 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -146.23 163.86 28.37 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.929 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.57 144.37 49.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.807 0.337 . . . . 0.0 110.94 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.2 t -129.44 135.73 60.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 6.2 m95 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.795 179.994 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.428 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.4 p . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.66 0.267 . . . . 0.0 110.948 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -157.14 152.91 22.63 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.803 0.335 . . . . 0.0 111.577 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.514 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 71.6 Cg_endo -77.04 162.1 32.17 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.769 2.313 . . . . 0.0 112.094 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.6 m -155.96 159.05 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.003 0.43 . . . . 0.0 111.503 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.505 ' CD2' HD12 ' A' ' 114' ' ' LEU . 10.5 t80 -147.24 118.89 7.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.486 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -115.78 122.54 45.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.25 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.405 ' O ' ' CD1' ' A' ' 163' ' ' TYR . . . -126.32 132.21 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.218 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.426 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -166.52 -153.76 7.98 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.817 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 1.025 HG12 HG22 ' A' ' 110' ' ' ILE . 6.0 m -134.7 170.53 19.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.63 0.253 . . . . 0.0 111.016 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -138.3 144.6 40.52 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.904 0.383 . . . . 0.0 111.317 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . 0.603 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.2 OUTLIER -127.24 133.51 50.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.566 179.745 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.71 137.2 36.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 179.706 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 32.0 mt . . . . . 0 C--O 1.232 0.165 0 CA-C-O 120.943 0.402 . . . . 0.0 111.651 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -140.03 155.53 47.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.089 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.8 m -101.02 149.97 23.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.481 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.401 ' NH1' ' HB3' ' A' ' 162' ' ' GLU . 0.0 OUTLIER -137.06 134.2 36.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.068 0.461 . . . . 0.0 111.8 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.4 tt -117.56 119.57 35.43 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.792 179.038 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.401 ' HB3' ' NH1' ' A' ' 160' ' ' ARG . 4.8 pt-20 -112.42 143.89 42.79 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.989 0.423 . . . . 0.0 111.703 -179.11 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.426 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 6.4 p90 -134.21 162.83 31.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.516 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.938 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.431 HD12 ' N ' ' A' ' 184' ' ' LEU . 3.7 mp . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.642 0.258 . . . . 0.0 110.703 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.8 m -141.51 151.55 43.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.926 0.394 . . . . 0.0 111.345 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -114.81 132.06 56.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.342 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -149.25 167.5 29.58 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.326 -0.94 . . . . 0.0 113.002 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.2 m -127.57 139.81 50.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.65 0.262 . . . . 0.0 110.706 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 80.6 p -140.11 173.98 10.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.999 0.428 . . . . 0.0 111.241 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -148.0 151.28 35.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.724 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.93 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.677 0.275 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 64.4 p-90 -150.33 148.74 29.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.974 0.416 . . . . 0.0 111.165 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.415 ' HB3' ' HA ' ' A' ' 191' ' ' ARG . 9.5 p90 -130.91 143.35 50.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.652 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.62 149.64 52.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.234 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.47 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.62 -159.98 19.1 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.779 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -132.19 142.36 13.8 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.349 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.423 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -127.67 140.34 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.97 0.414 . . . . 0.0 111.127 -179.86 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.684 HD13 ' HB2' ' A' ' 54' ' ' ALA . 19.2 tp -128.08 141.01 51.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.461 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.652 ' H ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.364 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.624 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.567 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.684 ' HB2' HD13 ' A' ' 25' ' ' LEU . . . -134.94 136.03 41.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.799 0.333 . . . . 0.0 110.878 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.403 ' CA ' ' O ' ' A' ' 72' ' ' TYR . . . -156.07 166.56 33.09 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.693 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.97 155.01 16.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 110.706 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.455 ' CZ ' ' NH2' ' A' ' 113' ' ' ARG . 47.0 m-85 -143.69 132.49 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.934 0.397 . . . . 0.0 111.124 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -130.83 124.8 4.31 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.377 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -100.5 130.65 10.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.494 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -122.09 120.69 35.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.825 0.345 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.98 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.943 0.401 . . . . 0.0 111.317 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -134.98 166.04 24.47 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.323 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -86.18 132.95 33.9 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.783 0.325 . . . . 0.0 111.069 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.727 ' HB3' HG23 ' A' ' 97' ' ' THR . 25.9 tt0 -109.98 112.09 23.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.171 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.0 mmt -108.28 111.98 24.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.945 179.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -118.37 163.74 12.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.35 -0.929 . . . . 0.0 113.104 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.403 ' O ' ' CA ' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -128.61 114.81 17.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.673 0.273 . . . . 0.0 110.471 179.701 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.69 129.63 34.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.416 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.633 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.631 0.253 . . . . 0.0 110.617 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -94.68 131.64 10.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.87 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -113.52 121.8 66.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.28 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 17.7 mt-30 -108.79 134.6 51.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.037 0.446 . . . . 0.0 111.712 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.485 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -128.86 112.48 14.17 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.868 179.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.727 HG23 ' HB3' ' A' ' 69' ' ' GLU . 0.9 OUTLIER -151.1 162.47 40.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.077 0.465 . . . . 0.0 111.658 -178.932 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.9 122.37 43.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.041 179.102 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.417 ' HG2' ' HB2' ' A' ' 69' ' ' GLU . 0.0 OUTLIER -112.58 132.13 55.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.145 0.498 . . . . 0.0 112.071 -179.039 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.504 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.9 pp -122.49 128.39 50.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.807 178.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.442 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -119.96 -179.91 16.5 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.133 -179.201 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -166.08 125.84 1.2 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.763 -0.219 . . . . 0.0 110.664 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo . . . . . 0 C--N 1.346 0.405 0 C-N-CA 122.553 2.169 . . . . 0.0 112.489 -179.785 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.09 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -138.53 162.99 33.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.106 0.479 . . . . 0.0 111.722 -179.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.966 HG22 HG12 ' A' ' 149' ' ' VAL . 1.4 pt -114.81 157.06 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.28 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.442 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 96.3 m-85 -153.47 144.82 23.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.081 0.467 . . . . 0.0 111.73 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 38.8 p -142.48 126.96 17.8 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.167 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.503 ' HD3' HG21 ' A' ' 97' ' ' THR . 1.4 ppt_? -118.27 134.7 54.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.009 0.433 . . . . 0.0 111.78 -179.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.8 tt -133.63 122.9 24.13 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.078 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.403 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . -177.65 -132.95 1.76 Allowed Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.602 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.528 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.43 165.55 31.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.302 -0.951 . . . . 0.0 113.082 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.7 ptt? -120.44 140.99 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.922 0.392 . . . . 0.0 110.744 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.478 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.8 t -134.32 124.5 45.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.926 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 54.2 p-90 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.925 179.926 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.4 p . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.752 0.311 . . . . 0.0 111.029 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 36.2 t -157.22 140.65 11.23 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.293 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.528 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.4 Cg_endo -80.65 148.15 17.83 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.73 2.286 . . . . 0.0 112.259 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 33.9 m -156.27 159.07 2.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.989 0.423 . . . . 0.0 111.492 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -149.1 123.54 9.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.499 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.36 145.32 40.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.838 0.352 . . . . 0.0 111.425 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.64 133.66 6.22 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.265 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -169.76 -149.99 6.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.556 -0.831 . . . . 0.0 113.023 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.966 HG12 HG22 ' A' ' 110' ' ' ILE . 13.8 m -135.23 168.78 22.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.813 0.34 . . . . 0.0 111.396 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.407 ' HB2' ' CD2' ' A' ' 111' ' ' TYR . 9.2 tt0 -131.6 136.61 47.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -125.14 131.59 53.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.033 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -91.53 137.2 32.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.074 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 62.2 t . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.899 0.38 . . . . 0.0 110.86 179.942 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.838 0.351 . . . . 0.0 110.988 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.47 160.18 38.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.187 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.1 m -100.96 153.34 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.45 124.99 29.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.294 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.1 tt -123.95 116.51 23.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.112 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.432 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 42.1 mt-10 -136.32 145.17 45.16 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.143 0.497 . . . . 0.0 111.45 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -123.48 166.01 16.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.625 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 8.5 mm-40 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 179.963 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 5.9 mp . . . . . 0 CA--C 1.526 0.057 0 CA-C-O 120.79 0.329 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -128.6 141.6 51.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.854 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.98 146.37 50.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.814 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . 0.423 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -163.42 -176.77 35.73 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.584 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.46 142.66 42.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.729 0.3 . . . . 0.0 110.825 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . 0.47 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 29.6 t -135.96 161.03 36.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.152 0.501 . . . . 0.0 111.857 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . 0.403 ' CE1' ' O ' ' A' ' 191' ' ' ARG . 7.0 t80 -125.01 135.16 52.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.363 179.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . 0.415 ' HA ' ' HB3' ' A' ' 20' ' ' TYR . 8.4 ptt180 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.113 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 t . . . . . 0 C--O 1.232 0.144 0 CA-C-O 120.741 0.305 . . . . 0.0 110.812 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.434 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 17.6 t90 -142.74 129.92 20.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.0 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.44 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 10.5 m-85 -119.69 135.91 54.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.833 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.57 139.98 35.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.073 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -171.1 -159.2 16.59 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -148.1 147.48 18.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.61 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.409 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 3.0 mttp -123.63 161.14 25.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.988 0.423 . . . . 0.0 111.031 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 2.5 tt -141.35 143.24 33.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.695 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.55 -179.998 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.612 -0.195 . . . . 0.0 112.612 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -129.24 153.68 47.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.721 0.296 . . . . 0.0 110.876 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.04 172.18 35.14 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.769 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.617 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -114.12 131.27 56.47 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.744 0.307 . . . . 0.0 110.887 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.402 ' CD1' ' HG3' ' A' ' 24' ' ' LYS . 30.0 m-85 -118.72 128.22 54.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.073 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.97 126.39 3.23 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.39 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -127.5 136.14 9.12 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.608 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.45 ' CZ ' ' CB ' ' A' ' 68' ' ' PHE . 42.1 p90 -134.25 130.62 37.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.993 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.766 0.317 . . . . 0.0 110.941 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 167.69 21.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.45 ' CB ' ' CZ ' ' A' ' 60' ' ' TYR . 0.3 OUTLIER -85.56 131.86 34.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 110.749 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 3.3 tm-20 -113.09 119.86 39.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.089 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.17 123.48 47.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.555 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 148.43 17.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.571 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.617 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 40.8 m-85 -130.04 115.05 16.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.802 0.334 . . . . 0.0 110.614 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.38 120.84 33.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.993 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.224 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.697 0.284 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -99.31 130.53 10.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.105 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.51 121.67 65.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 179.269 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -108.89 142.83 38.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.145 0.498 . . . . 0.0 111.8 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -132.3 110.62 10.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.738 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.481 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.8 p -150.85 167.39 27.64 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 120.932 0.396 . . . . 0.0 111.677 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -102.45 120.89 41.29 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.132 179.131 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.404 ' HB2' ' HB2' ' A' ' 69' ' ' GLU . 2.1 ttpm? -106.03 132.34 52.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.042 0.449 . . . . 0.0 111.909 -179.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.492 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.8 pp -135.87 128.35 30.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.281 179.305 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -150.25 -173.3 20.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.919 -179.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.816 ' CE2' HD11 ' A' ' 110' ' ' ILE . 30.4 p90 -166.17 143.12 4.31 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.585 0.231 . . . . 0.0 111.012 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo . . . . . 0 C--N 1.345 0.371 0 C-N-CA 122.778 2.319 . . . . 0.0 112.941 -179.763 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.487 HD23 ' CD1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.681 0.277 . . . . 0.0 110.302 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -144.76 158.4 43.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.966 0.413 . . . . 0.0 111.678 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.928 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 147.93 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.467 179.472 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.448 ' CZ ' ' HD3' ' A' ' 160' ' ' ARG . 17.7 p90 -142.33 143.32 32.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.11 0.481 . . . . 0.0 111.599 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 46.7 p -138.56 126.96 23.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.132 179.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.76 ' HG2' ' HB3' ' A' ' 146' ' ' ALA . 0.0 OUTLIER -121.2 138.48 54.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.982 0.42 . . . . 0.0 111.608 -179.241 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.49 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.8 tt -129.53 122.91 30.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.349 179.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.481 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -177.44 -141.76 4.22 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.723 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.526 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.19 169.13 25.89 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.434 -0.889 . . . . 0.0 112.843 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 14.7 tmm? -125.92 141.71 51.85 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 120.888 0.375 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -127.03 130.53 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.764 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 4.2 p-90 . . . . . 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 111.035 -179.85 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.637 0.256 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.437 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 4.5 p -157.11 131.85 5.28 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.368 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.526 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.5 Cg_exo -73.66 150.34 44.99 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.65 2.234 . . . . 0.0 111.791 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.1 m -156.28 163.53 1.41 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.26 0 CA-C-O 121.116 0.484 . . . . 0.0 111.84 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.49 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.9 t80 -137.07 118.76 15.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.245 179.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.76 ' HB3' ' HG2' ' A' ' 113' ' ' ARG . . . -103.63 126.72 50.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.929 0.395 . . . . 0.0 111.327 -179.636 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.57 124.88 3.61 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.176 179.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.75 -160.57 11.03 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.693 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.928 HG12 HG22 ' A' ' 110' ' ' ILE . 6.0 m -134.75 163.39 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.659 0.266 . . . . 0.0 110.915 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -127.71 142.54 51.3 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 120.918 0.39 . . . . 0.0 111.099 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . 0.487 ' CD1' HD23 ' A' ' 108' ' ' LEU . 7.6 t90 -126.57 119.16 26.42 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.66 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.59 137.23 32.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.388 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.511 179.631 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 21.5 mt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.887 0.375 . . . . 0.0 111.686 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -135.63 155.93 49.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.994 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 1.7 t -117.63 140.56 49.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.094 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.448 ' HD3' ' CZ ' ' A' ' 111' ' ' TYR . 0.0 OUTLIER -134.59 151.58 51.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.328 0.585 . . . . 0.0 112.123 -179.33 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -113.12 124.8 53.43 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.725 179.093 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -106.89 145.13 32.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.985 0.421 . . . . 0.0 111.622 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.672 ' CE2' HD21 ' A' ' 184' ' ' LEU . 0.8 OUTLIER -131.12 126.48 35.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.383 179.673 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.17 -179.787 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.672 HD21 ' CE2' ' A' ' 163' ' ' TYR . 2.5 mp . . . . . 0 N--CA 1.457 -0.089 0 CA-C-O 120.732 0.301 . . . . 0.0 110.771 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.3 p -136.76 155.78 49.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.068 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -119.33 133.06 55.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.461 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . 0.409 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -145.67 162.37 28.26 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.207 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.73 133.94 67.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.773 0.32 . . . . 0.0 110.402 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -136.14 175.09 9.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.943 0.401 . . . . 0.0 111.378 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -139.84 155.8 47.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.636 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . 0.44 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.933 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.498 HG22 ' H ' ' A' ' 19' ' ' TRP . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.72 0.295 . . . . 0.0 110.833 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.498 ' H ' HG22 ' A' ' 18' ' ' THR . 13.3 p-90 -143.79 148.17 35.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.955 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.8 m-85 -119.97 140.0 51.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.709 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.35 139.98 47.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.384 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.15 -158.47 19.82 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.499 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -155.86 150.45 21.81 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.533 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 9.1 ptmm? -131.71 154.04 49.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.914 0.388 . . . . 0.0 111.07 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -128.29 148.89 50.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.675 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.564 -179.932 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.38 144.4 34.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.426 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.55 130.85 3.36 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.747 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.765 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.91 145.67 24.75 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.689 0.28 . . . . 0.0 110.773 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -135.62 133.35 38.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.023 0.44 . . . . 0.0 111.425 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.82 125.04 1.89 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.849 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -134.39 164.36 24.58 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.934 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.404 ' CB ' ' HB3' ' A' ' 19' ' ' TRP . 48.5 p90 -143.91 134.04 24.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.897 0.38 . . . . 0.0 110.657 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.965 0.412 . . . . 0.0 111.325 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.75 177.1 18.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.294 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -98.04 142.37 29.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.653 0.263 . . . . 0.0 110.703 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -132.96 121.29 22.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.917 0.389 . . . . 0.0 111.07 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.16 129.32 53.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.421 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.01 156.91 15.35 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.636 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.765 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 40.0 m-85 -130.48 115.04 16.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.774 0.321 . . . . 0.0 110.463 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.83 120.48 30.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.186 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 . . . . . 0 C--N 1.331 -0.236 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.889 179.825 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.807 0.336 . . . . 0.0 110.645 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.36 128.47 8.5 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.666 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.66 117.96 51.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.641 0.258 . . . . 0.0 110.324 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -110.55 142.53 42.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.116 0.484 . . . . 0.0 111.72 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.5 tt -129.06 110.23 11.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.483 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.523 HG22 ' HA3' ' A' ' 115' ' ' GLY . 5.1 p -148.2 174.66 11.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.235 0.541 . . . . 0.0 111.769 -178.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -111.55 135.24 52.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.304 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.66 132.13 55.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.918 0.389 . . . . 0.0 111.448 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -132.18 131.69 42.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.587 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.38 -174.3 34.85 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.569 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.46 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -165.36 150.8 8.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.73 0.3 . . . . 0.0 110.925 -179.882 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.46 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 37.6 Cg_exo . . . . . 0 C--N 1.348 0.507 0 C-N-CA 122.709 2.272 . . . . 0.0 112.108 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.449 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.052 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.405 ' HB3' ' HA ' ' A' ' 103' ' ' PRO . 3.0 p30 -131.64 160.26 35.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.032 0.444 . . . . 0.0 112.016 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.968 HG22 HG12 ' A' ' 149' ' ' VAL . 1.4 pp -116.07 141.25 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.133 179.332 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -156.69 160.28 39.18 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.103 0.478 . . . . 0.0 111.925 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 9.3 t -138.4 151.07 47.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.02 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.517 ' NE ' ' HB3' ' A' ' 146' ' ' ALA . 3.7 ppt_? -120.5 127.99 52.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.514 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.6 tt -125.75 122.67 36.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.127 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.523 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -179.59 -141.52 4.59 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.512 -0.851 . . . . 0.0 112.669 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.491 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.11 168.65 25.64 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.796 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.462 ' HE3' HG11 ' A' ' 144' ' ' VAL . 8.3 ptp -126.56 142.48 51.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.879 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -124.45 144.05 35.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.807 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.7 t90 . . . . . 0 C--N 1.329 -0.307 0 CA-C-O 120.808 0.337 . . . . 0.0 110.974 -179.882 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 141' ' ' VAL . 9.1 p . . . . . 0 N--CA 1.457 -0.094 0 CA-C-O 120.667 0.27 . . . . 0.0 110.964 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.0 p -157.05 148.65 17.12 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.335 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.491 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 72.4 Cg_endo -76.55 158.47 36.08 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.665 2.243 . . . . 0.0 112.084 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.462 HG11 ' HE3' ' A' ' 117' ' ' MET . 35.0 m -155.92 154.41 6.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.031 0.443 . . . . 0.0 111.52 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 59.4 t80 -149.15 118.66 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.416 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.517 ' HB3' ' NE ' ' A' ' 113' ' ' ARG . . . -129.37 147.48 51.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.94 0.4 . . . . 0.0 111.345 -179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.22 145.37 17.19 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.078 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -164.77 -171.03 30.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.799 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.968 HG12 HG22 ' A' ' 110' ' ' ILE . 3.4 m -129.56 148.95 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.746 0.308 . . . . 0.0 111.107 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -110.83 127.15 55.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . 0.449 ' NE1' HD22 ' A' ' 108' ' ' LEU . 5.3 t90 -128.61 120.29 26.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.757 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.57 132.92 34.46 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.354 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.1 t . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.756 179.746 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 18.6 mt . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.766 0.317 . . . . 0.0 111.209 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -112.68 168.56 9.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.254 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.3 m -135.92 146.63 47.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.348 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 147.69 46.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.201 0.524 . . . . 0.0 111.902 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.2 tt -119.68 124.1 45.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.776 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -114.42 144.48 43.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.084 0.469 . . . . 0.0 111.592 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.43 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 18.7 p90 -134.14 155.17 50.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.494 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.972 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.622 HD12 ' N ' ' A' ' 184' ' ' LEU . 3.6 mp . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.712 0.291 . . . . 0.0 110.534 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 47.4 m -151.86 155.74 38.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.901 0.382 . . . . 0.0 111.264 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -118.26 135.77 54.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.366 179.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -147.92 167.24 28.84 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 119.967 -1.111 . . . . 0.0 113.139 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.3 m -123.74 145.07 31.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 67.4 p -152.29 174.98 13.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.055 0.455 . . . . 0.0 111.593 -179.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -145.16 152.37 39.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.541 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . 0.419 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.878 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.8 m . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.871 0.367 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.44 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 27.0 m-90 -131.78 131.93 43.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.986 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -128.26 135.96 50.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.722 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.14 141.25 34.17 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.49 -166.6 33.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.546 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -156.01 150.07 21.28 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.42 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -126.85 160.05 32.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.902 0.382 . . . . 0.0 111.157 -179.904 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.66 140.88 46.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.609 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.499 -179.888 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.645 -0.182 . . . . 0.0 112.645 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.11 144.54 33.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.34 117.78 1.2 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.619 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.73 136.1 35.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.75 0.31 . . . . 0.0 110.667 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 22.4 m-85 -125.93 132.8 52.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.974 0.416 . . . . 0.0 111.186 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.57 125.04 1.78 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.201 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 69' ' ' GLU . . . -155.87 -173.42 24.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.858 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.44 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 1.9 p90 -147.96 158.31 43.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.756 0.312 . . . . 0.0 110.8 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 32.8 mt-30 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.994 -179.787 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.6 pp . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.823 0.345 . . . . 0.0 110.7 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -137.97 175.66 21.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.615 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -115.36 138.16 51.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.823 0.344 . . . . 0.0 110.648 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.418 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . 1.2 pt-20 -140.13 143.14 36.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.002 0.43 . . . . 0.0 111.198 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -110.68 142.25 42.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.531 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 158.24 14.6 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.617 -0.802 . . . . 0.0 112.441 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -130.83 114.79 15.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.678 0.275 . . . . 0.0 110.77 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.412 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.4 t0 -90.35 119.36 30.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.914 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 2.2 t90 . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.955 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.782 0.325 . . . . 0.0 110.458 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.412 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -88.74 133.65 11.94 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.991 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.83 117.74 45.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -108.98 149.03 29.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.236 0.541 . . . . 0.0 111.875 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.6 tt -135.11 113.78 11.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.629 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 t -154.11 166.33 33.41 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.099 0.476 . . . . 0.0 111.638 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.34 134.57 50.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.481 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.59 130.18 54.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.315 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.557 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -135.25 124.27 24.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.537 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -166.89 -169.77 30.91 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.693 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -165.1 157.62 13.67 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.727 0.299 . . . . 0.0 111.112 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 109' ' ' ASP . 90.5 Cg_endo . . . . . 0 C--N 1.346 0.413 0 C-N-CA 122.787 2.325 . . . . 0.0 112.634 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.045 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 7.5 t0 -125.39 147.68 49.08 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.382 0.611 . . . . 0.0 112.385 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -129.33 123.54 58.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.763 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -143.04 168.84 18.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.027 0.441 . . . . 0.0 111.559 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.427 HG22 ' HA3' ' A' ' 147' ' ' GLY . 31.0 p -141.15 140.26 34.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.548 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.7 ptt-85 -111.64 127.93 55.9 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.205 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.5 tt -124.83 125.02 43.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.623 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 176.94 -132.74 2.1 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.512 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.03 169.18 32.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.982 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.0 tmm? -125.94 144.47 50.67 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 120.682 0.277 . . . . 0.0 110.639 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.63 129.65 64.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . 0.402 ' CZ2' ' HB3' ' A' ' 73' ' ' ASP . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.2 p . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.791 0.329 . . . . 0.0 111.036 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 38.1 m -157.24 148.18 16.47 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.387 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.512 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.5 Cg_endo -78.0 147.96 24.4 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.766 2.311 . . . . 0.0 112.049 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.11 158.38 3.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.988 0.423 . . . . 0.0 111.52 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -145.88 119.93 9.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.418 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -120.97 163.95 17.47 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.904 0.383 . . . . 0.0 111.396 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.427 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -140.7 148.42 20.06 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.246 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.37 -171.99 31.3 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.705 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.8 m -131.98 167.05 27.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.669 0.271 . . . . 0.0 111.08 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -134.64 151.49 51.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.946 0.403 . . . . 0.0 111.291 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -133.06 117.61 17.77 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.582 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 158' ' ' ALA . . . -81.68 122.46 27.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.422 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 56.4 t . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.957 179.706 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.4 mt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.925 0.393 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.432 ' HB2' ' HA ' ' A' ' 152' ' ' ALA . . . -113.25 167.91 10.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.288 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.4 t -123.27 143.3 50.15 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.261 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.09 147.19 45.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.13 0.49 . . . . 0.0 111.783 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -113.95 126.11 54.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.806 179.043 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.7 138.51 45.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.385 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -134.19 156.18 48.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.664 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.929 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.605 ' N ' HD12 ' A' ' 184' ' ' LEU . 4.2 mp . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.67 0.272 . . . . 0.0 110.629 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.22 155.46 37.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.01 0.433 . . . . 0.0 111.285 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -115.24 131.87 56.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.169 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . 0.42 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -146.15 168.06 27.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.367 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -127.59 141.01 47.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -144.57 174.98 10.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.043 0.449 . . . . 0.0 111.522 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -146.15 155.67 42.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.712 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 1.6 ptp180 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.977 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.763 0.316 . . . . 0.0 110.92 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -118.29 130.74 56.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.857 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -126.06 135.88 52.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.799 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.23 153.85 44.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.17 -165.28 37.91 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.42 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -160.54 151.51 22.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.532 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -133.05 157.91 44.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 0.0 111.034 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -127.46 146.19 50.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.7 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.546 -179.929 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.14 52.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.69 0.281 . . . . 0.0 110.948 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.5 135.46 7.44 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.737 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.487 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -103.75 135.64 44.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.781 0.324 . . . . 0.0 110.882 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -119.41 133.69 55.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.206 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -157.27 125.55 1.59 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.389 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -146.18 -178.65 21.78 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.69 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 14.3 p90 -153.35 160.81 42.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.843 0.354 . . . . 0.0 110.927 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.798 179.859 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.821 0.343 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.23 169.8 21.05 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.439 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.6 m-85 -98.75 138.74 35.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.63 0.253 . . . . 0.0 110.817 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -125.95 129.55 49.49 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.952 0.406 . . . . 0.0 110.965 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.11 129.31 55.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.424 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.27 17.43 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.362 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.487 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 81.5 m-85 -125.61 114.85 19.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.748 0.309 . . . . 0.0 110.676 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.448 ' HB2' ' CZ2' ' A' ' 119' ' ' TRP . 0.3 OUTLIER -87.15 118.28 26.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.758 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.968 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.695 0.283 . . . . 0.0 110.374 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.439 ' HA3' ' HB2' ' A' ' 73' ' ' ASP . . . -83.92 133.73 12.12 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.017 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.85 117.98 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.8 0.333 . . . . 0.0 110.208 179.355 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 -108.98 138.11 45.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.109 0.481 . . . . 0.0 111.728 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.441 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.7 tt -127.6 107.24 9.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.696 179.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.651 HG22 ' HA3' ' A' ' 115' ' ' GLY . 27.0 p -144.68 162.05 37.65 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 121.158 0.504 . . . . 0.0 111.796 -178.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -92.92 126.5 38.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.006 178.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -104.87 130.98 52.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.029 0.442 . . . . 0.0 111.845 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.51 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.8 pp -136.29 123.78 22.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 179.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.21 177.46 34.06 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.507 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.439 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.19 153.95 9.4 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.733 0.302 . . . . 0.0 111.344 -179.925 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.439 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 38.1 Cg_exo . . . . . 0 C--N 1.347 0.483 0 C-N-CA 122.76 2.306 . . . . 0.0 112.05 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.498 HD23 ' N ' ' A' ' 108' ' ' LEU . 0.0 OUTLIER . . . . . 0 CA--C 1.524 -0.048 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -135.03 160.09 39.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.722 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.914 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.93 144.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.209 179.359 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -142.26 141.82 32.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.008 0.432 . . . . 0.0 111.527 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.443 HG23 ' HG ' ' A' ' 100' ' ' LEU . 9.6 t -137.15 126.91 25.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.199 179.347 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.403 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 0.0 OUTLIER -114.41 131.6 56.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.913 0.387 . . . . 0.0 111.511 -179.358 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.0 tt -128.06 122.93 33.35 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.451 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.651 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -175.82 -135.45 2.12 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.622 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.509 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.12 161.7 26.4 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.899 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.47 138.63 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.716 0.293 . . . . 0.0 110.705 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -129.57 134.68 63.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . 0.448 ' CZ2' ' HB2' ' A' ' 73' ' ' ASP . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.8 p . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.621 0.248 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -157.1 144.72 13.92 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.337 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.509 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 90.9 Cg_endo -80.73 139.99 12.76 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.752 2.302 . . . . 0.0 112.115 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 143' ' ' PRO . 30.3 m -157.04 162.84 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 121.002 0.43 . . . . 0.0 111.504 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.9 p90 -142.35 121.12 12.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.45 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -105.74 141.16 37.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.976 0.417 . . . . 0.0 111.402 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.59 135.03 7.88 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.994 179.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -159.68 -171.99 26.26 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.895 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.914 HG12 HG22 ' A' ' 110' ' ' ILE . 4.4 m -131.12 150.98 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.663 0.268 . . . . 0.0 111.138 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -122.32 133.99 54.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.169 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 9.4 m95 -121.76 122.17 38.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.649 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.413 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -78.77 137.01 37.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.406 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 72.8 t . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.682 179.758 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 5.2 mt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.809 0.338 . . . . 0.0 111.226 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -132.5 161.85 32.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.375 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 9.7 t -117.72 143.98 45.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.965 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -137.0 150.87 48.39 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.204 0.526 . . . . 0.0 112.158 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.7 tt -114.39 123.87 50.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.585 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -107.83 139.54 42.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.986 0.422 . . . . 0.0 111.557 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.429 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 36.3 p90 -134.14 160.15 38.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.723 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.058 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 6.3 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.693 0.283 . . . . 0.0 110.65 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 11.0 p -142.53 158.91 43.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.73 134.64 54.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -149.29 172.62 29.31 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.004 -1.093 . . . . 0.0 113.404 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.65 141.37 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.677 0.275 . . . . 0.0 110.388 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 32.8 p -139.55 171.48 14.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.42 . . . . 0.0 111.268 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -148.03 157.51 43.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.776 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.95 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.7 p . . . . . 0 C--O 1.233 0.185 0 CA-C-O 120.818 0.342 . . . . 0.0 110.885 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -121.94 145.39 48.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.405 ' CE2' ' HG3' ' A' ' 191' ' ' ARG . 89.6 m-85 -142.16 135.98 29.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.569 ' HB3' ' CE1' ' A' ' 190' ' ' TYR . . . -144.41 140.02 28.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.08 -161.11 26.09 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.384 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.85 147.27 17.1 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.56 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.72 153.81 35.07 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.923 0.392 . . . . 0.0 110.906 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.462 HD12 ' O ' ' A' ' 53' ' ' GLY . 55.7 tp -136.7 138.61 41.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.649 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.604 -179.827 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.462 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.33 -0.308 . . . . 0.0 112.33 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -117.78 142.86 46.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.806 0.336 . . . . 0.0 111.137 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.419 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -143.17 134.73 6.07 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.67 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.641 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.9 140.28 30.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.304 . . . . 0.0 110.837 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.41 ' CD1' ' HG2' ' A' ' 69' ' ' GLU . 0.2 OUTLIER -126.45 134.31 51.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.935 0.398 . . . . 0.0 111.126 -179.777 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -161.62 126.42 1.58 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.254 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -158.55 -166.2 17.24 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.653 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -151.21 146.56 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.879 0.371 . . . . 0.0 110.989 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.756 179.877 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.785 0.326 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 158.38 23.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.483 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -105.28 129.03 53.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.632 0.253 . . . . 0.0 110.62 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.41 ' HG2' ' CD1' ' A' ' 57' ' ' PHE . 5.0 tt0 -122.54 128.46 50.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.86 0.362 . . . . 0.0 111.149 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.3 ttt -108.96 127.0 53.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.538 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 163.92 12.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.742 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.641 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 95.5 m-85 -138.18 114.85 10.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.24 120.27 25.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.023 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.224 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.832 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.698 0.285 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -115.1 141.01 16.76 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.203 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.11 128.11 67.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.175 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 145.29 35.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.135 0.493 . . . . 0.0 111.855 -178.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -140.08 116.14 10.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.742 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -153.01 165.43 35.6 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.211 0.529 . . . . 0.0 111.809 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -99.19 133.42 43.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.358 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 9.5 pttt -112.79 132.33 55.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.515 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.542 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.9 pp -136.08 122.33 20.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.534 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.31 -176.73 37.14 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.663 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.424 ' HB2' ' HD2' ' A' ' 103' ' ' PRO . 30.3 p90 -166.18 157.61 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 120.657 0.265 . . . . 0.0 111.009 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.424 ' HD2' ' HB2' ' A' ' 102' ' ' TYR . 19.9 Cg_endo . . . . . 0 C--N 1.346 0.427 0 C-N-CA 122.599 2.2 . . . . 0.0 111.813 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.077 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -127.43 155.91 42.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.983 0.42 . . . . 0.0 111.925 -178.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.055 HG22 HG12 ' A' ' 149' ' ' VAL . 1.5 pp -125.18 136.35 61.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.369 179.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 37.8 p90 -150.14 159.35 44.49 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.106 0.479 . . . . 0.0 111.494 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.407 HG22 ' HA3' ' A' ' 147' ' ' GLY . 36.8 p -130.86 149.22 52.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.479 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.1 ppt_? -123.75 127.85 48.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.87 0.367 . . . . 0.0 111.394 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -127.89 122.74 33.29 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.205 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -179.47 -133.18 1.91 Allowed Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.735 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.1 169.12 33.64 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.809 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -126.02 143.7 51.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.823 0.344 . . . . 0.0 110.906 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.3 t -124.89 125.23 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.839 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 19.7 m0 . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.904 -179.806 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.749 0.309 . . . . 0.0 111.286 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 54.4 p -157.02 130.6 4.69 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.489 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.9 Cg_endo -78.23 146.94 22.84 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.548 2.165 . . . . 0.0 112.152 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.6 m -156.09 151.11 9.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.872 0.368 . . . . 0.0 111.442 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.2 p90 -149.08 124.27 10.15 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.501 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.543 ' HB2' ' HG3' ' A' ' 164' ' ' GLN . . . -134.91 167.04 21.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.979 0.418 . . . . 0.0 111.447 -179.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.407 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -133.76 146.14 18.12 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.007 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -155.39 -179.83 30.82 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.901 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 1.055 HG12 HG22 ' A' ' 110' ' ' ILE . 11.4 m -128.42 153.31 37.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.828 0.347 . . . . 0.0 110.994 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -122.12 139.74 53.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.203 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -128.48 118.48 23.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.804 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.413 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -82.24 137.01 34.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.23 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 84.6 t . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 179.839 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.3 mt . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.801 0.334 . . . . 0.0 111.274 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.04 155.67 46.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.383 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 6.4 t -102.5 145.73 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.299 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.24 139.09 40.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.068 0.461 . . . . 0.0 111.823 -179.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -115.74 130.48 56.87 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.754 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.25 142.58 39.91 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.047 0.451 . . . . 0.0 111.626 -179.256 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.489 ' CZ ' HD21 ' A' ' 184' ' ' LEU . 0.1 OUTLIER -134.14 130.68 37.68 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.372 179.582 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . 0.543 ' HG3' ' HB2' ' A' ' 146' ' ' ALA . 5.6 mp0 . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.12 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.528 ' N ' HD12 ' A' ' 184' ' ' LEU . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.779 0.323 . . . . 0.0 110.696 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.9 m -125.43 151.01 46.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.104 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.47 128.44 52.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.414 179.712 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -145.7 167.24 27.67 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.997 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.7 m -129.56 137.34 57.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.659 0.266 . . . . 0.0 110.588 179.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.7 p -139.88 175.06 9.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.953 0.406 . . . . 0.0 111.318 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . 0.569 ' CE1' ' HB3' ' A' ' 21' ' ' ALA . 3.8 p90 -141.66 159.92 41.23 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.812 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . 0.405 ' HG3' ' CE2' ' A' ' 20' ' ' TYR . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.851 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.6 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.886 0.374 . . . . 0.0 110.775 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 70.2 p-90 -149.6 132.3 15.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.987 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.5 m-85 -114.38 141.15 48.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.55 141.64 28.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.884 0.373 . . . . 0.0 111.278 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.21 -166.55 30.21 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.879 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -134.3 141.76 13.12 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.466 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.515 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 6.3 ptpt -128.84 149.72 50.63 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.078 0.466 . . . . 0.0 111.412 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.79 HD12 ' O ' ' A' ' 53' ' ' GLY . 47.4 tp -126.46 150.11 48.89 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.511 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.567 ' H ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.342 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.79 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.453 -0.22 0 N-CA-C 112.413 -0.275 . . . . 0.0 112.413 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -118.05 170.02 9.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.688 0.28 . . . . 0.0 110.932 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.58 157.34 27.67 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.783 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.533 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -108.97 140.58 42.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 110.876 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.403 ' HE2' ' HZ2' ' A' ' 24' ' ' LYS . 3.0 m-85 -126.48 128.76 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.031 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.65 124.99 2.2 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.254 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.13 172.26 23.0 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.763 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -140.11 160.49 39.83 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.827 0.346 . . . . 0.0 110.786 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 . . . . . 0 C--N 1.331 -0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.908 -179.982 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.664 0.268 . . . . 0.0 110.831 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -121.23 161.56 15.25 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.584 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -114.08 134.7 54.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.779 0.323 . . . . 0.0 110.696 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.401 ' OE2' ' CD1' ' A' ' 57' ' ' PHE . 2.0 tt0 -129.95 129.93 44.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.918 0.389 . . . . 0.0 111.085 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 ttm -108.01 135.43 49.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.422 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 158.52 14.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.512 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.533 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 19.9 m-85 -138.0 115.02 10.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.646 0.26 . . . . 0.0 110.657 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.417 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.2 t0 -87.97 121.09 29.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.88 0.372 . . . . 0.0 110.924 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 21.3 t-105 . . . . . 0 C--N 1.332 -0.193 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.977 -179.958 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.617 0.246 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.417 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -85.26 135.76 13.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.926 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.42 120.33 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 179.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -108.95 148.51 30.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.154 0.502 . . . . 0.0 111.744 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 tt -138.13 114.04 9.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.703 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.423 HG22 ' HA3' ' A' ' 115' ' ' GLY . 8.6 p -149.72 164.45 35.22 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 121.054 0.455 . . . . 0.0 111.764 -178.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -97.52 132.28 43.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.314 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.86 132.23 53.66 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.036 0.446 . . . . 0.0 111.643 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.569 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.4 pp -135.93 124.07 23.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.431 179.322 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.96 -169.86 30.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.711 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.456 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 2.9 t80 -160.62 145.17 10.59 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.69 0.281 . . . . 0.0 111.12 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.456 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 95.3 Cg_endo . . . . . 0 C--N 1.347 0.472 0 C-N-CA 122.884 2.389 . . . . 0.0 112.479 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.61 HD22 ' CE2' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.087 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -131.38 155.11 47.83 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.031 0.443 . . . . 0.0 111.893 -179.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.956 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -119.91 146.82 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.271 179.351 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.441 ' CE2' ' HB2' ' A' ' 150' ' ' GLU . 4.4 p90 -162.44 164.01 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.103 0.478 . . . . 0.0 111.763 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.409 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 17.4 m -140.54 139.77 35.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.497 179.737 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.401 ' HB3' ' NH1' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -114.96 127.99 56.01 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.152 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -127.79 122.91 33.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.44 179.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.423 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.89 -134.54 2.15 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.536 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -149.42 163.06 29.19 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.751 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.9 ppp? -117.64 145.03 44.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 110.917 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.7 t -127.05 141.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.861 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.5 t90 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.003 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.714 0.293 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.02 117.33 2.84 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.347 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.489 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 6.3 Cg_exo -73.65 137.62 25.3 Favored 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 122.605 2.203 . . . . 0.0 111.85 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 143' ' ' PRO . 26.4 m -156.96 164.03 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.862 0.363 . . . . 0.0 111.386 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -148.59 122.37 9.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.796 179.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.52 142.85 45.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.173 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 112' ' ' THR . . . -134.34 142.12 13.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.299 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -170.55 -157.69 13.12 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.107 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.956 HG12 HG22 ' A' ' 110' ' ' ILE . 4.9 m -129.83 163.25 35.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 111.127 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.441 ' HB2' ' CE2' ' A' ' 111' ' ' TYR . 0.7 OUTLIER -133.19 129.38 37.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . 0.61 ' CE2' HD22 ' A' ' 108' ' ' LEU . 1.4 t-105 -118.43 132.55 56.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.792 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.425 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -99.36 134.43 42.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 0.0 111.528 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.681 ' O ' HG12 ' A' ' 153' ' ' VAL . 47.8 t . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.751 179.754 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.816 0.341 . . . . 0.0 111.073 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.425 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -115.88 154.26 30.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.342 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.99 151.53 22.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.247 179.499 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 2.1 ptm180 -136.93 132.76 34.89 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.9 0.381 . . . . 0.0 111.897 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.838 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 1.1 tt -123.61 120.79 33.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.734 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.435 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 0.7 OUTLIER -116.34 145.12 43.44 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.606 -179.043 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.838 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 2.1 m-85 -126.76 165.81 18.58 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.551 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.938 -179.998 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.499 HD12 ' N ' ' A' ' 184' ' ' LEU . 6.7 mp . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.826 0.346 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.2 m -132.59 145.8 51.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.91 137.84 49.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.568 179.705 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . 0.515 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -158.8 -176.65 31.09 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.449 -0.881 . . . . 0.0 113.042 -179.569 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -126.16 141.86 44.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.637 0.256 . . . . 0.0 110.52 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . 0.46 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 1.4 t -137.93 159.72 41.24 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.112 0.482 . . . . 0.0 111.576 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -117.81 146.42 43.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.41 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.235 0 CA-C-O 120.813 0.34 . . . . 0.0 110.822 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -121.19 146.97 46.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.421 ' CD1' ' HB2' ' A' ' 189' ' ' SER . 0.1 OUTLIER -142.35 135.81 29.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.724 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 145.22 31.03 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.336 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.72 -168.9 38.65 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.566 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -137.0 147.04 19.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.546 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.435 ' HE3' ' CE2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -121.2 153.14 37.98 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 -179.924 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.1 tt -133.43 139.34 46.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.723 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.383 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.577 -179.989 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.628 -0.189 . . . . 0.0 112.628 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -127.97 159.63 34.38 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.812 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.437 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -158.44 155.66 26.68 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.802 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -113.59 126.69 55.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.797 0.332 . . . . 0.0 110.856 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.435 ' CE2' ' HE3' ' A' ' 24' ' ' LYS . 38.9 p90 -115.59 133.46 56.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.111 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.1 125.15 1.78 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.132 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -150.41 -176.98 23.93 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.747 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -155.06 154.48 32.52 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.896 0.379 . . . . 0.0 111.006 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.567 179.867 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.976 0.417 . . . . 0.0 111.159 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.49 176.76 18.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.398 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.41 ' CE2' ' HG ' ' A' ' 96' ' ' LEU . 1.2 t80 -103.85 138.24 40.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.634 0.254 . . . . 0.0 110.724 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -134.51 125.9 28.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.852 0.358 . . . . 0.0 111.116 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.1 mtt -107.27 133.38 51.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.434 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.87 159.4 13.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.615 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.437 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -131.53 114.88 15.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.679 0.276 . . . . 0.0 110.613 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -86.18 120.51 27.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.998 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 42.8 t90 . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.917 -179.974 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.675 0.274 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -98.21 130.22 10.16 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.968 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.77 118.96 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 15.8 mt-30 -108.86 144.4 36.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.241 0.543 . . . . 0.0 111.937 -178.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.452 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -133.45 112.19 11.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.266 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.515 HG22 ' HA3' ' A' ' 115' ' ' GLY . 6.0 p -147.03 178.05 8.67 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.219 0.533 . . . . 0.0 111.984 -178.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -117.27 135.81 53.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.039 179.169 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -110.65 131.98 54.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.021 0.439 . . . . 0.0 111.379 -179.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.621 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -135.45 125.71 26.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.259 179.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.423 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -168.14 -169.82 32.09 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.944 -179.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.823 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 24.5 p90 -156.51 152.43 22.85 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.819 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo . . . . . 0 N--CA 1.463 -0.321 0 C-N-CA 122.721 2.281 . . . . 0.0 112.803 -179.617 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.227 -0.106 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -129.27 145.59 51.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.987 0.422 . . . . 0.0 111.809 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.969 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.9 142.17 28.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.657 179.314 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.423 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 33.4 m-85 -149.12 158.33 44.1 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.058 0.456 . . . . 0.0 111.695 -179.35 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.6 m -130.89 141.92 50.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.457 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 36.8 ttp180 -120.83 127.94 52.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.278 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -136.34 122.92 20.92 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.929 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.515 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -177.12 -140.71 3.73 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.583 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.7 167.74 25.48 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.868 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 9.0 ttp -130.2 141.1 50.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 0.0 110.735 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.4 t -125.69 115.63 43.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.826 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.888 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.409 HG13 ' O ' ' A' ' 141' ' ' VAL . 10.1 p . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.705 0.288 . . . . 0.0 110.97 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -157.16 148.49 16.84 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.831 0.348 . . . . 0.0 111.464 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.511 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -79.81 145.66 18.11 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.752 2.302 . . . . 0.0 112.222 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.7 m -156.71 157.1 4.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.927 0.394 . . . . 0.0 111.404 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -149.13 127.19 11.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.476 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -124.01 143.85 50.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.245 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -130.02 146.95 17.85 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.09 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.409 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -167.72 -164.39 23.31 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.936 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.969 HG12 HG22 ' A' ' 110' ' ' ILE . 6.7 m -128.65 166.89 25.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.685 0.279 . . . . 0.0 111.134 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -135.4 149.1 49.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.92 0.391 . . . . 0.0 111.196 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 5.2 m0 -131.39 123.07 27.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.735 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.86 130.2 34.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.225 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 51.1 t . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.052 179.942 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.442 HG12 ' CD2' ' A' ' 190' ' ' TYR . 22.8 mt . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.697 0.284 . . . . 0.0 110.754 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -132.99 160.86 35.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.984 0.421 . . . . 0.0 111.59 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . 0.494 ' OG1' HG12 ' A' ' 188' ' ' VAL . 24.5 m -119.35 145.45 46.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.973 179.518 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.408 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 147.42 46.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.179 0.514 . . . . 0.0 111.976 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.817 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 1.3 tt -113.92 123.57 50.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.533 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.409 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 1.1 mt-10 -107.5 143.88 35.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.044 0.45 . . . . 0.0 111.616 -179.074 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.823 ' CE1' HD23 ' A' ' 184' ' ' LEU . 45.4 m-85 -130.94 163.53 27.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.504 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.993 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.823 HD23 ' CE1' ' A' ' 163' ' ' TYR . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.166 0 CA-C-O 120.658 0.266 . . . . 0.0 110.605 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -135.71 152.37 51.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.973 0.416 . . . . 0.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.13 128.72 54.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.3 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -143.2 167.31 26.48 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.16 -1.019 . . . . 0.0 113.082 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . 0.494 HG12 ' OG1' ' A' ' 159' ' ' THR . 0.4 OUTLIER -128.42 139.49 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.687 0.28 . . . . 0.0 110.374 179.445 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . 0.421 ' HB2' ' CD1' ' A' ' 20' ' ' TYR . 0.3 OUTLIER -136.27 168.7 18.93 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 111.723 -179.125 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . 0.452 ' CD1' ' N ' ' A' ' 190' ' ' TYR . 2.7 m-85 -131.71 157.99 42.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.366 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 38.0 mtm180 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.943 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.511 HG21 ' HD3' ' A' ' 191' ' ' ARG . 1.4 p . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.815 0.341 . . . . 0.0 110.838 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 25.9 m-90 -117.28 132.45 56.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.055 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.429 ' CZ ' ' HG3' ' A' ' 191' ' ' ARG . 5.1 m-85 -120.41 135.87 54.91 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.522 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.22 140.26 43.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.488 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.409 ' HA3' ' HB3' ' A' ' 189' ' ' SER . . . 179.14 -163.78 31.57 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.414 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -162.73 161.33 33.67 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.552 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.458 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 0.1 OUTLIER -135.32 160.9 36.97 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.005 0.431 . . . . 0.0 111.044 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.417 HD12 ' HB2' ' A' ' 54' ' ' ALA . 3.9 tt -130.85 149.17 52.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.735 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.463 179.98 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.417 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -132.37 132.64 43.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.752 0.311 . . . . 0.0 110.914 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.37 158.08 26.79 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.753 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -126.85 134.72 50.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.51 0.195 . . . . 0.0 110.793 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.458 ' CE2' ' HG2' ' A' ' 24' ' ' LYS . 6.3 p90 -142.37 165.39 27.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.176 0.512 . . . . 0.0 111.738 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -140.13 141.87 11.96 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.79 179.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -114.59 143.26 17.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.896 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.441 ' CE2' ' HB3' ' A' ' 68' ' ' PHE . 1.8 p90 -144.62 121.3 11.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.898 0.38 . . . . 0.0 110.631 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.976 -179.775 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.861 0.362 . . . . 0.0 110.99 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 172.16 20.33 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.441 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . 0.9 OUTLIER -96.87 141.46 30.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.684 0.278 . . . . 0.0 110.611 179.902 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.77 120.24 28.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.976 0.417 . . . . 0.0 111.281 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.3 mtt -106.17 139.03 41.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.859 179.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . 0.45 ' CA ' ' HB3' ' A' ' 57' ' ' PHE . . . -133.0 166.63 23.61 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.643 -179.278 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -136.92 115.43 11.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.363 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -81.52 129.73 34.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.18 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 46.0 m95 . . . . . 0 C--N 1.33 -0.264 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.737 179.87 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.713 0.292 . . . . 0.0 110.519 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -105.53 140.56 15.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.429 -0.891 . . . . 0.0 112.913 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -115.81 122.62 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.201 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -108.53 143.85 36.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.115 0.483 . . . . 0.0 111.9 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -137.48 113.88 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.849 179.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.413 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 1.2 t -155.1 166.82 32.37 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 111.784 -179.01 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.1 139.45 39.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.32 179.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.9 ttpp -118.92 132.25 56.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.897 0.379 . . . . 0.0 111.598 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.8 pp -134.03 126.58 30.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.737 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 102' ' ' TYR . . . -167.99 -177.81 39.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.514 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.407 ' CG ' ' O ' ' A' ' 101' ' ' GLY . 6.5 m-85 -166.1 158.89 12.51 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.777 0.322 . . . . 0.0 110.987 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo . . . . . 0 C--N 1.346 0.442 0 C-N-CA 122.741 2.294 . . . . 0.0 111.944 179.806 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.6 HD22 ' CE2' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 N--CA 1.459 0.019 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -135.15 156.19 49.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.071 0.462 . . . . 0.0 111.996 -179.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.944 HG22 HG12 ' A' ' 149' ' ' VAL . 1.6 pp -121.34 138.86 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.394 179.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 48.1 p90 -151.28 163.51 38.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.071 0.463 . . . . 0.0 111.557 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.461 HG22 ' HA3' ' A' ' 147' ' ' GLY . 18.5 p -137.63 145.69 43.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.53 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -119.76 127.78 53.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.883 0.373 . . . . 0.0 111.315 -179.756 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -126.98 123.64 37.59 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.328 179.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.413 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.39 -132.49 1.94 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.42 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.497 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.89 168.61 33.95 Favored Glycine 0 C--N 1.331 0.3 0 C-N-CA 120.285 -0.96 . . . . 0.0 112.9 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.95 140.98 52.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.711 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.541 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.5 t -133.91 118.16 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.657 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 64.5 p-90 . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 120.833 0.349 . . . . 0.0 111.049 -179.792 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.444 HG23 HG22 ' A' ' 118' ' ' VAL . 10.8 p . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.744 0.307 . . . . 0.0 111.194 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.21 141.29 11.67 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.397 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.497 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 92.2 Cg_endo -78.69 149.95 23.96 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.603 2.202 . . . . 0.0 112.02 179.593 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.8 m -156.3 157.93 3.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.04 0.448 . . . . 0.0 111.702 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -149.08 118.9 7.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.303 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -127.76 159.21 35.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.986 0.422 . . . . 0.0 111.537 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.461 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -130.95 151.82 19.75 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.036 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -162.73 -177.71 35.96 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.346 -0.931 . . . . 0.0 112.979 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.944 HG12 HG22 ' A' ' 110' ' ' ILE . 4.2 m -127.82 154.27 38.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 0.0 111.005 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -124.75 140.46 52.91 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.938 0.399 . . . . 0.0 111.116 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . 0.6 ' CE2' HD22 ' A' ' 108' ' ' LEU . 1.9 t90 -131.63 127.77 37.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.779 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.401 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -82.62 137.2 34.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.329 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 76.0 t . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.664 179.819 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 33.4 mt . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.927 0.394 . . . . 0.0 111.288 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -136.35 164.35 28.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.233 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -118.53 144.8 45.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.151 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.408 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 0.0 OUTLIER -137.16 152.07 49.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.276 0.56 . . . . 0.0 112.051 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -117.97 125.36 50.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.551 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -117.72 137.54 52.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.049 0.452 . . . . 0.0 111.595 -179.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -134.19 152.29 51.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.489 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 4.3 mp . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.777 0.323 . . . . 0.0 110.681 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 72.0 m -148.71 153.25 37.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.975 0.416 . . . . 0.0 111.226 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.73 136.07 53.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.23 179.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.92 170.33 28.59 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.056 -1.069 . . . . 0.0 113.196 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.6 m -132.09 148.09 32.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.602 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . 0.409 ' HB3' ' HA3' ' A' ' 22' ' ' GLY . 89.4 p -151.79 175.06 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.054 0.455 . . . . 0.0 111.466 -179.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -145.92 156.54 43.59 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.621 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . 0.511 ' HD3' HG21 ' A' ' 18' ' ' THR . 8.4 ttm180 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.92 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 39.9 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.717 0.294 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.421 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.2 t-105 -135.66 135.07 39.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.432 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 7.9 m-85 -121.98 145.05 48.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.77 141.6 28.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.256 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.55 -166.67 34.06 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.552 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.38 146.71 18.42 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.544 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -127.93 149.32 50.37 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 120.858 0.361 . . . . 0.0 111.082 -179.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.465 ' HG ' ' HB2' ' A' ' 54' ' ' ALA . 2.0 tt -132.55 145.55 51.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.668 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.593 179.954 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.396 -0.282 . . . . 0.0 112.396 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.465 ' HB2' ' HG ' ' A' ' 25' ' ' LEU . . . -136.57 173.13 12.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.915 0.388 . . . . 0.0 111.052 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.87 156.6 26.06 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.626 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.656 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.95 160.17 14.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.822 0.344 . . . . 0.0 111.011 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -147.77 126.39 12.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.984 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.43 137.05 5.69 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.299 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.436 ' HA3' ' HB3' ' A' ' 69' ' ' GLU . . . -171.39 -165.84 29.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.649 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.421 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 6.0 p90 -143.57 161.01 39.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.994 0.426 . . . . 0.0 111.039 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.59 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.793 0.33 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -128.87 156.41 21.12 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.32 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -128.99 128.43 43.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.621 0.248 . . . . 0.0 110.769 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.436 ' HB3' ' HA3' ' A' ' 59' ' ' GLY . 1.4 pm0 -147.44 153.46 39.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.149 0.499 . . . . 0.0 111.505 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 4.0 ptt? -118.15 138.21 52.45 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.186 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.86 175.63 18.73 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.689 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.656 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 0.8 OUTLIER -134.71 114.94 13.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.661 0.267 . . . . 0.0 110.621 179.893 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -78.27 121.64 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.084 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 6.1 m95 . . . . . 0 C--N 1.331 -0.216 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.878 179.886 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.699 0.285 . . . . 0.0 110.631 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.85 141.54 15.32 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.898 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -112.05 126.0 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.249 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -108.86 146.84 33.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.224 0.535 . . . . 0.0 112.03 -178.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.425 ' O ' HD23 ' A' ' 96' ' ' LEU . 2.0 tt -139.13 116.1 10.92 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.347 179.527 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.424 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 0.9 OUTLIER -154.32 170.03 22.28 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.191 0.519 . . . . 0.0 112.054 -178.694 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -108.95 149.64 28.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.134 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.82 132.23 53.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.966 0.412 . . . . 0.0 111.704 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.575 ' O ' HD12 ' A' ' 100' ' ' LEU . 4.0 pp -133.34 125.11 28.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.18 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -163.06 -169.82 27.04 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.872 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.442 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -157.35 145.3 14.07 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.674 0.273 . . . . 0.0 110.923 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.442 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 84.7 Cg_endo . . . . . 0 C--N 1.347 0.485 0 C-N-CA 122.764 2.309 . . . . 0.0 112.643 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.456 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER . . . . . 0 N--CA 1.46 0.064 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -134.35 152.48 51.83 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.12 0.486 . . . . 0.0 112.09 -178.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.959 HG22 ' CG1' ' A' ' 149' ' ' VAL . 1.3 pt -114.82 147.63 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 179.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -157.77 166.19 33.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.1 0.476 . . . . 0.0 111.823 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.41 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 27.4 m -142.28 132.29 24.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.513 179.679 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 52.6 mtt180 -109.92 128.91 55.66 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.188 -179.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -132.98 125.52 29.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.715 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.424 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . -179.98 -135.51 2.49 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.477 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.508 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -152.19 169.04 31.45 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.48 -0.867 . . . . 0.0 112.792 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.5 ptp -128.13 140.91 51.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.849 0.357 . . . . 0.0 110.995 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.431 ' O ' HG23 ' A' ' 94' ' ' VAL . 2.1 t -130.63 111.88 21.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.715 179.774 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.5 p-90 . . . . . 0 C--N 1.329 -0.308 0 CA-C-O 120.927 0.394 . . . . 0.0 111.055 -179.831 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.9 p . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.732 0.301 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.17 147.4 15.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.247 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.508 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.3 Cg_endo -78.1 151.89 27.38 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.749 2.3 . . . . 0.0 112.209 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.8 m -156.38 157.29 3.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.379 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -149.13 123.78 9.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.628 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -118.34 124.83 48.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 112' ' ' THR . . . -125.59 137.33 10.22 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.306 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -170.87 -150.76 7.17 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.435 -0.888 . . . . 0.0 113.076 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.959 ' CG1' HG22 ' A' ' 110' ' ' ILE . 9.0 m -131.3 168.21 24.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.822 0.344 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -134.79 136.74 42.8 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . 0.456 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.6 OUTLIER -119.56 128.72 54.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.81 179.813 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -94.73 131.7 40.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.916 0.388 . . . . 0.0 111.456 -179.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.422 HG22 ' CZ3' ' A' ' 151' ' ' TRP . 59.5 t . . . . . 0 C--N 1.331 -0.21 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.2 mt . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.784 0.326 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -136.87 162.8 32.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.439 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . 0.468 HG23 ' CG1' ' A' ' 188' ' ' VAL . 1.7 m -109.73 150.6 28.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.202 179.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.07 136.58 38.49 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.077 0.465 . . . . 0.0 111.864 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.703 HD22 ' CE1' ' A' ' 163' ' ' TYR . 1.4 tt -119.17 120.76 38.04 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.505 178.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.417 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 5.2 mt-10 -117.39 145.13 44.29 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.115 0.483 . . . . 0.0 111.819 -178.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.703 ' CE1' HD22 ' A' ' 161' ' ' LEU . 0.0 OUTLIER -134.05 166.09 23.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.202 179.428 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.937 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.403 HD12 ' N ' ' A' ' 184' ' ' LEU . 2.0 mp . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.756 0.312 . . . . 0.0 110.615 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -156.13 149.23 24.33 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 111.401 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.96 136.0 53.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.439 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -151.85 169.78 31.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.405 -0.903 . . . . 0.0 112.911 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . 0.468 ' CG1' HG23 ' A' ' 159' ' ' THR . 1.0 OUTLIER -131.2 140.05 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.688 0.28 . . . . 0.0 110.714 179.663 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 90.3 p -144.77 175.0 10.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.93 0.395 . . . . 0.0 111.343 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -142.57 159.61 41.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.736 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . 0.432 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.75 0.31 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.455 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.0 OUTLIER -151.09 130.02 12.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.859 -179.924 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.5 m-85 -131.22 135.79 47.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.751 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.43 140.43 21.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.864 0.364 . . . . 0.0 111.341 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.86 173.74 43.42 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.696 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -125.5 141.25 12.84 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.297 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.504 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.4 OUTLIER -130.66 149.08 52.48 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.093 0.473 . . . . 0.0 111.434 -179.787 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.803 HD12 ' O ' ' A' ' 53' ' ' GLY . 31.9 tp -127.53 153.83 45.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.492 -179.947 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.803 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.393 -0.283 . . . . 0.0 112.393 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.542 ' HB2' HD13 ' A' ' 25' ' ' LEU . . . -119.97 149.1 42.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 111.177 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -153.69 152.11 23.76 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.398 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.618 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -105.84 148.04 28.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.776 0.322 . . . . 0.0 111.049 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.446 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 35.9 p90 -135.38 118.17 16.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -143.2 129.02 3.58 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.069 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -137.09 169.12 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.963 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.455 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 29.8 p90 -134.34 134.59 41.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.35 . . . . 0.0 110.846 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 . . . . . 0 C--N 1.327 -0.378 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.808 179.99 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.934 0.397 . . . . 0.0 111.355 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 174.5 20.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.369 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.42 ' HB2' ' CE1' ' A' ' 60' ' ' TYR . 2.0 m-85 -83.61 144.52 29.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.655 0.264 . . . . 0.0 110.703 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -128.05 125.23 38.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.884 0.373 . . . . 0.0 111.137 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.8 tpp -106.45 127.51 53.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.569 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.92 148.28 17.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.672 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.618 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 0.1 OUTLIER -127.23 120.03 27.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.696 0.284 . . . . 0.0 110.648 179.878 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -97.62 122.71 41.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.899 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.876 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.865 0.364 . . . . 0.0 110.747 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.62 139.29 14.32 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.911 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.65 122.77 61.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.712 0.291 . . . . 0.0 110.292 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.02 136.97 47.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.111 0.481 . . . . 0.0 111.721 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.404 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.9 tt -121.08 104.73 10.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.624 -0.717 . . . . 0.0 109.291 179.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.461 HG22 ' HA3' ' A' ' 115' ' ' GLY . 3.6 p -145.93 171.37 14.94 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.251 0.548 . . . . 0.0 112.078 -178.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -106.09 131.07 53.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.373 -0.83 . . . . 0.0 109.864 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 19.6 ttpt -116.55 132.12 56.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.148 0.499 . . . . 0.0 111.682 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -127.65 131.33 49.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.626 -0.716 . . . . 0.0 109.587 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.443 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -132.28 175.43 19.86 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 -179.203 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.47 ' O ' HG22 ' A' ' 110' ' ' ILE . 0.2 OUTLIER -166.1 134.4 2.36 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.698 -0.251 . . . . 0.0 110.701 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 C--N 1.347 0.471 0 C-N-CA 122.588 2.192 . . . . 0.0 112.39 179.998 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.523 -0.061 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -139.75 161.84 36.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.131 0.491 . . . . 0.0 111.811 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.47 HG22 ' O ' ' A' ' 102' ' ' TYR . 2.6 tt -114.51 144.93 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.037 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.443 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 60.7 m-85 -141.68 138.21 32.3 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.362 . . . . 0.0 111.445 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.87 128.18 30.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.715 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.534 ' NH2' ' HB3' ' A' ' 146' ' ' ALA . 18.6 mtm105 -118.38 127.91 54.13 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.264 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -134.38 122.78 23.06 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.491 179.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.461 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.93 -137.86 3.02 Favored Glycine 0 C--N 1.332 0.332 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.456 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -139.14 160.72 25.9 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.923 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 8.4 ptp -120.7 137.28 54.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.759 0.314 . . . . 0.0 110.775 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -131.62 113.2 22.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.842 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.7 p-90 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.917 -179.91 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.455 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.7 p . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.702 0.287 . . . . 0.0 110.969 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -157.12 149.22 17.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.777 0.322 . . . . 0.0 111.557 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.536 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 87.5 Cg_endo -80.59 140.9 13.54 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.923 2.416 . . . . 0.0 112.126 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 31.2 m -156.91 160.56 2.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.004 0.431 . . . . 0.0 111.583 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -149.06 130.28 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.377 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.534 ' HB3' ' NH2' ' A' ' 113' ' ' ARG . . . -116.51 155.37 28.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.895 0.378 . . . . 0.0 111.502 -179.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.34 136.49 7.93 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.22 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -162.85 -165.24 19.59 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.854 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -133.72 170.72 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.554 0.216 . . . . 0.0 110.95 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -146.72 149.7 33.93 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.941 0.401 . . . . 0.0 111.266 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 24.8 p90 -137.04 132.18 33.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.631 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.04 135.52 34.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.52 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.0 t . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.823 179.662 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.421 HG12 ' CE2' ' A' ' 190' ' ' TYR . 45.1 mt . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.781 0.324 . . . . 0.0 110.941 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -126.76 167.62 15.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.357 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.73 144.71 40.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.172 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.61 132.47 44.07 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.124 0.488 . . . . 0.0 111.89 -179.307 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -115.55 117.08 29.35 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.498 178.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.409 ' HG3' ' NZ ' ' A' ' 24' ' ' LYS . 23.8 mm-40 -107.04 145.03 32.85 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.127 0.489 . . . . 0.0 111.634 -178.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.432 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 48.9 t80 -133.95 158.28 43.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.455 179.656 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.008 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.498 HD12 ' N ' ' A' ' 184' ' ' LEU . 2.5 mp . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.774 0.321 . . . . 0.0 110.687 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 28.9 t -128.53 145.38 51.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.115 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -132.42 136.59 46.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.584 179.635 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . 0.504 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -154.63 -176.86 27.38 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.942 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -126.64 135.9 62.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.647 0.261 . . . . 0.0 110.442 179.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 43.3 p -130.84 165.37 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.208 0.528 . . . . 0.0 111.721 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 190' ' ' TYR . 2.2 m-85 -124.96 143.19 51.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.471 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 8.6 mtp180 . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.905 -179.813 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.457 -0.087 0 CA-C-O 120.782 0.325 . . . . 0.0 110.735 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 10.3 t90 -111.09 132.91 53.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.088 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.446 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 2.7 t80 -122.57 135.79 54.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.383 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.59 146.93 25.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.953 0.406 . . . . 0.0 111.5 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.407 ' HA3' ' HB3' ' A' ' 189' ' ' SER . . . 178.01 -172.84 45.44 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.482 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.65 148.57 20.24 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.489 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.27 151.0 47.21 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.072 0.463 . . . . 0.0 111.354 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.871 HD12 ' O ' ' A' ' 53' ' ' GLY . 18.7 tp -122.12 145.53 48.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.29 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.794 -179.854 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.871 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.417 -0.273 . . . . 0.0 112.417 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -114.93 142.18 46.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.718 0.294 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.5 143.83 11.13 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.293 -0.956 . . . . 0.0 112.895 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -98.07 164.46 12.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.648 0.261 . . . . 0.0 110.668 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.446 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 52.2 p90 -152.38 141.03 20.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.062 0.458 . . . . 0.0 111.409 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -133.55 124.92 3.81 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.044 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -97.39 145.73 17.96 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.893 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -131.93 112.26 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.698 0.285 . . . . 0.0 110.574 179.783 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 5.1 mm100 . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.101 -179.806 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.924 0.393 . . . . 0.0 111.256 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.67 159.19 26.82 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.313 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -82.9 127.57 33.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 110.566 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -114.64 127.08 55.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.966 0.412 . . . . 0.0 111.317 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.2 mtm -104.21 128.44 51.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.962 179.364 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.93 157.7 14.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.951 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -132.68 120.19 21.38 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.731 0.301 . . . . 0.0 110.508 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.424 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.8 OUTLIER -94.54 127.14 40.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.688 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t90 . . . . . 0 C--O 1.233 0.225 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.944 179.909 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.685 0.279 . . . . 0.0 110.547 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.424 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -81.66 128.08 8.27 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.795 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.2 m -133.21 117.77 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.716 0.293 . . . . 0.0 110.257 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . 0.408 ' CB ' ' HA ' ' A' ' 117' ' ' MET . 7.6 pt20 -123.92 149.74 45.53 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.107 0.48 . . . . 0.0 111.791 -179.269 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.533 ' O ' HD23 ' A' ' 96' ' ' LEU . 0.3 OUTLIER -124.63 120.1 30.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.517 179.658 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.465 HG22 ' HA3' ' A' ' 115' ' ' GLY . 4.3 p -148.28 171.81 15.38 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-O 121.088 0.471 . . . . 0.0 111.789 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.37 123.04 47.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.987 178.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.5 tttt -114.74 132.33 56.48 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.107 0.479 . . . . 0.0 111.7 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.535 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.6 pp -126.83 125.69 42.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.341 179.347 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.426 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -145.45 160.08 28.02 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.419 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.503 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.2 OUTLIER -166.27 148.49 6.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.676 0.274 . . . . 0.0 111.483 -179.758 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.503 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 73.3 Cg_endo . . . . . 0 C--N 1.348 0.505 0 C-N-CA 122.807 2.338 . . . . 0.0 112.332 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.525 HD23 ' N ' ' A' ' 108' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.083 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.455 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 0.6 OUTLIER -124.39 155.14 39.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.258 0.552 . . . . 0.0 112.045 -178.999 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.862 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 151.76 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.937 178.984 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.426 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 20.1 m-85 -146.86 146.1 30.08 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.948 0.404 . . . . 0.0 111.706 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.3 m -142.54 129.87 21.1 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.325 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.24 130.22 52.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 121.02 0.438 . . . . 0.0 111.752 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.407 ' C ' HD23 ' A' ' 114' ' ' LEU . 6.1 tt -133.59 122.94 24.25 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.252 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.465 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -175.87 -140.8 3.57 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.576 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.475 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.53 161.52 27.37 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.888 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.408 ' HA ' ' CB ' ' A' ' 95' ' ' GLN . 0.2 OUTLIER -119.53 146.55 45.37 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.847 0.356 . . . . 0.0 110.753 -179.943 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -129.82 144.08 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.985 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.913 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.6 p . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.752 0.31 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.463 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 1.5 t -157.08 130.19 4.48 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.228 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.475 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.7 Cg_exo -73.8 147.31 39.37 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.639 2.226 . . . . 0.0 112.009 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.2 m -156.49 153.79 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.918 0.389 . . . . 0.0 111.46 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -149.1 124.05 10.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.658 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -117.75 145.81 44.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 0.0 111.339 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.49 132.72 5.91 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.226 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.441 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -163.32 -154.49 7.72 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.962 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.862 HG12 HG22 ' A' ' 110' ' ' ILE . 12.9 m -137.3 170.88 17.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.631 0.253 . . . . 0.0 110.949 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -147.25 150.75 35.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.953 0.406 . . . . 0.0 111.267 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . 0.422 ' CE2' ' HB ' ' A' ' 159' ' ' THR . 37.1 p90 -126.74 138.61 53.41 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.811 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.405 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -91.65 137.24 32.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.411 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 52.3 t . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.48 179.62 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 27.2 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.982 0.42 . . . . 0.0 111.554 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . 0.405 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.11 161.15 38.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.057 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . 0.422 ' HB ' ' CE2' ' A' ' 151' ' ' TRP . 9.7 m -106.26 150.78 25.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.227 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? -137.09 142.23 42.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.172 0.511 . . . . 0.0 111.834 -179.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 162' ' ' GLU . 1.4 tt -123.65 117.89 26.02 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.601 178.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.409 ' N ' HD23 ' A' ' 161' ' ' LEU . 1.7 pt-20 -107.82 141.11 39.89 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.979 0.419 . . . . 0.0 111.635 -179.169 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.441 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 27.2 p90 -134.33 166.08 23.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.653 179.615 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.33 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.005 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.9 mp . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.792 0.33 . . . . 0.0 110.908 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 51.0 m -140.98 150.09 42.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.132 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.65 138.04 54.5 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.521 179.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -157.06 176.31 34.33 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.955 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -125.9 137.78 56.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.737 0.304 . . . . 0.0 110.496 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . 0.446 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 3.6 p -138.59 171.57 14.17 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.377 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -148.0 156.62 42.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.642 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . 0.446 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.038 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.862 0.363 . . . . 0.0 110.843 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.438 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 2.7 m-90 -132.3 129.97 40.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.037 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.422 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 0.2 OUTLIER -121.67 135.85 54.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.683 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.05 139.82 23.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.396 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.9 -158.56 20.49 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.417 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.79 149.65 21.52 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.534 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -130.61 154.91 47.37 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.055 0.455 . . . . 0.0 111.135 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.4 tt -127.04 141.7 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.641 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.592 -179.93 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.534 -0.226 . . . . 0.0 112.534 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -131.26 138.7 49.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.689 0.28 . . . . 0.0 110.863 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.62 156.32 26.8 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.336 -0.935 . . . . 0.0 112.921 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.45 133.84 49.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.717 0.294 . . . . 0.0 110.844 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -119.75 127.17 52.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.967 0.413 . . . . 0.0 111.075 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.56 124.85 2.18 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.139 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -128.5 173.38 19.17 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.798 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.438 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 21.7 p90 -154.02 131.75 11.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 110.781 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.883 -179.894 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.233 0.219 0 CA-C-O 120.764 0.316 . . . . 0.0 111.191 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.03 175.17 19.61 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.44 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -95.7 134.71 38.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.418 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 0.0 OUTLIER -114.67 128.41 56.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -114.15 119.76 38.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.33 179.437 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 154.59 16.48 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.481 -0.866 . . . . 0.0 112.783 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 -130.09 114.83 16.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.579 0.228 . . . . 0.0 110.659 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.32 125.77 35.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.115 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 10.8 m95 . . . . . 0 C--N 1.331 -0.219 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.844 179.876 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 12.1 pm0 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.761 0.315 . . . . 0.0 110.734 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -82.26 130.94 10.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.586 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.47 119.74 55.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.786 0.327 . . . . 0.0 110.446 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 139.87 43.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.534 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.416 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.7 tt -130.25 110.88 11.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.972 179.537 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.425 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 0.1 OUTLIER -150.49 168.94 22.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.993 0.425 . . . . 0.0 111.565 -179.147 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -104.1 125.91 50.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.197 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.421 ' HE3' ' CG ' ' A' ' 111' ' ' TYR . 0.6 OUTLIER -104.25 132.21 50.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.997 0.427 . . . . 0.0 111.752 -179.165 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.598 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.8 pp -134.82 115.74 14.01 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.388 179.114 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.05 41.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.672 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -166.28 167.05 8.83 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.713 0.292 . . . . 0.0 111.116 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo . . . . . 0 C--N 1.347 0.476 0 C-N-CA 122.488 2.125 . . . . 0.0 111.941 179.635 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.764 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.074 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.413 ' HB2' ' CG ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -125.41 152.95 44.16 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.225 0.536 . . . . 0.0 112.009 -178.903 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.93 130.88 73.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.044 179.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.421 ' CG ' ' HE3' ' A' ' 99' ' ' LYS . 53.1 p90 -144.06 153.62 42.38 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.915 0.388 . . . . 0.0 111.526 -179.446 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 2.1 t -136.94 133.11 35.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.69 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 5.8 ptp180 -111.42 128.36 55.96 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.145 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -124.64 123.61 40.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.619 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.425 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.82 -132.46 1.9 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.547 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.548 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -148.24 169.08 28.94 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.821 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.07 139.86 51.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.795 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -126.17 132.9 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.809 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 85.3 t90 . . . . . 0 C--N 1.33 -0.252 0 CA-C-O 120.864 0.364 . . . . 0.0 110.95 -179.822 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.444 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.2 p . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.697 0.284 . . . . 0.0 111.054 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.27 150.12 18.33 Favored Pre-proline 0 C--N 1.331 -0.217 0 CA-C-O 120.922 0.392 . . . . 0.0 111.421 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.548 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -78.77 141.14 16.91 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.758 2.306 . . . . 0.0 112.133 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.5 m -156.86 160.66 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.855 0.36 . . . . 0.0 111.418 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.6 p90 -141.6 122.47 14.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.472 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -111.8 138.2 48.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.962 0.41 . . . . 0.0 111.473 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -127.66 138.22 10.32 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.818 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -163.71 -165.71 21.34 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.078 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 17.2 m -135.47 167.05 26.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.659 0.266 . . . . 0.0 111.149 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.413 ' CG ' ' HB2' ' A' ' 109' ' ' ASP . 13.4 pt-20 -136.34 141.09 43.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.999 0.428 . . . . 0.0 111.172 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . 0.764 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.0 OUTLIER -122.31 123.07 40.57 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.628 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.16 131.86 35.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.013 179.948 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 28.3 mt . . . . . 0 C--O 1.232 0.178 0 CA-C-O 120.809 0.337 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.25 163.77 14.8 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.385 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.9 t -110.8 143.24 41.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.098 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 146.64 45.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.28 0.562 . . . . 0.0 111.855 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -116.63 124.8 50.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.698 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -116.51 141.01 48.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.029 0.442 . . . . 0.0 111.524 -179.181 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 14.2 p90 -134.22 157.61 45.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.468 179.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 -179.93 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 5.9 mp . . . . . 0 C--O 1.233 0.194 0 CA-C-O 120.719 0.295 . . . . 0.0 110.741 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.99 155.58 41.69 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.996 0.427 . . . . 0.0 111.221 -179.768 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.53 139.08 50.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.355 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -153.53 171.1 32.35 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.281 -0.961 . . . . 0.0 113.166 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.5 137.23 57.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.694 0.283 . . . . 0.0 110.489 179.584 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 77.9 p -140.77 174.95 10.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.992 0.425 . . . . 0.0 111.294 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -137.41 157.1 47.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.585 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . 0.422 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.916 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 68.9 p . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.82 0.343 . . . . 0.0 110.81 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.9 m95 -139.88 138.54 35.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.979 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.7 m-85 -131.8 135.88 47.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.685 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.71 146.03 30.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.322 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.36 -177.62 48.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.9 150.29 21.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.441 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.468 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -135.57 153.68 51.61 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 111.21 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.879 HD12 ' O ' ' A' ' 53' ' ' GLY . 41.9 tp -124.03 147.93 47.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.541 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.481 179.992 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.879 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.88 133.42 51.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.767 0.317 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.425 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -139.73 137.95 8.85 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.881 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.714 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -99.5 144.76 28.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.803 0.335 . . . . 0.0 110.563 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.435 ' CE2' ' HD3' ' A' ' 24' ' ' LYS . 51.3 m-85 -136.16 133.52 37.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.035 0.445 . . . . 0.0 111.345 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.73 126.52 2.22 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.963 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -125.58 169.45 17.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.839 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.422 ' CE2' ' HB3' ' A' ' 68' ' ' PHE . 42.6 p90 -147.12 135.53 21.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.846 -179.935 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.906 0.384 . . . . 0.0 111.148 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.43 159.53 22.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.472 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.422 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . 0.8 OUTLIER -82.09 144.86 30.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.554 0.216 . . . . 0.0 110.706 179.928 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.93 127.29 33.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.422 . . . . 0.0 111.074 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.0 ptp -109.26 133.21 53.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.86 17.34 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.766 -179.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.714 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 14.6 m-85 -129.93 118.13 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.615 0.245 . . . . 0.0 110.55 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.0 122.0 37.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.133 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.083 179.885 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.758 0.313 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.78 135.37 12.11 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.937 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -128.32 117.98 46.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.798 0.333 . . . . 0.0 110.123 179.252 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . 0.401 ' CG ' ' CB ' ' A' ' 117' ' ' MET . 8.2 mt-30 -108.86 145.39 35.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.192 0.52 . . . . 0.0 111.925 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.3 tt -130.02 110.32 11.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.256 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.8 p -150.22 170.04 19.9 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.233 0.54 . . . . 0.0 111.984 -178.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.51 45.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.014 178.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -118.85 131.95 56.1 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.062 0.458 . . . . 0.0 111.581 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.609 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -131.85 121.67 24.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.96 179.12 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.437 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -115.95 -177.02 18.34 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.088 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -166.07 122.58 0.99 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 115.803 -0.198 . . . . 0.0 110.71 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo . . . . . 0 C--N 1.349 0.567 0 C-N-CA 122.435 2.09 . . . . 0.0 112.391 -179.925 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.461 0.087 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -143.07 159.64 41.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.101 0.477 . . . . 0.0 111.628 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 1.031 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.64 154.81 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.316 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.437 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 91.5 m-85 -143.04 138.57 30.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.664 -179.508 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 31.6 m -125.2 127.63 47.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.313 179.393 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -116.54 127.88 54.92 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.38 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -137.96 122.58 18.59 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.511 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 179.26 -137.7 3.24 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.524 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.494 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.93 162.34 27.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.945 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.401 ' CB ' ' CG ' ' A' ' 95' ' ' GLN . 2.2 ptt? -119.63 142.31 48.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.801 0.334 . . . . 0.0 110.771 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.6 t -133.88 123.81 45.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.688 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 61.8 p-90 . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.003 -179.945 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.9 p . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.705 0.288 . . . . 0.0 111.012 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -157.01 137.38 8.99 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.329 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.494 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 89.4 Cg_endo -81.09 143.47 14.26 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 122.682 2.254 . . . . 0.0 112.084 179.75 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 143' ' ' PRO . 29.2 m -157.08 163.53 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 111.516 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -149.04 126.36 11.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.574 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.665 ' HB1' ' CD ' ' A' ' 162' ' ' GLU . . . -111.91 152.48 27.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.906 0.384 . . . . 0.0 111.267 -179.722 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.0 131.45 4.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.239 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -161.03 -160.05 10.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.824 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 1.031 HG12 HG22 ' A' ' 110' ' ' ILE . 5.5 m -134.41 167.72 25.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.628 0.252 . . . . 0.0 110.951 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -134.8 137.05 43.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.007 0.432 . . . . 0.0 111.189 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . 0.49 ' CZ3' HG22 ' A' ' 153' ' ' VAL . 1.4 t90 -114.91 123.32 48.85 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.574 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.81 130.74 36.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.523 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.49 HG22 ' CZ3' ' A' ' 151' ' ' TRP . 39.3 t . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.852 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.1 mt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.703 0.287 . . . . 0.0 111.008 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.32 168.55 18.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.952 0.406 . . . . 0.0 111.242 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . 0.704 HG22 HG12 ' A' ' 188' ' ' VAL . 29.1 p -113.43 153.18 29.04 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.135 179.614 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 14.8 ptp180 -137.19 141.66 42.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 111.892 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -121.54 118.16 28.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.656 178.853 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.665 ' CD ' ' HB1' ' A' ' 146' ' ' ALA . 0.4 OUTLIER -108.34 143.66 36.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.97 0.414 . . . . 0.0 111.768 -178.832 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.43 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.2 p90 -134.25 162.88 30.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.509 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.782 -179.935 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.5 mp . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.839 0.352 . . . . 0.0 110.973 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 30.2 t -118.52 147.42 43.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.768 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -126.52 139.36 53.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.709 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -156.67 -177.03 29.43 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.414 -0.898 . . . . 0.0 113.063 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . 0.704 HG12 HG22 ' A' ' 159' ' ' THR . 1.3 m -130.82 142.84 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.675 0.274 . . . . 0.0 110.598 179.61 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 89.0 p -143.24 170.83 15.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.998 0.427 . . . . 0.0 111.449 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 44.3 p90 -138.66 154.88 48.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.58 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 t . . . . . 0 N--CA 1.458 -0.059 0 CA-C-O 120.868 0.366 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -151.1 129.87 12.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.009 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.429 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 28.5 m-85 -127.24 135.92 51.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.718 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.15 146.29 30.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.359 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.409 ' HA3' ' CB ' ' A' ' 189' ' ' SER . . . 178.45 168.73 38.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.566 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.75 143.7 14.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.446 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.468 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 2.8 pttp -131.97 146.52 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.095 0.474 . . . . 0.0 111.286 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.853 HD12 ' O ' ' A' ' 53' ' ' GLY . 23.1 tp -121.14 152.03 39.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.514 -179.934 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.853 ' O ' HD12 ' A' ' 25' ' ' LEU . . . . . . . . 0 N--CA 1.452 -0.258 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -110.87 151.01 28.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.817 0.341 . . . . 0.0 111.078 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -143.36 122.92 1.97 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.404 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.82 135.93 35.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.682 0.277 . . . . 0.0 110.895 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.436 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 24.9 p90 -124.99 127.46 47.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.212 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.8 124.97 1.76 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.011 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -148.22 -172.59 18.32 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.759 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -150.63 156.03 40.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.871 0.367 . . . . 0.0 110.853 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.83 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.88 0.371 . . . . 0.0 111.434 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.91 177.0 19.43 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.249 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -99.74 134.59 42.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.619 0.247 . . . . 0.0 110.841 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.8 tp10 -124.03 131.51 53.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.989 0.424 . . . . 0.0 111.076 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 6.9 tpt -111.44 130.28 55.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.544 179.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.84 153.32 17.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.558 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.404 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 34.2 m-85 -134.19 114.95 13.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.829 0.347 . . . . 0.0 110.746 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.6 122.22 33.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.017 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.88 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 . . . . . 0 C--O 1.23 0.039 0 CA-C-O 120.678 0.275 . . . . 0.0 110.607 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.23 128.42 9.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.074 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -127.43 117.85 48.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 179.318 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -112.16 145.62 39.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.182 0.515 . . . . 0.0 112.016 -178.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -134.93 112.81 10.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.249 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.405 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.7 p -150.81 172.99 14.74 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.228 0.537 . . . . 0.0 112.027 -178.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.12 131.41 48.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.83 178.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.413 ' HD2' ' CD1' ' A' ' 111' ' ' TYR . 3.4 ttpt -118.79 132.11 56.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.101 0.477 . . . . 0.0 111.738 -179.035 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -134.95 133.64 39.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.916 179.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.436 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -147.62 -179.41 23.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.182 -1.009 . . . . 0.0 113.102 -179.437 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.408 ' O ' HG22 ' A' ' 110' ' ' ILE . 0.5 OUTLIER -166.3 128.84 1.44 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.734 -0.233 . . . . 0.0 110.654 -179.913 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo . . . . . 0 C--N 1.348 0.523 0 C-N-CA 122.391 2.061 . . . . 0.0 112.116 -179.97 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.051 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.403 ' OD1' ' CE2' ' A' ' 111' ' ' TYR . 8.8 t70 -144.46 155.7 43.85 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.065 0.46 . . . . 0.0 111.751 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.408 HG22 ' O ' ' A' ' 102' ' ' TYR . 3.0 tt -114.51 132.36 63.87 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.022 179.239 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.436 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 25.5 m-85 -133.14 147.64 52.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.975 0.417 . . . . 0.0 111.734 -179.307 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.49 129.55 23.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.446 179.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -121.33 129.13 52.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.424 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.4 tt -134.85 122.7 22.4 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.488 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.405 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -176.94 -136.98 2.54 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.467 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.484 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.12 161.62 27.58 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.801 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.11 142.96 48.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.777 0.322 . . . . 0.0 110.706 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.428 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.5 t -130.36 138.42 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.89 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 70.5 p-90 . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.963 -179.99 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.764 0.316 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.2 p -156.41 129.61 4.45 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.301 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.484 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 84.5 Cg_endo -77.92 142.57 19.95 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.595 2.197 . . . . 0.0 112.11 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 143' ' ' PRO . 27.8 m -157.07 162.4 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.015 0.436 . . . . 0.0 111.455 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.01 124.04 11.39 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.484 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.03 137.12 52.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.862 0.363 . . . . 0.0 111.458 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.04 134.26 7.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.07 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -159.39 -157.31 8.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.919 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -135.18 167.78 24.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.805 0.336 . . . . 0.0 111.207 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -131.42 140.24 49.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.969 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -124.38 125.77 44.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.771 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -88.1 137.11 32.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.423 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 99.2 t . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.95 179.848 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 18.0 mt . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.757 0.313 . . . . 0.0 110.954 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -117.76 162.45 18.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.213 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 61.1 p -100.99 150.83 22.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.145 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 4.6 ttt85 -137.14 133.12 34.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.062 0.458 . . . . 0.0 111.951 -179.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.11 119.23 33.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.448 178.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -110.04 145.22 37.42 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.189 0.519 . . . . 0.0 111.907 -178.569 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.436 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 8.4 t80 -131.79 147.87 52.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.232 179.474 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.388 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.637 ' N ' HD12 ' A' ' 184' ' ' LEU . 2.4 mp . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.801 0.334 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 88.1 p -121.13 146.5 46.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.084 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -125.48 141.04 52.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.647 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -161.7 -176.96 34.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.952 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -128.74 140.54 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.621 0.248 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . 0.436 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 97.1 p -139.51 175.0 9.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.055 0.455 . . . . 0.0 111.464 -179.497 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 14.8 p90 -146.85 151.43 37.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.653 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . 0.429 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 25.0 ptt-85 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.927 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.682 HG23 ' H ' ' A' ' 61' ' ' GLN . 2.2 t . . . . . 0 C--O 1.233 0.198 0 CA-C-O 120.814 0.34 . . . . 0.0 110.771 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -150.66 130.03 12.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.988 -179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -138.91 136.32 35.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.778 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 143.18 38.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.354 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.12 -157.9 10.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.541 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.22 145.87 15.32 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.597 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.91 156.08 32.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.939 0.4 . . . . 0.0 111.107 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -135.66 138.76 43.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.611 179.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.357 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.542 -179.891 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.374 -0.29 . . . . 0.0 112.374 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -132.76 156.72 46.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.843 0.354 . . . . 0.0 111.157 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.58 154.64 25.71 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.451 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.839 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -95.43 124.7 39.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.74 0.305 . . . . 0.0 110.946 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -111.69 119.06 37.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.039 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.75 124.94 2.84 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.058 179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.17 165.59 25.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.771 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.44 ' CZ ' ' HB2' ' A' ' 68' ' ' PHE . 4.9 p90 -154.26 134.78 13.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.994 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.682 ' H ' HG23 ' A' ' 18' ' ' THR . 11.1 mt-30 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.714 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.851 0.358 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -123.71 169.83 15.92 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.394 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 50.9 m-85 -83.98 134.49 34.64 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.682 0.277 . . . . 0.0 110.853 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.66 112.08 19.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.741 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.4 mtp -104.43 118.1 35.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.552 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.0 152.32 17.28 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.839 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 5.1 m-85 -130.7 115.02 16.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.846 0.355 . . . . 0.0 110.576 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -81.66 123.13 28.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.023 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.861 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.8 0.333 . . . . 0.0 110.722 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -95.92 134.01 11.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.753 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -120.68 117.86 54.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.755 0.312 . . . . 0.0 110.447 179.536 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' GLN . . . . . 0.556 ' OE1' HG21 ' A' ' 144' ' ' VAL . 3.4 tt0 -109.01 137.89 46.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.074 0.464 . . . . 0.0 111.744 -179.1 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.617 179.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.504 HG22 ' HA3' ' A' ' 115' ' ' GLY . 3.5 p -149.36 166.28 29.51 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.072 0.463 . . . . 0.0 111.796 -178.669 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.65 127.7 52.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.1 179.126 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.84 132.14 56.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.031 0.443 . . . . 0.0 111.749 -179.145 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.504 ' O ' HD12 ' A' ' 100' ' ' LEU . 4.0 pp -130.09 130.14 44.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.316 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -154.03 -173.52 23.17 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.442 -0.885 . . . . 0.0 113.032 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.664 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 10.2 p90 -166.15 148.95 6.4 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 120.596 0.236 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo . . . . . 0 C--N 1.345 0.383 0 C-N-CA 122.73 2.287 . . . . 0.0 112.7 -179.754 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.639 0.257 . . . . 0.0 110.561 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -144.91 157.89 43.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.887 0.375 . . . . 0.0 111.603 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.95 HG22 HG12 ' A' ' 149' ' ' VAL . 1.1 pt -120.81 144.5 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.471 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 4.7 p90 -148.05 149.07 31.42 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 121.225 0.536 . . . . 0.0 111.83 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 21.4 p -130.64 133.2 45.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.988 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.703 ' NE ' ' HB3' ' A' ' 146' ' ' ALA . 0.2 OUTLIER -115.46 130.73 56.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.063 0.459 . . . . 0.0 111.707 -179.261 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.503 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.9 tt -126.26 122.63 36.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.153 179.267 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.504 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.29 -142.09 4.56 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.294 -0.955 . . . . 0.0 112.869 -179.8 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.519 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.73 169.08 25.35 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.771 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.4 tmm? -127.57 137.84 52.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.849 0.357 . . . . 0.0 110.948 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.46 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.6 t -127.29 127.7 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.674 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 2.9 p-90 . . . . . 0 C--N 1.328 -0.354 0 CA-C-O 120.798 0.333 . . . . 0.0 110.987 -179.912 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.0 p . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.696 0.284 . . . . 0.0 110.994 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.491 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -157.18 141.38 11.75 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.436 -179.978 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.519 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.8 Cg_exo -73.91 153.41 47.54 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.869 2.379 . . . . 0.0 111.858 179.719 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.556 HG21 ' OE1' ' A' ' 95' ' ' GLN . 27.0 m -156.74 162.92 1.48 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.181 0 CA-C-O 121.221 0.534 . . . . 0.0 111.764 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' PHE . . . . . 0.503 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.2 t80 -143.05 118.84 10.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.256 179.619 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.703 ' HB3' ' NE ' ' A' ' 113' ' ' ARG . . . -117.15 140.96 48.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.991 0.424 . . . . 0.0 111.16 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.07 134.89 7.16 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.152 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.03 -167.5 21.58 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.81 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.95 HG12 HG22 ' A' ' 110' ' ' ILE . 4.1 m -127.18 160.02 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.869 0.366 . . . . 0.0 111.042 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.448 ' HG2' ' HB3' ' A' ' 160' ' ' ARG . 1.4 tm-20 -120.85 136.39 54.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 37.5 m95 -120.78 120.27 35.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.469 179.525 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.43 119.0 32.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.571 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 40.5 t . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.807 179.569 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.522 HG23 ' CE1' ' A' ' 190' ' ' TYR . 3.5 mp . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.829 0.347 . . . . 0.0 111.144 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.77 161.82 17.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.946 0.403 . . . . 0.0 111.35 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -131.39 144.02 50.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.173 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.448 ' HB3' ' HG2' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -137.1 155.12 50.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.243 0.544 . . . . 0.0 112.009 -179.288 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.853 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.4 OUTLIER -120.41 121.45 38.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.635 179.006 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -107.41 145.05 33.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.116 0.484 . . . . 0.0 111.787 -178.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' TYR . . . . . 0.867 ' CE2' HD23 ' A' ' 184' ' ' LEU . 5.7 m-85 -129.86 151.36 50.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.491 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.029 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 184' ' ' LEU . . . . . 0.867 HD23 ' CE2' ' A' ' 163' ' ' TYR . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.782 0.325 . . . . 0.0 110.717 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.9 m -131.87 151.52 51.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.93 0.395 . . . . 0.0 111.282 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -120.22 134.46 55.25 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.347 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -146.41 165.36 28.29 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.231 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.22 139.83 50.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.376 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.56 168.58 19.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.103 0.478 . . . . 0.0 111.694 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 190' ' ' TYR . . . . . 0.522 ' CE1' HG23 ' A' ' 157' ' ' ILE . 4.4 m-85 -123.47 146.61 47.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.466 179.624 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.958 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.326 0 CA-C-O 120.878 0.371 . . . . 0.0 111.044 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.99 91.29 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 22.8 mt -134.79 138.85 48.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.131 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.1 tpt -64.58 131.1 46.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.982 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.84 66.42 1.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.847 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -113.47 -73.45 0.66 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.04 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.1 pt -147.05 30.64 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.094 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -120.49 72.59 0.96 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.832 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.404 HG22 ' H ' ' A' ' 9' ' ' VAL . 10.2 m -83.85 130.7 35.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.111 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -110.74 -31.28 7.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.908 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -71.41 -50.7 29.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.908 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -147.5 139.37 24.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.174 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.765 ' HB1' ' HD2' ' A' ' 14' ' ' PRO . . . -64.76 168.15 7.64 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.035 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.765 ' HD2' ' HB1' ' A' ' 13' ' ' ALA . 60.0 Cg_endo -72.38 61.04 3.39 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.529 2.152 . . . . 0.0 112.437 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 3.8 mptt -153.16 128.19 9.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.85 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -89.3 41.08 1.02 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.289 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -108.11 80.84 1.41 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.863 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 m -108.03 161.84 14.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.906 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.437 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.8 t-105 -146.62 129.9 16.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.863 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.42 ' CE1' ' HA3' ' A' ' 59' ' ' GLY . 6.1 p90 -136.92 139.65 41.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.795 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.08 149.49 52.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.197 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.75 -164.44 22.37 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.471 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.16 138.59 6.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.583 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 2.0 pttp -120.18 150.92 39.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.985 0.421 . . . . 0.0 111.033 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.65 HD21 HD12 ' A' ' 52' ' ' LEU . 3.0 tp -129.27 139.66 51.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.595 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.81 -139.38 3.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.531 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 11.0 m0 -112.42 133.87 54.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.779 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.3 m -97.77 -48.68 5.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.942 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -130.48 158.14 40.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.02 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 18.6 t80 -176.7 146.24 0.56 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.864 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.1 t60 -102.77 126.48 49.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -137.31 -47.56 0.58 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -99.0 156.02 17.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.934 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.74 154.94 30.18 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.465 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -144.71 -178.63 6.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.817 0.341 . . . . 0.0 110.937 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -139.79 153.23 47.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.17 40.13 2.53 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.51 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -109.22 140.15 43.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.885 0.374 . . . . 0.0 110.847 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -61.84 -41.46 99.63 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.483 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -79.99 105.89 11.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.84 0.353 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -101.72 -65.48 0.98 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.886 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -109.11 96.87 6.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.96 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 18.2 p-10 -69.13 -37.06 78.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.843 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -131.97 144.42 50.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.799 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -130.45 65.39 0.59 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.52 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.51 -173.39 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.517 2.145 . . . . 0.0 112.248 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.44 25.65 5.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.064 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -142.3 112.01 6.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.899 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -98.78 58.57 1.19 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.854 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -75.67 88.91 2.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.95 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.695 ' C ' HD22 ' A' ' 52' ' ' LEU . 27.3 mt-30 -125.73 95.22 4.36 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.834 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.695 HD22 ' C ' ' A' ' 51' ' ' GLN . 4.2 mm? -132.23 124.89 29.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.059 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.98 132.09 10.47 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.304 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -99.95 144.52 28.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.768 0.318 . . . . 0.0 110.996 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.414 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -147.75 122.97 1.63 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.88 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.809 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.87 125.71 39.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.635 0.255 . . . . 0.0 110.459 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.435 ' HB2' ' NH2' ' A' ' 160' ' ' ARG . 2.8 m-85 -115.24 145.93 41.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.045 0.45 . . . . 0.0 111.583 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -144.92 124.84 2.23 Favored Glycine 0 N--CA 1.45 -0.382 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.786 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 20' ' ' TYR . . . -123.13 146.98 16.64 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.035 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.443 ' CZ ' ' HB2' ' A' ' 68' ' ' PHE . 53.4 p90 -153.53 126.04 8.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.851 0.358 . . . . 0.0 110.771 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -96.16 137.18 35.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.922 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 43.1 t -111.56 -30.27 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.092 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -137.35 153.62 74.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.799 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.26 63.61 1.08 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.596 2.198 . . . . 0.0 112.296 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.667 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.1 OUTLIER -154.36 -45.61 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.971 -179.932 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.667 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.3 OUTLIER -168.79 163.71 11.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.913 -179.881 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -127.24 155.09 19.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.435 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.443 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 2.4 m-85 -82.79 141.56 32.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.617 0.246 . . . . 0.0 110.564 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.577 ' HB3' HG23 ' A' ' 97' ' ' THR . 14.2 tp10 -125.67 118.67 26.13 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.88 0.371 . . . . 0.0 111.133 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 10.3 mtt -108.19 124.72 50.7 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.5 179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 163.05 12.47 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.541 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.809 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 57.4 m-85 -137.54 114.91 11.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.684 0.278 . . . . 0.0 110.76 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.43 114.96 22.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.059 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 17.0 t90 -139.16 148.83 43.72 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.097 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.4 tp 61.86 157.86 0.05 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.897 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 160.52 -28.21 0.32 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.518 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 11.7 ttt180 -112.16 149.63 31.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.762 0.315 . . . . 0.0 110.946 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -107.2 104.85 14.58 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.838 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -171.64 98.46 0.18 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.146 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -153.08 75.89 1.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.889 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.1 tttm -163.59 100.46 0.91 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.876 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -167.11 160.08 33.64 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.498 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 50.6 m -69.07 -48.15 63.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.329 . . . . 0.0 110.924 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.5 m -140.98 128.82 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.107 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -116.58 -177.7 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -117.83 146.55 43.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.898 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -145.46 39.21 1.18 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.551 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -64.07 -61.04 2.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.81 0.338 . . . . 0.0 111.055 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -112.63 142.48 45.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.905 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 4.4 mtmp? -107.58 138.37 43.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.79 145.57 30.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.11 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.97 131.91 7.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.715 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -85.59 135.3 13.29 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.639 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.1 OUTLIER -123.81 122.03 63.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -108.88 142.25 39.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.189 0.519 . . . . 0.0 111.878 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -128.6 114.5 16.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.617 179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.828 HG21 ' HD2' ' A' ' 113' ' ' ARG . 0.9 OUTLIER -153.69 165.2 36.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.066 0.46 . . . . 0.0 111.739 -179.007 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.02 129.73 51.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.307 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.53 132.2 55.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.051 0.453 . . . . 0.0 111.517 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.518 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.8 pp -132.76 127.8 35.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.279 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.24 -171.66 23.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.455 -0.879 . . . . 0.0 112.971 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.434 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.09 147.06 5.64 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.897 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.434 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 90.6 Cg_endo -81.03 171.7 13.81 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.745 2.297 . . . . 0.0 112.617 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 18.4 mm -106.1 -30.88 2.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.727 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 4.5 m -154.9 -62.35 0.12 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.71 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 177.89 45.64 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.586 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.409 ' OD2' HD21 ' A' ' 108' ' ' LEU . 21.9 p-10 179.07 -30.11 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.49 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.409 HD21 ' OD2' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -112.67 122.33 47.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.617 0.246 . . . . 0.0 110.367 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 4.0 p30 -141.41 152.84 44.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.041 0.448 . . . . 0.0 111.763 -179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.98 HG22 ' CG1' ' A' ' 149' ' ' VAL . 1.1 pt -116.93 146.24 21.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.318 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -153.59 156.34 37.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.111 0.481 . . . . 0.0 111.693 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 68.2 p -136.37 135.72 39.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.246 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.828 ' HD2' HG21 ' A' ' 97' ' ' THR . 0.0 OUTLIER -116.35 128.33 55.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.998 0.427 . . . . 0.0 111.518 -179.564 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.6 tt -126.78 124.45 39.73 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.445 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.408 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.71 -133.56 2.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.462 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -153.24 168.68 32.02 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.404 -0.903 . . . . 0.0 112.939 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -119.17 141.99 48.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.785 0.326 . . . . 0.0 110.731 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.524 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.9 t -135.03 112.01 14.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.73 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.428 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 40.7 p-90 -129.14 161.04 30.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.914 0.388 . . . . 0.0 111.115 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 11.6 ptm180 -112.08 155.55 23.67 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.874 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -89.93 157.53 17.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.129 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.86 127.45 32.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.92 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 13.3 t -61.24 164.26 5.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.898 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -72.13 135.89 46.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.913 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.64 -144.78 4.02 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.426 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 24.6 m-20 -87.38 66.6 9.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.927 0.394 . . . . 0.0 110.889 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -105.01 162.34 13.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.813 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -135.22 109.39 8.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.088 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . 0.474 ' HG ' ' HB3' ' A' ' 133' ' ' SER . 0.6 OUTLIER -139.78 156.14 46.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.5 p -138.1 30.67 2.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.901 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 179.96 -71.46 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.451 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.494 HG13 ' O ' ' A' ' 132' ' ' VAL . 12.3 p -101.0 120.44 50.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.829 0.347 . . . . 0.0 111.018 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.474 ' HB3' ' HG ' ' A' ' 129' ' ' SER . 79.4 p -170.66 164.12 8.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 23.8 mtt180 -111.61 104.57 12.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.877 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 23.9 m -110.83 31.81 5.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -127.68 161.53 28.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 6.2 p80 -122.6 72.81 1.09 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.899 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -112.47 166.64 11.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.861 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 26.5 p -105.15 119.92 40.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.428 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -79.14 127.51 8.04 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.4 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.9 p -146.02 130.18 11.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.674 0.274 . . . . 0.0 111.136 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.1 134.76 7.04 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.349 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.483 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 96.4 Cg_endo -79.99 142.32 15.48 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.633 2.222 . . . . 0.0 112.12 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.9 m -156.84 158.48 3.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.968 0.413 . . . . 0.0 111.46 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.445 ' CZ ' ' HB2' ' A' ' 181' ' ' ASN . 5.0 p90 -149.04 124.04 10.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.582 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.567 ' HB3' ' NH1' ' A' ' 113' ' ' ARG . . . -119.7 168.86 10.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.933 0.396 . . . . 0.0 111.23 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -152.57 138.77 6.58 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.382 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -160.77 -159.7 10.14 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.756 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.98 ' CG1' HG22 ' A' ' 110' ' ' ILE . 5.7 m -130.66 166.91 27.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.702 0.287 . . . . 0.0 110.933 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -136.03 148.09 48.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.873 0.368 . . . . 0.0 111.178 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 10.1 m0 -131.29 128.68 40.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.791 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.53 122.53 40.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.303 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 45.5 t -110.32 -64.82 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.944 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . 0.468 HG22 ' H ' ' A' ' 155' ' ' ARG . 1.4 m -81.75 171.2 14.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . 0.468 ' H ' HG22 ' A' ' 154' ' ' THR . 4.2 mtt-85 -67.14 -26.69 66.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.119 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -143.83 31.45 1.29 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.155 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 15.9 mt -151.1 100.85 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.221 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.82 167.72 10.52 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.189 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . 0.889 HG22 HG12 ' A' ' 188' ' ' VAL . 22.3 p -125.52 144.41 50.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.354 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.435 ' NH2' ' HB2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 153.45 50.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.127 0.489 . . . . 0.0 111.87 -179.504 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.423 HD23 ' N ' ' A' ' 162' ' ' GLU . 1.5 tt -126.55 124.38 39.86 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.913 179.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.423 ' N ' HD23 ' A' ' 161' ' ' LEU . 2.8 mt-10 -106.83 145.15 32.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.162 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.677 ' CG ' HD23 ' A' ' 184' ' ' LEU . 0.7 OUTLIER -131.16 166.02 22.04 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.625 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . 0.531 ' HG2' HD11 ' A' ' 184' ' ' LEU . 0.0 OUTLIER -82.28 -34.35 28.75 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.067 -179.884 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -108.97 156.97 19.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.98 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.481 HG12 ' H ' ' A' ' 168' ' ' ASN . 23.1 t -117.57 145.06 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.004 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -59.98 -40.75 90.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.956 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . 0.481 ' H ' HG12 ' A' ' 166' ' ' VAL . 0.7 OUTLIER -114.75 -179.86 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.905 179.981 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . 0.489 ' O ' HG23 ' A' ' 169' ' ' ILE . 8.4 tt -139.39 119.63 14.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.108 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -77.43 -100.75 0.18 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.494 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -128.15 134.22 49.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.794 0.331 . . . . 0.0 110.86 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -163.76 131.65 3.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.086 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -104.75 -31.49 4.49 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.509 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.0 t -151.35 148.54 28.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.802 0.334 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.449 ' O ' HG23 ' A' ' 175' ' ' VAL . 31.4 m -132.92 119.96 39.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -121.19 90.39 0.46 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.448 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . 0.65 HG21 ' HA ' ' A' ' 181' ' ' ASN . 2.3 p -137.87 104.45 5.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.849 0.357 . . . . 0.0 110.935 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . 0.416 ' N ' ' HD2' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -73.32 -61.02 1.55 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.198 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . 0.416 ' HD2' ' N ' ' A' ' 178' ' ' ARG . 36.5 Cg_endo -66.34 -52.22 0.88 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.42 2.08 . . . . 0.0 112.47 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -173.56 170.31 4.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.984 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . 0.65 ' HA ' HG21 ' A' ' 177' ' ' THR . 9.7 p30 -96.72 -44.62 7.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.953 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -138.49 -170.68 11.92 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.564 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.98 132.36 25.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.763 0.316 . . . . 0.0 110.852 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.677 HD23 ' CG ' ' A' ' 163' ' ' TYR . 1.0 OUTLIER -89.55 136.55 32.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.817 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 12.7 p -171.07 166.73 7.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.97 0.414 . . . . 0.0 111.547 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.64 140.15 49.72 Favored 'General case' 0 N--CA 1.462 0.134 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.275 179.578 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -154.06 171.21 32.69 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 119.945 -1.122 . . . . 0.0 113.48 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . 0.889 HG12 HG22 ' A' ' 159' ' ' THR . 0.6 OUTLIER -130.48 139.85 50.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.683 -0.259 . . . . 0.0 110.359 179.456 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 83.6 p -134.95 175.08 9.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.041 0.448 . . . . 0.0 111.497 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -145.38 149.81 35.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.696 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -78.94 156.98 28.29 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.942 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -78.49 90.36 4.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.913 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -118.68 134.59 10.96 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.474 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.77 111.32 3.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.891 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -82.21 156.43 24.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.9 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.77 161.43 25.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.84 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -148.93 131.09 15.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.029 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . 0.434 ' O ' HG23 ' A' ' 200' ' ' VAL . . . -144.03 128.26 9.22 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.059 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.75 93.78 0.04 OUTLIER 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.432 2.088 . . . . 0.0 112.276 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 198' ' ' ALA . 21.2 t -141.98 95.09 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . 0.423 ' O ' HG23 ' A' ' 201' ' ' VAL . 14.6 m -79.43 69.89 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.044 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . 0.751 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -75.75 -61.03 0.96 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.212 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.751 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 63.5 Cg_endo -73.58 -44.45 0.51 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.577 2.185 . . . . 0.0 112.514 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -70.98 112.05 12.0 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.159 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -77.03 111.79 3.3 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.469 2.113 . . . . 0.0 112.424 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . 0.796 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -93.18 -55.05 0.24 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.289 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.796 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 53.8 Cg_exo -52.45 98.99 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.5 2.133 . . . . 0.0 112.39 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.797 ' HB3' ' HD3' ' A' ' 209' ' ' PRO . . . -83.68 -62.88 0.26 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.262 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . 0.797 ' HD3' ' HB3' ' A' ' 208' ' ' ALA . 64.0 Cg_endo -74.37 -45.96 0.31 Allowed 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 122.399 2.066 . . . . 0.0 112.444 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.895 -179.979 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.856 0.36 . . . . 0.0 110.998 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 6.8 ptp180 -132.57 84.61 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.94 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.3 pt -121.63 153.7 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.126 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.4 ttp -138.93 101.34 4.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.963 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.13 139.3 50.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.9 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -98.35 33.69 2.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.024 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.571 HG23 ' O ' ' A' ' 7' ' ' ILE . 5.7 tt -71.91 111.73 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.073 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -159.14 81.76 0.77 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.846 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 27.4 t -115.98 -59.02 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.065 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -92.86 165.85 12.7 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.843 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 27.8 m120 -89.02 53.33 2.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -94.5 114.62 26.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.095 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.7 147.4 78.27 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.105 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.97 -40.62 2.48 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.596 2.198 . . . . 0.0 112.367 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.8 ttmt -131.85 111.15 11.35 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.95 167.41 9.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.02 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -108.07 -71.48 0.76 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.937 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.2 t -156.7 154.28 29.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.826 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.1 m0 -121.29 132.32 54.72 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 45.1 m-85 -129.76 135.97 49.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.974 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.45 141.63 29.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.232 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.23 -172.14 41.49 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.586 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.08 148.24 19.71 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.98 152.52 51.8 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.937 0.398 . . . . 0.0 111.278 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 1.043 HD12 ' HB2' ' A' ' 54' ' ' ALA . 0.6 OUTLIER -130.35 148.75 52.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.443 179.716 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -164.23 -165.35 21.32 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.542 -0.837 . . . . 0.0 112.772 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -143.12 160.36 40.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.925 0.393 . . . . 0.0 111.142 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.66 145.87 46.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.919 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -146.85 117.03 7.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.9 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -119.09 170.47 9.04 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.914 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 8.3 t60 -143.5 124.02 14.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.953 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -134.58 153.24 52.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.949 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 2.7 t -109.71 -29.28 8.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.971 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 102.98 141.03 11.21 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.483 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -116.69 -67.78 0.97 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.893 0.378 . . . . 0.0 110.836 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -129.61 -51.81 1.16 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.883 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.88 119.32 6.37 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.467 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -74.74 -36.88 62.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.339 . . . . 0.0 110.808 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -136.29 -169.63 11.79 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -108.79 170.12 8.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.862 0.363 . . . . 0.0 110.839 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -61.97 -50.38 72.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -92.34 143.54 26.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -60.26 98.09 0.06 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.904 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -129.34 106.12 8.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.915 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.61 138.26 5.86 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.469 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -74.64 -173.93 1.69 Allowed 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.622 2.215 . . . . 0.0 112.299 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.0 p -144.84 -73.12 0.25 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.2 mmt85 -148.21 29.88 0.87 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.91 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -119.68 162.83 18.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.005 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -98.62 176.77 5.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 1.3 tp-100 -106.31 84.23 2.0 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.839 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.75 144.77 50.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.825 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -154.43 159.2 28.74 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.458 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 1.043 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -116.52 161.08 19.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.762 0.315 . . . . 0.0 110.938 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -163.81 146.64 11.77 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.681 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.727 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -96.25 160.99 14.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.73 0.3 . . . . 0.0 110.898 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.429 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 19.6 p90 -151.6 139.52 19.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.988 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -136.33 125.05 3.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.349 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -98.13 129.98 10.08 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.581 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 18.4 m-85 -129.14 110.24 11.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.82 0.343 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -89.5 137.02 32.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.805 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 22.6 t -133.6 -49.41 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.966 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -107.05 143.71 27.65 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.591 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.02 73.08 0.47 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.329 2.019 . . . . 0.0 112.236 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.429 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.2 OUTLIER -177.05 -38.69 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.206 -179.926 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.429 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.3 OUTLIER -168.35 164.05 12.89 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.095 -179.716 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 165.22 22.11 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 -81.83 132.49 35.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.775 0.322 . . . . 0.0 110.624 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -112.08 115.92 29.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.172 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -105.53 115.48 30.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.17 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.8 157.25 15.17 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.803 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.727 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 34.1 m-85 -128.95 129.56 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.738 0.304 . . . . 0.0 110.718 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.405 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.9 OUTLIER -96.34 121.01 37.67 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.754 -179.979 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -136.8 118.64 15.16 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.785 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.23 81.09 1.86 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.877 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 155.33 173.38 23.98 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.469 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.61 -173.01 2.4 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.801 0.334 . . . . 0.0 111.002 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.7 mmm -99.12 31.36 3.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.825 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -107.44 56.75 0.63 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.134 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -112.51 -34.8 5.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.986 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 17.8 mttt -59.37 150.27 26.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.861 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -92.83 -149.02 24.24 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -154.85 -46.8 0.09 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 110.912 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.608 HG22 ' O ' ' A' ' 84' ' ' VAL . 12.9 p -135.09 42.82 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -86.08 -176.9 6.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.911 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -113.21 -61.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.867 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -69.47 -158.79 1.93 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.484 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -116.0 130.82 56.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.931 0.396 . . . . 0.0 111.075 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . 0.419 ' CE2' ' HA ' ' A' ' 123' ' ' SER . 0.7 OUTLIER -116.96 109.4 16.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 -179.982 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.85 135.87 19.96 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -148.75 133.48 17.88 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 17.8 tt0 -175.12 138.98 0.46 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.567 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.405 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -84.3 141.27 19.73 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.718 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.89 121.03 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.746 0.308 . . . . 0.0 110.31 179.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . 0.409 ' HG3' ' CB ' ' A' ' 117' ' ' MET . 3.4 mp0 -108.91 136.09 49.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.055 0.455 . . . . 0.0 111.817 -179.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.456 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.6 tt -122.18 106.57 11.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.58 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.572 HG22 ' HA3' ' A' ' 115' ' ' GLY . 7.5 p -145.45 168.77 19.75 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.044 0.449 . . . . 0.0 111.644 -178.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.68 121.97 45.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.009 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.34 132.42 56.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.146 0.498 . . . . 0.0 111.885 -179.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.6 ' HG ' HG23 ' A' ' 112' ' ' THR . 3.4 pp -126.96 127.39 44.77 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.814 179.096 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -120.2 -177.49 16.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.467 -0.873 . . . . 0.0 113.323 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.428 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 24.3 t80 -166.11 123.12 1.02 Allowed Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.455 0.169 . . . . 0.0 110.738 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.428 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 83.7 Cg_endo -78.02 160.64 30.15 Favored 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.457 2.105 . . . . 0.0 112.671 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 17.9 mm -116.28 -37.51 2.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -161.62 39.2 0.13 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.065 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 57.56 47.86 15.33 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.935 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.473 ' HB3' HD23 ' A' ' 108' ' ' LEU . 12.4 t70 -177.56 -38.19 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.64 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.485 HD23 ' N ' ' A' ' 108' ' ' LEU . 0.0 OUTLIER -117.53 105.29 11.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.164 179.688 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -126.04 163.27 23.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.066 0.46 . . . . 0.0 111.451 -179.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.989 HG22 HG12 ' A' ' 149' ' ' VAL . 1.6 pt -114.79 158.93 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.343 179.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -156.09 138.74 15.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.028 0.442 . . . . 0.0 111.604 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.6 HG23 ' HG ' ' A' ' 100' ' ' LEU . 1.8 t -132.99 126.94 33.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.243 179.389 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.439 ' CD ' ' HB3' ' A' ' 146' ' ' ALA . 0.5 OUTLIER -118.47 130.46 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.954 0.407 . . . . 0.0 111.43 -179.416 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -131.52 122.84 26.82 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.438 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.572 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -176.37 -140.18 3.44 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.591 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.482 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -138.6 163.31 25.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.832 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.409 ' CB ' ' HG3' ' A' ' 95' ' ' GLN . 1.1 ptt? -122.26 135.65 54.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.764 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -129.17 119.81 49.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 19.4 t90 -114.52 143.75 44.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.021 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 14.2 mtp180 -140.18 119.95 13.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.954 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.39 155.21 50.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.087 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -159.24 131.69 6.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.847 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . 0.419 ' HA ' ' CE2' ' A' ' 89' ' ' PHE . 32.0 t -130.59 96.28 4.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 6.4 mtmt -125.89 88.14 2.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.746 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -84.9 79.11 1.94 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.575 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -112.73 144.58 42.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.892 0.377 . . . . 0.0 110.892 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -82.89 -35.25 26.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.886 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -116.2 -176.04 2.87 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.08 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 39.1 t -106.91 44.21 1.08 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.939 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.8 t -70.6 161.17 31.19 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.914 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -105.36 157.15 16.47 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.588 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.0 m -144.55 163.78 13.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.735 0.302 . . . . 0.0 111.16 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 65.2 m -79.12 -34.01 43.78 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.818 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 12.3 ttt85 -104.02 144.45 31.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -124.35 154.59 40.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.985 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.91 84.85 2.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.79 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 11.5 t-160 -141.64 121.28 13.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.91 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -131.85 148.35 52.54 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 5.1 t -133.4 115.84 15.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -90.4 132.25 11.17 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.486 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.416 ' O ' HG13 ' A' ' 141' ' ' VAL . 11.1 p -146.05 126.13 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.733 0.301 . . . . 0.0 111.152 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 32.7 t -157.1 143.18 12.94 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.291 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.482 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 98.9 Cg_endo -79.55 147.45 19.9 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.658 2.239 . . . . 0.0 112.113 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.7 m -156.98 161.83 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.951 0.405 . . . . 0.0 111.528 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.8 p90 -149.01 119.44 7.37 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.572 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.439 ' HB3' ' CD ' ' A' ' 113' ' ' ARG . . . -109.79 129.07 55.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.935 0.398 . . . . 0.0 111.321 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.4 124.98 4.05 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.224 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.421 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -158.56 -152.16 6.33 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.309 -0.948 . . . . 0.0 113.04 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.989 HG12 HG22 ' A' ' 110' ' ' ILE . 6.1 m -135.48 167.31 25.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 111.317 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -136.8 137.4 39.75 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -119.93 127.25 52.49 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.731 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -88.43 124.34 33.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.479 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.535 ' O ' HG12 ' A' ' 153' ' ' VAL . 53.1 t -116.07 60.06 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.824 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . 0.509 HG22 ' O ' ' A' ' 153' ' ' VAL . 14.6 t 45.85 -168.56 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.366 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . 0.485 ' CG ' HD12 ' A' ' 157' ' ' ILE . 9.5 tpp180 57.6 21.87 7.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.266 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 56.29 24.3 8.09 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.204 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.485 HD12 ' CG ' ' A' ' 155' ' ' ARG . 6.5 mt -129.3 137.48 56.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.856 0.36 . . . . 0.0 110.959 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -131.69 158.82 40.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.314 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -101.0 141.63 33.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.201 179.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -124.29 122.95 39.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.11 0.481 . . . . 0.0 111.881 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.415 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 1.4 tt -117.41 116.69 27.67 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.536 178.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.421 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 0.2 OUTLIER -109.48 145.02 36.92 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.793 -178.922 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.421 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.4 p90 -133.99 165.77 24.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.557 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -178.12 108.16 0.05 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.877 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 24.1 t90 -162.88 118.92 1.83 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.477 ' O ' HG13 ' A' ' 166' ' ' VAL . 10.7 p -124.23 120.28 58.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.079 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -113.88 -37.71 4.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -70.15 67.34 0.3 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.856 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . 0.437 ' O ' HD12 ' A' ' 169' ' ' ILE . 2.7 pp -153.25 30.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -96.56 59.74 1.28 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.43 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -97.35 126.72 42.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.778 0.323 . . . . 0.0 110.927 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -131.47 125.87 33.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.11 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -137.01 -63.97 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.564 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 25.6 p -113.51 -42.47 3.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.822 0.344 . . . . 0.0 110.892 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 15.8 m -130.27 166.17 28.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.008 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -111.76 164.18 12.14 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.491 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.4 m -136.79 158.37 44.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.839 0.352 . . . . 0.0 111.024 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -98.49 103.61 19.45 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.81 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.0 137.48 37.77 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.396 2.064 . . . . 0.0 112.314 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -119.73 111.56 18.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.819 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 11.7 p-10 -96.29 150.33 20.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -110.94 -149.35 11.71 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.51 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -155.37 167.03 31.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.837 0.351 . . . . 0.0 110.956 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 7.2 mp -94.8 153.98 17.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.776 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 67.2 m -152.44 150.89 30.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.949 0.404 . . . . 0.0 111.298 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -116.31 145.18 43.38 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.454 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -160.64 173.66 37.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.921 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 2.1 m -127.49 138.16 55.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.759 0.314 . . . . 0.0 110.652 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . 0.429 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 60.7 p -139.86 170.59 15.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.258 -179.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 1.9 p90 -147.95 160.02 43.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 -95.15 150.15 20.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.929 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -67.63 109.19 3.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.81 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -140.97 -171.03 12.36 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.529 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 -126.33 82.03 2.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.847 0.356 . . . . 0.0 110.903 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -93.6 171.36 8.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.001 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -127.6 164.53 21.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.95 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -132.33 33.5 3.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.167 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -151.83 73.97 7.87 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.124 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -78.35 55.86 5.58 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.656 2.237 . . . . 0.0 112.436 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . 0.911 HG13 HG23 ' A' ' 201' ' ' VAL . 10.8 p -118.44 -29.15 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.356 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . 0.911 HG23 HG13 ' A' ' 200' ' ' VAL . 24.9 t -117.61 148.5 20.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.212 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -114.01 112.42 47.34 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.982 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.16 110.83 2.08 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.47 2.113 . . . . 0.0 112.2 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -112.52 91.5 17.11 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.188 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_exo -51.01 119.61 5.57 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.534 2.156 . . . . 0.0 112.426 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -77.39 -53.23 1.64 Allowed Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.101 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 50.2 Cg_exo -53.12 112.17 0.86 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.484 2.123 . . . . 0.0 112.381 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.767 ' HB3' ' HD3' ' A' ' 209' ' ' PRO . . . -69.99 -61.05 3.13 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.08 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . 0.767 ' HD3' ' HB3' ' A' ' 208' ' ' ALA . 60.5 Cg_endo -72.66 144.54 39.86 Favored 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.534 2.156 . . . . 0.0 112.303 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.985 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.303 0 CA-C-O 120.888 0.375 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 10.9 mtp180 -151.57 -47.15 0.11 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.866 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.2 mt -84.97 136.23 23.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.959 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -138.11 40.03 2.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.979 0.419 . . . . 0.0 110.763 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.8 mttt -140.25 115.65 9.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.846 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.91 96.55 1.7 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.066 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.92 157.64 3.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.079 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -158.84 116.31 2.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.735 HG12 HD12 ' A' ' 10' ' ' LEU . 21.4 t -131.42 -66.76 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.145 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.735 HD12 HG12 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -148.89 72.78 1.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.929 -179.972 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 26.6 m-20 -76.97 -59.73 2.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.021 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -123.99 31.46 5.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.095 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.43 ' HB3' HD23 ' A' ' 10' ' ' LEU . . . -108.75 116.68 55.57 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.034 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.72 -44.69 1.96 Allowed 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.372 2.048 . . . . 0.0 112.325 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 12.3 mttm -150.84 119.27 6.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.943 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.94 83.87 0.67 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.799 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -87.84 137.49 32.29 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.939 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -154.66 177.01 11.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.933 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.429 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.2 OUTLIER -141.83 154.58 45.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.885 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.444 ' CE1' ' HB3' ' A' ' 191' ' ' ARG . 1.2 m-85 -145.71 135.92 23.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.801 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.34 140.0 27.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.222 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -177.7 -171.55 41.27 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.424 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.04 150.46 22.69 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.368 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.32 154.57 48.4 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.898 0.38 . . . . 0.0 111.114 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.699 HD12 ' O ' ' A' ' 53' ' ' GLY . 49.4 tp -128.17 139.6 52.39 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.528 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -146.41 171.31 27.29 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.545 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 1.5 m-90 -78.97 144.51 34.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.765 0.317 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.65 -69.47 0.75 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.829 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 50.4 mt-30 -146.82 155.18 42.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.898 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -117.96 122.17 42.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -70.18 105.75 3.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.926 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 32.0 p-10 -116.29 -38.44 3.57 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.907 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 61.1 m -59.4 -57.93 10.84 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.01 -154.52 26.64 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.393 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -141.62 -69.35 0.37 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.818 0.342 . . . . 0.0 110.858 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 8.2 p90 -156.81 175.23 14.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.931 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -158.43 93.81 0.13 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.534 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 23.1 m-20 -77.21 -52.02 9.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 111.015 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -157.72 -65.74 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.511 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 76.9 t80 -85.65 139.87 31.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.778 0.323 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -151.32 172.34 16.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.868 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -116.63 81.07 1.57 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.936 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -75.23 -57.32 3.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.887 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -144.94 39.75 1.23 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.913 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -92.03 -91.54 1.43 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.56 -61.74 0.45 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.588 2.192 . . . . 0.0 112.367 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.8 p -138.99 156.53 47.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 4.2 ptp180 -119.25 -40.41 2.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.95 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 21.8 p30 -59.27 162.14 4.87 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.852 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -114.74 -172.11 2.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -55.79 158.0 3.92 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.921 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.439 HD13 HD11 ' A' ' 25' ' ' LEU . 2.5 pp -139.01 164.82 28.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.042 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.699 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -131.47 134.47 7.7 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.488 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.402 ' HB3' ' O ' ' A' ' 74' ' ' TRP . . . -101.19 139.88 36.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.02 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -145.57 126.85 2.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.424 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.498 ' HB3' ' CB ' ' A' ' 72' ' ' TYR . . . -94.89 141.82 28.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.747 0.308 . . . . 0.0 110.97 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -123.8 126.16 45.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.957 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -154.65 124.99 1.62 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.284 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -157.98 -168.31 20.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.429 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 8.8 p90 -154.97 161.08 41.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.782 0.325 . . . . 0.0 110.807 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -109.58 135.22 50.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.595 ' O ' HG12 ' A' ' 62' ' ' VAL . 15.9 t -141.46 29.22 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.036 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -162.32 163.53 18.36 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.78 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.37 -40.8 69.99 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.611 2.207 . . . . 0.0 112.328 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 24.7 p90 -148.63 37.59 0.82 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.899 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -139.39 115.7 10.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.798 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -129.41 153.49 19.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.525 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -96.07 128.37 42.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.66 0.266 . . . . 0.0 110.439 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -122.2 130.16 52.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.984 0.421 . . . . 0.0 111.417 -179.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 19.1 mtt -118.97 127.17 53.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.328 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.73 158.2 14.65 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.495 -0.859 . . . . 0.0 112.699 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.498 ' CB ' ' HB3' ' A' ' 56' ' ' ALA . 0.7 OUTLIER -129.18 114.94 16.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.781 0.324 . . . . 0.0 110.78 179.947 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -83.41 115.55 22.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.889 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . 0.402 ' O ' ' HB3' ' A' ' 54' ' ' ALA . 1.7 t90 -139.08 133.85 32.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.931 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.85 69.38 1.12 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.882 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 177.41 -144.97 6.94 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.41 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.0 ttt180 -165.9 156.61 13.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.773 0.32 . . . . 0.0 110.875 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 6.7 ttt -63.39 96.85 0.12 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.897 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -154.45 -174.49 4.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.007 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -58.78 178.79 0.1 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.93 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.7 mttp -60.79 125.5 23.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.881 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -87.46 -94.26 0.94 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.498 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 19.1 m -74.89 177.16 6.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.787 0.327 . . . . 0.0 110.905 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 84' ' ' VAL . 17.1 m -123.99 120.94 60.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.205 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -166.27 163.01 17.7 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.538 ' HB3' ' HB2' ' A' ' 128' ' ' ALA . 2.3 t-20 -134.83 138.79 44.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 129.27 -93.66 0.34 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.488 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -66.55 -30.74 71.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.819 0.342 . . . . 0.0 111.099 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 12.0 t80 60.93 95.01 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.893 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.35 -177.61 0.1 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.888 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -139.04 160.92 38.64 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.074 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -158.45 125.06 4.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.668 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.414 ' HA2' ' CB ' ' A' ' 119' ' ' TRP . . . -99.68 142.64 16.07 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.122 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.76 122.1 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 117' ' ' MET . 2.2 mt-30 -108.8 140.32 42.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.065 0.459 . . . . 0.0 111.678 -179.125 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.4 tt -128.43 116.21 19.39 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.613 -0.722 . . . . 0.0 109.751 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.885 HG21 ' HD2' ' A' ' 113' ' ' ARG . 0.6 OUTLIER -153.97 164.38 38.52 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.035 0.445 . . . . 0.0 111.84 -178.851 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.25 124.98 46.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.285 179.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -102.76 132.53 48.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.029 0.442 . . . . 0.0 111.71 -179.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.587 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -134.95 124.16 24.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.347 179.296 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -156.3 -175.84 27.73 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.821 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -166.02 159.97 12.85 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.656 0.265 . . . . 0.0 110.993 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -73.97 169.79 21.59 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.631 2.22 . . . . 0.0 112.132 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.871 HG23 HG23 ' A' ' 105' ' ' THR . 0.7 OUTLIER -122.26 -39.85 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.495 -0.321 . . . . 0.0 111.367 -179.88 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.871 HG23 HG23 ' A' ' 104' ' ' ILE . 71.8 p -136.78 -59.17 0.72 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.021 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -166.81 -42.95 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.166 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.748 ' C ' HD23 ' A' ' 108' ' ' LEU . 9.0 m-20 -125.35 28.15 6.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.272 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.748 HD23 ' C ' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -143.37 119.09 10.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.081 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -136.76 160.01 40.13 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 111.812 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.063 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -115.09 147.27 18.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.219 179.436 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -149.06 145.13 27.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.114 0.483 . . . . 0.0 111.51 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.502 HG22 ' CA ' ' A' ' 147' ' ' GLY . 0.6 OUTLIER -137.81 129.82 28.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.179 179.554 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.885 ' HD2' HG21 ' A' ' 97' ' ' THR . 0.6 OUTLIER -111.93 133.11 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.081 0.467 . . . . 0.0 111.522 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.515 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.8 tt -124.34 122.86 38.87 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.296 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.416 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 179.91 -134.07 2.16 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.815 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.524 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -151.43 169.1 30.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.933 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.406 ' HB3' ' HG2' ' A' ' 95' ' ' GLN . 0.6 OUTLIER -122.68 138.82 54.49 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 111.24 -179.791 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.1 125.89 60.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.503 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.414 ' CB ' ' HA2' ' A' ' 93' ' ' GLY . 1.1 p-90 -150.95 179.88 7.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 111.244 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.0 mtm180 -97.93 161.2 13.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.899 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -134.69 134.2 40.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.992 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -144.8 162.03 37.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.902 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 19.7 p -163.79 -44.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 21.9 mtpt -102.51 112.63 25.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.907 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -177.59 107.66 0.24 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.505 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -142.8 -50.64 0.36 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.817 0.342 . . . . 0.0 110.946 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -112.96 118.01 33.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.538 ' HB2' ' HB3' ' A' ' 86' ' ' ASN . . . -96.63 152.76 18.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.044 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -137.79 165.39 26.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 7.1 p -91.15 98.84 11.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.841 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -105.63 140.2 15.01 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.541 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 21.5 t -66.81 -44.78 88.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.842 0.353 . . . . 0.0 111.123 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.3 m -75.81 166.56 23.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.955 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -128.07 100.56 5.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.935 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 25.5 p -82.34 153.12 25.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.883 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 17.0 mm-40 -80.0 170.84 15.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.914 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.0 p-80 -114.38 163.0 15.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.954 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -76.21 141.28 41.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.89 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 78.3 p -135.07 147.69 49.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.968 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -116.42 135.56 12.16 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.329 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.9 p -146.07 127.67 7.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.645 0.26 . . . . 0.0 111.132 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -157.07 142.67 12.64 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.496 -179.842 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.524 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 4.7 Cg_exo -73.93 153.4 47.47 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.834 2.356 . . . . 0.0 111.768 179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.8 m -156.33 161.19 2.0 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 121.084 0.469 . . . . 0.0 111.717 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.515 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.5 t80 -142.94 118.96 10.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.237 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.49 136.38 52.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.014 0.435 . . . . 0.0 111.397 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.502 ' CA ' HG22 ' A' ' 112' ' ' THR . . . -133.73 125.74 4.05 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.004 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -157.96 -164.99 14.67 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.354 -0.927 . . . . 0.0 112.873 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 1.063 HG12 HG22 ' A' ' 110' ' ' ILE . 6.8 m -131.75 162.68 39.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.806 0.336 . . . . 0.0 111.046 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -129.51 140.11 51.36 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.188 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 18.8 m95 -123.22 120.02 31.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.808 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.51 126.71 35.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.391 -179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 48.4 t -116.14 -68.6 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.009 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . 0.471 HG22 ' H ' ' A' ' 155' ' ' ARG . 0.2 OUTLIER -75.88 -173.69 2.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.903 -179.986 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . 0.471 ' H ' HG22 ' A' ' 154' ' ' THR . 5.0 mtt-85 -75.05 -31.81 61.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.957 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -146.26 36.06 1.0 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.114 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 17.7 mt -149.52 100.95 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.035 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -116.47 168.83 9.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.008 0.432 . . . . 0.0 111.362 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . 0.416 ' HB ' HG12 ' A' ' 188' ' ' VAL . 5.8 t -126.77 144.41 50.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.198 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 150.19 47.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.232 0.539 . . . . 0.0 112.016 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.791 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.9 OUTLIER -115.56 122.35 45.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.482 178.943 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -111.94 145.09 40.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.05 0.452 . . . . 0.0 111.7 -178.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.791 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 17.5 m-85 -128.71 147.05 50.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.657 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -58.87 -53.65 55.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.978 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 3.9 m95 -143.63 134.06 24.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.788 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 23.1 m -85.67 -32.9 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.177 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -85.37 168.38 14.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.835 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -128.88 -52.01 1.23 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.83 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 7.6 pt -69.58 157.53 6.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.105 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -162.92 -87.81 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.546 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -138.05 144.5 41.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.787 0.327 . . . . 0.0 110.899 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -115.75 108.19 16.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.137 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -99.93 -28.52 7.31 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.445 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 68.7 p -125.43 -47.73 1.72 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.724 0.297 . . . . 0.0 110.866 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.484 HG22 ' N ' ' A' ' 176' ' ' GLY . 11.3 p -156.51 158.5 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.119 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . 0.484 ' N ' HG22 ' A' ' 175' ' ' VAL . . . -86.59 55.34 4.69 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.413 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.5 m -138.75 59.67 1.62 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.971 0.415 . . . . 0.0 110.861 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 16.1 mtm-85 -79.59 155.24 76.19 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.941 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.05 134.95 50.97 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.512 2.141 . . . . 0.0 112.304 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -100.14 146.79 26.41 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.974 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 60.65 160.68 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.872 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -131.49 -85.22 0.31 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.586 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 4.4 tpp -147.88 149.18 31.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.829 0.347 . . . . 0.0 110.863 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -130.49 136.12 48.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.784 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 9.5 t -138.51 147.88 43.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.918 0.389 . . . . 0.0 111.103 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.8 131.97 54.01 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.407 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.85 168.63 28.71 Favored Glycine 0 N--CA 1.453 -0.213 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.236 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . 0.416 HG12 ' HB ' ' A' ' 159' ' ' THR . 1.1 m -127.99 143.51 40.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.671 0.272 . . . . 0.0 110.472 179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.42 172.98 11.96 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 121.006 0.431 . . . . 0.0 111.468 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.7 p90 -138.05 160.03 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.444 ' HB3' ' CE1' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -113.26 141.88 46.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -91.41 106.65 18.65 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.819 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -122.73 152.89 16.89 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.515 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -90.81 140.42 29.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.773 0.32 . . . . 0.0 110.991 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -124.24 -71.51 0.71 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.928 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.36 91.08 3.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.93 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -81.97 98.81 8.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.051 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . 0.746 ' HB3' ' HD3' ' A' ' 199' ' ' PRO . . . -173.11 -63.05 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.171 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.746 ' HD3' ' HB3' ' A' ' 198' ' ' ALA . 57.3 Cg_endo -70.74 72.03 1.96 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.464 2.109 . . . . 0.0 112.298 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . 0.495 HG13 ' N ' ' A' ' 201' ' ' VAL . 10.9 p -138.91 -45.67 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.085 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . 0.495 ' N ' HG13 ' A' ' 200' ' ' VAL . 20.8 m -127.67 141.15 47.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.103 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -119.48 135.74 24.23 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.071 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -77.52 105.98 2.13 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.584 2.189 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . 0.855 ' HB3' ' HD3' ' A' ' 205' ' ' PRO . . . -81.62 -61.93 0.36 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.105 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . 0.855 ' HD3' ' HB3' ' A' ' 204' ' ' ALA . 86.5 Cg_endo -77.98 58.27 6.46 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.589 2.193 . . . . 0.0 112.397 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . 0.711 ' HB1' ' HD2' ' A' ' 207' ' ' PRO . . . -138.29 172.95 5.85 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.139 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.711 ' HD2' ' HB1' ' A' ' 206' ' ' ALA . 55.6 Cg_exo -51.95 -45.55 37.99 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.56 2.174 . . . . 0.0 112.293 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -131.61 140.31 37.94 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.107 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -75.0 -44.07 0.36 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.536 2.157 . . . . 0.0 112.363 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.916 -179.975 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.887 0.375 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.79 178.21 4.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.77 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.6 pt -73.1 81.77 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.102 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 13.8 mtt -127.96 54.56 1.7 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.928 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.09 173.94 11.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.931 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -58.9 179.4 0.09 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.146 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 mp -67.43 -50.28 63.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.092 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -117.03 139.47 50.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.931 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.6 t -106.29 72.23 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.111 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.2 pp -161.13 29.21 0.14 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.927 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -89.09 -61.29 1.74 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -167.91 -169.68 1.2 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.088 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -120.99 77.83 31.62 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.074 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -54.99 -36.32 92.18 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.618 2.212 . . . . 0.0 112.204 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.44 112.55 24.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.011 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -88.98 150.75 22.67 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.862 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -89.56 116.06 27.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.933 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.4 m -151.08 132.79 14.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.914 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 3.9 m-90 -135.64 148.4 48.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.106 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.432 ' CZ ' ' HA3' ' A' ' 59' ' ' GLY . 6.6 p90 -159.95 149.0 17.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.69 153.75 46.09 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.171 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -173.87 -171.18 38.07 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.463 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -143.7 147.64 19.06 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.39 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 3.1 pptp? -134.59 146.94 50.09 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.911 0.386 . . . . 0.0 111.043 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.807 HD12 ' HB2' ' A' ' 54' ' ' ALA . 1.9 tt -121.5 146.29 47.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.653 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -155.73 175.57 33.52 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.486 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 11.9 m-90 -108.55 159.93 16.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.791 0.329 . . . . 0.0 111.0 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 84.9 p -137.79 58.39 1.69 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.927 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -169.29 -169.75 0.99 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -95.98 148.06 23.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.948 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.2 t60 -147.66 -64.66 0.26 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 68.5 m-20 -146.35 31.9 0.99 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.94 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.5 154.8 19.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.863 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.37 -110.86 3.96 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.566 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 38.0 m-85 -122.46 -178.11 3.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.836 0.35 . . . . 0.0 110.922 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 13.4 m-85 -71.56 168.15 18.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.829 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -158.13 124.49 1.4 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.418 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -114.45 101.78 9.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.928 0.394 . . . . 0.0 110.866 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -160.91 -150.99 6.06 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.509 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -92.8 170.2 9.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.786 0.326 . . . . 0.0 110.886 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -113.16 -170.25 1.64 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -90.99 125.48 35.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.834 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 11.5 m-20 -131.6 -48.18 0.97 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.8 m-80 -120.25 85.41 2.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.851 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -157.78 90.13 0.11 Allowed Glycine 0 CA--C 1.518 0.247 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.447 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -70.09 -28.18 23.99 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.49 2.126 . . . . 0.0 112.295 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 9.8 t -71.47 -31.32 67.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.901 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -59.56 107.41 0.58 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -127.35 134.62 49.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.846 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -75.72 151.6 37.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 21.7 mt-30 -109.12 87.98 2.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.813 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -108.21 139.41 42.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.922 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -139.3 143.09 13.52 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.436 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.807 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -125.07 148.48 48.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.662 0.268 . . . . 0.0 110.837 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.04 147.85 18.48 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.322 -0.942 . . . . 0.0 112.937 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.83 128.76 53.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.635 0.255 . . . . 0.0 110.643 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -120.3 143.96 48.07 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 0.0 111.397 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -128.15 124.89 4.92 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.969 -0.634 . . . . 0.0 112.045 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.432 ' HA3' ' CZ ' ' A' ' 20' ' ' TYR . . . -100.3 139.72 14.56 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.987 -179.492 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -135.39 114.11 11.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.702 0.287 . . . . 0.0 110.593 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.79 126.76 33.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.256 -179.627 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 19.0 t -153.82 -44.22 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.105 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -80.55 173.64 7.4 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.895 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.49 ' O ' HD23 ' A' ' 66' ' ' LEU . 21.4 Cg_exo -65.95 98.69 0.37 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.868 2.379 . . . . 0.0 113.029 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 57.24 44.88 21.33 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.496 179.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.49 HD23 ' O ' ' A' ' 64' ' ' PRO . 1.9 pp -176.65 115.72 0.11 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.871 179.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -107.14 177.02 21.46 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.548 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 36.6 m-85 -90.55 142.77 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.833 0.349 . . . . 0.0 110.654 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.401 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 0.6 OUTLIER -122.49 111.96 17.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.151 -179.738 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.9 mtt -100.39 114.82 28.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.888 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 152.16 17.28 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.392 -0.909 . . . . 0.0 113.261 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.46 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 38.6 m-85 -130.3 114.96 16.28 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.5 122.94 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.763 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . 0.437 ' CD1' ' HA2' ' A' ' 55' ' ' GLY . 17.9 p-90 -139.2 148.09 42.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.646 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.09 176.25 5.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.041 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.24 178.94 39.92 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.523 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 10.3 ttt180 -98.15 30.05 3.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.818 0.342 . . . . 0.0 110.857 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 5.8 mtt -160.38 -172.63 3.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.778 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -167.54 -57.57 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.14 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -157.07 35.95 0.29 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 3.7 mtpm? -98.53 31.06 2.98 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.825 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -103.22 135.09 12.13 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.42 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 5.3 p -99.67 -39.09 8.44 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.77 0.319 . . . . 0.0 110.874 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -87.98 -31.8 5.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.074 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -135.43 148.8 49.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -84.3 -59.03 2.51 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.88 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.75 119.64 1.21 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.567 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.75 -30.61 14.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.338 . . . . 0.0 111.122 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 64.27 -78.93 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.97 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 3.0 mtmt -158.57 -54.67 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.904 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -176.37 -178.0 0.91 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.082 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -121.33 135.72 55.06 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.679 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.48 124.5 8.1 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.596 -0.812 . . . . 0.0 112.783 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.09 117.8 56.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.08 139.76 46.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.124 0.488 . . . . 0.0 111.831 -178.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.407 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -129.98 110.97 12.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.556 179.377 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.444 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.5 p -150.02 178.12 9.24 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.083 0.468 . . . . 0.0 111.812 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.2 44.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.033 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.401 ' HB2' ' HB2' ' A' ' 69' ' ' GLU . 8.8 tttt -126.57 132.01 51.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.096 0.475 . . . . 0.0 111.841 -179.286 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.488 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.6 pp -134.55 123.96 24.73 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.981 179.274 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.435 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -126.24 -175.04 14.02 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.437 -0.887 . . . . 0.0 113.302 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.406 ' CD1' ' HD2' ' A' ' 103' ' ' PRO . 0.8 OUTLIER -166.15 122.96 1.0 Allowed Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 115.674 -0.263 . . . . 0.0 110.576 -179.881 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.406 ' HD2' ' CD1' ' A' ' 102' ' ' TYR . 58.3 Cg_endo -71.6 167.24 27.0 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.485 2.123 . . . . 0.0 112.672 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 20.4 mm -109.68 -63.96 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.714 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.99 -50.21 2.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.664 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.1 t0 179.05 -36.21 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.165 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.734 ' O ' HD23 ' A' ' 108' ' ' LEU . 1.0 OUTLIER -113.66 16.47 18.62 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -179.468 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.734 HD23 ' O ' ' A' ' 107' ' ' ASP . 0.1 OUTLIER -141.86 125.84 17.23 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.675 0.274 . . . . 0.0 110.443 179.756 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -145.07 159.28 43.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.009 0.433 . . . . 0.0 111.522 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.025 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.63 148.58 17.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.351 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.435 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 5.7 m-85 -138.13 144.46 40.82 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.049 0.452 . . . . 0.0 111.736 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -128.91 127.1 41.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.356 179.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.25 130.07 56.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.338 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.505 HD12 ' CD2' ' A' ' 145' ' ' PHE . 7.2 tt -137.4 122.95 19.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.636 179.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.444 ' HA3' HG22 ' A' ' 97' ' ' THR . . . 179.51 -143.05 5.5 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.488 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.514 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -146.23 163.86 28.37 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.929 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.57 144.37 49.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.807 0.337 . . . . 0.0 110.94 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.2 t -129.44 135.73 60.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.864 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 6.2 m95 -123.41 141.08 52.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.795 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 2.0 ptt180 -150.61 126.83 10.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.0 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -88.34 139.61 30.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.065 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 -156.68 156.89 34.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.936 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 30.9 t -126.24 112.12 15.37 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.952 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -143.82 90.95 2.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.789 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -108.84 168.27 13.39 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.479 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -88.05 -37.29 16.41 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.771 0.319 . . . . 0.0 110.885 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -110.26 31.71 5.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.972 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -135.62 171.99 13.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.048 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.2 m -86.28 141.78 29.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.925 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.7 m -84.92 107.79 17.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -69.96 135.3 26.13 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.517 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 8.9 m -120.35 -42.02 2.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.874 0.368 . . . . 0.0 111.125 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 22.5 t -76.45 107.21 8.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.853 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 15.4 mtt180 -68.44 104.97 2.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.929 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 93.4 p -106.12 -50.99 3.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.921 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -131.8 79.68 1.88 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.005 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -140.68 124.75 17.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -125.99 137.35 53.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.835 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 60.0 p -108.79 165.89 11.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.943 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -145.31 140.05 8.78 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.518 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.428 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.4 p -146.02 123.94 4.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 120.66 0.267 . . . . 0.0 110.948 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 67.1 m -157.14 152.91 22.63 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.803 0.335 . . . . 0.0 111.577 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.514 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 71.6 Cg_endo -77.04 162.1 32.17 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.769 2.313 . . . . 0.0 112.094 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.6 m -155.96 159.05 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.003 0.43 . . . . 0.0 111.503 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.505 ' CD2' HD12 ' A' ' 114' ' ' LEU . 10.5 t80 -147.24 118.89 7.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.486 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -115.78 122.54 45.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.25 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.405 ' O ' ' CD1' ' A' ' 163' ' ' TYR . . . -126.32 132.21 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.218 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.426 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -166.52 -153.76 7.98 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.817 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 1.025 HG12 HG22 ' A' ' 110' ' ' ILE . 6.0 m -134.7 170.53 19.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.63 0.253 . . . . 0.0 111.016 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -138.3 144.6 40.52 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.904 0.383 . . . . 0.0 111.317 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . 0.603 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.2 OUTLIER -127.24 133.51 50.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.566 179.745 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -97.71 137.2 36.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.64 -63.68 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 33.6 p -90.55 -169.47 2.4 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.295 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 4.5 mtp180 -96.38 38.89 1.17 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.919 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -179.58 -28.33 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.941 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 32.0 mt -111.7 133.13 58.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-O 120.943 0.402 . . . . 0.0 111.651 -179.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -140.03 155.53 47.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.089 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.8 m -101.02 149.97 23.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.481 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.401 ' NH1' ' HB3' ' A' ' 162' ' ' GLU . 0.0 OUTLIER -137.06 134.2 36.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.068 0.461 . . . . 0.0 111.8 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.4 tt -117.56 119.57 35.43 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.792 179.038 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.401 ' HB3' ' NH1' ' A' ' 160' ' ' ARG . 4.8 pt-20 -112.42 143.89 42.79 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.989 0.423 . . . . 0.0 111.703 -179.11 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.426 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 6.4 p90 -134.21 162.83 31.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.516 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -82.52 155.04 24.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.938 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 13.8 t-105 -140.82 -62.33 0.48 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.984 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.464 HG12 ' HB3' ' A' ' 145' ' ' PHE . 11.3 p -65.53 130.03 30.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.086 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 65.8 m-80 -127.88 120.66 28.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.951 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 30.3 m120 -111.27 83.27 1.74 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.877 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 4.4 tp -112.15 138.74 39.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.052 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -141.37 -51.61 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.472 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -99.29 159.98 14.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.775 0.321 . . . . 0.0 110.863 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -92.41 166.39 12.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.001 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -133.13 131.31 6.06 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.417 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.7 m -89.55 -62.06 1.56 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.798 0.332 . . . . 0.0 110.761 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 24.5 t -113.12 -40.81 3.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.033 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -86.31 158.63 31.56 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.464 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 30.8 p -143.6 99.51 3.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.871 0.367 . . . . 0.0 110.999 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . 0.404 ' CB ' ' CD ' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -72.98 -60.41 1.85 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.857 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . 0.404 ' CD ' ' CB ' ' A' ' 178' ' ' ARG . 63.2 Cg_endo -73.7 135.83 22.35 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.614 2.21 . . . . 0.0 112.301 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.7 101.55 12.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.833 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -66.09 130.06 41.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.896 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 64.12 137.2 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.393 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 1.6 ttp -162.06 109.17 1.35 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.758 0.313 . . . . 0.0 111.213 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.431 HD12 ' N ' ' A' ' 184' ' ' LEU . 3.7 mp -125.11 141.45 52.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.703 179.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.8 m -141.51 151.55 43.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.926 0.394 . . . . 0.0 111.345 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -114.81 132.06 56.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.342 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -149.25 167.5 29.58 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.326 -0.94 . . . . 0.0 113.002 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.2 m -127.57 139.81 50.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.65 0.262 . . . . 0.0 110.706 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 80.6 p -140.11 173.98 10.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.999 0.428 . . . . 0.0 111.241 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -148.0 151.28 35.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.724 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 -86.32 153.51 21.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -83.03 119.2 24.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.819 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -108.78 156.57 15.61 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.398 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -77.5 -32.03 53.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.792 0.329 . . . . 0.0 110.871 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -94.57 123.99 38.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.904 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.19 144.94 28.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.945 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -109.24 118.07 35.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.016 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -72.1 154.43 92.33 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.128 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.23 164.23 1.32 Allowed 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.572 2.181 . . . . 0.0 112.271 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.92 103.99 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.142 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 21.3 t -102.05 84.83 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.042 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -124.07 117.76 26.95 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.061 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -73.52 -39.07 2.14 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.415 2.076 . . . . 0.0 112.48 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -89.09 159.45 45.18 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.253 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -53.98 134.83 61.43 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.664 2.243 . . . . 0.0 112.371 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . 0.824 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -88.37 -63.5 0.21 Allowed Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.446 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.824 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 73.1 Cg_endo -76.12 161.94 34.86 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.44 2.093 . . . . 0.0 112.539 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.649 ' HB1' ' HD2' ' A' ' 209' ' ' PRO . . . -133.91 170.94 10.0 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.081 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . 0.649 ' HD2' ' HB1' ' A' ' 208' ' ' ALA . 51.8 Cg_exo -52.75 -31.23 50.08 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.475 2.117 . . . . 0.0 112.396 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.329 -0.844 . . . . 0.0 110.91 -179.964 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 120.773 0.32 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 39.6 mmt180 -136.94 -57.32 0.72 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.865 HD12 ' HB2' ' A' ' 6' ' ' ALA . 1.4 pt -75.03 113.52 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.095 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.5 tpt -102.49 39.73 1.47 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.873 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.3 tptm -150.0 36.86 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.838 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.865 ' HB2' HD12 ' A' ' 3' ' ' ILE . . . -95.18 -2.24 50.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.702 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.589 HG22 ' O ' ' A' ' 7' ' ' ILE . 22.1 mt -98.09 30.63 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.844 0.354 . . . . 0.0 111.138 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -142.89 22.09 1.94 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.094 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.552 ' C ' HD12 ' A' ' 10' ' ' LEU . 3.7 m -120.12 -32.75 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.348 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.552 HD12 ' C ' ' A' ' 9' ' ' VAL . 7.6 mp -133.47 87.51 2.39 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.843 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 35.1 m120 -75.65 118.2 18.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.978 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -81.8 -76.36 0.26 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.131 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -117.87 92.96 43.07 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.134 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -54.98 152.22 30.48 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.542 2.161 . . . . 0.0 112.255 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -107.21 -44.39 4.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 55.5 m-20 -77.96 101.57 6.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.916 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -87.1 -43.77 12.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.858 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.55 131.8 13.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.683 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 64.4 p-90 -150.33 148.74 29.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.974 0.416 . . . . 0.0 111.165 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.415 ' HB3' ' HA ' ' A' ' 191' ' ' ARG . 9.5 p90 -130.91 143.35 50.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.652 179.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.62 149.64 52.18 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.234 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.47 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.62 -159.98 19.1 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.779 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -132.19 142.36 13.8 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.349 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.423 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -127.67 140.34 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.97 0.414 . . . . 0.0 111.127 -179.86 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.684 HD13 ' HB2' ' A' ' 54' ' ' ALA . 19.2 tp -128.08 141.01 51.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.461 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.652 ' H ' HD12 ' A' ' 25' ' ' LEU . . . -173.11 -173.4 39.47 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.624 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 11.0 m0 -100.5 148.16 25.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.875 0.369 . . . . 0.0 110.858 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 32.2 p -117.69 175.37 5.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.84 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -151.64 90.69 1.58 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.873 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.451 ' CE2' ' CE ' ' A' ' 117' ' ' MET . 3.8 m-85 -133.82 106.03 7.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.909 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -107.73 121.52 44.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.849 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -136.31 31.71 2.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.2 p -101.27 -31.26 11.07 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.53 -116.08 5.42 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.483 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -151.67 128.83 11.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.866 0.365 . . . . 0.0 110.836 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -89.11 140.5 29.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.85 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.43 161.38 33.92 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.523 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -62.75 138.85 58.62 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.86 0.362 . . . . 0.0 110.892 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -110.25 179.86 20.52 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.476 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -74.39 -67.73 0.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -158.31 83.51 0.84 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.921 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -118.15 174.01 6.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.917 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 12.4 m-80 -129.3 163.24 26.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.932 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -122.08 165.99 15.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -81.95 -150.19 8.02 Favored Glycine 0 CA--C 1.519 0.285 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.493 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.11 171.43 0.18 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.564 2.176 . . . . 0.0 112.331 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.9 p -90.82 -55.12 3.68 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.938 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -87.33 146.08 26.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.931 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 -121.36 142.1 50.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.916 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -74.72 64.34 1.23 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.756 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -89.98 82.31 6.16 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.959 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.458 HD12 ' O ' ' A' ' 52' ' ' LEU . 2.9 pp -127.72 144.35 51.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.84 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.567 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -123.81 135.85 9.99 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.473 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.684 ' HB2' HD13 ' A' ' 25' ' ' LEU . . . -134.94 136.03 41.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.799 0.333 . . . . 0.0 110.878 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.403 ' CA ' ' O ' ' A' ' 72' ' ' TYR . . . -156.07 166.56 33.09 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.693 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.97 155.01 16.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.789 0.328 . . . . 0.0 110.706 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.455 ' CZ ' ' NH2' ' A' ' 113' ' ' ARG . 47.0 m-85 -143.69 132.49 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.934 0.397 . . . . 0.0 111.124 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -130.83 124.8 4.31 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.377 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -100.5 130.65 10.3 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.494 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -122.09 120.69 35.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.825 0.345 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.82 135.31 42.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.98 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 24.4 t -129.25 -47.26 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.833 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -117.94 146.22 38.54 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.589 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.4 67.9 0.7 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.434 2.09 . . . . 0.0 112.183 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.755 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.7 OUTLIER -167.21 -40.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.277 -179.888 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.755 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.4 OUTLIER -167.78 164.14 14.2 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.943 0.401 . . . . 0.0 111.317 -179.765 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -134.98 166.04 24.47 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.323 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -86.18 132.95 33.9 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.783 0.325 . . . . 0.0 111.069 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.727 ' HB3' HG23 ' A' ' 97' ' ' THR . 25.9 tt0 -109.98 112.09 23.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.171 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.0 mmt -108.28 111.98 24.21 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.945 179.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -118.37 163.74 12.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.35 -0.929 . . . . 0.0 113.104 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.403 ' O ' ' CA ' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -128.61 114.81 17.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.673 0.273 . . . . 0.0 110.471 179.701 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -79.69 129.63 34.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.416 -179.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -132.69 124.81 28.92 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.633 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.513 HD12 ' HA2' ' A' ' 53' ' ' GLY . 0.2 OUTLIER -141.64 173.19 11.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.924 -179.953 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -135.23 178.89 18.23 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.451 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 60.47 171.93 0.09 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.807 0.337 . . . . 0.0 110.887 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -176.17 -66.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.929 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.99 -169.95 0.15 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.112 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -106.87 -42.16 5.01 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.921 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 16.8 mmtm -139.87 31.12 2.03 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -165.72 84.5 0.1 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.528 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -145.34 31.29 1.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.748 0.309 . . . . 0.0 110.868 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.578 ' O ' HG23 ' A' ' 84' ' ' VAL . 29.5 m -107.93 71.58 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.096 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -118.08 -176.04 2.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.881 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -61.43 148.65 41.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.844 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.74 28.74 13.0 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.481 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -64.78 -59.54 4.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.837 0.351 . . . . 0.0 111.006 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -144.55 102.37 3.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 -67.69 0.85 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.827 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -175.17 161.29 2.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.236 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -145.11 128.88 17.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.617 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -94.68 131.64 10.8 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.87 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -113.52 121.8 66.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.28 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 17.7 mt-30 -108.79 134.6 51.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.037 0.446 . . . . 0.0 111.712 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.485 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -128.86 112.48 14.17 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.868 179.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.727 HG23 ' HB3' ' A' ' 69' ' ' GLU . 0.9 OUTLIER -151.1 162.47 40.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.077 0.465 . . . . 0.0 111.658 -178.932 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -100.9 122.37 43.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.041 179.102 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.417 ' HG2' ' HB2' ' A' ' 69' ' ' GLU . 0.0 OUTLIER -112.58 132.13 55.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.145 0.498 . . . . 0.0 112.071 -179.039 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.504 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.9 pp -122.49 128.39 50.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.807 178.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.442 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -119.96 -179.91 16.5 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.423 -0.894 . . . . 0.0 113.133 -179.201 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -166.08 125.84 1.2 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.763 -0.219 . . . . 0.0 110.664 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.01 163.7 32.7 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.553 2.169 . . . . 0.0 112.489 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.582 HG22 ' OG1' ' A' ' 105' ' ' THR . 22.8 mm -119.45 -69.87 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.769 179.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.582 ' OG1' HG22 ' A' ' 104' ' ' ILE . 0.0 OUTLIER -177.7 149.33 0.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.626 -179.994 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 66.16 -74.95 0.06 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.972 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.802 ' O ' HD23 ' A' ' 108' ' ' LEU . 10.1 p-10 -168.72 59.8 0.06 Allowed 'General case' 0 C--O 1.233 0.232 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.335 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.802 HD23 ' O ' ' A' ' 107' ' ' ASP . 0.1 OUTLIER -144.66 127.15 15.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.092 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -138.53 162.99 33.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.106 0.479 . . . . 0.0 111.722 -179.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.966 HG22 HG12 ' A' ' 149' ' ' VAL . 1.4 pt -114.81 157.06 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.28 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.442 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 96.3 m-85 -153.47 144.82 23.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.081 0.467 . . . . 0.0 111.73 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 38.8 p -142.48 126.96 17.8 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.167 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.503 ' HD3' HG21 ' A' ' 97' ' ' THR . 1.4 ppt_? -118.27 134.7 54.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.009 0.433 . . . . 0.0 111.78 -179.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.8 tt -133.63 122.9 24.13 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.078 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.403 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . -177.65 -132.95 1.76 Allowed Glycine 0 C--N 1.332 0.329 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.602 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.528 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.43 165.55 31.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.302 -0.951 . . . . 0.0 113.082 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.451 ' CE ' ' CE2' ' A' ' 30' ' ' TYR . 1.7 ptt? -120.44 140.99 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.922 0.392 . . . . 0.0 110.744 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.478 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.8 t -134.32 124.5 45.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.926 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.434 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 54.2 p-90 -139.14 161.01 38.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.925 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.638 ' HD3' HG22 ' A' ' 139' ' ' THR . 1.9 mmm-85 -138.18 130.59 29.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.861 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -141.74 142.65 33.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.058 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -151.93 162.04 41.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.896 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 8.3 t -93.86 47.2 1.21 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.816 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.8 33.56 3.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.894 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -99.64 -92.91 2.07 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.531 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -109.47 -31.25 7.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.855 0.36 . . . . 0.0 110.824 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -59.57 -36.97 77.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.934 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -94.97 110.98 22.82 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.002 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 15.0 p -143.4 -54.4 0.38 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.999 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.6 t -66.62 -39.86 88.52 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -179.69 166.87 36.38 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.504 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.587 HG13 ' O ' ' A' ' 132' ' ' VAL . 9.0 p -178.38 67.47 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.897 0.38 . . . . 0.0 111.06 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 3.9 t -101.32 -46.86 4.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.94 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -59.69 -31.22 69.37 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.93 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.2 t -91.61 110.81 22.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.897 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -85.62 177.08 7.83 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.905 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -76.3 175.88 8.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.81 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -144.29 149.29 36.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.022 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.638 HG22 ' HD3' ' A' ' 120' ' ' ARG . 20.8 p -131.74 141.77 49.61 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.995 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.434 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -119.87 123.0 5.47 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.499 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.4 p -146.11 130.5 11.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.752 0.311 . . . . 0.0 111.029 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 36.2 t -157.22 140.65 11.23 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.293 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.528 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.4 Cg_endo -80.65 148.15 17.83 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.73 2.286 . . . . 0.0 112.259 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 33.9 m -156.27 159.07 2.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.989 0.423 . . . . 0.0 111.492 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -149.1 123.54 9.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.499 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -112.36 145.32 40.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.838 0.352 . . . . 0.0 111.425 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.64 133.66 6.22 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.265 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -169.76 -149.99 6.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.556 -0.831 . . . . 0.0 113.023 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.966 HG12 HG22 ' A' ' 110' ' ' ILE . 13.8 m -135.23 168.78 22.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.813 0.34 . . . . 0.0 111.396 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.407 ' HB2' ' CD2' ' A' ' 111' ' ' TYR . 9.2 tt0 -131.6 136.61 47.91 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.881 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -125.14 131.59 53.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.033 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.519 ' HB3' ' HB2' ' A' ' 107' ' ' ASP . . . -91.53 137.2 32.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.074 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 62.2 t -112.34 -47.54 5.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.899 0.38 . . . . 0.0 110.86 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.08 -164.04 1.06 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.574 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.15 37.02 1.36 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.781 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . 0.444 ' HB3' ' CE2' ' A' ' 190' ' ' TYR . 0.4 OUTLIER 173.67 -28.39 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.405 179.953 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 7.5 mt -101.36 130.5 50.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.838 0.351 . . . . 0.0 110.988 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.47 160.18 38.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.187 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.1 m -100.96 153.34 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.45 124.99 29.68 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.294 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.1 tt -123.95 116.51 23.0 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.112 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.432 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 42.1 mt-10 -136.32 145.17 45.16 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.143 0.497 . . . . 0.0 111.45 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -123.48 166.01 16.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.625 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 8.5 mm-40 -99.42 -179.11 4.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . 0.404 ' CE3' ' HA ' ' A' ' 165' ' ' TRP . 0.2 OUTLIER -61.28 111.55 1.79 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.977 180.0 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 11.0 p -130.69 139.01 52.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.041 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 19.0 p30 -105.96 157.79 17.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.924 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -144.23 -47.43 0.26 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.861 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . 0.498 ' H ' HD12 ' A' ' 169' ' ' ILE . 3.3 mp -60.7 -60.23 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.157 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -75.53 159.14 51.02 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.385 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 6.1 p30 -109.41 151.91 26.05 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.821 0.344 . . . . 0.0 110.944 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -95.27 153.34 17.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -105.51 64.91 0.29 Allowed Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.489 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.2 p -148.69 -177.61 5.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.761 0.315 . . . . 0.0 110.919 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 16.1 m -85.05 136.32 23.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.111 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -163.37 163.14 35.4 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.532 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.9 m -109.9 -65.81 1.12 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.825 0.345 . . . . 0.0 110.881 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -119.07 78.98 17.62 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.888 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.67 84.96 0.77 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.484 2.122 . . . . 0.0 112.303 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -140.78 145.89 36.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.961 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 60.23 -178.97 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -137.68 -106.91 0.78 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.465 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 14.2 mtm -131.38 101.61 5.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.808 0.337 . . . . 0.0 110.972 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 5.9 mp -114.64 135.31 54.29 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.9 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -128.6 141.6 51.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.854 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -128.98 146.37 50.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.814 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . 0.423 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -163.42 -176.77 35.73 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.584 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.46 142.66 42.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.729 0.3 . . . . 0.0 110.825 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . 0.47 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 29.6 t -135.96 161.03 36.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.152 0.501 . . . . 0.0 111.857 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . 0.444 ' CE2' ' HB3' ' A' ' 156' ' ' ASP . 7.0 t80 -125.01 135.16 52.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.363 179.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.415 ' HA ' ' HB3' ' A' ' 20' ' ' TYR . 8.4 ptt180 -90.92 136.96 32.72 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.113 -179.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -142.01 151.52 42.54 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.837 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -144.28 171.01 25.86 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.558 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 56.8 mt-30 -90.46 132.72 35.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.874 0.369 . . . . 0.0 110.965 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -102.79 162.9 12.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.809 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -121.38 -65.47 1.13 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -95.41 115.56 27.6 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.065 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -129.84 69.43 81.62 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.148 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.42 91.98 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.588 2.192 . . . . 0.0 112.259 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 27.1 t -127.79 -52.27 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.158 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 5.5 m -120.81 113.42 39.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.133 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . 0.745 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -74.08 -60.77 1.41 Allowed Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.161 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.745 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 59.2 Cg_endo -72.61 160.58 46.18 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.478 2.119 . . . . 0.0 112.421 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . 0.74 ' HB1' ' HD2' ' A' ' 205' ' ' PRO . . . -100.87 166.63 12.11 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.12 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . 0.74 ' HD2' ' HB1' ' A' ' 204' ' ' ALA . 39.5 Cg_endo -66.98 111.77 2.3 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.605 2.203 . . . . 0.0 112.275 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -125.95 78.88 69.58 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.165 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.66 -35.76 9.48 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.533 2.156 . . . . 0.0 112.282 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.594 ' HB1' ' HD2' ' A' ' 209' ' ' PRO . . . -99.4 168.63 9.29 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.145 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . 0.594 ' HD2' ' HB1' ' A' ' 208' ' ' ALA . 54.3 Cg_exo -52.08 -51.45 11.13 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.461 2.107 . . . . 0.0 112.323 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.858 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.843 0.354 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 6.0 mtt180 -150.59 -73.59 0.16 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.839 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.9 pt -140.92 129.46 24.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.162 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 2.9 mtm -115.57 147.56 40.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.867 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.6 mttm -135.08 117.38 15.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.92 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -113.75 130.17 56.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 2.5 pt -106.33 179.57 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.13 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -102.96 133.71 47.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.896 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 9' ' ' VAL . 10.9 m -85.49 88.5 2.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.102 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -151.05 175.51 12.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -57.7 99.98 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.914 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -86.86 55.36 3.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.756 ' HB3' ' HD3' ' A' ' 14' ' ' PRO . . . -86.82 -52.57 0.42 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.088 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.756 ' HD3' ' HB3' ' A' ' 13' ' ' ALA . 31.4 Cg_exo -59.16 84.55 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.509 2.14 . . . . 0.0 112.125 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 19.1 mmtt -88.52 99.73 12.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.914 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -83.94 65.54 8.71 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.774 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -98.73 141.62 31.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.946 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.6 t -150.51 172.52 15.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.812 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.434 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 17.6 t90 -142.74 129.92 20.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.0 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.44 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 10.5 m-85 -119.69 135.91 54.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.833 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.57 139.98 35.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.073 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -171.1 -159.2 16.59 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.503 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -148.1 147.48 18.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.61 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.409 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 3.0 mttp -123.63 161.14 25.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.988 0.423 . . . . 0.0 111.031 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 2.5 tt -141.35 143.24 33.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.695 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.77 -163.37 27.18 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.55 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -104.8 140.25 38.37 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.88 0.372 . . . . 0.0 110.811 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.7 t -121.56 127.82 51.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.949 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -110.07 141.2 43.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.91 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -67.12 150.96 48.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.837 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -99.06 107.05 19.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.867 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 25.0 p30 -144.37 160.46 41.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.927 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 41.2 m -69.37 -47.53 64.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.988 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 94.99 44.58 3.28 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.508 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -98.73 32.24 2.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.92 0.39 . . . . 0.0 110.959 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -96.27 132.7 41.47 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.825 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.95 -94.13 0.9 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.486 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -86.0 126.85 34.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.769 0.319 . . . . 0.0 110.898 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -152.46 97.2 0.17 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.52 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -122.23 105.81 10.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.835 0.35 . . . . 0.0 110.906 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.74 124.01 28.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -86.09 92.21 8.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.875 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -102.27 131.02 49.1 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.904 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -127.02 70.66 1.29 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.864 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -129.98 160.12 22.8 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.53 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.21 -45.69 1.27 Allowed 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.6 2.2 . . . . 0.0 112.303 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.0 m -146.73 153.5 40.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.918 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.83 154.22 45.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.927 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -99.1 166.74 11.1 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.959 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -100.97 155.64 17.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.903 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -78.58 77.06 5.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.906 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 3.5 pp -90.97 134.9 34.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.85 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.02 143.5 14.89 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.612 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -129.24 153.68 47.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.721 0.296 . . . . 0.0 110.876 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.04 172.18 35.14 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.769 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.617 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -114.12 131.27 56.47 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.744 0.307 . . . . 0.0 110.887 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.402 ' CD1' ' HG3' ' A' ' 24' ' ' LYS . 30.0 m-85 -118.72 128.22 54.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.073 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.97 126.39 3.23 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.39 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -127.5 136.14 9.12 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.608 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.45 ' CZ ' ' CB ' ' A' ' 68' ' ' PHE . 42.1 p90 -134.25 130.62 37.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -100.91 136.8 40.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 34.5 t -111.92 -34.23 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.188 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 7.3 p-10 -128.63 153.79 79.59 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.87 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.63 65.4 1.21 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.54 2.16 . . . . 0.0 112.162 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -159.07 -44.99 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.001 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -174.35 164.08 3.83 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 167.69 21.75 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.45 ' CB ' ' CZ ' ' A' ' 60' ' ' TYR . 0.3 OUTLIER -85.56 131.86 34.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 110.749 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 3.3 tm-20 -113.09 119.86 39.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.089 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.17 123.48 47.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.555 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 148.43 17.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.571 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.617 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 40.8 m-85 -130.04 115.05 16.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.802 0.334 . . . . 0.0 110.614 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -92.38 120.84 33.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.993 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -127.69 115.2 18.36 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.588 HD12 ' N ' ' A' ' 75' ' ' LEU . 3.4 mp -106.33 124.51 49.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.821 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -74.85 -129.38 0.21 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.445 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 22.7 tpt180 59.95 104.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.847 0.356 . . . . 0.0 110.957 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.25 170.13 16.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.933 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -137.12 131.54 32.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.125 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -107.63 125.34 51.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.92 106.08 8.38 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.986 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.7 -72.89 0.89 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.407 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 4.1 t -83.61 -165.62 1.16 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.84 0.353 . . . . 0.0 110.844 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.41 ' O ' HG23 ' A' ' 84' ' ' VAL . 35.7 m -91.04 49.64 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.145 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -178.63 136.72 0.15 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.839 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -124.5 -44.56 1.98 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.93 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.22 -37.54 3.75 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.525 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -149.92 156.09 41.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.894 0.378 . . . . 0.0 111.109 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -117.4 -58.03 2.08 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.792 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -148.6 165.58 30.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.759 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -163.33 156.99 19.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.335 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -152.11 130.8 12.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.418 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -99.31 130.53 10.25 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.424 -0.893 . . . . 0.0 113.105 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.51 121.67 65.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 179.269 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -108.89 142.83 38.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.145 0.498 . . . . 0.0 111.8 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -132.3 110.62 10.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.738 179.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.481 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.8 p -150.85 167.39 27.64 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 120.932 0.396 . . . . 0.0 111.677 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -102.45 120.89 41.29 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.132 179.131 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.404 ' HB2' ' HB2' ' A' ' 69' ' ' GLU . 2.1 ttpm? -106.03 132.34 52.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.042 0.449 . . . . 0.0 111.909 -179.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.492 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.8 pp -135.87 128.35 30.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.281 179.305 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -150.25 -173.3 20.38 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.919 -179.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.816 ' CE2' HD11 ' A' ' 110' ' ' ILE . 30.4 p90 -166.17 143.12 4.31 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.585 0.231 . . . . 0.0 111.012 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -85.45 166.35 10.62 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.778 2.319 . . . . 0.0 112.941 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.601 ' O ' HG22 ' A' ' 104' ' ' ILE . 25.9 mt -138.4 37.13 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.779 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.482 HG22 ' H ' ' A' ' 106' ' ' ASP . 0.7 OUTLIER 63.63 173.71 0.17 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.64 -179.782 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.482 ' H ' HG22 ' A' ' 105' ' ' THR . 0.6 OUTLIER 63.41 20.74 12.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.192 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.549 ' HB3' ' HB3' ' A' ' 152' ' ' ALA . 33.0 m-20 61.93 46.23 6.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.137 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.487 HD23 ' CD1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER -137.43 130.31 30.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.302 179.639 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -144.76 158.4 43.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.966 0.413 . . . . 0.0 111.678 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.928 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 147.93 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.467 179.472 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.448 ' CZ ' ' HD3' ' A' ' 160' ' ' ARG . 17.7 p90 -142.33 143.32 32.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.11 0.481 . . . . 0.0 111.599 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 46.7 p -138.56 126.96 23.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.132 179.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.76 ' HG2' ' HB3' ' A' ' 146' ' ' ALA . 0.0 OUTLIER -121.2 138.48 54.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.982 0.42 . . . . 0.0 111.608 -179.241 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.49 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.8 tt -129.53 122.91 30.17 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.349 179.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.481 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -177.44 -141.76 4.22 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.723 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.526 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.19 169.13 25.89 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.434 -0.889 . . . . 0.0 112.843 -179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 14.7 tmm? -125.92 141.71 51.85 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 120.888 0.375 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -127.03 130.53 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.764 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.434 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 4.2 p-90 -137.79 173.72 11.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 111.035 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.99 134.76 40.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.831 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.666 ' HB3' ' HB3' ' A' ' 138' ' ' ASP . . . -87.95 156.13 19.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.118 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -145.01 145.82 31.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.817 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -60.5 -179.93 0.14 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.922 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.48 -34.46 9.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.988 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 179.98 -173.81 45.32 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.51 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -115.36 80.78 1.48 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.848 0.356 . . . . 0.0 110.797 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 26.4 t80 -117.78 -58.45 2.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.882 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -100.72 156.43 17.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.125 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 30.9 t -171.76 99.33 0.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -144.35 31.28 1.22 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.908 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -142.5 -157.56 7.2 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.509 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.534 HG13 ' O ' ' A' ' 132' ' ' VAL . 11.2 p -116.06 58.84 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.954 0.407 . . . . 0.0 111.016 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 40.1 t -116.7 33.99 5.3 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.934 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 34.1 mtt180 -60.78 -53.68 54.4 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.951 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 1.6 m -115.53 33.15 5.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.934 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -60.08 155.24 17.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.893 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 8.7 m80 -141.01 114.9 9.07 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.885 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.666 ' HB3' ' HB3' ' A' ' 121' ' ' ALA . 13.5 t70 -116.51 154.06 31.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.965 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.01 149.98 50.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.987 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.434 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -105.21 144.66 15.81 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.464 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.7 p -145.97 132.26 13.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.637 0.256 . . . . 0.0 111.074 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.437 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 4.5 p -157.11 131.85 5.28 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.368 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.526 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.5 Cg_exo -73.66 150.34 44.99 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.65 2.234 . . . . 0.0 111.791 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 27.1 m -156.28 163.53 1.41 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.26 0 CA-C-O 121.116 0.484 . . . . 0.0 111.84 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.49 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.9 t80 -137.07 118.76 15.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.245 179.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.76 ' HB3' ' HG2' ' A' ' 113' ' ' ARG . . . -103.63 126.72 50.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.929 0.395 . . . . 0.0 111.327 -179.636 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.57 124.88 3.61 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.176 179.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.75 -160.57 11.03 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.693 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.928 HG12 HG22 ' A' ' 110' ' ' ILE . 6.0 m -134.75 163.39 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.659 0.266 . . . . 0.0 110.915 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -127.71 142.54 51.3 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-O 120.918 0.39 . . . . 0.0 111.099 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . 0.487 ' CD1' HD23 ' A' ' 108' ' ' LEU . 7.6 t90 -126.57 119.16 26.42 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.66 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.549 ' HB3' ' HB3' ' A' ' 107' ' ' ASP . . . -90.59 137.23 32.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.388 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.8 t -114.22 -51.53 5.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.511 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 19.3 p -108.1 -175.55 2.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.3 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 12.5 mtm180 -91.84 45.22 1.21 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.917 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 173.61 -26.81 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.678 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 21.5 mt -115.35 123.26 70.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.887 0.375 . . . . 0.0 111.686 -179.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -135.63 155.93 49.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.994 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 1.7 t -117.63 140.56 49.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.094 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.448 ' HD3' ' CZ ' ' A' ' 111' ' ' TYR . 0.0 OUTLIER -134.59 151.58 51.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.328 0.585 . . . . 0.0 112.123 -179.33 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -113.12 124.8 53.43 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.725 179.093 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -106.89 145.13 32.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.985 0.421 . . . . 0.0 111.622 -179.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.672 ' CE2' HD21 ' A' ' 184' ' ' LEU . 0.8 OUTLIER -131.12 126.48 35.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.383 179.673 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? -54.63 -66.67 0.36 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.17 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -155.8 150.74 26.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.888 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.463 HG22 ' CE1' ' A' ' 163' ' ' TYR . 21.3 t -141.16 104.19 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.09 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.8 t-20 -64.23 125.39 24.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -111.94 -179.0 3.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.932 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 1.4 pt -71.11 92.18 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.064 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -142.78 66.25 0.47 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.441 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -158.2 163.02 37.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.797 0.332 . . . . 0.0 110.95 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -100.49 -54.39 2.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.11 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -78.87 -137.62 1.34 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.522 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.4 t -131.45 131.13 43.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.87 0.367 . . . . 0.0 110.901 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.4 t -109.04 -64.56 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.181 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -131.81 -128.6 2.95 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.506 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.95 -64.18 0.23 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.866 0.365 . . . . 0.0 110.899 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 12.4 mtt180 -123.7 102.8 35.04 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.822 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -68.32 148.26 73.63 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 122.323 2.015 . . . . 0.0 112.385 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -171.9 94.44 0.15 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -170.75 151.47 3.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 139.25 -164.01 25.94 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.575 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 8.3 tmm? -147.23 124.92 11.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.879 0.371 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.672 HD21 ' CE2' ' A' ' 163' ' ' TYR . 2.5 mp -114.04 137.33 51.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.771 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 18.3 p -136.76 155.78 49.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.068 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -119.33 133.06 55.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.461 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . 0.409 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -145.67 162.37 28.26 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.207 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.73 133.94 67.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.773 0.32 . . . . 0.0 110.402 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -136.14 175.09 9.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.943 0.401 . . . . 0.0 111.378 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -139.84 155.8 47.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.636 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.44 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -99.66 148.73 24.04 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.933 -179.915 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -95.35 136.63 35.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.831 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -154.76 175.21 32.92 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.645 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -123.02 83.42 2.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.836 0.351 . . . . 0.0 110.853 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -82.16 144.3 30.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.919 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -112.6 112.25 23.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.809 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -137.14 -54.94 0.71 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.184 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . 0.428 ' O ' HG13 ' A' ' 200' ' ' VAL . . . -110.99 96.37 29.28 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.189 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -54.23 88.13 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.523 2.149 . . . . 0.0 112.286 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . 0.428 HG13 ' O ' ' A' ' 198' ' ' ALA . 30.3 m -80.81 157.25 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.157 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 13.3 m -130.26 47.54 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.083 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -103.55 92.3 4.0 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.061 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.18 -27.08 29.67 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.531 2.154 . . . . 0.0 112.366 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.97 140.74 90.25 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.099 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.91 171.45 0.35 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.423 2.082 . . . . 0.0 112.33 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -90.35 -52.66 0.31 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 48.0 Cg_exo -56.09 84.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.614 2.209 . . . . 0.0 112.41 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.859 ' HB3' ' HD3' ' A' ' 209' ' ' PRO . . . -107.83 -57.83 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.454 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . 0.859 ' HD3' ' HB3' ' A' ' 208' ' ' ALA . 40.3 Cg_exo -57.05 -163.42 0.02 OUTLIER 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.327 2.018 . . . . 0.0 112.313 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.904 179.948 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.779 0.323 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -126.39 -46.28 1.63 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 24.1 pt -138.08 150.03 24.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.106 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -117.17 149.39 40.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.945 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.07 81.42 1.72 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.801 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -87.55 101.72 13.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.14 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.0 tt -72.04 -33.03 45.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.058 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -166.44 117.29 0.97 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.3 m -131.68 179.78 4.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.187 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -90.71 -24.78 20.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.047 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -56.98 150.82 16.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.977 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.29 104.31 3.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -91.68 122.35 65.76 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.986 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -68.87 -28.17 30.04 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.421 2.081 . . . . 0.0 112.394 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.18 53.86 2.02 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.889 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.3 p30 -89.31 15.95 8.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.481 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -67.13 138.45 57.07 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.804 0.335 . . . . 0.0 110.963 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.498 HG22 ' H ' ' A' ' 19' ' ' TRP . 0.5 OUTLIER -142.02 174.99 10.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.833 -179.961 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.498 ' H ' HG22 ' A' ' 18' ' ' THR . 13.3 p-90 -143.79 148.17 35.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.955 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.446 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.8 m-85 -119.97 140.0 51.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.709 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.35 139.98 47.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.384 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.15 -158.47 19.82 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.499 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -155.86 150.45 21.81 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.533 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 9.1 ptmm? -131.71 154.04 49.42 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.914 0.388 . . . . 0.0 111.07 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -128.29 148.89 50.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.675 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -167.36 -144.66 4.21 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.564 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 9.9 m-90 -116.85 144.12 44.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.852 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.2 m -145.37 138.9 26.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -154.39 109.46 3.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.913 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 14.3 p90 -112.83 35.82 3.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 47.0 t-80 -135.36 95.7 3.33 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -113.64 141.23 47.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.797 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 2.2 m -97.55 80.05 2.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.976 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.78 163.69 35.66 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.508 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -74.6 84.91 2.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.842 0.354 . . . . 0.0 110.859 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -113.87 86.65 2.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.859 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -91.77 47.46 2.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.55 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 53.9 t-20 -109.63 112.11 23.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.913 0.387 . . . . 0.0 110.866 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -59.38 -27.71 63.6 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.606 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -87.54 129.67 35.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.848 0.356 . . . . 0.0 110.867 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 20.6 mt-30 -160.13 115.41 2.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.81 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -84.15 -66.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -63.38 173.4 1.58 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.928 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 11.5 p30 -70.49 162.68 28.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.8 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -140.19 -141.61 4.06 Favored Glycine 0 CA--C 1.518 0.258 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.348 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.57 -20.67 53.47 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.453 2.102 . . . . 0.0 112.241 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.2 t -127.7 120.32 27.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.926 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -98.8 -59.1 1.8 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.844 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -99.82 164.66 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -74.59 132.36 41.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -117.39 155.22 29.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.875 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -134.09 151.59 51.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.98 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -136.28 145.04 16.94 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.515 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.38 144.4 34.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.781 0.324 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.426 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -150.55 130.85 3.36 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.747 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.765 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.91 145.67 24.75 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.689 0.28 . . . . 0.0 110.773 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -135.62 133.35 38.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.023 0.44 . . . . 0.0 111.425 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.82 125.04 1.89 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.849 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -134.39 164.36 24.58 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.934 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.404 ' CB ' ' HB3' ' A' ' 19' ' ' TRP . 48.5 p90 -143.91 134.04 24.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.897 0.38 . . . . 0.0 110.657 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -90.4 137.14 32.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 41.6 t -137.09 -47.8 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.798 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.437 ' HA ' ' HD3' ' A' ' 64' ' ' PRO . 81.4 m-20 -88.69 134.49 33.85 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.423 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 63' ' ' ASN . 22.5 Cg_exo -64.65 64.39 0.27 Allowed 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.516 2.144 . . . . 0.0 112.256 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.432 ' N ' ' O ' ' A' ' 63' ' ' ASN . 1.3 t80 179.62 -33.04 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.505 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -164.35 164.1 22.29 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.965 0.412 . . . . 0.0 111.325 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.75 177.1 18.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.294 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -98.04 142.37 29.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.653 0.263 . . . . 0.0 110.703 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -132.96 121.29 22.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.917 0.389 . . . . 0.0 111.07 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.16 129.32 53.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.421 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.01 156.91 15.35 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.636 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.765 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 40.0 m-85 -130.48 115.04 16.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.774 0.321 . . . . 0.0 110.463 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.83 120.48 30.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.186 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 -139.04 119.42 13.78 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.889 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -115.75 157.08 24.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.783 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -101.55 -56.98 0.84 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.468 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.4 mtp180 -121.07 145.97 47.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.842 0.353 . . . . 0.0 110.891 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.7 ptp -130.35 -49.62 1.09 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.967 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -172.84 -44.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.061 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -102.5 139.55 37.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.922 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 27.3 mtmt -99.21 148.85 23.68 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.82 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -68.87 109.68 3.02 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.512 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -157.61 -58.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.771 0.32 . . . . 0.0 110.913 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.567 ' O ' HG12 ' A' ' 84' ' ' VAL . 29.2 t -96.35 48.18 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.082 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -111.88 -176.26 2.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.92 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 23.6 p-10 -112.21 38.71 2.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.868 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 98.67 177.99 32.39 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.554 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -60.25 163.94 4.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 0.0 111.132 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -137.93 159.6 41.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.85 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 16.4 mtmt -89.91 125.89 35.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -174.66 143.33 0.77 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.247 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -175.18 136.68 0.38 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.645 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.36 128.47 8.5 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.666 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.66 117.96 51.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.641 0.258 . . . . 0.0 110.324 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -110.55 142.53 42.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.116 0.484 . . . . 0.0 111.72 -179.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.5 tt -129.06 110.23 11.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.483 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.523 HG22 ' HA3' ' A' ' 115' ' ' GLY . 5.1 p -148.2 174.66 11.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.235 0.541 . . . . 0.0 111.769 -178.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -111.55 135.24 52.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.304 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.66 132.13 55.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.918 0.389 . . . . 0.0 111.448 -179.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -132.18 131.69 42.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.587 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.38 -174.3 34.85 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.551 -0.833 . . . . 0.0 112.569 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.46 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -165.36 150.8 8.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.73 0.3 . . . . 0.0 110.925 -179.882 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.46 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 37.6 Cg_exo -60.74 165.44 11.74 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.709 2.272 . . . . 0.0 112.108 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.765 HG22 ' O ' ' A' ' 108' ' ' LEU . 0.5 OUTLIER -124.97 -31.06 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.558 -179.923 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.524 ' OG1' HG23 ' A' ' 104' ' ' ILE . 1.1 m -139.06 -65.95 0.48 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.805 0.336 . . . . 0.0 110.82 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -156.82 -50.49 0.07 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.79 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.761 ' C ' HD23 ' A' ' 108' ' ' LEU . 77.5 m-20 -125.15 30.91 5.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.819 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.765 ' O ' HG22 ' A' ' 104' ' ' ILE . 0.0 OUTLIER -140.89 117.63 10.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.014 179.965 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.405 ' HB3' ' HA ' ' A' ' 103' ' ' PRO . 3.0 p30 -131.64 160.26 35.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.032 0.444 . . . . 0.0 112.016 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.968 HG22 HG12 ' A' ' 149' ' ' VAL . 1.4 pp -116.07 141.25 34.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.133 179.332 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -156.69 160.28 39.18 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.103 0.478 . . . . 0.0 111.925 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 9.3 t -138.4 151.07 47.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.02 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.517 ' NE ' ' HB3' ' A' ' 146' ' ' ALA . 3.7 ppt_? -120.5 127.99 52.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.514 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.6 tt -125.75 122.67 36.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.127 179.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.523 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -179.59 -141.52 4.59 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.512 -0.851 . . . . 0.0 112.669 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.491 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.11 168.65 25.64 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.796 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.462 ' HE3' HG11 ' A' ' 144' ' ' VAL . 8.3 ptp -126.56 142.48 51.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.879 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -124.45 144.05 35.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.807 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.7 t90 -144.74 148.47 34.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.808 0.337 . . . . 0.0 110.974 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.09 131.44 50.1 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.946 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -135.58 147.23 48.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.103 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -150.77 157.95 43.56 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.952 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 2.4 t -129.07 33.84 4.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.959 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 4.3 tttm -120.42 83.87 2.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.838 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -143.61 -92.25 0.15 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.536 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 20.0 p30 -83.37 -175.58 5.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.88 0.371 . . . . 0.0 110.894 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 23.4 t80 -155.82 94.82 1.59 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.917 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -89.22 -67.89 0.81 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.33 -68.26 0.25 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 41.3 p -85.86 78.89 9.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.766 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . 0.505 ' O ' HG13 ' A' ' 132' ' ' VAL . . . -129.2 126.98 5.39 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.51 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.505 HG13 ' O ' ' A' ' 131' ' ' GLY . 5.3 m -158.04 104.79 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.824 0.345 . . . . 0.0 111.266 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.5 m -160.5 124.0 3.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.842 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 6.8 ttp85 -136.57 -66.26 0.54 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.33 31.37 6.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.878 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -110.15 88.56 2.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.898 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -92.71 131.32 37.88 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.88 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -117.53 149.36 40.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.829 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.3 m -140.91 137.85 33.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.978 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -97.61 99.31 2.22 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.536 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 141' ' ' VAL . 9.1 p -125.14 125.02 68.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.667 0.27 . . . . 0.0 110.964 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 3.0 p -157.05 148.65 17.12 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.335 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.491 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 72.4 Cg_endo -76.55 158.47 36.08 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.665 2.243 . . . . 0.0 112.084 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.462 HG11 ' HE3' ' A' ' 117' ' ' MET . 35.0 m -155.92 154.41 6.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.031 0.443 . . . . 0.0 111.52 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 59.4 t80 -149.15 118.66 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.416 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.517 ' HB3' ' NE ' ' A' ' 113' ' ' ARG . . . -129.37 147.48 51.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.94 0.4 . . . . 0.0 111.345 -179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.22 145.37 17.19 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.915 -0.659 . . . . 0.0 112.078 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -164.77 -171.03 30.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.799 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.968 HG12 HG22 ' A' ' 110' ' ' ILE . 3.4 m -129.56 148.95 33.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.746 0.308 . . . . 0.0 111.107 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -110.83 127.15 55.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . 0.449 ' NE1' HD22 ' A' ' 108' ' ' LEU . 5.3 t90 -128.61 120.29 26.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.757 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.56 ' HB3' ' HB3' ' A' ' 107' ' ' ASP . . . -84.57 132.92 34.46 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.354 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.1 t -107.22 -66.34 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.756 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . 0.413 HG22 ' H ' ' A' ' 155' ' ' ARG . 0.2 OUTLIER -79.94 174.57 11.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.843 179.874 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . 0.413 ' H ' HG22 ' A' ' 154' ' ' THR . 0.0 OUTLIER -72.25 -25.49 61.64 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.005 -179.981 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -135.11 27.64 3.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.186 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 18.6 mt -151.96 116.44 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.209 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -112.68 168.56 9.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.254 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 4.3 m -135.92 146.63 47.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.348 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 147.69 46.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.201 0.524 . . . . 0.0 111.902 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.2 tt -119.68 124.1 45.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.776 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -114.42 144.48 43.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.084 0.469 . . . . 0.0 111.592 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.43 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 18.7 p90 -134.14 155.17 50.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.494 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -105.0 -70.18 0.79 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.972 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -131.25 149.14 52.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.5 t -137.23 127.91 39.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -146.9 29.86 0.98 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.877 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -100.32 -59.36 1.72 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.958 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 14.8 pt -71.48 -30.42 39.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.086 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -128.81 127.35 5.57 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.514 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 41.1 m-20 -98.13 36.29 1.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.903 0.383 . . . . 0.0 110.934 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -96.79 101.89 13.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.077 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -159.64 129.89 2.32 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.488 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.39 -59.16 1.76 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.775 0.321 . . . . 0.0 110.824 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -141.95 78.61 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -139.3 -77.47 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.534 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 43.9 p -136.73 119.54 16.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.778 0.323 . . . . 0.0 110.93 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.75 -60.59 1.9 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.51 147.08 45.54 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.58 2.186 . . . . 0.0 112.248 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -91.05 104.83 17.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.957 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 10.5 m-20 -132.03 -67.12 0.68 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.909 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 68.79 151.37 0.38 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.452 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -134.71 100.05 4.5 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.91 0.386 . . . . 0.0 110.995 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.622 HD12 ' N ' ' A' ' 184' ' ' LEU . 3.6 mp -114.62 155.19 27.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.534 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 47.4 m -151.86 155.74 38.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.901 0.382 . . . . 0.0 111.264 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -118.26 135.77 54.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.366 179.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -147.92 167.24 28.84 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 119.967 -1.111 . . . . 0.0 113.139 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.3 m -123.74 145.07 31.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 67.4 p -152.29 174.98 13.14 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.055 0.455 . . . . 0.0 111.593 -179.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 36.7 t80 -145.16 152.37 39.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.541 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.419 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -95.81 144.32 26.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.878 -179.972 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . 0.427 ' HB3' ' CZ2' ' A' ' 19' ' ' TRP . 0.5 OUTLIER -149.59 135.48 18.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.789 179.968 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -142.36 128.21 3.45 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.544 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -120.78 144.67 48.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.863 0.363 . . . . 0.0 110.859 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -99.34 29.87 3.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.858 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -149.06 -69.89 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.884 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -69.78 67.71 0.26 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.105 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . 0.81 ' HB3' ' HD3' ' A' ' 199' ' ' PRO . . . -81.98 -62.22 0.33 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.398 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.81 ' HD3' ' HB3' ' A' ' 198' ' ' ALA . 61.5 Cg_endo -74.11 -46.43 0.3 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.416 2.077 . . . . 0.0 112.609 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 11.4 p -121.39 145.72 27.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.19 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . 0.453 ' O ' HG13 ' A' ' 201' ' ' VAL . 11.0 p -139.33 123.29 19.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.048 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -74.13 113.16 20.77 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.078 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -55.57 106.71 0.2 Allowed 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.421 2.08 . . . . 0.0 112.283 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -84.61 139.53 38.1 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.106 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.71 148.48 44.94 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.437 2.091 . . . . 0.0 112.355 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . 0.759 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -88.78 -52.98 0.36 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.182 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.759 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 48.1 Cg_exo -55.54 96.92 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.454 2.103 . . . . 0.0 112.36 179.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.722 ' HB1' ' HD2' ' A' ' 209' ' ' PRO . . . -145.51 165.96 19.43 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.041 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . 0.722 ' HD2' ' HB1' ' A' ' 208' ' ' ALA . 42.5 Cg_endo -67.8 -25.48 39.43 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.611 2.207 . . . . 0.0 112.251 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.941 179.99 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 120.822 0.344 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.6 ttp180 -153.94 37.82 0.45 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.862 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.6 mp -101.99 -64.0 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.083 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 5.9 ttt -134.08 118.7 18.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.843 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 4.0 mtpm? -90.44 57.62 3.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.831 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -110.3 119.46 39.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.108 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 32.3 pt -73.44 174.19 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.107 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 36.3 p90 -162.0 154.35 19.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.942 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 15.7 m -80.04 150.08 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.183 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.57 -42.99 2.72 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.918 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -74.83 132.69 41.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.991 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.02 -68.33 0.38 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.055 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -102.56 132.28 21.5 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.118 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.03 61.66 5.73 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.478 2.119 . . . . 0.0 112.306 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.5 mmtt -135.23 84.88 2.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.903 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -68.92 -58.38 4.22 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.817 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -79.47 111.49 15.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.928 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.8 m -118.13 149.9 40.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.839 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.44 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 27.0 m-90 -131.78 131.93 43.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.986 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -128.26 135.96 50.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.722 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.14 141.25 34.17 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.49 -166.6 33.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.546 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -156.01 150.07 21.28 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.42 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.0 OUTLIER -126.85 160.05 32.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.902 0.382 . . . . 0.0 111.157 -179.904 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -134.66 140.88 46.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.609 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -152.59 -175.04 23.7 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.499 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 5.6 m0 -95.83 144.29 26.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.826 0.346 . . . . 0.0 110.882 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -100.6 156.23 17.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.52 114.54 26.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.891 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 38.7 t80 -106.11 -50.45 3.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.2 t60 -113.81 179.97 3.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.846 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -103.75 -59.73 1.68 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.994 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.0 m -72.46 -56.88 4.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.898 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 96.97 -161.02 21.68 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.582 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -127.43 130.63 49.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.784 0.326 . . . . 0.0 110.918 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -143.56 152.02 40.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.858 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.48 136.78 13.06 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.562 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -98.85 -52.92 3.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.871 0.367 . . . . 0.0 110.872 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -150.0 -113.99 0.67 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.534 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -81.3 88.97 6.05 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.877 0.37 . . . . 0.0 110.914 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -125.44 113.46 17.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.894 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -71.77 78.69 0.85 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -123.7 83.97 2.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.876 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 -91.21 89.37 7.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.2 139.66 22.85 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.368 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -74.02 173.18 14.51 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.485 2.123 . . . . 0.0 112.371 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 70.6 m -73.6 78.91 1.48 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.909 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 2.0 mmm180 -151.8 160.66 43.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 29.2 m-20 -100.27 161.01 13.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.863 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.09 -58.59 3.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.897 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -163.57 135.54 5.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.872 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.0 pp -131.02 154.82 47.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.801 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -135.52 134.5 7.29 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.645 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.11 144.54 33.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.34 117.78 1.2 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.619 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.73 136.1 35.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.75 0.31 . . . . 0.0 110.667 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 22.4 m-85 -125.93 132.8 52.04 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.974 0.416 . . . . 0.0 111.186 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.57 125.04 1.78 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.201 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 69' ' ' GLU . . . -155.87 -173.42 24.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.858 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.44 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 1.9 p90 -147.96 158.31 43.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.756 0.312 . . . . 0.0 110.8 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 32.8 mt-30 -107.61 127.3 53.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.994 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 61.0 t -139.66 -41.42 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.069 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.445 ' CB ' ' HD2' ' A' ' 64' ' ' PRO . 6.5 m-80 -52.32 167.13 0.37 Allowed Pre-proline 0 CA--C 1.531 0.22 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.988 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.445 ' HD2' ' CB ' ' A' ' 63' ' ' ASN . 7.6 Cg_endo -49.9 -45.33 32.92 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.824 2.349 . . . . 0.0 112.97 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 27.3 t80 -150.0 50.82 0.91 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.863 0.364 . . . . 0.0 111.666 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.421 ' O ' ' HB2' ' A' ' 63' ' ' ASN . 3.6 pp -179.84 164.12 1.17 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.7 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -137.97 175.66 21.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.615 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -115.36 138.16 51.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.823 0.344 . . . . 0.0 110.648 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.418 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . 1.2 pt-20 -140.13 143.14 36.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.002 0.43 . . . . 0.0 111.198 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.2 mpp? -110.68 142.25 42.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.531 179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.95 158.24 14.6 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.617 -0.802 . . . . 0.0 112.441 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -130.83 114.79 15.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.678 0.275 . . . . 0.0 110.77 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.412 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.4 t0 -90.35 119.36 30.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.914 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -135.3 124.08 23.9 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.829 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 4.4 mt -98.89 -67.75 0.83 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.998 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 84.58 103.5 0.61 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.544 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.3 ttt-85 60.01 -176.7 0.1 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.743 0.306 . . . . 0.0 110.851 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -139.98 -78.27 0.31 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.957 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -178.5 -50.11 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.009 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -69.02 156.42 38.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 2.9 tttt -73.71 170.16 15.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.942 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 179.1 -176.77 48.14 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.503 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 5.3 t -120.5 105.45 10.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.832 0.349 . . . . 0.0 110.862 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.6 m -99.51 118.95 46.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.072 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -130.32 -77.45 0.54 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.994 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -99.94 -59.85 1.64 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.933 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -169.67 110.58 0.38 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.456 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -105.75 -39.25 6.12 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.809 0.337 . . . . 0.0 111.103 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -164.5 57.56 0.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.877 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -91.46 137.78 32.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.874 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -155.4 176.41 12.62 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.219 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.43 127.93 8.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.458 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.412 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -88.74 133.65 11.94 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.522 -0.847 . . . . 0.0 112.991 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.83 117.74 45.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -108.98 149.03 29.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.236 0.541 . . . . 0.0 111.875 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.6 tt -135.11 113.78 11.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.629 179.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 t -154.11 166.33 33.41 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.099 0.476 . . . . 0.0 111.638 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.34 134.57 50.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.481 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.59 130.18 54.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.315 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.557 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -135.25 124.27 24.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.537 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -166.89 -169.77 30.91 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.693 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -165.1 157.62 13.67 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.727 0.299 . . . . 0.0 111.112 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 109' ' ' ASP . 90.5 Cg_endo -78.44 170.97 17.6 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.787 2.325 . . . . 0.0 112.634 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 14.2 mm -102.4 -29.88 3.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.918 0.389 . . . . 0.0 110.539 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.22 -60.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.519 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 176.74 46.17 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.753 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 176.63 -31.65 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.219 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -105.45 120.46 41.67 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 7.5 t0 -125.39 147.68 49.08 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.382 0.611 . . . . 0.0 112.385 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -129.33 123.54 58.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.763 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -143.04 168.84 18.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.027 0.441 . . . . 0.0 111.559 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.427 HG22 ' HA3' ' A' ' 147' ' ' GLY . 31.0 p -141.15 140.26 34.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.548 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.7 ptt-85 -111.64 127.93 55.9 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.205 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.5 tt -124.83 125.02 43.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.623 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 176.94 -132.74 2.1 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.512 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -154.03 169.18 32.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.982 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.0 tmm? -125.94 144.47 50.67 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 120.682 0.277 . . . . 0.0 110.639 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t -130.63 129.65 64.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.914 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.402 ' CZ2' ' HB3' ' A' ' 73' ' ' ASP . 0.2 OUTLIER -126.13 135.31 51.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 -179.934 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.442 ' HA ' HG22 ' A' ' 139' ' ' THR . 55.3 mtt180 -130.68 148.37 52.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.886 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -138.0 162.65 33.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.07 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -147.57 128.22 14.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.996 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -108.15 53.96 0.67 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.84 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -100.16 87.15 3.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -134.86 -172.49 12.78 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.518 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 6.0 p30 -111.26 91.29 3.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.873 0.368 . . . . 0.0 110.92 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -157.38 76.17 0.82 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -77.85 177.62 8.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.07 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 32.3 m -126.98 -65.61 0.94 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.904 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 43.2 p -146.7 -70.16 0.25 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.95 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -165.3 48.22 0.28 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.428 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 14.7 m -125.03 133.93 68.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.846 0.355 . . . . 0.0 111.118 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -110.38 121.64 45.78 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.955 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.67 152.55 42.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.774 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -122.32 130.68 53.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.943 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -124.06 119.2 28.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.848 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -123.33 125.08 44.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 20.2 m-20 -121.23 117.84 28.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.944 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.442 HG22 ' HA ' ' A' ' 120' ' ' ARG . 6.9 p -139.6 126.81 21.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.938 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -117.08 113.03 2.63 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.459 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.2 p -131.3 123.53 53.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.791 0.329 . . . . 0.0 111.036 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 38.1 m -157.24 148.18 16.47 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.387 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.512 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.5 Cg_endo -78.0 147.96 24.4 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.766 2.311 . . . . 0.0 112.049 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.11 158.38 3.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.988 0.423 . . . . 0.0 111.52 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -145.88 119.93 9.43 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.418 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -120.97 163.95 17.47 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.904 0.383 . . . . 0.0 111.396 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.427 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -140.7 148.42 20.06 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.246 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.37 -171.99 31.3 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.514 -0.85 . . . . 0.0 112.705 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.8 m -131.98 167.05 27.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.669 0.271 . . . . 0.0 111.08 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -134.64 151.49 51.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.946 0.403 . . . . 0.0 111.291 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 4.6 m-90 -133.06 117.61 17.77 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.582 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.432 ' HA ' ' HB2' ' A' ' 158' ' ' ALA . . . -81.68 122.46 27.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.422 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 56.4 t -116.17 -63.24 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.957 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . 0.516 HG22 ' H ' ' A' ' 155' ' ' ARG . 1.1 m -80.61 174.17 11.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.925 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . 0.516 ' H ' HG22 ' A' ' 154' ' ' THR . 0.0 OUTLIER -60.04 -34.81 73.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.029 -179.885 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -147.36 38.75 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.108 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.4 mt -148.87 100.84 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.072 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.432 ' HB2' ' HA ' ' A' ' 152' ' ' ALA . . . -113.25 167.91 10.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.288 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 2.4 t -123.27 143.3 50.15 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.261 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.09 147.19 45.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.13 0.49 . . . . 0.0 111.783 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -113.95 126.11 54.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.806 179.043 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.7 138.51 45.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.385 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -134.19 156.18 48.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.664 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -124.57 46.73 2.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.929 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . 0.428 ' CE3' ' HA ' ' A' ' 165' ' ' TRP . 0.0 OUTLIER -81.79 86.07 6.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 11.1 p -70.55 144.21 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.029 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 70.2 m-20 -89.84 139.98 30.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.937 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -133.8 118.59 18.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.89 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 10.8 pt -82.4 -179.87 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.078 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -137.63 35.78 2.02 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.482 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -107.65 -40.01 5.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.887 0.375 . . . . 0.0 110.903 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -112.7 143.31 44.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -141.47 28.69 2.31 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.402 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 4.4 m -101.79 34.65 2.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.766 0.317 . . . . 0.0 110.899 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 13.7 m -133.13 169.05 22.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.153 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -63.91 -153.97 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.562 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 2.7 t -121.39 122.33 39.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.794 0.33 . . . . 0.0 110.838 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 6.6 mtt-85 -84.21 154.68 63.51 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.99 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.92 106.09 0.73 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.623 2.215 . . . . 0.0 112.238 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -99.63 35.97 1.88 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.912 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -80.44 -46.43 15.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.939 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 64.12 141.15 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.458 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . 0.596 ' C ' HD12 ' A' ' 184' ' ' LEU . 2.9 tpp -162.0 142.91 10.62 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.816 0.341 . . . . 0.0 111.017 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.605 HD12 ' N ' ' A' ' 184' ' ' LEU . 4.2 mp -125.88 157.35 37.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.629 179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.22 155.46 37.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.01 0.433 . . . . 0.0 111.285 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -115.24 131.87 56.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.169 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . 0.42 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -146.15 168.06 27.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.367 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -127.59 141.01 47.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -144.57 174.98 10.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.043 0.449 . . . . 0.0 111.522 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -146.15 155.67 42.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.712 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 1.6 ptp180 -110.08 149.06 30.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -77.18 120.58 22.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.927 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -154.51 134.81 4.42 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.428 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.05 86.08 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.758 0.313 . . . . 0.0 110.787 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -98.88 -177.78 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.001 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -78.79 -64.18 1.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.981 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -98.01 169.58 9.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.13 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -143.99 77.1 14.86 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.048 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -80.73 3.91 7.36 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.657 2.238 . . . . 0.0 112.879 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . 0.575 ' O ' HG13 ' A' ' 200' ' ' VAL . 10.7 p -74.39 64.02 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.875 0.369 . . . . 0.0 111.093 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 7.8 m -100.58 125.96 54.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.161 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -70.6 111.39 9.43 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.159 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.94 61.94 1.85 Allowed 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.402 2.068 . . . . 0.0 112.329 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . 0.813 ' HB3' ' HD3' ' A' ' 205' ' ' PRO . . . -81.03 -62.0 0.37 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.189 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . 0.813 ' HD3' ' HB3' ' A' ' 204' ' ' ALA . 74.0 Cg_endo -75.33 157.51 41.36 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.499 2.132 . . . . 0.0 112.439 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . 0.76 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -87.14 -53.0 0.41 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.211 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.76 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 75.5 Cg_exo -50.69 120.37 6.41 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.6 2.2 . . . . 0.0 112.361 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -99.47 105.92 36.32 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.079 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.35 148.66 74.29 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.473 2.115 . . . . 0.0 112.284 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.192 -0.909 . . . . 0.0 110.891 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.297 0 CA-C-O 120.815 0.34 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . 0.595 ' C ' HD12 ' A' ' 3' ' ' ILE . 0.4 OUTLIER -123.58 28.84 6.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.945 179.992 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.595 HD12 ' C ' ' A' ' 2' ' ' ARG . 3.6 mp -145.78 109.72 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.183 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -168.55 142.57 3.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.901 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.7 mmtt -92.21 -69.29 0.75 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.968 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -90.36 156.7 18.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.124 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.9 mt -123.3 -43.79 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.004 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -140.1 117.39 11.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.805 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.6 m -84.19 -31.14 7.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.092 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.594 HD13 ' N ' ' A' ' 11' ' ' ASN . 0.2 OUTLIER -71.41 135.54 47.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.848 -179.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.594 ' N ' HD13 ' A' ' 10' ' ' LEU . 19.9 m-20 -60.35 113.67 2.52 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -118.6 -50.01 2.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.051 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.67 151.07 93.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.096 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.89 -175.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.582 2.188 . . . . 0.0 112.369 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -88.57 174.23 8.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.904 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -70.01 -62.48 1.37 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.871 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 -68.58 165.75 18.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.887 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.7 t -161.93 151.97 16.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.92 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -118.29 130.74 56.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.857 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -126.06 135.88 52.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.799 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.23 153.85 44.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.17 -165.28 37.91 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.42 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -160.54 151.51 22.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.532 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.405 ' HA ' ' CA ' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -133.05 157.91 44.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 0.0 111.034 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -127.46 146.19 50.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.7 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -147.85 -172.06 17.5 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.546 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 5.0 p-90 -132.93 131.13 40.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.848 0.356 . . . . 0.0 110.94 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 10.6 t -159.97 121.24 3.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.949 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -159.3 128.19 5.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.936 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -67.3 87.7 0.18 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.905 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -130.35 167.21 18.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.853 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -126.71 -176.01 3.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.841 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 51.1 m -110.97 -68.84 0.9 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.956 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.79 104.59 0.72 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.488 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -79.82 83.1 5.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.927 0.394 . . . . 0.0 110.897 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -112.06 -34.29 6.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.89 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -134.6 108.6 0.72 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.46 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -76.27 -31.15 58.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.864 0.364 . . . . 0.0 110.871 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -70.82 -173.73 15.14 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.536 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.18 149.06 23.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.834 0.35 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 9.9 mt-30 -94.53 149.65 21.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.935 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -99.57 101.33 12.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -138.67 137.39 36.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.7 t30 -143.51 31.59 1.33 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.954 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -105.23 -148.48 17.52 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.529 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -68.57 160.67 48.36 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.539 2.159 . . . . 0.0 112.245 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 63.1 m -131.75 84.99 2.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -73.32 146.32 45.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.927 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.4 p30 -105.55 158.94 16.33 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.953 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -80.64 -178.21 6.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.87 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -97.24 129.28 44.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.934 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.495 HD22 ' N ' ' A' ' 52' ' ' LEU . 3.4 mm? -98.81 172.84 7.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.81 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.66 132.29 10.64 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.488 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.14 52.07 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.69 0.281 . . . . 0.0 110.948 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.5 135.46 7.44 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.737 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.487 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -103.75 135.64 44.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.781 0.324 . . . . 0.0 110.882 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -119.41 133.69 55.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.206 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -157.27 125.55 1.59 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.389 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -146.18 -178.65 21.78 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.69 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 14.3 p90 -153.35 160.81 42.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.843 0.354 . . . . 0.0 110.927 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -102.38 137.09 41.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.798 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.604 ' O ' HG12 ' A' ' 62' ' ' VAL . 16.3 t -129.21 21.02 2.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.232 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 175.73 144.51 0.23 Allowed Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.603 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -69.31 63.74 1.53 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.429 2.086 . . . . 0.0 112.119 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.444 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.2 OUTLIER -160.98 -43.29 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.084 -179.872 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.444 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.4 OUTLIER -171.62 164.02 6.68 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.093 -179.79 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.23 169.8 21.05 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.439 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.6 m-85 -98.75 138.74 35.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.63 0.253 . . . . 0.0 110.817 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -125.95 129.55 49.49 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.952 0.406 . . . . 0.0 110.965 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -111.11 129.31 55.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.424 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.27 17.43 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.362 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.487 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 81.5 m-85 -125.61 114.85 19.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.748 0.309 . . . . 0.0 110.676 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.448 ' HB2' ' CZ2' ' A' ' 119' ' ' TRP . 0.3 OUTLIER -87.15 118.28 26.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.758 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -132.63 137.43 47.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.968 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.562 HD13 ' HA ' ' A' ' 79' ' ' ALA . 0.2 OUTLIER -106.14 -31.62 8.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 179.988 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 129.13 -100.65 0.51 Allowed Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.472 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 21.6 mmt180 -120.6 -55.35 2.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.763 0.316 . . . . 0.0 110.892 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.1 ttm -114.91 128.8 56.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.562 ' HA ' HD13 ' A' ' 75' ' ' LEU . . . -59.31 -69.02 0.22 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.018 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 80' ' ' TYR . 1.5 p90 -144.48 -55.52 0.34 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.912 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.6 mttp -166.08 170.78 13.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.866 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 176.92 167.94 36.14 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.473 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -68.89 163.81 23.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.75 0.31 . . . . 0.0 110.81 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 84' ' ' VAL . 11.6 p -94.58 45.63 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.999 0.428 . . . . 0.0 111.067 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -102.84 -176.91 3.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.985 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 -79.42 122.9 26.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.943 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 160.0 158.2 9.06 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.645 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -129.37 -163.53 1.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.674 0.273 . . . . 0.0 110.966 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -109.54 -54.48 2.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.828 0.347 . . . . 0.0 110.825 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 46.08 40.76 7.56 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.313 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.28 163.87 13.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.41 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -168.68 127.7 1.12 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.374 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.439 ' HA3' ' HB2' ' A' ' 73' ' ' ASP . . . -83.92 133.73 12.12 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.017 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.85 117.98 51.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.8 0.333 . . . . 0.0 110.208 179.355 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 -108.98 138.11 45.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.109 0.481 . . . . 0.0 111.728 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.441 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.7 tt -127.6 107.24 9.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.696 179.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.651 HG22 ' HA3' ' A' ' 115' ' ' GLY . 27.0 p -144.68 162.05 37.65 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 121.158 0.504 . . . . 0.0 111.796 -178.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -92.92 126.5 38.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.006 178.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -104.87 130.98 52.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.029 0.442 . . . . 0.0 111.845 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.51 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.8 pp -136.29 123.78 22.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 179.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -157.21 177.46 34.06 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.636 -0.793 . . . . 0.0 112.507 -179.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.439 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -166.19 153.95 9.4 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.733 0.302 . . . . 0.0 111.344 -179.925 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.439 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 38.1 Cg_exo -60.6 172.04 3.04 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.76 2.306 . . . . 0.0 112.05 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.653 HG23 HG23 ' A' ' 105' ' ' THR . 0.9 OUTLIER -125.26 -38.36 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.477 -179.934 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.653 HG23 HG23 ' A' ' 104' ' ' ILE . 56.6 p -140.34 -55.96 0.53 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -159.3 -63.28 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.206 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.813 ' C ' HD23 ' A' ' 108' ' ' LEU . 1.0 OUTLIER -113.22 29.8 7.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.219 -179.784 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.813 HD23 ' C ' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -138.21 121.33 16.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.031 179.73 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -135.03 160.09 39.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.05 0.452 . . . . 0.0 111.722 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.914 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.93 144.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.209 179.359 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -142.26 141.82 32.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.008 0.432 . . . . 0.0 111.527 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.443 HG23 ' HG ' ' A' ' 100' ' ' LEU . 9.6 t -137.15 126.91 25.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.199 179.347 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.403 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 0.0 OUTLIER -114.41 131.6 56.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.913 0.387 . . . . 0.0 111.511 -179.358 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.0 tt -128.06 122.93 33.35 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.451 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.651 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -175.82 -135.45 2.12 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.622 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.509 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.12 161.7 26.4 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.462 -0.875 . . . . 0.0 112.899 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.47 138.63 54.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.716 0.293 . . . . 0.0 110.705 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -129.57 134.68 63.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.448 ' CZ2' ' HB2' ' A' ' 73' ' ' ASP . 0.9 OUTLIER -138.54 131.97 30.41 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.975 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 2.0 tpp180 -104.4 134.02 48.31 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.872 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -108.69 134.78 50.95 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.159 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -113.91 146.66 39.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -137.75 134.08 34.86 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 34.1 mttt -137.09 150.63 48.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 179.99 174.9 46.26 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.499 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -113.03 78.57 1.14 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.856 0.36 . . . . 0.0 110.867 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -172.75 106.1 0.16 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -141.36 170.59 15.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.074 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.3 t -99.85 -65.46 0.96 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.904 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.4 t -173.56 -50.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.92 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -105.58 -80.28 1.35 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.433 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 132' ' ' VAL . 32.9 m -113.77 120.69 64.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.784 0.326 . . . . 0.0 111.141 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.6 m -65.39 169.79 5.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.009 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.24 -31.19 62.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 56.1 m -65.39 145.69 55.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.866 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -122.36 166.19 15.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.935 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -105.69 127.75 53.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -118.28 151.73 37.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.902 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 42.9 p -125.68 123.34 38.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.871 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -84.98 108.22 3.15 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.418 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.8 p -136.42 128.35 44.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.621 0.248 . . . . 0.0 110.993 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.4 m -157.1 144.72 13.92 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.337 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.509 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 90.9 Cg_endo -80.73 139.99 12.76 Favored 'Trans proline' 0 C--N 1.347 0.482 0 C-N-CA 122.752 2.302 . . . . 0.0 112.115 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 143' ' ' PRO . 30.3 m -157.04 162.84 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 121.002 0.43 . . . . 0.0 111.504 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.407 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.9 p90 -142.35 121.12 12.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.45 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -105.74 141.16 37.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.976 0.417 . . . . 0.0 111.402 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -132.59 135.03 7.88 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.994 179.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -159.68 -171.99 26.26 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.895 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.914 HG12 HG22 ' A' ' 110' ' ' ILE . 4.4 m -131.12 150.98 35.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.663 0.268 . . . . 0.0 111.138 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -122.32 133.99 54.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.169 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 9.4 m95 -121.76 122.17 38.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.649 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.621 ' HB3' ' HB3' ' A' ' 107' ' ' ASP . . . -78.77 137.01 37.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.406 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 72.8 t -101.71 -30.08 3.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.682 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.66 -70.62 0.69 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.792 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 177.75 -36.23 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.958 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -103.89 -26.96 12.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.326 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 5.2 mt -116.73 122.83 70.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.809 0.338 . . . . 0.0 111.226 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -132.5 161.85 32.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.375 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 9.7 t -117.72 143.98 45.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.965 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -137.0 150.87 48.39 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.204 0.526 . . . . 0.0 112.158 -179.232 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.7 tt -114.39 123.87 50.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.585 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -107.83 139.54 42.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.986 0.422 . . . . 0.0 111.557 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.429 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 36.3 p90 -134.14 160.15 38.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.723 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -58.1 -49.99 75.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.058 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 21.1 t-105 -179.59 -39.27 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.696 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 16.6 m -137.07 167.83 22.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.153 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -109.77 -37.67 5.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.832 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -100.06 140.12 34.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.824 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . 0.466 HG22 ' N ' ' A' ' 170' ' ' GLY . 31.2 mt -138.84 157.69 29.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.094 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . 0.466 ' N ' HG22 ' A' ' 169' ' ' ILE . . . -69.36 130.56 23.89 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.776 -0.725 . . . . 0.0 112.582 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -112.81 -54.89 2.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.879 0.371 . . . . 0.0 110.905 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.13 80.29 0.96 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.096 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -172.06 -71.31 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.505 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.0 p -132.76 108.39 8.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.929 0.395 . . . . 0.0 110.981 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 10.7 p -159.6 146.96 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.0 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -168.11 -70.8 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.555 -0.831 . . . . 0.0 112.705 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 17.3 p -112.1 -18.77 12.51 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.599 0.238 . . . . 0.0 111.471 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 48.1 ttt180 -108.49 100.83 40.07 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.666 -0.243 . . . . 0.0 111.113 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -63.4 -158.82 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.568 2.179 . . . . 0.0 112.103 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -111.13 97.55 6.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.88 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -95.86 149.24 21.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.929 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -145.27 160.74 28.11 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.497 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . 0.434 ' C ' HD12 ' A' ' 184' ' ' LEU . 50.2 mtt -108.33 96.92 6.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.904 0.383 . . . . 0.0 111.011 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.434 HD12 ' C ' ' A' ' 183' ' ' MET . 6.3 mp -132.94 126.4 31.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.65 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 11.0 p -142.53 158.91 43.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.73 134.64 54.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 24' ' ' LYS . . . -149.29 172.62 29.31 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.004 -1.093 . . . . 0.0 113.404 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.65 141.37 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.677 0.275 . . . . 0.0 110.388 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 32.8 p -139.55 171.48 14.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.42 . . . . 0.0 111.268 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 17.4 p90 -148.03 157.51 43.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.776 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.87 147.71 22.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.95 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -137.3 168.96 18.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.952 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -147.1 174.56 26.86 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.606 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -103.36 -177.45 3.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.816 0.341 . . . . 0.0 110.875 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -73.79 134.88 43.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.846 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -72.05 -31.3 66.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.943 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -97.4 47.45 1.03 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.116 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -119.62 83.82 28.9 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.081 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.13 149.69 20.97 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.559 2.173 . . . . 0.0 112.287 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . 0.457 HG13 HG22 ' A' ' 201' ' ' VAL . 12.4 p -116.15 -38.01 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.147 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . 0.571 ' O ' HG23 ' A' ' 201' ' ' VAL . 16.6 m -132.84 94.05 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.218 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . 0.755 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -89.91 -53.39 0.32 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.157 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.755 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 50.8 Cg_exo -52.87 176.63 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.507 2.138 . . . . 0.0 112.307 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -100.78 123.83 44.24 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.068 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.01 122.06 7.8 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.405 2.07 . . . . 0.0 112.408 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . 0.814 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -77.2 -61.42 0.68 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.108 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.814 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 74.5 Cg_endo -75.16 65.44 6.2 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.495 2.13 . . . . 0.0 112.355 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -140.4 147.82 51.21 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.131 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.67 -177.95 2.78 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.513 2.142 . . . . 0.0 112.338 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 . . . . . 0 C--O 1.248 0.975 0 CA-C-O 118.243 -0.884 . . . . 0.0 110.965 179.927 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 120.846 0.355 . . . . 0.0 111.052 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.2 ptp85 -159.79 172.92 16.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.823 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.525 HD11 ' CE1' ' A' ' 8' ' ' PHE . 6.6 pt -138.45 163.43 28.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.086 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 3.9 tmm? -114.98 41.89 2.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.917 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.53 157.95 25.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.892 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -90.74 -49.41 6.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.148 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -87.67 135.26 25.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.081 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.525 ' CE1' HD11 ' A' ' 3' ' ' ILE . 1.8 m-85 -99.03 137.29 37.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.921 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 9' ' ' VAL . 27.5 m -74.95 111.07 10.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -118.49 61.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.847 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 15.0 p30 -89.01 53.16 2.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.975 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -153.6 173.25 16.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.152 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.33 87.95 36.79 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.053 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_exo -66.25 65.07 0.48 Allowed 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.774 2.316 . . . . 0.0 112.274 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -110.99 -27.87 8.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.025 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -85.97 54.85 3.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.966 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -108.05 -177.8 3.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.882 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.7 p -122.9 135.46 54.51 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.885 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -121.94 145.39 48.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.405 ' CE2' ' HG3' ' A' ' 191' ' ' ARG . 89.6 m-85 -142.16 135.98 29.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.569 ' HB3' ' CE1' ' A' ' 190' ' ' TYR . . . -144.41 140.02 28.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.122 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.08 -161.11 26.09 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.384 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.85 147.27 17.1 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.56 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.72 153.81 35.07 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.923 0.392 . . . . 0.0 110.906 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.462 HD12 ' O ' ' A' ' 53' ' ' GLY . 55.7 tp -136.7 138.61 41.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.649 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.72 -161.66 24.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.604 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -87.03 140.26 29.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.812 0.339 . . . . 0.0 110.868 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.6 p -91.84 170.88 9.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 -155.71 127.39 7.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.958 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.419 ' HH ' ' HZ3' ' A' ' 119' ' ' TRP . 0.2 OUTLIER -109.83 -172.92 2.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.813 -179.941 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 5.0 p-80 -106.35 154.24 21.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.842 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -129.43 144.15 51.13 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.858 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 68.7 p -103.49 -66.61 0.93 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.845 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 103.03 76.09 1.12 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.531 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -107.36 -62.62 1.4 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.946 0.403 . . . . 0.0 110.879 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -129.58 75.58 1.66 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.852 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.56 158.98 23.99 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.586 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -120.73 166.13 14.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.859 0.361 . . . . 0.0 110.835 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -135.78 48.01 0.95 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.486 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -122.23 166.93 13.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.772 0.32 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -85.63 89.23 7.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.951 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 26.6 p30 -103.18 174.0 6.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -88.11 120.62 29.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.949 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 7.1 t30 -130.89 163.39 27.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.903 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.74 -102.65 1.37 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.529 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.55 159.46 6.43 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.474 2.116 . . . . 0.0 112.338 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.4 p -135.27 105.71 6.4 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.41 90.68 2.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 20.5 m-20 -110.48 -31.01 7.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -78.01 137.05 38.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.888 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 15.0 mt-30 -132.3 144.51 50.63 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.439 HD13 ' HA ' ' A' ' 52' ' ' LEU . 3.9 mm? -110.91 139.57 46.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.077 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.462 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -140.88 132.78 5.55 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.33 179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -117.78 142.86 46.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.806 0.336 . . . . 0.0 111.137 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.419 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -143.17 134.73 6.07 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.67 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.641 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.9 140.28 30.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.739 0.304 . . . . 0.0 110.837 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.41 ' CD1' ' HG2' ' A' ' 69' ' ' GLU . 0.2 OUTLIER -126.45 134.31 51.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.935 0.398 . . . . 0.0 111.126 -179.777 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -161.62 126.42 1.58 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.254 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -158.55 -166.2 17.24 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.653 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 49.4 p90 -151.21 146.56 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.879 0.371 . . . . 0.0 110.989 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -110.2 129.3 55.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.756 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 36.4 t -118.27 -39.32 2.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.078 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -84.53 149.26 54.15 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.848 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_exo -51.54 -26.72 22.96 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.555 2.17 . . . . 0.0 112.347 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.465 ' CE2' HD13 ' A' ' 100' ' ' LEU . 0.9 OUTLIER -148.81 43.23 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.921 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -159.12 115.79 2.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.932 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 158.38 23.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.483 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -105.28 129.03 53.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.632 0.253 . . . . 0.0 110.62 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.41 ' HG2' ' CD1' ' A' ' 57' ' ' PHE . 5.0 tt0 -122.54 128.46 50.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.86 0.362 . . . . 0.0 111.149 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.3 ttt -108.96 127.0 53.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.538 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 163.92 12.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.742 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.641 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 95.5 m-85 -138.18 114.85 10.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.735 0.302 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.24 120.27 25.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.023 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -136.13 123.89 22.51 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.832 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -118.27 -36.37 3.58 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.073 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 78.1 -162.05 49.58 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.393 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.5 tpt180 -165.6 149.03 7.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.909 0.385 . . . . 0.0 110.95 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 30.6 ttm -100.65 33.43 2.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.862 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -91.4 159.52 15.94 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.175 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -115.71 -174.58 2.55 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.774 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.43 28.08 2.71 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.042 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -110.56 26.25 13.49 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.394 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 52.2 p -158.07 -176.2 5.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.735 0.302 . . . . 0.0 110.824 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.6 m -138.75 120.89 17.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 120.953 0.406 . . . . 0.0 111.125 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -137.41 -81.52 0.36 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 -143.11 26.11 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.05 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 87.06 -138.11 15.21 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.48 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -122.43 -73.39 0.65 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.896 0.379 . . . . 0.0 111.159 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -80.68 77.55 7.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -113.23 -30.54 6.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.0 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -96.42 129.39 43.79 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.974 0.416 . . . . 0.0 111.366 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -168.77 124.86 0.95 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.302 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -115.1 141.01 16.76 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.203 -179.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.11 128.11 67.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 179.175 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 145.29 35.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.135 0.493 . . . . 0.0 111.855 -178.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -140.08 116.14 10.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.742 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -153.01 165.43 35.6 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.211 0.529 . . . . 0.0 111.809 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -99.19 133.42 43.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.358 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 9.5 pttt -112.79 132.33 55.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.515 -179.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.542 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.9 pp -136.08 122.33 20.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.534 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.31 -176.73 37.14 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.663 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.424 ' HB2' ' HD2' ' A' ' 103' ' ' PRO . 30.3 p90 -166.18 157.61 11.75 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 120.657 0.265 . . . . 0.0 111.009 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.424 ' HD2' ' HB2' ' A' ' 102' ' ' TYR . 19.9 Cg_endo -60.4 167.48 7.87 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.599 2.2 . . . . 0.0 111.813 179.623 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.666 HG22 ' O ' ' A' ' 108' ' ' LEU . 0.8 OUTLIER -128.72 -5.36 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.568 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 24.3 m -164.04 -64.22 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.832 0.348 . . . . 0.0 110.878 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -168.11 -42.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.979 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.485 ' C ' HD23 ' A' ' 108' ' ' LEU . 0.6 OUTLIER -127.61 27.12 5.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.072 179.894 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.666 ' O ' HG22 ' A' ' 104' ' ' ILE . 0.0 OUTLIER -142.63 117.88 10.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.936 179.875 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -127.43 155.91 42.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.983 0.42 . . . . 0.0 111.925 -178.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.055 HG22 HG12 ' A' ' 149' ' ' VAL . 1.5 pp -125.18 136.35 61.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.369 179.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 37.8 p90 -150.14 159.35 44.49 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 121.106 0.479 . . . . 0.0 111.494 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.407 HG22 ' HA3' ' A' ' 147' ' ' GLY . 36.8 p -130.86 149.22 52.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.479 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.1 ppt_? -123.75 127.85 48.72 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.87 0.367 . . . . 0.0 111.394 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -127.89 122.74 33.29 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.205 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -179.47 -133.18 1.91 Allowed Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.735 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.1 169.12 33.64 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.809 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -126.02 143.7 51.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.823 0.344 . . . . 0.0 110.906 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.3 t -124.89 125.23 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.839 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.419 ' HZ3' ' HH ' ' A' ' 30' ' ' TYR . 19.7 m0 -102.76 157.16 17.15 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.904 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.401 ' NH1' ' HB3' ' A' ' 120' ' ' ARG . 6.6 mtm105 -146.73 149.28 33.11 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.028 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -119.43 148.02 43.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.114 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -117.88 139.26 51.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.924 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.18 131.97 56.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.817 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -175.24 -40.59 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.929 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -56.72 -100.21 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.569 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -118.96 94.89 4.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.723 0.296 . . . . 0.0 110.926 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -176.65 165.71 2.59 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.863 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -59.79 96.91 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.03 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.7 m -153.18 99.92 2.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.876 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 9.1 t -119.25 -44.01 2.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.912 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -76.91 126.86 8.15 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.457 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 27.8 m -98.42 31.09 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.823 0.344 . . . . 0.0 111.173 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 1.6 t -124.91 -49.83 1.72 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.931 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.07 128.15 42.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.969 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.1 m -152.47 97.4 2.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.939 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -70.19 118.81 13.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.834 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 22.7 p80 -113.34 179.95 3.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.881 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -87.97 118.12 27.3 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.907 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 4.2 t -106.35 135.59 47.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.86 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -112.95 141.98 17.16 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.457 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.5 p -146.07 129.97 10.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.749 0.309 . . . . 0.0 111.286 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 54.4 p -157.02 130.6 4.69 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.152 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.489 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 88.9 Cg_endo -78.23 146.94 22.84 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.548 2.165 . . . . 0.0 112.152 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 32.6 m -156.09 151.11 9.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.872 0.368 . . . . 0.0 111.442 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 13.2 p90 -149.08 124.27 10.15 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.501 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.543 ' HB2' ' HG3' ' A' ' 164' ' ' GLN . . . -134.91 167.04 21.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.979 0.418 . . . . 0.0 111.447 -179.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.407 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -133.76 146.14 18.12 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.007 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -155.39 -179.83 30.82 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.356 -0.926 . . . . 0.0 112.901 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 1.055 HG12 HG22 ' A' ' 110' ' ' ILE . 11.4 m -128.42 153.31 37.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.828 0.347 . . . . 0.0 110.994 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -122.12 139.74 53.37 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.203 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -128.48 118.48 23.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.804 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.413 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -82.24 137.01 34.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.23 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 84.6 t -107.24 -70.01 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -78.3 -79.49 0.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.735 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.66 -40.98 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.091 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -108.39 -23.36 11.92 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.439 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.3 mt -104.5 128.82 57.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.801 0.334 . . . . 0.0 111.274 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.04 155.67 46.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.383 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 6.4 t -102.5 145.73 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.299 179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.24 139.09 40.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.068 0.461 . . . . 0.0 111.823 -179.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -115.74 130.48 56.87 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.754 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.25 142.58 39.91 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.047 0.451 . . . . 0.0 111.626 -179.256 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.489 ' CZ ' HD21 ' A' ' 184' ' ' LEU . 0.1 OUTLIER -134.14 130.68 37.68 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.372 179.582 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . 0.543 ' HG3' ' HB2' ' A' ' 146' ' ' ALA . 5.6 mp0 -98.21 -79.85 0.46 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.12 -179.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -92.3 124.39 36.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.927 0.394 . . . . 0.0 111.009 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 31.3 m -80.76 142.73 13.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.093 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -116.5 142.68 46.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.927 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -122.99 138.69 54.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.954 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 20.9 pt -70.04 -28.47 36.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.192 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -58.5 -54.79 34.88 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.492 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -129.48 102.09 6.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.84 0.352 . . . . 0.0 110.847 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.86 -37.81 67.26 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -162.85 74.79 0.18 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.531 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.0 t -99.75 31.88 3.07 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.852 0.358 . . . . 0.0 110.905 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 3.1 m -140.67 179.48 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.108 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -105.73 49.91 0.86 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.561 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -104.32 150.82 24.13 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.845 0.355 . . . . 0.0 110.829 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . 0.42 ' HB2' ' HD3' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -82.32 -52.05 0.73 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.957 -179.984 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . 0.42 ' HD3' ' HB2' ' A' ' 178' ' ' ARG . 71.2 Cg_exo -50.88 119.31 5.11 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.502 2.135 . . . . 0.0 112.209 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.48 144.52 37.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.018 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 60.97 173.63 0.1 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -103.64 -131.45 7.24 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.429 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 20.7 tpp -162.0 128.52 3.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.841 0.353 . . . . 0.0 110.973 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.528 HD12 ' N ' ' A' ' 184' ' ' LEU . 0.7 OUTLIER -129.54 129.18 44.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.696 179.821 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.9 m -125.43 151.01 46.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.104 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.47 128.44 52.11 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.414 179.712 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -145.7 167.24 27.67 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.997 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.7 m -129.56 137.34 57.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.659 0.266 . . . . 0.0 110.588 179.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 86.7 p -139.88 175.06 9.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.953 0.406 . . . . 0.0 111.318 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . 0.569 ' CE1' ' HB3' ' A' ' 21' ' ' ALA . 3.8 p90 -141.66 159.92 41.23 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.812 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.405 ' HG3' ' CE2' ' A' ' 20' ' ' TYR . 0.4 OUTLIER -103.86 155.48 18.59 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.851 179.967 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -82.91 134.94 35.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.886 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -112.6 -167.65 17.37 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.549 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.98 142.48 27.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.762 0.315 . . . . 0.0 110.925 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -86.38 -43.99 12.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -88.53 131.02 35.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.913 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -111.32 145.96 37.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.096 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -168.82 75.61 0.77 Allowed Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.079 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.29 93.39 0.57 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.532 2.155 . . . . 0.0 112.337 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . 0.512 ' O ' HG12 ' A' ' 200' ' ' VAL . 21.6 t -114.97 48.69 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 5.7 m -119.21 135.47 59.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.177 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . 0.729 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -67.58 -61.38 4.5 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.729 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 49.5 Cg_endo -69.28 124.13 10.97 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.564 2.176 . . . . 0.0 112.24 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -77.06 148.27 78.19 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.027 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.54 150.76 51.98 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.562 2.175 . . . . 0.0 112.336 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -88.92 158.59 47.15 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.011 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -51.92 -61.46 0.51 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.534 2.156 . . . . 0.0 112.352 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.722 ' HB1' ' HD2' ' A' ' 209' ' ' PRO . . . -109.29 166.61 10.47 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . 0.722 ' HD2' ' HB1' ' A' ' 208' ' ' ALA . 53.0 Cg_endo -69.48 169.08 19.39 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.587 2.191 . . . . 0.0 112.281 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.815 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.34 0 CA-C-O 120.853 0.359 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . 0.679 ' HG3' HG22 ' A' ' 3' ' ' ILE . 12.4 ptm180 -103.07 -33.32 9.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.993 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.679 HG22 ' HG3' ' A' ' 2' ' ' ARG . 5.6 tt -169.51 138.44 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.06 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 12.9 ptp -153.73 130.67 10.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.878 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -130.48 -46.38 1.08 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.739 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -66.64 101.98 0.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.098 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 mt -78.17 -58.85 3.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.077 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -157.64 156.47 31.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.901 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 9' ' ' VAL . 31.3 m -64.77 118.61 7.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.079 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.6 tp -161.99 -67.75 0.05 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.878 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 22.9 m120 -86.15 122.25 29.89 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.91 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -78.12 -57.24 3.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.089 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -114.87 145.89 34.94 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.087 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -54.97 -33.22 81.98 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.53 2.153 . . . . 0.0 112.227 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.4 55.49 1.73 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.957 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -79.23 -30.04 43.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.712 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 70.2 m-80 -66.0 -174.69 0.26 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.94 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 13.6 p -108.88 156.2 19.95 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.775 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.423 ' CZ2' ' HB2' ' A' ' 192' ' ' PHE . 70.2 p-90 -149.6 132.3 15.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.987 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.445 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.5 m-85 -114.38 141.15 48.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.55 141.64 28.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.884 0.373 . . . . 0.0 111.278 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 189' ' ' SER . . . -171.21 -166.55 30.21 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.879 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -134.3 141.76 13.12 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.466 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.515 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 6.3 ptpt -128.84 149.72 50.63 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.078 0.466 . . . . 0.0 111.412 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.79 HD12 ' O ' ' A' ' 53' ' ' GLY . 47.4 tp -126.46 150.11 48.89 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.511 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.567 ' H ' HD12 ' A' ' 25' ' ' LEU . . . -172.8 -160.66 21.79 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.342 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -78.92 147.41 33.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 0.0 110.917 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.6 t -102.64 -61.54 1.38 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.931 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -147.34 125.87 12.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -106.02 33.95 3.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.936 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -128.04 153.28 46.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -82.75 79.44 9.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.863 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.1 m -67.78 146.82 53.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 102.17 -144.58 16.3 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.464 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -72.31 158.4 35.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.852 0.358 . . . . 0.0 110.886 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -128.84 -45.84 1.28 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.859 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -109.27 -35.04 2.38 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.561 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 25.2 m120 -90.6 112.34 24.0 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 176.98 155.81 14.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.499 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -120.62 159.08 26.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.834 0.35 . . . . 0.0 110.899 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -157.35 100.99 1.85 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.923 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -95.98 -57.15 2.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.936 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -136.41 96.88 3.45 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.91 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -118.87 142.97 47.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.917 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.439 ' O ' HG23 ' A' ' 47' ' ' THR . . . -135.95 75.83 0.39 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.569 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -52.33 102.71 0.07 OUTLIER 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.645 2.23 . . . . 0.0 112.288 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.439 HG23 ' O ' ' A' ' 45' ' ' GLY . 74.5 p -94.72 -41.36 9.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.957 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 43.0 mtt180 -137.13 83.31 1.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -97.86 37.48 1.4 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.971 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -111.22 83.01 1.69 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.851 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 56.9 mt-30 -61.85 111.47 1.9 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.865 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 3.6 pp -126.73 142.4 51.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.79 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -125.4 143.88 14.78 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.413 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -118.05 170.02 9.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.688 0.28 . . . . 0.0 110.932 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.58 157.34 27.67 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.783 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.533 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -108.97 140.58 42.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 110.876 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.403 ' HE2' ' HZ2' ' A' ' 24' ' ' LYS . 3.0 m-85 -126.48 128.76 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.031 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.65 124.99 2.2 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.254 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.13 172.26 23.0 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.763 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -140.11 160.49 39.83 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.827 0.346 . . . . 0.0 110.786 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -113.35 130.38 56.29 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.908 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 42.0 t -131.87 -45.43 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.07 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 68.4 m-80 -86.34 156.1 56.94 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.789 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_endo -61.55 -24.37 77.96 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.596 2.197 . . . . 0.0 112.283 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -150.15 45.85 0.9 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.706 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -162.81 115.76 1.63 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.831 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -121.23 161.56 15.25 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.584 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -114.08 134.7 54.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.779 0.323 . . . . 0.0 110.696 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.401 ' OE2' ' CD1' ' A' ' 57' ' ' PHE . 2.0 tt0 -129.95 129.93 44.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.918 0.389 . . . . 0.0 111.085 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 ttm -108.01 135.43 49.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.422 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.94 158.52 14.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.512 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.533 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 19.9 m-85 -138.0 115.02 10.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.646 0.26 . . . . 0.0 110.657 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.417 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 2.2 t0 -87.97 121.09 29.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.88 0.372 . . . . 0.0 110.924 -179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 21.3 t-105 -136.76 132.75 35.21 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.977 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.45 ' C ' HD23 ' A' ' 75' ' ' LEU . 6.0 tt -83.5 -66.0 0.94 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.939 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 155.76 -138.9 6.26 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.497 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.5 ttm105 -84.3 -52.19 6.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.8 0.333 . . . . 0.0 110.879 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.17 90.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.815 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -127.21 -43.39 1.64 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.18 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 62.5 m-85 -57.05 95.24 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -110.99 157.01 20.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.862 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.83 107.04 0.25 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.551 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.4 t -146.05 -47.41 0.2 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.818 0.342 . . . . 0.0 110.886 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.5 t -96.85 -45.75 12.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.125 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 6.6 t0 -168.39 138.08 2.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.895 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -81.65 98.67 8.48 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.914 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -140.55 46.55 0.92 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.451 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -140.89 138.37 33.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.869 0.366 . . . . 0.0 111.158 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 39.9 m-85 -143.85 -68.03 0.33 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.9 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.11 132.14 55.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.774 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -151.67 154.37 36.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.212 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.0 tt0 -175.05 130.3 0.3 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.534 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.417 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -85.26 135.76 13.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.926 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.42 120.33 57.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 179.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -108.95 148.51 30.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.154 0.502 . . . . 0.0 111.744 -179.096 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 tt -138.13 114.04 9.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.703 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.423 HG22 ' HA3' ' A' ' 115' ' ' GLY . 8.6 p -149.72 164.45 35.22 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-O 121.054 0.455 . . . . 0.0 111.764 -178.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -97.52 132.28 43.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.314 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.86 132.23 53.66 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.036 0.446 . . . . 0.0 111.643 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.569 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.4 pp -135.93 124.07 23.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.431 179.322 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.96 -169.86 30.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.711 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.456 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 2.9 t80 -160.62 145.17 10.59 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.69 0.281 . . . . 0.0 111.12 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.456 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 95.3 Cg_endo -86.48 172.09 7.1 Favored 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 122.884 2.389 . . . . 0.0 112.479 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.423 ' O ' HG22 ' A' ' 104' ' ' ILE . 17.7 mt -142.28 62.67 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 121.032 0.444 . . . . 0.0 111.262 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 8.1 p 56.71 172.99 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.511 179.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.6 t70 60.77 -87.13 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.043 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.867 ' HB3' ' HB3' ' A' ' 152' ' ' ALA . 0.3 OUTLIER -179.87 36.79 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.075 0.464 . . . . 0.0 110.739 -179.991 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.61 HD22 ' CE2' ' A' ' 151' ' ' TRP . 0.0 OUTLIER -121.67 115.77 23.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.149 179.888 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -131.38 155.11 47.83 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.031 0.443 . . . . 0.0 111.893 -179.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.956 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -119.91 146.82 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.271 179.351 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.441 ' CE2' ' HB2' ' A' ' 150' ' ' GLU . 4.4 p90 -162.44 164.01 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.103 0.478 . . . . 0.0 111.763 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.409 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 17.4 m -140.54 139.77 35.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.497 179.737 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.401 ' HB3' ' NH1' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -114.96 127.99 56.01 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.152 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.3 tt -127.79 122.91 33.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.44 179.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.423 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.89 -134.54 2.15 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.536 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.489 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -149.42 163.06 29.19 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.417 -0.897 . . . . 0.0 112.751 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.9 ppp? -117.64 145.03 44.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 110.917 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.7 t -127.05 141.79 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.861 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 3.5 t90 -131.65 148.88 52.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.003 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 20.1 ttt180 -118.54 152.23 36.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -163.19 149.19 11.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.001 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -107.37 131.1 54.62 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.964 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -98.45 101.09 12.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.855 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.71 169.95 15.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.831 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -129.22 -174.16 13.63 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.455 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -70.08 -31.77 69.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.812 0.339 . . . . 0.0 110.894 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -85.3 158.85 20.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.868 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -115.34 76.31 0.99 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.135 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.1 m -84.14 120.63 26.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.922 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 23.4 p -143.05 123.69 14.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.865 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -135.49 -96.67 0.51 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.519 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 16.8 m -142.87 30.82 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 111.19 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 18.7 t -120.47 166.8 13.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.905 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.03 155.48 17.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.939 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.93 165.95 23.46 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.809 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -87.65 143.2 27.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.841 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -116.68 112.73 21.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.898 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -116.0 132.52 56.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.958 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 69.7 p -136.71 129.78 31.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -89.53 135.23 12.84 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.433 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p -132.65 136.12 56.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.714 0.293 . . . . 0.0 111.015 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -153.02 117.33 2.84 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.347 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.489 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 6.3 Cg_exo -73.65 137.62 25.3 Favored 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 122.605 2.203 . . . . 0.0 111.85 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 143' ' ' PRO . 26.4 m -156.96 164.03 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.862 0.363 . . . . 0.0 111.386 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -148.59 122.37 9.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.796 179.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.52 142.85 45.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.173 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 112' ' ' THR . . . -134.34 142.12 13.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.299 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -170.55 -157.69 13.12 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.257 -0.973 . . . . 0.0 113.107 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.956 HG12 HG22 ' A' ' 110' ' ' ILE . 4.9 m -129.83 163.25 35.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.843 0.354 . . . . 0.0 111.127 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.441 ' HB2' ' CE2' ' A' ' 111' ' ' TYR . 0.7 OUTLIER -133.19 129.38 37.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.936 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . 0.61 ' CE2' HD22 ' A' ' 108' ' ' LEU . 1.4 t-105 -118.43 132.55 56.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.792 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.867 ' HB3' ' HB3' ' A' ' 107' ' ' ASP . . . -99.36 134.43 42.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 0.0 111.528 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.681 ' O ' HG12 ' A' ' 153' ' ' VAL . 47.8 t -116.06 39.92 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.751 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . 0.424 HG22 ' H ' ' A' ' 155' ' ' ARG . 0.2 OUTLIER 59.08 -175.84 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.218 179.692 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . 0.534 ' HB3' HD12 ' A' ' 157' ' ' ILE . 1.3 mtt-85 60.8 26.26 16.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.126 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 56.33 22.83 6.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.245 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.534 HD12 ' HB3' ' A' ' 155' ' ' ARG . 5.7 mt -125.47 109.65 22.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.073 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.425 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -115.88 154.26 30.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.342 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.99 151.53 22.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.247 179.499 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 2.1 ptm180 -136.93 132.76 34.89 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.9 0.381 . . . . 0.0 111.897 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.838 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 1.1 tt -123.61 120.79 33.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.734 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.435 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 0.7 OUTLIER -116.34 145.12 43.44 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.606 -179.043 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.838 ' CZ ' HD22 ' A' ' 161' ' ' LEU . 2.1 m-85 -126.76 165.81 18.58 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.551 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -120.38 145.38 47.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.938 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 5.6 t-105 -97.12 135.41 39.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.585 HG11 ' HB3' ' A' ' 181' ' ' ASN . 17.2 m -140.22 31.97 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.1 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -117.3 153.92 32.12 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -98.0 -62.9 1.18 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.898 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 170' ' ' GLY . 2.3 pp -154.93 -46.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.163 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . 0.656 ' N ' HD12 ' A' ' 169' ' ' ILE . . . -130.71 -178.25 15.34 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.35 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -95.87 129.79 43.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.842 0.353 . . . . 0.0 110.933 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -93.71 -45.52 7.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.007 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -78.96 162.69 48.77 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.509 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.2 p -105.49 -30.69 9.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.899 0.38 . . . . 0.0 110.915 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 12.3 p -116.08 141.73 32.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.036 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -145.32 110.93 0.57 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.508 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.97 -54.58 1.72 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.833 0.349 . . . . 0.0 110.844 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 1.1 mtp180 -93.67 143.13 26.07 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.939 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.85 128.0 14.46 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.489 2.126 . . . . 0.0 112.185 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -107.41 -33.26 7.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.825 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . 0.585 ' HB3' HG11 ' A' ' 166' ' ' VAL . 63.3 m-80 -145.96 151.35 37.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.834 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 120.16 151.58 8.78 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.391 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . 0.614 ' C ' HD12 ' A' ' 184' ' ' LEU . 8.9 ttm -143.05 122.1 12.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.78 0.324 . . . . 0.0 110.971 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.614 HD12 ' C ' ' A' ' 183' ' ' MET . 6.7 mp -114.71 133.36 55.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.779 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.2 m -132.59 145.8 51.4 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.111 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.91 137.84 49.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.568 179.705 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . 0.515 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -158.8 -176.65 31.09 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.449 -0.881 . . . . 0.0 113.042 -179.569 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -126.16 141.86 44.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.637 0.256 . . . . 0.0 110.52 179.474 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . 0.46 ' HA ' ' HA3' ' A' ' 22' ' ' GLY . 1.4 t -137.93 159.72 41.24 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.112 0.482 . . . . 0.0 111.576 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -117.81 146.42 43.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.41 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.26 143.64 45.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . 0.423 ' HB2' ' CZ2' ' A' ' 19' ' ' TRP . 60.3 m-85 -148.29 123.99 10.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.878 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -149.38 167.07 29.64 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.538 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -116.51 170.47 8.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -98.23 169.16 9.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -59.91 -169.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.859 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -97.69 35.38 1.68 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.031 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -124.05 136.15 27.19 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.992 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.483 ' HG2' ' HB3' ' A' ' 202' ' ' ALA . 74.2 Cg_endo -75.4 -167.82 0.47 Allowed 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.489 2.126 . . . . 0.0 112.253 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 10.6 m -92.91 -30.58 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.088 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 29.3 t -74.13 -32.89 33.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.981 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . 0.483 ' HB3' ' HG2' ' A' ' 199' ' ' PRO . . . -89.21 157.49 47.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.08 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.438 ' HD2' ' HB1' ' A' ' 202' ' ' ALA . 49.9 Cg_endo -69.04 134.97 30.89 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.517 2.145 . . . . 0.0 112.222 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . 0.766 ' HB3' ' HD3' ' A' ' 205' ' ' PRO . . . -78.54 -52.65 1.35 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.174 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . 0.766 ' HD3' ' HB3' ' A' ' 204' ' ' ALA . 31.6 Cg_exo -59.13 -159.64 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.482 2.121 . . . . 0.0 112.115 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -103.34 139.71 20.37 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.963 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.84 90.05 0.74 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.471 2.114 . . . . 0.0 112.35 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -89.17 145.17 33.7 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.093 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.38 94.9 0.84 Allowed 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.53 2.153 . . . . 0.0 112.338 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.24 -0.886 . . . . 0.0 110.887 179.975 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 120.789 0.328 . . . . 0.0 111.052 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.79 31.25 6.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.905 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 30.6 mt -144.74 145.53 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.155 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -167.69 128.93 1.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.83 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -72.56 131.24 42.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.827 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -110.98 96.25 6.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.18 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.1 tt -148.68 36.47 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.979 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -117.28 -40.25 3.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.859 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 31.2 m -137.14 142.25 37.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.078 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -139.44 -47.39 0.47 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.945 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -71.43 120.39 16.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.941 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -138.02 36.88 2.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.031 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -90.24 112.05 50.43 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.077 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -54.87 -176.6 0.04 OUTLIER 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.304 2.003 . . . . 0.0 112.324 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 27.8 mttm -95.94 80.94 3.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.939 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -87.72 152.72 21.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.827 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -103.8 100.51 10.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.872 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.98 130.09 55.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.822 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -121.19 146.97 46.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.917 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.421 ' CD1' ' HB2' ' A' ' 189' ' ' SER . 0.1 OUTLIER -142.35 135.81 29.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.724 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 145.22 31.03 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.336 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.72 -168.9 38.65 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.566 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -137.0 147.04 19.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.546 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.435 ' HE3' ' CE2' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -121.2 153.14 37.98 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.832 0.348 . . . . 0.0 110.922 -179.924 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.1 tt -133.43 139.34 46.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.723 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -165.1 -172.37 32.48 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.577 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -92.09 153.61 19.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.773 0.321 . . . . 0.0 110.85 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 25.2 p -111.82 112.1 23.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.973 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.89 94.71 7.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.934 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -136.9 -47.67 0.6 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.95 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -67.12 154.86 40.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.918 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -176.61 -41.47 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.864 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 49.7 p -110.99 165.46 11.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.995 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 96.69 39.49 4.13 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.439 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -138.23 31.6 2.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.749 0.309 . . . . 0.0 110.851 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -64.46 142.04 58.56 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.827 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -170.98 66.05 0.15 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -67.26 -31.48 71.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.868 0.366 . . . . 0.0 110.822 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -68.76 -140.11 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.492 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -119.09 144.33 46.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.345 . . . . 0.0 110.903 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -126.99 89.57 3.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.935 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -100.09 -29.72 12.35 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.94 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -58.64 160.97 5.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.874 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -136.32 151.92 50.13 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.967 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -114.55 171.07 13.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.493 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -52.79 -61.9 0.42 Allowed 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.518 2.146 . . . . 0.0 112.308 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -149.45 173.53 13.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.835 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 2.8 mtt85 -84.15 143.41 29.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.844 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -86.35 106.3 17.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.909 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.25 168.47 10.21 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.908 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -149.05 92.13 1.93 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.941 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.8 pp -94.54 161.67 14.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.735 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.34 140.33 11.72 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.628 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -127.97 159.63 34.38 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.759 0.314 . . . . 0.0 110.812 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.437 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -158.44 155.66 26.68 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.236 -0.983 . . . . 0.0 112.802 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -113.59 126.69 55.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.797 0.332 . . . . 0.0 110.856 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.435 ' CE2' ' HE3' ' A' ' 24' ' ' LYS . 38.9 p90 -115.59 133.46 56.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.111 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.1 125.15 1.78 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.132 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -150.41 -176.98 23.93 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.747 -179.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -155.06 154.48 32.52 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.896 0.379 . . . . 0.0 111.006 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -102.89 137.33 41.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.567 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 24.0 t -122.54 -49.17 2.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.004 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 27.3 m-80 -96.18 142.62 24.82 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.491 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.412 ' O ' ' CG ' ' A' ' 65' ' ' TYR . 45.3 Cg_endo -68.15 64.14 1.03 Allowed 'Trans proline' 0 C--N 1.343 0.264 0 C-N-CA 122.399 2.066 . . . . 0.0 111.996 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.412 ' CG ' ' O ' ' A' ' 64' ' ' PRO . 9.0 m-85 -168.24 -37.77 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.414 -179.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -169.55 164.08 10.32 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.976 0.417 . . . . 0.0 111.159 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.49 176.76 18.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.398 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.41 ' CE2' ' HG ' ' A' ' 96' ' ' LEU . 1.2 t80 -103.85 138.24 40.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.634 0.254 . . . . 0.0 110.724 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -134.51 125.9 28.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.852 0.358 . . . . 0.0 111.116 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.1 mtt -107.27 133.38 51.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.434 179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.87 159.4 13.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.615 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.437 ' O ' ' HA2' ' A' ' 55' ' ' GLY . 0.2 OUTLIER -131.53 114.88 15.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.679 0.276 . . . . 0.0 110.613 179.909 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -86.18 120.51 27.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.998 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 42.8 t90 -139.09 142.21 38.14 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.917 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 4.8 mp -114.6 -175.79 2.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -107.31 -158.44 20.86 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.503 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.1 tpt180 60.55 108.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.767 0.318 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -96.18 152.21 18.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.796 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.16 134.63 49.1 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.151 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 28.0 m-85 -114.66 31.72 6.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.967 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.2 mptt -98.6 84.56 3.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -147.82 78.37 0.23 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.542 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.4 m -135.65 -70.18 0.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.782 0.325 . . . . 0.0 110.924 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 17.3 m -140.69 32.37 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.165 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -160.87 118.44 2.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.929 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -90.13 128.28 36.3 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 171.49 40.9 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.499 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -118.31 156.13 29.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.848 0.356 . . . . 0.0 111.055 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -85.38 107.72 17.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.989 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 3.3 mmmt -138.77 124.04 19.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.869 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -168.32 176.97 5.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.2 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 -154.54 127.75 8.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.566 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -98.21 130.22 10.16 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.968 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.77 118.96 58.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 15.8 mt-30 -108.86 144.4 36.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.241 0.543 . . . . 0.0 111.937 -178.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.452 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.3 tt -133.45 112.19 11.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.266 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.515 HG22 ' HA3' ' A' ' 115' ' ' GLY . 6.0 p -147.03 178.05 8.67 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.219 0.533 . . . . 0.0 111.984 -178.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -117.27 135.81 53.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.039 179.169 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -110.65 131.98 54.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.021 0.439 . . . . 0.0 111.379 -179.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.621 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -135.45 125.71 26.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.259 179.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.423 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -168.14 -169.82 32.09 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.944 -179.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.823 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 24.5 p90 -156.51 152.43 22.85 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.282 . . . . 0.0 110.819 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -83.1 165.52 14.89 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.721 2.281 . . . . 0.0 112.803 -179.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.488 ' N ' ' O ' ' A' ' 108' ' ' LEU . 9.6 mt -142.09 139.89 30.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.411 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 88.1 m 64.06 -76.02 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.028 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.7 t0 178.38 -34.78 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.087 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.34 19.86 11.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.415 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.488 ' O ' ' N ' ' A' ' 104' ' ' ILE . 0.1 OUTLIER -138.15 113.38 9.36 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.814 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -129.27 145.59 51.32 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.987 0.422 . . . . 0.0 111.809 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.969 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.9 142.17 28.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.657 179.314 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.423 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 33.4 m-85 -149.12 158.33 44.1 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.058 0.456 . . . . 0.0 111.695 -179.35 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.6 m -130.89 141.92 50.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.457 179.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 36.8 ttp180 -120.83 127.94 52.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.278 -179.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -136.34 122.92 20.92 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.929 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.515 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -177.12 -140.71 3.73 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.583 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -140.7 167.74 25.48 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.868 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 9.0 ttp -130.2 141.1 50.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 0.0 110.735 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.4 t -125.69 115.63 43.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.826 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -110.97 133.81 53.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.888 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 3.2 tpt180 -102.84 144.77 30.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.932 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -112.91 143.81 43.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.061 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 2.1 t0 -126.64 127.29 44.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 10.3 m -159.67 37.06 0.19 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.967 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 6.3 tptt -137.31 119.16 15.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.847 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -169.75 -49.2 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.481 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 23.2 t30 -92.08 171.96 8.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.89 0.376 . . . . 0.0 110.905 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -69.33 -31.43 69.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.938 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -73.72 171.4 13.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.067 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 29.1 t -152.22 165.54 34.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.842 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.54 56.05 0.68 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.89 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -153.36 -145.35 4.13 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.546 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.452 HG13 ' N ' ' A' ' 133' ' ' SER . 12.3 p -110.86 -42.86 4.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.818 0.342 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.452 ' N ' HG13 ' A' ' 132' ' ' VAL . 84.6 p -135.08 -46.99 0.71 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.927 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -154.47 119.56 5.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.856 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 54.4 p -62.31 106.53 0.76 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.991 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -61.43 141.4 57.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.871 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 50.9 p-80 -60.5 142.51 55.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.907 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -122.78 135.5 54.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.878 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.1 p -135.27 130.53 35.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -105.54 89.04 0.6 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.341 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.409 HG13 ' O ' ' A' ' 141' ' ' VAL . 10.1 p -118.65 126.12 74.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.705 0.288 . . . . 0.0 110.97 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.0 t -157.16 148.49 16.84 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 120.831 0.348 . . . . 0.0 111.464 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.511 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -79.81 145.66 18.11 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.752 2.302 . . . . 0.0 112.222 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.7 m -156.71 157.1 4.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.927 0.394 . . . . 0.0 111.404 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -149.13 127.19 11.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.476 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -124.01 143.85 50.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.245 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -130.02 146.95 17.85 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.09 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.409 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -167.72 -164.39 23.31 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.208 -0.996 . . . . 0.0 112.936 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.969 HG12 HG22 ' A' ' 110' ' ' ILE . 6.7 m -128.65 166.89 25.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.685 0.279 . . . . 0.0 111.134 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -135.4 149.1 49.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.92 0.391 . . . . 0.0 111.196 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 5.2 m0 -131.39 123.07 27.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.735 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.86 130.2 34.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.225 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.02 -70.44 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.052 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -96.65 -176.68 3.67 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.962 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 7.3 ttm180 -72.51 117.13 13.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.909 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 62.06 23.78 14.07 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.153 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.442 HG12 ' CD2' ' A' ' 190' ' ' TYR . 22.8 mt -137.47 106.27 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.754 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -132.99 160.86 35.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.984 0.421 . . . . 0.0 111.59 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . 0.494 ' OG1' HG12 ' A' ' 188' ' ' VAL . 24.5 m -119.35 145.45 46.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.973 179.518 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.408 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 0.0 OUTLIER -137.1 147.42 46.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.179 0.514 . . . . 0.0 111.976 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.817 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 1.3 tt -113.92 123.57 50.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.533 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.409 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 1.1 mt-10 -107.5 143.88 35.27 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.044 0.45 . . . . 0.0 111.616 -179.074 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.823 ' CE1' HD23 ' A' ' 184' ' ' LEU . 45.4 m-85 -130.94 163.53 27.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.504 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -111.89 -70.04 0.83 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 15.8 t-105 -103.61 108.06 19.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 14.4 m -142.65 157.03 18.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.151 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -95.57 -68.6 0.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 14.4 p-10 -130.6 113.95 14.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 3.1 pt -84.75 153.42 3.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.139 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -172.03 -118.76 0.49 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.581 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -110.71 31.6 5.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.799 0.333 . . . . 0.0 110.958 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -145.93 -179.83 6.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.098 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -158.92 66.41 0.28 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.523 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.6 m -149.37 91.19 1.8 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 176' ' ' GLY . 6.1 m -125.94 -46.15 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . 0.41 ' N ' HG23 ' A' ' 175' ' ' VAL . . . -179.73 146.47 7.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.462 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.5 -53.89 0.21 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.871 0.367 . . . . 0.0 110.968 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . 0.404 ' CB ' ' CD ' ' A' ' 179' ' ' PRO . 2.0 mtm180 -71.76 -61.16 2.13 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.859 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . 0.404 ' CD ' ' CB ' ' A' ' 178' ' ' ARG . 60.1 Cg_endo -72.83 -44.6 0.61 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.588 2.192 . . . . 0.0 112.352 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -76.49 147.07 38.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.91 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -100.72 81.8 2.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.927 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -124.18 -165.65 12.28 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.387 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 2.1 mtm -155.01 111.74 3.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.785 0.326 . . . . 0.0 110.984 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.823 HD23 ' CE1' ' A' ' 163' ' ' TYR . 0.5 OUTLIER -112.65 126.53 55.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.605 179.772 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -135.71 152.37 51.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.973 0.416 . . . . 0.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.13 128.72 54.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.3 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -143.2 167.31 26.48 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.16 -1.019 . . . . 0.0 113.082 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . 0.494 HG12 ' OG1' ' A' ' 159' ' ' THR . 0.4 OUTLIER -128.42 139.49 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.687 0.28 . . . . 0.0 110.374 179.445 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . 0.421 ' HB2' ' CD1' ' A' ' 20' ' ' TYR . 0.3 OUTLIER -136.27 168.7 18.93 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 111.723 -179.125 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . 0.452 ' CD1' ' N ' ' A' ' 190' ' ' TYR . 2.7 m-85 -131.71 157.99 42.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.366 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 38.0 mtm180 -94.09 132.54 38.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.943 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -106.22 114.22 28.21 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.933 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -135.49 163.97 24.9 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.52 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -103.59 110.47 22.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.837 0.351 . . . . 0.0 110.866 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -80.24 164.41 23.26 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.91 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -127.69 128.77 46.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.933 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -79.07 -30.92 44.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.168 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -101.58 96.18 6.05 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.043 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.45 92.1 0.35 Allowed 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.447 2.098 . . . . 0.0 112.271 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 12.7 m -85.61 -25.41 6.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.222 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . 0.634 HG22 ' O ' ' A' ' 201' ' ' VAL . 14.6 p -92.26 15.45 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.385 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -140.13 63.32 23.47 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 120.78 0.324 . . . . 0.0 111.066 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.75 -169.38 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.558 2.172 . . . . 0.0 112.33 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -120.27 115.65 32.74 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.012 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.64 155.24 69.53 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.501 2.134 . . . . 0.0 112.255 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . 0.653 ' HB3' ' HD3' ' A' ' 207' ' ' PRO . . . -69.98 -61.61 2.81 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.168 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.653 ' HD3' ' HB3' ' A' ' 206' ' ' ALA . 36.2 Cg_endo -65.23 140.4 64.47 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.483 2.122 . . . . 0.0 112.236 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.415 ' HB1' ' HD2' ' A' ' 209' ' ' PRO . . . -100.87 162.82 19.43 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.073 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . 0.415 ' HD2' ' HB1' ' A' ' 208' ' ' ALA . 51.4 Cg_exo -53.8 -43.89 54.03 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.455 2.103 . . . . 0.0 112.173 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.253 -0.88 . . . . 0.0 110.85 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 120.805 0.336 . . . . 0.0 111.004 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.42 -31.3 9.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.897 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.8 pt -90.99 133.8 31.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.123 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 1.2 tpp -162.06 -52.11 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.844 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.65 107.27 19.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.859 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.39 -62.45 1.39 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.083 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.448 HG22 ' N ' ' A' ' 8' ' ' PHE . 31.7 mt -123.08 157.22 28.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.078 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' N ' HG22 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -122.15 159.05 28.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.942 179.975 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.56 128.34 37.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.106 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -143.4 168.89 18.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -88.44 150.65 23.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.859 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.54 158.31 27.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.096 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.766 ' HB3' ' HD3' ' A' ' 14' ' ' PRO . . . -87.63 -52.63 0.4 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.026 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.766 ' HD3' ' HB3' ' A' ' 13' ' ' ALA . 53.0 Cg_exo -54.93 97.91 0.05 OUTLIER 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.542 2.161 . . . . 0.0 112.224 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.89 34.07 4.12 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.902 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -88.98 -33.48 17.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.933 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -86.88 137.45 32.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.008 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.511 HG21 ' HD3' ' A' ' 191' ' ' ARG . 1.4 p -148.39 168.87 21.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.838 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 25.9 m-90 -117.28 132.45 56.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.055 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.429 ' CZ ' ' HG3' ' A' ' 191' ' ' ARG . 5.1 m-85 -120.41 135.87 54.91 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.522 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.22 140.26 43.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.488 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.409 ' HA3' ' HB3' ' A' ' 189' ' ' SER . . . 179.14 -163.78 31.57 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.414 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -162.73 161.33 33.67 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.552 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.458 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 0.1 OUTLIER -135.32 160.9 36.97 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.005 0.431 . . . . 0.0 111.044 -179.957 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.417 HD12 ' HB2' ' A' ' 54' ' ' ALA . 3.9 tt -130.85 149.17 52.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.735 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -157.89 177.6 34.57 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.463 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . 0.421 ' CD1' ' N ' ' A' ' 27' ' ' TRP . 2.5 p-90 -142.81 141.49 31.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.835 0.35 . . . . 0.0 110.961 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.3 t -101.09 117.78 35.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.93 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -140.96 151.48 44.21 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.746 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -138.32 100.88 4.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.961 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -91.85 160.66 15.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.817 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -110.3 155.41 22.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -94.53 122.55 37.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.28 28.35 8.63 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.586 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 18.9 t80 -144.2 135.1 25.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.787 0.327 . . . . 0.0 110.95 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 11.6 p90 -165.48 148.35 7.87 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -157.36 125.35 1.56 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.511 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -114.49 30.5 7.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.711 0.291 . . . . 0.0 110.901 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -106.87 159.68 14.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.75 117.89 17.98 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.775 0.321 . . . . 0.0 110.817 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 -141.46 87.24 2.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.881 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -67.83 -37.87 82.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.928 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -141.19 88.46 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.911 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -136.57 -62.45 0.65 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.841 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.6 126.18 1.73 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.464 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.92 92.46 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.471 2.114 . . . . 0.0 112.232 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.1 m -99.52 -39.89 8.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.985 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 54.4 ttt180 -72.77 132.38 43.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.881 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -114.85 98.92 7.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -82.12 112.5 19.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -150.81 77.86 1.29 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.947 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.7 mp -90.3 129.56 36.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.82 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -134.52 127.46 4.49 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.502 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.417 ' HB2' HD12 ' A' ' 25' ' ' LEU . . . -132.37 132.64 43.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.752 0.311 . . . . 0.0 110.914 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -142.37 158.08 26.79 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.753 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -126.85 134.72 50.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.51 0.195 . . . . 0.0 110.793 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.458 ' CE2' ' HG2' ' A' ' 24' ' ' LYS . 6.3 p90 -142.37 165.39 27.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.176 0.512 . . . . 0.0 111.738 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -140.13 141.87 11.96 Favored Glycine 0 N--CA 1.45 -0.425 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.79 179.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -114.59 143.26 17.99 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.896 -179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.441 ' CE2' ' HB3' ' A' ' 68' ' ' PHE . 1.8 p90 -144.62 121.3 11.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.898 0.38 . . . . 0.0 110.631 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 3.3 tt0 -93.3 137.11 32.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.976 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.4 t -123.86 -45.06 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.728 179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.428 ' O ' ' N ' ' A' ' 65' ' ' TYR . 0.8 OUTLIER -102.73 132.59 21.11 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.364 179.605 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 63' ' ' ASN . 31.4 Cg_exo -59.04 77.42 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.552 2.168 . . . . 0.0 112.361 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.428 ' N ' ' O ' ' A' ' 63' ' ' ASN . 0.6 OUTLIER 178.28 -36.16 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.126 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -171.31 164.06 7.09 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.861 0.362 . . . . 0.0 110.99 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.21 172.16 20.33 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.441 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . 0.9 OUTLIER -96.87 141.46 30.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.684 0.278 . . . . 0.0 110.611 179.902 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.77 120.24 28.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.976 0.417 . . . . 0.0 111.281 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.3 mtt -106.17 139.03 41.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.859 179.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.45 ' CA ' ' HB3' ' A' ' 57' ' ' PHE . . . -133.0 166.63 23.61 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.643 -179.278 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -136.92 115.43 11.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.363 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -81.52 129.73 34.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.18 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . 0.401 ' CZ3' ' O ' ' A' ' 91' ' ' ALA . 46.0 m95 -135.67 135.78 40.4 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.737 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.736 HD23 ' N ' ' A' ' 76' ' ' GLY . 8.1 tt -146.11 162.95 36.8 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.936 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.736 ' N ' HD23 ' A' ' 75' ' ' LEU . . . 168.68 112.8 0.27 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.498 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 8.5 mmm180 -145.25 157.85 43.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.783 0.325 . . . . 0.0 110.957 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.1 mtp -101.6 97.77 8.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.816 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -160.42 32.19 0.16 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.151 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -120.62 140.93 50.84 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 4.2 mtmm -95.95 92.13 6.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.959 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -114.2 169.39 12.88 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.507 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 25.4 t -168.94 -51.42 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.905 0.384 . . . . 0.0 110.893 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.0 m -132.29 126.86 56.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.101 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -176.09 172.97 2.29 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 62.4 m-20 -127.15 112.14 14.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.961 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 121.04 105.9 2.0 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.523 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -125.16 70.01 1.15 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.906 0.384 . . . . 0.0 111.089 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -110.37 152.89 25.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.925 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.77 -177.31 5.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.926 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.401 ' O ' ' CZ3' ' A' ' 74' ' ' TRP . . . -123.93 163.69 20.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.065 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -157.19 124.99 5.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.519 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -105.53 140.56 15.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.429 -0.891 . . . . 0.0 112.913 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -115.81 122.62 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 109.976 -0.379 . . . . 0.0 109.976 179.201 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -108.53 143.85 36.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.115 0.483 . . . . 0.0 111.9 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -137.48 113.88 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.849 179.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.413 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 1.2 t -155.1 166.82 32.37 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-O 121.047 0.451 . . . . 0.0 111.784 -179.01 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -105.1 139.45 39.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.718 -0.673 . . . . 0.0 110.32 179.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.9 ttpp -118.92 132.25 56.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.897 0.379 . . . . 0.0 111.598 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.8 pp -134.03 126.58 30.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.737 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 102' ' ' TYR . . . -167.99 -177.81 39.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.514 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.407 ' CG ' ' O ' ' A' ' 101' ' ' GLY . 6.5 m-85 -166.1 158.89 12.51 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.777 0.322 . . . . 0.0 110.987 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -61.13 171.98 3.51 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.741 2.294 . . . . 0.0 111.944 179.806 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.527 HG22 ' O ' ' A' ' 108' ' ' LEU . 0.6 OUTLIER -124.73 -37.1 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.445 -179.906 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 14.7 p -140.4 -46.7 0.42 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.942 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -169.51 -67.76 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.143 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.845 ' HB3' ' HB3' ' A' ' 152' ' ' ALA . 2.6 m-20 -108.31 26.4 10.49 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.367 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.803 HD23 ' C ' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -136.28 122.74 20.75 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.828 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -135.15 156.19 49.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.071 0.462 . . . . 0.0 111.996 -179.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.944 HG22 HG12 ' A' ' 149' ' ' VAL . 1.6 pp -121.34 138.86 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.394 179.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 48.1 p90 -151.28 163.51 38.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.071 0.463 . . . . 0.0 111.557 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.461 HG22 ' HA3' ' A' ' 147' ' ' GLY . 18.5 p -137.63 145.69 43.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.53 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -119.76 127.78 53.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.883 0.373 . . . . 0.0 111.315 -179.756 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -126.98 123.64 37.59 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.328 179.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.413 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.39 -132.49 1.94 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.42 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.497 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -156.89 168.61 33.95 Favored Glycine 0 C--N 1.331 0.3 0 C-N-CA 120.285 -0.96 . . . . 0.0 112.9 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.95 140.98 52.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.711 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.541 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.5 t -133.91 118.16 28.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.657 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 64.5 p-90 -137.1 176.12 8.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.833 0.349 . . . . 0.0 111.049 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -148.62 150.86 34.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.825 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -162.58 165.64 25.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.089 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -86.58 156.88 19.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.874 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 3.5 t -149.5 -47.44 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.886 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 7.4 mtmt -101.94 117.15 34.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.886 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -109.72 -77.1 0.93 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.45 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -126.42 34.11 4.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.866 0.365 . . . . 0.0 110.795 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 60.1 m-85 -98.47 35.76 1.74 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -113.28 -171.06 1.8 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 38.2 t -159.79 -45.69 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.961 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 4.0 p -92.42 -32.09 15.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.016 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -100.87 120.05 6.74 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.449 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.459 HG13 ' N ' ' A' ' 133' ' ' SER . 11.1 p -123.66 -43.6 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 120.751 0.31 . . . . 0.0 111.078 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.459 ' N ' HG13 ' A' ' 132' ' ' VAL . 96.6 p -93.88 -39.43 10.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.85 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.01 106.8 17.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.948 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 61.7 p -145.66 157.81 43.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -132.15 168.04 18.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.849 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.49 153.25 22.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.891 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -96.49 150.75 20.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.835 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.9 t -140.07 138.36 35.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.033 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -112.32 128.21 8.41 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.354 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.444 HG23 HG22 ' A' ' 118' ' ' VAL . 10.8 p -146.14 130.84 11.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.744 0.307 . . . . 0.0 111.194 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.21 141.29 11.67 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.397 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.497 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 92.2 Cg_endo -78.69 149.95 23.96 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.603 2.202 . . . . 0.0 112.02 179.593 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 34.8 m -156.3 157.93 3.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 121.04 0.448 . . . . 0.0 111.702 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -149.08 118.9 7.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.303 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -127.76 159.21 35.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.986 0.422 . . . . 0.0 111.537 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.461 ' HA3' HG22 ' A' ' 112' ' ' THR . . . -130.95 151.82 19.75 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.036 179.748 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -162.73 -177.71 35.96 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.346 -0.931 . . . . 0.0 112.979 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.944 HG12 HG22 ' A' ' 110' ' ' ILE . 4.2 m -127.82 154.27 38.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 0.0 111.005 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -124.75 140.46 52.91 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.938 0.399 . . . . 0.0 111.116 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . 0.6 ' CE2' HD22 ' A' ' 108' ' ' LEU . 1.9 t90 -131.63 127.77 37.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.779 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.845 ' HB3' ' HB3' ' A' ' 107' ' ' ASP . . . -82.62 137.2 34.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.329 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 76.0 t -104.75 -67.12 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.664 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -80.46 -77.24 0.2 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.875 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 5.6 ttp180 -173.93 -37.56 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.136 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -105.78 -24.85 12.4 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.498 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 33.4 mt -112.79 135.66 51.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.927 0.394 . . . . 0.0 111.288 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -136.35 164.35 28.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.233 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -118.53 144.8 45.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.151 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.408 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 0.0 OUTLIER -137.16 152.07 49.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.276 0.56 . . . . 0.0 112.051 -179.221 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -117.97 125.36 50.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.551 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -117.72 137.54 52.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.049 0.452 . . . . 0.0 111.595 -179.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 3.0 p90 -134.19 152.29 51.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.489 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -94.7 114.89 26.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 65.0 p-90 -103.78 132.45 50.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.99 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.415 HG23 ' N ' ' A' ' 167' ' ' ASN . 5.9 m -140.07 -47.1 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . 0.415 ' N ' HG23 ' A' ' 166' ' ' VAL . 1.5 t-20 -121.8 111.64 17.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.879 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -96.67 40.45 1.13 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.894 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . 0.568 ' O ' HG23 ' A' ' 169' ' ' ILE . 0.9 OUTLIER -149.98 113.27 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.076 179.987 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -84.2 171.31 48.06 Favored Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.394 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.23 171.97 10.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.815 0.341 . . . . 0.0 110.805 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -135.64 121.9 20.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.032 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -149.71 -55.14 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.463 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.442 ' O ' HG13 ' A' ' 175' ' ' VAL . 8.7 m -144.95 -55.64 0.32 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.897 0.379 . . . . 0.0 110.822 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.442 HG13 ' O ' ' A' ' 174' ' ' THR . 6.0 m -156.38 149.36 11.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.047 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -140.35 -172.73 13.01 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.426 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 16.1 m -143.2 -67.26 0.36 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.806 0.336 . . . . 0.0 110.887 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 16.9 ttt85 -132.06 119.91 17.0 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.79 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -55.26 87.3 0.04 OUTLIER 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 122.436 2.091 . . . . 0.0 112.316 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 58.24 -178.46 0.07 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.96 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -149.59 -59.32 0.21 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.834 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 95.54 -99.29 2.37 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.567 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -143.67 121.23 11.77 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.738 0.304 . . . . 0.0 110.925 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 4.3 mp -120.08 142.45 48.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.681 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 72.0 m -148.71 153.25 37.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.975 0.416 . . . . 0.0 111.226 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.73 136.07 53.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.23 179.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -147.92 170.33 28.59 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.056 -1.069 . . . . 0.0 113.196 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 1.6 m -132.09 148.09 32.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.602 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . 0.409 ' HB3' ' HA3' ' A' ' 22' ' ' GLY . 89.4 p -151.79 175.06 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.054 0.455 . . . . 0.0 111.466 -179.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -145.92 156.54 43.59 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.621 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.511 ' HD3' HG21 ' A' ' 18' ' ' THR . 8.4 ttm180 -99.45 146.63 26.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.92 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -81.37 106.13 13.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.939 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -143.03 148.88 20.77 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.525 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -109.8 126.94 54.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.794 0.33 . . . . 0.0 110.835 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -105.75 -43.26 4.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.907 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -115.48 97.09 5.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.942 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -97.61 50.24 1.05 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.093 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . 0.709 ' HB1' ' HD2' ' A' ' 199' ' ' PRO . . . -74.54 165.62 52.08 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.119 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.709 ' HD2' ' HB1' ' A' ' 198' ' ' ALA . 40.0 Cg_endo -66.95 94.93 0.35 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.514 2.143 . . . . 0.0 112.282 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . 0.476 HG12 ' N ' ' A' ' 201' ' ' VAL . 21.7 t -117.69 158.7 18.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.136 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . 0.476 ' N ' HG12 ' A' ' 200' ' ' VAL . 20.5 m -104.12 55.51 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.04 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -101.28 106.34 44.79 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.152 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -55.02 168.0 1.41 Allowed 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.462 2.108 . . . . 0.0 112.315 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -126.91 127.08 24.47 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.054 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -53.34 106.17 0.15 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.464 2.11 . . . . 0.0 112.272 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . 0.654 ' HB1' ' HD2' ' A' ' 207' ' ' PRO . . . -67.71 163.61 47.24 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.079 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.654 ' HD2' ' HB1' ' A' ' 206' ' ' ALA . 37.4 Cg_endo -66.26 132.6 30.09 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.512 2.142 . . . . 0.0 112.17 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.892 ' HB3' ' HD3' ' A' ' 209' ' ' PRO . . . -160.12 -59.72 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.429 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . 0.892 ' HD3' ' HB3' ' A' ' 208' ' ' ALA . 53.9 Cg_exo -52.23 90.35 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.245 1.964 . . . . 0.0 112.364 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.943 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.839 0.352 . . . . 0.0 111.02 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.67 31.47 3.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.81 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.2 pt -149.53 140.9 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.238 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -147.44 166.0 28.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.909 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -136.34 -50.96 0.69 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.813 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -112.79 123.49 50.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.078 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 22.5 mt -135.74 142.69 38.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.148 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -99.69 121.37 41.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.019 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.9 m -74.49 154.27 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.148 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -127.22 -61.78 1.14 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.911 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -83.44 58.69 4.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.886 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -171.69 114.62 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.035 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.14 128.99 93.96 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.008 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -55.02 -31.78 76.13 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.451 2.101 . . . . 0.0 112.223 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 15.2 mtmm -132.1 111.61 11.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.04 -45.36 23.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.841 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 40.9 m-80 -91.44 111.97 23.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.935 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 39.9 p -129.54 136.16 49.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.869 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.421 ' CE3' ' HB3' ' A' ' 60' ' ' TYR . 3.2 t-105 -135.66 135.07 39.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.432 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 7.9 m-85 -121.98 145.05 48.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.77 141.6 28.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.256 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.55 -166.67 34.06 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.552 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.38 146.71 18.42 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.544 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -127.93 149.32 50.37 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 120.858 0.361 . . . . 0.0 111.082 -179.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.751 HD21 HD13 ' A' ' 52' ' ' LEU . 2.0 tt -132.55 145.55 51.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.668 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -153.31 171.13 32.22 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.593 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . 0.41 ' CZ2' ' HB3' ' A' ' 50' ' ' ASP . 0.6 OUTLIER -113.92 149.71 34.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.783 0.325 . . . . 0.0 110.795 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.7 m -114.1 167.44 10.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.32 92.24 3.75 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.919 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 13.4 p90 -103.7 137.05 42.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.943 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 25.1 t-80 -82.93 -66.34 0.9 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.92 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.01 139.06 42.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.789 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.7 m -76.48 -36.94 57.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.933 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.38 125.19 4.53 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.588 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -143.19 142.57 31.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.79 0.328 . . . . 0.0 110.907 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -102.12 -48.46 4.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.783 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.31 91.36 1.35 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.473 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -93.14 113.64 25.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.818 0.342 . . . . 0.0 110.97 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -154.87 -134.8 1.95 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.502 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -127.48 79.9 1.92 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.792 0.329 . . . . 0.0 110.971 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.92 140.83 40.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.933 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -69.71 106.79 3.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.884 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -138.91 96.42 3.12 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.91 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 12.3 m-80 -89.18 120.64 30.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.826 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.402 ' N ' ' HD2' ' A' ' 46' ' ' PRO . . . -173.79 -62.95 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.628 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . 0.402 ' HD2' ' N ' ' A' ' 45' ' ' GLY . 18.2 Cg_endo -59.94 -25.71 80.3 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.582 2.188 . . . . 0.0 112.257 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.0 p -127.58 35.16 4.55 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.893 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -136.61 -51.68 0.69 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.931 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -109.28 -177.01 3.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.906 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.41 ' HB3' ' CZ2' ' A' ' 27' ' ' TRP . 21.4 m-20 -116.97 -179.81 3.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.89 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -140.57 111.92 7.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.874 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.751 HD13 HD21 ' A' ' 25' ' ' LEU . 1.7 pp -118.14 165.86 13.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.918 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.94 137.96 9.78 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.396 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.465 ' HB2' ' HG ' ' A' ' 25' ' ' LEU . . . -136.57 173.13 12.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.915 0.388 . . . . 0.0 111.052 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -171.87 156.6 26.06 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.54 -0.838 . . . . 0.0 112.626 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.656 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.95 160.17 14.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.822 0.344 . . . . 0.0 111.011 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -147.77 126.39 12.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.984 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -152.43 137.05 5.69 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.299 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.436 ' HA3' ' HB3' ' A' ' 69' ' ' GLU . . . -171.39 -165.84 29.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.649 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.421 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 6.0 p90 -143.57 161.01 39.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.994 0.426 . . . . 0.0 111.039 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -118.94 136.61 53.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.59 179.766 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 26.0 t -121.58 -41.91 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.151 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.403 ' HB2' ' CB ' ' A' ' 66' ' ' LEU . 7.0 m-20 -92.82 160.82 33.31 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.805 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -67.75 -14.28 41.24 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.559 2.173 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.768 ' CZ ' HD13 ' A' ' 100' ' ' LEU . 4.3 t80 -149.39 28.23 0.81 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.788 0.327 . . . . 0.0 111.099 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.513 HD22 ' O ' ' A' ' 65' ' ' TYR . 0.4 OUTLIER -145.41 115.84 7.59 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.88 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -128.87 156.41 21.12 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.32 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -128.99 128.43 43.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.621 0.248 . . . . 0.0 110.769 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.436 ' HB3' ' HA3' ' A' ' 59' ' ' GLY . 1.4 pm0 -147.44 153.46 39.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.149 0.499 . . . . 0.0 111.505 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 4.0 ptt? -118.15 138.21 52.45 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.186 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.86 175.63 18.73 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.689 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.656 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 0.8 OUTLIER -134.71 114.94 13.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.661 0.267 . . . . 0.0 110.621 179.893 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -78.27 121.64 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.084 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 6.1 m95 -139.04 117.08 11.7 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.878 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 6.8 tp -74.09 -57.59 3.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.949 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 153.18 176.05 25.26 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.476 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.26 88.45 4.92 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.823 0.344 . . . . 0.0 110.932 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -105.4 -178.6 3.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -159.47 141.04 13.07 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.986 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.44 ' CD1' ' HB3' ' A' ' 83' ' ' SER . 0.3 OUTLIER -93.33 142.87 26.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.976 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -120.29 -42.02 2.59 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.86 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -99.51 36.52 4.02 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.471 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.44 ' HB3' ' CD1' ' A' ' 80' ' ' TYR . 8.5 t -154.66 79.82 1.08 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.814 0.34 . . . . 0.0 110.894 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 9.3 m -81.97 120.55 33.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.142 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.71 152.16 37.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.859 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -90.57 137.19 32.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 103.85 61.48 0.68 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.516 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -61.77 111.45 1.87 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.867 0.365 . . . . 0.0 111.112 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -126.45 143.36 51.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -97.58 139.68 33.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.83 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.11 159.39 18.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.233 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -164.5 129.64 2.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.631 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.85 141.54 15.32 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.898 -179.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -112.05 126.0 69.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.249 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -108.86 146.84 33.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.224 0.535 . . . . 0.0 112.03 -178.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.425 ' O ' HD23 ' A' ' 96' ' ' LEU . 2.0 tt -139.13 116.1 10.92 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.347 179.527 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.424 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 0.9 OUTLIER -154.32 170.03 22.28 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.191 0.519 . . . . 0.0 112.054 -178.694 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -108.95 149.64 28.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.134 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.82 132.23 53.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.966 0.412 . . . . 0.0 111.704 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.768 HD13 ' CZ ' ' A' ' 65' ' ' TYR . 4.0 pp -133.34 125.11 28.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.18 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -163.06 -169.82 27.04 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.872 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.442 ' CD2' ' HD2' ' A' ' 103' ' ' PRO . 0.3 OUTLIER -157.35 145.3 14.07 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.674 0.273 . . . . 0.0 110.923 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.442 ' HD2' ' CD2' ' A' ' 102' ' ' TYR . 84.7 Cg_endo -82.59 167.83 14.77 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.764 2.309 . . . . 0.0 112.643 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.64 ' O ' HG23 ' A' ' 105' ' ' THR . 5.3 mm -115.64 -32.21 1.92 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.204 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.956 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.64 HG23 ' O ' ' A' ' 104' ' ' ILE . 0.5 OUTLIER -170.65 46.89 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.847 0.356 . . . . 0.0 111.208 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 50.7 32.0 6.5 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.858 0.361 . . . . 0.0 111.133 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.67 ' OD1' ' HB3' ' A' ' 152' ' ' ALA . 38.5 t0 -153.78 -41.98 0.09 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.707 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.456 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.0 OUTLIER -119.72 118.22 30.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.915 179.699 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -134.35 152.48 51.83 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.12 0.486 . . . . 0.0 112.09 -178.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.959 HG22 ' CG1' ' A' ' 149' ' ' VAL . 1.3 pt -114.82 147.63 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.166 179.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -157.77 166.19 33.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.1 0.476 . . . . 0.0 111.823 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.41 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 27.4 m -142.28 132.29 24.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.513 179.679 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 52.6 mtt180 -109.92 128.91 55.66 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.188 -179.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.9 tt -132.98 125.52 29.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.715 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.424 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . -179.98 -135.51 2.49 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.477 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.508 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -152.19 169.04 31.45 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.48 -0.867 . . . . 0.0 112.792 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 7.5 ptp -128.13 140.91 51.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.849 0.357 . . . . 0.0 110.995 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.431 ' O ' HG23 ' A' ' 94' ' ' VAL . 2.1 t -130.63 111.88 21.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.715 179.774 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.5 p-90 -128.47 176.13 7.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.927 0.394 . . . . 0.0 111.055 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -119.82 127.6 52.92 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.833 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.636 ' HB3' ' HB3' ' A' ' 138' ' ' ASP . . . -88.52 152.11 22.08 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.143 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -126.4 158.79 35.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.854 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 9.2 p -176.75 -40.27 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.971 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.77 -174.45 2.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -161.45 -151.65 6.35 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.561 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 7.1 m-20 -82.95 150.86 26.17 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.916 0.388 . . . . 0.0 110.863 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -80.96 -63.15 1.47 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.893 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -144.25 -56.21 0.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.109 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 16.1 m -150.21 120.84 7.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.844 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -163.0 169.53 19.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.877 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -131.43 -60.0 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.499 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 11.1 p -134.4 140.44 45.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.771 0.32 . . . . 0.0 111.093 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -138.25 171.27 14.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.807 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 2.8 ptm85 -79.65 -30.57 41.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.897 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.2 t -82.59 110.43 17.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.888 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -84.45 161.03 20.44 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.071 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -66.19 171.36 4.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.971 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.636 ' HB3' ' HB3' ' A' ' 121' ' ' ALA . 4.8 t0 -77.64 136.23 38.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.799 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 14.9 p -124.9 135.34 52.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.007 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -113.83 131.22 9.81 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.406 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.9 p -146.04 128.27 8.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.732 0.301 . . . . 0.0 111.055 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -157.17 147.4 15.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.247 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.508 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 85.3 Cg_endo -78.1 151.89 27.38 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.749 2.3 . . . . 0.0 112.209 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 28.8 m -156.38 157.29 3.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.379 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -149.13 123.78 9.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.628 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -118.34 124.83 48.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 112' ' ' THR . . . -125.59 137.33 10.22 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.306 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -170.87 -150.76 7.17 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.435 -0.888 . . . . 0.0 113.076 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.959 ' CG1' HG22 ' A' ' 110' ' ' ILE . 9.0 m -131.3 168.21 24.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.822 0.344 . . . . 0.0 111.365 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -134.79 136.74 42.8 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . 0.456 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.6 OUTLIER -119.56 128.72 54.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.81 179.813 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.67 ' HB3' ' OD1' ' A' ' 107' ' ' ASP . . . -94.73 131.7 40.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.916 0.388 . . . . 0.0 111.456 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.422 HG22 ' CZ3' ' A' ' 151' ' ' TRP . 59.5 t -116.09 -69.21 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . 0.447 HG22 ' H ' ' A' ' 155' ' ' ARG . 0.2 OUTLIER -73.66 -167.32 0.45 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.989 -179.882 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . 0.447 ' H ' HG22 ' A' ' 154' ' ' THR . 6.3 ttm180 -81.6 -35.89 29.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.988 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -135.85 33.31 2.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.124 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 26.2 mt -148.14 124.45 2.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.063 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -136.87 162.8 32.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.439 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . 0.468 HG23 ' CG1' ' A' ' 188' ' ' VAL . 1.7 m -109.73 150.6 28.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.202 179.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.07 136.58 38.49 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.077 0.465 . . . . 0.0 111.864 -179.409 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.703 HD22 ' CE1' ' A' ' 163' ' ' TYR . 1.4 tt -119.17 120.76 38.04 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.505 178.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.417 ' HA ' ' HA3' ' A' ' 148' ' ' GLY . 5.2 mt-10 -117.39 145.13 44.29 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.115 0.483 . . . . 0.0 111.819 -178.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.703 ' CE1' HD22 ' A' ' 161' ' ' LEU . 0.0 OUTLIER -134.05 166.09 23.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.202 179.428 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -112.46 -32.44 6.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.937 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . 0.434 ' CG ' ' HB2' ' A' ' 181' ' ' ASN . 71.7 t90 -153.37 102.17 2.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.987 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 10.9 p -178.51 -39.39 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.034 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 10.9 p-10 -72.71 -36.49 67.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -134.88 139.49 45.05 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.867 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . 0.713 HD12 ' N ' ' A' ' 170' ' ' GLY . 2.7 pp -129.83 -42.81 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.187 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . 0.713 ' N ' HD12 ' A' ' 169' ' ' ILE . . . -138.92 129.65 4.54 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.468 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -113.95 -40.33 3.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.824 0.345 . . . . 0.0 110.899 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -163.65 -53.69 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.065 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -110.52 156.3 15.64 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.51 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.4 p -111.57 108.67 18.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.852 0.358 . . . . 0.0 110.892 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -138.04 141.78 37.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.061 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -117.32 136.1 12.35 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.429 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -144.05 -48.59 0.28 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.866 0.365 . . . . 0.0 110.935 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 3.8 ptp85 -84.47 113.86 51.46 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.736 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -50.96 -46.79 28.8 Favored 'Trans proline' 0 C--N 1.347 0.451 0 C-N-CA 122.407 2.071 . . . . 0.0 112.319 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.51 152.75 20.79 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.89 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . 0.434 ' HB2' ' CG ' ' A' ' 165' ' ' TRP . 30.2 p-10 -145.09 -46.69 0.23 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.97 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -74.06 110.36 3.08 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.58 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -162.0 113.78 1.69 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.75 0.309 . . . . 0.0 110.956 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.403 HD12 ' N ' ' A' ' 184' ' ' LEU . 2.0 mp -129.9 157.17 43.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.615 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.5 m -156.13 149.23 24.33 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.901 0.381 . . . . 0.0 111.401 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.96 136.0 53.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.439 179.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -151.85 169.78 31.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.405 -0.903 . . . . 0.0 112.911 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . 0.468 ' CG1' HG23 ' A' ' 159' ' ' THR . 1.0 OUTLIER -131.2 140.05 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.688 0.28 . . . . 0.0 110.714 179.663 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 90.3 p -144.77 175.0 10.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.93 0.395 . . . . 0.0 111.343 -179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -142.57 159.61 41.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.736 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.432 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -101.74 138.08 39.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.956 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -148.8 166.61 27.95 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -166.94 -178.13 39.17 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.49 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -129.64 98.77 4.93 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.836 0.35 . . . . 0.0 110.897 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -102.38 -47.71 4.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.953 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.69 127.2 32.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.785 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -80.9 -177.19 6.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.105 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -170.32 91.56 0.5 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.071 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.14 176.47 5.43 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.508 2.139 . . . . 0.0 112.304 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . 0.533 HG22 ' H ' ' A' ' 202' ' ' ALA . 11.9 p -153.74 145.03 14.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.053 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 30.0 m -96.64 26.93 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.321 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . 0.533 ' H ' HG22 ' A' ' 200' ' ' VAL . . . -140.12 84.15 15.12 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.004 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_exo -50.92 -27.63 21.45 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.579 2.186 . . . . 0.0 112.341 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -116.27 147.78 40.21 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.01 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.42 136.43 28.68 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.58 2.187 . . . . 0.0 112.352 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -78.88 151.59 76.56 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.046 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -69.44 -42.31 3.85 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.596 2.197 . . . . 0.0 112.222 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -129.14 72.6 81.98 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.072 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.16 173.68 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.631 2.221 . . . . 0.0 112.278 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.184 -0.912 . . . . 0.0 110.885 -179.993 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.786 0.327 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 9.1 mtp-105 -115.7 167.28 11.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.1 mt -126.7 141.98 44.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.089 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -108.0 141.36 39.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.994 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 13.3 mmmt -128.09 156.35 42.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.968 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -104.92 -174.03 2.44 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.061 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.625 HG12 HG22 ' A' ' 9' ' ' VAL . 20.7 tt -102.48 116.8 46.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.116 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.574 ' CE2' HD21 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -121.17 30.08 7.0 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.978 -179.991 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.625 HG22 HG12 ' A' ' 7' ' ' ILE . 20.6 m -71.77 88.99 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.574 HD21 ' CE2' ' A' ' 8' ' ' PHE . 1.5 pp -141.87 107.59 5.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.876 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 18.9 p30 -73.53 142.56 46.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.951 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -150.12 93.57 2.02 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.124 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -112.31 74.56 1.52 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.162 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.34 -45.68 1.21 Allowed 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.565 2.176 . . . . 0.0 112.351 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -76.12 -43.32 43.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -84.25 124.09 30.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.926 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -85.92 171.32 11.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.835 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -132.6 179.47 6.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.913 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.455 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 0.0 OUTLIER -151.09 130.02 12.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.859 -179.924 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.455 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.5 m-85 -131.22 135.79 47.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.751 179.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.43 140.43 21.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.864 0.364 . . . . 0.0 111.341 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.86 173.74 43.42 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.696 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -125.5 141.25 12.84 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.297 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.504 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.4 OUTLIER -130.66 149.08 52.48 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.093 0.473 . . . . 0.0 111.434 -179.787 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 1.064 HD11 HD12 ' A' ' 52' ' ' LEU . 31.9 tp -127.53 153.83 45.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -154.22 160.66 29.61 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.492 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . 0.408 ' CH2' HD11 ' A' ' 186' ' ' LEU . 41.9 p90 -143.01 154.86 44.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.948 0.404 . . . . 0.0 110.918 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 8.2 m -77.7 165.7 23.9 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.921 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.91 126.62 30.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.908 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -110.07 174.52 5.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.848 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 -126.65 167.1 16.16 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.892 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -85.17 -56.48 3.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.951 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.4 m -82.43 -65.93 0.95 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.45 176.69 51.5 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.506 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -136.95 113.52 10.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.791 0.329 . . . . 0.0 110.903 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -166.11 35.83 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.17 -177.82 6.51 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.5 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -92.38 146.8 23.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.825 0.345 . . . . 0.0 110.853 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -165.74 -75.41 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.442 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -137.51 149.72 46.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.796 0.331 . . . . 0.0 110.914 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 6.5 mt-30 -132.64 31.6 3.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 -86.29 -43.65 12.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.816 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -82.95 175.42 10.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.867 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 24.4 m120 -91.72 107.13 18.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.84 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -101.85 171.7 22.02 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.535 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -52.25 125.63 18.06 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.606 2.204 . . . . 0.0 112.268 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.1 t -134.69 31.66 3.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.906 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -101.79 169.77 8.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.95 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -104.7 114.28 28.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.857 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -72.66 90.05 1.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -118.3 158.63 24.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 1.064 HD12 HD11 ' A' ' 25' ' ' LEU . 0.3 OUTLIER -76.37 168.22 20.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.886 -179.954 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.803 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -123.54 136.64 10.49 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.393 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.542 ' HB2' HD13 ' A' ' 25' ' ' LEU . . . -119.97 149.1 42.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 111.177 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -153.69 152.11 23.76 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.398 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.618 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -105.84 148.04 28.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.776 0.322 . . . . 0.0 111.049 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.446 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 35.9 p90 -135.38 118.17 16.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -143.2 129.02 3.58 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.069 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -137.09 169.12 24.09 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.963 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.455 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 29.8 p90 -134.34 134.59 41.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.35 . . . . 0.0 110.846 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 55.5 tt0 -86.92 137.1 32.66 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.808 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 36.7 t -140.76 -48.16 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.832 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 8.1 m120 -85.13 141.25 37.25 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.225 179.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.02 60.28 1.81 Allowed 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.269 1.98 . . . . 0.0 112.225 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER 178.64 -32.16 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.563 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -161.35 164.11 30.27 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.934 0.397 . . . . 0.0 111.355 -179.406 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.99 174.5 20.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.369 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.42 ' HB2' ' CE1' ' A' ' 60' ' ' TYR . 2.0 m-85 -83.61 144.52 29.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.655 0.264 . . . . 0.0 110.703 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -128.05 125.23 38.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.884 0.373 . . . . 0.0 111.137 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.8 tpp -106.45 127.51 53.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.569 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.92 148.28 17.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.672 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.618 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 0.1 OUTLIER -127.23 120.03 27.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.696 0.284 . . . . 0.0 110.648 179.878 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -97.62 122.71 41.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.899 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -139.03 119.34 13.7 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.876 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -102.94 175.98 5.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -101.31 113.39 4.66 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.467 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 30.3 ttt180 -143.31 112.65 6.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.793 0.33 . . . . 0.0 110.841 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.28 166.98 22.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.918 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.11 157.71 16.37 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 34.0 p90 -159.48 143.17 14.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.848 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.89 86.85 1.77 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.899 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -95.39 -98.58 1.75 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.519 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.3 m -170.2 166.49 8.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.769 0.319 . . . . 0.0 110.925 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.7 m -107.14 97.26 5.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.104 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -135.3 -69.76 0.5 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.883 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 24.6 m-20 -112.96 139.71 48.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.85 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 97.33 173.19 33.97 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.448 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -140.09 21.47 2.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.747 0.308 . . . . 0.0 111.404 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 3.8 t80 53.44 85.49 0.05 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.127 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.3 127.89 7.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.888 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -156.6 113.14 3.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.183 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -170.42 126.46 0.77 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.747 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.62 139.29 14.32 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.911 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.65 122.77 61.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.712 0.291 . . . . 0.0 110.292 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.02 136.97 47.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.111 0.481 . . . . 0.0 111.721 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.404 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.9 tt -121.08 104.73 10.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.624 -0.717 . . . . 0.0 109.291 179.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.461 HG22 ' HA3' ' A' ' 115' ' ' GLY . 3.6 p -145.93 171.37 14.94 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.251 0.548 . . . . 0.0 112.078 -178.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -106.09 131.07 53.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.373 -0.83 . . . . 0.0 109.864 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 19.6 ttpt -116.55 132.12 56.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.148 0.499 . . . . 0.0 111.682 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 2.9 pp -127.65 131.33 49.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.626 -0.716 . . . . 0.0 109.587 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.443 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -132.28 175.43 19.86 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.246 -0.978 . . . . 0.0 113.263 -179.203 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.47 ' O ' HG22 ' A' ' 110' ' ' ILE . 0.2 OUTLIER -166.1 134.4 2.36 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.698 -0.251 . . . . 0.0 110.701 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -76.71 169.01 22.57 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 122.588 2.192 . . . . 0.0 112.39 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.583 HG22 HG23 ' A' ' 105' ' ' THR . 26.2 mm -116.22 -52.79 4.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.99 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.583 HG23 HG22 ' A' ' 104' ' ' ILE . 18.0 p -134.48 -47.31 0.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.836 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.2 t0 178.67 -37.1 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.077 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.508 ' C ' HD23 ' A' ' 108' ' ' LEU . 6.5 p-10 -118.25 16.32 13.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.663 -179.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.508 HD23 ' C ' ' A' ' 107' ' ' ASP . 0.1 OUTLIER -137.07 125.23 23.03 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.379 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -139.75 161.84 36.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.131 0.491 . . . . 0.0 111.811 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.47 HG22 ' O ' ' A' ' 102' ' ' TYR . 2.6 tt -114.51 144.93 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.037 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.443 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 60.7 m-85 -141.68 138.21 32.3 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.362 . . . . 0.0 111.445 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.87 128.18 30.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.715 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.534 ' NH2' ' HB3' ' A' ' 146' ' ' ALA . 18.6 mtm105 -118.38 127.91 54.13 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.264 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.1 tt -134.38 122.78 23.06 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.491 179.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.461 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.93 -137.86 3.02 Favored Glycine 0 C--N 1.332 0.332 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.456 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -139.14 160.72 25.9 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.923 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 8.4 ptp -120.7 137.28 54.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.759 0.314 . . . . 0.0 110.775 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.1 t -131.62 113.2 22.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.842 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 8.7 p-90 -138.68 170.07 16.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.917 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 12.8 ttp180 -121.65 138.84 54.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.875 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -113.26 129.31 56.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.153 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -96.09 130.88 43.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.928 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 15.5 p -76.13 177.55 7.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.832 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 20.4 mttp -77.14 -71.98 0.38 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.897 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -168.27 -166.55 27.53 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.557 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 24.1 p30 -67.47 154.07 42.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.788 0.327 . . . . 0.0 110.938 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -169.4 112.74 0.51 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.872 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -108.46 140.42 41.8 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.079 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -124.19 -70.09 0.78 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.935 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 40.1 p -147.27 -48.32 0.18 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.949 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -164.66 79.47 0.13 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.517 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.467 HG13 ' O ' ' A' ' 132' ' ' VAL . 12.5 p -108.6 121.16 61.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.807 0.337 . . . . 0.0 111.07 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.84 45.08 1.0 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.31 104.21 9.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.818 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 23.5 m -145.63 31.66 1.07 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.95 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -112.42 159.65 18.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.79 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -76.39 132.64 39.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.894 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -75.43 144.6 42.08 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 52.9 p -124.51 114.88 20.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.908 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -93.56 105.73 3.33 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.493 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.455 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.7 p -140.78 122.8 15.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.702 0.287 . . . . 0.0 110.969 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -157.12 149.22 17.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.777 0.322 . . . . 0.0 111.557 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.536 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 87.5 Cg_endo -80.59 140.9 13.54 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.923 2.416 . . . . 0.0 112.126 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 31.2 m -156.91 160.56 2.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.004 0.431 . . . . 0.0 111.583 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -149.06 130.28 14.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.377 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.534 ' HB3' ' NH2' ' A' ' 113' ' ' ARG . . . -116.51 155.37 28.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.895 0.378 . . . . 0.0 111.502 -179.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -139.34 136.49 7.93 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.22 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 162' ' ' GLU . . . -162.85 -165.24 19.59 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.478 -0.868 . . . . 0.0 112.854 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -133.72 170.72 19.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.554 0.216 . . . . 0.0 110.95 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -146.72 149.7 33.93 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 120.941 0.401 . . . . 0.0 111.266 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 24.8 p90 -137.04 132.18 33.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.631 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.04 135.52 34.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.52 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 46.0 t -116.18 -63.05 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.823 179.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -105.22 -171.98 2.01 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.834 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -75.07 113.81 12.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.989 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 33.2 m-20 62.94 32.83 15.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.167 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.421 HG12 ' CE2' ' A' ' 190' ' ' TYR . 45.1 mt -147.79 105.44 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.941 179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -126.76 167.62 15.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.357 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.73 144.71 40.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.172 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.61 132.47 44.07 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.124 0.488 . . . . 0.0 111.89 -179.307 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -115.55 117.08 29.35 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.498 178.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.409 ' HG3' ' NZ ' ' A' ' 24' ' ' LYS . 23.8 mm-40 -107.04 145.03 32.85 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.127 0.489 . . . . 0.0 111.634 -178.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.432 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 48.9 t80 -133.95 158.28 43.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.455 179.656 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -107.27 123.68 48.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.008 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -123.69 107.89 11.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.723 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 31.2 m -65.27 174.45 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.071 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -155.11 -55.64 0.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.9 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -153.97 32.22 0.44 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 2.3 pt -70.35 -28.68 36.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.207 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -125.98 -159.34 10.24 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.47 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -124.47 -44.5 1.99 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.778 0.323 . . . . 0.0 110.918 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -61.02 -174.97 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.015 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -150.34 -92.04 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.586 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 59.8 m -143.35 106.71 4.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.928 0.394 . . . . 0.0 110.919 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 6.4 m -140.61 31.32 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.111 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -161.86 -83.59 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.551 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . 0.817 HG22 ' HD2' ' A' ' 179' ' ' PRO . 0.2 OUTLIER -105.45 135.68 46.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.862 0.363 . . . . 0.0 110.877 179.977 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . 0.427 ' N ' ' CD ' ' A' ' 179' ' ' PRO . 0.3 OUTLIER -70.07 -51.76 13.8 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.98 179.963 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . 0.817 ' HD2' HG22 ' A' ' 177' ' ' THR . 51.4 Cg_exo -55.12 129.72 36.83 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.45 2.1 . . . . 0.0 112.313 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -111.74 148.31 33.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.855 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 23.3 p-10 -87.74 80.86 7.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.912 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -78.04 176.62 53.88 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.52 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 17.8 ttp -118.6 129.58 55.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.922 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.498 HD12 ' N ' ' A' ' 184' ' ' LEU . 2.5 mp -132.8 125.07 29.25 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.687 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 28.9 t -128.53 145.38 51.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.115 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . 0.408 HD11 ' CH2' ' A' ' 27' ' ' TRP . 0.0 OUTLIER -132.42 136.59 46.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.584 179.635 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . 0.504 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -154.63 -176.86 27.38 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.942 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -126.64 135.9 62.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.647 0.261 . . . . 0.0 110.442 179.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 43.3 p -130.84 165.37 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.208 0.528 . . . . 0.0 111.721 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . 0.447 ' CD1' ' N ' ' A' ' 190' ' ' TYR . 2.2 m-85 -124.96 143.19 51.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.471 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 8.6 mtp180 -108.14 147.33 31.42 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.905 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -104.63 129.25 52.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.82 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -126.13 164.58 19.65 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.49 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -68.62 -31.07 69.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.75 0.31 . . . . 0.0 110.873 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -108.02 161.18 15.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.821 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -97.91 -33.78 11.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.861 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -140.84 173.3 11.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.159 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -120.64 129.36 25.35 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.013 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.98 151.86 25.74 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.377 2.051 . . . . 0.0 112.345 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 3.6 m -109.34 90.47 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.135 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 23.1 m -114.06 -35.6 2.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.24 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -107.71 108.27 61.32 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.088 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.84 -44.13 2.2 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.37 2.047 . . . . 0.0 112.226 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -117.35 92.86 41.4 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.981 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.72 -49.36 1.62 Allowed 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.566 2.177 . . . . 0.0 112.416 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -136.65 109.08 9.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.157 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_exo -51.85 153.93 10.77 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.468 2.112 . . . . 0.0 112.277 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.903 ' HB3' ' HD3' ' A' ' 209' ' ' PRO . . . -160.12 -59.71 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.327 179.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . 0.903 ' HD3' ' HB3' ' A' ' 208' ' ' ALA . 68.2 Cg_exo -51.17 93.09 0.03 OUTLIER 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.285 1.99 . . . . 0.0 112.314 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.142 -0.932 . . . . 0.0 110.955 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.312 0 CA-C-O 120.838 0.351 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -170.27 98.06 0.27 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.977 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.6 mp -131.89 100.95 4.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.073 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -134.4 130.25 36.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.868 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -78.72 100.8 7.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.932 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.85 71.97 6.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.025 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 6.6 tp -178.14 -39.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.994 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -153.49 145.24 23.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.4 138.03 37.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.15 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.3 mp -120.99 -42.86 2.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.931 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 23.2 p30 -60.52 151.54 28.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -103.65 118.68 37.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.183 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.92 84.91 33.36 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.01 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -70.07 -37.59 8.22 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.625 2.216 . . . . 0.0 112.33 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -136.65 118.58 15.26 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.964 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -83.69 109.69 17.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.875 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -104.17 131.8 51.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.932 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -137.03 148.66 46.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.735 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 10.3 t90 -111.09 132.91 53.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.088 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.446 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 2.7 t80 -122.57 135.79 54.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.383 179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.59 146.93 25.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.953 0.406 . . . . 0.0 111.5 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.407 ' HA3' ' HB3' ' A' ' 189' ' ' SER . . . 178.01 -172.84 45.44 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.482 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -147.65 148.57 20.24 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.489 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.27 151.0 47.21 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.072 0.463 . . . . 0.0 111.354 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.871 HD12 ' O ' ' A' ' 53' ' ' GLY . 18.7 tp -122.12 145.53 48.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.29 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -144.53 178.9 22.13 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.794 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . 0.418 ' CD1' ' HB3' ' A' ' 52' ' ' LEU . 0.5 OUTLIER -106.11 159.94 15.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.792 0.33 . . . . 0.0 110.834 -179.904 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.98 -60.71 1.49 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.825 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 68.6 mt-30 -104.42 146.14 29.27 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.881 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 18.0 p90 -143.81 -179.89 6.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.924 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -137.06 99.41 4.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.878 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -65.07 -67.49 0.43 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.026 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 82.6 p -78.52 -66.71 0.82 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.948 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 92.14 154.01 30.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -84.34 -179.97 7.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.851 0.358 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 18.0 m-85 -141.81 96.16 2.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -121.01 -166.1 12.89 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.527 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -79.81 -32.56 40.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.818 0.342 . . . . 0.0 110.894 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -153.14 104.43 0.26 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.515 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -126.07 31.69 5.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.816 0.341 . . . . 0.0 110.876 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -141.87 -46.12 0.35 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.981 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -58.5 -57.45 12.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.897 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 66.1 m-20 -64.47 -30.72 71.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.915 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -98.1 30.47 3.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.907 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -97.63 -99.07 2.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.508 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -79.96 55.24 5.56 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.521 2.148 . . . . 0.0 112.498 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.9 m -164.98 -46.51 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.776 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 7.7 tpm_? -64.63 140.09 58.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.93 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 53.2 m-20 -105.33 146.42 29.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.768 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -101.42 162.48 12.87 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.838 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -116.78 106.72 13.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.85 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.614 HD12 HD11 ' A' ' 25' ' ' LEU . 0.7 OUTLIER -134.32 164.43 27.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.06 -179.902 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.871 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -141.14 145.79 16.61 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.417 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -114.93 142.18 46.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.718 0.294 . . . . 0.0 110.981 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.5 143.83 11.13 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.293 -0.956 . . . . 0.0 112.895 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -98.07 164.46 12.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.648 0.261 . . . . 0.0 110.668 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.446 ' CE1' ' HB3' ' A' ' 189' ' ' SER . 52.2 p90 -152.38 141.03 20.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.062 0.458 . . . . 0.0 111.409 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -133.55 124.92 3.81 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.044 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -97.39 145.73 17.96 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.893 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -131.93 112.26 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.698 0.285 . . . . 0.0 110.574 179.783 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 5.1 mm100 -90.8 137.0 32.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.101 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.629 ' O ' HG12 ' A' ' 62' ' ' VAL . 21.6 t -148.87 23.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.948 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.1 m-20 173.22 137.48 0.12 Allowed Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.352 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -67.78 67.97 0.84 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.386 2.057 . . . . 0.0 112.276 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -169.07 -40.59 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.334 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -168.62 164.04 12.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.924 0.393 . . . . 0.0 111.256 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.67 159.19 26.82 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.313 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -82.9 127.57 33.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.739 0.304 . . . . 0.0 110.566 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -114.64 127.08 55.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.966 0.412 . . . . 0.0 111.317 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 7.2 mtm -104.21 128.44 51.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.962 179.364 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.93 157.7 14.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.951 -179.295 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -132.68 120.19 21.38 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.731 0.301 . . . . 0.0 110.508 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.424 ' CB ' ' HA3' ' A' ' 93' ' ' GLY . 0.8 OUTLIER -94.54 127.14 40.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.688 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t90 -139.1 125.2 20.01 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.944 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.5 mt -86.53 157.41 19.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.889 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -95.55 113.24 4.58 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.537 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 2.5 ppt_? -170.4 167.07 8.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.835 0.35 . . . . 0.0 110.888 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 15.3 mmm -131.72 166.63 21.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.903 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -98.48 166.78 11.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.081 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -142.45 -49.17 0.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.931 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.03 106.71 17.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.946 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.39 68.49 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.553 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 17.1 m -84.1 -67.81 0.76 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.822 0.344 . . . . 0.0 110.939 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.556 ' O ' HG12 ' A' ' 84' ' ' VAL . 14.1 t -142.36 34.21 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.084 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -135.75 167.58 20.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.925 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 86.3 m-20 -60.02 164.46 3.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.898 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -101.73 -129.93 6.85 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.529 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -149.95 -52.57 0.15 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.819 0.343 . . . . 0.0 111.123 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -108.35 137.09 46.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.02 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 15.7 mttp -161.67 112.8 1.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.866 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -173.94 169.95 3.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.259 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -149.97 137.86 20.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.547 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.424 ' HA3' ' CB ' ' A' ' 73' ' ' ASP . . . -81.66 128.08 8.27 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.795 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.2 m -133.21 117.77 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.716 0.293 . . . . 0.0 110.257 179.391 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . 0.408 ' CB ' ' HA ' ' A' ' 117' ' ' MET . 7.6 pt20 -123.92 149.74 45.53 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.107 0.48 . . . . 0.0 111.791 -179.269 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.533 ' O ' HD23 ' A' ' 96' ' ' LEU . 0.3 OUTLIER -124.63 120.1 30.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.517 179.658 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.465 HG22 ' HA3' ' A' ' 115' ' ' GLY . 4.3 p -148.28 171.81 15.38 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-O 121.088 0.471 . . . . 0.0 111.789 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -107.37 123.04 47.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.987 178.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.5 tttt -114.74 132.33 56.48 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.107 0.479 . . . . 0.0 111.7 -178.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.535 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.6 pp -126.83 125.69 42.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.341 179.347 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.426 ' HA3' ' CD2' ' A' ' 111' ' ' TYR . . . -145.45 160.08 28.02 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.419 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.503 ' CG ' ' HD2' ' A' ' 103' ' ' PRO . 0.2 OUTLIER -166.27 148.49 6.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.676 0.274 . . . . 0.0 111.483 -179.758 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.503 ' HD2' ' CG ' ' A' ' 102' ' ' TYR . 73.3 Cg_endo -75.38 172.04 17.1 Favored 'Trans proline' 0 C--N 1.348 0.505 0 C-N-CA 122.807 2.338 . . . . 0.0 112.332 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 29.4 mt -132.08 -70.05 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.14 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.16 -67.95 0.72 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.906 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -161.11 -51.04 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.882 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.816 ' C ' HD23 ' A' ' 108' ' ' LEU . 14.4 m-20 -121.24 25.36 9.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.087 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.816 HD23 ' C ' ' A' ' 107' ' ' ASP . 0.2 OUTLIER -125.14 112.77 16.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.085 179.794 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.455 ' HA ' ' HA ' ' A' ' 103' ' ' PRO . 0.6 OUTLIER -124.39 155.14 39.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.258 0.552 . . . . 0.0 112.045 -178.999 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.862 HG22 HG12 ' A' ' 149' ' ' VAL . 1.0 OUTLIER -114.92 151.76 16.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.937 178.984 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.426 ' CD2' ' HA3' ' A' ' 101' ' ' GLY . 20.1 m-85 -146.86 146.1 30.08 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.948 0.404 . . . . 0.0 111.706 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.3 m -142.54 129.87 21.1 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.325 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.24 130.22 52.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-O 121.02 0.438 . . . . 0.0 111.752 -179.47 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.407 ' C ' HD23 ' A' ' 114' ' ' LEU . 6.1 tt -133.59 122.94 24.25 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.252 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.465 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -175.87 -140.8 3.57 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.494 -0.86 . . . . 0.0 112.576 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.475 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -142.53 161.52 27.37 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.888 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.408 ' HA ' ' CB ' ' A' ' 95' ' ' GLN . 0.2 OUTLIER -119.53 146.55 45.37 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.847 0.356 . . . . 0.0 110.753 -179.943 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -129.82 144.08 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.985 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -130.23 141.55 50.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.913 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 5.4 mmm180 -137.22 151.21 48.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.917 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -101.9 168.63 9.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.053 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -124.78 134.4 52.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.958 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -75.65 141.94 42.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.905 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.72 122.64 28.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.847 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -164.42 91.53 0.11 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.486 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -60.32 -47.94 83.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.802 0.334 . . . . 0.0 110.895 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -124.54 124.48 42.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.902 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -124.99 148.85 48.25 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.104 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.1 m -109.16 -48.72 3.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.4 p -134.57 174.97 9.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.989 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -67.32 -163.53 1.98 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.506 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 7.7 m -141.49 126.43 17.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.837 0.351 . . . . 0.0 111.126 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -85.92 -37.25 19.28 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -67.1 81.52 0.12 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.852 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.7 m -87.42 100.47 12.76 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.941 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -140.57 104.02 4.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 70.2 m80 -148.96 -179.02 6.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.867 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -135.46 131.17 35.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.868 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.5 t -114.06 143.72 44.31 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -94.93 143.95 16.9 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.563 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.6 p -146.1 132.1 13.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.752 0.31 . . . . 0.0 110.962 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.463 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 1.5 t -157.08 130.19 4.48 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.228 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.475 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.7 Cg_exo -73.8 147.31 39.37 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.639 2.226 . . . . 0.0 112.009 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.2 m -156.49 153.79 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.918 0.389 . . . . 0.0 111.46 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -149.1 124.05 10.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.658 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -117.75 145.81 44.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 0.0 111.339 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.49 132.72 5.91 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.226 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.441 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -163.32 -154.49 7.72 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.405 -0.902 . . . . 0.0 112.962 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.862 HG12 HG22 ' A' ' 110' ' ' ILE . 12.9 m -137.3 170.88 17.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.631 0.253 . . . . 0.0 110.949 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -147.25 150.75 35.44 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.953 0.406 . . . . 0.0 111.267 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . 0.422 ' CE2' ' HB ' ' A' ' 159' ' ' THR . 37.1 p90 -126.74 138.61 53.41 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.811 179.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.405 ' HA ' ' CB ' ' A' ' 158' ' ' ALA . . . -91.65 137.24 32.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.411 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 52.3 t -108.94 -47.58 7.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.48 179.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -109.69 -165.07 0.98 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.282 179.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 4.1 ttm180 -100.56 41.86 1.15 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.758 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.2 t0 178.13 -28.64 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.788 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 27.2 mt -114.95 134.29 58.47 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.982 0.42 . . . . 0.0 111.554 -179.518 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . 0.405 ' CB ' ' HA ' ' A' ' 152' ' ' ALA . . . -140.11 161.15 38.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.057 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . 0.422 ' HB ' ' CE2' ' A' ' 151' ' ' TRP . 9.7 m -106.26 150.78 25.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.227 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? -137.09 142.23 42.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.172 0.511 . . . . 0.0 111.834 -179.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 162' ' ' GLU . 1.4 tt -123.65 117.89 26.02 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.601 178.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.409 ' N ' HD23 ' A' ' 161' ' ' LEU . 1.7 pt-20 -107.82 141.11 39.89 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.979 0.419 . . . . 0.0 111.635 -179.169 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.441 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 27.2 p90 -134.33 166.08 23.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.653 179.615 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -77.96 128.93 34.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.005 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -70.06 103.81 2.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.86 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.453 ' O ' HG13 ' A' ' 166' ' ' VAL . 12.4 p -166.97 122.64 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.091 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 20.4 m-80 -83.85 -34.95 24.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.848 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.09 138.88 35.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.842 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 1.7 pp -111.47 -30.25 2.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.14 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . 179.95 62.95 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.492 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -116.16 -51.68 2.62 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.762 0.315 . . . . 0.0 110.828 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.427 ' HB1' ' HA3' ' A' ' 176' ' ' GLY . . . -60.96 -177.76 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.119 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 178.02 -36.33 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.476 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.455 HG23 HG13 ' A' ' 175' ' ' VAL . 4.0 t -113.04 -46.34 3.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.875 0.369 . . . . 0.0 110.924 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.455 HG13 HG23 ' A' ' 174' ' ' THR . 27.6 m -87.17 -30.67 5.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.166 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . 0.427 ' HA3' ' HB1' ' A' ' 172' ' ' ALA . . . -83.31 77.66 2.1 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.412 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 19.3 p -125.69 79.44 1.82 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.882 0.372 . . . . 0.0 110.865 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.55 93.24 43.21 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -67.99 95.62 0.43 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.451 2.101 . . . . 0.0 112.313 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 22.4 p30 -120.09 174.8 6.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.911 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -113.35 151.8 30.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.862 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 160.07 137.92 2.33 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.495 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . 0.563 ' HE2' HD12 ' A' ' 184' ' ' LEU . 0.0 OUTLIER -154.23 171.6 18.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.768 0.318 . . . . 0.0 110.861 -179.986 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.563 HD12 ' HE2' ' A' ' 183' ' ' MET . 3.9 mp -94.42 127.8 40.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.908 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 51.0 m -140.98 150.09 42.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.132 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -121.65 138.04 54.5 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.521 179.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -157.06 176.31 34.33 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.955 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -125.9 137.78 56.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.737 0.304 . . . . 0.0 110.496 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . 0.446 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . 3.6 p -138.59 171.57 14.17 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.377 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -148.0 156.62 42.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.642 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.446 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 0.0 OUTLIER -123.94 157.03 35.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.038 -179.918 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -141.43 160.93 39.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.777 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -112.2 113.15 3.21 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.488 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -135.26 121.58 20.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.845 0.355 . . . . 0.0 110.891 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -95.48 170.6 9.24 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -63.89 125.81 25.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.847 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -112.2 120.78 42.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.132 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . 0.779 ' HB3' ' HD3' ' A' ' 199' ' ' PRO . . . -173.06 -63.15 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.229 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.779 ' HD3' ' HB3' ' A' ' 198' ' ' ALA . 59.7 Cg_endo -72.34 140.17 33.18 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.454 2.103 . . . . 0.0 112.327 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 21.5 t -60.09 95.77 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.143 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . 0.639 HG22 ' O ' ' A' ' 201' ' ' VAL . 14.6 p -115.66 26.72 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.216 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . 0.805 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -79.76 -61.8 0.44 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.208 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.805 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 73.7 Cg_endo -75.16 151.14 38.47 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.513 2.142 . . . . 0.0 112.397 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -119.13 83.56 24.8 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.006 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.54 -17.37 38.61 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.642 2.228 . . . . 0.0 112.483 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -55.18 147.74 34.03 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.198 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -52.82 -176.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.481 2.12 . . . . 0.0 112.303 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -129.78 98.96 21.02 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.992 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.98 147.27 73.72 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.454 2.103 . . . . 0.0 112.264 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.221 -0.895 . . . . 0.0 110.841 -179.964 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 120.775 0.322 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.3 ttt85 -103.55 142.3 34.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.633 HD13 HD11 ' A' ' 7' ' ' ILE . 2.5 pp -67.57 134.85 29.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.134 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -137.27 31.56 2.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.872 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -123.04 170.14 10.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.818 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.7 113.64 19.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.026 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.693 HG21 HD12 ' A' ' 10' ' ' LEU . 3.3 mp -95.44 111.69 26.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.17 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -92.04 -31.77 15.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.907 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 11.6 p -117.47 127.8 74.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.06 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.693 HD12 HG21 ' A' ' 7' ' ' ILE . 0.5 OUTLIER -167.54 -49.47 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.845 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -89.11 -38.01 14.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.947 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -107.22 99.99 9.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.165 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.684 ' HB1' ' HD2' ' A' ' 14' ' ' PRO . . . -87.53 165.33 31.01 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.992 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.684 ' HD2' ' HB1' ' A' ' 13' ' ' ALA . 18.3 Cg_endo -59.87 83.86 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.498 2.132 . . . . 0.0 112.18 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.2 tttp -89.43 -7.71 54.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.349 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 -89.19 45.33 1.28 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.766 0.317 . . . . 0.0 111.309 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.428 ' HB3' ' CZ3' ' A' ' 19' ' ' TRP . 3.7 m-20 -108.22 156.93 18.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.82 0.343 . . . . 0.0 110.974 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.1 t -147.02 145.93 29.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.843 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.438 ' CD1' ' HB3' ' A' ' 60' ' ' TYR . 2.7 m-90 -132.3 129.97 40.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.037 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.422 ' CE2' ' HB3' ' A' ' 191' ' ' ARG . 0.2 OUTLIER -121.67 135.85 54.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.683 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.05 139.82 23.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.396 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -176.9 -158.56 20.49 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.417 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.79 149.65 21.52 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.534 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -130.61 154.91 47.37 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 121.055 0.455 . . . . 0.0 111.135 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.638 HD21 HD13 ' A' ' 52' ' ' LEU . 1.4 tt -127.04 141.7 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.641 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -148.76 171.86 29.01 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.592 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 2.1 m95 -99.16 133.42 43.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.773 0.32 . . . . 0.0 110.871 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.8 m -162.13 121.81 2.42 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.889 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -140.27 83.09 1.89 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -163.81 85.38 0.48 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.8 m80 -105.28 -38.93 6.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.869 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -156.65 156.11 32.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.872 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.37 117.16 27.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.932 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 81.49 -177.22 54.17 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.48 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -136.09 138.7 42.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.87 0.367 . . . . 0.0 110.921 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 1.1 t80 -108.19 37.21 2.54 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.91 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.7 141.66 15.3 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.464 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -120.17 164.09 16.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.824 0.345 . . . . 0.0 110.831 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -101.4 144.85 16.64 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.499 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -126.43 -62.62 1.14 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.872 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -130.78 -56.33 1.06 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.912 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -81.8 178.51 8.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.846 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -132.21 -47.85 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.777 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 7.5 m-80 -77.95 151.92 33.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.969 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -116.35 156.03 15.88 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.518 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.11 -61.34 0.52 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.543 2.162 . . . . 0.0 112.261 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.8 m -79.31 162.39 25.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.922 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 3.3 ttt-85 -84.13 -178.39 6.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.751 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -89.51 -42.19 11.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.847 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -93.42 151.53 19.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.852 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -157.63 135.29 10.59 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.638 HD13 HD21 ' A' ' 25' ' ' LEU . 0.3 OUTLIER -88.05 167.75 13.41 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.91 138.54 14.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.534 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -131.26 138.7 49.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.689 0.28 . . . . 0.0 110.863 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.62 156.32 26.8 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.336 -0.935 . . . . 0.0 112.921 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -105.45 133.84 49.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.717 0.294 . . . . 0.0 110.844 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -119.75 127.17 52.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.967 0.413 . . . . 0.0 111.075 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -145.56 124.85 2.18 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.139 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -128.5 173.38 19.17 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.55 -0.833 . . . . 0.0 112.798 -179.727 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.438 ' HB3' ' CD1' ' A' ' 19' ' ' TRP . 21.7 p90 -154.02 131.75 11.51 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 110.781 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -94.48 137.03 34.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.883 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.3 t -119.68 -45.2 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.886 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -109.25 146.53 34.11 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.613 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.41 ' O ' ' CD2' ' A' ' 65' ' ' TYR . 41.1 Cg_endo -67.53 65.37 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.545 2.164 . . . . 0.0 112.148 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.41 ' CD2' ' O ' ' A' ' 64' ' ' PRO . 9.9 m-85 -164.82 -42.28 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.178 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -170.29 164.17 8.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.191 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -131.03 175.17 19.61 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.44 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -95.7 134.71 38.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.418 ' HB2' ' HB2' ' A' ' 99' ' ' LYS . 0.0 OUTLIER -114.67 128.41 56.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.931 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -114.15 119.76 38.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.33 179.437 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.91 154.59 16.48 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.481 -0.866 . . . . 0.0 112.783 -179.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 -130.09 114.83 16.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.579 0.228 . . . . 0.0 110.659 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.32 125.77 35.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.115 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 10.8 m95 -139.18 140.66 37.89 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.844 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.539 HD23 ' N ' ' A' ' 75' ' ' LEU . 1.2 pt? -169.24 46.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.968 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -168.52 152.34 20.17 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.674 -0.775 . . . . 0.0 112.508 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 19.9 mtp180 -114.3 115.92 28.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.878 0.371 . . . . 0.0 110.825 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 63.6 mtp -61.5 160.82 10.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.945 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -109.36 167.91 9.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.984 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . 0.419 ' CE2' ' HG2' ' A' ' 81' ' ' LYS . 47.8 p90 -67.13 -31.01 71.17 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.843 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . 0.419 ' HG2' ' CE2' ' A' ' 80' ' ' TYR . 41.0 mmtt -66.41 169.62 7.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.83 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -173.98 162.45 33.08 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.582 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -76.71 160.97 28.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.808 0.337 . . . . 0.0 110.955 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 84' ' ' VAL . 15.8 t -127.96 31.58 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.126 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -151.56 -67.09 0.18 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.853 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.7 t-20 -95.51 89.44 5.4 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.902 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -144.36 54.43 0.57 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.56 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -69.73 -46.86 64.96 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.817 0.342 . . . . 0.0 111.068 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 18.8 p90 -148.01 161.17 41.91 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.898 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.14 -167.59 1.93 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.837 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -125.0 142.89 51.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.124 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 12.1 pm0 -175.01 157.42 2.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.734 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -82.26 130.94 10.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.586 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.47 119.74 55.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.786 0.327 . . . . 0.0 110.446 179.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 139.87 43.06 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.534 -179.362 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.416 ' O ' HD23 ' A' ' 96' ' ' LEU . 1.7 tt -130.25 110.88 11.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.972 179.537 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.425 ' HB ' ' HA3' ' A' ' 115' ' ' GLY . 0.1 OUTLIER -150.49 168.94 22.72 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.993 0.425 . . . . 0.0 111.565 -179.147 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 113' ' ' ARG . . . -104.1 125.91 50.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.197 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.421 ' HE3' ' CG ' ' A' ' 111' ' ' TYR . 0.6 OUTLIER -104.25 132.21 50.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.997 0.427 . . . . 0.0 111.752 -179.165 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.598 ' O ' HD12 ' A' ' 100' ' ' LEU . 2.8 pp -134.82 115.74 14.01 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.388 179.114 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.05 41.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.672 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -166.28 167.05 8.83 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.713 0.292 . . . . 0.0 111.116 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -53.3 167.87 0.73 Allowed 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.488 2.125 . . . . 0.0 111.941 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.615 HG23 ' OG1' ' A' ' 105' ' ' THR . 1.0 OUTLIER -121.13 -34.38 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 120.693 0.282 . . . . 0.0 111.679 -179.818 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.615 ' OG1' HG23 ' A' ' 104' ' ' ILE . 0.2 OUTLIER -157.6 -53.45 0.07 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.761 0.315 . . . . 0.0 110.991 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -175.22 109.89 0.11 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.092 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.592 ' O ' HD23 ' A' ' 108' ' ' LEU . 0.1 OUTLIER 71.35 22.33 4.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.539 179.657 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.764 HD22 ' NE1' ' A' ' 151' ' ' TRP . 0.1 OUTLIER -142.81 117.38 9.75 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.582 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.413 ' HB2' ' CG ' ' A' ' 150' ' ' GLU . 0.4 OUTLIER -125.41 152.95 44.16 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.225 0.536 . . . . 0.0 112.009 -178.903 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.93 130.88 73.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.044 179.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.421 ' CG ' ' HE3' ' A' ' 99' ' ' LYS . 53.1 p90 -144.06 153.62 42.38 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.915 0.388 . . . . 0.0 111.526 -179.446 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 2.1 t -136.94 133.11 35.3 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.69 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 98' ' ' ALA . 5.8 ptp180 -111.42 128.36 55.96 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.145 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -124.64 123.61 40.42 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.619 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.425 ' HA3' ' HB ' ' A' ' 97' ' ' THR . . . 178.82 -132.46 1.9 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.547 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.548 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -148.24 169.08 28.94 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.821 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.07 139.86 51.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.795 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 2.0 t -126.17 132.9 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.809 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 85.3 t90 -134.23 140.38 46.43 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.864 0.364 . . . . 0.0 110.95 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.97 164.03 14.34 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.769 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -100.07 152.92 19.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.124 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -62.95 131.46 48.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.041 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 1.6 m -102.29 139.09 38.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.948 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 19.3 tttt -145.6 131.1 18.74 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.854 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -122.5 28.59 5.7 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.5 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -103.8 32.26 4.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.857 0.361 . . . . 0.0 110.863 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -81.53 111.17 17.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.882 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -98.89 31.19 3.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.963 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -174.78 136.87 0.43 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.95 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -127.48 38.55 4.04 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.811 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . 0.483 ' O ' HG13 ' A' ' 132' ' ' VAL . . . -142.3 28.43 2.21 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.509 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.483 HG13 ' O ' ' A' ' 131' ' ' GLY . 6.2 m -157.48 -46.87 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.86 0.362 . . . . 0.0 111.17 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.409 ' N ' HG23 ' A' ' 132' ' ' VAL . 1.1 t -97.63 179.89 4.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.898 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -150.08 162.37 40.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.875 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.88 105.34 13.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.886 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -83.28 93.26 7.67 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.886 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -93.56 113.35 25.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.906 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -141.43 163.41 33.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.7 p -138.59 146.17 41.46 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.875 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -122.34 102.5 0.79 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.53 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.444 ' O ' HG13 ' A' ' 141' ' ' VAL . 10.2 p -136.11 123.61 34.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.697 0.284 . . . . 0.0 111.054 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.27 150.12 18.33 Favored Pre-proline 0 C--N 1.331 -0.217 0 CA-C-O 120.922 0.392 . . . . 0.0 111.421 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.548 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 94.7 Cg_endo -78.77 141.14 16.91 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.758 2.306 . . . . 0.0 112.133 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 35.5 m -156.86 160.66 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.855 0.36 . . . . 0.0 111.418 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 145' ' ' PHE . 4.6 p90 -141.6 122.47 14.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.472 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -111.8 138.2 48.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.962 0.41 . . . . 0.0 111.473 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -127.66 138.22 10.32 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.818 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -163.71 -165.71 21.34 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.078 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 17.2 m -135.47 167.05 26.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.659 0.266 . . . . 0.0 111.149 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.413 ' CG ' ' HB2' ' A' ' 109' ' ' ASP . 13.4 pt-20 -136.34 141.09 43.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.999 0.428 . . . . 0.0 111.172 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . 0.764 ' NE1' HD22 ' A' ' 108' ' ' LEU . 0.0 OUTLIER -122.31 123.07 40.57 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.628 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.16 131.86 35.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.786 HG12 HG22 ' A' ' 154' ' ' THR . 48.8 t -100.56 -64.01 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.013 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . 0.786 HG22 HG12 ' A' ' 153' ' ' VAL . 9.0 t -176.59 173.9 1.95 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.981 0.42 . . . . 0.0 111.826 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 65.62 -86.09 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.378 179.683 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -174.44 32.59 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.839 0.352 . . . . 0.0 110.653 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 28.3 mt -140.05 117.88 10.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.875 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.25 163.77 14.8 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.385 -179.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.9 t -110.8 143.24 41.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.098 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.02 146.64 45.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.28 0.562 . . . . 0.0 111.855 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 1.3 tt -116.63 124.8 50.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.698 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -116.51 141.01 48.73 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.029 0.442 . . . . 0.0 111.524 -179.181 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . . . . . . . . . 14.2 p90 -134.22 157.61 45.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.468 179.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 -83.52 -68.58 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 8.2 t90 -140.55 103.13 4.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.811 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.3 t -123.89 121.96 63.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.211 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -132.47 30.72 4.11 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.821 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -77.4 136.14 38.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.884 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . . . . . . . . . 23.0 mt -107.08 -26.85 3.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.24 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -56.32 114.6 5.25 Favored Glycine 0 C--N 1.33 0.217 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.52 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 6.9 t0 -97.28 39.07 1.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.865 0.364 . . . . 0.0 110.889 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -91.1 -31.23 16.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.083 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -149.58 92.34 0.14 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.498 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.0 m -86.3 -31.62 21.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.9 0.381 . . . . 0.0 110.96 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.0 100.96 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.147 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -103.65 -108.24 3.25 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.52 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 84.4 m -128.26 -70.37 0.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.794 0.33 . . . . 0.0 110.908 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 16.5 mmt180 -132.13 97.77 17.94 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.871 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.94 134.86 33.32 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.438 2.092 . . . . 0.0 112.231 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -127.43 31.94 5.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.946 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . 0.508 ' O ' HD11 ' A' ' 184' ' ' LEU . 0.9 OUTLIER -95.66 79.33 3.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.859 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 92.17 -129.76 9.99 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.448 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 2.3 ttt -124.32 97.68 5.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.508 HD11 ' O ' ' A' ' 181' ' ' ASN . 5.9 mp -122.23 142.02 50.88 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.741 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.99 155.58 41.69 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.996 0.427 . . . . 0.0 111.221 -179.768 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -116.53 139.08 50.88 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.355 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -153.53 171.1 32.35 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.281 -0.961 . . . . 0.0 113.166 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.5 137.23 57.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.694 0.283 . . . . 0.0 110.489 179.584 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 77.9 p -140.77 174.95 10.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.992 0.425 . . . . 0.0 111.294 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -137.41 157.1 47.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.585 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.422 ' HB3' ' CE2' ' A' ' 20' ' ' TYR . 0.4 OUTLIER -113.88 124.8 53.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.916 -179.968 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -65.45 89.03 0.09 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.854 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -124.13 138.46 11.33 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.47 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -144.55 31.49 1.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.8 0.333 . . . . 0.0 110.815 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.62 158.46 29.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.865 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -129.72 144.46 51.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.923 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -65.73 124.0 21.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.033 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . 0.653 ' HB3' ' CD ' ' A' ' 199' ' ' PRO . . . -173.08 -63.54 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.247 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.653 ' CD ' ' HB3' ' A' ' 198' ' ' ALA . 19.4 Cg_endo -59.35 -67.46 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.455 2.103 . . . . 0.0 112.27 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 7.0 m -153.05 179.62 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.142 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 13.5 m -125.85 179.63 3.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.068 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . 0.753 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -59.41 -61.28 8.17 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.07 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.753 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 59.7 Cg_endo -72.16 141.95 37.03 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.611 2.208 . . . . 0.0 112.315 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -125.42 146.63 55.06 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.981 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -72.89 132.32 18.25 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.466 2.111 . . . . 0.0 112.353 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -126.76 87.29 56.85 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.019 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.15 -61.55 0.49 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.555 2.17 . . . . 0.0 112.282 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -94.66 149.4 36.42 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.073 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.57 -28.3 36.14 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.55 2.167 . . . . 0.0 112.289 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.157 -0.925 . . . . 0.0 110.906 179.912 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.395 0 CA-C-O 120.864 0.364 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.0 tpt180 -138.78 -62.03 0.56 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.406 HG23 ' N ' ' A' ' 4' ' ' MET . 4.9 tp -120.3 -40.39 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.266 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.406 ' N ' HG23 ' A' ' 3' ' ' ILE . 6.0 mtt -129.41 92.71 3.4 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.021 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.74 -34.53 3.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.038 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -88.92 60.25 5.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.088 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 26.1 mm -102.0 -63.24 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.044 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -173.0 126.62 0.46 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.937 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.776 ' O ' HD22 ' A' ' 10' ' ' LEU . 12.5 p -141.98 -45.81 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.183 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.776 HD22 ' O ' ' A' ' 9' ' ' VAL . 0.4 OUTLIER -149.05 -56.02 0.19 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.921 179.925 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 59.5 t30 -62.4 123.92 19.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.993 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -126.99 134.83 50.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.066 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -87.71 144.25 34.92 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.185 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -74.27 -168.1 0.45 Allowed 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.584 2.189 . . . . 0.0 112.329 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.23 111.13 23.57 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.886 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -64.3 152.73 40.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 22.7 m-20 -107.99 151.84 25.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 68.9 p -117.61 157.73 25.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.81 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.9 m95 -139.88 138.54 35.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.979 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 1.7 m-85 -131.8 135.88 47.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.685 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.71 146.03 30.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.322 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.36 -177.62 48.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.9 150.29 21.37 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.441 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.468 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 0.6 OUTLIER -135.57 153.68 51.61 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 111.21 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.879 HD12 ' O ' ' A' ' 53' ' ' GLY . 41.9 tp -124.03 147.93 47.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.541 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -151.42 175.74 30.16 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.481 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 4.0 m-90 -124.79 144.99 49.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.741 0.305 . . . . 0.0 110.885 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.9 t -102.5 168.8 9.06 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.932 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 1.1 mm100 -72.13 160.02 33.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.889 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 40.1 p90 -103.16 132.21 49.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.868 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -60.82 178.36 0.24 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -115.71 106.45 13.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.921 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 71.4 p -93.72 -48.12 6.47 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.85 -61.59 3.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.528 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -96.82 135.54 38.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.785 0.326 . . . . 0.0 110.832 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 14.5 p90 -149.34 -47.16 0.14 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.888 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -103.34 126.4 8.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.512 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -65.53 -57.51 8.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 110.924 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -137.36 -45.09 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.477 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -124.14 174.36 7.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 110.916 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -158.53 126.25 5.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.938 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -108.22 157.01 18.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.905 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -123.4 30.49 6.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.003 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -104.37 30.41 5.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.761 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -141.88 -136.91 3.31 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.432 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -67.99 167.02 22.77 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.505 2.136 . . . . 0.0 112.187 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 61.9 p -131.27 121.27 24.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.027 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -71.86 119.01 15.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -105.82 158.16 16.94 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.973 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -65.85 152.21 44.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.957 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.14 117.07 7.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.756 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.77 147.26 25.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.848 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.879 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -136.38 130.63 5.34 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.449 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.88 133.42 51.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.767 0.317 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.425 ' HA2' ' O ' ' A' ' 72' ' ' TYR . . . -139.73 137.95 8.85 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.881 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.714 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -99.5 144.76 28.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.803 0.335 . . . . 0.0 110.563 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.435 ' CE2' ' HD3' ' A' ' 24' ' ' LYS . 51.3 m-85 -136.16 133.52 37.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.035 0.445 . . . . 0.0 111.345 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -149.73 126.52 2.22 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.963 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -125.58 169.45 17.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.839 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.422 ' CE2' ' HB3' ' A' ' 68' ' ' PHE . 42.6 p90 -147.12 135.53 21.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -88.45 137.01 32.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.846 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 32.5 t -130.13 -46.78 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.921 0.391 . . . . 0.0 110.931 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -106.82 143.23 26.64 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.47 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.42 ' O ' ' CG ' ' A' ' 65' ' ' TYR . 46.6 Cg_endo -68.39 63.16 1.13 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.436 2.091 . . . . 0.0 112.139 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.655 ' HB3' HD23 ' A' ' 66' ' ' LEU . 8.3 m-85 -168.49 -38.31 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.434 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.655 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.2 OUTLIER -161.78 164.14 29.07 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.906 0.384 . . . . 0.0 111.148 -179.63 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -130.43 159.53 22.83 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.472 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.422 ' HB3' ' CE2' ' A' ' 60' ' ' TYR . 0.8 OUTLIER -82.09 144.86 30.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.554 0.216 . . . . 0.0 110.706 179.928 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.93 127.29 33.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.422 . . . . 0.0 111.074 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.0 ptp -109.26 133.21 53.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.98 151.86 17.34 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.766 -179.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.714 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 14.6 m-85 -129.93 118.13 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.615 0.245 . . . . 0.0 110.55 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.0 122.0 37.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.133 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 -139.06 125.38 20.29 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.083 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.5 mp -100.41 -32.69 10.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.873 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 78.72 -151.75 36.23 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.506 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.37 133.11 51.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.786 0.327 . . . . 0.0 110.814 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -156.5 -58.81 0.09 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.934 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -78.54 135.56 37.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.092 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -91.54 50.41 1.72 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.895 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 4.8 tttt -142.96 116.79 9.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.892 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -149.02 167.66 29.44 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.536 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 35.9 m -82.32 109.56 16.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.835 0.35 . . . . 0.0 110.814 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.592 ' O ' HG12 ' A' ' 84' ' ' VAL . 16.2 t -129.71 31.48 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.098 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -107.87 -72.88 0.71 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.926 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -133.87 103.6 5.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.911 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 98.04 163.08 30.96 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.471 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -137.79 175.64 9.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.792 0.329 . . . . 0.0 111.049 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 25.8 p90 -159.37 164.02 35.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.012 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 18.7 mmtt -121.66 -178.4 3.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.852 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -147.9 108.33 4.12 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.072 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -147.7 125.01 11.54 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.608 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -100.78 135.37 12.11 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.937 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -128.32 117.98 46.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.798 0.333 . . . . 0.0 110.123 179.252 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . 0.401 ' CG ' ' CB ' ' A' ' 117' ' ' MET . 8.2 mt-30 -108.86 145.39 35.38 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.192 0.52 . . . . 0.0 111.925 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.3 tt -130.02 110.32 11.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.256 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.8 p -150.22 170.04 19.9 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.233 0.54 . . . . 0.0 111.984 -178.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.68 134.51 45.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.014 178.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -118.85 131.95 56.1 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.062 0.458 . . . . 0.0 111.581 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.609 ' O ' HD12 ' A' ' 100' ' ' LEU . 3.5 pp -131.85 121.67 24.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.96 179.12 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.437 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -115.95 -177.02 18.34 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.433 -0.889 . . . . 0.0 113.088 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -166.07 122.58 0.99 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 115.803 -0.198 . . . . 0.0 110.71 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -69.12 168.75 19.81 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.435 2.09 . . . . 0.0 112.391 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.645 HG22 HG23 ' A' ' 105' ' ' THR . 27.6 mm -117.22 -43.32 3.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.894 179.758 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.645 HG23 HG22 ' A' ' 104' ' ' ILE . 29.6 p -147.63 -82.71 0.12 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.823 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -155.31 21.83 0.42 Allowed 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.205 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.882 ' O ' HD23 ' A' ' 108' ' ' LEU . 5.3 p-10 -175.61 24.69 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.609 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.882 HD23 ' O ' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -154.38 124.48 6.81 Favored 'General case' 0 C--N 1.331 -0.199 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.588 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -143.07 159.64 41.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.101 0.477 . . . . 0.0 111.628 -179.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 1.031 HG22 HG12 ' A' ' 149' ' ' VAL . 1.3 pt -114.64 154.81 15.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.316 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.437 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 91.5 m-85 -143.04 138.57 30.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.951 0.405 . . . . 0.0 111.664 -179.508 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 31.6 m -125.2 127.63 47.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.313 179.393 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -116.54 127.88 54.92 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.38 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.5 tt -137.96 122.58 18.59 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.511 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . 179.26 -137.7 3.24 Favored Glycine 0 C--N 1.332 0.359 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.524 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.494 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.93 162.34 27.09 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.945 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.401 ' CB ' ' CG ' ' A' ' 95' ' ' GLN . 2.2 ptt? -119.63 142.31 48.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.801 0.334 . . . . 0.0 110.771 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.6 t -133.88 123.81 45.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.688 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.488 ' HZ3' ' HB3' ' A' ' 121' ' ' ALA . 61.8 p-90 -133.21 161.61 33.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.003 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.08 150.27 50.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.921 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.488 ' HB3' ' HZ3' ' A' ' 119' ' ' TRP . . . -173.53 150.95 1.85 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.069 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -125.57 120.61 31.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 2.4 p -119.12 31.38 6.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 5.3 mttp -121.73 137.59 54.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.84 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -144.83 -100.42 0.3 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.49 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 17.5 m-80 -77.6 83.51 3.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.799 0.333 . . . . 0.0 110.845 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -146.23 32.67 0.99 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.875 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -68.66 119.95 13.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.213 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 4.0 p -86.13 -56.65 3.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.2 p -146.7 -48.27 0.19 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.93 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -169.45 41.05 0.21 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.523 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 9.6 p -73.97 149.17 7.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.878 0.37 . . . . 0.0 111.076 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 88.4 p -135.01 165.37 25.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.899 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 24.2 mtt85 -91.84 99.78 12.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.931 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 1.3 m -95.89 -37.08 10.86 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.868 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -140.07 127.65 21.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.817 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 42.2 m80 -73.36 -179.72 3.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.012 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -124.62 130.5 52.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.914 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 8.8 m -129.44 121.73 27.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.927 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.422 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -70.18 147.29 44.13 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.43 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 8.9 p -146.13 133.58 15.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.705 0.288 . . . . 0.0 111.012 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.8 m -157.01 137.38 8.99 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.329 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.494 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 89.4 Cg_endo -81.09 143.47 14.26 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 122.682 2.254 . . . . 0.0 112.084 179.75 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 143' ' ' PRO . 29.2 m -157.08 163.53 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 120.931 0.396 . . . . 0.0 111.516 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -149.04 126.36 11.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.574 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.665 ' HB1' ' CD ' ' A' ' 162' ' ' GLU . . . -111.91 152.48 27.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.906 0.384 . . . . 0.0 111.267 -179.722 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -145.0 131.45 4.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.239 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA2' ' CE2' ' A' ' 163' ' ' TYR . . . -161.03 -160.05 10.44 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.824 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 1.031 HG12 HG22 ' A' ' 110' ' ' ILE . 5.5 m -134.41 167.72 25.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.628 0.252 . . . . 0.0 110.951 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -134.8 137.05 43.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.007 0.432 . . . . 0.0 111.189 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . 0.49 ' CZ3' HG22 ' A' ' 153' ' ' VAL . 1.4 t90 -114.91 123.32 48.85 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.574 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -89.81 130.74 36.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.523 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.49 HG22 ' CZ3' ' A' ' 151' ' ' TRP . 39.3 t -115.99 -57.44 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.852 179.647 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.22 -165.39 1.34 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.743 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.19 -28.64 23.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.076 -179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -139.51 18.66 2.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.312 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 20.1 mt -137.62 116.64 14.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.566 -0.288 . . . . 0.0 111.008 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -134.32 168.55 18.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.952 0.406 . . . . 0.0 111.242 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . 0.704 HG22 HG12 ' A' ' 188' ' ' VAL . 29.1 p -113.43 153.18 29.04 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.135 179.614 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 14.8 ptp180 -137.19 141.66 42.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.233 0.539 . . . . 0.0 111.892 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -121.54 118.16 28.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.656 178.853 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.665 ' CD ' ' HB1' ' A' ' 146' ' ' ALA . 0.4 OUTLIER -108.34 143.66 36.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.97 0.414 . . . . 0.0 111.768 -178.832 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.43 ' CE2' ' HA2' ' A' ' 148' ' ' GLY . 9.2 p90 -134.25 162.88 30.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.509 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -78.22 -44.16 26.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.782 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -177.13 164.15 2.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.935 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 11.5 p -58.65 142.5 14.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.138 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 2.5 t30 -110.78 161.71 15.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.865 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -130.78 -175.04 3.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . 0.446 HD12 ' N ' ' A' ' 170' ' ' GLY . 2.6 pp -124.11 -37.05 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.247 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . 0.446 ' N ' HD12 ' A' ' 169' ' ' ILE . . . -95.94 28.34 13.04 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.525 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -91.65 -51.01 5.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.804 0.335 . . . . 0.0 110.883 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -82.1 -175.69 5.77 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.033 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -131.89 -133.25 3.43 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.445 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.8 m -76.02 -64.83 1.01 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.794 0.33 . . . . 0.0 110.814 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.522 ' O ' HG23 ' A' ' 175' ' ' VAL . 31.9 m -92.92 116.96 35.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.149 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -117.35 96.25 0.69 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.54 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -100.09 -66.93 0.88 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.74 0.305 . . . . 0.0 110.813 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . 0.438 ' N ' ' CD ' ' A' ' 179' ' ' PRO . 0.0 OUTLIER -73.45 -51.07 5.8 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.025 -179.917 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . 0.438 ' CD ' ' N ' ' A' ' 178' ' ' ARG . 32.5 Cg_exo -57.86 84.95 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.516 2.144 . . . . 0.0 112.301 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -162.79 87.57 0.59 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 10.7 t-20 -127.36 102.13 6.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.843 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -148.17 113.21 0.61 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.563 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 1.5 tpp -130.02 97.18 4.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.794 0.33 . . . . 0.0 110.815 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . . . . . . . . . 3.5 mp -111.28 116.2 30.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.973 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 30.2 t -118.52 147.42 43.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.768 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -126.52 139.36 53.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.709 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -156.67 -177.03 29.43 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.414 -0.898 . . . . 0.0 113.063 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . 0.704 HG12 HG22 ' A' ' 159' ' ' THR . 1.3 m -130.82 142.84 42.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.675 0.274 . . . . 0.0 110.598 179.61 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 89.0 p -143.24 170.83 15.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.998 0.427 . . . . 0.0 111.449 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 44.3 p90 -138.66 154.88 48.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.58 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.13 154.25 40.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -96.68 96.14 8.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.958 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -82.46 -168.4 42.07 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.51 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -97.85 120.79 38.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.824 0.345 . . . . 0.0 110.888 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -70.98 178.05 3.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.901 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -130.61 165.84 21.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -122.89 33.13 5.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.084 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -103.09 104.86 42.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.003 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -68.28 -42.8 5.16 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.504 2.136 . . . . 0.0 112.283 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . 0.536 HG22 ' H ' ' A' ' 202' ' ' ALA . 11.5 p -137.64 120.7 20.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.213 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . 0.578 ' O ' HG12 ' A' ' 201' ' ' VAL . 16.9 t -103.72 34.91 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.986 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . 0.536 ' H ' HG22 ' A' ' 200' ' ' VAL . . . -122.23 84.79 46.53 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.018 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.14 -70.07 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.561 2.174 . . . . 0.0 112.254 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . 0.739 ' HB3' ' HD3' ' A' ' 205' ' ' PRO . . . -73.21 -61.19 1.54 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.139 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . 0.739 ' HD3' ' HB3' ' A' ' 204' ' ' ALA . 59.7 Cg_endo -72.3 -173.77 1.22 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.499 2.133 . . . . 0.0 112.374 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -112.61 152.45 44.7 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.153 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . 0.441 ' HB3' HG23 ' A' ' 200' ' ' VAL . 52.0 Cg_endo -69.34 -46.21 1.49 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.563 2.176 . . . . 0.0 112.229 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -149.92 146.31 20.23 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.113 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.23 125.84 19.69 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.57 2.18 . . . . 0.0 112.328 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.234 -0.888 . . . . 0.0 110.91 179.963 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 120.856 0.36 . . . . 0.0 111.046 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -97.92 123.37 41.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.6 tp -150.8 147.15 15.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.151 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -119.9 -55.71 2.07 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HE2' ' CD2' ' A' ' 8' ' ' PHE . 28.5 tttt -158.9 135.5 9.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.935 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -118.1 -43.19 2.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.084 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 36.2 mm -67.88 122.39 18.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.164 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.416 ' CD2' ' HE2' ' A' ' 5' ' ' LYS . 0.2 OUTLIER -134.7 171.48 14.3 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 -179.895 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.612 ' O ' HG13 ' A' ' 9' ' ' VAL . 9.0 p -130.31 105.57 11.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.115 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.471 ' O ' HD12 ' A' ' 10' ' ' LEU . 2.2 pp -175.07 141.33 0.57 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.88 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -62.45 155.17 26.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.91 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.01 85.59 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.125 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.743 ' HB3' ' HD3' ' A' ' 14' ' ' PRO . . . -76.86 -52.5 1.99 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.145 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.743 ' HD3' ' HB3' ' A' ' 13' ' ' ALA . 47.8 Cg_exo -55.81 86.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.58 2.187 . . . . 0.0 112.248 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.2 pttt -95.96 55.89 1.63 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.854 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.74 147.07 43.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 16.4 m-20 -80.67 165.45 21.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.5 t -147.72 179.8 7.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.853 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -151.1 129.87 12.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.009 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.429 ' CD2' ' HB3' ' A' ' 191' ' ' ARG . 28.5 m-85 -127.24 135.92 51.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.718 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.15 146.29 30.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.359 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.409 ' HA3' ' CB ' ' A' ' 189' ' ' SER . . . 178.45 168.73 38.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.566 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -129.75 143.7 14.87 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.446 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.468 ' HA ' ' HA3' ' A' ' 187' ' ' GLY . 2.8 pttp -131.97 146.52 52.14 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.095 0.474 . . . . 0.0 111.286 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.853 HD12 ' O ' ' A' ' 53' ' ' GLY . 23.1 tp -121.14 152.03 39.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.531 179.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -169.66 -164.35 25.23 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.514 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 24.2 p90 -122.5 119.28 30.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.804 0.335 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -160.22 148.66 16.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.871 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -135.82 107.81 7.15 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.822 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -134.35 79.97 1.83 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.887 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 9.9 p80 -112.13 130.27 55.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.943 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -100.46 104.95 16.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.897 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.05 -53.92 2.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 96.53 -28.13 14.6 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.556 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -60.25 161.33 7.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.821 0.343 . . . . 0.0 110.887 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -133.88 168.4 18.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -131.45 28.35 3.62 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.476 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -97.29 133.9 41.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.881 0.372 . . . . 0.0 110.875 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.58 -61.33 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.511 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -112.31 166.12 11.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.808 0.337 . . . . 0.0 110.871 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -67.45 117.49 9.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.828 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -79.19 156.06 28.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.773 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -106.37 -42.06 5.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.903 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -86.17 154.18 21.51 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.873 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.57 153.78 31.98 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.559 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.17 122.64 9.2 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.561 2.174 . . . . 0.0 112.347 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 21.3 p -135.17 102.73 5.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.14 136.93 34.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.935 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 19.4 m-80 -82.79 153.38 25.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.894 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -93.63 92.92 7.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 13.2 mm100 -78.68 129.94 35.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.929 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 3.6 pp -99.81 139.51 35.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.853 ' O ' HD12 ' A' ' 25' ' ' LEU . . . -137.67 159.94 25.07 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.507 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -110.87 151.01 28.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.817 0.341 . . . . 0.0 111.078 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -143.36 122.92 1.97 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.404 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -94.82 135.93 35.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.682 0.277 . . . . 0.0 110.895 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.436 ' CZ ' ' HB3' ' A' ' 189' ' ' SER . 24.9 p90 -124.99 127.46 47.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.212 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -151.8 124.97 1.76 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.011 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -148.22 -172.59 18.32 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.759 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 27.7 p90 -150.63 156.03 40.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.871 0.367 . . . . 0.0 110.853 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -99.25 137.21 38.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.83 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.6 t -126.76 -48.16 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.765 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -93.57 141.09 23.4 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.46 179.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.77 64.63 0.89 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.497 2.131 . . . . 0.0 112.074 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.479 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.2 OUTLIER 179.82 -32.94 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.614 -179.938 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.479 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.4 OUTLIER -162.24 164.1 27.86 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.88 0.371 . . . . 0.0 111.434 -179.51 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -133.91 177.0 19.43 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.249 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -99.74 134.59 42.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.619 0.247 . . . . 0.0 110.841 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 22.8 tp10 -124.03 131.51 53.57 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.989 0.424 . . . . 0.0 111.076 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 6.9 tpt -111.44 130.28 55.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.544 179.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -109.84 153.32 17.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.558 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.404 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 34.2 m-85 -134.19 114.95 13.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.829 0.347 . . . . 0.0 110.746 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.6 122.22 33.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.017 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -137.71 150.6 47.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 3.5 mt -122.98 135.89 54.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.909 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -107.73 -165.19 21.63 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.561 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 9.2 mtp180 60.88 93.23 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.839 0.352 . . . . 0.0 110.904 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -94.34 155.9 16.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.877 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -84.8 153.89 22.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.077 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -144.9 85.14 1.74 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.839 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -110.28 -31.51 7.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.998 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -128.31 170.79 19.58 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.558 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 84.3 p -92.88 -52.52 4.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.787 0.327 . . . . 0.0 110.829 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.58 ' O ' HG23 ' A' ' 84' ' ' VAL . 28.1 m -66.22 76.69 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.244 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -176.71 110.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.86 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -65.98 -65.58 0.66 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -178.59 141.39 4.96 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.492 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.4 115.17 27.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.767 0.318 . . . . 0.0 111.047 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -86.51 106.88 17.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 1.1 tptm -67.89 -66.8 0.52 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.818 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.566 ' HB1' ' O ' ' A' ' 120' ' ' ARG . . . 179.49 164.97 1.04 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.1 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -114.67 131.7 56.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.607 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.23 128.42 9.53 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.074 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -127.43 117.85 48.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 179.318 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -112.16 145.62 39.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.182 0.515 . . . . 0.0 112.016 -178.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.1 tt -134.93 112.81 10.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.249 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.405 HG22 ' HA3' ' A' ' 115' ' ' GLY . 2.7 p -150.81 172.99 14.74 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.228 0.537 . . . . 0.0 112.027 -178.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -102.12 131.41 48.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.83 178.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.413 ' HD2' ' CD1' ' A' ' 111' ' ' TYR . 3.4 ttpt -118.79 132.11 56.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.101 0.477 . . . . 0.0 111.738 -179.035 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 3.5 pp -134.95 133.64 39.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.916 179.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.436 ' HA3' ' CD1' ' A' ' 111' ' ' TYR . . . -147.62 -179.41 23.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.182 -1.009 . . . . 0.0 113.102 -179.437 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.408 ' O ' HG22 ' A' ' 110' ' ' ILE . 0.5 OUTLIER -166.3 128.84 1.44 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.734 -0.233 . . . . 0.0 110.654 -179.913 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -67.4 171.31 11.91 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.391 2.061 . . . . 0.0 112.116 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 18.6 mm -114.65 -42.42 3.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.608 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 49.5 m -145.24 -48.53 0.23 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.675 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 177.7 -37.47 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.995 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.759 ' O ' HD23 ' A' ' 108' ' ' LEU . 64.3 m-20 -114.79 21.82 14.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.523 -179.761 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.759 HD23 ' O ' ' A' ' 107' ' ' ASP . 0.0 OUTLIER -147.22 127.28 13.69 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 179.731 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.403 ' OD1' ' CE2' ' A' ' 111' ' ' TYR . 8.8 t70 -144.46 155.7 43.85 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.065 0.46 . . . . 0.0 111.751 -179.099 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.408 HG22 ' O ' ' A' ' 102' ' ' TYR . 3.0 tt -114.51 132.36 63.87 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.022 179.239 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.436 ' CD1' ' HA3' ' A' ' 101' ' ' GLY . 25.5 m-85 -133.14 147.64 52.09 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.975 0.417 . . . . 0.0 111.734 -179.307 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.49 129.55 23.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.446 179.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -121.33 129.13 52.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.424 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 7.4 tt -134.85 122.7 22.4 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.488 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.405 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -176.94 -136.98 2.54 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.467 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.484 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -143.12 161.62 27.58 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.476 -0.868 . . . . 0.0 112.801 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -120.11 142.96 48.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.777 0.322 . . . . 0.0 110.706 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.428 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.5 t -130.36 138.42 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.89 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.437 ' CE2' ' HA3' ' A' ' 140' ' ' GLY . 70.5 p-90 -146.22 157.65 43.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.963 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.566 ' O ' ' HB1' ' A' ' 91' ' ' ALA . 0.0 OUTLIER -134.58 149.12 50.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.817 -179.982 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -109.82 124.06 50.65 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.001 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -151.9 147.95 27.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.917 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.58 153.54 33.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.859 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 2.7 tttt -172.49 113.45 0.28 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.862 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -170.48 -145.92 4.94 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.411 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 -95.17 113.87 25.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.911 0.386 . . . . 0.0 110.819 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -155.21 -167.88 2.69 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.856 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -127.14 109.1 11.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.117 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 1.2 m -92.81 117.04 29.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.906 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 36.2 p -111.84 -64.64 1.26 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -97.01 -77.0 1.33 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.545 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.2 m -144.6 163.86 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.77 0.319 . . . . 0.0 111.116 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 36.9 p -119.89 -55.34 2.09 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.881 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 30.5 mtt180 -136.58 150.19 48.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.84 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 73.9 m -100.96 -55.62 2.52 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.935 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -117.49 -176.6 3.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.963 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 12.0 m80 -108.41 141.98 39.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.834 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -91.04 137.35 32.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.838 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 65.8 p -138.4 128.17 25.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.857 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.437 ' HA3' ' CE2' ' A' ' 119' ' ' TRP . . . -118.84 138.88 13.97 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 9.1 p -144.64 135.42 20.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.764 0.316 . . . . 0.0 111.027 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 4.2 p -156.41 129.61 4.45 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.301 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.484 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 84.5 Cg_endo -77.92 142.57 19.95 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.595 2.197 . . . . 0.0 112.11 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 143' ' ' PRO . 27.8 m -157.07 162.4 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.015 0.436 . . . . 0.0 111.455 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.01 124.04 11.39 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.484 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -114.03 137.12 52.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.862 0.363 . . . . 0.0 111.458 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -134.04 134.26 7.33 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.07 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -159.39 -157.31 8.49 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.919 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 11.1 m -135.18 167.78 24.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.805 0.336 . . . . 0.0 111.207 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -131.42 140.24 49.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.969 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -124.38 125.77 44.85 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.771 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.601 ' HB3' ' HA ' ' A' ' 107' ' ' ASP . . . -88.1 137.11 32.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.423 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 99.2 t -108.88 -69.4 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.95 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 47.1 p -88.26 -81.96 0.24 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.045 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -159.42 -60.88 0.07 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.821 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -103.03 26.42 8.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.957 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 18.0 mt -150.98 101.06 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.954 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -117.76 162.45 18.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.213 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 61.1 p -100.99 150.83 22.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.145 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 4.6 ttt85 -137.14 133.12 34.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.062 0.458 . . . . 0.0 111.951 -179.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.11 119.23 33.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.448 178.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -110.04 145.22 37.42 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.189 0.519 . . . . 0.0 111.907 -178.569 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.436 ' CD1' ' HG ' ' A' ' 184' ' ' LEU . 8.4 t80 -131.79 147.87 52.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.232 179.474 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -71.32 -79.14 0.07 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.388 -179.586 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . 0.412 ' O ' ' CD2' ' A' ' 163' ' ' TYR . 0.4 OUTLIER -80.4 -177.14 6.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.843 0.354 . . . . 0.0 111.171 -179.782 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 167' ' ' ASN . 21.3 t -123.18 159.12 27.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.07 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . 0.485 ' N ' HG12 ' A' ' 166' ' ' VAL . 2.8 m-80 -70.63 71.62 0.49 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.96 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -140.57 143.99 35.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.978 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . 0.54 ' O ' HG23 ' A' ' 169' ' ' ILE . 8.5 tp -162.44 115.74 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.087 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -89.84 -104.22 1.15 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.622 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -104.75 171.1 7.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.903 0.382 . . . . 0.0 110.795 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -112.72 164.26 13.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.069 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -168.68 -91.57 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.454 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.9 t -99.22 130.22 45.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.769 0.319 . . . . 0.0 110.951 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 28.7 t -128.12 131.96 68.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.043 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -135.44 -80.19 0.12 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.521 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -94.6 106.65 18.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.752 0.311 . . . . 0.0 110.861 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . 0.406 ' HB2' ' HD3' ' A' ' 179' ' ' PRO . 11.4 mtt-85 -72.47 -61.28 1.79 Allowed Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.986 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . 0.406 ' HD3' ' HB2' ' A' ' 178' ' ' ARG . 56.9 Cg_endo -70.66 69.99 2.1 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.443 2.095 . . . . 0.0 112.314 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -119.59 -51.75 2.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.906 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 28.1 m120 -120.5 115.63 23.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 160.6 63.19 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.553 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 5.8 ptt? -117.16 131.54 56.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.781 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.637 HD12 ' N ' ' A' ' 184' ' ' LEU . 2.4 mp -114.95 127.82 55.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 88.1 p -121.13 146.5 46.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.084 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -125.48 141.04 52.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.647 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 24' ' ' LYS . . . -161.7 -176.96 34.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.412 -0.899 . . . . 0.0 112.952 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -128.74 140.54 48.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.621 0.248 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . 0.436 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 97.1 p -139.51 175.0 9.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.055 0.455 . . . . 0.0 111.464 -179.497 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . . . . . . . . . 14.8 p90 -146.85 151.43 37.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.653 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . 0.429 ' HB3' ' CD2' ' A' ' 20' ' ' TYR . 25.0 ptt-85 -128.56 152.4 48.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.927 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -71.11 94.26 1.11 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.927 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -75.55 163.83 53.85 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.513 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -141.67 144.18 33.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.899 0.381 . . . . 0.0 110.804 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 41.3 mm-40 -64.99 111.85 3.05 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.897 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.76 -32.5 69.67 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.818 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -93.91 117.31 29.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.048 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . 0.752 ' O ' HG22 ' A' ' 200' ' ' VAL . . . -139.02 84.73 16.69 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.178 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -54.07 88.27 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.684 2.256 . . . . 0.0 112.229 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . 0.752 HG22 ' O ' ' A' ' 198' ' ' ALA . 11.0 m -152.59 179.64 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.076 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 21.5 t -142.23 80.86 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.079 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . . . . . . . . . . . -114.88 127.65 26.63 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.988 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -55.51 -64.21 0.15 Allowed 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.379 2.053 . . . . 0.0 112.395 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -127.17 113.65 21.64 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.26 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.28 141.74 36.17 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.407 2.071 . . . . 0.0 112.259 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -140.3 134.51 15.5 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.21 -43.63 0.23 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.427 2.085 . . . . 0.0 112.421 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -109.84 93.95 16.01 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.099 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -69.26 -41.98 4.37 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.478 2.119 . . . . 0.0 112.25 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.264 -0.874 . . . . 0.0 110.932 -179.943 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.836 0.351 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 44.0 mtt85 -81.96 73.97 8.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.747 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 3.7 tt -148.54 128.89 4.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.112 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -166.83 -44.36 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.948 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -99.24 30.83 3.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.926 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -70.6 -76.1 0.11 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.999 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.452 HD13 ' H ' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -65.65 145.4 13.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.11 -179.945 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -138.73 -47.28 0.5 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 26.8 t -99.5 135.95 32.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.092 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.579 ' H ' HD12 ' A' ' 10' ' ' LEU . 5.2 mp -63.44 101.5 0.33 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.981 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -80.52 138.85 36.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.833 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.533 ' HB1' ' HD2' ' A' ' 15' ' ' LYS . . . -95.35 77.07 3.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.104 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.761 ' HB3' ' HD3' ' A' ' 14' ' ' PRO . . . -74.3 -61.13 1.26 Allowed Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.173 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.761 ' HD3' ' HB3' ' A' ' 13' ' ' ALA . 61.2 Cg_endo -73.12 87.01 1.06 Allowed 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.447 2.098 . . . . 0.0 112.357 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.533 ' HD2' ' HB1' ' A' ' 12' ' ' ALA . 0.1 OUTLIER -153.01 94.89 1.9 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.964 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.75 113.05 2.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.825 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -106.0 116.52 32.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.0 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.682 HG23 ' H ' ' A' ' 61' ' ' GLN . 2.2 t -136.69 156.01 49.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.771 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -150.66 130.03 12.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.988 -179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -138.91 136.32 35.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.778 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 143.18 38.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.354 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.12 -157.9 10.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.541 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -146.22 145.87 15.32 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.597 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.91 156.08 32.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.939 0.4 . . . . 0.0 111.107 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.743 HD21 ' HB2' ' A' ' 52' ' ' LEU . 0.7 OUTLIER -135.66 138.76 43.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.611 179.709 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -131.82 155.01 21.21 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.542 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -133.24 99.99 4.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.796 0.331 . . . . 0.0 110.855 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 m -161.58 102.37 1.2 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.845 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 14.2 mm-40 -148.52 99.06 2.97 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.955 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . . . . . . . . . 11.4 m-85 -117.97 94.76 4.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -154.1 -48.19 0.09 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.901 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -67.64 119.56 12.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.91 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.3 163.67 12.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.48 48.55 3.69 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.479 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -100.92 112.8 25.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.337 . . . . 0.0 110.824 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 4.4 p90 -161.19 -44.27 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.997 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -163.54 132.37 2.72 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.512 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 24.1 p30 -87.08 148.26 25.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.695 0.283 . . . . 0.0 110.945 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -93.76 -154.53 31.14 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.529 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.66 161.52 9.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.802 0.334 . . . . 0.0 110.829 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -148.06 86.68 1.57 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.867 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -99.35 -68.15 0.82 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -129.74 -54.0 1.15 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -63.66 91.77 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.837 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -102.68 96.43 1.39 Allowed Glycine 0 CA--C 1.519 0.288 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.553 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -67.89 168.1 19.66 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.55 2.167 . . . . 0.0 112.339 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.19 44.32 1.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.863 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.97 -31.27 56.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.834 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -73.91 160.45 31.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.826 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.51 168.9 14.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.923 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 10.2 tm0? -140.73 161.02 38.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.912 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.743 ' HB2' HD21 ' A' ' 25' ' ' LEU . 0.2 OUTLIER -105.37 150.16 25.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.862 179.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -108.94 143.6 16.31 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.374 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -132.76 156.72 46.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.843 0.354 . . . . 0.0 111.157 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -158.58 154.64 25.71 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.451 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.839 ' HB3' ' HB2' ' A' ' 72' ' ' TYR . . . -95.43 124.7 39.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.74 0.305 . . . . 0.0 110.946 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -111.69 119.06 37.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.039 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -139.75 124.94 2.84 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.058 179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -138.17 165.59 25.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.771 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.44 ' CZ ' ' HB2' ' A' ' 68' ' ' PHE . 4.9 p90 -154.26 134.78 13.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.994 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.682 ' H ' HG23 ' A' ' 18' ' ' THR . 11.1 mt-30 -103.41 137.07 42.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.714 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 53.9 t -108.25 -30.06 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.259 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.5 t30 -147.22 153.18 44.42 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.852 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_exo -64.49 70.36 0.23 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.646 2.231 . . . . 0.0 112.176 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.683 ' HB3' HD23 ' A' ' 66' ' ' LEU . 0.5 OUTLIER -159.74 -45.72 0.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -179.974 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.683 HD23 ' HB3' ' A' ' 65' ' ' TYR . 0.5 OUTLIER -178.22 149.15 0.52 Allowed 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.946 -179.935 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -123.71 169.83 15.92 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.394 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . 50.9 m-85 -83.98 134.49 34.64 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.682 0.277 . . . . 0.0 110.853 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.66 112.08 19.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.741 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 3.4 mtp -104.43 118.1 35.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.552 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -110.0 152.32 17.28 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.581 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.839 ' HB2' ' HB3' ' A' ' 56' ' ' ALA . 5.1 m-85 -130.7 115.02 16.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.846 0.355 . . . . 0.0 110.576 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -81.66 123.13 28.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.023 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -130.89 109.03 10.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.861 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -120.04 172.27 7.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -102.78 104.43 2.57 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.514 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.24 109.12 20.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.86 0.362 . . . . 0.0 110.905 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 50.2 mtp -72.71 106.42 4.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.907 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -174.05 121.02 0.29 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.019 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 2.3 p90 -170.9 147.68 2.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.878 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 4.8 mttt -128.06 140.57 51.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.92 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -76.72 -59.52 3.21 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.564 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.66 173.18 3.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.898 0.38 . . . . 0.0 110.81 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 84' ' ' VAL . 5.5 m -65.8 102.88 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.161 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -149.41 158.62 44.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.859 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.3 m120 -102.04 176.28 5.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 163.32 -87.71 0.1 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.458 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -114.75 136.22 53.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.795 0.331 . . . . 0.0 111.086 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -123.0 -49.46 1.96 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -123.27 134.55 54.07 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.861 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -158.48 116.21 2.92 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.051 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -175.02 141.68 0.59 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.722 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -95.92 134.01 11.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.753 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 118' ' ' VAL . 0.0 OUTLIER -120.68 117.86 54.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.755 0.312 . . . . 0.0 110.447 179.536 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' GLN . . . . . 0.556 ' OE1' HG21 ' A' ' 144' ' ' VAL . 3.4 tt0 -109.01 137.89 46.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.074 0.464 . . . . 0.0 111.744 -179.1 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.8 tt -126.21 111.32 14.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.617 179.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.504 HG22 ' HA3' ' A' ' 115' ' ' GLY . 3.5 p -149.36 166.28 29.51 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.072 0.463 . . . . 0.0 111.796 -178.669 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -104.65 127.7 52.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.1 179.126 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.84 132.14 56.6 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.031 0.443 . . . . 0.0 111.749 -179.145 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.504 ' O ' HD12 ' A' ' 100' ' ' LEU . 4.0 pp -130.09 130.14 44.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.316 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -154.03 -173.52 23.17 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.442 -0.885 . . . . 0.0 113.032 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.664 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 10.2 p90 -166.15 148.95 6.4 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 120.596 0.236 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -81.23 170.65 14.69 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.73 2.287 . . . . 0.0 112.7 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 16.8 mm -102.91 -42.19 8.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.631 179.726 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.99 -60.53 0.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.776 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 177.02 46.51 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.776 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.462 ' OD2' HD21 ' A' ' 108' ' ' LEU . 21.4 p-10 178.79 -29.66 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.426 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.462 HD21 ' OD2' ' A' ' 107' ' ' ASP . 0.1 OUTLIER -112.61 128.82 56.48 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.561 -179.849 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -144.91 157.89 43.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.887 0.375 . . . . 0.0 111.603 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.95 HG22 HG12 ' A' ' 149' ' ' VAL . 1.1 pt -120.81 144.5 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.471 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 4.7 p90 -148.05 149.07 31.42 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 121.225 0.536 . . . . 0.0 111.83 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 21.4 p -130.64 133.2 45.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.988 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.703 ' NE ' ' HB3' ' A' ' 146' ' ' ALA . 0.2 OUTLIER -115.46 130.73 56.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.063 0.459 . . . . 0.0 111.707 -179.261 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.503 HD12 ' HD2' ' A' ' 145' ' ' PHE . 7.9 tt -126.26 122.63 36.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.153 179.267 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.504 ' HA3' HG22 ' A' ' 97' ' ' THR . . . -178.29 -142.09 4.56 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.294 -0.955 . . . . 0.0 112.869 -179.8 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.519 ' HA2' ' HA ' ' A' ' 143' ' ' PRO . . . -141.73 169.08 25.35 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.771 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 4.4 tmm? -127.57 137.84 52.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.849 0.357 . . . . 0.0 110.948 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.46 ' O ' HG23 ' A' ' 94' ' ' VAL . 1.6 t -127.29 127.7 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.674 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 2.9 p-90 -142.78 162.64 34.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.798 0.333 . . . . 0.0 110.987 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 18.3 mtp180 -126.44 156.13 41.12 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.971 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -129.62 153.68 47.85 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.026 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -135.63 149.34 49.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.911 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 5.5 p -175.07 70.25 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.89 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 3.1 ttpp -126.51 82.83 2.11 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.857 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -114.3 -162.99 14.5 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.467 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -117.14 93.37 4.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.86 0.362 . . . . 0.0 110.878 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' TYR . . . . . . . . . . . . . 31.2 t80 -156.81 -50.89 0.07 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.852 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -118.62 -42.9 2.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.118 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 25.3 m -112.85 125.97 54.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.2 m -120.83 -53.92 2.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.952 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -89.07 -179.82 45.56 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.494 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.88 136.52 34.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.862 0.363 . . . . 0.0 111.173 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 3.1 p -132.59 -64.09 0.77 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.915 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -159.46 41.67 0.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.891 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 1.1 p -102.75 131.88 49.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.942 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.15 174.38 6.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' HIS . . . . . . . . . . . . . 72.2 m-70 -67.11 144.52 56.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -121.52 120.55 35.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.93 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 30.0 p -119.66 160.0 23.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.96 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -122.72 129.65 7.57 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.485 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 10.0 p -146.04 128.86 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.696 0.284 . . . . 0.0 110.994 -179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.491 ' HA ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -157.18 141.38 11.75 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.436 -179.978 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.519 ' HA ' ' HA2' ' A' ' 116' ' ' GLY . 5.8 Cg_exo -73.91 153.41 47.54 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.869 2.379 . . . . 0.0 111.858 179.719 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.556 HG21 ' OE1' ' A' ' 95' ' ' GLN . 27.0 m -156.74 162.92 1.48 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.181 0 CA-C-O 121.221 0.534 . . . . 0.0 111.764 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' PHE . . . . . 0.503 ' HD2' HD12 ' A' ' 114' ' ' LEU . 10.2 t80 -143.05 118.84 10.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.256 179.619 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.703 ' HB3' ' NE ' ' A' ' 113' ' ' ARG . . . -117.15 140.96 48.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.991 0.424 . . . . 0.0 111.16 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -138.07 134.89 7.16 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.152 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -161.03 -167.5 21.58 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.81 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.95 HG12 HG22 ' A' ' 110' ' ' ILE . 4.1 m -127.18 160.02 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.869 0.366 . . . . 0.0 111.042 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.448 ' HG2' ' HB3' ' A' ' 160' ' ' ARG . 1.4 tm-20 -120.85 136.39 54.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.217 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' TRP . . . . . . . . . . . . . 37.5 m95 -120.78 120.27 35.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.469 179.525 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.43 119.0 32.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.571 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 40.5 t -116.17 97.26 5.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.807 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' THR . . . . . . . . . . . . . 6.4 m 63.97 131.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.739 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.23 89.23 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.027 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . 0.869 ' HB3' HD12 ' A' ' 157' ' ' ILE . 3.8 t0 -177.87 -57.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.02 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.869 HD12 ' HB3' ' A' ' 156' ' ' ASP . 3.5 mp -141.74 133.61 27.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.144 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' ALA . . . . . . . . . . . . . . . -114.77 161.82 17.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.946 0.403 . . . . 0.0 111.35 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' THR . . . . . . . . . . . . . 8.8 t -131.39 144.02 50.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.173 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.448 ' HB3' ' HG2' ' A' ' 150' ' ' GLU . 0.9 OUTLIER -137.1 155.12 50.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.243 0.544 . . . . 0.0 112.009 -179.288 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.853 HD22 ' CZ ' ' A' ' 163' ' ' TYR . 0.4 OUTLIER -120.41 121.45 38.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.635 179.006 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -107.41 145.05 33.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.116 0.484 . . . . 0.0 111.787 -178.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' TYR . . . . . 0.867 ' CE2' HD23 ' A' ' 184' ' ' LEU . 5.7 m-85 -129.86 151.36 50.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.491 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.58 97.14 6.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.029 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -179.95 -167.81 0.1 Allowed 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.845 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.6 t -118.04 130.43 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.172 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -169.95 148.86 3.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.849 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -70.37 -173.21 0.68 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.848 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' ILE . . . . . 0.455 HD13 ' OH ' ' A' ' 102' ' ' TYR . 1.1 pp -96.95 -28.75 3.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.172 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' GLY . . . . . . . . . . . . . . . -175.78 68.17 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.616 -0.802 . . . . 0.0 112.464 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -164.54 32.04 0.07 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.882 0.372 . . . . 0.0 110.901 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -169.71 -173.26 1.58 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.096 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -164.74 119.82 0.9 Allowed Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.562 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.494 ' O ' HG23 ' A' ' 174' ' ' THR . 4.8 t -78.39 90.76 4.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.858 0.361 . . . . 0.0 110.783 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 5.7 m -146.47 129.63 9.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.14 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' GLY . . . . . . . . . . . . . . . -151.46 -119.21 0.84 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.508 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 66.4 p -103.97 -74.14 0.65 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.775 0.321 . . . . 0.0 111.007 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -98.07 152.44 38.04 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.847 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.39 155.66 9.37 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.592 2.194 . . . . 0.0 112.355 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -120.31 45.86 2.11 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.849 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -64.14 110.67 2.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -108.93 -75.9 0.9 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.579 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' MET . . . . . . . . . . . . . 2.7 ttm -148.08 100.62 3.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.883 0.373 . . . . 0.0 110.865 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' LEU . . . . . 0.867 HD23 ' CE2' ' A' ' 163' ' ' TYR . 0.5 OUTLIER -121.45 137.19 54.82 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.717 179.921 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.9 m -131.87 151.52 51.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.93 0.395 . . . . 0.0 111.282 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -120.22 134.46 55.25 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.347 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' GLY . . . . . . . . . . . . . . . -146.41 165.36 28.29 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.055 -1.069 . . . . 0.0 113.231 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.22 139.83 50.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.376 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.56 168.58 19.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.103 0.478 . . . . 0.0 111.694 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 190' ' ' TYR . . . . . 0.522 ' CE1' HG23 ' A' ' 157' ' ' ILE . 4.4 m-85 -123.47 146.61 47.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.466 179.624 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 191' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -104.34 153.55 20.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.958 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 192' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -135.22 145.92 48.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.81 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 193' ' ' GLY . . . . . . . . . . . . . . . -145.53 -170.17 14.22 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 194' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -82.65 -42.54 18.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.823 0.344 . . . . 0.0 110.913 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 195' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -111.78 159.19 18.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.967 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 196' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -122.47 -43.48 2.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.851 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 197' ' ' ALA . . . . . . . . . . . . . . . -135.27 106.27 6.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.041 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 198' ' ' ALA . . . . . . . . . . . . . . . -103.94 90.95 3.25 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.109 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -68.73 -168.0 0.21 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.57 2.18 . . . . 0.0 112.203 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 200' ' ' VAL . . . . . . . . . . . . . 17.2 m -93.01 -31.04 4.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.122 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 201' ' ' VAL . . . . . . . . . . . . . 21.1 t -72.05 134.39 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.156 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 202' ' ' ALA . . . . . 0.753 ' HB3' ' HD3' ' A' ' 203' ' ' PRO . . . -88.7 -53.2 0.36 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.162 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.753 ' HD3' ' HB3' ' A' ' 202' ' ' ALA . 53.2 Cg_exo -52.23 132.64 44.71 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.542 2.161 . . . . 0.0 112.307 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -127.01 82.05 68.79 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.079 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 205' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.44 -45.17 2.72 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.537 2.158 . . . . 0.0 112.358 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 206' ' ' ALA . . . . . . . . . . . . . . . -132.8 142.33 44.35 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.072 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 207' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.95 -45.38 0.48 Allowed 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.53 2.153 . . . . 0.0 112.292 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -159.97 131.72 4.1 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.116 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 209' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.62 -62.12 0.36 Allowed 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.425 2.083 . . . . 0.0 112.278 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 210' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.169 -0.92 . . . . 0.0 110.893 179.996 . . . . . . . . 1 1 . 1 stop_ save_